<SEC-DOCUMENT>0001558370-24-015612.txt : 20241114
<SEC-HEADER>0001558370-24-015612.hdr.sgml : 20241114
<ACCEPTANCE-DATETIME>20241114070327
ACCESSION NUMBER:		0001558370-24-015612
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		55
CONFORMED PERIOD OF REPORT:	20240930
FILED AS OF DATE:		20241114
DATE AS OF CHANGE:		20241114

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protalix BioTherapeutics, Inc.
		CENTRAL INDEX KEY:			0001006281
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				650643773
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33357
		FILM NUMBER:		241457125

	BUSINESS ADDRESS:	
		STREET 1:		2 UNIVERSITY PLAZA
		STREET 2:		SUITE 100
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601
		BUSINESS PHONE:		201-696-9345

	MAIL ADDRESS:	
		STREET 1:		2 UNIVERSITY PLAZA
		STREET 2:		SUITE 100
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ORTHODONTIX INC
		DATE OF NAME CHANGE:	19980422

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EMBASSY ACQUISITION CORP
		DATE OF NAME CHANGE:	19960124
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>plx-20240930x10q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.8.0.95 -->
<!-- Based on: iXBRL 1.1 -->
<!-- Created on: 11/13/2024 11:42:09 PM -->
<!-- iXBRL Library version: 1.0.9027.2259 -->
<!-- iXBRL Service Job ID: f3bfef74-a7ca-4ea4-bca8-84d46dd79197 -->
<html xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:plx="http://www.protalix.com/20240930" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2024" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type"/><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" xs:nil="true" contextRef="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g" name="us-gaap:CommitmentsAndContingencies" id="Hidden_BnJKc6cYMECkbSqz4tNmhQ"/><ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" xs:nil="true" contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q" name="us-gaap:CommitmentsAndContingencies" id="Hidden_ZE0iLoUV80CQ00P_T_VKHw"/><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" name="dei:EntityCentralIndexKey" id="Tc_lrdZw1pa30CPd-cD4nhV5Q_2_1">0001006281</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" name="dei:CurrentFiscalYearEndDate" id="Tc_e3hUVPLCUE2fZi-S61JwQg_3_1">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" name="dei:DocumentFiscalYearFocus" id="Tc_cPvjmaDfRkWco1btGDM3uA_4_1">2024</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" name="dei:DocumentFiscalPeriodFocus" id="Tc_p34_EdIPWEed2GU5LxPypg_5_1">Q3</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" name="dei:AmendmentFlag" id="Tc_TkXGng-EjEiXcyhd84OD4g_6_1">false</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_pure_KYNrm9UG9EeMn48Y0if07Q" contextRef="Duration_7_2_2024_To_7_2_2024_srt_TitleOfIndividualAxis_plx_VicePresidentResearchAndDevelopmentMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_Cp-s3NgOGkGiTXZG6ZzZdA" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" id="Hidden_Wv5n4SFqLUalXo86fgRQdg">0.333</ix:nonFraction><ix:nonNumeric contextRef="Duration_7_2_2024_To_7_2_2024_srt_TitleOfIndividualAxis_plx_VicePresidentResearchAndDevelopmentMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_Cp-s3NgOGkGiTXZG6ZzZdA" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Hidden_HDd_9eUnQUuEPgjlLh4OWA">P1Y</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_pure_KYNrm9UG9EeMn48Y0if07Q" contextRef="Duration_7_2_2024_To_7_2_2024_srt_TitleOfIndividualAxis_plx_VicePresidentResearchAndDevelopmentMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_fsxZjtrzyEyb_e85-FjXKw" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" id="Hidden_UMFZm-Gn_k61nFAdjEsS9w">0.666</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="plx-20240930.xsd"/></ix:references><ix:resources><xbrli:context id="As_Of_9_30_2024_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_1blOGzJfIE-UlAziRRMUpw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_kuJQxZc4AESkk-yYQ3ajEg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_M3cptLGAykWR18u7qZj8rA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Cz0rkmpxTkehEUfvAgkZxw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_AlOFNjsJxk-mD6nKmhSf7A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_xF7FRPyjM0KtHl4ouLxL6A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_e96ler1a0U-r6gjxosRRSw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_c7VyEDTT0Ei2Nt_xe1-AZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_73hlr4ekFUSMz6sOdxmmxw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_YMjyliv9AkaFVW600tbKzg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_IAh-6HHWoUOrjiOkQywBhw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_7nASCJwWaUKNuXPn2KOuug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_EOHIo_NnGUyQjFf3rWGMHg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_mturlRZStkyYVoFlmzAAKA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_igBrNBUN8kSCsy4h33jyHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_357KMU0kkEKUaBvrKS9OkQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_hU3txrf14keCcHLR8hwO8w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_b_5zJrCjPUuLgiN0Qyd3yA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_UZznz_h0nU6MCrNFCI65kA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_3O2OkQ1pv0CKVkSu2N82xA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jyJnbb5Xj02LTfUAsaSZlA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_sY0xRPgRwEmrWK7PpsEQ0g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2u7hpIDa8UWFhyZbeZAEeQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_9_23_2024_To_9_23_2024_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_fjlRxFeRF0GsDO6ftqcY3w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:SeniorVicePresidentAndChiefFinancialOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-23</xbrli:startDate><xbrli:endDate>2024-09-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_2_2024_To_7_2_2024_srt_TitleOfIndividualAxis_plx_VicePresidentResearchAndDevelopmentMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_AvLDv7dryEm2YrB3OLun0Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:VicePresidentResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-02</xbrli:startDate><xbrli:endDate>2024-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2024_To_4_1_2024_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_p_CUFtHXL0eyiopN2TaoPQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_2_2024_To_7_2_2024_srt_TitleOfIndividualAxis_plx_VicePresidentResearchAndDevelopmentMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_Cp-s3NgOGkGiTXZG6ZzZdA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:VicePresidentResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-02</xbrli:startDate><xbrli:endDate>2024-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2024_To_9_30_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_m3nBp_5RP0q3hxfAVIwsKA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2024_To_9_30_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_YVdXplgBIUiqKREQvvCQYg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2024_To_9_30_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_Y25APrw9YkGqE9QGp-2pBw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2024_To_9_30_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_pLP50Bgxbk-D1hnRjPhAlA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2024_To_9_30_2024_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_-EAKZ_94e02kTPJSHJ6-mQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_vw8by47NDUq5QE7hoakywQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_E4kb99v7l0mAZMrPKuEUEA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_R2V45jNs50i3ZjlXVw6V4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_A3ezJBQ1MUmqg7U3imJLCA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_RrGB_Ovo00Ok686p6jPzbA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_xT5o1Ih3q0CS-6-uYmd1nw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_xv7pHWEqdkuqLB4zfoGlgQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_uM6rCcqim06Mqh7Y7r7_hA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_ierukmxCL0qBG6i8bMqdsw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_j4Hh_9X_vkGuiao5PBkobw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_7mSydPVUmEmHGUlub7tPJg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_z371xjvvpUqBogUfxstw5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_-gw8gqnXX0q0q6EWX9kyGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_DR0rv8wVu0yrFx2bdJFyPQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_Mxt-hPsr9EG5KGrzdcGbQQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_u2CliSsMKUa6PUPveJHdTg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_14_2024_To_11_14_2024_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_IuBQ2oW-QUW8AyxcNROv4A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-14</xbrli:startDate><xbrli:endDate>2024-11-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_SrS-_DJJqkCTLZ9dXxqUAw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ndUCQHw1p0S3US6p-dGFDg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_xlxVJaEkm0Cl5SxIoEuaJQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_hHjoVDl78USlzlUtO3Htzg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_Vdzpjd4fMUGT4CcCzCt5ig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_orKpnVhEbkGbW5YdvkXelA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_qFQhXtC8OkS0z_OP8CBUzQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_v1JvrDW3HkajOYmzxLbG4A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2024_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsAndWarrantsMember_C0t9LFxG80iLLT4GrVHt5Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">plx:OutstandingStockOptionsAndWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsWarrantsAnd2024NotesMember_pHC6uKO6gUK7SAy-_PDCuw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">plx:OutstandingStockOptionsWarrantsAnd2024NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsAndWarrantsMember_jNIclNrn20-gLZ0NF4hAeg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">plx:OutstandingStockOptionsAndWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsAndWarrantsMember_I8uK516psE6zNy3vZsdCVQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">plx:OutstandingStockOptionsAndWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_jTQDJIj1aEykP0X3ByOvLQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_CXybZU5St0uHedL7onjfxA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_tZ6IRwK5mk6fHAJ4kYRAJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUsAgreementAndChiesiExUsAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-07-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_lxgklNBaXU2pjfcaFonqKA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUsAgreementAndChiesiExUsAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ojV2ETGPxU-tgxipZ4iH_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3sUNQWsOgkuiFe-1dqA4tg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_H1-pSjk9fUqYJ7iVy7K5tg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_-IUAcf8ZvUOvvarlRWC6wg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_n3sdM3d8VEGt5dkutaAe0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3-IpBWJWhU6nof7a6J-CqQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023__jyu8G4bX02xwWm0pGi6zA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jMEt6MgVmU2McANkIiOctQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sULEv8JSLkKw5iYh_rNi0w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_23_2024_To_9_23_2024_srt_TitleOfIndividualAxis_plx_OfficersAndOtherEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_dTpdI5xPrkiwpnGVkyHdmQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:OfficersAndOtherEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-23</xbrli:startDate><xbrli:endDate>2024-09-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_2_2024_To_7_2_2024_srt_TitleOfIndividualAxis_plx_VicePresidentResearchAndDevelopmentMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_fsxZjtrzyEyb_e85-FjXKw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:VicePresidentResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-02</xbrli:startDate><xbrli:endDate>2024-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_15_2024_To_1_15_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_ELprQe2rdEavBiEcVE57Fg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-15</xbrli:startDate><xbrli:endDate>2024-01-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_23_2024_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_ypJyopAyWUGn0-upITXFlQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:SeniorVicePresidentAndChiefFinancialOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_23_2024_srt_TitleOfIndividualAxis_plx_OfficersAndOtherEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_b8NTuk7QZkmYLH_vN0r7-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:OfficersAndOtherEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_2_2024_srt_TitleOfIndividualAxis_plx_VicePresidentResearchAndDevelopmentMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_VcyDlSSU_UuXWR7-Z6srjw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:VicePresidentResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_1_2024_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_fW2CAIqwS0yFawiF2Xq3Pw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_15_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_wjItBW8ElUS5zStQFNkaTQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_lsKt_FH16UaE7aDEdbwFUg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_27_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_glBx8-GKQUagOk_5tVbhmg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_YET2ryP2dEill85k2_nFHg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_8CtKgL9lj0K2stR5YPRj0Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-23</xbrli:startDate><xbrli:endDate>2018-07-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_nRvfA8aPdUu85RbZO37WRQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-23</xbrli:startDate><xbrli:endDate>2018-07-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_mw7kn8o2CUWR-j1nLxbVfQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-19</xbrli:startDate><xbrli:endDate>2017-10-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_znGsm8ayME60HPVCk9kYOA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-19</xbrli:startDate><xbrli:endDate>2017-10-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_yf1yBqYb3ki32oo6H-lkuQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_pm7aApgkcEqj6XWAS_4N3w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_29_2022_To_8_29_2022_us-gaap_TypeOfArrangementAxis_plx_FillFinishAgreementMember_Ol0Pxko4TEuK_ACCWu0Zww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:FillFinishAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-29</xbrli:startDate><xbrli:endDate>2022-08-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2015_To_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_HI7XdKpS_0KkIxReGTPNCg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">plx:ProtalixBioTherapeuticsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:AmendedPfizerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-10-01</xbrli:startDate><xbrli:endDate>2015-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_13_2021_To_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_MxJMMq-010ClsaMCqYEAAA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-13</xbrli:startDate><xbrli:endDate>2021-05-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_f8J7ygmkjUK2ukgA-2oQ1w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_eO8PT46mE0CgmO5dj_kuPw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-07-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_vK2rvFHWSU-qe_rFcemZww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2024_To_9_30_2024_5srFek9aZ0STe4olK5gckA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_1_2024_FKdLzARpm02W48BIunrkDA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_KYNrm9UG9EeMn48Y0if07Q"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_agreement_ukZC-6VifkuWtCWLoRpkbA"><xbrli:measure>plx:agreement</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_installment_GQ9uxVOtz0-sYFwS4P9Gzg"><xbrli:measure>plx:installment</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_A4-BaHg86EmBShQ9tsexWA"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_ou5xw0ZH3UOzwMqFkX8ZXw_11_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_aC_OasVPQ0KRxRUvZLjfIw_25_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_VWvVYHPsI0-a0UWwtx9QAA_19_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_e_OsxemFjU2UD0V-bpKAXw_31_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_gP3Z8K24QEi0StlfU4I0xA_8_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_9_aCVK5OUUSmQnmWd-Iaag_12_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_pVxwznRJPEKMo6T8bA4g8Q_6_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_S08bm8fgO0i5HiSEl0Rfgg_22_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_UyvHhvotHUadHVP182UZOQ_27_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_UtQwCJekdUasg7dOkWRNag_14_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_Lh0LWu1Zxk6bjyikcZldlg_15_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_LmE8scvYJEOagyeAR2Z9NA_28_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_fgMVVUijQkKbf4CfNl5g6Q_33_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_Ho1JiaXHzkKwcRlvVUSVZw_21_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_A02-y9pBqUamMTVlXsWeHw_9_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"/></ix:resources></ix:header></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:9.2pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="border-bottom-style:none;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:0pt;padding-top:1pt;text-align:center;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="border-top-style:none;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_2f33002e_569d_4be2_bf1c_ea397217565a"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" name="dei:DocumentType" id="Narr_JF6He4iTUk2-i0VF7vsr3g"><b style="font-weight:bold;">10-Q</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(Mark One)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" name="dei:DocumentQuarterlyReport" id="Narr_q_v7q10hUUeNYvpmqdxeNw"><b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9746;</b></ix:nonNumeric><b style="font-weight:bold;">&#160;&#160;&#160;QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><b style="font-size:8pt;font-weight:bold;">For</b><span style="font-size:8pt;"> </span><b style="font-size:8pt;font-weight:bold;">the quarterly period ended </b><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" name="dei:DocumentPeriodEndDate" id="Narr_dJcGPkurOk-NcKDQ-wiHGQ"><b style="font-size:8pt;font-weight:bold;">September 30, 2024</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OR</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" name="dei:DocumentTransitionReport" id="Narr_xve6g4LYsE6GVu0zPWyNAA"><b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9744;</b></ix:nonNumeric><b style="font-weight:bold;">&#160;&#160;&#160;TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 18pt;"><b style="font-weight:bold;">For the transition period from </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b><b style="font-weight:bold;">&#160; to</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" name="dei:EntityFileNumber" id="Narr_1Rw5Xu5800mghE6PFwXBGQ"><b style="font-size:8pt;font-weight:bold;">001-33357</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Commission file number)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" name="dei:EntityRegistrantName" id="Narr_-vzBKGZaNU-VWhgn5WJvkA"><b style="font-weight:bold;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Exact name of registrant as specified in its charter)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_a1bb36ca_e2bf_4dc9_949a_f711226b91ef"></a><a id="Tc_0JbR7OZr00mQ82MMJDMlmw_1_1"></a><a id="Tc_KGtWVp90N0e6MAhpve9oiQ_2_0"></a><a id="Tc_dD2JGV7G_06woXxaqwocng_2_1"></a><a id="Tc_vXYn4Nwgvki2PZ1j267Nvg_4_0"></a><a id="Tc_lzSSKCkYc0Wi5gtPuPJuEA_5_0"></a><a id="Tc_zioGNrKqTU6FwJ_Am4MM2A_5_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" name="dei:EntityIncorporationStateCountryCode" id="Tc_gsW8iMHxaEe8iT_Ck5thaw_1_0"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;">&#160;</span><b style="font-size:8pt;font-weight:bold;">__</b><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" name="dei:EntityTaxIdentificationNumber" id="Narr_whcBgMgogEODbSJ4zMmIOw"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">65-0643773</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">__</b></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(State or other jurisdiction</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">of incorporation or organization)&#160;</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(I.R.S. Employer</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identification No.)&#160;</b></p></td></tr><tr><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" name="dei:EntityAddressAddressLine1" id="Narr_dkcOZsoB2U-9RUh0S_1fsw"><b style="font-size:8pt;font-weight:bold;">2 University Plaza</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" name="dei:EntityAddressAddressLine2" id="Narr_oBOPY5gkJE2N15b76HHbgQ"><b style="font-size:8pt;font-weight:bold;">Suite 100</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" name="dei:EntityAddressCityOrTown" id="Narr_xMYE0P891UmLepl5bJzDRQ"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Hackensack</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">, </b><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" name="dei:EntityAddressStateOrProvince" id="Narr_BeUvbE1MrUSkgHbhwjXzFQ"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">NJ</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" name="dei:EntityAddressPostalZipCode" id="Tc_ExF2KH9ZF023A9hl23PbjQ_4_1"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">07601</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Address of principal executive offices)</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Zip Code)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(</b><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" name="dei:CityAreaCode" id="Narr_vmHO5LLbH0WKx0GYob0FhQ"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">201</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">)-</b><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" name="dei:LocalPhoneNumber" id="Narr_4Wi6khCXkEGpqwcFhvC9Bg"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">696-9345</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Registrant&#8217;s telephone number, including area code)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">N/A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Former name, former address and former fiscal&#160;year, if changed since last report)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_45e8230e_f727_4422_812c_a1e35f80e47e"></a><a id="Tc_loUJtin_TkmVQpHC0svEzA_1_0"></a><a id="Tc_WbTu19hC_Ea4L_KyrwEIDQ_1_2"></a><a id="Tc_UFIBjwZ41UirrJDA4q2PuA_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"/><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.88%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"/><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"/></tr><tr><td style="vertical-align:bottom;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.88%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading Symbol(s)</b></p></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of each exchange on which registered</b></p></td></tr><tr><td style="vertical-align:top;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" name="dei:Security12bTitle" id="Tc_cVNwL6K8SUGK28sk57_cfA_2_0"><span style="font-size:8pt;">Common stock, $0.001 par value</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.88%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" name="dei:TradingSymbol" id="Tc_5LrqQ2i300KBmei0gAz04g_2_2"><span style="font-size:8pt;">PLX</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" name="dei:SecurityExchangeName" id="Tc_0TJ9JAVD9UyFP0MovLSKYg_2_4"><span style="font-size:8pt;">NYSE American</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:5pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. </span><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" name="dei:EntityCurrentReportingStatus" id="Narr_6SLX4P3ktU-GUASbr1eakg"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;">&#160;&#160;</span><span style="font-family:'Times New Roman';font-size:8pt;">&#8999;</span><span style="font-size:8pt;">&#160;&#160;No&#160;&#160;</span><span style="font-family:'Times New Roman';font-size:8pt;">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;&#160;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). </span><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" name="dei:EntityInteractiveDataCurrent" id="Narr_XOTA3CSerUqEIaChc5TAjQ"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Times New Roman';font-size:8pt;">&#8999;</span><span style="font-size:8pt;">&#160; No&#160;&#160;</span><span style="font-family:'Times New Roman';font-size:8pt;">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_a975f266_f6c7_407d_aa80_42ce67244ae1"></a><a id="Tc_N0I97aFWFkSw26olTVgWSg_1_0"></a><a id="Tc_dd_3O3XBTE-VdZIOwoEoMg_1_1"></a><a id="Tc_XsJGv9o1p0GWtbbrl7izZA_1_2"></a><a id="Tc_OUGLUv_GX0SvzkyGLI1u9A_1_3"></a><a id="Tc__FxQAxH7m0eidsSFij8DpQ_2_1"></a><a id="Tc__gLhQnWgl0CuO5IHUPwHUQ_2_2"></a><a id="Tc_Md1rsj27ikuMBhX-U0U9sw_3_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:90.1%;"><tr style="height:1pt;"><td style="vertical-align:top;width:25.99%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:38.02%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:10.97%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;width:25.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Large accelerated filer</p></td><td style="vertical-align:top;width:38.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Accelerated filer</p></td><td style="vertical-align:top;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td></tr><tr><td style="vertical-align:top;width:25.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" name="dei:EntityFilerCategory" id="Tc_9b52T48ot0m5mM_uB100Sg_2_0"><span style="font-size:8pt;">Non-accelerated filer</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:38.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Times New Roman';">&#8999;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Smaller reporting company</p></td><td style="vertical-align:top;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" name="dei:EntitySmallBusiness" id="Tc_NW0Vjz1F3EC1YuO2xC8xgQ_2_3"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:25.99%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:38.02%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Emerging growth company</p></td><td style="vertical-align:top;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" name="dei:EntityEmergingGrowthCompany" id="Tc_07mVxZiMYUeaz-j3fBgNRw_3_3"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family:'Times New Roman';">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). Yes&#160;&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" name="dei:EntityShellCompany" id="Narr_kwy-xJdZTE2AseZjmsl-qA"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric><span style="font-size:8pt;"> &#160;&#160;No&#160;&#160; </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">On November&#160;1, 2024, approximately <ix:nonFraction unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_11_1_2024_FKdLzARpm02W48BIunrkDA" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_XVCuFD_zeUao-OAhfssTSg">73,633,583</ix:nonFraction> shares of the Registrant&#8217;s common stock, $0.001 par value, were outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_2095f030_6187_467c_b240_bf7fee3a51d5"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM 10-Q</b></p><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">TABLE OF CONTENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:7.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:86.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:5.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td></tr><tr><td style="vertical-align:middle;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><a href="#PARTIFINANCIALINFORMATION_363674"><b style="font-style:normal;font-weight:bold;">PART I &#8211; FINANCIAL INFORMATION</b></a></p></td><td style="vertical-align:top;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1FinancialStatements_969154"><span style="font-style:normal;font-weight:normal;">Item&#160;1.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1FinancialStatements_969154"><span style="font-style:normal;font-weight:normal;">Financial Statements</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONDENSEDCONSOLIDATEDBALANCESHEETS_49495"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Balance Sheets (Unaudited) &#8211; As of September&#160;30, 2024 and December&#160;31, 2023</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATI"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Statements of Operations (Unaudited) &#8211; For the Nine and Three Months Ended September&#160;30, 2024 and 2023</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGES"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Statements of Changes in </span><span style="font-style:normal;font-weight:normal;">Stockholders&#8217; Equity (</span><span style="font-style:normal;font-weight:normal;">Capital Deficiency) (Unaudited) &#8211; For the Nine and Three Months Ended September&#160;30, 2024 and 2023</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#ffffff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLO"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Statements of Cash Flows (Unaudited) &#8211; For the Nine Months Ended September&#160;30, 2024 and 2023</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#ffffff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#NOTE1SIGNIFICANTACCOUNTINGPOLICIES_79340"><span style="font-style:normal;font-weight:normal;">Notes to Condensed Consolidated Financial Statements</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">7</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Item&#160;2.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">16</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3QuantitativeandQualitativeDisclosur"><span style="font-style:normal;font-weight:normal;">Item&#160;3.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3QuantitativeandQualitativeDisclosur"><span style="font-style:normal;font-weight:normal;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">32</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4ControlsandProcedures_865226"><span style="font-style:normal;font-weight:normal;">Item&#160;4.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4ControlsandProcedures_865226"><span style="font-style:normal;font-weight:normal;">Controls and Procedures</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">33</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><a href="#PARTIIOTHERINFORMATION_770480"><b style="font-style:normal;font-weight:bold;">PART II &#8211; OTHER INFORMATION</b></a></p></td><td style="vertical-align:top;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1LegalProceedings_676392"><span style="font-style:normal;font-weight:normal;">Item&#160;1.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1LegalProceedings_676392"><span style="font-style:normal;font-weight:normal;">Legal Proceedings</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">34</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors_983377"><span style="font-style:normal;font-weight:normal;">Item&#160;1A.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors_983377"><span style="font-style:normal;font-weight:normal;">Risk Factors</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">34</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2UnregisteredSalesofEquitySecurities"><span style="font-style:normal;font-weight:normal;">Item&#160;2.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2UnregisteredSalesofEquitySecurities"><span style="font-style:normal;font-weight:normal;">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">34</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3DefaultsUponSeniorSecurities_505234"><span style="font-style:normal;font-weight:normal;">Item&#160;3.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3DefaultsUponSeniorSecurities_505234"><span style="font-style:normal;font-weight:normal;">Defaults Upon Senior Securities</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">34</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4MineSafetyDisclosure_204781"><span style="font-style:normal;font-weight:normal;">Item&#160;4.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4MineSafetyDisclosure_204781"><span style="font-style:normal;font-weight:normal;">Mine Safety Disclosures</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">34</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5OtherInformation_679200"><span style="font-style:normal;font-weight:normal;">Item&#160;5.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5OtherInformation_679200"><span style="font-style:normal;font-weight:normal;">Other Information</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">34</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item6Exhibits_829552"><span style="font-style:normal;font-weight:normal;">Item&#160;6.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item6Exhibits_829552"><span style="font-style:normal;font-weight:normal;">Exhibits</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">34</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:94.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#SIGNATURES_574709"><span style="font-style:normal;font-weight:normal;">Signatures</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">36</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_4064c4ff_65a4_4648_8f54_647f9a9461b2"></a><a id="PARTIFINANCIALINFORMATION_363674"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PART&#160;I&#160;&#8211; FINANCIAL INFORMATION</p><a id="Item1FinancialStatements_969154"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;">Item&#160;1. Financial Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><a id="CONDENSEDCONSOLIDATEDBALANCESHEETS_49495"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED BALANCE SHEETS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(U.S. dollars in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_26ebb788_9b3d_4dbb_85f8_adaa92a7253b"></a><a id="Tc_A03qtnZwIECpwxqD29WBRQ_1_2"></a><a id="Tc_p_TNs5MbAUu9D-C_HxF0qA_1_5"></a><a id="Tc_dwkzuLhBl0aNkcG6OGjUjg_3_0"></a><a id="Tc_NwLCZD17IUmfCcgx9YLkoA_5_0"></a><a id="Tc_6sA5xJgin0uEd5qKxC7v2Q_6_0"></a><a id="Tc_4fghGI_VNkCz6-KejlnEbQ_6_2"></a><a id="Tc_HUPNuDSqDEGU3bzhwOoByA_6_5"></a><a id="Tc_HfnXiuYD5U-ZMtEginYdwA_7_0"></a><a id="Tc_VX8LvSBtwU2yzA6kt4-5xA_7_3"></a><a id="Tc_jqYT9rgacEyOyLuPt_KcnA_8_0"></a><a id="Tc_tMkxgwb_EUezqJHqr6TBnQ_9_0"></a><a id="Tc_LsnMUm25u0WuMqUEnu5qLA_10_0"></a><a id="Tc_IpEJYZs2NkO5S4iW8GZ1uA_11_0"></a><a id="Tc_NAmnxgKDtUW8wr9aEIcqkQ_11_2"></a><a id="Tc_Wy7KGk8xCUGVYohKDhxh2A_11_5"></a><a id="Tc_jHd0wDWHXEOPWwVbgwms9Q_13_0"></a><a id="Tc_4OhdkfkOk0GTgWSpNarKmQ_14_0"></a><a id="Tc_X-0bjqBZDUKHLLnDp9gDxQ_14_2"></a><a id="Tc_joH0ztQTUU6XoIDDuUM1rQ_14_5"></a><a id="Tc_Gk3Rd1n4GkSaP5w5oJ3U7A_15_0"></a><a id="Tc_1nFVbDrGbUi7pR556wjVnA_16_0"></a><a id="Tc_V641htfAHke-WutVTSFFow_17_0"></a><a id="Tc_MpvXMaJmiUibMc-bTxPEiQ_18_0"></a><a id="Tc_0i9dUFZ8l0GHgS8GkqyXIg_18_2"></a><a id="Tc_qQspKE-Sek2czpzwVa3t1Q_18_5"></a><a id="Tc_uyXfqt31Qk2D_PwZuOt1hw_20_0"></a><a id="Tc_mTPMLgDawkOVI7dI7HGvtA_22_0"></a><a id="Tc_dRMaV_qF2UizR-D5c-J_-w_23_0"></a><a id="Tc_ELPnwhiaGU6i8ovJh4rROQ_24_0"></a><a id="Tc_wr3BmcblZUCL8B0ZvkyweA_24_2"></a><a id="Tc_ettr-gu-Ok2cws8oAujJZA_24_5"></a><a id="Tc_yP_N1071rUuwrVn757L7Rw_25_0"></a><a id="Tc_12bysOKRBk27OK_9heQo5w_26_0"></a><a id="Tc_Cv_jbJK2hkapg4__VbUm5Q_27_0"></a><a id="Tc_Pa3v-VNJCUmc6kM95kBiSw_27_3"></a><a id="Tc_-ZSK9B6z8k-UtIjAZ93NiQ_28_0"></a><a id="Tc_xusEvZghnUG3_E3mw46auA_28_2"></a><a id="Tc_iK0pPYenMUGWVgvdfvgjUg_28_5"></a><a id="Tc_JSSdxOvESkODIVk1CuA0NQ_30_0"></a><a id="Tc_ftnmHpqUYEeeuxK6XKrp8w_31_0"></a><a id="Tc_IAQ9a76AE0mzSJjoryV-xw_31_2"></a><a id="Tc_BphEhnWr10i9cE9Lj0Z1kw_31_5"></a><a id="Tc_wNnn-X3yEUCxoR0iB3CZaA_32_0"></a><a id="Tc_Ca361wKApUWpC0VR_dT1SA_33_0"></a><a id="Tc_wM5XRkwNNUODc9IIWYrnIw_33_2"></a><a id="Tc_G5SajJQMF0uzBjxWQaiPZA_33_5"></a><a id="Tc_BxcDvczj90q1iJIJwYul5A_34_0"></a><a id="Tc_sU2Gy1pBf0eUkeyETpJkQw_34_2"></a><a id="Tc_-MmjqfG-JUiui5Aze5L-ng_34_5"></a><a id="Tc_6yyTg-eOEEWRNPv3joIMmw_36_0"></a><a id="Tc_EveboqZ1KUG5QW6ouMzS6w_38_0"></a><a id="Tc_w-yVcNMf7kWWpYhPdz8D4Q_39_0"></a><a id="Tc_bm9IqlcOr0mR98Iq6Y63xg_39_2"></a><a id="Tc_lYNm_zDWiU6_aXRKTJR4gw_39_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">ASSETS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CURRENT ASSETS:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_ZFldj6egR0SwNm6jrT6RXQ_6_3">27,409</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_re7cqt390kCRRis3RqMVPw_6_6">23,634</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Short-term bank deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q" decimals="-3" format="ixt:numdotdecimal" name="plx:ShortTermBankDeposits" scale="3" id="Tc_kebPAPmmqkS2xSibZEGCgw_7_6">20,926</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Accounts receivable &#8211; Trade</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="Tc_SU7vpANuXkaHY9tiY-ID6A_8_3">2,195</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="Tc_qkNcvgXomkG-9EezBkXlsw_8_6">5,272</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="Tc_xEMNvZujcUWgaGofgy2DNg_9_3">1,050</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="Tc_1vPYOThJpkWdrqZ-VfCKZg_9_6">1,055</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Inventories</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_zedPMHoR10Ket3a-1nk75Q_10_3">17,199</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_Hu_8MEGjt0KlhpR_DF9pGQ_10_6">19,045</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_hDnEJbsfi0GzvifBokhWxg_11_3">47,853</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_GjEsYNEIXkqWTMvLdGjYYQ_11_6">69,932</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">NON-CURRENT ASSETS:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Funds in respect of employee rights upon retirement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="3" id="Tc_eCYNBhbiuEW6d_ePjxoXwg_14_3">561</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="3" id="Tc_l9EjWA4aBk2mKpqp5l9FJQ_14_6">528</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc__Zxd33hr00ONwy5aQDMpyA_15_3">4,648</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_NvVK_ks-WEKnCs1_UUtf1g_15_6">4,973</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Deferred income tax asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="3" id="Tc_2O_2qbkiR0mDG0fSSNjqtQ_16_3">2,856</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="3" id="Tc_HuOTr_7REU6uos9AHhiEMw_16_6">3,092</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease right of use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_wuYKXkqY2ESpmjcXWH_tIg_17_3">5,645</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_xFuSgDTbCUS1k1rcglWxbA_17_6">5,909</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_hIQWg2XjFESaFOW69OVZzg_18_3">61,563</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_D5pojc0bPUG2n_yRLyEZdA_18_6">84,434</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">LIABILITIES AND STOCKHOLDERS' EQUITY</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CURRENT LIABILITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Accounts payable and accruals:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Trade</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableTradeCurrent" scale="3" id="Tc_zt9ZLhTNhkWv3SINu3cjXA_24_3">3,135</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableTradeCurrent" scale="3" id="Tc_ueS4d2qNS0SSMQ8ORhdVjQ_24_6">4,320</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableOtherCurrent" scale="3" id="Tc_YstaWRzH20-c-eveGB-qyg_25_3">19,577</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableOtherCurrent" scale="3" id="Tc_taHEbyIXm0eWEqrbL0jlnw_25_6">19,550</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_yJYdrc8trEmsZl4BaZ5Dzg_26_3">1,508</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_Q9xF3kQh4Ui8Di_soFoRHQ_26_6">1,409</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Convertible notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtCurrent" scale="3" id="Tc_99GJrmrq7UCL_QIPY4K_bg_27_6">20,251</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_YO5yYM1S3UqwXirK1nBbUg_28_3">24,220</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_2ruWZnvdNEurNbLM06u_eg_28_6">45,530</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">LONG TERM LIABILITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Liability for employee rights upon retirement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" scale="3" id="Tc_1yATXY4_LEauozEfN1aXQg_31_3">730</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" scale="3" id="Tc_kt5Oh5WN9EiSc9Xpfamg0A_31_6">714</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_eUuMWDtMkk2QpC7FBC7-2g_32_3">4,176</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_Vm2-VKR6PUONbEKrvLI1hw_32_6">4,621</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total long term liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="Tc_O2tRGS2iiUK5M2HQTmhHwQ_33_3">4,906</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="Tc_S44eH9T2u0KqWcWsdab-XA_33_6">5,335</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_IbkWoITQUku62gB6AACBOQ_34_3">29,126</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_bPjtTkIkyUSc5eAB9zR_NA_34_6">50,865</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">COMMITMENTS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">STOCKHOLDERS' EQUITY</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_Z-IBhgnCHk6e4oqijbMwqQ_38_3">32,437</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_MX0sHRyu6EyI-uTbRonH5A_38_6">33,569</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total liabilities and stockholders' equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_2Uu4piMGqkafoTmdYw1rcg_39_3">61,563</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_rd_rHeMEy0Op4J3yFj5ezA_39_6">84,434</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_815c86c3_e9aa_4e1e_870d_60c6defdebc8"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><a id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATI"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt -13.5pt;">(U.S. dollars in thousands, except share and per share data)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_245770eb_1795_4abb_94f5_de46e607fba1"></a><a id="Tc_lQCzuRZ8CU2_eDuTQm3wRA_1_1"></a><a id="Tc_ag-TD4Ya30-1a99q5BnrOg_1_7"></a><a id="Tc_twa1-39eXEWhyhdxerTN-A_2_1"></a><a id="Tc_x9Y576q1LU-TQWQVFVuGNA_2_4"></a><a id="Tc_Wl6RcEqSV0C74EkpY35isA_2_7"></a><a id="Tc_LQDqglEGb0Oiojs3doXiVA_2_10"></a><a id="Tc_hD6N3Q1GUkOPYzBqHKJTtg_3_0"></a><a id="Tc_xEn5475pekevxn6hwoFTMQ_3_1"></a><a id="Tc_7GHUrgxsNUOAvWP2G4VIGg_3_4"></a><a id="Tc_J3k_syEwR0SGpZrYLhr08Q_3_7"></a><a id="Tc_Lk6gsvDHZESZFS4DQ0A2wQ_3_10"></a><a id="Tc_liOmGjTrm0etK7zGC_ILKA_4_0"></a><a id="Tc_RiTD_sP6LkehRAzAmIruAg_5_0"></a><a id="Tc_mcBpbzJujEG7dKwqYLXOLg_6_0"></a><a id="Tc_NuopZybIe0icmeKx5DDgXg_7_0"></a><a id="Tc_mpOeN5mct0yK00dOZN-ZvA_8_0"></a><a id="Tc_Y0j2Ug5ZaUex3_qu9hoVkg_9_0"></a><a id="Tc_DF_Afd2TdUOlPWRBIwWdrA_10_0"></a><a id="Tc_B-aS4JyjaU-xxArqofdeAg_11_0"></a><a id="Tc_fRNBG9HMkkm7UZWy2UsW4A_12_0"></a><a id="Tc_NrmZRcvQ10WwUCE1lmK3RQ_13_0"></a><a id="Tc_1wpuruL-4U2aujgLOgoGqg_14_0"></a><a id="Tc_m9L3Fc59XUKbgP0uCQot5g_15_0"></a><a id="Tc_6wzv906Ct0i-uCQZ4zOaIA_15_1"></a><a id="Tc_pZ8qv2jjzECgardae8bBVQ_15_4"></a><a id="Tc_W1ThvFMyRUOt-vtlW7enIQ_15_7"></a><a id="Tc_TV45biSJhUe4VSUEnzxCHg_15_10"></a><a id="Tc_orxzvEcBr0S7AQ8a-Dcd4w_16_0"></a><a id="Tc_ZJSNSzeZvUGY2CQyrrgzaA_17_0"></a><a id="Tc_UyTrFEl8P0uh9lbqLT8fAA_17_1"></a><a id="Tc_mb-ZTgxi9k2gE-bqvyOw2A_17_4"></a><a id="Tc_x0CdqmSdW0eL8NsM4YH0DA_17_7"></a><a id="Tc_xbgLZtgccU-CibGtnNdgAg_17_10"></a><a id="Tc_IhemowWdJEeMKRV65l-7Ug_18_0"></a><a id="Tc_iCajEr4gYUmiMHr9B6qPjA_18_1"></a><a id="Tc_d43cRG6uREqQOsySsMv0kw_18_4"></a><a id="Tc_Tx6BZmrkmk-RoPN1OwObNQ_18_7"></a><a id="Tc_BkZlw9FHNE6ix0ThlUN2FA_18_10"></a><a id="Tc_qlVKP66xc0qFWw4EGybl_Q_19_0"></a><a id="Tc_v3lejTy5gkSXECXWchdtRg_20_0"></a><a id="Tc_3S6Aoddo2Em6sIiGNtCkdg_21_0"></a><a id="Tc_jayeIN_lzEOW9zN7AkWYOA_22_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.82870865%;padding-left:0pt;padding-right:0pt;width:101.65%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:46.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:46.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">REVENUES FROM SELLING GOODS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2024_To_9_30_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_A3ezJBQ1MUmqg7U3imJLCA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_IN_Ph4oCH06mA3SEpWshxA_3_2">34,820</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_DR0rv8wVu0yrFx2bdJFyPQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_KFZSdkO-vEyqOn2_xZIjWA_3_5">30,309</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_7_1_2024_To_9_30_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_pLP50Bgxbk-D1hnRjPhAlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_5pLw20mK50GOTguKqVDzVA_3_8">17,839</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_7_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_ierukmxCL0qBG6i8bMqdsw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_T0bVoQSqYkCbgxp00aABLA_3_11">10,168</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">REVENUES FROM LICENSE AND R&amp;D SERVICES</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2024_To_9_30_2024_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_RrGB_Ovo00Ok686p6jPzbA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_kq6jgpYvQ0Wx56cPN2h83g_4_2">361</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_Mxt-hPsr9EG5KGrzdcGbQQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_3OS7b-DSSEW2gnwI9uYUIw_4_5">24,699</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_7_1_2024_To_9_30_2024_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_-EAKZ_94e02kTPJSHJ6-mQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_G60jqX5JQk6mdCZyyKV5jw_4_8">120</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_7_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_j4Hh_9X_vkGuiao5PBkobw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_uMA7Yi40SUCjwayWJx3tPA_4_11">177</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">TOTAL REVENUE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_MsPPoSxQ_EC_5lO0TVJQnw_5_2">35,181</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_EKcKLFOsiU-TYU5AJp-x0Q_5_5">55,008</ix:nonFraction></p></td><td style="vertical-align:middle;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_7_1_2024_To_9_30_2024_5srFek9aZ0STe4olK5gckA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_moNucDbNAEC36QRAmXf2CQ_5_8">17,959</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_7_1_2023_To_9_30_2023__jyu8G4bX02xwWm0pGi6zA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_yiwcupd-RU6AOqxzoAwXCw_5_11">10,345</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">COST OF GOODS SOLD</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_iC0f4O7vr0iLPXCFaqdTbQ_6_2">20,433</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_EdCqXVjyIk-eemvEzWeUyA_6_5">14,126</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_7_1_2024_To_9_30_2024_5srFek9aZ0STe4olK5gckA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_Ipwlu9g14EWxgE4ak5nkHA_6_8">8,375</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_7_1_2023_To_9_30_2023__jyu8G4bX02xwWm0pGi6zA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_jXsr4WXmY0yAQ-A0TYcCDA_6_11">4,893</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">RESEARCH AND DEVELOPMENT EXPENSES</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_p-bW5f9b40Km5zOOkoX91w_7_2">8,846</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_cOeT3_-8eEGr27c00_QhwQ_7_5">13,991</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_7_1_2024_To_9_30_2024_5srFek9aZ0STe4olK5gckA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_LNrQQec4fEmDM1MKZ4DTVA_7_8">2,998</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_7_1_2023_To_9_30_2023__jyu8G4bX02xwWm0pGi6zA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_j465Hu22kkGsZdvCELTOlw_7_11">3,669</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_4SxNu3naGUGopmjIz730_w_8_2">9,194</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_sELVoedwvEqSlS-Bvdd1gg_8_5">10,816</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_7_1_2024_To_9_30_2024_5srFek9aZ0STe4olK5gckA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_GsFAHHAYT0CGmYeSQRhV4Q_8_8">2,595</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_7_1_2023_To_9_30_2023__jyu8G4bX02xwWm0pGi6zA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_iEzKWr2Rfk2jLANwX-mKdg_8_11">3,670</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:46.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">OPERATING INCOME (LOSS)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_dmKJIMce8U65E8wEpVRXSw_9_2">3,292</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="Tc_LTxkhUxpuUqneqxBc-i7tA_9_5">16,075</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_7_1_2024_To_9_30_2024_5srFek9aZ0STe4olK5gckA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="Tc_jqVWQouuWEuTkUMKHtQ1mw_9_8">3,991</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_7_1_2023_To_9_30_2023__jyu8G4bX02xwWm0pGi6zA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_Azi6L4-vDECNvxxDQQGhlg_9_11">1,887</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:46.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">FINANCIAL EXPENSES</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingExpense" scale="3" id="Tc_tlW_5gdNiE-dgJqaFOp7JA_10_2">1,056</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingExpense" scale="3" id="Tc_6IV9KW7KFkuYu9eOR4yXxg_10_5">2,406</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_7_1_2024_To_9_30_2024_5srFek9aZ0STe4olK5gckA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingExpense" scale="3" id="Tc_IbccAA4r6kydLSiQQvKIug_10_8">299</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_7_1_2023_To_9_30_2023__jyu8G4bX02xwWm0pGi6zA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingExpense" scale="3" id="Tc_sujEFWOtx02ECKjzna7zBw_10_11">460</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:46.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">FINANCIAL INCOME</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncome" scale="3" id="Tc_Rd9G1mYDvkusNsbkXgpy8g_11_2">1,186</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncome" scale="3" id="Tc_0_gh3K8j80O-Dip6I_VM1w_11_5">1,323</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_7_1_2024_To_9_30_2024_5srFek9aZ0STe4olK5gckA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncome" scale="3" id="Tc_dytleh4ogEilePxXBTyH0g_11_8">151</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_7_1_2023_To_9_30_2023__jyu8G4bX02xwWm0pGi6zA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncome" scale="3" id="Tc_6uCBQcBsQkqI6jDDX2bUfQ_11_11">628</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">FINANCIAL INCOME (EXPENSES), NET</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="Tc_kSheb7fKxUOZKDnotrPInw_12_2">130</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" sign="-" scale="3" id="Tc_rmVqRcyStUSWH2aj8_C-UQ_12_5">1,083</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_7_1_2024_To_9_30_2024_5srFek9aZ0STe4olK5gckA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" sign="-" scale="3" id="Tc_y6_1OufTmEeC1n0fcVQbxg_12_8">148</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_7_1_2023_To_9_30_2023__jyu8G4bX02xwWm0pGi6zA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="Tc_fBTFoH1k5kW_L4rTY0PYoA_12_11">168</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">INCOME (LOSS) BEFORE TAXES ON INCOME</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_woQge4JJxUiclf50MQonCg_13_2">3,162</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="Tc_SWaE2LnoZE-jRxaceK7c0A_13_5">14,992</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_7_1_2024_To_9_30_2024_5srFek9aZ0STe4olK5gckA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="Tc_-0VXj8OVjEadIYdQ8L9m_g_13_8">3,843</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_7_1_2023_To_9_30_2023__jyu8G4bX02xwWm0pGi6zA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_NlSnUSTKiUSpAMBCcPFGJw_13_11">1,719</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:46.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">TAXES ON INCOME</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_iYeQwoaei0S1or9fgb_Umg_14_2">400</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_HeUtQ3vjyUuK2sR8pJI5jw_14_5">636</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_7_1_2024_To_9_30_2024_5srFek9aZ0STe4olK5gckA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_cnyR9gAoIk6lrpbTXAoU6w_14_8">607</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_7_1_2023_To_9_30_2023__jyu8G4bX02xwWm0pGi6zA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_4mll5q8YoU2tTjpuKpoxJg_14_11">133</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">NET INCOME (LOSS) FOR THE PERIOD</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_lmD_6Vgq_0-7tRFDYgYaEQ_15_2">3,562</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_ma1dQ8Fl5kW5ZC64KI17NQ_15_5">14,356</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_7_1_2024_To_9_30_2024_5srFek9aZ0STe4olK5gckA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_mEWZ_9x7zk6Bg0IZhnDz8w_15_8">3,236</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_7_1_2023_To_9_30_2023__jyu8G4bX02xwWm0pGi6zA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_CFyGrjpjYEyjhmVTzJAgPw_15_11">1,852</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EARNINGS (LOSS) PER SHARE OF COMMON STOCK:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">BASIC</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_A4-BaHg86EmBShQ9tsexWA" contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_ChAGSeNjZUefqzVxxaOHFw_17_2">0.05</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_A4-BaHg86EmBShQ9tsexWA" contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" scale="0" id="Tc_IAyQq3-j9U2xSbcAooDNPw_17_5">0.22</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_A4-BaHg86EmBShQ9tsexWA" contextRef="Duration_7_1_2024_To_9_30_2024_5srFek9aZ0STe4olK5gckA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" scale="0" id="Tc_1e1vsrjZgU--zkryJ58d0w_17_8">0.04</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_A4-BaHg86EmBShQ9tsexWA" contextRef="Duration_7_1_2023_To_9_30_2023__jyu8G4bX02xwWm0pGi6zA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_W6t9lk2N4EuAuLV1J_ktuw_17_11">0.03</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">DILUTED</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_A4-BaHg86EmBShQ9tsexWA" contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_OC6ZNx3Uuk2u0jOtawv4dQ_18_2">0.05</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_A4-BaHg86EmBShQ9tsexWA" contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" scale="0" id="Tc_j7mYoao6vUafenJbdyQUtw_18_5">0.16</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_A4-BaHg86EmBShQ9tsexWA" contextRef="Duration_7_1_2024_To_9_30_2024_5srFek9aZ0STe4olK5gckA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" scale="0" id="Tc_4ciRM8_QFk-osZ25s92LUg_18_8">0.03</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_A4-BaHg86EmBShQ9tsexWA" contextRef="Duration_7_1_2023_To_9_30_2023__jyu8G4bX02xwWm0pGi6zA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_Pn93ad-aFUKV7RHaE66BcA_18_11">0.04</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">USED IN COMPUTING EARNINGS (LOSS) PER SHARE:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">BASIC</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA" contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_EwdRb5m4pE-vWiggf9NNcg_21_2">73,301,091</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA" contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_LmboOzyO2EaBqoVg3agj0g_21_5">65,811,506</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA" contextRef="Duration_7_1_2024_To_9_30_2024_5srFek9aZ0STe4olK5gckA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_aZSrUC7Mb0Obv2oo4XFb-Q_21_8">73,549,745</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA" contextRef="Duration_7_1_2023_To_9_30_2023__jyu8G4bX02xwWm0pGi6zA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_DeoZiMq5G0KflTc4jzdiqA_21_11">72,281,681</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">DILUTED</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA" contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_lv-EeENe5UWduXPiYXmQRg_22_2">73,301,091</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA" contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_0Ph82C-GkU-SVYxuzNjV2w_22_5">81,040,281</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA" contextRef="Duration_7_1_2024_To_9_30_2024_5srFek9aZ0STe4olK5gckA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_KCuxtnDqNUujUrGMB-FhHQ_22_8">81,217,068</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA" contextRef="Duration_7_1_2023_To_9_30_2023__jyu8G4bX02xwWm0pGi6zA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_77GvNQqa_UCgbVltR9qWFw_22_11">83,782,679</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_568e3741_d80a_4640_984a_7a1956956a74"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><a id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGES"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">STOCKHOLDERS&#8217; EQUITY (CAPITAL DEFICIENCY)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(U.S. dollars in thousands, except share data)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_51b0fa27_d06a_4470_84d5_013b9f213bd8"></a><a id="Tc_-3txLF4agkOqYuv_sAvO2A_1_7"></a><a id="Tc_S3KeAuIZzUKjognTkz0s8Q_2_2"></a><a id="Tc_eR65iU8ySU2mOiHP_tSj-A_2_4"></a><a id="Tc_E_ddpVZ2QUSNHA0pFhXZFQ_2_7"></a><a id="Tc_WoBhXYVcfkKd6PeDl96AHw_2_10"></a><a id="Tc_fWYAC0kbO0Sg5xcF4d3-xg_3_2"></a><a id="Tc_bhcv2rhDlUOoYGaLI8V9lA_3_4"></a><a id="Tc_uye_Oak090uxHFVEbmG1cA_3_7"></a><a id="Tc_pUPYmIFF_0SiAXLJDZ0QZw_3_10"></a><a id="Tc_0qc3ME31MEGnQ-Z8pKlQTQ_3_13"></a><a id="Tc_gEQilWb09ku70Kz06VzkBA_4_2"></a><a id="Tc_ArzG4_qDxEyRLovs8sqNuQ_5_2"></a><a id="Tc_akrt-R5IWEWFsKWtqvpoTg_5_4"></a><a id="Tc_haa6yUrPU0eevBfo39uICw_6_0"></a><a id="Tc_zmz6M9P_wkKzO6P3lKSGDw_6_4"></a><a id="Tc_TeONnjP4iku4y4xA7Mq0GA_6_7"></a><a id="Tc_syJctc0r2EKy79O6BjWfyQ_6_10"></a><a id="Tc_b8i0R-DDIE-ZPhKtCEh7YA_6_13"></a><a id="Tc_Vmd9ntJKE0uRxKhr8Hanzg_7_0"></a><a id="Tc_YRJYHyLCRUWrRClBUkAMKg_8_0"></a><a id="Tc_TAKS5eCsrEe1AbnU3JlyeQ_9_0"></a><a id="Tc_6HiuEo4w5kaR_wyAAx6X6A_10_0"></a><a id="Tc_wFqWX76G-ki2tBCiCROaoA_11_0"></a><a id="Tc__uqE2avqlEGy4lXLy_zzuA_12_0"></a><a id="Tc_rKBznh81bUy2-vTID7xqbg_12_5"></a><a id="Tc_2X9_pqZEUEumfjVrW9AVtg_13_0"></a><a id="Tc_ei4lk_hVxEaPFuP5xDoy_g_14_0"></a><a id="Tc_pc0cF_Gs2EiXdFkQZanh8Q_14_4"></a><a id="Tc_Rqsr2bsV806zKC2qUvNaZA_14_7"></a><a id="Tc_AiNYGWaYcUqC9Qt0T4_vyw_14_10"></a><a id="Tc_0grNW2pUZk6q6b2Jleoc6Q_14_13"></a><a id="Tc_KZx9iP0RUkuHPCKNAceJ4g_15_0"></a><a id="Tc_d_zX1Dn9ekirl75c0bMiDA_15_4"></a><a id="Tc_4a0gR-BnB0uTqDawd729yw_15_7"></a><a id="Tc_XVdPokUvVEm3n_48yi48NQ_15_10"></a><a id="Tc_i8rFra2y5UKfiDISEZtM4Q_15_13"></a><a id="Tc_WJHnTuRLw0WfROqJrQEHVw_16_0"></a><a id="Tc_Tw0FQbG_A0SFvBkYPDKvkA_17_0"></a><a id="Tc_RX9SX7w5iUKgKNZv7_Gt9w_18_0"></a><a id="Tc_4D27AEXzsU2HwQ0o6VGzdg_19_0"></a><a id="Tc_KLWgvp7tIEiVCt7slj_R1w_20_0"></a><a id="Tc_eNqhloUMAEyajkZpWjdGXw_21_0"></a><a id="Tc_B0wmP5NJAUegoDKI1vYaQw_21_4"></a><a id="Tc_W6m4nIQBjka8nvcjP17WBA_21_7"></a><a id="Tc_W2ip03kSB0aFvolOVt0mRw_21_10"></a><a id="Tc_gR2vDYBGB0KYDRAWyMVWBQ_21_13"></a><a id="Tc_a8psRzi7REuKsmvFKgiQLw_22_0"></a><a id="Tc_EAexR0QwykaXOSrlHwvnYQ_22_4"></a><a id="Tc_FTzx8xKp1Ee3_jNgE6O_5A_22_7"></a><a id="Tc_hhnUxaPzUUKSe8Imx1UIjQ_22_10"></a><a id="Tc_oE4yl9a89kKU8KTWjcYugA_22_13"></a><a id="Tc_9liGykrJdEWgRCcR6qPG1w_23_0"></a><a id="Tc_NKMTLS827E26zmUM9dvSwQ_24_0"></a><a id="Tc_Cc0MY_62TE2Ffah2XJhN1A_25_0"></a><a id="Tc_7Jk9rJYSLEacquRLc03vpQ_26_0"></a><a id="Tc_VnY7Ivf78EmNv0mV2LMv9g_27_0"></a><a id="Tc_HCi2D4nwSkq15x79KOJe3w_27_4"></a><a id="Tc_kURGAauCr0OUV-33FTvklg_27_7"></a><a id="Tc_nZ_oYElYr0OhzrfCgXLH9Q_27_10"></a><a id="Tc_KFEgqM2pj0KyUIXLL953lg_27_13"></a><a id="Tc_BvQORN2RYUWvQvTyWKexUg_28_0"></a><a id="Tc_gGou1a8bwkGbSOlXbPYGSw_28_4"></a><a id="Tc_4fvn5RRYqE-FiblEqbkS2A_28_7"></a><a id="Tc_CIe3-qAYYkqVbJLbl2gveA_28_10"></a><a id="Tc_0Yl6Cui3WUyJ7k_xk6ygvA_28_13"></a><a id="Tc_ClDb1KtSK0qf6ba3BO9ofQ_29_0"></a><a id="Tc_2I-AYo6JZUOQQZj3SJVWOA_30_0"></a><a id="Tc_ErLgZaxtLEOE9IESs8kcBA_31_0"></a><a id="Tc_Scecr5RHDESFv8EZY3yoBw_32_0"></a><a id="Tc_XpKPiQaVpUifoDCEe1ilBw_33_0"></a><a id="Tc_O8aEALdg0kGNlHI1lhSEWQ_33_4"></a><a id="Tc_M6f0T5_UEkGj8cOmN9XGIw_33_7"></a><a id="Tc_BMcumuaDBEy_PPsj2-_-EA_33_10"></a><a id="Tc_Z7I2wSbW0EuUdTHI6i3bMA_33_13"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Paid-In</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stock (1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at January 1, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2u7hpIDa8UWFhyZbeZAEeQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_pVxwznRJPEKMo6T8bA4g8Q_6_2">53,790,167</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2u7hpIDa8UWFhyZbeZAEeQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_qIKUMzYsA0mxXjlAfmIeCQ_6_5">54</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_hU3txrf14keCcHLR8hwO8w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_zXBvjONncUuX6hWJkLxvdQ_6_8">379,167</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_357KMU0kkEKUaBvrKS9OkQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_7rzgTjE-QkafWODWhreeNQ_6_11">389,861</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_12_31_2022_v1JvrDW3HkajOYmzxLbG4A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_f8lPDruj8Uu1wnwFdbKn5Q_6_14">10,640</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Changes during the nine-month period ended September&#160;30,&#160;2023:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock under the Sales Agreement, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jMEt6MgVmU2McANkIiOctQ" decimals="INF" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodSharesSalesAgreement" scale="0" id="Tc_gP3Z8K24QEi0StlfU4I0xA_8_2">12,560,150</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jMEt6MgVmU2McANkIiOctQ" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_mb8gaEgMgkumJ2T_Cm3J1g_8_5">13</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sULEv8JSLkKw5iYh_rNi0w" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_pSU_l2GqDUiV87tiCr4owg_8_8">23,941</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_uphekxLbC0mAuxjFn1cn5g_8_14">23,954</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Convertible notes conversions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jMEt6MgVmU2McANkIiOctQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="Tc_A02-y9pBqUamMTVlXsWeHw_9_2">4,691,623</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jMEt6MgVmU2McANkIiOctQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="Tc_jwq0YuTWx0Ki9Z3AdkBCZA_9_5">5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sULEv8JSLkKw5iYh_rNi0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="Tc_2sozLZJNmECXGPz4KtHrdA_9_8">7,778</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="Tc_C2q14ehRlEOo0_naYR8cmg_9_14">7,783</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sULEv8JSLkKw5iYh_rNi0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_iQbl8-3IekOYfTw7x_T7Gg_10_8">1,195</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_eSZ5iLU90UCKX0scHVHb1A_10_14">1,195</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to restricted stock awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jMEt6MgVmU2McANkIiOctQ" decimals="INF" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" scale="0" id="Tc_ou5xw0ZH3UOzwMqFkX8ZXw_11_2">1,371,362</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jMEt6MgVmU2McANkIiOctQ" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_n3EbmtnYO06ZZwGMV6A9dA_11_5">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sULEv8JSLkKw5iYh_rNi0w" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc__yB92M0gYEuW4H1TRVZXjw_11_8">886</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_TZIqxllf5k2W-Uwki1EIeg_11_14">887</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Exercise of warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jMEt6MgVmU2McANkIiOctQ" decimals="INF" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodSharesWarrantsExercises" scale="0" id="Tc_9_aCVK5OUUSmQnmWd-Iaag_12_2">538,822</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sULEv8JSLkKw5iYh_rNi0w" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueWarrantsExercises" scale="3" id="Tc_JUu79IYFmEm0yyZtImuguA_12_8">712</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueWarrantsExercises" scale="3" id="Tc_ZYxf8mw2B0SQ7F7AfLAT4w_12_14">712</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net income for the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_hHjoVDl78USlzlUtO3Htzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_rg1EhVY_R06v3FDec_L2wg_13_11">14,356</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_M8YiT7HQkUKaLbjkFAyGqg_13_14">14,356</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at September&#160;30,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA" contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jyJnbb5Xj02LTfUAsaSZlA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_UtQwCJekdUasg7dOkWRNag_14_2">72,952,124</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jyJnbb5Xj02LTfUAsaSZlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_Af_gUFLus0yOwbfNY3ehSA_14_5">73</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_7nASCJwWaUKNuXPn2KOuug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_SvapjiBLNUykyMy0uGP46Q_14_8">413,679</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_IAh-6HHWoUOrjiOkQywBhw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_3BODSVNJ_EukxQZYQzfSXw_14_11">375,505</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_9_30_2023_qFQhXtC8OkS0z_OP8CBUzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_rG7m2Km8x0-nxykZnOdBrA_14_14">38,247</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at January 1, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_3O2OkQ1pv0CKVkSu2N82xA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_Lh0LWu1Zxk6bjyikcZldlg_15_2">72,952,124</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_3O2OkQ1pv0CKVkSu2N82xA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_RBPA-dVnU0Cr_Z1lC7mcbA_15_5">73</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_YMjyliv9AkaFVW600tbKzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_yxXCjkG1BUKTQc1kpBbuhw_15_8">415,045</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_73hlr4ekFUSMz6sOdxmmxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_jLB3IvR-gUudefDPBy46rA_15_11">381,549</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_ettfR7XzQk6v7un9DFuHNA_15_14">33,569</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Changes during the nine-month period ended September&#160;30,&#160;2024:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Initial adoption of ASU 2020-06</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_9_30_2024_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_kuJQxZc4AESkk-yYQ3ajEg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_ZkkO4M1iU0WhFtnc69cAdA_17_8">393</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_9_30_2024_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_1blOGzJfIE-UlAziRRMUpw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_owd4aMzRKEu8tT_9bmtsqQ_17_11">224</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_9_30_2024_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_M3cptLGAykWR18u7qZj8rA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_26Ebrrl7a0q3NSeVYGr6rw_17_14">169</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_-IUAcf8ZvUOvvarlRWC6wg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_a-kLkescvU-euu9-drCWfg_18_8">1,191</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_T6T7q3TwkE2tDy-gtCQfDA_18_14">1,191</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to restricted stock awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_H1-pSjk9fUqYJ7iVy7K5tg" decimals="INF" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" scale="0" id="Tc_VWvVYHPsI0-a0UWwtx9QAA_19_2">681,459</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_H1-pSjk9fUqYJ7iVy7K5tg" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_l1PBOW9sBU-Slb8YhNF1og_19_5">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_-IUAcf8ZvUOvvarlRWC6wg" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_puL8hellS0WOEyvmdTzRbA_19_8">1,407</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_h0TJcu76AEGuyOq0Q-ZMGQ_19_14">1,408</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net loss for the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ndUCQHw1p0S3US6p-dGFDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_Mos_V_Gf4kKWMWYnMeA0Uw_20_11">3,562</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_nGFsIEH2gEGmMZh8p1ZUOA_20_14">3,562</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at September&#160;30,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA" contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_b_5zJrCjPUuLgiN0Qyd3yA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_Ho1JiaXHzkKwcRlvVUSVZw_21_2">73,633,583</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_b_5zJrCjPUuLgiN0Qyd3yA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_kPeLE32VREaQK_PQQOj6gg_21_5">74</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_AlOFNjsJxk-mD6nKmhSf7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_r0FnZtZK1kiC_4mw-nKdKA_21_8">417,250</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Cz0rkmpxTkehEUfvAgkZxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc__tTeNxa4cEmdPPYSBgwAXg_21_11">384,887</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_pzNZzNFp30u3JsVTrwVZcg_21_14">32,437</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at June&#160;30,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA" contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_sY0xRPgRwEmrWK7PpsEQ0g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_S08bm8fgO0i5HiSEl0Rfgg_22_2">71,580,762</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_sY0xRPgRwEmrWK7PpsEQ0g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_cXBwp6bOu0qGCDkSFY4x1g_22_5">72</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_mturlRZStkyYVoFlmzAAKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc__gQMfK9550uVdvllfD-E8w_22_8">412,582</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_EOHIo_NnGUyQjFf3rWGMHg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_2wWqLzpf7kymQRhH2TSb8g_22_11">373,653</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_6_30_2023_igBrNBUN8kSCsy4h33jyHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_BJ6y6XOeAkOpA4G7VA9MvQ_22_14">39,001</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Changes during the three-month period ended September&#160;30,&#160;2023:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3-IpBWJWhU6nof7a6J-CqQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_ysYu5ObRzk-wJypf2_qeDQ_24_8">383</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_7_1_2023_To_9_30_2023__jyu8G4bX02xwWm0pGi6zA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_74VnDwYThkegU4DlXsEKqw_24_14">383</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to restricted stock awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_n3sdM3d8VEGt5dkutaAe0A" decimals="INF" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" scale="0" id="Tc_aC_OasVPQ0KRxRUvZLjfIw_25_2">1,371,362</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_n3sdM3d8VEGt5dkutaAe0A" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_fiGq0qMM70yEw5SJHZ55Cw_25_5">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3-IpBWJWhU6nof7a6J-CqQ" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_IRHF428KZU6ke_uDo2MVuA_25_8">714</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_7_1_2023_To_9_30_2023__jyu8G4bX02xwWm0pGi6zA" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_lfDoXrhXP06wepA3uj4EwQ_25_14">715</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net loss for the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_xlxVJaEkm0Cl5SxIoEuaJQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc__ojOuu40eUiwQIwQHGev9A_26_11">1,852</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_7_1_2023_To_9_30_2023__jyu8G4bX02xwWm0pGi6zA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_ZyqwOHfWNESKSzLQD3F-6A_26_14">1,852</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at September&#160;30,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA" contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jyJnbb5Xj02LTfUAsaSZlA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_UyvHhvotHUadHVP182UZOQ_27_2">72,952,124</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jyJnbb5Xj02LTfUAsaSZlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_c5-rEDh23Uu_P9mo32v4UQ_27_5">73</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_7nASCJwWaUKNuXPn2KOuug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_HfIiICoeYkK-A_B0ceDMYA_27_8">413,679</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_IAh-6HHWoUOrjiOkQywBhw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_9Gh1VzBayEOj7iLAf13ELQ_27_11">375,505</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_9_30_2023_qFQhXtC8OkS0z_OP8CBUzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_zgjvu7LTL0irlNM4DWa_kw_27_14">38,247</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at June&#160;30,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA" contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_UZznz_h0nU6MCrNFCI65kA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_LmE8scvYJEOagyeAR2Z9NA_28_2">73,292,674</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_UZznz_h0nU6MCrNFCI65kA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_E-5DRkN9lUmzT1ENVwCW7Q_28_5">73</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_e96ler1a0U-r6gjxosRRSw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_sHQSSfANJUqTYc2oSKAvaQ_28_8">416,631</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_xF7FRPyjM0KtHl4ouLxL6A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_PtcJQ-M8w0myKu9ewLiMkg_28_11">388,123</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_6_30_2024_c7VyEDTT0Ei2Nt_xe1-AZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_-OhaBczME06g5ribHFTiKg_28_14">28,581</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Changes during the three-month period ended September&#160;30,&#160;2024:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3sUNQWsOgkuiFe-1dqA4tg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_0C1r3llR-kyAHMK2RaybAg_30_8">358</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_7_1_2024_To_9_30_2024_5srFek9aZ0STe4olK5gckA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_2TLpOlQsPU6y5Qij-xeAdg_30_14">358</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to restricted stock awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA" contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ojV2ETGPxU-tgxipZ4iH_A" decimals="INF" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" scale="0" id="Tc_e_OsxemFjU2UD0V-bpKAXw_31_2">340,909</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ojV2ETGPxU-tgxipZ4iH_A" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_rKN6zfKTREmU024KVveFZA_31_5">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3sUNQWsOgkuiFe-1dqA4tg" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_4yaz7D1jqUGFwCZSAtpGsQ_31_8">261</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_7_1_2024_To_9_30_2024_5srFek9aZ0STe4olK5gckA" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_isIBTlcC3EevCePGj8Uofg_31_14">262</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net income for the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_SrS-_DJJqkCTLZ9dXxqUAw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_3tRr0-tt5kK_IzT76IBEWQ_32_11">3,236</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_7_1_2024_To_9_30_2024_5srFek9aZ0STe4olK5gckA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_tLXwdRuN8k-6yn2wuXScAw_32_14">3,236</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at September&#160;30,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA" contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_b_5zJrCjPUuLgiN0Qyd3yA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_fgMVVUijQkKbf4CfNl5g6Q_33_2">73,633,583</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_b_5zJrCjPUuLgiN0Qyd3yA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_ou9U20TWNkydlFdg4xkdvQ_33_5">74</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_AlOFNjsJxk-mD6nKmhSf7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_C9zk7myqykaAizqr94Ul1A_33_8">417,250</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Cz0rkmpxTkehEUfvAgkZxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_kDCMOWkaJUWJ8fUzpczGIw_33_11">384,887</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_veTwFSQxrkW-h3mLk4IcoQ_33_14">32,437</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="background:#ffffff;">*Represents an amount equal to less than $1.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_a2e03645_2643_4168_926d_13e04faf108a"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(1)&#160;<ix:footnote xml:lang="en-US" id="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7">Common stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_A4-BaHg86EmBShQ9tsexWA" contextRef="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_1wNyvYqvL0aGRZEI_8OCtw"><ix:nonFraction unitRef="Unit_Divide_USD_shares_A4-BaHg86EmBShQ9tsexWA" contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_ygoxfnuvhUqSnLAtWPaQSw">0.001</ix:nonFraction></ix:nonFraction> par value; Authorized &#8211; as of September&#160;30, 2024 and December&#160;31, 2023 &#8211; <ix:nonFraction unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA" contextRef="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_gMMq1MOHVUO3JRRobwiIew"><ix:nonFraction unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA" contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_5CRZFZknkUuY4eW3C1WKrw">185,000,000</ix:nonFraction></ix:nonFraction> shares.</ix:footnote></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_cc783e76_2f1a_47cb_969a_65abb1094562"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><a id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLO"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(U.S. dollars in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_036b0258_18a7_4ba6_9dee_ce3a7dd27b55"></a><a id="Tc_TgIXWXyd00mCLyf2wLFAnw_1_2"></a><a id="Tc_C36viUoVu0q7ovCC4mJPyA_2_2"></a><a id="Tc_TB2B2DownEesvn1eqgkvQA_2_5"></a><a id="Tc_mS0LCetSn0uLMSwFtP8WIg_3_0"></a><a id="Tc_3U26jsKgCkumT_w3huqOYg_4_0"></a><a id="Tc_x1NbW1V5REmkugrYyP6FyQ_4_2"></a><a id="Tc_l1plg1FUsUCJBNflyz3a8A_4_5"></a><a id="Tc_hyx-1Iqwl06f-G0tAWp78g_5_0"></a><a id="Tc_LcNf0wPM30C4oR5xbG8oVQ_6_0"></a><a id="Tc_RwjYCjLn7kajJq1fUIGYrg_7_0"></a><a id="Tc_Sg0LJA8zn0eejqNC0Y2How_8_0"></a><a id="Tc_LqcDcILc2ESU0dfG78ddVw_9_0"></a><a id="Tc_1kKGBWcXKkaCQZ_Ao2D1Rw_10_0"></a><a id="Tc_IkWms0pNJ0SSbHzHQfCB4Q_11_0"></a><a id="Tc_0ofelz5SrEOTjWA_oeiM1Q_12_0"></a><a id="Tc_QCSpQyuf3EStFrkULtIVbA_12_6"></a><a id="Tc_VwCIILTOyUS0A-rSS0mDdA_13_0"></a><a id="Tc_BcWtNuL7qUafNbPCvRW_9w_13_3"></a><a id="Tc_nOQlqbBK1UeZ1ySHkvwcYw_14_0"></a><a id="Tc_wUFDJCZxvECBeL-HuYLAxQ_14_3"></a><a id="Tc_dgcD4keUN0uNl2cOa9oK-A_15_0"></a><a id="Tc_NBQIXn0uyEmz9IAy6xd0Sw_16_0"></a><a id="Tc_9SCviSUGOUKc5usQq6nlfQ_16_3"></a><a id="Tc_X2SDQW7UvEaFjljN7hTIzw_17_0"></a><a id="Tc_FwueO-WBfUOBdCtF-c8gGQ_18_0"></a><a id="Tc_b97sOens-0q1VUjIEqoDxA_19_0"></a><a id="Tc_qtipuI-mBU-zKuFs0FBwuA_20_0"></a><a id="Tc_puTppegu40qqTJcCG9erow_21_0"></a><a id="Tc_4kleAGm-UE-B34CgGygxYw_21_2"></a><a id="Tc_j-qnNXwEOEm2jD2qVVA_SQ_21_5"></a><a id="Tc_MIoMMpDwxUiAiGfk-lhX4A_23_0"></a><a id="Tc_TIS0yrNjAk6Fev02cTxf6Q_24_0"></a><a id="Tc_b1AK4HvtvEuUDtoSxJumLw_24_5"></a><a id="Tc_ML5_Kfugh0iriedX3YTedA_25_0"></a><a id="Tc_dQMhpBVhBE2I96fWpUycyA_25_2"></a><a id="Tc_Nk69Qsx3oEWkAtDGHeU6IQ_26_0"></a><a id="Tc_aRUxlhivUkO-AtvgCchHkA_27_0"></a><a id="Tc_Y0W0Zg6PFUe9rT6xLuM8wg_27_6"></a><a id="Tc_Jbd1WBeP4kmQXlF7Gmda8A_28_0"></a><a id="Tc_OLxuKNvJrU6mBQcwWWuFeg_29_0"></a><a id="Tc_jNcdlZNo30OpfNKiv8EK2Q_29_2"></a><a id="Tc_WuU0NpjmvkSa7Kiwf_J1fQ_29_5"></a><a id="Tc_AILFuQvbqUuXn1sr6j9KRw_31_0"></a><a id="Tc_f_uhRdN26EeJjjK7eg2oIQ_32_0"></a><a id="Tc_a-LqEhFnb0i3wJJ_42oC8w_32_2"></a><a id="Tc_4vIDT_iLckyT6sgmLCHG8g_33_0"></a><a id="Tc_Kh5-Ydb9DUmPM_E3VwJXgQ_33_3"></a><a id="Tc_GP0HkGb9wEe53VV3OuYygQ_33_5"></a><a id="Tc_ToVv6z3YnkeQcXcYLPVqJA_34_0"></a><a id="Tc_jIiUBMKTc02rtx7C_BG9LQ_34_3"></a><a id="Tc_cJRAvNZbv0-2_xkfln590g_35_0"></a><a id="Tc_F7QyeB71W06LLmvCdTXG9A_35_2"></a><a id="Tc_rPepMZg0Lkuziywc5KElpw_35_5"></a><a id="Tc_sR3trTZLFE2xKLK6rzyrVg_36_0"></a><a id="Tc_U_KdN03tF0CLWoWOONkt0g_36_2"></a><a id="Tc_r8lHHzJ1y0maamNyPrrIvA_36_5"></a><a id="Tc_LXS4YITdS0KmR12MSUFwPg_37_0"></a><a id="Tc_uS9_CSaDFkq1VuoMs0KPGg_38_0"></a><a id="Tc_x06vvRfhIUe7FNxMv-e9dg_39_0"></a><a id="Tc_aZS6wTLg2USNoOwMdculjQ_39_2"></a><a id="Tc_TlyKyUDPHEiDFzf6Sy8jiA_39_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CASH FLOWS FROM OPERATING ACTIVITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net Income (loss)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_r0kYSenwBEuYG-R-lm5qNQ_4_3">3,562</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="Tc_7CZSYne8YESx8oEXXJxEGw_4_6">14,356</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Adjustments required to reconcile net income (loss) to net cash provided by operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_7IvMAo3Xj0CZ3d_18jh__g_6_3">2,599</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_ccZsTwKN0UCVClXoIbAu6g_6_6">2,081</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Tc_-wvhMXPQukuH-_QkQApB_w_7_3">970</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Tc_jT2BrHkqKEC-tXCNXBsucw_7_6">878</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Financial expenses (income), net </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" sign="-" scale="3" id="Tc_3PKTWX5ZnUqCTkXRq4qndw_8_3">173</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="3" id="Tc_wf5v1Y2Tg02hdgY51o0Liw_8_6">511</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Changes in accrued liability for employee rights upon retirement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementBenefitExpense" scale="3" id="Tc_6gbjyajnnEqmslWNHYmGJw_9_3">32</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementBenefitExpense" sign="-" scale="3" id="Tc_xQwYR4F260Gneat-OBvsTg_9_6">50</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Changes in deferred income tax asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="Tc_wp3ZoHassUqMRTZ_jlEj7Q_10_3">236</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_-J8OQ4NSlUiDKmSp2IE0MA_10_6">3,092</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Gain on amounts funded in respect of employee rights upon retirement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" decimals="-3" format="ixt:numdotdecimal" name="plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" scale="3" id="Tc_mchNWKMvMUikqCM-DYHurw_11_3">20</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g" decimals="-3" format="ixt:numdotdecimal" name="plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" scale="3" id="Tc_GUQoiAtOEEOK1XHOoMbcMQ_11_6">49</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Gain on sale of fixed assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="Tc_22OLz8nZLEiix06OC8PROA_12_3">3</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Gain on conversions of convertible notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g" decimals="-3" format="ixt:numdotdecimal" name="plx:GainLossOnDebtConversion" scale="3" id="Tc_GpGs8WdW1Uu-2k0L3bKU_A_13_6">421</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Amortization of debt issuance costs and debt discount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="Tc_-mF9V-spkkGCY87YiWKh1g_14_6">208</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Changes in operating assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Decrease in contracts liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" sign="-" scale="3" id="Tc_SCGb-Ibq10OkrJ_8C7FDlw_16_6">13,178</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Decrease (increase) in accounts receivable-trade and other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" sign="-" scale="3" id="Tc_lBFQnQsPLkKeNN5elBsorw_17_3">3,069</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="Tc_XwqK2sHiYkGsBJSr2pfZDQ_17_6">4,188</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Changes in operating lease right of use assets, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" decimals="-3" format="ixt:numdotdecimal" name="plx:ChangeInOperatingLeaseRightOfUseAssets" sign="-" scale="3" id="Tc_HUwLcawlREabpp_P9HyV_Q_18_3">13</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g" decimals="-3" format="ixt:numdotdecimal" name="plx:ChangeInOperatingLeaseRightOfUseAssets" sign="-" scale="3" id="Tc_aBkuDJk9mU6PFpmXIwjzyg_18_6">12</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Decrease (increase) in inventories</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" sign="-" scale="3" id="Tc_ftHO0D07Ik-ojl7UO-R9Lw_19_3">1,846</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="Tc_Pk1cH_ixF0-RnnSNRE5hrg_19_6">4,779</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Increase (decrease) in accounts payable and accruals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" sign="-" scale="3" id="Tc__R61YuQAoEyDukzxwpC0lQ_20_3">670</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="Tc_2a2AZDd9IkeNvl3LM44gqg_20_6">3,820</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net cash provided by (used in) operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="Tc_2erb4O7pc0S21YowM8n3Bw_21_3">4,683</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_pA3IBab2BUyUPWkmtYJEqA_21_6">4,913</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CASH FLOWS FROM INVESTING ACTIVITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Investment in bank deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g" decimals="-3" format="ixt:numdotdecimal" name="plx:IncreaseDecreaseInBankDeposits" scale="3" id="Tc_-s2VQqvO_kSHp2dmevm_RA_24_6">20,420</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Short-term deposit withdrawal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" decimals="-3" format="ixt:numdotdecimal" name="plx:ProceedsFromWithdrawalOfShortTermDeposits" scale="3" id="Tc_RCAXJxJMTkixium-3WolVA_25_3">20,420</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g" decimals="-3" format="ixt:numdotdecimal" name="plx:ProceedsFromWithdrawalOfShortTermDeposits" scale="3" id="Tc_bUXMTL0XMkSn0WuF0FDYrA_25_6">5,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Purchase of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_OXF8pxHKx06ntmlZOpCbMw_26_3">857</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_UswGTp0NP0eDZu4X-C4TrQ_26_6">899</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Proceeds from sale of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="Tc_Vo_7o86fMkeFSbG6hamPTg_27_3">3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Amounts funded in respect of employee rights upon retirement, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="3" id="Tc_17JhM5Kew0ugzUX05mfKgg_28_3">25</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="3" id="Tc_Cu312memVkyGUn9lFxSTFg_28_6">50</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net cash provided by (used in) investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="Tc_peiBoWB2EkqjYMntFk2hUA_29_3">19,541</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_gVYAQmRD6USYwscjsY00XA_29_6">16,369</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CASH FLOWS FROM FINANCING ACTIVITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Payment for convertible notes redemption</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfConvertibleDebt" scale="3" id="Tc_lkyePe2DzUK3-z7SyfS9UA_32_3">20,420</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Proceeds from issuance of common stock under the Sales Agreement, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_CkuYHLZSHEiyUzqAL4asCQ_33_6">23,954</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Exercise of warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="Tc_0qSAFvHOikOqisvpyz072Q_34_6">712</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net cash provided by (used in) financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" sign="-" scale="3" id="Tc_M1aALg82XkCk9EnwMigXmQ_35_3">20,420</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_C_qECooC0Ei9u5PS1AEXvw_35_6">24,666</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" sign="-" scale="3" id="Tc_tHrKn_nwh0i2NZbkCr0H6A_36_3">29</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" sign="-" scale="3" id="Tc_bZZ61RPW6EeRroGOHBgrQg_36_6">87</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">NET INCREASE IN CASH AND CASH EQUIVALENTS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="Tc_dmSYFJ5fsE2mFxhKuQBT5A_37_3">3,775</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="Tc_uLlFtV4V1EO31WEU6vsCMw_37_6">3,297</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_SsZTmKGA0Ee81F7tJRDeGw_38_3">23,634</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_12_31_2022_v1JvrDW3HkajOYmzxLbG4A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_6kKGBwlSjEitz0Ha79ukwA_38_6">17,111</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_RxR_QudTFUmcR2wyQYM9og_39_3">27,409</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_9_30_2023_qFQhXtC8OkS0z_OP8CBUzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_vwPcKPoiJ062NyPWqKrtEg_39_6">20,408</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(U.S. dollars in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Continued)&#160;&#8211; 2</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_46a503f9_bdde_4384_ae1e_7932ccc325a6"></a><a id="Tc_2Py46wm7kkGkb0ef9JEDJA_1_2"></a><a id="Tc_56HFjh0_XEOSBtNd3XZaFg_2_2"></a><a id="Tc_dM3GOZM3WkOu6aBVIg-lSQ_2_5"></a><a id="Tc_3zxJZKSpI0mXs7LLM2iIRQ_3_0"></a><a id="Tc__FbjBVA1d0SJAtWRd2lW0g_4_0"></a><a id="Tc_PmzaJKR8gEu0J118_Fb5aw_4_2"></a><a id="Tc_ZXUdEDBjxkWey0L-KtC9mg_4_5"></a><a id="Tc_HMiMLExUaUO0khXIKNEBAg_5_0"></a><a id="Tc_veFVZ8oKek-FXTuDOYvWzw_5_2"></a><a id="Tc__dita8M-xEKwNXLzpHXqPA_5_5"></a><a id="Tc_IZUgWK3b6EOtQQx1SWtyCg_6_0"></a><a id="Tc_REGA4GsY-USMJ86b4hC4Bg_6_2"></a><a id="Tc_-WnQEY6e2UeCLikyi8_lLg_6_3"></a><a id="Tc_z07bScp8lECW2DlW7zxdIw_6_5"></a><a id="Tc_wflrQQDX70uLGmNXpHOd2g_8_0"></a><a id="Tc_cwYlyC_5O0m2kMSeoP4tOQ_9_0"></a><a id="Tc_MZJUs9OFqEuSWdQ2qNynnA_9_2"></a><a id="Tc_JbKICXLKpEWKgnQ3bqBCuQ_9_5"></a><a id="Tc_OqgO6yi0V0qtHRt6GgcS5A_10_0"></a><a id="Tc_qoJqNMjMpEyQ3FPc9-B9pA_10_2"></a><a id="Tc_UkRgNTvdl0eKPPq4Ghj9lg_10_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Purchase of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="Tc_RZR7HsFOb0y9a-9s8-clxQ_4_3">402</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="Tc_P2x9BJiP2EWEN0RATkc1Lg_4_6">253</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease right of use assets obtained in exchange for new operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_4dLG6yNTzkOzZqahBDdzxQ_5_3">376</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_NwjdexfMlU-JmkwR92QMqQ_5_6">1,395</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Convertible notes conversions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="3" id="Tc_2a4UJ9-EWEynEtnAYhGpkA_6_6">7,783</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">SUPPLEMENTARY DISCLOSURE ON CASH FLOWS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Interest paid</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_8Idvm_GVdkKZ-oGg0-fQLw_9_3">1,532</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_nmt1uYSX_EW50gAR6w8q0Q_9_6">2,743</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Interest received</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" decimals="-3" format="ixt:numdotdecimal" name="plx:InterestReceivedNet" scale="3" id="Tc_Vf4nsDLW3kOXDn4UJBrOTQ_10_3">1,481</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g" decimals="-3" format="ixt:numdotdecimal" name="plx:InterestReceivedNet" scale="3" id="Tc_AXfB0Is3eUyA3c4nLyfuKA_10_6">303</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="NOTE1SIGNIFICANTACCOUNTINGPOLICIES_79340"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="Tb_i0MCB9qVkEmyTZvNqiIC0w" continuedAt="Tb_i0MCB9qVkEmyTZvNqiIC0w_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;1&#160;- SIGNIFICANT ACCOUNTING POLICIES</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" name="plx:NatureOfOperationsPolicyTextBlock" id="Tb_aDze9TXe4EK0XQAR-9HDhQ" continuedAt="Tb_aDze9TXe4EK0XQAR-9HDhQ_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">a.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">General</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#8220;Company&#8221;) and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (collectively, the &#8220;Subsidiaries&#8221;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#8217;s proprietary ProCellEx<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> protein expression system (&#8220;ProCellEx&#8221;). To date, the Company has successfully developed two enzyme replacement therapies (ERTs); Elfabrio<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (pegunigalsidase alfa) for the treatment of adult patients with a confirmed diagnosis of Fabry disease and Elelyso<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (taliglucerase alfa) for the treatment of adult patients with Gaucher disease. Elfabrio, which the Company referred to as PRX-102 during its development stage, has been approved for marketing in the United States, the European Union, Great Britain, Switzerland, Peru and Israel. The Company has partnered with Chiesi Farmaceutici S.p.A. (&#8220;Chiesi&#8221;) for the development and commercialization of Elfabrio.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company has licensed the rights to commercialize Elelyso worldwide (other than Brazil) to Pfizer Inc. (&#8220;Pfizer&#8221;), and in Brazil to Funda&#231;&#227;o Oswaldo Cruz (&#8220;Fiocruz&#8221;), an arm of the Brazilian Ministry of Health (the &#8220;Brazilian MoH&#8221;). Elelyso is marketed as BioManguinhos alfataliglicerase in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company is committed to leveraging its track record of success as the Company progresses with the development of treatments for rare and orphan diseases. In addition, the Company continuously works on the further development of its ProCellEx technology and bioreactor system. Accordingly, the Company is turning its focus to new, early-stage product candidates that treat indications for which there are high unmet needs in terms of efficacy and safety, including renal diseases. Treatments of interest will address both genetic and non-genetic diseases. The Company intends to use its ProCellEx platform and PEGylization capabilities, as well as other modalities such as small molecules and antibodies, to take advantage of highly innovative opportunities. The Company is also exploring novel platform technologies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On May&#160;5, 2023, the European Commission (&#8220;EC&#8221;) announced that it had approved the Marketing Authorization Application (&#8220;MAA&#8221;) for Elfabrio and on May&#160;9, 2023, the U.S. Food and Drug Administration (&#8220;FDA&#8221;) announced that it had approved the Biologics License Application (&#8220;BLA&#8221;) for Elfabrio, each for adult patients with a confirmed diagnosis of Fabry disease. Both approvals cover the 1&#160;mg/kg every two weeks dosage. The European Medicines Agency (&#8220;EMA&#8221;) approval followed the February 2023 adoption of a positive opinion and recommendation of marketing authorization for Elfabrio by the EMA&#8217;s Committee for Medicinal Products for Human Use the (&#8220;CHMP&#8221;). Elfabrio was approved by the FDA with a boxed warning for hypersensitivity reactions/anaphylaxis, consistent with Enzyme Replacement Therapy (ERT) class labeling, and warnings/precautions providing guidance on the signs and symptoms of hypersensitivity and infusion-associated reactions seen in the clinical studies as well as treatments to manage such events should they occur. The warnings/precautions for membranoproliferative glomerulonephritis (MPGN) alert prescribers to the possibility of MPGN and provide guidance for appropriate patient management. Overall, the FDA review team concluded that in the context of Fabry disease as a rare, serious disease with limited therapeutic options that may not be suitable to all individual patients, the benefit-risk of Elfabrio is favorable for the treatment of adults with confirmed Fabry disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">The Company has entered into <ix:nonFraction unitRef="Unit_Standard_agreement_ukZC-6VifkuWtCWLoRpkbA" contextRef="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g" decimals="INF" format="ixt-sec:numwordsen" name="plx:NumberOfGlobalLicensingAndSupplyAgreements" scale="0" id="Narr_kOVvU26-wEWQNQiZHxbKgw">two</ix:nonFraction> exclusive global licensing and supply agreements for Elfabrio with Chiesi. On October&#160;19, 2017, Protalix Ltd., the Company&#8217;s wholly-owned subsidiary, entered into an Exclusive License and Supply Agreement with Chiesi (the &#8220;Chiesi Ex-US Agreement&#8221;) pursuant to which Chiesi was granted an exclusive license for all markets outside of the United States to commercialize Elfabrio. On July&#160;23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#8220;Chiesi US Agreement&#8221;), with respect to the commercialization of Elfabrio in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">Elfabrio was the subject of a phase&#160;III clinical program studying the drug as a treatment of patients with Fabry disease, a rare, genetic lysosomal disorder. The phase&#160;III clinical program included three separate studies, which are referred to as the <i style="font-style:italic;">BALANCE</i> study, the <i style="font-style:italic;">BRIDGE</i> study and the <i style="font-style:italic;">BRIGHT</i> study. The phase&#160;III clinical program analyzed two potential dosing regimens: 1&#160;mg/kg every two weeks and 2&#160;mg/kg every four weeks. In addition, the phase&#160;III clinical program included two extension studies in which subjects that participated in the Company&#8217;s phase&#160;I/II clinical trials and phase&#160;III clinical trials had the opportunity to enroll and continue to be treated with PRX-102. As of March&#160;1, 2023, sponsorship </p></ix:nonNumeric></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_i0MCB9qVkEmyTZvNqiIC0w_cont1" continuedAt="Tb_i0MCB9qVkEmyTZvNqiIC0w_cont2"><ix:continuation id="Tb_aDze9TXe4EK0XQAR-9HDhQ_cont1" continuedAt="Tb_aDze9TXe4EK0XQAR-9HDhQ_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">of the two open label extension studies was transferred to Chiesi, which is now administering the extension studies. From time to time, and as Elfabrio is approved for marketing in different jurisdictions, participants switch out of the open label extension studies. Most of the participants transfer to a commercial setting and others withdraw for other reasons.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">The BLA for Elfabrio for the treatment of adult patients with Fabry disease was resubmitted to the FDA on November&#160;9, 2022. An initial BLA for Elfabrio was submitted to the FDA on May&#160;27, 2020 under the FDA&#8217;s Accelerated Approval pathway, but resulted in a Complete Response Letter (&#8220;CRL&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">The MAA was submitted to the EMA on February&#160;7, 2022, after the October&#160;8, 2021 meeting the Company held, together with Chiesi, with the Rapporteur and Co-Rapporteur of the EMA regarding PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">The FDA publicly released the internal review documents for Elfabrio (pegunigalsidase alfa-iwxj) injection BLA 761161. These documents provide previously unavailable additional information regarding the basis for the FDA&#8217;s May 2023 approval decision. In particular, the FDA determined that substantial evidence of effectiveness for Elfabrio in Fabry patients was established with one adequate and well-controlled study (Study PB-102-F01/02) with confirmatory evidence provided by the <i style="font-style:italic;">BALANCE</i> study (also referred to as Study PB-102-F20). The FDA review team also concluded that the <i style="font-style:italic;">BALANCE</i> study met its primary efficacy endpoint, which assessed the annualized rate of change in eGFR (estimated glomerular filtration rate) over 104 weeks. However, the FDA also determined that the results from the <i style="font-style:italic;">BALANCE</i> study did not support a non-inferiority claim to the comparator product due to the lack of data to support a non-inferiority margin.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company continuously evaluates potential strategic marketing partnerships as well as collaboration programs with biotechnology and pharmaceutical companies and academic research institutions. Except with respect to Elfabrio and Elelyso, the Company holds the worldwide commercialization rights to its other proprietary development drug candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">The Company&#8217;s product pipeline currently includes, among other candidates:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:11pt;margin-left:54pt;margin-top:0pt;text-indent:0pt;"><span style="display:inline-block;min-width:18pt;white-space:nowrap;">(1)</span>PRX-115, the Company&#8217;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#8211; a chemically modified enzyme to treat uncontrolled gout; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-top:0pt;text-indent:0pt;"><span style="display:inline-block;min-width:18pt;white-space:nowrap;">(2)</span>PRX-119, the Company&#8217;s plant cell-expressed PEGylated recombinant human DNase&#160;I product candidate being designed to elongate half-life in the circulation for NETs-related diseases.</div><div style="margin-top:11pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#8217;s ability to implement the necessary regulatory steps required to obtain such approvals, and demonstrate the safety and efficacy of its product candidates. The Company cannot reasonably predict the outcome of these activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In March 2024, the Company initiated a phase&#160;I First-in-Human clinical trial of PRX-115. This study included 64 adult male and female subjects in a dose escalation design with eight sequential dosing cohorts, each composed of eight subjects (six active and two placebo). As of September&#160;30, 2024, the data is locked and is currently being analyzed. The Company plans to announce the results at an upcoming scientific meeting. In addition, the Company has commenced preparations for a phase&#160;II clinical trial of PRX-115 which the Company expects will commence in the second half of 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On July&#160;2, 2021, the Company entered into an At The Market Offering Agreement (the &#8220;2021 Sales Agreement&#8221;) with H.C.&#160;Wainwright &amp; Co., LLC, as the Company&#8217;s sales agent (the &#8220;Agent&#8221;) which was amended on May&#160;2, 2022. Pursuant to the terms of the 2021 Sales Agreement, the Company was able to sell, from time to time through the Agent, shares of its common stock, par value $<ix:nonFraction unitRef="Unit_Divide_USD_shares_A4-BaHg86EmBShQ9tsexWA" contextRef="As_Of_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_YET2ryP2dEill85k2_nFHg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_ZasDT-AZF0aPBSjX9exAFw">0.001</ix:nonFraction> per share (the &#8220;Common Stock&#8221;), having an aggregate offering price of up to $<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_YET2ryP2dEill85k2_nFHg" decimals="-5" format="ixt:numdotdecimal" name="plx:SaleOfStockMaximumOfferingPrice" scale="6" id="Narr_MMAjGF6MZEy9bSFslsxsfg">20.0</ix:nonFraction>&#160;million (the &#8220;ATM Shares&#8221;).</p></ix:continuation></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_i0MCB9qVkEmyTZvNqiIC0w_cont2" continuedAt="Tb_i0MCB9qVkEmyTZvNqiIC0w_cont3"><ix:continuation id="Tb_aDze9TXe4EK0XQAR-9HDhQ_cont2" continuedAt="Tb_aDze9TXe4EK0XQAR-9HDhQ_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">During the term of the 2021 Sales Agreement which ended during the quarter ended March&#160;31, 2023, the Company sold a total of <ix:nonFraction unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_u2CliSsMKUa6PUPveJHdTg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_aQTeLIg0LUGH8VsmwvcIiw">13,980,060</ix:nonFraction> ATM Shares for total gross proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_u2CliSsMKUa6PUPveJHdTg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_wpvCtzIgI0moVACzAyhTAw">20.0</ix:nonFraction>&#160;million thereby completing the ATM program under said agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On February&#160;27, 2023, the Company entered into an At The Market Offering Agreement (the &#8220;2023 Sales Agreement&#8221;) with the Agent. Pursuant to the terms of the 2023 Sales Agreement, the Company may sell, from time to time through the Agent, ATM Shares having an aggregate offering price of up to $<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_2_27_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_glBx8-GKQUagOk_5tVbhmg" decimals="-5" format="ixt:numdotdecimal" name="plx:SaleOfStockMaximumOfferingPrice" scale="6" id="Narr_9SALtpsUNUSl_qJ75QIz9Q">20.0</ix:nonFraction>&#160;million. As of September&#160;30, 2024, shares of Common Stock for total gross proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_9_30_2024_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_lsKt_FH16UaE7aDEdbwFUg" decimals="-5" format="ixt:numdotdecimal" name="plx:SaleOfStockMaximumOfferingPrice" scale="6" id="Narr_Sgo6YwFhN0-xfWkRb5JB_g">6.4</ix:nonFraction>&#160;million remain available to be sold under the 2023 Sales Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively, the &#8220;Chiesi Agreements&#8221;), Chiesi made an upfront payment to Protalix&#160;Ltd. of $<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_lxgklNBaXU2pjfcaFonqKA" decimals="-5" format="ixt:numdotdecimal" name="plx:UpfrontNonrefundableNoncreditablePaymentReceivable" scale="6" id="Narr_vh35iPa5SE6mQDq5cG0ulA"><ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_tZ6IRwK5mk6fHAJ4kYRAJA" decimals="-5" format="ixt:numdotdecimal" name="plx:UpfrontNonrefundableNoncreditablePaymentReceivable" scale="6" id="Narr_asMXL0RT60ehWrr4cL61fg">25.0</ix:nonFraction></ix:nonFraction>&#160;million in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&#160;Ltd. is entitled to additional payments of up to $<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_vK2rvFHWSU-qe_rFcemZww" decimals="-5" format="ixt:numdotdecimal" name="plx:AdditionalAmountsPayableToCoverDevelopmentCosts" scale="6" id="Narr_LGRxsw_Ni0Gzm4SLhQEZrA">25.0</ix:nonFraction>&#160;million in pegunigalsidase alfa development costs and to receive additional payments of up to $<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_vK2rvFHWSU-qe_rFcemZww" decimals="-5" format="ixt:numdotdecimal" name="plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" scale="6" id="Narr_hLFiaI0NvESNQj7pH5c6lw">320.0</ix:nonFraction>&#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&#160;Ltd. is entitled to payments of up to a maximum of $<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_eO8PT46mE0CgmO5dj_kuPw" decimals="-5" format="ixt:numdotdecimal" name="plx:AdditionalAmountsPayableToCoverDevelopmentCosts" scale="6" id="Narr_aJp-uj9i90GgLi4vyaQQZg">20.0</ix:nonFraction>&#160;million to cover development costs for pegunigalsidase alfa and to receive additional payments of up to a maximum of $<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_eO8PT46mE0CgmO5dj_kuPw" decimals="-5" format="ixt:numdotdecimal" name="plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" scale="6" id="Narr_FJQe7_oQQEm9hErY_e8BcA">760.0</ix:nonFraction>&#160;million, in the aggregate, in regulatory and commercial milestone payments. To date, Protalix Ltd. has received the complete amount of development costs to which it is entitled under the Chiesi Agreements. In addition, following the approval of Elfabrio by the FDA, the Company received a milestone payment equal to $<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_yf1yBqYb3ki32oo6H-lkuQ" decimals="-5" format="ixt:numdotdecimal" name="plx:MilestonePaymentReceived" scale="6" id="Narr_Dyk2PBKaQ0OduNS0hPMsSg">20.0</ix:nonFraction>&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">On May&#160;13, 2021, the Company signed a binding term sheet with Chiesi pursuant to which the Company and Chiesi amended the Chiesi Agreements in order to provide the Company with near-term capital. Chiesi agreed to make a $<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_f8J7ygmkjUK2ukgA-2oQ1w" decimals="-5" format="ixt:numdotdecimal" name="plx:AgreementAmendmentPaymentReceivable" scale="6" id="Narr_a0zBQLVtVkuCFQ1JCvomNA">10.0</ix:nonFraction>&#160;million payment to the Company before the end of the second quarter of 2021 in exchange for a $<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_5_13_2021_To_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_MxJMMq-010ClsaMCqYEAAA" decimals="-5" format="ixt:numdotdecimal" name="plx:ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" scale="6" id="Narr_I3HB4jujpUS9Y36CwsLiow">25.0</ix:nonFraction>&#160;million reduction in a longer term regulatory milestone payment provided in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. The Company received the payment in June&#160;2021. The Company also agreed to negotiate certain manufacturing related matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Under the terms of both of the Chiesi Agreements, Protalix Ltd. is required to manufacture all of the Elfabrio drug substance needed under the agreements, subject to certain exceptions, and Chiesi will purchase Elfabrio drug product from Protalix, subject to certain terms and conditions. The consideration for Protalix Ltd. is based on the drug product supplied to Chiesi and the average selling price of the drug product in the relevant territory multiplied by tiered payments as described in the relevant agreement. Under the Chiesi Ex-US Agreement, the price payable to the Company for drug product supplied is based on a range of <ix:nonFraction unitRef="Unit_Standard_pure_KYNrm9UG9EeMn48Y0if07Q" contextRef="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_mw7kn8o2CUWR-j1nLxbVfQ" decimals="INF" format="ixt:numdotdecimal" name="plx:PaymentOnNetSalesPercentage" scale="-2" id="Narr_nz7r3h842kqbMr7sKD_laA">15</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_KYNrm9UG9EeMn48Y0if07Q" contextRef="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_znGsm8ayME60HPVCk9kYOA" decimals="INF" format="ixt:numdotdecimal" name="plx:PaymentOnNetSalesPercentage" scale="-2" id="Narr_wvpZBpKCd02FzEzV8so9qw">35</ix:nonFraction>% of the average selling price of the drug product in the applicable territory, and under the Chiesi US Agreement, such price is based on a range of <ix:nonFraction unitRef="Unit_Standard_pure_KYNrm9UG9EeMn48Y0if07Q" contextRef="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_8CtKgL9lj0K2stR5YPRj0Q" decimals="INF" format="ixt:numdotdecimal" name="plx:PaymentOnNetSalesPercentage" scale="-2" id="Narr_OsLhKTKzGk-0k3FYQppqaw">15</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_KYNrm9UG9EeMn48Y0if07Q" contextRef="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_nRvfA8aPdUu85RbZO37WRQ" decimals="INF" format="ixt:numdotdecimal" name="plx:PaymentOnNetSalesPercentage" scale="-2" id="Narr_WOyYn23SfUydoxlzToDoyA">40</ix:nonFraction>% of the average selling price of the drug product in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">On August&#160;29, 2022, the Company entered into a Fill/Finish Agreement (the &#8220;F/F Agreement&#8221;) and a Letter Agreement (the &#8220;Letter Agreement&#8221;), in each case with Chiesi. The Company agreed to supply Chiesi with drug substance for pegunigalsidase alfa in connection with the commercial fill/finish services. Under the F/F Agreement, and, following relevant technology and technical information transfer activities, Chiesi agreed, among other things, to provide the Company with commercial fill/finish services for pegunigalsidase alfa, including to support the anticipated global launch of pegunigalsidase alfa. The F/F Agreement shall continue in force until December&#160;31, 2025, unless terminated earlier in accordance with the terms of the F/F Agreement and the term may be extended by mutual agreement for an additional period of&#160;<ix:nonNumeric contextRef="Duration_8_29_2022_To_8_29_2022_us-gaap_TypeOfArrangementAxis_plx_FillFinishAgreementMember_Ol0Pxko4TEuK_ACCWu0Zww" format="ixt-sec:durwordsen" name="plx:ExtendedTermOfAgreement" id="Narr_oJBJGQTDxUqZsPtkEhMunA">seven years</ix:nonNumeric>&#160;upon mutual written agreement prior to expiration of the initial term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer in accordance with the exclusive license and supply agreement entered into between Protalix Ltd. and Pfizer, which is referred to herein as the Pfizer Agreement. In October 2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement, which is referred to herein as the Amended Pfizer Agreement, pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for <ix:nonFraction unitRef="Unit_Standard_pure_KYNrm9UG9EeMn48Y0if07Q" contextRef="Duration_10_1_2015_To_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_HI7XdKpS_0KkIxReGTPNCg" decimals="2" format="ixt:numdotdecimal" name="plx:CollaborativeArrangementRevenuesExpensesSharingPercentage" scale="-2" id="Narr_lu1R9KxvZ06-rE5iUwR1-Q">100</ix:nonFraction>% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.</p></ix:continuation></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_i0MCB9qVkEmyTZvNqiIC0w_cont3" continuedAt="Tb_i0MCB9qVkEmyTZvNqiIC0w_cont4"><ix:continuation id="Tb_aDze9TXe4EK0XQAR-9HDhQ_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#8220;Brazil Agreement&#8221;) with Fiocruz for BioManguinhos alfataliglicerase. Fiocruz&#8217;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Because the Company&#8217;s operations are conducted in the State of Israel, the business and operations may be directly affected by economic, political, geopolitical and military conditions in Israel.&#160;In October 2023, Hamas terrorists infiltrated Israel&#8217;s southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Hamas also launched extensive rocket attacks on Israeli population and industrial centers located along Israel&#8217;s border with the Gaza Strip and in other areas within the State of Israel attacking a number of civilian and military targets. At the same time, clashes between Israel and Hezbollah in Lebanon have increased. In response, Israel&#8217;s security cabinet declared war against the Hamas and a military campaign against these terrorist organizations commenced in parallel to their continued rocket and terror attacks. Moreover, the attacks by Hamas and Hezbollah, and Israel&#8217;s defensive measures, may result in a greater regional conflict. Since the outbreak of the war, other regional actors, including Iran, have taken military action against Israel. It is currently not possible to predict the duration or severity of the ongoing conflict or its effects on the Company&#8217;s business, operations and financial conditions. The ongoing conflict is rapidly evolving and developing, and could disrupt certain of the Company&#8217;s business and operations, among others. The Company has elected to store manufactured drug substance in multiple locations, both within and outside of Israel, to mitigate the risk of loss due to the military operations. As of the issuance of these financial statements, the impact of the war has not had an adverse effect on the Company&#8217;s operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">The Company expects to continue to incur significant expenditures in the near future due to research and developments efforts with respect to the product candidates. The Company believes that its cash and cash equivalents as of September&#160;30, 2024 are sufficient to satisfy the Company&#8217;s capital needs for at least 12&#160;months from the date that these financial statements are issued.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Tb_VcHi3DXIdUmPAVfz-jLYLw" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">b.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">Basis of presentation</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States (&#8220;GAAP&#8221;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form&#160;10-K for the year ended December&#160;31, 2023, filed by the Company with the U.S.&#160;Securities and Exchange Commission (the &#8220;Commission&#8221;). The comparative balance sheet at December&#160;31, 2023 has been derived from the audited financial statements at that date. There have been no material changes in our significant accounting policies as described in our consolidated financial statements for the year ended December&#160;31, 2023, except for convertible notes, as described below.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_NxQumnbvmESY_6_Q_m545A" continuedAt="Tb_NxQumnbvmESY_6_Q_m545A_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">c.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Earnings (loss) per share</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt 0pt 0pt 54pt;">Basic earnings (loss) per share is calculated by dividing the net income (loss) by the weighted average number of shares of Common Stock outstanding during each period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt 0pt 0pt 54pt;"><span style="color:#212529;">Diluted earnings per share is calculated by dividing the net income by the weighted-average number of shares of Common Stock outstanding during each period increased to include the number of additional shares of Common Stock that would have been outstanding if the potentially dilutive shares had been issued.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 0pt 54pt;"><span style="color:#212529;">In computing diluted earnings per share, basic earnings per share are adjusted to take into account the potential dilution that could occur upon: (i)&#160;the exercise of options granted under employee stock compensation plans using the treasury </span></p></ix:nonNumeric></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc_BF42SoWvh0qlM2ezDU_XZg_1_0"></a><a id="Tc_2iaxvzttPkKYoLVy0gHRQA_1_2"></a><a id="Tc_tcQmcxll2keeqQSEaKLk8Q_1_5"></a><a id="Tc_Gu-iyzcCnkOJLAvCevDuvg_1_8"></a><a id="Tc_nYrdjfDl3ECqgLwUMThSyQ_2_0"></a><a id="Tc_sgrsaiUXEkux4apXzOvTCQ_2_2"></a><a id="Tc_HlUZmX_lBkOnrk-k9DKRKw_2_5"></a><a id="Tc_LnFi9sMeLUiA2x8eJ0DLLw_2_8"></a><a id="Tc_eHFsYQlmoUSzAKHReo9qnA_3_0"></a><a id="Tc_lFIdF6UuuUq427R8ajQyMg_4_0"></a><ix:continuation id="Tb_i0MCB9qVkEmyTZvNqiIC0w_cont4" continuedAt="Tb_i0MCB9qVkEmyTZvNqiIC0w_cont5"><ix:continuation id="Tb_NxQumnbvmESY_6_Q_m545A_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 54pt;"><span style="color:#212529;">stock method; (ii)&#160;the exercise of warrants using the treasury stock method; and (iii)&#160;the conversion of the convertible notes using the &#8220;if-converted&#8221; method.</span></p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" name="us-gaap:DebtPolicyTextBlock" id="Tb_BYU7xUQsbUGjn0iapJoYRA" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">d.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">Convertible notes</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In September 2024, the Company repaid in full all of the outstanding principal and interest payable under its <ix:nonFraction unitRef="Unit_Standard_pure_KYNrm9UG9EeMn48Y0if07Q" contextRef="As_Of_9_30_2024_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_orKpnVhEbkGbW5YdvkXelA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_KAoP65LjmUu3gpbZkwehwQ">7.50</ix:nonFraction>% Senior Secured Convertible Promissory Notes due September 2024 (the &#8220;2024 Notes&#8221;). The repayment of the convertible notes at maturity was financed entirely with available cash.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Prior to January&#160;1, 2024, the Company accounted for its outstanding convertible notes using the guidance set forth in the Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 815 which required that the Company determine whether the embedded conversion option must be separated from the other features of the applicable note instrument and accounted for separately. ASC 470-20 regarding debt with conversion and other options requires the issuer of a convertible debt instrument that may be settled in cash upon conversion to separately account for the liability (debt) and equity (conversion option) components of the instrument in a manner that reflects the issuer&#8217;s nonconvertible debt borrowing rate. <span style="background:#ffffff;">The Company&#8217;s outstanding 2024 Notes were accounted for as a liability (debt) and equity component (conversion option) as the convertible notes may be settled wholly or partly in cash, at the option of the Company, when converted.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="background:#ffffff;">In August 2020, the FASB issued </span>ASU 2020-06 &#8220;Debt &#8211; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#8211; Contracts in Entity&#8217;s Own Equity (Subtopic 815 &#8211; 40)&#8221; (&#8220;<span style="background:#ffffff;">ASU 2020-06&#8221;). </span>ASU&#160;2020-06 simplifies the accounting for convertible instruments by removing certain separation models in ASC 470-20, Debt&#8212;Debt with Conversion and Other Options, for convertible instruments. ASU&#160;2020-06 updates the guidance on certain embedded conversion features that are not required to be accounted for as derivatives under Topic 815, Derivatives and Hedging, or that do not result in substantial premiums accounted for as paid-in capital, such that those features are no longer required to be separated from the host contract. The convertible debt instruments will be accounted for as a single liability measured at amortized cost. This will also result in the interest expense recognized for convertible debt instruments to be typically closer to the coupon interest rate when applying the guidance in Topic 835. On January&#160;1, 2024, the Company adopted ASU 2020-06<span style="background:#ffffff;"> </span>using the modified retrospective method of adoption. Under this method, the Company applied the guidance to the 2024 Notes at the adoption date and was required to make an adjustment to January&#160;1, 2024, opening accumulated deficit balance and additional paid in capital. <span style="background:#ffffff;">The prior period consolidated financial statements have not been retrospectively adjusted and continue to be reported under the accounting standards in effect for those periods. </span>Under ASU 2020-06, the 2024 Notes (debt and conversion option) are accounted for as a liability. <ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" name="us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" id="Group_RrlFzQKII0iQQXfy_AomQw" continuedAt="Group_RrlFzQKII0iQQXfy_AomQw_2" escape="true">The impact to the Company's consolidated balance sheet as of December&#160;31, 2023 resulting from its adoption of ASU 2020-06 is as follows:</ix:nonNumeric></p><ix:continuation id="Group_RrlFzQKII0iQQXfy_AomQw_2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:62.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As Reported December 31, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:13.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Updated January 1, 2024</b></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Effect of Change</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Convertible notes</p></td><td style="vertical-align:bottom;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtCurrent" scale="3" id="Tc_Zxr79h5DIkGY94A-izHHyg_2_3">20,251</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_CXybZU5St0uHedL7onjfxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtCurrent" scale="3" id="Tc_wyoXbJOv5kSDNvM0k6kdbQ_2_6">20,420</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_jTQDJIj1aEykP0X3ByOvLQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtCurrent" scale="3" id="Tc_R27LvcrdgE2-H5yzWs2xxw_2_9">169</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Additional paid in capital</p></td><td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="Tc_JGD7mYjmjUO8d6yG0zEZcA_3_3">415,045</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_CXybZU5St0uHedL7onjfxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="Tc_82Z6h3QackmmRit33WKJFg_3_6">414,652</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_jTQDJIj1aEykP0X3ByOvLQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" sign="-" scale="3" id="Tc_R_BI19Bpzk2C9hWw9HMdeg_3_9">393</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:62.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="Tc_SH9sebtF4USd-LMx9umR-g_4_3">381,549</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_CXybZU5St0uHedL7onjfxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="Tc_nEmDOI68mkOD79ISjokutg_4_6">381,325</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_jTQDJIj1aEykP0X3ByOvLQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="Tc_7Z3AmloPEUC2kJsl5F3qFw_4_9">224</ix:nonFraction></p></td></tr></table></ix:continuation></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_6Sc0X9aaK0Oa-akDs6CX2Q" continuedAt="Tb_6Sc0X9aaK0Oa-akDs6CX2Q_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><b style="font-weight:bold;background:#ffffff;">e.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><b style="font-weight:bold;background:#ffffff;">New accounting </b><b style="font-weight:bold;">pronouncements</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><i style="font-style:italic;background:#ffffff;">Recently adopted accounting pronouncements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="background:#ffffff;">ASU 2020-06, which was issued by the FASB in August 2020 and adopted by the Company in January 2024, simplifies the accounting for certain financial instruments with characteristics of both liability and equity, including convertible instruments and contracts on an entity&#8217;s own equity. The amendments to this guidance are effective for fiscal years beginning after December&#160;15, 2023, and interim periods within those fiscal years. See Note&#160;1(d).</span></p></ix:nonNumeric></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_i0MCB9qVkEmyTZvNqiIC0w_cont5"><ix:continuation id="Tb_6Sc0X9aaK0Oa-akDs6CX2Q_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><i style="font-style:italic;background:#ffffff;">Recently issued accounting pronouncements, not yet adopted</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="background:#ffffff;">In December 2023, the FASB issued ASU 2023-09 &#8220;Income Taxes (Topic 740): Improvements to Income Tax Disclosures.&#8221; This guidance is intended to enhance the transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid both in the United States and in foreign jurisdictions. ASU 2023-09 is effective for fiscal years beginning after December&#160;15, 2024 on a prospective basis. Early adoption is permitted, with the option to apply the standard retrospectively. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="background:#ffffff;">In November 2023, the FASB issued ASU 2023-07 &#8220;Segment Reporting: Improvements to Reportable Segment Disclosures.&#8221; This guidance expands public entities&#8217; segment disclosures primarily by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment&#8217;s profit or loss and assets. Public entities with a single reportable segment are required to provide the new disclosures and all of the disclosures required under ASC 280. The guidance is effective for fiscal years beginning after December&#160;15, 2023, and interim periods within fiscal years beginning after December&#160;15, 2024, with early adoption permitted. The amendments are required to be applied retrospectively to all prior periods presented in an entity&#8217;s financial statements. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements and related disclosures</span><span style="font-family:'Palatino Linotype';background:#ffffff;">.</span></p></ix:continuation></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><a id="Tc_iIM3T8EKB0ivwquw-qD7fA_1_2"></a><a id="Tc_auef6d9SSE-TVtCmfoHHHQ_1_5"></a><a id="Tc_NegkS7kUME2kda2JZ3-jCg_2_0"></a><a id="Tc_fuOf1yWdOkibNBivLcYl2w_2_2"></a><a id="Tc_WMlpGmwULkOE793pzC3zgQ_2_5"></a><a id="Tc_wh_u8N83PkyCtc4WtBSn4w_3_0"></a><a id="Tc_p6CWJjKcNUOBq_jC27r2lA_3_2"></a><a id="Tc_5owEsv_b3UiWnSxG_xwhDg_3_5"></a><a id="Tc_Ryxi75LJEUeUWenQ1eb5LQ_4_0"></a><a id="Tc_K8sdTuczDUKDskJvAK2Xaw_5_0"></a><a id="Tc_Fd9nufrPgEmq9_NUfph7Pg_6_0"></a><a id="Tc_9i_BL9myDEWZeWsYNXndDw_6_2"></a><a id="Tc_sOkq7tveDkOa-sqLVQk16A_6_5"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" name="us-gaap:InventoryDisclosureTextBlock" id="Tb_6kuR6yNL90-no4ihd_VVhA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;2&#160;- INVENTORIES</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="Group_b5ooBZXmiEC4SooBNfm6LQ" continuedAt="Group_b5ooBZXmiEC4SooBNfm6LQ_2" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Inventories at September&#160;30, 2024 and December&#160;31, 2023 consisted of the following:</p></ix:nonNumeric><ix:continuation id="Group_b5ooBZXmiEC4SooBNfm6LQ_2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="Tc_Wsbf5Ad71U6-WEWHPWAA6A_3_3">4,242</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="Tc_s9HEtqO64ki5Nc8dQyiopw_3_6">4,176</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Work in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="Tc_iCuKjpdOckeTKpp2GFTM-A_4_3">12,251</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="Tc_om4ERAP4ZU-NlOnUnLd2Ig_4_6">9,055</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="Tc_hgRWz7o4qkCoYro957K19A_5_3">706</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="Tc_3GlnPn-v40qH7w6wSBPcUw_5_6">5,814</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_4SSmcKPCj0q8rYUhmoneJA_6_3">17,199</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_8XqTqb6pBk28tNtuk16_mQ_6_6">19,045</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:continuation></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb_7c9gyTgsakykNPYk1W6YzA" continuedAt="Tb_7c9gyTgsakykNPYk1W6YzA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;3&#160;&#8211; FAIR VALUE MEASUREMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The Company discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level&#160;1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level&#160;2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level&#160;3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The fair value of the financial instruments included in the working capital of the Company is identical or close to their carrying value.</p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_7c9gyTgsakykNPYk1W6YzA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="Tc_nfR1nI3wMU2ZwqCOcOIrbg_1_2"></a><a id="Tc_NigDbZ84xEiRbmWu0IQK1A_1_10"></a><a id="Tc_OsNVN3v25k2ZwNZZKZLO_Q_2_0"></a><a id="Tc_Yz_QOA86lEWOo7OfRlU1rQ_2_2"></a><a id="Tc_tXqkH79QGE2LzMjR4ozMrg_2_5"></a><a id="Tc_w7SiBaTPAkWs1HWh-XqcKA_2_10"></a><a id="Tc_u0ZpxvLEJUaQEd2K_K_Xog_2_13"></a><a id="Tc_9b7KODTl_UGb1Jx_6z1x3g_3_0"></a><a id="Tc_t_0R0CfpjkKUnKYH4YoTAA_3_2"></a><a id="Tc_9ARXpd3K1ku_1wPz5e5PnA_3_5"></a><a id="Tc_fRTg_F9dgES0XQrp4jYTIQ_3_10"></a><a id="Tc_TwzYCYZ930mN2UEEjchEiw_3_13"></a><a id="Tc_yHV8_ArEAECH9qMPTKidgg_4_0"></a><a id="Tc_NmLYaEJO20KP_k0hU2GROw_4_2"></a><a id="Tc_HW6bBW0hSUy_w0jWFb4izQ_4_5"></a><a id="Tc_OYABh-9zkUaNOkNaRecduA_4_10"></a><a id="Tc_e_-Snd_iUEq3RcgOmR3DqA_4_13"></a><a id="Tc_j_ZFrFYWYUO8ewPoRxOoKg_5_0"></a><a id="Tc_n9llRROEw029leWGDVVEZg_5_2"></a><a id="Tc_QClOR0KmF06c6_1wh40cIw_5_5"></a><a id="Tc_eSCqtFOT40aGOto6vCgNtg_5_10"></a><a id="Tc_TtAbr2L5A06ZxRrdwJCK7Q_5_13"></a><a id="Tc_mLVxUltZME2cF1kHHPs5EA_6_0"></a><a id="Tc_BpEi5fNiI0mlJpzfmA_eNw_6_2"></a><a id="Tc_bRVKv_H-YUqCGaL38j9oDA_6_5"></a><a id="Tc_6c4AfbB6IkC3VECQQzRMYw_6_10"></a><a id="Tc_8HM_jhXZEUmneCpwiHyAvg_6_13"></a><a id="Tc_7k42b8pJekuTwX4di5dL-g_7_0"></a><a id="Tc_0Z0bJHZhkUuBoLfYdLBUXQ_7_2"></a><a id="Tc_0veZOKjNJEy4FHLRNH2icg_7_5"></a><a id="Tc_AvBJ1xgij0SamUpd7i1kKg_7_10"></a><a id="Tc_Kqm-xXtU_EqXW1cFFMARUA_7_13"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" name="plx:RevenueDisclosureTextBlock" id="Tb_iQ485AwSzUq1EIFw2DtGvQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;background:#ffffff;">NOTE&#160;4&#160;&#8211; REVENUES</b></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="Group_xj8SuOihxkyoh0Lb-XagbQ" continuedAt="Group_xj8SuOihxkyoh0Lb-XagbQ_2" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="background:#ffffff;">The following table summarizes the Company&#8217;s disaggregation of revenues:</span></p></ix:nonNumeric><ix:continuation id="Group_xj8SuOihxkyoh0Lb-XagbQ_2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:39.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:39.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Pfizer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2024_To_9_30_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_vw8by47NDUq5QE7hoakywQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_k_lhp7mDR02MBhSxEpVNGQ_3_3">11,431</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_7mSydPVUmEmHGUlub7tPJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_Ctnw80YbfESa_kEwi0MkrQ_3_6">7,972</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_7_1_2024_To_9_30_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_m3nBp_5RP0q3hxfAVIwsKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_byejTCKGLE6hd2sbcC9xYw_3_11">3,430</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_7_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_xT5o1Ih3q0CS-6-uYmd1nw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_ZLfW11TXr0Sbais4rLbqmA_3_14">2,304</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Brazil</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2024_To_9_30_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_R2V45jNs50i3ZjlXVw6V4Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_k-dBpIp4OkeLdImWwLYl0w_4_3">9,314</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_-gw8gqnXX0q0q6EWX9kyGA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_1YCDz_0_U02fL9CohGyVFg_4_6">5,120</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_7_1_2024_To_9_30_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_Y25APrw9YkGqE9QGp-2pBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc__OlH1ac-TEqPG9FFcKq1oA_4_11">2,048</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_7_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_uM6rCcqim06Mqh7Y7r7_hA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_UmIhyshtfUGlk_oHwMx_OA_4_14">2,320</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Chiesi</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2024_To_9_30_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_E4kb99v7l0mAZMrPKuEUEA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_0bK2vaAJBUCxGQxsoWejhw_5_3">14,075</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_z371xjvvpUqBogUfxstw5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_pQvGm-qyeEOVRWxk3PA57w_5_6">17,217</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_7_1_2024_To_9_30_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_YVdXplgBIUiqKREQvvCQYg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_OHIuqrGxdECb_29cvtgofA_5_11">12,361</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_7_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_xv7pHWEqdkuqLB4zfoGlgQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_9FLouBigv0CjM--QbQ1uYg_5_14">5,544</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total revenues from selling goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2024_To_9_30_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_A3ezJBQ1MUmqg7U3imJLCA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_tieSArUOKECmcwPMLxgNWQ_6_3">34,820</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_DR0rv8wVu0yrFx2bdJFyPQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_2QjG0kmQikevPqBsqq4_ww_6_6">30,309</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_7_1_2024_To_9_30_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_pLP50Bgxbk-D1hnRjPhAlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_Bc2eobMCp0ubhh0l8PjUEw_6_11">17,839</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_7_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_ierukmxCL0qBG6i8bMqdsw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_6ydTpw3_RUqEEAnylF_KrA_6_14">10,168</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues from license and R&amp;D services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2024_To_9_30_2024_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_RrGB_Ovo00Ok686p6jPzbA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_t00uraDNoE2g9ClX3M5LEA_7_3">361</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_Mxt-hPsr9EG5KGrzdcGbQQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_iDXubHNV7UG-lMSRKCsGzw_7_6">24,699</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_7_1_2024_To_9_30_2024_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_-EAKZ_94e02kTPJSHJ6-mQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_NIZRHHnEYkuJXwkU_iD2cg_7_11">120</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_7_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_j4Hh_9X_vkGuiao5PBkobw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_kvID1KAyXUu1hGZYuy2pGw_7_14">177</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="color:#212529;font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:continuation></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_Q_HNgMkPWUudjk6aDAcK-w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 5 &#8211; STOCK TRANSACTIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">On January&#160;15, 2024, the Company granted, with the approval of the Company&#8217;s compensation committee, <ix:nonFraction unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA" contextRef="Duration_1_15_2024_To_1_15_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_ELprQe2rdEavBiEcVE57Fg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr_f3f39kfMd0OHJikNz7FUnA">100,000</ix:nonFraction> shares of restricted Common Stock, in the aggregate, to certain of the Company&#8217;s employees under the Company&#8217;s Amended and Restated 2006 Employee Stock Incentive Plan, as amended (the &#8220;Plan&#8221;). All such shares of restricted Common Stock vest over a <ix:nonNumeric contextRef="Duration_1_15_2024_To_1_15_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_ELprQe2rdEavBiEcVE57Fg" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_N5srNWE9uEO69aaivj1Qww">three-year</ix:nonNumeric> period in <ix:nonFraction unitRef="Unit_Standard_installment_GQ9uxVOtz0-sYFwS4P9Gzg" contextRef="Duration_1_15_2024_To_1_15_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_ELprQe2rdEavBiEcVE57Fg" decimals="INF" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" scale="0" id="Narr_G9KRprAbZ06uf8pmOuKX6w">12</ix:nonFraction>&#160;equal quarterly increments. The Company estimated the fair value of the restricted stock on the date of grant to be approximately $<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_1_15_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_wjItBW8ElUS5zStQFNkaTQ" decimals="-5" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" scale="6" id="Narr_euL2_ugiF02_fVPcKD7vpw">0.2</ix:nonFraction>&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">On April&#160;1, 2024, the Company granted, with the approval of the Company&#8217;s compensation committee, <ix:nonFraction unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA" contextRef="Duration_4_1_2024_To_4_1_2024_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_p_CUFtHXL0eyiopN2TaoPQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr_hAeYy9tQTUKLvkg852n_2w">263,960</ix:nonFraction> shares of fully-vested restricted Common Stock to the Company&#8217;s President and Chief Executive Officer under the Plan instead of a cash bonus. The Company estimated the fair value of the restricted stock on the date of grant to be approximately $<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_4_1_2024_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_fW2CAIqwS0yFawiF2Xq3Pw" decimals="-5" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" scale="6" id="Narr_xRLWyUiq9EuBeAYGkvpBuQ">0.3</ix:nonFraction>&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">On July&#160;2, 2024, the Company granted, with the approval of the Company&#8217;s compensation committee,&#160;<ix:nonFraction unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA" contextRef="Duration_7_2_2024_To_7_2_2024_srt_TitleOfIndividualAxis_plx_VicePresidentResearchAndDevelopmentMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_AvLDv7dryEm2YrB3OLun0Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr_7KJKLEwbf0mLhBFHAplLGg">250,000</ix:nonFraction>&#160;shares of restricted Common Stock to its new Vice President, Research and Development, under the Plan. The&#160;<span style="-sec-ix-hidden:Hidden_Wv5n4SFqLUalXo86fgRQdg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">first third</span></span>&#160;of such shares of restricted Common Stock vest on the&#160;<span style="-sec-ix-hidden:Hidden_HDd_9eUnQUuEPgjlLh4OWA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">first</span></span>&#160;anniversary of the date of grant and the remaining&#160;<span style="-sec-ix-hidden:Hidden_UMFZm-Gn_k61nFAdjEsS9w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two-thirds</span></span>&#160;of the shares vest over the subsequent&#160;<ix:nonNumeric contextRef="Duration_7_2_2024_To_7_2_2024_srt_TitleOfIndividualAxis_plx_VicePresidentResearchAndDevelopmentMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_fsxZjtrzyEyb_e85-FjXKw" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_Kp1m-pRQe0aNkYGFPN53hw">two-year</ix:nonNumeric>&#160;period in&#160;<ix:nonFraction unitRef="Unit_Standard_installment_GQ9uxVOtz0-sYFwS4P9Gzg" contextRef="Duration_7_2_2024_To_7_2_2024_srt_TitleOfIndividualAxis_plx_VicePresidentResearchAndDevelopmentMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_fsxZjtrzyEyb_e85-FjXKw" decimals="INF" format="ixt-sec:numwordsen" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" scale="0" id="Narr_jfAxyhDmwUKrrnLh6g2bwA">eight</ix:nonFraction>&#160;equal quarterly increments. The Company estimated the fair value of the restricted stock on the date of grant to be approximately $<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_7_2_2024_srt_TitleOfIndividualAxis_plx_VicePresidentResearchAndDevelopmentMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_VcyDlSSU_UuXWR7-Z6srjw" decimals="-5" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" scale="6" id="Narr_TAXW9f8FSUekqpcxZWCzsQ">0.3</ix:nonFraction>&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">On September&#160;23, 2024, the Company granted, with the approval of the Company&#8217;s compensation committee, <ix:nonFraction unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA" contextRef="Duration_9_23_2024_To_9_23_2024_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_fjlRxFeRF0GsDO6ftqcY3w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr_u3gK4KZFzUqdvZapqmO9Wg">90,909</ix:nonFraction> shares of fully-vested restricted Common Stock, in the aggregate, to its Sr.&#160;Vice President and Chief Financial Officer under the Plan. The Company estimated the fair value of the restricted stock on the date of grant to be approximately $<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_9_23_2024_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_ypJyopAyWUGn0-upITXFlQ" decimals="-5" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" scale="6" id="Narr_dx3x61WEG0SAtbW1kesRWw">0.1</ix:nonFraction>&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">On September&#160;23, 2024, the Company granted, with the approval of the Company&#8217;s compensation committee, <ix:nonNumeric contextRef="Duration_9_23_2024_To_9_23_2024_srt_TitleOfIndividualAxis_plx_OfficersAndOtherEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_dTpdI5xPrkiwpnGVkyHdmQ" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_ZYEYujJi7ESXPzd9QB0bZg">10-year</ix:nonNumeric> options to purchase <ix:nonFraction unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA" contextRef="Duration_9_23_2024_To_9_23_2024_srt_TitleOfIndividualAxis_plx_OfficersAndOtherEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_dTpdI5xPrkiwpnGVkyHdmQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_85niEQdOskKfun8eR1eedg">1,015,725</ix:nonFraction> shares of Common Stock, in the aggregate, to certain of the Company&#8217;s officers and other employees under the Plan. The options have an exercise price equal to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_A4-BaHg86EmBShQ9tsexWA" contextRef="Duration_9_23_2024_To_9_23_2024_srt_TitleOfIndividualAxis_plx_OfficersAndOtherEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_dTpdI5xPrkiwpnGVkyHdmQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_fklgoYw2SUWoLbd4bA4obA">1.10</ix:nonFraction> per share and vest over a <ix:nonNumeric contextRef="Duration_9_23_2024_To_9_23_2024_srt_TitleOfIndividualAxis_plx_OfficersAndOtherEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_dTpdI5xPrkiwpnGVkyHdmQ" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_uWTi_sTojU674DstaBB6yQ">three-year</ix:nonNumeric> period in <ix:nonFraction unitRef="Unit_Standard_installment_GQ9uxVOtz0-sYFwS4P9Gzg" contextRef="Duration_9_23_2024_To_9_23_2024_srt_TitleOfIndividualAxis_plx_OfficersAndOtherEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_dTpdI5xPrkiwpnGVkyHdmQ" decimals="INF" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" scale="0" id="Narr_LidDnV9RcEaaMdOfvyxdWg">12</ix:nonFraction>&#160;equal quarterly increments. Vesting of the options granted to executive officers is subject to automatic acceleration in full upon a Corporate Transaction or a Change in Control, as those terms are defined in the Plan, and are subject to certain other terms and conditions. The Company estimated the aggregate fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately $<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_9_23_2024_srt_TitleOfIndividualAxis_plx_OfficersAndOtherEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_b8NTuk7QZkmYLH_vN0r7-Q" decimals="-5" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" scale="6" id="Narr_wfuckwXjMUOnbZfQ8elezg">0.8</ix:nonFraction>&#160;million.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" name="us-gaap:EarningsPerShareTextBlock" id="Tb_M8dPWnpSMU6shfuv_CJv8w" continuedAt="Tb_M8dPWnpSMU6shfuv_CJv8w_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_3d5db4dd_2f7b_4a6f_b103_830a1a6a36a2"></a><a id="Tc_Lk8OuNn9UUC4fGrDnfbjrw_1_3"></a><a id="Tc_9v2D4L2afkmGe3robHxSkA_1_9"></a><a id="Tc_6JbVrNDIzESfeKlOvAdRPQ_2_0"></a><a id="Tc_LrhAe9KYnE20BxL3kanLIA_2_3"></a><a id="Tc_m3O7m4kM8Em9fEL5q64k1g_2_6"></a><a id="Tc_LTtwgnpJNk-dluvrujNu2Q_2_9"></a><a id="Tc__zdZbhXas0-EfN3QlISlwQ_2_11"></a><a id="Tc_aFa3C1p-fkmz6iwYUWBEug_3_0"></a><a id="Tc_doXWUcyYy0Ky-0X7Ty1FCA_4_0"></a><a id="Tc_hlFRc_b6SECWAQ-WuEJIQw_4_2"></a><a id="Tc_pDnAmnuDa0a6AF5s1tGxWA_4_5"></a><a id="Tc_yfLNEZvpPkWFAEk-R-raWA_4_8"></a><a id="Tc_hly_2WHTgkif77mxgHuclw_4_11"></a><a id="Tc_6SQqRVL_yEuuyiM-UlkXhg_5_0"></a><a id="Tc_XwwhFvZQMk22XsDwxrvQIw_6_0"></a><a id="Tc_0aoRBR-Puk-IsdcQ00FTPw_7_0"></a><a id="Tc_BgX2G5ClTU6ojtuelflkDg_7_2"></a><a id="Tc_Cdd05tH5tkiz1HZhWVvuew_7_5"></a><a id="Tc_QRn2uGBejkCRUyPWYaobCQ_7_8"></a><a id="Tc_8Vb_wrRR10-PDk4nkrjPlg_7_11"></a><a id="Tc_kFBruuPijEOrIgzRzPOm0Q_8_0"></a><a id="Tc_sIRg17RR5k6MzWy0g3I8pg_9_0"></a><a id="Tc_yxby_JnK_k6036eNbKgWVg_10_0"></a><a id="Tc_w7AIzAS3m0CSgAcW8_RMEw_11_0"></a><a id="Tc_Yphx-FOCdUeUBxm34famSg_11_9"></a><a id="Tc_IvUkkJZjmkuv7hxnU03K-Q_11_12"></a><a id="Tc_5BKIWKp4cECaKntEYXFaXg_12_0"></a><ix:continuation id="Tb_M8dPWnpSMU6shfuv_CJv8w_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 6 &#8211; EARNINGS (LOSS) PER SHARE</b></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="Group_SA1jJOjq70mIfWp6QFqBcg" continuedAt="Group_SA1jJOjq70mIfWp6QFqBcg_2" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="color:#212529;">Basic and diluted net earnings (loss) per share attributable to common stockholders were calculated as follows:</span></p></ix:nonNumeric><ix:continuation id="Group_SA1jJOjq70mIfWp6QFqBcg_2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.17%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:28.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:29.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(In&#160;thousands,&#160;except&#160;share&#160;data)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Numerator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_NMS38b7Zi0GQpMtFO-uRzg_4_3">3,562</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_rD-3OU4n7kCdgCKbh6sVeg_4_6">14,356</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_7_1_2024_To_9_30_2024_5srFek9aZ0STe4olK5gckA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_-TP_4EwxCE2qJoWLXiWDQg_4_9">3,236</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_7_1_2023_To_9_30_2023__jyu8G4bX02xwWm0pGi6zA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_1MGZEvsbKECZ2cVOjvWdbw_4_12">1,852</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:40.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Add:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Financial expenses of 2024 Notes*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DilutiveSecurities" sign="-" scale="3" id="Tc_lGM9Vo-1q0G-JfQxMcvVHw_6_6">1,610</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_7_1_2024_To_9_30_2024_5srFek9aZ0STe4olK5gckA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DilutiveSecurities" sign="-" scale="3" id="Tc_6J3DqoDXN0ayPiXM094-_A_6_9">503</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_7_1_2023_To_9_30_2023__jyu8G4bX02xwWm0pGi6zA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DilutiveSecurities" sign="-" scale="3" id="Tc_6Ajqc4-Yu0uVCPSqVlQUSQ_6_12">1,766</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:40.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net income (loss) for diluted calculation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" sign="-" scale="3" id="Tc_uZn-cIKf1UGOmYmZpqxOrA_7_3">3,562</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="Tc_eOOZN5R90E2bKfeluiF3sg_7_6">12,746</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_7_1_2024_To_9_30_2024_5srFek9aZ0STe4olK5gckA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="Tc_ZSiPk-3PY0Kjv2samNbSUg_7_9">2,733</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_7_1_2023_To_9_30_2023__jyu8G4bX02xwWm0pGi6zA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" sign="-" scale="3" id="Tc_a4CiWWGd3kyA9CE6NUh3CQ_7_12">3,618</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:40.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Denominator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average shares of Common Stock outstanding for basic calculation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA" contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_ZLmVtJIl_EGoLpJjVPZibw_9_3">73,301,091</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA" contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_0lddb4zKt0SPh5NXP2uevQ_9_6">65,811,506</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA" contextRef="Duration_7_1_2024_To_9_30_2024_5srFek9aZ0STe4olK5gckA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_2vOBnVHtuEW-jLGIulSSCA_9_9">73,549,745</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA" contextRef="Duration_7_1_2023_To_9_30_2023__jyu8G4bX02xwWm0pGi6zA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_1Ia0wqhJIUuKzY-8-5orjw_9_12">72,281,681</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:40.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average dilutive effect of 2024 Notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA" contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" scale="0" id="Tc_amEH7UAuSUOxmpYHfWscnA_10_6">13,981,660</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA" contextRef="Duration_7_1_2024_To_9_30_2024_5srFek9aZ0STe4olK5gckA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" scale="0" id="Tc_DRsKqxyHpUqD8z43fT5DGg_10_9">7,667,323</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA" contextRef="Duration_7_1_2023_To_9_30_2023__jyu8G4bX02xwWm0pGi6zA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" scale="0" id="Tc_S5dlk0po3Euc57lL7iuueg_10_12">11,500,998</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:40.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average dilutive effect of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA" contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="0" id="Tc_9aybVS5APEGmT6KZthxWBQ_11_6">1,247,115</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td></tr><tr><td style="vertical-align:bottom;width:40.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average shares of Common Stock outstanding for diluted calculation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA" contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_j5fhJsYTY06HxePAF9bI9g_12_3">73,301,091</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA" contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_4fpQ3D_TDUCSLuvS1v4Grw_12_6">81,040,281</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA" contextRef="Duration_7_1_2024_To_9_30_2024_5srFek9aZ0STe4olK5gckA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_ehRjnO_nXEWwsxyD2cOntA_12_9">81,217,068</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA" contextRef="Duration_7_1_2023_To_9_30_2023__jyu8G4bX02xwWm0pGi6zA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_f-IMY_cZgkCTOrAjIjTbCA_12_12">83,782,679</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 54pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 10pt 54pt;">* Financial expenses on 2024 Notes consists of add back of financial expense incurred during the period and inclusion of make-whole interest payments that will be incurred upon conversion.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 10pt 36pt;"><span style="font-size:10pt;">Diluted earnings (loss) per share do not include </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsWarrantsAnd2024NotesMember_pHC6uKO6gUK7SAy-_PDCuw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_nEyGdbqn_0aai-MovgPtOQ">30,515,287</ix:nonFraction></span> <span style="font-size:10pt;">shares of Common Stock underlying outstanding stock options, warrants and the 2024 Notes for the nine months ended September&#160;30, 2024, and </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA" contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsAndWarrantsMember_C0t9LFxG80iLLT4GrVHt5Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_EkOqxYuVi0eBIsIb8C9BRw">20,173,438</ix:nonFraction></span><span style="font-size:10pt;"> shares of Common Stock underlying outstanding stock options and warrants for the three months ended September&#160;30, 2024, because the effect would be anti-dilutive.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Diluted earnings (loss) per share do not include <ix:nonFraction unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsAndWarrantsMember_jNIclNrn20-gLZ0NF4hAeg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_tdv3rlLt-UKtmCNVsQz8_w">19,429,910</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsAndWarrantsMember_I8uK516psE6zNy3vZsdCVQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_S3XMSL1-jkypieXim4JJAw">18,399,260</ix:nonFraction> shares of Common Stock underlying outstanding stock options and warrants of the Company for the three and nine months ended September&#160;30, 2023, respectively, because the effect would be anti-dilutive.</p></ix:continuation><a id="Tc_TxPBG87q70WGx5mfsdIm2w_1_2"></a><a id="Tc_aSlq4A7IBkGefpv50js-jA_1_8"></a><a id="Tc_5HW0FZi-aEmBQV8Ula8AZQ_2_0"></a><a id="Tc_0hXbNAMcw0-CxtwOBkNjRQ_2_2"></a><a id="Tc_NR68NbCgeUeD3Rpe-qxvmQ_2_5"></a><a id="Tc_yF617RfmukKHKbpX0C88sw_2_8"></a><a id="Tc_bZ9dVUTseUO9ZWoSyiQeow_2_11"></a><a id="Tc_xjIBei9o70GNW4lcn8EpSA_3_0"></a><a id="Tc_P254YT62fEqd8PSv-z9SAg_3_2"></a><a id="Tc_qUKztvaMh0u5sONpf8uM8Q_3_5"></a><a id="Tc_28Xni6k_8UC6StXaXarjKA_3_8"></a><a id="Tc_ZMLgokcdQkW-rJHzZ6llyg_3_11"></a><a id="Tc_Rd_tfppbmEqpHdoVTm_3Lg_4_0"></a><a id="Tc_KcOS0V-N30aPqcmrmgMsQg_5_0"></a><a id="Tc_7ZLOFlutW0qMfJCJ9qg-4g_5_2"></a><a id="Tc_VJfrQQ0Tv0CmAcbmTgGA7A_5_5"></a><a id="Tc_fd1T7wlEvUKyyNf8nDk4ng_5_8"></a><a id="Tc_G0znNPXtsEe4-8bK_rIlDA_5_11"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_S5M4TwA52E6FetM_t2BsWA" continuedAt="Tb_S5M4TwA52E6FetM_t2BsWA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 7 &#8211; TAXES ON INCOME</b></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="Group_HSGtdPZsQUKUrNj7aw9hIg" continuedAt="Group_HSGtdPZsQUKUrNj7aw9hIg_2" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="background:#ffffff;">The following table summarizes the Company&#8217;s taxes on income:</span></p></ix:nonNumeric><ix:continuation id="Group_HSGtdPZsQUKUrNj7aw9hIg_2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current taxes on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="Tc_EOeTGbmmPEWu4AraUnlrJg_3_3">164</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="Tc_PvstwrXySUir5labijZTKg_3_6">3,728</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_7_1_2024_To_9_30_2024_5srFek9aZ0STe4olK5gckA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="Tc_9y184QZ8VkOrYrbAayyFhg_3_9">164</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_7_1_2023_To_9_30_2023__jyu8G4bX02xwWm0pGi6zA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="Tc_z6dhq4Ii3kiwBeIMofWXJA_3_12">95</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:40.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred taxes on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="Tc_LD3ToC6W7k656NvMagod3w_4_3">236</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_MumwioNuUkaGwZ4iTlPMlg_4_6">3,092</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_7_1_2024_To_9_30_2024_5srFek9aZ0STe4olK5gckA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="Tc_naMq9xP2sECqjIuRLWpC5A_4_9">443</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_7_1_2023_To_9_30_2023__jyu8G4bX02xwWm0pGi6zA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="Tc_Qlf-kLi4Vk-ow7XMD1NScg_4_12">38</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:40.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total taxes on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_7X0NndZyQ0qqt4iSMYfX5w_5_3">400</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_rTruQbzBwk6LN0j6Mxs3wg_5_6">636</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_7_1_2024_To_9_30_2024_5srFek9aZ0STe4olK5gckA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_3fazCOAKhUODFYIlh0qkvg_5_9">607</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_7_1_2023_To_9_30_2023__jyu8G4bX02xwWm0pGi6zA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_GEfZrFQzXUSMM6GL9X2laQ_5_12">133</ix:nonFraction></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The Company had an effective tax rate of (<ix:nonFraction unitRef="Unit_Standard_pure_KYNrm9UG9EeMn48Y0if07Q" contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" sign="-" scale="-2" id="Narr_S0COT9Yfn0m8D02wlMordw">13</ix:nonFraction>)% for the nine months ended September&#160;30, 2024, compared to an effective tax rate of <ix:nonFraction unitRef="Unit_Standard_pure_KYNrm9UG9EeMn48Y0if07Q" contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Narr_67bm9otCD06sKsOeyDWPNw">4</ix:nonFraction>% for the nine months ended September&#160;30, 2023. For the nine months ended September&#160;30, 2024, the difference between the Company&#8217;s effective tax rate and the U.S.&#160;federal statutory rate of <ix:nonFraction unitRef="Unit_Standard_pure_KYNrm9UG9EeMn48Y0if07Q" contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_aWt8HsEKTE2UBqbFQlXlug">21</ix:nonFraction>% was the result of forecasted profits derived primarily from U.S.&#160;taxable GILTI income mainly due to Section&#160;174 of the U.S.&#160;Tax Cuts and Jobs Act, which was enacted in December 2017 (the &#8220;TCJA&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="color:#212529;background:#ffffff;">In the second quarter ended June&#160;30, 2023, following the regulatory approvals for Elfabrio in May 2023, the receipt of the </span><span style="color:#212529;background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_pm7aApgkcEqj6XWAS_4N3w" decimals="-5" format="ixt:numdotdecimal" name="plx:MilestonePaymentReceived" scale="6" id="Narr_pNiQ3UYvHEiZlQEcDGKk1g">20.0</ix:nonFraction></span><span style="color:#212529;background:#ffffff;">&#160;million milestone payment and the launch of Elfabrio in the United States, the Company released valuation allowance previously recorded on deferred tax assets in respect of its net operating losses (&#8220;NOLs&#8221;) in the United States resulting in a net tax benefit of </span><span style="color:#212529;background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_4_1_2023_To_6_30_2023_Vdzpjd4fMUGT4CcCzCt5ig" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="6" id="Narr_0YJa2WD0S0GEOSKn_fKrXQ">3.1</ix:nonFraction></span><span style="color:#212529;background:#ffffff;">&#160;million. The Company concluded that, based upon the preponderance of positive evidence over negative evidence and the anticipated ability to use the deferred tax assets, it was more likely than not that these deferred tax </span></p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_S5M4TwA52E6FetM_t2BsWA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="color:#212529;background:#ffffff;">assets would be realizable due to forecasted profits. The Company considered the following: (i)&#160;cumulative profits for tax over the previous 12 quarters in its U.S. operations; (ii)&#160;the impact of Section&#160;174 of the TCJA which requires the Company to capitalize and amortize its research and development expenses over 15 years; and (iii) its forecasted profits in the United States following the regulatory approvals of Elfabrio.</span></p></ix:continuation><a id="Tc_SuVyukiaXUmz7ZVjMkY5dA_1_2"></a><a id="Tc_NiKR5qRajku0IAdkgwtKGw_1_5"></a><a id="Tc_5MUq1Ar5rUKtNA0bnK_fOQ_2_0"></a><a id="Tc_nuMjmw_79060jwSAoz8P1Q_2_2"></a><a id="Tc_CTOwsW7paESw98vxj9IK8g_2_5"></a><a id="Tc_caX1PIXSYE6RX2xtBnCgiA_3_0"></a><a id="Tc_ICDm9SYEsU2ujzbbtRNA8Q_4_0"></a><a id="Tc_TstsK9NNWkO6q_iuHf9Guw_4_2"></a><a id="Tc_Xq-ji1CMOkOB3jI6eKdnQw_4_5"></a><a id="Tc_j3NHe0z2K0a_ISfxRBp3PQ_5_0"></a><a id="Tc_QLcBbqbKNUmgQ0m-fBTVSA_5_3"></a><a id="Tc_gf2JZjvm00CLJ87D9QrEhQ_6_0"></a><a id="Tc_EBPmn3_rakCNiTW5nrZZVQ_7_0"></a><a id="Tc_7eMoUqLzrUCD3D8BL0FE7g_8_0"></a><a id="Tc_2Xwi1JTmK0OCLcGl6XGyDw_9_0"></a><a id="Tc_C831kaZzVkSjh-wO0wqoNg_10_0"></a><a id="Tc_wns2O-dxbUya3V7ZqVzLvw_11_0"></a><a id="Tc_2v3sdFIx70KyLKSJcnlCkg_12_2"></a><a id="Tc_oo92c2Bldku7FCGZxk9_gQ_12_5"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" name="us-gaap:AdditionalFinancialInformationDisclosureTextBlock" id="Tb_oPxE6xHOr0mwUYcBjKLj8Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 8 &#8211; </b><b style="font-weight:bold;background:#ffffff;">SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><b style="font-weight:bold;">Balance sheets:</b></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" name="plx:SupplementaryBalanceSheetsInformationTableTextBlock" id="Tb_4wejWjfZQk2fw_R22MvBQQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accounts payable and accruals &#8211; other:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payroll and related expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_uMym4rSoZUWbWQzjyJCi_w_4_3">1,251</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_NXIzvPHC6EaNXSMk_6A0ng_4_6">1,437</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPayableCurrent" scale="3" id="Tc_Op2ynv5x-EaQvfI0zWql7Q_5_6">511</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Provision for vacation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedVacationCurrent" scale="3" id="Tc_zrhDC6p0bkaUBMMx6o6yCw_6_3">1,713</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedVacationCurrent" scale="3" id="Tc_Od6_CrlEq0KdafkdtsILpg_6_6">1,605</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_Xa97ueMsJk2Be6D71oVcYw_7_3">8,342</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_WlaMpkVOO0CmhvF6oD1QRg_7_6">9,009</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Royalties payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedRoyaltiesCurrent" scale="3" id="Tc_NDesqp1A1UGSe4YBWBM66Q_8_3">571</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedRoyaltiesCurrent" scale="3" id="Tc_RZeQRDG8tkKJ9rnDGty29Q_8_6">637</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income tax payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TaxesPayableCurrent" scale="3" id="Tc_GrBnWbAfXE-AOi9nkf7luQ_9_3">3,040</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TaxesPayableCurrent" scale="3" id="Tc_FZJyfHNLYECIQwGx_gzgRg_9_6">2,876</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Sales reserve</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g" decimals="-3" format="ixt:numdotdecimal" name="plx:ReserveForDeductionsFromRevenueCurrent" scale="3" id="Tc_Y_Fj-GyFw0KZxVW6W65M9Q_10_3">4,258</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q" decimals="-3" format="ixt:numdotdecimal" name="plx:ReserveForDeductionsFromRevenueCurrent" scale="3" id="Tc_K20v4CqCc0erpBnvqB82XA_10_6">2,861</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property and equipment suppliers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g" decimals="-3" format="ixt:numdotdecimal" name="plx:AccountsPayablePropertyAndEquipmentSuppliersCurrent" scale="3" id="Tc_DlvofN2HzEepQRL9_G7kag_11_3">402</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q" decimals="-3" format="ixt:numdotdecimal" name="plx:AccountsPayablePropertyAndEquipmentSuppliersCurrent" scale="3" id="Tc_5gyyiDkx9UuSKM3eTCD07w_11_6">614</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_rsSRdAGya0Wf6Vx4In6e8w_12_3">19,577</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_gcSAObl54Uu5ly-MaYSMjw_12_6">19,550</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg" name="us-gaap:SubsequentEventsTextBlock" id="Tb_UOZ386WrTkK0QCPfgAhYsg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 9 &#8211; SUBSEQUENT EVENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">Since the end of the quarter ended September 30, 2024, the Company collected approximately $<ix:nonFraction unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA" contextRef="Duration_11_14_2024_To_11_14_2024_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_IuBQ2oW-QUW8AyxcNROv4A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromCustomers" scale="6" id="Narr_mQ5onepGKkm85fULKhxQPw">3.9</ix:nonFraction>&#160;million from sales to Chiesi<span style="background:#ffffff;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_f1f021a7_e3e6_40b9_89e5_fd6ec08dba80"></a><a id="Item2ManagementsDiscussionandAnalysisofF"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">2.  Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">AND RISK FACTORS SUMMARY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the consolidated financial statements and the related notes included elsewhere in this Form</i>&#160;<i style="font-style:italic;">10-Q and in our Annual Report on Form</i>&#160;<i style="font-style:italic;">10-K for the year ended December</i>&#160;<i style="font-style:italic;">31, 2023. Some of the information contained in this discussion and analysis, particularly with respect to our plans and strategy for our business and related financing, includes forward-looking statements within the meanings of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, including statements regarding expectations, beliefs, intentions or strategies for the future. When used in this report, the terms &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;can,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and words or phrases of similar import, as they relate to our company, our subsidiaries or our management, are intended to identify forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are only predictions and reflect our views as of the date they are made with respect to future events and financial performance, and we undertake no obligation to update or revise, nor do we have a policy of updating or revising, any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events, except as may be required under applicable law. Forward-looking statements are subject to many risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements as a result of several factors, including those set forth in our Quarterly Report on Form&#160;10-Q for the quarter ended June&#160;30, 2024 and in this Quarterly Report on Form 10-Q.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Examples of the risks and uncertainties include, but are not limited to, the following:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to the commercialization of Elfabrio<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (pegunigalsidase alfa-iwxj), our approved product for the treatment of adult patients with Fabry disease;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to Elfabrio&#8217;s market acceptance, competition, reimbursement and regulatory actions, including as a result of the boxed warning contained in the FDA approval received for the product;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the possible disruption of our operations due to the war declared by Israel&#8217;s security cabinet against the Hamas terrorist organization located in the Gaza Strip, the military campaign against the Hezbollah and other terrorist activities and armed conflict, including as a result of the disruption of the operations of certain regulatory authorities and of certain of our suppliers, collaborative partners, licensees, clinical trial sites, distributors and customers, and the risk that the current hostilities will result in a greater regional conflict;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to the regulatory approval and commercial success of our other product and product candidates, if approved;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to our expectations with respect to the projected market for our products and product candidates;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>failure or delay in the commencement or completion of our preclinical studies and clinical trials, which may be caused by several factors, including: slower than expected rates of patient recruitment; unforeseen safety issues; determination of dosing issues; lack of effectiveness during clinical trials; inability to satisfactorily demonstrate non-inferiority to approved therapies; inability or unwillingness of medical investigators and institutional review boards to follow our clinical protocols; inability to monitor patients adequately during or after treatment; and/or lack of sufficient funding to finance our clinical trials;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>delays in the approval or potential rejection of any applications we file with the FDA, EMA or other health regulatory authorities for our other product candidates, and other risks relating to the review process;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks associated with global conditions and developments such as supply chain challenges, the inflationary environment and tight labor market, and instability in the banking industry, which may adversely impact our business, operations and ability to raise additional financing if and as required and on terms acceptable to us;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to any transactions we may effect in the public or private equity or debt markets to raise capital to finance future research and development activities, general and administrative expenses and working capital;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to our evaluation and pursuit of strategic partnerships;</div></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the risk that the results of our clinical trials will not support the applicable claims of safety or efficacy and that our product candidates will not have the desired effects or will be associated with undesirable side effects or other unexpected characteristics;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to our ability to manage our relationship with our collaborators, distributors or partners, including, but not limited to, Pfizer and Chiesi;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to the amount and sufficiency of our cash and cash equivalents;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to changes to interim, topline or preliminary data from clinical trials that we announce or publish;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to the compliance by Fiocruz with its purchase obligations under our supply and technology transfer agreement, which may have a material adverse effect on us and may also result in the termination of such agreement;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risk of significant lawsuits, including stockholder litigation, which is common in the life sciences sector;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>our dependence on performance by third-party providers of services and supplies, including without limitation, clinical trial services;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the inherent risks and uncertainties in developing drug platforms and products of the type we are developing;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the impact of development of competing therapies and/or technologies by other companies;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to our supply of drug products to Pfizer;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>potential product liability risks, and risks of securing adequate levels of related insurance coverage;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the possibility of infringing a third-party&#8217;s patents or other intellectual property rights and the uncertainty of obtaining patents covering our products and processes and successfully enforcing our intellectual property rights against third-parties; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to changes in healthcare laws, rules and regulations in the United States or elsewhere.</div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Given these uncertainties, you should not place undue reliance on these forward-looking statements. Companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in advanced or late-stage clinical trials, even after obtaining promising earlier trial results or preliminary findings for such clinical trials. Even if favorable testing data is generated from clinical trials of a drug product, the FDA or foreign regulatory authorities may not accept or approve a marketing application filed by a pharmaceutical or biotechnology company for the drug product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Recent Company Developments</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>In September 2024, we repaid in full all of the outstanding principal and interest payable under our 2024 Notes. The repayment of the convertible notes at maturity was financed entirely with available cash.</div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">ProCellEx: Our Proprietary Protein Expression System</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">ProCellEx is our proprietary platform used to produce and manufacture recombinant proteins through plant cell-based expression in suspension. We are the first and only company to gain FDA approval of a protein produced through plant cell-based expression, and with the recent approval of Elfabrio, we now have two commercial proteins produced through our platform.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">ProCellEx consists of a comprehensive set of proprietary technologies and capabilities, including the use of advanced genetic engineering and plant cell culture technology, enabling us to produce complex, proprietary, and biologically equivalent proteins for a variety of human diseases. Our protein expression system facilitates the creation and selection of high-expressing, genetically-stable cell lines capable of expressing recombinant proteins. The system plays an important role in the execution of our corporate strategy as its allows us to develop and produce tailored complex recombinant therapeutic proteins and to genetically engineer and/or chemically modify such proteins pre- and/or post-production. The engineering and modification of the therapeutic proteins have the potential to provide added clinical benefits by improving the biological characteristics (e.g., glycosylation, half-life, immunogenicity).</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:222pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our ProCellEx technology allows for many unique advantages, including: biologic optimization; an ability to handle complex protein expressions; flexible manufacturing with improvements through efficiencies, enhancements and/or rapid horizontal scale-ups; a simplified production process; elimination of the risk of viral contaminations from mammalian components; and intellectual property advantages.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We developed ProCellEx based on our plant cell culture technology for the development, expression and manufacture of recombinant proteins which are the essential foundation of modern biotechnology. We develop new, recombinant therapeutic proteins by using the natural capability of agrobacterium to transfer a DNA fragment into the plant chromosome, allowing the genome of the plant cell to code for specific proteins of interest. The agrobacterium-mediated transformed cells are then able to produce specific proteins, which are extracted and purified and can be used as therapies to treat a variety of diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our ProCellEx technology can be utilized to express complex therapeutic proteins belonging to different drug classes, such as enzymes, monoclonal antibodies, hormones, cytokines and vaccines. The entire protein expression process, from initial nucleotide cloning to large-scale production of the protein product, occurs under Current Good Manufacturing Practice-, or cGMP-, compliant, controlled processes. Our plant cell culture technology uses cells, such as carrot and tobacco (BY-2) cells, which undergo advanced genetic engineering and/or chemical modifications, and are grown on an industrial scale in a disposable, flexible bioreactor system. Our system does not involve mammalian or animal-derived components or transgenic field-grown or whole plants at any point in the production process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Cell growth, from initiating scale-up steps from a cell-bank through large-scale production takes place in a clean-room environment in flexible, sterile, custom-designed polyethylene bioreactors, and does not require the use of large stainless-steel bioreactors commonly used in mammalian-based systems for recombinant protein production. The ProCellEx reactors are easy to use and maintain, allow for rapid horizontal scale-up and do not involve the risk of mammalian viral contamination. Our bioreactors are well-suited for plant cell growth using a simple, inexpensive, chemically defined growth medium. The reactors, which are custom-designed and optimized for plant cell cultures, require low initial capital investment and are rapidly scalable at a low cost.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Plant Cell Production Advantages</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><img src="plx-20240930x10q005.jpg" alt="Graphic" style="display:inline-block;height:221.95pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:540pt;"/></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:228pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><div style="height:0pt;position:relative;width:100%;"><div style="height:171pt;left:-6.67%;position:absolute;top:-77.5pt;width:540pt;z-index:251658240;"><div style="height:170.55pt;left:0pt;padding-bottom:0.45pt;position:relative;width:540pt;"><div style="height:0pt;position:relative;width:100%;"><div style="height:170.55pt;left:0pt;position:absolute;width:540pt;"></div></div></div></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">ProCellEx</b><sup style="font-size:7.5pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><b style="font-weight:bold;">: Protalix&#8217;s Differentiated Plant Cell Protein Expression Platform</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><img src="plx-20240930x10q007.jpg" alt="Graphic" style="display:inline-block;height:227.85pt;left:0%;padding-bottom:0.15pt;position:relative;top:0pt;width:540pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Products and Product Pipeline</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><img src="plx-20240930x10q008.jpg" alt="Graphic" style="display:inline-block;height:166.6pt;width:540pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Our Marketed Products</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have two commercial products, each of which is an ERT; Elelyso and Elfabrio.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Elelyso for the Treatment of Gaucher Disease</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Elelyso (taliglucerase alfa), our first commercial product, was approved by the FDA in 2012 for injection as an ERT for the long-term treatment of adult patients with a confirmed diagnosis of type&#160;1 Gaucher disease. In August 2014, the FDA approved Elelyso for injection for pediatric patients. Elelyso is the first plant cell derived recombinant protein to be approved by the FDA for the treatment of Gaucher disease and is now approved in 23&#160;markets including the United States, Brazil, Israel and others.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Gaucher disease, also known as glucocerebrosidase, or GCD, deficiency, is a rare genetic autosomal recessive disorder and one of the most common Lysosomal Storage Disorders, or LSDs, in the world. It is one of a group of disorders that affect specific enzymes that normally break down fatty substances for reuse in the cells. If the enzymes are missing or do not work properly, the substances can build up and become toxic. Gaucher disease occurs when a lipid called glucosylceramide accumulates in the cells of the bone marrow, lungs, spleen, liver, and sometimes the brain. Gaucher disease symptoms can include fatigue, anemia, easy bruising and bleeding, severe bone pain and easily broken bones, and distended stomach due to an enlarged spleen and thrombocytopenia. Epidemiology of Gaucher disease varies; Recent literature provides that prevalence of Gaucher disease ranges from 0.70 to 1.75 per 100,000 in the </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">general population. In people of Ashkenazi Jewish heritage, estimates of occurrence vary from approximately 1&#160;in 400 to 1&#160;in 850 people.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The global market for Gaucher disease, that includes Sanofi&#8217;s Cerezyme<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, Shire&#8217;s (acquired by Takeda Pharmaceutical Company Limited) Vpriv<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> and Sanofi&#8217;s Cerdelga<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, among others, was $1.6&#160;billion in 2023, is forecasted to be approximately $1.65&#160;billion in 2024 and is forecasted to grow at a compound annual growth rate (CAGR) of approximately -0.12% from 2023-2030.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">The current standard of care for Gaucher disease is ERT, which is a medical treatment where recombinant enzymes are injected into patients to replace the lacking or dysfunctional enzyme. In Gaucher disease, recombinant GCD is infused to replace the mutated or deficient natural GCD enzyme. Elelyso is the only alternative ERT treatment of Gaucher disease to Sanofi Genzyme&#8217;s Cerezyme<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> and Takeda&#8217;s (Shire) Vpriv.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Elfabrio for the Treatment of Fabry Disease</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">Elfabrio, our second commercial product, was approved by the EC for marketing in the EU and by the FDA for marketing in the United States in May 2023 for adult patients with Fabry disease. Both approvals cover the 1&#160;mg/kg every two weeks dosage. Overall, the FDA review team concluded that in the context of Fabry disease as a rare, serious disease with limited therapeutic options that may not be suitable to all individual patients, the benefit-risk of Elfabrio is favorable for the treatment of adults with confirmed Fabry disease. According to the EMA, overall, the benefit/risk balance of Elfabrio is positive in the claimed indication (Fabry disease). The FDA publicly released the internal review documents for Elfabrio. These documents provide previously unavailable additional information regarding the basis for the FDA&#8217;s May 2023 approval decision. In particular, the FDA determined that substantial evidence of effectiveness for Elfabrio in Fabry patients was established with one adequate and well-controlled study, our phase&#160;I\II clinical trial of Fabry disease, with confirmatory evidence provided by the <i style="font-style:italic;">BALANCE</i> study. The FDA review team also concluded that the <i style="font-style:italic;">BALANCE</i> study met its primary efficacy endpoint, which assessed the annualized rate of change in eGFR (estimated glomerular filtration rate) over 104 weeks. However, the FDA also determined that the results from the <i style="font-style:italic;">BALANCE</i> study did not support a non-inferiority claim to the comparator product due to the lack of data to support the non-inferiority margin.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">Since the approvals by the FDA and the EMA, Elfabrio has also been approved for marketing in Great Britain, Switzerland, Peru and Israel for long-term enzyme replacement therapy in adult patients with a confirmed diagnosis of Fabry disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-bottom:10pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;">Fabry disease is a serious life-threatening rare genetic disorder. Fabry patients lack or have low levels of &#945;-galactosidase-A resulting in the progressive accumulation of abnormal deposits of a fatty substance called globotriaosylceramide, or Gb</span><sub style="font-size:5.62pt;vertical-align:sub;">3</sub><span style="font-size:10pt;">, in blood vessel walls throughout their body. The ultimate consequences of Gb</span><sub style="font-size:5.62pt;vertical-align:sub;">3</sub><span style="font-size:10pt;">&#160;deposition range from episodes of pain and impaired peripheral sensation to end-organ failure, particularly of the kidneys, but also of the heart and the cerebrovascular system. Fabry disease occurs in one person per 40,000 to 60,000 males.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">The standard of care for Fabry disease is ERT. Currently, the ERTs for Fabry disease are agalsidase alfa, agalsidase beta, and now Elfabrio. Through an ERT, the missing &#945;-galactosidase-A is replaced with a recombinant form of the protein via intravenous, or IV, infusion once every two weeks. Fabry disease, if left untreated, will progress from a less severe condition to a more serious one. It can have a significant impact on quality of life due to presence of serious, chronic and debilitating complications, including cardiovascular and renal complications, and comorbid conditions such as pain can have a significant impact on the psychological well-being of Fabry patients and their social functioning. Fabry disease involves substantial reduction in life expectancy. Causes of death are most often cardiovascular disease and, to a lesser extent, cerebrovascular disease and renal disease. The life expectancy of Fabry patients is significantly shorter compared to the general population. Untreated male Fabry patients may experience shortened lifespans to approximately 50&#160;years, and 70&#160;years for untreated female patients with Fabry disease. This represents a 20- and 10-year reduction of their respective lifespans. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">The global market for Fabry disease, that includes agalsidase beta, Sanofi&#8217;s Fabrazyme<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, agalsidase alfa, Shire&#8217;s Replagal<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> and Amicus Therapeutics&#8217; Galafold<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, among others, is forecasted to be approximately $2.1&#160;billion in 2024 and is forecasted to grow at a CAGR of 7.4% from 2023-2030 reaching approximately $3.3&#160;billion in annual sales in 2030.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Elfabrio Regulatory Background</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">On November&#160;9, 2022, we, together with Chiesi, resubmitted to the FDA a BLA for PRX-102, the name we assigned to Elfabrio internally prior to its approvals, for the potential treatment of adult patients with Fabry disease. The initial BLA for PRX-102 was submitted to the FDA on May&#160;27, 2020 under the FDA&#8217;s Accelerated Approval pathway, and the submission was subsequently accepted by the FDA and granted Priority Review designation. However, in April 2021, the FDA issued a complete response letter, or CRL, in response to the initial BLA. In preparation for the BLA resubmission, we and Chiesi participated in a Type A (End of Review) meeting with the FDA on September&#160;9, 2021. As part of the meeting minutes provided by the FDA, which included the </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">preliminary comments and meeting discussion, the FDA, in principle, agreed that the data package proposed to the FDA for a BLA resubmission had the potential to support a traditional approval of PRX-102 for the treatment of Fabry disease. The data package in the BLA resubmission, given the change in the regulatory landscape in the United States, included the final two-year analyses of our&#160;<i style="font-style:italic;">BALANCE&#160;</i>study, which were completed in July 2022, and long-term data from our open-label extension study of PRX-102 in adult patients treated with a 2&#160;mg/kg every four&#160;weeks dosage of PRX-102. The initial BLA included a comprehensive set of preclinical, clinical and manufacturing data compiled from our completed phase&#160;I/II clinical trial of PRX-102, including the related extension study, interim clinical data from our phase III BRIDGE clinical trial of PRX-102 for the treatment of Fabry disease, or the <i style="font-style:italic;">BRIDGE</i>&#160;study, and safety data from our then on-going clinical studies of PRX-102 in adult patients receiving 1&#160;mg/kg every two weeks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">No concerns relating to the potential safety or efficacy of PRX-102 in the submitted data package were raised in the CRL. The FDA noted in CRL that an inspection of our manufacturing facility in Carmiel, Israel, including the FDA&#8217;s subsequent assessment of any related FDA findings, is required before the FDA can approve a new drug. Due to travel restrictions during the COVID-19 pandemic, the FDA was unable to conduct the required pre-approval inspection during the review cycle. In addition to the foregoing, the FDA noted that agalsidase beta had recently been converted to full approval, a change in regulatory circumstances which had to be addressed in the resubmitted BLA for PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">On February&#160;7, 2022, the PRX-102 MAA was submitted to, and subsequently validated by, the EMA. The submission was made after the October&#160;8, 2021 meeting we held, together with Chiesi, with the Rapporteur and Co-Rapporteur of the EMA regarding PRX-102. At the meeting, we and Chiesi discussed the scope of the anticipated MAA submission for the European Union, and the Rapporteur and Co-Rapporteur were generally supportive of the planned MAA submission. The MAA submission included a comprehensive set of preclinical, clinical and manufacturing data compiled from our completed and ongoing clinical studies evaluating PRX-102 as a potential alternative treatment for adult patients with Fabry disease. The submission was supported by the 12-month interim data analysis generated from our <i style="font-style:italic;">BALANCE</i> study, which was released in June 2021. Data generated from the completed&#160;<i style="font-style:italic;">BRIDGE</i>&#160;study, the phase&#160;I/II clinical trial in naive or untreated patients, and from the extension studies with 1&#160;mg/kg every two weeks were also included in the submission. In addition, the MAA included data from the completed 12-month switch&#8211;over phase&#160;III BRIGHT clinical trial of PRX-102 for the treatment of Fabry disease for adult patients with Fabry disease treated with the 2&#160;mg/kg every four&#160;weeks dosage, or the <i style="font-style:italic;">BRIGHT</i> study. As part of the EMA review process, we and Chiesi received the Day 120 list of questions in June 2022, and the full response package thereto was submitted to the EMA in September 2022 (following a 3-month clock-stop period). An essential portion of the response included the submission of the final analysis of the two-year&#160;<i style="font-style:italic;">BALANCE</i>&#160;study (the final Clinical Study Report), and an interim analysis of the long-term, open-label extension study of PRX-102 in adult patients with Fabry disease treated with the 2&#160;mg/kg every four&#160;weeks dosage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On February&#160;24, 2023, we, together with Chiesi, announced that the CHMP had adopted a positive opinion, recommending marketing authorization for PRX-102. The CHMP opinion was then referred for final action to the EC. <span style="background:#ffffff;">As disclosed above, Elfabrio was subsequently approved by the EC for marketing in the EU and in the United States in May 2023 for adult patients with Fabry disease. Both approvals cover the 1&#160;mg/kg every two weeks dosage.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="font-style:italic;font-weight:bold;">Elfabrio Key Trials and Design</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our PRX-102 clinical development program was designed to show that PRX-102 has a potential clinical benefit in all adult Fabry patient populations when compared to the then marketed Fabry disease enzymes, agalsidase beta and agalsidase alfa. In preclinical studies, PRX-102 showed significantly longer half-life due to higher enzyme stability, enhanced activity in Fabry disease affected organs leading to reduction of the accumulated substrate and reduced immunogenicity, which together can potentially lead to improved efficacy through increased substrate clearance and significantly lower formation of anti-drug antibodies, or ADAs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The phase&#160;III clinical program included three individual studies; the <i style="font-style:italic;">BALANCE</i> study, the <i style="font-style:italic;">BRIDGE</i> study the <i style="font-style:italic;">BRIGHT</i> study, all of which have been completed. In the phase&#160;III clinical program overall, two potential dosing regimens for PRX-102 were analyzed; 1&#160;mg/kg every two weeks, with the potential for improved efficacy and safety offering a potential alternative to existing enzyme replacement therapies, and 2&#160;mg/kg every four weeks. The phase&#160;III program was preceded by the phase&#160;I/II clinical trial, a dose range finding study in ERT-na&#239;ve adult patients with Fabry disease, which was completed in 2016.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><span style="font-style:italic;font-weight:bold;">Phase III BALANCE Study</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The <i style="font-style:italic;">BALANCE</i> study (PB-102-F20, NCT02795676) was a pivotal 24-month, randomized, double blind, active control study of PRX-102 in adult Fabry patients with deteriorating renal function designed to evaluate the safety and efficacy of 1&#160;mg/kg of PRX-102 administered every two weeks compared to agalsidase beta. The Clinical Study Report for the <i style="font-style:italic;">BALANCE</i> study was completed in July 2022. The final analysis confirmed the positive top-line results (announced in April 2022) and favorable tolerability profile. A total of 78 patients who were previously treated with agalsidase beta for at least one year with an eGFR slope at screening worse than -</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">2&#160;mL/min/1.73 m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year were enrolled in the study. Patients were randomized on a 2:1 ratio for switching to PRX-102 or continuing on agalsidase beta. A total of 77&#160;patients were treated; 52 with PRX-102 and 25 with agalsidase beta. Approximately 40% of the enrolled patients were female.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Forty-seven (90.4%) patients in the PRX-102 arm experienced at least one treatment-emergent adverse event (TEAE) compared to 24 (96.0%) in the agalsidase beta arm. The number of events adjusted to 100&#160;years of exposure is 572.36 events for the PRX-102 arm and 816.85 events for the agalsidase beta arm.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">TEAEs were reported for 21 (40.4%) patients in the PRX-102 arm compared to 11 (44.0%) in the agalsidase beta arm. The number of treatment-related events adjusted to 100 years of exposure is 42.85 events for the PRX-102 arm and 152.91 events for the agalsidase beta arm.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Usage of infusion pre-medication was tapered down during the study, if possible, for all patients. At baseline, 21 (40.4%) patients in the PRX-102 arm used infusion premedication compared to 16 (64.0%) in the agalsidase beta arm. At the end of the study, only three out of 47 (6.4%) patients in the PRX-102 arm used infusion premedication compared to three out of 24 (12.5%) in the agalsidase beta arm. Even with this reduction in use of premedication, there were fewer reported infusion-related reactions with PRX-102: 11&#160;(21.2%)&#160;patients in the PRX-102 arm experienced a total of 13&#160;events compared to six (24.0%) patients experiencing a total of 51&#160;events in the agalsidase beta arm. The number of infusion-related reactions adjusted to 100 infusions is 0.5 for the PRX-102 arm and 3.9 for agalsidase beta arm.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Assessment of immunogenicity, that is, the existence and development of anti PRX-102 antibodies or anti-agalsidase beta antibodies, in the study indicated that for the PRX-102 arm, 18 (34.6%) patients were ADA positive at baseline, of which 17 (94.4%) had neutralizing antibody activity. For the agalsidase beta arm, eight (32.0%) patients were ADA positive at baseline, of which seven (87.5%) had neutralizing antibody activity. Only a small number of patients showed treatment-emergent ADA. At the end of the two-year study, 11 (23.4%) patients that received PRX-102 were ADA positive, of which seven (63.6%) had neutralizing antibody activity, while in the agalsidase beta arm six (26.1%) were ADA-positive and all six (100%) had neutralizing antibody activity. There was little change in the percentage of patients who were ADA positive, with a trend of reduction observed in the PRX-102 arm and stability in the agalsidase beta arm. The proportion of patients with neutralizing ADA decreased in the PRX-102 arm while it remained stable in the agalsidase beta arm.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Out of the 78 randomized patients, six patients discontinued the study: out of the five (9.4%) from the PRX-102 arm, one patient withdrew consent prior to the first infusion, two discontinued due to personal reasons, and two due to adverse events (one due to an unrelated adverse event and one due to a treatment related adverse event); one (4%) patient from the agalsidase beta arm discontinued for personal reasons. There were no deaths in this study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Considering that in the trial patients in the PRX-102 arm were exposed for the first time to the novel enzyme, tolerability data appear favorable for PRX-102 and in-line with what was observed in the previous clinical studies of PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Of the patients that completed the trial from both the PRX-102 and agalsidase beta treatment arms, 69 opted, with the advice of the treating physician, to receive PRX-102 1&#160;mg/kg every two weeks in the long-term open-label extension study which is now sponsored by Chiesi.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The results of the direct, blinded comparison of PRX-102 to agalsidase beta, for the primary efficacy renal endpoints (i.e., eGFR change, eGFR slope) and for the main secondary endpoints (e.g., urine protein to creatinine ratio [UPCR] LVMI, MSSI, BPI) strongly suggest comparability in treatment effects between the two treatments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">At the same time a potentially favorable safety profile was identified based on lower rates of IRR, lower ADA positivity, and less premedication use in the PRX-102 arm compared to agalsidase beta. Overall, a positive benefit-risk balance was confirmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><span style="font-style:italic;font-weight:bold;">Phase&#160;III BRIDGE Study</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">The <i style="font-style:italic;">BRIDGE</i> study (PB-102-F30, NCT03018730) was a 12-month open-label, single arm switch-over study evaluating the safety and efficacy of PRX-102, 1&#160;mg/kg infused every two weeks, in up to 22 Fabry patients previously treated with agalsidase alfa for at least two years and on a stable dose for at least six months. In the study, patients were screened and evaluated over three months while continuing agalsidase alfa treatment. The study was completed in December 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Final results of the data generated in the <i style="font-style:italic;">BRIDGE</i> study showed substantial improvement in renal function as measured by mean annualized eGFR slope in both male and female patients. Twenty of 22 patients completed the 12-month treatment duration. Eighteen of the patients who completed the study opted to roll over to a long-term extension study and continue to be treated with PRX-102. In </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">the study, the mean annualized eGFR slope of the study participants improved from -5.90&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year while on agalsidase alfa to -1.19&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year on PRX-102 in all patients. Male patients improved from -6.36&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year to -1.73mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year and female patients improved from -5.03&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year to -0.21&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year. Following the switch to PRX-102, there was a decrease in patients with progressing or fast progressing kidney disease which is consistent with the therapeutic goals for Fabry disease, as identified by Christoph Wanner, et. al., in 2019, and most patients achieved a stable status post-switch.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">PRX-102 was well-tolerated in the <i style="font-style:italic;">BRIDGE</i> study, with all adverse events being transient in nature without sequelae. Of the 22 patients enrolled in the <i style="font-style:italic;">BRIDGE</i> study, the majority of TEAEs were mild or moderate in severity, with two patients (9.1%) withdrawing from the therapy due to hypersensitivity reaction that was resolved. The most common moderate TEAEs were nasopharyngitis, headache and dyspnea. An immunogenicity assessment indicated that four out of 20 patients (20%) developed persistent ADAs over the course of the study, of which two had neutralizing activity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">Of the patients that completed the trial, 18 opted, with the advice of the treating physician, to continue receiving PRX-102 1&#160;mg/kg every two weeks in a long-term open-label extension study which is now sponsored by Chiesi.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><span style="font-style:italic;font-weight:bold;">Phase&#160;III BRIGHT Study</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">The <i style="font-style:italic;">BRIGHT</i> study (PB-102-F50, NCT03180840) was a multicenter, multinational open-label, switch-over study designed to evaluate the safety, efficacy and pharmacokinetics of treatment with 2&#160;mg/kg of PRX-102 administered every four weeks for 52 weeks (a total of 14&#160;infusions). The study was completed in June 2020. The 2&#160;mg/kg every four weeks dosage has not been approved by the EMA, FDA or any other jurisdiction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Enrollment in the study included 30 adult patients (24 males and 6 females) with mean (SD) age of 40.5 (11.3) years, ranging from 19 to 58 years previously treated with a commercially available ERT (agalsidase beta or agalsidase alfa), for at least three years and on a stable dose administered every two weeks. To determine eligibility for participation in the study, candidates were screened to identify and select Fabry patients with clinically stable kidney disease. The most common Fabry disease symptoms at baseline were acroparesthesia, heat intolerance, angiokeratomas and hypohydrosis. Patients who matched the criteria were enrolled in the study and switched from their current treatment of IV infusions every two weeks to 2&#160;mg/kg of PRX-102 every four weeks for 12 months. Patients participating in the study were evaluated, among other disease parameters, to determine if their kidney disease had not further deteriorated while being treated with the four-week dosing regimen as measured by eGFR and for lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3 </sub>levels as a Fabry biomarker, as well as other parameters. In addition, participating patients were evaluated to assess the safety and tolerability of PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The final results from the <i style="font-style:italic;">BRIGHT</i> study indicate that 2&#160;mg/kg of PRX-102 administered by intravenous infusion every four weeks was well tolerated, and Fabry disease assessed by eGFR slope and plasma lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> was stable throughout PRX-102 treatment in adult Fabry patients. None of the patients without ADAs at screening developed treatment-induced ADAs following the switch to PRX-102 treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">All 30 patients received at least one dose of PRX-102, and 29 patients completed the one-year study. Of these 29 patients, 28 received the intended regimen of 2&#160;mg/kg every four weeks throughout the entire study, while one patient was switched to 1&#160;mg/kg PRX-102 every two weeks per protocol at the 11th infusion. One patient withdrew from the study after the first infusion due to a traffic accident.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">First infusions of PRX-102 were administered under controlled conditions at the investigation site. Based on the protocol-specified criteria, patients were able to receive their PRX-102 infusions at a home care setup once the applicable Investigator and Sponsor Medical Monitor agreed that it was safe to do so. Safety and efficacy exploratory endpoints were assessed throughout the 52-week study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Overall, 33 of 183 total TEAEs reported in nine (30.0%) of the patients were considered treatment related; all were mild or moderate in severity and the majority were resolved at the end of the study. There were no serious or severe treatment-related TEAEs and no TEAEs led to death or study withdrawal. Of the treatment-related TEAEs, 27 were infusion-related reactions (IRRs) and the remainder were single events of diarrhea, erythema, fatigue, influenza-like illness, increases urine protein/creatinine ratio, and urine positive for white blood cells. The 27 IRRs were reported in five (16.7%) patients, all male. All IRRs occurred during the infusion or within two hours post-infusion; no events were recorded between two and 24 hours post-infusion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Study outcome measures show that plasma lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> concentrations remained stable during the study with a mean change (&#177;SE) of 3.01&#160;nM (0.94) from baseline (19.36 nM &#177;3.35) to Week&#160;52 (22.23 &#177;3.60 nM). Mean absolute eGFR values were stable during the 52-week treatment period, with a mean change from baseline of -1.27&#160;mL/min/1.73 m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> (1.39). Mean (SE) eGFR slope, at the end of the study, for the overall population, was -2.92&#160;(1.05) mL/min/1.73 m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year indicating stability.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The study suggests that Fabry patients who are currently receiving ERT every two weeks may be successfully transitioned to PRX-102 2&#160;mg/kg every four weeks as an effective and tolerable alternative treatment option. Additional long term data is being collected as part of the ongoing long term extension study (PB-102-F51, NCT03614234) of the 2&#160;mg/kg PRX-102 every four weeks dose.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Following a survey of participants using the Quality of Life EQ-5D-5L questionnaire, responses indicate that patient perception of their own health remained high and stable throughout the 52-week study duration, with overall health mean (SE) scores of 78.3 (3.1) and 82.1 (2.9) at baseline and Week 52, respectively, in a 0 to 100 scale. Using the short-form Brief Pain Inventory, or, questionnaire, approximately 75% of study participants had an improvement or no change in average pain severity at Week 52 (compared to baseline). The short-form BPI interference items also remained stable during the study. Pain-related results indicate that there was no increase and/or relapse in pain. No Fabry clinical events were reported during the study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Of the patients that completed the trial, 29 opted, with the advice of the treating physician, to continue receiving PRX-102 2&#160;mg/kg every four weeks in a long-term open-label extension study which is now sponsored by Chiesi. Two of such patients are being treated with 1&#160;mg/kg every two weeks dosage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><span style="font-style:italic;font-weight:bold;">Phase I/II Study</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The phase&#160;I/II clinical trial of PRX-102 (NCT01678898) was a worldwide, multi-center, open-label, dose ranging study designed to evaluate the safety, tolerability, pharmacokinetics, immunogenicity and efficacy parameters of PRX-102 in adult patients with Fabry disease. It was completed in 2015.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We initiated the phase&#160;I\II study after PRX-102, in preclinical studies, showed significantly longer half-life due to higher enzyme stability, enhanced activity in Fabry disease affected organs leading to reduction of the accumulated substrate and reduced immunogenicity, which together can potentially lead to improved efficacy through increased substrate clearance and significantly lower formation of ADAs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Sixteen adult, na&#239;ve Fabry patients (9 male and 7 female) completed the phase&#160;I/II study, each in one of three dosing groups, 0.2&#160;mg/kg, 1&#160;mg/kg and 2&#160;mg/kg. Each patient received IV&#160;infusions of PRX-102 every two weeks for 12 weeks, with efficacy follow-up after six-month and twelve-month periods. The overall results demonstrate that PRX-102 reaches the affected tissue and reduces kidney Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> inclusions burden and lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3 </sub>in the circulation. A high correlation was found between the two Fabry disease biomarkers, reduction of kidney Gb<sub style="font-size:7.5pt;vertical-align:sub;">3 </sub>inclusions and the reduction of plasma lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> over six months of treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Data was recorded at 24&#160;months from 11 patients who completed 12&#160;months of the long-term open-label extension trial that succeeded the phase&#160;I/II study. Patients who did not continue in the extension trial included female patients who became or planned to become pregnant and therefore were unable to continue in accordance with the study protocol and patients who relocated to a location where treatment was not available under the clinical study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Results show that lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> levels decreased approximately 90% from baseline. Renal function remained stable with mean eGFR levels of 108.02 and 107.20 at baseline and 24&#160;months, respectively, with a modest annual eGFR slope of -2.1. An improvement across all the gastrointestinal symptoms evaluated, including severity and frequency of abdominal pain and frequency of diarrhea, was noted. Cardiac parameters, including LVM, LVMI and EF, remained stable with no cardiac fibrosis development detected. In conclusion, an improvement of over 40% in disease severity was shown as measured by the Mainz Severity Score Index, or MSSI, a score compiling the different elements of the disease severity including neurological, renal and cardiovascular parameters. In addition, an improvement was noted in each of the individual parameters of the MSSI.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The majority of adverse events were mild-to-moderate in severity, and transient in nature. During the first 12 months of treatment, only three of 16 patients (less than 19%) formed ADAs of which two of these patients (less than 13%) had neutralizing antibodies. Importantly, however, the ADAs turned negative for all three of these patients following 12&#160;months of treatment. The ADA positivity effect had no observed impact on the safety, efficacy or continuous biomarker reduction of PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Of the patients who completed the trial, 10 patients opted to continue receiving PRX-102 in an open-label, 60-month extension study under which all patients were switched to receive 1&#160;mg/kg of the drug, the selected dose for our <i style="font-style:italic;">BALANCE</i> and <i style="font-style:italic;">BRIDGE</i> studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><span style="font-style:italic;font-weight:bold;">Extension Studies</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Patients who completed the <i style="font-style:italic;">BALANCE</i>, <i style="font-style:italic;">BRIDGE</i> and <i style="font-style:italic;">BRIGHT</i> studies, and the extension of the phase I/II study, were offered the opportunity to continue PRX-102 treatment in one of two long-term open-label extension studies. Overall, 126 patients who participated in our PRX-102 clinical program initially opted, with the advice of the treating physician, to enroll in one of our long-</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">term, open label, extension studies of PRX-102: 97 patients in the 1&#160;mg/kg every two weeks extension study (PB-102-F60, NCT03566017) (10 patients who completed an extension study from the phase&#160;I/II study, 18 patients who completed the <i style="font-style:italic;">BRIDGE</i> study; 69 patients who completed the <i style="font-style:italic;">BALANCE</i> study), and 29 patients who completed the <i style="font-style:italic;">BRIGHT</i> study in the 2&#160;mg/kg every four weeks extension study (PB-102-F51, NCT03614234). Two of the patients in the PB-102-F51 study are being treated with 1&#160;mg/kg every two weeks. As of March&#160;1, 2023, sponsorship of the two extension studies was transferred to Chiesi, and Chiesi is now administering the open-label extension studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Over time, and as Elfabrio is approved for marketing in different jurisdictions, patients switch-out of the open-label extension studies. Most of them have transferred to a commercial setting; others withdraw for other reasons.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><span style="font-style:italic;font-weight:bold;">Pediatric FLY Study</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">Chiesi is sponsoring, with our collaborative efforts, a clinical trial entitled &#8220;Multi-Centre, Open-label Trial to Assess the Safety, Pharmacodynamics, Efficacy and Pharmacokinetics of pegunigalsidase alfa in Patients From 2 Years to Less Than 18 Years of Age With Confirmed Fabry Disease,&#8221; or the <i style="font-style:italic;">FLY</i> study (NCT06328608). The<i style="font-style:italic;"> FLY</i> study is currently in the start-up phase. The design of the study is based on the Initial Pediatric Study Plan (iPSP) agreed to with the FDA and the paediatric investigation plan (PIP) for Elfabrio, which has been accepted, as amended, by the Paediatric Committee (PDCO) of the EMA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><span style="font-style:italic;font-weight:bold;">Japanese RISE Study</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Chiesi is currently enrolling patients in its clinical trial entitled &#8220;A Multicenter Open-Label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Pegunigalsidase Alfa (PRX-102) in Japanese Patients With Fabry Disease,&#8221; or the <i style="font-style:italic;">RISE</i> study (NCT05710692). The aim of the <i style="font-style:italic;">RISE</i> study is to evaluate the safety and efficacy of pegunigalsidase alfa in Japanese patients (adults and adolescents) affected by Fabry disease. It is planned that a total of approximately 18-20 male and female Fabry disease patients between the ages of 13 and 60 years will be enrolled in the study which is being conducted in Japan.</p><a id="_DV_M79"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="font-style:italic;font-weight:bold;">Commercialization of Approved Products</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><span style="font-style:italic;font-weight:bold;">Commercialization Agreements with Chiesi Farmaceutici</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have entered into two exclusive global licensing and supply agreements for PRX-102 for the treatment of Fabry disease with Chiesi. The agreements have significant revenue potential for Protalix. Under the agreements, Protalix&#160;Ltd. has received $50.0&#160;million in upfront payments and development cost reimbursements of $45.0&#160;million, and is entitled to approximately $1.0&#160;billion in potential milestone payments as well as additional payments as consideration for drug product supply. The additional payments for drug product supplied are based on the average selling price of the drug product in the relevant territory multiplied by tiered payments, as detailed below. During the quarter ended June&#160;30, 2023, we received net proceeds of $20.0&#160;million representing a milestone payment earned upon the FDA&#8217;s approval of Elfabrio for adult Fabry patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On October&#160;19, 2017, Protalix&#160;Ltd. and Chiesi entered into the Chiesi Ex-US Agreement pursuant to which Chiesi was granted an exclusive license for all markets outside of the United States to commercialize PRX-102. Under the Chiesi Ex-US Agreement, Chiesi made an upfront payment to Protalix&#160;Ltd. of $25.0&#160;million in connection with the execution of the agreement, and Protalix&#160;Ltd. was entitled to additional payments of up to $25.0&#160;million in development costs in the aggregate, capped at $10.0&#160;million per&#160;year. Protalix&#160;Ltd. is also eligible to receive additional payments of up to a maximum of $320.0&#160;million in regulatory and commercial milestone payments. Protalix&#160;Ltd. agreed to manufacture all of the PRX-102 needed for all purposes under the agreement, subject to certain exceptions, and Chiesi will purchase PRX-102 from Protalix&#160;Ltd., subject to certain terms and conditions. Chiesi is required to make tiered payments for drug product purchased from Protalix based on the average selling price of the drug product in the relevant territory multiplied by 15% to 35%, depending on the amount of annual net sales outside of the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On July&#160;23, 2018, Protalix&#160;Ltd. entered into the Chiesi US Agreement with respect to the development and commercialization of PRX-102 in the United States. Protalix&#160;Ltd. received an upfront, non-refundable, non-creditable payment of $25.0&#160;million from Chiesi and was entitled to additional payments of up to a maximum of $20.0&#160;million to cover development costs for PRX-102, capped at $7.5&#160;million per&#160;year. Protalix&#160;Ltd. is also eligible to receive additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Chiesi agreed to make tiered payments for drug product purchased from Protalix based on the average selling price of the drug product in the United States multiplied by 15% to 40%, subject to certain terms and conditions, depending on the amount of annual net sales in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">On May&#160;13, 2021, we signed a binding term sheet with Chiesi amending the Chiesi Agreements in order to provide our company with near-term capital. Chiesi agreed to make a $10.0&#160;million payment to us before the end of the second quarter of 2021 in exchange for a $25.0&#160;million reduction in a longer term regulatory milestone payment provided in the Chiesi EX-US Agreement. All other regulatory </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">and commercial milestone payments remain unchanged. We received the payment in June&#160;2021. We also agreed to negotiate certain manufacturing related matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">On August&#160;29, 2022, we entered into the F/F Agreement and the Letter Agreement with Chiesi. Under the F/F Agreement, we agreed to supply Chiesi with drug substance for PRX-102 and, following relevant technology and technical information transfer activities, Chiesi agreed, among other things, to provide us with commercial fill/finish services for PRX-102, including to support the anticipated global launch of PRX-102. The F/F Agreement will expire December&#160;31, 2025, unless terminated earlier in accordance with its terms and may be extended by mutual agreement in writing for an additional period of seven years. The Letter Agreement changed our obligations and those of Chiesi under the License Agreements with respect to, among other things, the evaluation, selection and establishment of an initial alternate source of commercial fill/finish services for PRX-102. In addition, the Letter Agreement amended certain provisions of the License Agreements to reflect the appointment of Chiesi as a supplier to our company of commercial fill/finish services and the potential establishment of an initial alternate source of commercial fill/finish services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">As of March&#160;1, 2023, sponsorship of the two extension studies was transferred to Chiesi, and Chiesi is now the sponsor of the extension studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><span style="font-style:italic;font-weight:bold;">Commercialization Agreements for Elelyso</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have licensed to Pfizer the global rights to Elelyso in all markets excluding Brazil. Pfizer retains 100% of revenue and reimburses 100% of direct costs.<span style="font-family:'Times-Roman';"> </span>We manufacture drug substance for Pfizer, subject to certain terms and conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">For the first 10-year period after the execution of the October 2015 Amended Pfizer Agreement, we have agreed to sell drug substance to Pfizer for the production of Elelyso, and Pfizer maintains the right to extend the supply period for up to two additional 30-month periods subject to certain terms and conditions. In a subsequent amendment, we agreed that after the completion of the first 10-year supply period, the supply term would automatically extend for a five-year period (i.e., until October 2030).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We maintain distribution rights to Elelyso in Brazil through a supply and technology transfer agreement with Fiocruz, an arm of the Brazilian MoH.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Product Development Pipeline</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our corporate strategy includes development of treatments for rare and orphan diseases. To execute on the strategy, we are turning our focus to new, early-stage product candidates that treat indications for which there are high unmet needs in terms of efficacy and safety, including renal diseases. Treatments of interest will address both genetic and non-genetic diseases. We intend to use our ProCellEx platform and PEGylization capabilities, as well as other modalities such as small molecules and antibodies, to take advantage of highly innovative opportunities. Our current pipeline of product candidates includes PEGylated uricase for the treatment of uncontrolled gout, Long Acting (LA) DNase&#160;I for the treatment of NETs and other technologies and preclinical assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="font-style:italic;font-weight:bold;">PEGylated Uricase (PRX-115)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">PRX-115 is our recombinant PEGylated uricase (urate oxidase) &#8211; a chemically modified enzyme under development for the potential treatment of patients with uncontrolled gout. The uricase enzyme, that does not exist naturally in humans, converts uric acid to allantoin, which is easily eliminated through urine. This recombinant enzyme, expressed via our ProCellEx system, is designed to lower uric acid levels and improve clinical manifestation of the disease while having low immunogenicity and increased half-life of the drug in the blood. Pre-clinical data demonstrates long half-life, reduced immunogenic risk and high specific activity which supports the potential of PRX-115 to be a safe and effective treatment for patients with gout. One-month multiple dosing toxicity studies in two species and 6-month multiple dosing toxicity study in one species were conducted to support single and multiple dose studies in humans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In March 2024, we initiated our phase&#160;I clinical trial of PRX-115 for the potential treatment of uncontrolled gout entitled &#8220;A Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Properties of PRX-115 in Adult Volunteers With Elevated Uric Acid Levels&#8221; (NCT05745727), or the <i style="font-style:italic;">FIH</i> study. The study is being conducted at New Zealand Clinical Research (NZCR) under the New Zealand Medicines and Medical Devices Safety Authority (MedSafe) and the Health and Disability Ethics Committee (HDEC) guidelines. The study was initially designed to include seven sequential dosing cohorts, each composed of eight subjects (six active and two placebo), a 3:1 ratio. Subjects in each cohort, males and females aged 18 through 65, received a single dose of PRX-115 and are analyzed for safety, pharmacokinetics (PK) and pharmacodynamics (PD) (concentrations of plasma uric acid) for 85 days.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">After a review of initial positive top-line results from the initial seven cohorts, and following the review and acceptance of the safety data from such seven cohorts by the safety and monitoring committee for dose escalation for the <i style="font-style:italic;">FIH</i> study, we decided to expand the study by adding an eighth cohort of eight new subjects to analyze a higher dose and its potential to result in increased exposure time. Currently, all eight cohorts have completed the study and the data is locked and is being analyzed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Preliminary results from the full <i style="font-style:italic;">FIH</i> study are as follows:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>Exposure to PRX-115 increased in a dose-dependent manner. PRX-115 levels were observed in plasma for up to 12&#160;weeks from subjects in cohorts 6, 7, and 8.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>In all tested doses, a single dose of PRX-115 rapidly reduced plasma uric acid levels. The effect and duration of response were found to be dose dependent. Following a single dose, mean plasma uric acid levels remained below 6.0&#160;mg/dL for up to 12&#160;weeks at the highest dose levels.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>All randomized participants completed the study. PRX-115 was found to be well-tolerated with only 25% of the subjects treated with PRX-115 in the study (12/48) having reported study drug-related adverse events. The majority of such adverse events were mild to moderate and transient in nature. One subject experienced an anaphylactic reaction in cohort&#160;2 immediately following the commencement of the infusion (6 minutes) and, accordingly, was exposed to 5% of the applicable PRX-115 dose. The reaction resolved completely and the subject continued in the study for follow-up safety assessments. Premedication with anti-histamines and steroids were administered to all subjects following the anaphylaxis event. No other subjects experienced a similar reaction and no other serious adverse events were reported in the study. No related adverse events were reported for subjects treated in cohorts 6 and 7, and only for one patient per cohort in cohorts 4, 5 and 8.</div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The preliminary findings from the <i style="font-style:italic;">FIH</i> study suggest that PRX-115 has the potential to be a promising treatment option for patients with gout. The results demonstrate that PRX-115 may offer an effective uric acid-lowering treatment with an added benefit of a potentially wide dosing interval, which may enhance patient compliance and treatment flexibility. Further studies are needed to confirm the long-term safety and efficacy of PRX-115 in the gout patient population.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We plan to present the preliminary results in more detail in a poster at an upcoming scientific meeting being held November&#160;14-19, 2024. In addition, we have commenced preparations for a phase&#160;II clinical trial of PRX-115 for the treatment of uncontrolled gout which we expect will commence in the second half of 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Gout is the most common inflammatory arthritis, affecting an estimated 14.0&#160;million adults in the United States, 2.0&#160;million in France, 2.0&#160;million in United Kingdom, 0.7&#160;million in Italy, 1.5&#160;million in Germany, 0.7&#160;million in Spain and over 190.0&#160;million in China. An estimated approximately 5% of the gout population is considered to have chronic refractory disease. The risk of gout increases with age, and it is thus more common in ageing populations. Gout results from sustained elevation of serum urate levels (hyperuricaemia). Urate levels may increase due to diet, genetic predisposition and environmental factors leading to the deposition of monosodium urate crystals and\or tophi in joints, tendons and other tissues, which triggers recurrent episodes of pronounced acute inflammation, known as gout flares. Gout leads to substantial morbidity, severe pain, reduced quality of life, decreased physical function, increased healthcare costs, and lost economic productivity. Furthermore, gout is strongly associated with a number of comorbidities, including hypertension, cardiovascular disease, renal impairment, diabetes, obesity, hyperlipidaemia and frequently in a combination known as the metabolic syndrome.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Uncontrolled gout is when serum uric acid (sUA) levels are above the maximum medically appropriate level (6.8 mg/dL) and cannot be treated with available urate lowering therapies. It is also reported to involve urate crystal deposition and associated inflammation in joints, soft tissues and organs. Currently available ULTs can be effective in treating gout. However, factors such as low adherence, under dosing, disease progression that cause high patient burden or patients that are not suitable for available therapy, require new, effective and safe therapies to treat these underserved uncontrolled gout patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">To date, two variants of recombinant uricases are approved for marketing: (i)&#160;Krystexxa<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (pegloticase) for treatment of chronic gout refractory to conventional therapy (gout patients who have contraindication/failure of other lowering uric acid treatments) and (ii)&#160;Elitek<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, indicated for the treatment of tumor lysis syndrome but not gout. Both have a black box warning for anaphylaxis and other major side-effects. The FDA label of Krystexxa was amended in 2022 to include co-treatment of methotrexate to prolong efficacy and increases tolerability in patients with refractory gout. Krystexxa is no longer marketed in the European Union. The EC withdrew the marketing authorization for Krystexxa in 2016 at the request of the marketing authorization holder which notified the EC of its decision not to market the product in the European Union for commercial reasons. We believe that new effective, safe therapies are needed to treat severe gout, chronic refractory and uncontrolled<b style="font-weight:bold;"> </b>gout, regardless of treatment history.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"><span style="font-style:italic;">PRX-119</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">PRX-119 is our plant cell-expressed PEGylated recombinant human DNase&#160;I product candidate being designed to elongate half-life in the circulation for NETs-related diseases. NETs, Neutrophil extracellular traps, are web-like structures, released by activated neutrophils that trap and kill a variety of microorganisms. NETs are composed of DNA, histones, antimicrobial and pro-inflammatory proteins. Excessive formation or ineffective clearance of NETs can cause different pathological effects. NETs formation has been observed in various autoimmune, inflammatory and fibrotic conditions, diverse forms of thrombosis, cancer and metastasis. According to scientific literature, animal studies have demonstrated that DNase treatment reduces NETs toxicity. Our proprietary modified DNase&#160;I design for long and customized systemically circulating in the bloodstream, may potentially enable effective treatment of these conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The administration of PRX-119 resulted in a decrease in circulating of DNA levels and significantly enhanced the survival of mice in both a CLP-induced sepsis model and an ARDS model. Additional preclinical development is ongoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Intellectual Property</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">A key element of our overall strategy is to establish a broad portfolio of patents to protect our proprietary technology, proprietary product and product candidates and their methods of use. As of September 30, 2024, we hold a broad portfolio of more than 15 patent families consisting of over 70 patents in Europe, the United States, Israel and additional countries worldwide, as well as approximately 50 pending patent applications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;"><b style="color:#212529;font-weight:bold;">Scientific Presentations and Publications</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">On October&#160;28, 2024, Chiesi Global Rare Diseases, a business unit of Chiesi, announced the publication of results from the <i style="font-style:italic;">BRIGHT</i> study in the&#160;Journal of Inherited Metabolic Disease. The article may be accessed on the journal&#8217;s website.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">Data from our <i style="font-style:italic;">FIH </i>Study will be presented in a late-breaking poster at the American College of Rheumatology (ACR) Convergence 2024, being held November&#160;14-19, 2024 at the Walter E. Washington Convention Center in Washington, D.C. An abstract containing data generated in the trial may be accessed on the ACR Convergence 2024 website.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Research &amp; Development</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We continuously work on the further development of our ProCellEx plant cell expression technology and bioreactor system.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Consistent with our corporate strategy, we are focusing on new, early-stage product candidates that treat indications for which there are high unmet needs in terms of efficacy and safety, including renal diseases. Treatments of interest will address both genetic and non-genetic diseases. We intend to use our ProCellEx platform and PEGylation capabilities, as well as other modalities such as small molecules and oligonucleotides, to take advantage of highly innovative opportunities. We are also exploring novel platform technologies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Critical Accounting Policies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our significant accounting policies are more fully described in Note&#160;1 to our consolidated financial statements appearing in this Quarterly Report. There have been no material changes to our critical accounting policies since we filed our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The discussion and analysis of our financial condition and results of operations is based on our financial statements, which we prepared in accordance with U.S.&#160;generally accepted accounting principles. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues and expenses during the reporting periods. On an ongoing basis, we evaluate such estimates and judgments, including those described in greater detail below. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="font-style:italic;font-weight:bold;">Three months ended September&#160;30, 2024 compared to the three months ended September&#160;30, 2023</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Revenues from Selling Goods</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We recorded revenues from selling goods of $&#160;17.8&#160;million during the three months ended September&#160;30, 2024, an increase of $7.6&#160;million, or 75%, compared to revenues of $10.2&#160;million for the three months ended September&#160;30, 2023. The increase resulted primarily from an increase of $6.8&#160;million in sales to Chiesi and an increase of $1.1&#160;million in sales to Pfizer, partially offset by a decrease of $0.3&#160;million in sales to Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Revenues from License and R&amp;D Services</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We recorded revenues from license and R&amp;D services of $0.1&#160;million for the three months ended September&#160;30, 2024, a decrease of $0.1&#160;million, or 50%, compared to revenues of $0.2&#160;million for the three months ended September&#160;30, 2023. Revenues from license and R&amp;D services are comprised primarily of revenues we recognized in connection with the Chiesi Agreements including compensation for research and development obligations with respect to Elfabrio<span style="background:#ffffff;">. As a result of the completion of the </span>Fabry clinical program in 2023 with the approval of Elfabrio in the United States and the European Union in May 2023, we expect to generate minimal revenues from license and R&amp;D services other than potential regulatory milestone payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Cost of Goods Sold</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Cost of goods sold was $8.4&#160;million for the three months ended September&#160;30, 2024, an increase of $3.5&#160;million, or 71%, from cost of goods sold of $4.9&#160;million for the three months ended September&#160;30, 2023. The increase in cost of goods sold was primarily the result of an increase in sales to Chiesi and Pfizer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Research and Development Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 21.6pt 10pt 0pt;">For the three months ended September<span style="direction:rtl;">&#160;</span>30, 2024, our total research and development expenses were approximately $3.0&#160;million comprised of approximately $0.6&#160;million in subcontractor-related expenses, approximately $1.6&#160;million of salary and related expenses, approximately $0.2&#160;million of materials-related expenses and approximately $0.6&#160;million of other expenses. For the three months ended September<span style="direction:rtl;">&#160;</span>30, 2023, our total research and development expenses were approximately $3.7&#160;million comprised of approximately $1.0&#160;million of subcontractor-related expenses, approximately $1.9&#160;million of salary and related expenses, approximately $0.2&#160;million of materials-related expenses and approximately $0.6&#160;million of other expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 21.6pt 10pt 0pt;">Total decrease in research and developments expenses for the three months ended September<span style="direction:rtl;">&#160;</span>30, 2024 was $0.7&#160;million, or 19%, compared to the three months ended September<span style="direction:rtl;">&#160;</span>30, 2023. The decrease in research and development expenses resulted primarily from the completion of our Fabry clinical program and the regulatory processes related to the BLA and MAA review of Elfabrio by the applicable regulatory agencies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 21.6pt 10pt 0pt;">We expect to continue to incur significant, increasing research and development expenses as we enter into a more advanced stage of preclinical and clinical trials for certain of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Selling, General and Administrative Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Selling, general and administrative expenses were $2.6&#160;million for the three months ended September<span style="direction:rtl;">&#160;</span>30, 2024, a decrease of $1.1&#160;million, or 30%, compared to $3.7&#160;million for the three months ended September<span style="direction:rtl;">&#160;</span>30, 2023. The decrease resulted primarily from a decrease of $0.5&#160;million in salary and related expenses and a decrease of $0.4&#160;million in professional fees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Financial Income, Net</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Financial expenses, net was $0.1&#160;million for the three months ended September&#160;30, 2024, compared to financial income, net of $0.2&#160;million for the three months ended September&#160;30, 2023. The difference resulted primarily from lower interest income on bank deposits, higher exchange rate costs partially offset by lower notes interest expenses due to the September 2024 repayment in full of all the outstanding principal and interest payable under the 2024 Notes.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Income Taxes</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">For the three months ended September&#160;30, 2024, we recorded income taxes of approximately $0.6&#160;million, compared to income taxes of $0.1&#160;million for the three months ended September&#160;30, 2023. Income taxes recorded are primarily the result of tax expenses in respect of Section&#160;174 of the TCJA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="font-style:italic;font-weight:bold;">Nine months ended September&#160;30, 2024 compared to the nine months ended September&#160;30, 2023</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Revenues from Selling Goods</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We recorded revenues from selling goods of $34.8&#160;million during the nine months ended September&#160;30, 2024, an increase of $4.5&#160;million, or 15%, compared to revenues of $30.3&#160;million for the nine months ended September&#160;30, 2023. The increase resulted primarily from an increase of $4.2&#160;million in sales to Brazil and an increase of $3.4&#160;million in sales to Pfizer which were partially offset by a decrease of $3.1&#160;million in sales to Chiesi. Sales to Chiesi in the nine months ended September&#160;30, 2023 were in connection with the commercial launch and inventory buildup of Elfabrio after its approval for marketing in the United States and the European Union.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Revenues from License and R&amp;D Services</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We recorded revenues from license and R&amp;D services of $0.4&#160;million for the nine months ended September&#160;30, 2024, a decrease of $24.3&#160;million, or 98%, compared to revenues of $24.7&#160;million for the nine months ended September&#160;30, 2023. Revenues from license and R&amp;D services are comprised primarily of revenues we recognized in connection with the Chiesi Agreements. The revenues from license and R&amp;D services for the nine months ended September&#160;30, 2023 included <span style="background:#ffffff;">the $20.0&#160;million regulatory milestone payment from Chiesi in connection with the FDA approval of Elfabrio granted during that period.</span> The remaining decrease resulted from the completion of our revenue-generating research and development obligations with respect to Elfabrio and, as Elfabrio was approved in the United States and the European Union in May 2023, from the completion of the regulatory processes related to the review of the BLA and the MAA for Elfabrio by the FDA and EMA, respectively. <span style="background:#ffffff;">As a result of the completion of the </span>Fabry clinical program in 2023, we expect to generate minimal revenues from license and R&amp;D services other than potential regulatory milestone payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Cost of Goods Sold</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Cost of goods sold was $20.4&#160;million for the nine months ended September&#160;30, 2024, an increase of $6.3&#160;million, or 45%, from cost of goods sold of $14.1&#160;million for the nine months ended September&#160;30, 2023. <span style="background:#ffffff;">The increase in cost of goods sold was primarily the result of the increase in sales to Pfizer and to Brazil. </span>In addition, during the nine months ended September&#160;30, 2023 a significantly higher portion of the costs for certain drug substance sold, as compared to the nine months ended September&#160;30, 2024, were recognized as research and development expenses, not cost of goods sold, as such drug substance was produced as part of our research and development activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Research and Development Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 21.6pt 10pt 0pt;">For the nine months ended September&#160;30, 2024, our total research and development expenses were approximately $8.8&#160;million comprised of approximately $1.6&#160;million in subcontractor-related expenses, approximately $4.8&#160;million of salary and related expenses, approximately $0.5&#160;million of materials-related expenses and approximately $1.9&#160;million of other expenses. For the nine months ended September&#160;30, 2023, our total research and development expenses were approximately $14.0&#160;million comprised of approximately $6.2&#160;million of subcontractor-related expenses, approximately $5.5&#160;million of salary and related expenses, approximately $0.5&#160;million of materials-related expenses and approximately $1.8&#160;million of other expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 21.6pt 10pt 0pt;">Total decrease in research and developments expenses for the nine months ended September&#160;30, 2024 was $5.2&#160;million, or 37%, compared to the nine months ended September&#160;30, 2023. The decrease in research and development expenses resulted primarily from the completion of our Fabry clinical program and the regulatory processes related to the BLA and MAA review of Elfabrio by the applicable regulatory agencies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 21.6pt 10pt 0pt;">We expect to continue to incur significant, increasing research and development expenses as we enter into a more advanced stage of preclinical and clinical trials for certain of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Selling, General and Administrative Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Selling, general and administrative expenses were $9.2&#160;million for the nine months ended September&#160;30, 2024, a decrease of $1.6&#160;million, or 15%, compared to $10.8&#160;million for the nine months ended September&#160;30, 2023. The decrease resulted primarily from </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">a decrease of $1.3&#160;million in professional fees and of $0.7&#160;million in salaries and related expenses which was partially offset by a $0.5&#160;million increase in selling and marketing expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Financial Income, Net</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Financial income, net was $0.1&#160;million for the nine months ended September&#160;30, 2024, compared to financial expenses, net of $1.1&#160;million for the nine months ended September&#160;30, 2023. The difference resulted primarily from a decrease of approximately $1.1&#160;million in lower interest expenses due to the note conversions executed in 2023 and the September 2024 repayment in full of all the outstanding principal and interest payable under the 2024 Notes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Income Taxes</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In the nine months ended September&#160;30, 2024, we recorded income tax of approximately $0.4&#160;million, compared to income taxes of $0.6&#160;million for the nine months ended September&#160;30, 2023. Income taxes recorded are primarily the result of tax expenses in respect of Section&#160;174 of the TCJA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Liquidity and Capital Resources</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our sources of liquidity include our cash and cash equivalents balances. At September 30, 2024, we had $27.4&#160;million in cash and cash equivalents. In September 2024, we satisfied the outstanding principal and accrued interest under the 2024 Notes with a cash payment of approximately $21.2&#160;million which was available primarily from the withdrawal of short term deposits. We have primarily financed our operations through equity and debt financings, business collaborations, grants funding and revenues from selling goods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">During the year ended December&#160;31, 2023, we raised gross proceeds equal to approximately $24.9&#160;million from the sale of 12,560,150 shares of our common stock under our ATM program. All such sales were completed during the quarters ended March&#160;31, 2023 and June&#160;30, 2023. No sales under our ATM program have been completed since the quarter ended June&#160;30, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We believe that our cash and cash equivalents as of September&#160;30, 2024 are sufficient to satisfy our capital needs for at least 12&#160;months from the date that these financial statements are issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Cash Flows </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">Net cash provided by operations was $4.7&#160;million for the nine months ended September&#160;30, 2024. The net loss for the nine months ended September&#160;30, 2024 of $3.6&#160;million was increased by a $0.7&#160;million decrease in accounts payable and accruals and was offset by a $3.1&#160;million decrease in accounts receivable-trade and other assets, $2.6&#160;million in share-based compensation, a $1.8&#160;million decrease in inventories and $1.0&#160;million in depreciation. Net cash provided by investing activities for the nine months ended September&#160;30, 2024 was $19.5&#160;million and consisted primarily of $20.4&#160;million in proceeds from the sale of deposits partially offset by a $0.9&#160;million purchase of property and equipment.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">Net cash used in financing activities for the nine months ended September&#160;30, 2024 was $20.4&#160;million representing the payment of the outstanding principal and accrued interest under our 2024 Notes which matured in September 2024.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">Net cash used in operations was $4.9&#160;million for the nine months ended September&#160;30, 2023. The net income for the nine months ended September&#160;30, 2023 of $14.4&#160;million was decreased by a $13.2&#160;million decrease in contracts liability, a $3.1&#160;million increase in deferred tax assets, a $4.8&#160;million increase in inventories, a $4.2&#160;million increase in accounts receivable-trade and other assets and a $0.5&#160;million financial income-net (mainly currency exchange differences). The net income was increased by a $3.8&#160;million increase in accounts payable and accruals, $2.1&#160;million in share-based compensation and $0.9&#160;million in depreciation. Net cash used in investing activities for the nine months ended September&#160;30, 2023 was $16.4&#160;million and consisted primarily of net investment in bank deposits.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">Net cash provided by financing activities for the nine months ended September&#160;30, 2023 was $24.7&#160;million resulting primarily from the sale of common stock under our ATM program.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As of September&#160;30, 2024, there were outstanding warrants to purchase 13,439,712 shares at an exercise price equal to $2.36 per share. The warrants expire in March 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Future Funding Requirements </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Since our inception, we have incurred significant research and development expenditures which have not been offset by revenues. We have not generated significant revenues from sales of Elelyso, and commercial sales of Elfabrio only commenced in the middle of </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">2023. W<span style="background:#ffffff;">e have generated operating losses from our continuing operations since our inception although the revenues generated in the year ended December&#160;31, 2023</span><span style="font-family:'28mugxoulnobhnx';"> exceeded our expenditures for the same period.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As the 2024 Notes were paid in full during the three months ended September&#160;30, 2024, we are no longer subject to the financial limitations related to such notes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As we increase our research and developments efforts with respect to our current and future product candidates, we expect to continue to incur significant expenditures. We cannot anticipate the costs or the timing of the occurrence of such costs. Although we expect the revenues generated from the sales of Elfabrio and Elelyso will increase, such revenues may not be sufficient to fund the expenditures. To the extent we need to obtain additional financing in excess of such anticipated revenues, it may be difficult for us to do so given the volatility of the price of our common stock. Our material cash needs for the next 24&#160;months will include, among other expenses, (i)&#160;costs of preclinical and clinical trials, (ii)&#160;employee salaries, (iii)&#160;payments for rent and operation of our manufacturing facilities, (iv)&#160;fees to our consultants and legal advisors, patent advisors and fees for service providers in connection with our research and development efforts, and (v)&#160;tax payments. We believe that our cash and cash equivalents as of September&#160;30, 2024 are sufficient to satisfy our capital needs for at least 12&#160;months from the date that these financial statements are issued. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As discussed above, we may be required to raise additional capital to develop our product candidates and continue research and development activities. Our ability to raise capital, and the amounts of necessary capital, will depend on many other factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the duration and cost of discovery and preclinical development and laboratory testing and clinical trials for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Chiesi&#8217;s progress in commercializing Elfabrio;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our progress in commercializing BioManguinhos alfataliglicerase in Brazil;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing and outcome of regulatory review of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims and other intellectual property rights; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs associated with any litigation claims.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We expect to finance our future cash needs through sales of Elfabrio and Elelyso, corporate collaborations, licensing or similar arrangements, public or private equity offerings and/or debt financings. We currently do not have any commitments for future external funding, except with respect to the milestone payments that may become payable under the Chiesi Agreements. On February&#160;27, 2023, we entered into the 2023 Sales Agreement pursuant to which we may sell from time to time through the Agent ATM Shares having an aggregate offering price of up to $20.0&#160;million as we had then completed the ATM program under the 2021 Sales Agreement. As of September&#160;30, 2024, shares of our common stock for total gross proceeds of approximately $6.4&#160;million remain available to be sold under the 2023 Sales Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Effects of Currency Fluctuations </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Currency fluctuations could affect us through increased or decreased acquisition costs for certain goods and services and salaries expenses. We do not believe currency fluctuations have had a material effect on our results of operations during the three and nine months ended September&#160;30, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Off-Balance Sheet Arrangements </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have no off-balance sheet arrangements as of each of September&#160;30, 2024 and December&#160;31, 2023.</p><a id="_a5eb0403_0cd1_4f8c_b1c6_e8aa39e7648a"></a><a id="Item3QuantitativeandQualitativeDisclosur"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">3.  Quantitative and Qualitative Disclosures about Market Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Currency Exchange Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The currency of the primary economic environment in which our operations are conducted is the U.S.&#160;dollar. Most of our revenues and more than 50% of our expenses and capital expenditures are and were incurred in dollars, and a significant source of our financing has been provided in U.S.&#160;dollars. Since the dollar is the functional currency, monetary items maintained in currencies other than the dollar are remeasured using the rate of exchange in effect at the balance sheet dates and non-monetary items are remeasured at </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">historical exchange rates. Revenue and expense items are remeasured at the average rate of exchange in effect during the period in which they occur. Foreign currency translation gains or losses are recognized in the statement of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Approximately 44% of our costs, including salaries, expenses and office expenses, are incurred in NIS. Inflation in Israel may have the effect of increasing the U.S.&#160;dollar cost of our operations in Israel. If the U.S.&#160;dollar declines in value in relation to the NIS, it will become more expensive for us to fund our operations in Israel. A revaluation of 1% of the NIS will affect our loss before tax by less than 1%. The exchange rate of the U.S.&#160;dollar to the NIS, based on exchange rates published by the Bank of Israel, was as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:47.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:17.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:17.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:17.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:17.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Average rate for period</p></td><td style="vertical-align:bottom;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.715</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.745</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.701</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.643</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.687</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Rate at period-end</p></td><td style="vertical-align:bottom;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.710</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.824</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.710</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.824</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.627</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:10pt 0pt 10pt 0pt;">To date, we have not engaged in hedging transactions. In the future, we may enter into currency hedging transactions to decrease the risk of financial exposure from fluctuations in the exchange rate of the U.S.&#160;dollar against the NIS. These measures, however, may not adequately protect us from material adverse effects due to the impact of inflation in Israel.</p><a id="_1539c0b0_a9f5_4ff0_a95c_01ba71d394a4"></a><a id="Item4ControlsandProcedures_865226"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">4.  Controls and Procedures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Evaluation of Disclosure Controls and Procedures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form&#160;10-Q. The evaluation was conducted under the supervision and with the participation of management, including our Chief Executive Officer and Chief Financial Officer. Disclosure controls and procedures are controls and procedures designed to reasonably assure that information required to be disclosed in our reports filed under the Exchange Act, such as this Quarterly Report on Form&#160;10-Q, is recorded, processed, summarized and reported within the time periods specified in the Commission&#8217;s rules and forms. Disclosure controls and procedures are also designed to reasonably assure that such information is accumulated and communicated to our management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Based on the evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this Quarterly Report on Form&#160;10-Q, our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified by the Commission, and that material information relating to our company and our consolidated subsidiary is made known to management, including the Chief Executive Officer and Chief Financial Officer, particularly during the period when our periodic reports are being prepared.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Inherent Limitations on Effectiveness of Controls</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all error and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within a company have been detected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Changes in Internal Control over Financial Reporting</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">There were no changes in our internal control over financial reporting (as defined in Rules 13a-15f and 15d-15f under the Exchange Act) that occurred during the quarter ended September&#160;30, 2024 that have materially affected, or that are reasonably likely to materially affect, our internal control over financial reporting.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_5c0c9850_86fb_430e_81e2_4b5532dddcd3"></a><a id="PARTIIOTHERINFORMATION_770480"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">PART II &#8211; OTHER INFORMATION</b></p><a id="Item1LegalProceedings_676392"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">1.  Legal Proceedings</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We are not involved in any material legal proceedings.</p><a id="_8b54fd8a_8f14_41b3_a92b_6d6ef6a472c1"></a><a id="Item1ARiskFactors_983377"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">1A.  Risk Factors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 18pt 10pt 0pt;">Except as set forth below, there have been no material changes to the risk factors previously disclosed in our Annual Report on Form 10-K for the year ended December&#160;31, 2023 and in our Quarterly Report on Form 10-Q for the quarter ended June&#160;30, 2024<span style="background:#ffffff;">.</span></p><p style="font-family:'Courier New';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Significant parts of our operations are located in Israel and, therefore, our results may be adversely affected by current political, economic and military conditions in Israel.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In October 2023, terrorists primarily from the Hamas organization infiltrated Israel&#8217;s southern border from the Gaza Strip and in other areas within the State of Israel attacking a number of civilian and military targets while simultaneously launching extensive rocket attacks on the Israeli population and industrial centers. At the same time, clashes between Israel and Hezbollah in Lebanon increased. In response, Israel&#8217;s security cabinet declared war against the Hamas and a military campaign against these terrorist organizations commenced in parallel to their continued rocket, drone and terror attacks. Since the outbreak of the war, other regional actors, including Iran, have taken military action against Israel. It is currently not possible to predict the duration or severity of the ongoing conflict or its effects on our business, results of operations and financial condition. To date, our operations have not been adversely affected by this situation. Hostilities have not taken place where our facilities are located. We do not anticipate any disruption to the supply of Elfabrio or Elelyso. However, our facilities are in range of certain of the rockets and drones originating from Lebanon and elsewhere. Any damage to our facilities or disruption of supplies as a result of war or other hostile action may have a material adverse effect on our business, results of operations and financial condition. Further, the potential for the war between Israel and Hamas to lead to a broader conflict in the Middle East may adversely affect geopolitical stability, the global economy and specific markets.</p><a id="_e509f916_1319_422b_a67c_c9f10df6542c"></a><a id="Item2UnregisteredSalesofEquitySecurities"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">2.  Unregistered Sales of Equity Securities and Use of Proceeds</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">None.</p><a id="_72a9f339_fb68_4f13_b776_64dfffc8bcd8"></a><a id="Item3DefaultsUponSeniorSecurities_505234"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">3.  Defaults Upon Senior Securities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">None.</p><a id="_cadb4c68_3b5c_4bfa_b8bf_13fafcea4898"></a><a id="Item4MineSafetyDisclosure_204781"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">4.  Mine Safety Disclosure</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Not applicable.</p><a id="_395f84b0_8b66_4939_95af_8442a8b6017c"></a><a id="Item5OtherInformation_679200"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">5.  Other Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">During the quarter ended September&#160;30, 2024, none of our directors or officers </span><ix:nonNumeric contextRef="Duration_7_1_2024_To_9_30_2024_5srFek9aZ0STe4olK5gckA" format="ixt:booleanfalse" name="ecd:Rule10b51ArrAdoptedFlag" id="Narr_B9qvXggsfUGCl-WUu8g5wQ"><span style="background:#ffffff;">adopted</span></ix:nonNumeric><span style="background:#ffffff;"> or </span><ix:nonNumeric contextRef="Duration_7_1_2024_To_9_30_2024_5srFek9aZ0STe4olK5gckA" format="ixt:booleanfalse" name="ecd:NonRule10b51ArrAdoptedFlag" id="Narr_G6WSRul9BE2r4Hr4bLvkeA"><span style="background:#ffffff;">terminated</span></ix:nonNumeric><span style="background:#ffffff;"> a </span><ix:nonNumeric contextRef="Duration_7_1_2024_To_9_30_2024_5srFek9aZ0STe4olK5gckA" format="ixt:booleanfalse" name="ecd:Rule10b51ArrTrmntdFlag" id="Narr_91g6uR2LJUyeAx7tWtqI0Q"><span style="background:#ffffff;">Rule&#160;</span>10b5-1</ix:nonNumeric> <span style="background:#ffffff;">trading arrangement or&#160;</span><ix:nonNumeric contextRef="Duration_7_1_2024_To_9_30_2024_5srFek9aZ0STe4olK5gckA" format="ixt:booleanfalse" name="ecd:NonRule10b51ArrTrmntdFlag" id="Narr_STuqb18ZakGqqKYcDBnXMg">non-Rule<span style="background:#ffffff;">&#160;</span>10b5-1</ix:nonNumeric><span style="background:#ffffff;">&#160;trading arrangement (as such terms are defined in Item 408 of Regulation&#160;</span>S-K).</p><a id="_a40fd0ee_0355_47c6_90ec_68c1a6ec3962"></a><a id="Item6Exhibits_829552"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">6.  Exhibits</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.00925827%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:7.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:36.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:7.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:8.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:9.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:15.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:13.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:7.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:36.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:7.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:8.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:15.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:13.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:13.5pt;"><td style="vertical-align:bottom;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;width:41.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="font-weight:bold;">Incorporated by Reference</b></p></td><td style="vertical-align:bottom;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="font-weight:bold;">Exhibit Number</b></p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="font-weight:bold;">Exhibit Description</b></p></td><td style="vertical-align:bottom;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="font-weight:bold;">Form</b></p></td><td style="vertical-align:bottom;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="font-weight:bold;">File Number</b></p></td><td style="vertical-align:bottom;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="font-weight:bold;">Exhibit</b></p></td><td style="vertical-align:bottom;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="font-weight:bold;">Date</b></p></td><td style="vertical-align:bottom;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="font-weight:bold;">Filed or Furnished Herewith</b></p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.1</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">3.1</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">April&#160;1, 2016</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:22.5pt;"><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.2</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420416111273/v443094_def14a.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment to Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">Def 14A</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">Appen. A</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">July&#160;1, 2016</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.3</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420418054229/tv504383-def14a.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amendment to Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">Def 14A</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">Appen. A</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">October&#160;17, 2018</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.4</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465919074602/tm1926620d1_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Third Amendment to Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">3.1</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">December&#160;19, 2019</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.5</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837022013560/plx-20220630xex3d5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Fourth Amendment to Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">10-Q</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">3.5</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">August&#160;15, 2022</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.00925827%;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.6</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837023013483/plx-20230630xex3d6.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Fifth Amendment to Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">10-Q</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">3.6</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">August&#160;7, 2023</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.7</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Bylaws of the Company</span></a> </p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">3.2</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">April&#160;1, 2016</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:13pt;"><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.1&#8224;</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420412040015/v318898_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Restricted Stock Agreement/Notice</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.1</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">July&#160;18, 2012</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:13pt;"><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.2</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837024003161/plx-20231231xex4d7.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Description of Capital Stock</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">10-K</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.7</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">March&#160;14, 2024</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.3</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465920032169/tm2012488d1_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Warrant</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.1</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">March&#160;12, 2020</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.4&#8224;</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465920092375/plx-20200630xex4d8.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Stock Option Agreement (Executives)</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">10-Q</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.8</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">August&#160;10, 2020</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.5</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465920092375/plx-20200630xex4d9.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Stock Option Agreement (Standard)</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">10-Q</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.9</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">August&#160;10, 2020</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">31.1</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20240930xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Chief Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">31.2</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20240930xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Chief Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">32.1</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20240930xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Certification of Chief Executive Officer</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">32.2</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20240930xex32d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Certification of Chief Financial Officer</span></a> </p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.INS</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">XBRL Instance Document - <span style="color:#333333;background:#ffffff;">the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</span></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.SCH</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="background:#ffffff;">Inline XBRL Taxonomy Extension Schema Document</span></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.CAL</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="background:#ffffff;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.DEF</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="background:#ffffff;">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.LAB</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="background:#ffffff;">Inline XBRL Taxonomy Extension Labels Linkbase Document</span></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.PRE</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="background:#ffffff;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">104</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">COVER PAGE INTERACTIVE DATA FILE (formatted as Inline XBRL and contained in Exhibit 101).</p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="8" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 3pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 3pt 0pt;">&#8224;&#160;&#160;&#160;&#160;&#160;Management contracts or compensation plans or arrangements in which directors or executive officers are eligible to participate.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_4f1a45c1_4042_4bfa_93d1_f6dbbd54c2a3"></a><a id="SIGNATURES_574709"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:25.9pt;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:12pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PROTALIX BIOTHERAPEUTICS, INC.</p></td></tr><tr style="height:10.5pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Registrant)</p></td></tr><tr style="height:15.75pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:10.8pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: November&#160;14, 2024</p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:47.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Dror Bashan</p></td></tr><tr style="height:20.25pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dror Bashan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Executive Officer)</p></td></tr><tr style="height:17.25pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:13.5pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: November&#160;14, 2024</p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:47.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Eyal Rubin</p></td></tr><tr style="height:13.5pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Eyal Rubin</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Senior Vice President and Chief Financial Officer, Treasurer and Secretary</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Financial and Accounting Officer)</p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;width:458.2pt;"></span><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>plx-20240930xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 11/13/2024 11:42:05 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EXHIBIT&#160;31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">CERTIFICATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">I, Dror Bashan, certify that:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">I have reviewed this quarterly report on Form 10-Q of Protalix BioTherapeutics, Inc.;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">4.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">c)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">d)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">5.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 0pt 24.5pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:98.94%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: November&#160;14, 2024</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;">/s/ Dror Bashan</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dror Bashan</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>plx-20240930xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 11/13/2024 11:42:05 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EXHIBIT&#160;31.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">CERTIFICATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 10pt 0pt;">I, Eyal Rubin, certify that:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"> I have reviewed this quarterly report on Form 10-Q of Protalix BioTherapeutics, Inc.;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">4.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">c)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">d)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36.05pt;text-indent:-36.05pt;margin:0pt 0pt 10pt -0.04pt;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: November&#160;14, 2024</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;">/s/ Eyal Rubin</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Eyal Rubin</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sr. Vice President &amp; Chief Financial Officer,</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Treasurer</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>plx-20240930xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 11/13/2024 11:42:06 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EXHIBIT&#160;32.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">PROTALIX BIOTHERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CERTIFICATION</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In connection with the quarterly report of Protalix BioTherapeutics, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended September&#160;30, 2024 as filed with the Securities and Exchange Commission (the &#8220;Report&#8221;), I, Dror Bashan, President and Chief Executive Officer of the Company, hereby certify as of the date hereof, solely for the purposes of Title 18, Chapter 63, Section&#160;1350 of the United States Code, that to the best of my knowledge:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">1)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">the Report fully complies with the requirements of Section&#160;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">2)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">This Certification has not been, and shall not be deemed, &#8220;filed&#8221; with the Securities and Exchange Commission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: November&#160;14, 2024</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;">/s/ Dror Bashan</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dror Bashan</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>plx-20240930xex32d2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 11/13/2024 11:42:05 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EXHIBIT&#160;32.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">PROTALIX BIOTHERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CERTIFICATION</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In connection with the quarterly report of Protalix BioTherapeutics, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended September&#160;30, 2024 as filed with the Securities and Exchange Commission (the &#8220;Report&#8221;), I, Eyal Rubin, Senior Vice President and Chief Financial Officer of the Company, hereby certify as of the date hereof, solely for the purposes of Title 18, Chapter 63, Section&#160;1350 of the United States Code, that to the best of my knowledge:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">1)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">the Report fully complies with the requirements of Section&#160;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">2) </p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">This Certification has not been, and shall not be deemed, &#8220;filed&#8221; with the Securities and Exchange Commission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: November&#160;14, 2024</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;">/s/ Eyal Rubin</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Eyal Rubin</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Senior Vice President and Chief Financial Officer</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>plx-20240930x10q005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20240930x10q005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $J M4# 2(  A$! Q$!_\0
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MA&D\#5<VU[U^CT\D+NHW4E%;'SXNZC=244 +NHW4E% "[J-U)10 NZC=244
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M[7';$R'9\O,JL,9XR.#1[6H_M!_8N6_] \/_  %?Y#?^&7_AK_T+W_DU-_\
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M4W_Q=>K8HQ1[6I_,P_L7+?\ H'A_X"O\CRG_ (9?^&O_ $+W_DU-_P#%T?\
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MX9?^&O\ T+W_ )-3?_%UZMBC%'M:G\S#^Q<M_P"@>'_@*_R/*?\ AE_X:_\
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M#&(XY(XP-S'A4FD '^UZ@5?U+P'H^JWEY<7$,K&\7;<Q).Z13'9L#,@(!.W
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MMTQG(:1L%S;FW)Z_\\F*_KUJ&U^%OAZUN9+G[//-<2 AY9[F21FS$8>K,?\
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M'X&QW!N=0OE++ P>(QA6/)V%<#IV;/U%>%_$I[RWU'6%><F7.W"-T/F)@GZ
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MC>C#*G!YZ5Q.N?&&WT.[\36DMI*UUI4T44*I#*Z3!XT;+.J%4^^1R>WO2VU
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M--E\^UNI)(H&68*/*FD4/'$V&)W%2#QD?,,GFBS0'9T4@Z4M !1110 4444
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MU]J^BLE12?;]#PE=U';^M3],?^"7#(WP$UO9G UZ8$GN?*BKZZO?]6:^1?\
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M2!O7(8;AP<4O,;W')\,](3P['HV;AK5;U;\ON57:82B3)VJ% +#D  5/X<\
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M1)#( N4VM(@YQ]X4#ZB6WPCT6UCBACFO!:J\<DMMYH\NX:.0R1L_RYRK'/!
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M=%E>2%K.7S(EC56=G7;E0%=3DCH:$,2P^$^AZ5#!'8FYLTM[J2\A\J0?NW>
MPG&0> AX![^M7?#?@J/PI=.;&[D:WN))+B[25$!GF8(H?Y555PJ8PH&<Y.3S
M523XK^'$0'[5<,QD>/REM)3("D:R,2NW(&QU;)XP:H6'QCT>ZU75+:9XX(+*
M5HTE#L[7"A+=E9%"\Y-RB@9SG& <\ %NW^$>AVRZB%:Z_P!/:,S;I1_!<R7
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M%% !1110 4444 %%%% !1110 4444 %4-9_X]%_WQ5^J&L_\>B_[XH L6/\
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M<YJO\1D6A?ZF;_KH?Y5=O+.#4+66VN88[BWE4I)#*H9'4C!4@\$$=C5+0O\
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ML2#B/ D+ CY=NY<[L8W#U% &!IGP@C\-V:/IFH2O>VUW+?VQN$!3S6M1;A6
M_A  /'-;'B[X?6OCF/2EU.=U-HQ:580 MP"O*-GG;O$;X]8USQFII?B?X5@L
M?M<FMVT<'F-$2V00ZKO(*XSPI#=.G/2I5^(OAI[![Q-9MGMDD$.]&+98KN&
M!E@5^;(R, GH,T=D(Y6P^!ECIOV1X=6NC-;QVD?F2(C&0PF<EF&.K_:9,^A
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MI+" D2#.&0<'GOS73AL/'#0<5U.:O6==IL/AC\*U\*?:+B34;[4);DEF^TL
MH8L22% ')S7K6DZ:$(PH%/T[3-L:+CH.:Z'3[#!QBNI(P+%K!B+ 'Y4R2#<>
M?RK72TV1@=.*;]E!IV)1CBTXZ<4HL@16RMD1QCBI5M..>#2&<W/8 ]JH7>F
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M&R.-LR6Z,4^?Y2/L^1G(^?G.*K67P!2RU>TO8]8)2WNS<K&8,D@W33[<[O\
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *H:S_P >B_[XJ_5#6?\
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M/.;C3I-#9&U)1;0@Y6*21?.G_P!S!PO..3QQ5QKZ'QBL^EW4;RW$*;V1H]A
M[8[9 QR.O%7IM(TN&Y2UUOP_/87**Q\R-L\8R3]!BNDT?P=/H4*WFCQSWRW"
MJ8H+A>$3.2=V.,]!2A14(W2W)E.4GJS+UO1$TOP7\.K=&W"#4IGR_P![OC\>
M35@Z5K7B9;-6TJS6*V0QJ]R3(S?,2&Q]"*W/B-+HXT'PE;:W83B:6[E,,EC+
MEK5\ $YQSUQ7HWPI\-:/<>&(GTJ]NK^U$C*6O"3*C#[R'(&,>E2P/K__ ()Y
M:-<Z+\'-6AN71G;6)& CC" #RHN./I7TQ>_ZLUX[^R58)IWP[OXT& =0<_\
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M8]J[O_A&]/\ ^??_ ,>/^-'_  C>G_\ /#_QX_XT<Z#E9PP7!Z\4[;R*[?\
MX1S3_P#G@?\ OH_XT?\ ".6'_/#_ ,>-3S)BY&</M'&*".*[C_A'-/\ ^>'_
M (\:/^$<T_\ YX'_ +Z/^-',@Y&<$XSGCM526/@\\5Z.?#6G'_EW_P#'C_C3
M6\+::W6W/_?9_P :7,A\C/(KV+(.![UR_B'0AJ%LPQ\W8U[^_@O2)/O6I/\
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MP;U6'6-*UO4A96RQE9)-/"D[,&^X QC_ )>T^FUJ]:_M6?\ Y]U_,T?VK/\
M\^Z_F: /'(/AIKNC2>%]%BM8]0CM+K2Y[G49 <1"V4!O*)[';T.#ECP0<CH=
M3^'^K^(?%?B3=%;6.G3:C;7<5\V?M$GEVJ+M7 ^Z6RI).<;A@YS7H7]JS_\
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MC<* (/LB^E'V1?2I]PHW"@"#[(OI1]D7TJ?<*-PH A%N!VJ18]M.W"EW T
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M(_X3;7A_S&+W_O\ &C_A-M>_Z#%[_P!_C0!];_VJG]X?G_\ 7H_M5/[P_/\
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M[53^\/S_ /KT?VJG]X?G_P#7KY(_X3;7O^@Q>_\ ?XT?\)MKW_08O?\ O\:
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MDC_A-M>_Z#%[_P!_C2?\)MKW_08O?^_QH ^N/[53^\/S_P#KT?VJG]X?G_\
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M +53^\/S_P#KT?VJG]X?G_\ 7KY(_P"$VU[_ *#%[_W^-'_";:]_T&+W_O\
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MJ-Z-0CC>W%HX+2#/EDE5#_AG/X5K2^$8[/PY#IUS;^7JSW\8EE1-TB(WF*%
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** />_V?S_ ,4Y>?\
M7T?_ $$5ZAJ!Q$>:\N_9_P#^1<O/^OH_^@BO3]1_U1H ^/\ 5/\ D)7?_75_
MYFNBT#3[)M!ANK@6:.VH>2TEWOV^7L!Q\O3J>:Y[4_\ D)7?_79_YFI[/7+F
MQLQ:JL,L E\X)-$K@/C&>?8#B@#H9_ J7%[JBV[RVRPRW'E1/%E0L8+;6?(&
M2!VS[U!9>%M.CUZ#3[N^DDF641W$4<)&"1D[6SS@\'./;-4!XRU3=([3))*X
ME!D>)68"3[X!QQG)Z>],_P"$LU(2)()(A*KI(SB%=SE1A2QQSQZT"-7_ (0'
M-O#(U_'$\T2W"))L7,;-A1]_.\CYMN,>]22^#+?;-!#=^?Y-ZUM).MJQD+*A
M)"@,01QWQ[D"L4>*]0$:*)(P8U\M'$2[U3=N"[L9QGMZ<40>*]2MQ<A)E*W$
MCRRJT:D.S ALC'3!Z4#);_PLUAX@M]->8E9TCD618BS!64-]Q<\C., _C5ZZ
M\$PV$37%U?R0VXB20 V^9,L[+M*AL @J3UZ5DS>);Z?4X;]GC%Q%&(4V1*JA
M NW;MQC&WBDO?$E[?6BVTC(L"HL8CCC5  I+ <#U8G\: -^S\%VMCJT,&I78
M=I6F$42Q$K(J!AECD%<L.!@].<5F^&-,L=>2YLIW%M<)_I*7)R<QJ"9%QZ[<
ML/H1WJ%/&6J+(9#)$\FYV5WA5F0L,-M)' /M_.LRQOY].G::!@CM&\1)&?E9
M2K?H30!U%_X.BGC-W#/%8B:+[3#;.RX$9/RKG=N+D<X"X/K0WP_"M$3?-'&[
M2)B:$1R,R*#A59AUSQN*GVK%@\4:A;0Q)'*@:%/*CE,:F14SN"[L9QFII/&6
MI21-$6@\EF=GC\A,.7^\3QSG ^F.* +&M>'[32=#67S)VO?MCPD21; 4"*PX
M)R#\WI_]>6_BL-&NK&P_LL7OF6T4LLA9A)(\B!ALP<#;N '!R0<]:R+_ ,0W
MNIV[0W,BR1F02 ! -IVA?E]!A0,>PJ6W\4:A:Q6ZI(A>W4I!,T2M)$I[*Q&1
MC)QZ9XH W=-\!JL^GM=749=_(FDMG*J&C=E^4'=N+88'&WIGGBFW6A6,?C/1
M[-8 +:9(FDCW'#$YS[UB0^*M1@6$)*@:)402F)3)M0Y52V,D @=?05$WB"^D
MU&VOVD!NK<*$8J, #IQWH T+311KVJ1V$$]HMS(&$(MT?#OV0D],C.#_ /KJ
M=/!UL[V\2ZINGN;A[:!1 <,ZX&221@$G'0GVK'BUZYMC(UNL5O(Z-&7BC"MM
M/7GMGIQVR.]:=QXXO9;.V4",W<<LLK7#1(6W,%&X''!^7D^O/6F!:/@6)9)4
M.HEC;PQ2SXB VF10RJI9P&.#STZ=ZB;P0JP73KJ$<[0LPS;J)$"@ AG(;*@@
M]<$#!R162OB*^$T\CO'+YT:12+)&K*ZH %R".P4<]:F3Q;J4;,ZRQB4[MLGE
M+O3<,$*<<#'&!^%(#:7P$RSR0P3+=%XF$<DL1",VY "C*Q!^]U/3N*AMO T%
MY-.(M3_<VSRQW$C0$;&2-W^49Y!V,,\'VK,?Q?JC)(BS)"CEF80QJN68KEN!
MU^5>?:B3Q?J<AD/G(GF&1I-D2KO9U*LS8')()'MF@"MK6E+I<EL8YO/AN(%G
MC<KM.TY&",G!!![UG58N[^:]6!9FW""(0Q\ 84$D#]35>@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ J_H)QK>G_ /7Q'_Z$*H5?T+_D
M-6'_ %W3_P!"% 'VII?-A#]#_,T4:5_R#X?H?YFB@#D_%GPZTGQ[J;_VF9Q]
MFQL\B3;U SG@^E8W_#.WA3^]?_\ ?\?_ !->A6W_ "$[W_@'\A5Z@#R__AG;
MPI_>O_\ O^/_ (FC_AG;PI_>O_\ O^/_ (FO4*1C@4 >8?\ #.WA3^]?_P#?
M\?\ Q-'_  SMX4_O7_\ W_'_ ,35NW^+D$6M:C9:E9R6:6UQ) C@[BY7:02,
M<9#9%65^+FEO.T?D7(  (<J,-[5A[:FM&S7V4^QE_P##.WA3^]?_ /?\?_$T
M?\,[>%/[U_\ ]_Q_\373>"/%T_BP7\DEF;6*"4)&2<EP1GGW''YUU5:QDI*Z
M,VFG9GE__#.WA3^]?_\ ?\?_ !-'_#.WA3^]?_\ ?\?_ !->GGI6-8:Q?W/B
M74].FT:YM;&UCB>#5'DC,5TS9W*J@[@5XSN SGBJ$<3_ ,,[>%/[U_\ ]_Q_
M\31_PSMX4_O7_P#W_'_Q-;OQ"\0:OH=WX732(H[B6^U7[-+!*_EK)']GG?&_
M:VWE%.<=L=Z\G@^//B33KG78;^.QAFM([B97O),6\?ERWN(MRJI+%;= #WP3
MC(Y-P.[_ .&=O"G]Z_\ ^_X_^)H_X9V\*?WK_P#[_C_XFLOX1_%+7O%5TL.K
MI;/#=OJ<MO)&I1HD@N1&J-V(VN.>ORY.<UF#X_:VRV=NFCV<M_*LLLC+=1+;
M($6)EC$S3!&+"0D,K$X4G9V (Z?_ (9V\*?WK_\ [_C_ .)H_P"&=O"G]Z__
M ._X_P#B:KZ1\4=1LO"WAZZU1(YYKW4C:W=YM\N"!#+(H^8' 8;5'/'/O5#X
M>?'#4/&FLZ;;R6U@(+R80&&VD8SQ VGVCSFR<;,C9TZLO/:G;6P&O_PSMX4_
MO7__ '_'_P 31_PSMX4_O7__ '_'_P 36=/\9;]8%?SM#MI)9KA?*N)V#VBQ
M>=\LZYR&?RL \?Q<';SS4OQZ\0ZBFF,D.GZ/+->1.]O+()$\@A\I),&*QG<%
M!W!&4Y&#@DH9VW_#.WA3^]?_ /?\?_$T?\,[>%/[U_\ ]_Q_\363?_&74H/A
MG=Z^+> ZE9WL5O-;PD&/YMC8# NK##=58_@>!2F^/&N:5>06=YHD-Y=7;0PV
MHLM^))7AAG*$'.-L3RG/?RNV: .C_P"&=O"G]Z__ ._X_P#B:/\ AG;PI_>O
M_P#O^/\ XFN2?X]:PL]A>-#:/I\>GG4[U;3<ZB(K$[ID\^9$C.2!UXR!TIT'
MQWU^6\N633;86R6S:@8YMV\0B.T947&,,1<DDMGD>AX.EPZV_K^M3J_^&=O"
MG]Z__P"_X_\ B:/^&=O"G]Z__P"_X_\ B:R=.^,&K:]X;\5W,:6=K=6.@C5;
M=;?+RVTC";$4RMD;U,0R,=<\5C1_M!:Q-XHT+0[*VL;S^T_E%RX8&(K($?<@
M;))).,A!QQN'-'D):JYU_P#PSMX4_O7_ /W_ !_\31_PSMX4_O7_ /W_ !_\
M37'#]H?7'O+:VATS3KB6YLHK[*W"QK;%ED8P3&21 KCR\'GC#':<8K?\9?%3
M6?#GBJ%(C9BV?0X;[^S97#/+,]P(RL3K]X@,.F0>..<AV&M78TO^&=O"G]Z_
M_P"_X_\ B:/^&=O"G]Z__P"_X_\ B:XW3/V@M=OM(TF2.PL?M5[>0:?Y$[.9
MHBQ@!N)%7'R-YV0 !U7GG TD^.^K(]Q'=V%C8M]HDM86DF0GS4D=2&C$VX!@
MC,&?RP.!R2,KI<%J=!_PSMX4_O7_ /W_ !_\31_PSMX4_O7_ /W_ !_\37)6
M/QSUSQ3X7_M*V.F:-.MU91&RE8O<2(YMVD=!G!0B9ESVQG-6M.^.?B#5[FQ@
MM;'2=USI;:J[RRNL=OB-F^SR,2 K@@ L>!G.!BG8#H_^&=O"G]Z__P"_X_\
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M!YG_ ,,[>%/[U_\ ]_Q_\31_PSMX4_O7_P#W_'_Q->CMJ%NDBQM/&)&^ZA<
MGZ"DGU"WM;>2>::.*&,;GD=@%4>YH%<\Y_X9V\*?WK__ +_C_P")H_X9V\*?
MWK__ +_C_P")KM]"\6:=XC$WV*9V:(C<DT3Q/@]#M< D'L>AJ*Z\76D=]+96
MT<^HW<2[GBM(]X3T5GX56/8$@XYZ4[,7,K7.-_X9V\*?WK__ +_C_P")H_X9
MV\*?WK__ +_C_P")KJV\2WP$2OIAMI)L^7!),KS'ZJF0/KNQ[ULZ=+<36J-<
MQF*4C)0XR/R)_F:&K;C33V/._P#AG;PI_>O_ /O^/_B:/^&=O"G]Z_\ ^_X_
M^)KM]%UF^U/4-6@NM&N=,ALYQ%;W$\D;+>)M!\Q I) R2,-@\5F>)?$DFC>+
M?#=HUU%;6-Y]I\_S2H#%$!49/3DFD%SF_P#AG;PI_>O_ /O^/_B:/^&=O"G]
MZ_\ ^_X_^)KG#\:?$3ZG-:VEI82P+J?V!9;DN6.YKK:WRX& +<<=]W7O7-Z1
M^T/XEOM2AN1:1O:7BI%':$)^Y=G3YR[-&"H#;<%AR1SS1N-Z.S_K^K'H_P#P
MSMX4_O7_ /W_ !_\31_PSMX4_O7_ /W_ !_\363X?^+6M^(O&'ARQD6PTV"X
MNI(+FRCE6>64"R:82*ZDKY>\J 5_NXR<XJ#0?C#K0U:;3[TV%U)#J*V^P;DG
MG26\FA'EJ#C]VL8+=<@\XZEV=["OI<W?^&=O"G]Z_P#^_P"/_B:/^&=O"G]Z
M_P#^_P"/_B:QM9^-FLZ3K5];'3K-K0:G)IL$K%P8MLELAFE/38!<$G&.$Z\\
M+H7QLUC4=76*?3;62P755TEGM-[/,QCE831Y.-I\H8'.=W7CE+6S0S8_X9V\
M*?WK_P#[_C_XFC_AG;PI_>O_ /O^/_B:YGQ3\;M<34WL-.AL["5M36Q2"Z#&
MZ15FME+NG0(ZS-CVP0>>+%C\>M2U"9%-A9:<D-O.UP][(ZJ]S T23VT9XRV^
M0A3SG;T.:%JKB-[_ (9V\*?WK_\ [_C_ .)H_P"&=O"G]Z__ ._X_P#B:P/^
M%YZJJPNT&F20&.&XFN()=_EK(FXQB,N&9TXW;-Q&Y/D^;BNWQVU1]3M/-CM[
M"*%9[&\C:-G3^T$E@C*@G!V RC!R =V20!F@9T__  SMX4_O7_\ W_'_ ,31
M_P ,[>%/[U__ -_Q_P#$UQ.E_'WQ%=1S7/V2RG%Q<+;P0;XXT@VI,69G>55(
M<Q8'S<9XW8P>E^'_ ,5M8\:^-+&WN?L-A:26=\\NEPRB6>&2&>.-6D<9&&!9
MEV\$,/O<&G81H_\ #.WA3^]?_P#?\?\ Q-'_  SMX4_O7_\ W_'_ ,37-7'Q
MRUL7=O;):61O'N!#Y<;^9 %>6-$;S$9@_P!YC\K*>F5&135^.^N1ZKI>G7<6
MBV$FH<K=W+R)#$%:Z5MV3R2;8$<C <]<9*Z7'UL=/_PSMX4_O7__ '_'_P 3
M1_PSMX4_O7__ '_'_P 37$?#S]H'Q'XGOXH)](B03W"2?Z5/%!LBDD""-2[H
M6*#GA7))48&0:W?%GQMUC0O$.KZ=9VNFW1MM5BTN*%G?SDWPPR>?( ?N RE<
M#';FG9AY&U_PSMX4_O7_ /W_ !_\31_PSMX4_O7_ /W_ !_\37)^)/C7XCMH
M[:*W6PBG_M-8)T@1FEACCOXK=U=6.%\U7+*>P]>M);?'GQ'?0Z5*NE6EJ]\T
M2QI)<1N%\V2)<2)'([*5\PGDIN_NC%"5P.M_X9V\*?WK_P#[_C_XFC_AG;PI
M_>O_ /O^/_B:@\(_%W4-=\2Z?IU[:VEO%<O-;[H'\QVFC>96RH;=&I$)8;EP
M0?O9X/JPI;"/,/\ AG;PI_>O_P#O^/\ XFC_ (9V\*?WK_\ [_C_ .)KU"B@
M9Y?_ ,,[>%/[U_\ ]_Q_\31_PSMX4_O7_P#W_'_Q->H44 >7_P##.WA3^]?_
M /?\?_$T?\,[>%/[U_\ ]_Q_\37J%% 'E_\ PSMX4_O7_P#W_'_Q-'_#.WA3
M^]?_ /?\?_$UZA10!Y?_ ,,[>%/[U_\ ]_Q_\31_PSMX4_O7_P#W_'_Q->H4
M4 >7_P##.WA3^]?_ /?\?_$TZ/X >%[&1;B)K[S(B)%S.,9'(_A]J].J*Y_U
M$G^Z?Y4 0Z7S80_0_P S11I7_(/A^A_F:* &6W_(3O?^ ?R%7JHVW_(3O?\
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MQZ ?[*_ACI706\<R#$KK(WJJ[?ZFIL =J"..*S;-4K!4-Q9PW0 GBCF Z"1
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M>_\  /Y"HM=\06OAZ&W>YWL]S,(((84+R2R$%MJ@>RL?8*3VJ6V_Y"=[_P
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M7KI'M05!'(!HZ6'?6YXU8S>,-$^'>J3:O?7BW_\ HS-).B0>4H9/M 20S/\
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M]]"N:P/048'H* .E,\/_ #U3_OH4>?#_ ,]4_P"^A7-8'H*,#T% '3">$?\
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M/_/5/^^A7,8'H*,#T% '3_:H?^>J?]]"C[5#_P ]4_[Z%<Q@>@HP/04 =/\
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I_OH4V:>,PN ZG(QP<USJ*/05=M@/2@#5LEV6L:^F?YT5)#_JEHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>plx-20240930x10q007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20240930x10q007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $T MH# 2(  A$! Q$!_\0
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M#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MLM0M]2@6>TGBNH&Z20N'4_B.*LT#"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#(\5^)[
M#P?H5UJNHR-':VX&=BEF9B0%50.K$D #U-<WX?\ BSIVK7L]GJ5C?^&;N*W-
MWY6LQK%OA! ,@8,1@9&><C/-7?BCX0NO&GA*6RL9HX-0AGAO+9IP3&98I%D4
M-CG:=N#]:\P^(/ASQ9XDT;7]?U[3;32OL.@W=G;6%E<FZ>9Y%&YRVU<#"\*
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M ,) VE^< JZ>-2^V[U^S^46*YWY]OI5^V\7:)>6]I/!J]E-#=L5MY([A"LI
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M8_'_ ,(:I8VUY;7LJ03M;E6O;6:V)BF#&.50Z E"$;YNG!Y%+?4-M#C?@/\
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M:[B< [ER,$\UW'Q0^,%S\/\ 4HHK:SM-0AB-LUY%OE,\:33")6PD;*HZD%V
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M-;V*0C35>[\F1FW.%<!2#ERJ@]< &HM3^-WQ N+&+6=6\0VVGBX\(7]W:Z;
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M$\TSG"QQJ2S'T %>T_#W]FK4-8\J\\1R-IMF?F%JF#,_U/1?U/TKV[P-\*]
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ME=R6-Y!<1';)$X=3Z$'- 'US2U5TV^34M/M;N/[D\:R#\1FK5 !12$\9I-U
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MHHK<\\**** .Y^!W_)7/"O\ U_)_6OT)U1BFG7!!P0AY_"OSV^!W_)7/"O\
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MT;AEE1'!63:P!V$<C->.:AX5\>7\<(MK/4+:TN+V1Y)[5/L$]PC3VI,L\<;
M+(56;)&. 3@9HBKNP;(^GC5*^US3=,FBAN[^VM9I!F..:949QN"Y )Y^9E'U
M8#O7ROXZ\/>+?!_AK5=01]?BM1>:K'*R7\I9;0W,7V0(2_RY7=M(YY/-7M0\
M$>,[_P 71ZCI^G:W!HHDE2QCNIV^T6\#SZ<9%8ERRAC%<, 3]T'IFA+J"7]?
M<?2FD>*M%U^>Y@TS5K'49K5ML\5K<)*T1R1A@I.TY!'/H:N7=_:Z?$);JXBM
MHRZQAYG" LQ 5<GN20 .Y-?*6F_#[QWX>T[1[:RM-5LM&A2!]1M(&>5G'GWI
M8(@D4L<O;LP4C*@=<8.KJG@KQ1<-IEMJ-GXDUUA?Z3<:?<2.42UACN@\PG02
M%00!GYMQ("\Y6G;6WF)Z*_E<^G\@4%E Y->%>/?!/B/7/'U]=P?VO]A.J:4L
M9MKR2./[+M87.%5@,=-W&:XZ_P!*^(:VNDVJZ5K:WEG<0F*\2:9RT*WTNY7/
MFA5Q!L^\&+ CKBENKCMK8^G[:^MKRT6YMYXY[=AN6:-PR$>H(XHL[VWU"UBN
M;6:.XMY5W1S1,&5P>A!'45\U:;X&\<R63W5TFM'41J&F1HKWDFW[,2RW7R[\
M8*M\Q// ]*@\&>"O&.G2^';&=->TNTMK2QAM4M86=8'C<_:%D8S*JAO5E;<I
MP.0*=@/J+(]:7('>OEO3O#7COPWHVA*VF:WJ:7&D6W]K)+>SR.MR+CYV*B0,
MS!#]U2 1UZ54\+^#_B--I.J75]%K\>H6<"#3$DNI%PW]J3M]WS"#_HYB^\3\
MN!2L(^K\B@'K7S-?Z!XQ:QC5;+Q*NJ0ZH[ZY=K-)+!=6IEE,8@B$J[\!HCA,
M$*I!/:NH\5^'?&<?PGT$Z%<:M>:Y!<M%(EPPAN&MYQ)"2X#$?NA*L@R21Y0[
MT/0:/9=0UK3]*Q]MO;>TW*6'GRJF0,9(R>@R/S%2V>H6NHQ&2UN(KF-7:,O"
MX<!E8JRY'<$$$=B"*^7]6^'GCW4_"1MM6AU34GB@N;,P"X9C-';B-89& 89>
M7:[^I+5UGPE\%:YX;\0Z->+9:E965Y?ZY-?Q7$K;%C>Y+VI:,L0I()(P,\G-
M.VMA/1)GM\.LZ?.;SRKVVD-D^RZV2J?(;:&P_/RG:0><<'-2V=];:A:PW-K<
M1W-M,H>.:%PR.I&001P01WKY4U_X7>-K'XB>*/$NBPZY#->^)V BMKQTMYK%
MM,5#(8@P4GS44!B,@J,5YYXE\4:_H'BOP[X?UK5=?A\5"V\.K;6\.KF*-%,Z
M"ZCE@W@RNQR20&X!R0 <RM4N[M^*N-Z7\K_Y'W98:G9ZK;+<V5U#>6S$J)K>
M0.A()!&1QP013;#5++5%E:RNX+M896AD,$@?9(IPR-@\,#U'45\W_L_?#7Q9
MX#\9:--=1:S!IEY8:D=1M[N[>2VAG^UJUOMC+%4)0N?E'/.:XW2_ WQ%T#QW
MXEN]%\.^(XY)-7U>]E:35##IU]:2!O)CC02?)*SD$,%![[J+6:7D+I<^R);J
M&W,8DE2,R-L0,P&YO0>IJ&^U:QTL0M>7<%H)Y5@B,\@3S)&^ZBY/+'L!R:^+
MK#X8>/;^PTFZO-$\5K'I_BF*^T^SN]3EDN+:"2RVNS,T[%E6?D@L2 6&,,15
MW_A5OC7Q1X=TG3-0T;QC%<)X@TN;5[K4-8\U9)$>3[1<VF&+Q)A@=RLH^[A0
M1FFEM\OQL.WZ_K_P#[+GGBMH7FED6**,%F=VPJ@=23V%/617564[@>A%?*WB
M#X:?$[Q'^SYKOAAKEIK=(=1MQ87QE?4[L+(YM-EQYHX("9W@[AP>M1:7X1^(
M8\>Z/)8V7BFQVRV3V5U>ZFSV%IIRPH)K>YA,IWS%@V20220=W%%M1?9OZGU,
M-5LVU!K 7<!OEC$QM?,'FB,G ?;G.W((STR*EFGCMHGEED6.) 69W; 4=R3V
M%?'OQ4^'GQ1O/B&=2GM-1UC6GT2.TLM9\)2OI]I!<BZ=D,Z-,2Z*IRP)8<].
M:S?&OP[^)7C75_&$%SH7B.UMKS2]0MIXUU>62UO9U,+6S0J9B$#;7X54')4Y
MS26NOJ'6WH?:4]Y!;6KW,LR16\:&1Y78!%4#)8GIC'.:+*]M]1M(KJUGCN;:
M91)%-$P9'4C(92."".<BODF/P5XUEO-2@?0O&4GGZ2\6G/)JW^A06AL2GV:X
MB9VWS>;GMN)(.\ 5W?[,W@/Q-\/;QM.U%=631W\/Z:XCU*[:=8;T(RSQQ[F.
MP#"_*N%':JM_7WB>G]>A]! TM-%.I%!1110 C=*\(U_X+:M\0_$WC6QU>Z73
M_">HZC;72K' #<SF.W1<I+NPJ[EP05S\O!P:]W;I7@OQ$_:9O/A_K/C.*3PJ
MMWI/ALVD+7RW[;YKBY"^4GE+$Q"Y;YF!8@#A23BE=)_UY#LWHB[)\ =3O[C3
M[S4/$-M->V"6MI$T%BT49MH1(,,OF$^8PE;Y@0 0,+2>'OV=6T:3P]NO=,SH
M=U;O!<6^G,EQ-#"L@"2N96R3O!R !D$[>:XG7OVN]:U/P)/=>&O")AUR+2;O
M4KP:E<M#%9I$YC#QB2-6G!;D JF5ZX/%=''^U-_9]DSW^AB0V^KP:1-)'=8+
M;[!;MIE39VR5V9]]W:GJOZ\R+IO^NQ<C_9POK<.EOXECA622WF9Q9?O$>&^F
MND*'S,#B9E.0>0#ZBL+5?V4M6U^=KC4?%T,MR;:.V:;['*[R;$F3>S/.Q+'S
MLG&!E> ,TNO?M<:AX7\'6>LZIX*6WN=6F@&D6\6JBX6XAEC>17E\J)Y(V"QG
M*B-AEAAB 2*WB7]J?7-2LK.;PQX9^RVRR:2=1O-5G$<MJ;NX1/+6W90S_+O^
M;(P<<&FKMI>?XE;_ '?AM^IW'PP^%4_A/X@:KJ+-.FFV]E;VEO%*BHDER(U2
MXN(P"2 ZQ1#GN&]:J6_[.TL4NLN=<1O[1GBF ^R']WLU*>]Q]_G(F"=ONY[X
MI_Q6^/-[\-O%5YIUMH@UAH[*RFCA-V( [W%T8 ,^6V,<'.<>PZUR;_M>:I9Z
M=>W5_P" Q:_9X-1"A-760275E(J31 ^4,(=ZD2$<\C:.IE-[KH#_ #+*_ ?Q
M''\1_$L$&H01^'==L)A>7DEGN;]]=O(T,?[P%7"M]X@@YZ<"NC7]G^]T[34M
M]+UZ"&9[6_TZ>2YLO-5K>ZF\P[5WC$B\ $DJ>ZUS5E^U;K OVBU3P(+"*&\F
MTZ>:/5UFVW"V9NXE5?*!*M&,,W&UL !NM,U']KJ\A?P_!8>#4O[W6+32KB*#
M^U-@5[UW4(6\H\)LZ]\]!5ZK3Y?Y ]=7YO\ S-N?]ENT;4-;DCUN86-U:P16
M%G+%N6TG0QF24_,-_F&&,LO'0\\U-J'[/NHS6NHS:?JFC:3JNJ64^G7TEOI3
M&!XI-N&5#-N\P;0-S,V1@8X%82_M:WD^F&:V\%^;>Z;;W5WKMLVJ(BV45O.T
M,GDN4_?MN1B!A 1C)!XJ67]K@IJ/VI?";MX4:_NK"/53?J+AVMX&EE/V;9D<
MKM&6YZG' ,^0/3<[;QG\(]4\0W>CS:?K=K8K:Z)<Z'<K<61F,L4WD[G0B1=K
M 0\9W#YN>E<Q9_LT7&CIK5OIOB*..UUJVET^]6XLC(XM6(P(V#C;(!N&X@CD
M';Q7.>'?VR;_ ,6Z3ISZ3X#EGU34-4BL+>UFO)+>%TE@EE23S9+=<D>40P"D
M#.0S=Y[+]K>XOQ9M:^&FFO\ 4K:RCL]-DOUCC^V3SS0E'E\OY44PL=^#D8PN
M:=F_G^HMMOZZ'167[.5WI=MJUC;>(81I^M%H]066QW2&+[1)*HB;?A&Q(5)(
M8=P!7-Z3\'?$OB/Q+::?>"73O#VAV[6UK/=6BK+(/MD4RC<LK>9E8L;\*.0=
MN<TOC[]I#QAHCVL&E>%[,:L]O:/<6=WJB/#"\E[]G=5DC1MW.,'(QG)7((KN
MO!'QTE\7>.O^$1DT$6>L6<MZNJH+LNMFD+JL+@^6-XE#J1TP,]<4*_\ 7E_P
MXVK*YT?@?P/K7A3PU-H,FMP2Z?#;FVTZ2WM#'/ OS89V+L'89'0*/EZ<UPME
M^SWJ\.M0ZK=>)K>YO(FLVWM:RMYGD><"7+S,2S+,W< $ @8XJ;QM^T9-X-UB
M^MH]$M-5M8ENE@EMM0D+M- H9HY/W'EIG)'$C,".5ZXBU3X\^(FBUG2+'PU8
MQ^*K"WNKAXY-3)M4BB@CD#K(806;]]&-A51U^;')G5^\&RM_78T]"^!5UI>D
M36<VM0S.ZZ8B2):%=JV;[AD%SDL,#M@UF6'[/.J06.@?:?$5I+J/AZ"VM]-E
MCL&2+;%('S,OF98G&."N,5#\1?VEI/A?X'\$7]QHSZ[K/B"U6<P0>8B#;$KR
M$>7%(<\X5=N">K*.:S5_:OO;W7&A@\&R0Z";Z#31JMQ>[)HYI[43Q;K<QYXS
MM8;N,=^@J[N):_/_ "-(?LV7C^3)+K]K/<QR&X.^P;RVF%Y/<+E1*#LQ<LI7
M.3@$$5O7'P4O#+IDME?:7H]Q P>XNM,L9;>9CYOF,$99ONMR"L@<')/>N ^'
MO[4VO:IX8M8]<\/6$'B"XT6TU6P>74_)AU'S9#'M(6-S$V]3A0')!'?($"?M
ME:C=6\5Q:^ _.@M]*.K:H[ZIY9M8TNVMI @:',A!7<,[<]#C%%G>R#?5GLGC
M+P/J?Q$\'66GZE<V^G7\=W%=2-!&9(_D?(4 L#R,<YX-<LOP#N[2XT*^M-<A
M34-&LK"VMFFM"T3/;+(I=U#@D,)#P"",=:S-4_:??2HO$^KR^%F?PEHPN8AJ
M2:C']HFN((][)]G(!"G. RLQ[E0.:P],_:TU3Q1X=M1HW@MCXCN9+E?LUW>/
M;VR10PB5I4EFA1I.& "E%R0><#-3_P /_7W#_P"&.QU3X(:S?Z[J.MIXBM$U
M:^\Q)6?3R8@DEI#;R;5$@.<PAAS@9P0>M93?LWZA'HMIHD'B.W32899+IA)8
M%IFF>R:V.'\P )\V_&,]LXIX^/&OZ;\+_A;JL>A6WB#Q!XOCAB,+7HLHDF:W
M:4G=L?C*D8QW[UCV'[7-QJ337,'@X_V78:(=8U.=M2 D@*RS0F*-/+Q)^\AP
M&W*"K9.,8-.ZOY:?J).Z3[_\,;>J? &6W\*+:C4Y+N2TNKV_6.VMP))6FA**
MBAG ^4X/)^;IQUKJ?@]I6OV\GB;5?$,(M[G5+Y)8T\@0G8D*1Y*!WVY*GJQ-
M>:ZA^TKXO3Q'H&BMX/L-.U"35(8-4A.J_:$6VEMY)T:*18QE]L3Y!48*@<[M
MPJ>%_P!LA?&UHLUGX:N[%'U*R@@E9Y-DMO/-Y>69X%4..I1"PP1A_05_T$^W
MS_K[CZ>%.KQ#X+?M%7WQ1U[3].U+PG_PCR:GI+:M83+J N?-B2;RG#*(UV'.
M".N0>U>WT6:W*"D-+2&D!\(_M66!L_C-J<A'RW,,$J_]^U4_JIKR"OHO]M/1
MV@\8:'J07Y+BS,);_:1B<?DU?.E>U1=Z:/@L;'DQ$UYA1116QPA1110!W/P.
M_P"2N>%?^OY/ZU^A&K?\@RY_W#_*OSW^!W_)7/"O_7\G]:_0C5O^09<_[A_E
M7EXKXT?6Y/\ PI>OZ&1\._\ D3M._P!UO_0C725S?P[X\':</]EO_0C725QG
MO'BMCXVL_"OQ&\;06VE)";G4$:ZN6ED/FS+:08;E=H^3 P#GY<^M6M1UCP_!
M)HCV6F7CSOJ:WEK*',9(F8J\@.>4.[E3UR.*[:7X:Z%-KE_JTD#R75ZP>4,^
M4W!57<%Z [5 SZ5-;?#[1;2621+=BS3K.-S9"%3D!?1<DG'O0!YC>:AX%CLX
M[C5+.^TS[>/M4^D_:GC@EW#>SF,.$(.3D=SU!K:U?6_"6H7DVK26%]<FWBCD
M=H%(4P6\K%'VY&5#EL#OCIQ7::E\/=$U:.);BU+>4L:HP;!"ID!<^A!(([@T
MW6/AWHFNVZPW5NVP,['RVVE@Y+,IQU4DYQ0!Q/B_Q'X.UZ.&_P!9M[RU(AN+
M2VN<F(S(9$255(/3>J'YL=,BI+ >&;W3/[5M[G5+^012622R7+/*%F9=R!L]
MS".<\8X/-=1;?"KP_:P7D0MY)%N=V3(^3&2V\E/[I+8/'<"K"_#?1$NK&X$#
MB2S0+'\_!()(9AW89;G_ &C0&YR?@[5=%^S2+#HDPENXT$\"IYGEQ;5PK9.
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MV09R9,MG@;>IJQ=?LFZWJ$FKV,VLZ-;:2JZ@VFW=K9.+^=[J0R%;QB<.B'C
MY88Z8JFK?B2M3VCPQ\:/!OB_4+NTTO7;.Y-O=)9K*LJ^7/*\9D"Q-G#G:"3C
MT/I6HOQ(\*2W6FVR>(]+:YU//V&$7<>^YP2#Y8S\V"#T]*\ T[]FWQ[8'^UX
M=1\)6'B&+7;;5H(+*SF2PVI:O;NK("&SA]PP>2.U3>!/V8O%/@R_\.RG4/#&
MHQ1PV\6IR7VG//+"89WE5K0D@*6W\[OND9&:73^NP]#UC3?CYX*U'Q!%HK:U
M!9:A/#%/!'=RI&LXD=T58VW$,V8VX&>U/N/CEX7MM0N+*2XD\^".YE;&S:%@
ME6*3+;MH.YQP2#7A5Q^R#XJFFCMQJOATV%SI]MIUW/-;22W4"QW$DS26S8 5
M_G &??IBMZ]_9>UZYDUTKJVG[=035$CW&3*_:;R.=,_+V6,@X[GBG_P?^ '5
M'L?ACXR^"O&%Q?P:5XCL+F>QFFAGC\]0RF( R'!/*J&&3TK;O_&N@:7I%OJM
MYK%E;:;<J'ANY9U6.0$9!5B<$8YXKYE\=_ /Q#I&F7&F:88)+W5_%,ES:7&E
MV<FZ*QN8C%>+</C:@",2ISR5& 3Q7MGQ!^'^L:KHVA:;X:N;6SL[%'MYK::5
MX-T1A,:[9$5F&W.=HV[NFY:.EU_6@;.W0ZB#X@^&+O44T^#7]-FOG4,MNETA
M=@5WCC/=3N^G-5M"^)GAOQ+JFJ6.F:I!>MIL$=Q<S0N&A1'W8^<''\#9]*\7
MTG]F#5K?P-'H5UJUE%.;RQEDN[7?N$<-FMNVTE0<D@D9['K7:^#/A=K^EGQ$
M=4.C0&^T6VT:W&FE\'R4D02/N48W;P=HSMZ9.,D?]?=_GH+?^O,[73?BAX.U
MBQU"]L?%&D7EGIZ+)=SPWL;) K#(9R#A01ZU=@\:^'[GPTWB&+6K"70EC,K:
MFEPAMP@ZL7SC'OFOG6W_ &0]2L=(M;:RO]'LY(/#VG6!C6!F@N;VUN#-NF0!
M=\;YP<G=R>*[&W^ VKM\#_&OA.XO=+37/$[3SRBRA>'3[:255&R-.6V +G/4
MDDXYH>E[?(.USO3\9_!207EU+XETN#3K81;M0EO(A WF9V /NZ_*WY<9JS;?
M%'PU=>()=&75(%ND2W>-G<".<3AC$(VS\Y(1C@5Y#\1_V:=3\1R:S-H@\/PM
M,MA]AAO4GC2V:"-T9U,)7:?G..&!Y!%+H/[-_B'1_B'X?\9S^(+34=7TNRL;
M)]Z&.&=$1TN&\L+A6(8;&'/R\X!--6;^8/:Z/;]6\;>']#UBRTG4=;L+'5+T
M9MK.XN426;'7:I.3^%<?X7^)?P]^(USJVNV;6%U_PCEV;&36+J.("&3.TA)#
ME@,G&>,YXS7)_$[X :QXW^(5QJMG?Z/%I&J+9+?O?6C27UI]FD+I]D<$!=^<
M'/3J,UO>"/@C%H7P\\8^%]1-J\6OWU_<,]HN-L<[,4!X'S*"/H1Q4K9M_P!;
M#ZV1V.I_$OPUHVI&SN]7LX6C65IY&N(U2W"(';S,ME?E(/3OVJ*'XL>"[N[L
MK6W\4Z1<75\C26D$5[&SW"J2&,8!RW((X]#7AFJ?LIZ_J7@*WTR;7+"ZU^>T
MU--2OY@X6XN+J-8T887.U0JCUP.*U_''[.OB3Q%XXT"]T_4-!L_#NDR6,T%G
M]E>*>)H2?,57CP"K9+?,#SQQUIM=%_6]Q=W_ %T_X)['IGQ&\/W_ ()M_%LF
MH16&@31><+R_80*JYQEBQP*ENOB1X4LH])DG\1Z5"FK$#3V>\C N\]/+Y^?\
M*\SU;X':Q>?!+PSX4MK[36UK09X+N(WL3RV-Q)&S$)*O#%#N],@@<5RGB;]F
M+Q)KB6+1WOA:*2\TLZ3JD8TMEBLXS,TIDL%#?(^7(RW7 /6AVN[=Q=%<]FU3
MXR^!M'&J"Y\5Z2DNF12SW<*W:-+"D7^L)0'/'0C%.TCXO^"M9&E+;>)]+:?5
M+87EG;-=()98B,[@F<] <_0UXA/^R+=36DD:7NF+/-?ZQ//>-$S2R0W=M)#$
MK';DE2ZDC...*K3?LQ>.]4U+PK)?ZQX96QT5++;%:6TL<B-#$8W5'&,JV=V6
M!.>/E'-%OZ_KY%Z'O5E\7_ VIM$EGXOT2Y>:9((UBOXF+R,,J@^;DD<@5#%\
M9/!@,,=WXCTS3KB>1HHK>\O(DDD(D,7 W<Y=2![BO#M(_9!N],TJTA$NAI=V
M^C:18":.%ABXM;AI9I0=F?G4@ ]3CG%-N?V1-4O9->EN+S1[B>[T:[T^SDD5
MV-O-+J$ERL@RO&%<#(YR#VIZ:B9[OK?Q?\%: NM?;O$VF1S:+;FZU"W6Y1IK
M>,=69 <CJ!T[BHM/^,O@V^T2ZUG^WK&UT>W,6^_N;F-(?WB!T^;=QD,.#BO$
MKW]ESQ;KOB37K[6=<T.Z@O--U'3;9XK61)@EQ&HC,O\ "VQE'09QSDG@6$_9
MI\61:8MXMYX8;7(+ZVO8;&XM99=,D*68MG5TX8=V4C./QJ4K;_UK_D+K_78]
MUG^)_A"TU"SL)O$^DQ7MX(VMK=[V,/,'SL*#.6W8.,=<5T]?+4/[(-[;6.HH
M+_2[F]DL-/M[6ZEB93;R0W4D\NP8)1#YFU "2 H!KZD3(&#5-"ZCJ***10AZ
M5R^J_#;PSK2:XE_HUM=)K@C_ +1$@)^T>6NV,GG@J.A&#74-P*^<?'OQ0\4:
M5\=6\+6_B-8;*_M_)LM.T^QCGG@<Q$^?+O ;:&&=RDKC (I/L.QZ/J?[/7PZ
MUG1]-TN^\*65Q8:<CQVL;E\QJYRPW;LG)YY)YYJ=_@/X F\21>(&\+V+:O&8
MRET0V<I'Y:G&<$A/ER1R,9KY>\.?M!^*M)\'?#>V@\87.JZN\%K)J<-[I:;;
MH27)BE0RX+!HN58C'0$GG%5?#'QI\:V7AJ^T^U\12Z_M@U&6ZM)[)A-I134-
ML#-,>9!(K, "<80 8P:IIW?E^A*V7G^I]1I^SO\ #>/1[W2T\(Z>EC>3K<31
MJK F1<[2&SE<;FP%( W'UJ?5/@/X UG4--O[WPQ93W>FI%':2D,#$L;!HQP>
M=I (SFOFSQ#XW\9C_A.+/3-;OK2<0^(KB"X53+)$819F-8]V=HPT@&.F[(Z5
MN77QN\;Z-]GT.SU@:](^E1Z];ZK]C1?M-G]E9?+P%QN:Y\M<_>PU"5K->7]?
M*S&U^OZ'TCKOPX\->)M1:^U/28;R[*PH99"V<12>9&.#_"_S5GW/P<\%7MN\
M$V@6TD+O=2,I+8+7#!ISU_C*@GZ<8KY^UGXS>+O OC^P\+:-J=SKCZ;;?V=<
MZ/?V(#RS)9&1)EFY=][KC)(!.0 >M9:_%CQ5K^G^"]0_X61)<6HU^VBU*>WT
M3[,D3RV[LUI(2-K!9 $]07&[D"I2[!Y'T]_PJKPF;AISH=NTC7?VXELG,_D^
M1O(SR?*^3TQ6+HG[/'PY\.7,5QIOA2RLYXYHKA'C+Y$D3%HV'S?PEB17CNB?
M%CX@1Q> ])@<SMXOA46UY]E4K8O!<.UV7X.=\&-N[H1Q7(^&?B9X^@O[K5O^
M$HGS;^%TU>/19;1#'<+#>O\ :0I(X;RD(R.?G'H*JUM>WZ?\,):I-?U<^F-1
M^ _@#6#:_;/"UC<FVN9;N,R*QQ)(YDD)YY#,22IR,]JXNQ_96TNW^,%YXWN-
M5^V6UQ=27O\ 94EC&,2/$8B#*#\R!2?EV]^2:[;X*>)]5\;^"(O$>IS!X]5N
M)KJPC$80Q6;.?(4X R=@4DGGFN] ]Z5G%Z[BOS(X?0?@GX)\,):KI?AZVLUM
M;S^T( A?]W/L9-XRW'RLPQTYZ5%)\"/ 4VF7&G2>&+)[.>)()(FW$%%D:50#
MG((=V8$8.37? 8[TM!1P4WP+\!SZ5_9C^&+(V/V1;'R & \E9/,5>#GA_FSU
MSWIW@WX5V?A/QKXF\4-+%<:GK?D1$Q0>4(H(4V1IRS%CCJV1GT%=UBBCS#R.
M*O/@SX-U"]FNKC0H999GEE?=+)MW2?ZPA=V%+?Q8 R>34^L_"?PIK_VK[=HT
M4QN6+3,)'1G)C$9!*L#@H I'0@<@UUU+1Y <AXE^$_A+QAHFFZ1K&AV]]I^F
M[?LD+EAY&T  *P((& !C//>B3X3>$I3(7T*V/F7<=\V"PS.B"-'Z]0H ]*Z^
MB@#SZ_\ @)X U2PM[*[\+V<]M;VD=A#&Y;]W!&^]$'/&&)(/7WI]E\"_ FG6
M5U:6WAFT@MKFS:PEB4L%:!I#*8\9X&\EN/6N]I:!'#/\$? LFNW^L2>%]/DU
M&^@:VN9GCW>9&R[6!4G&2O!.,D=ZI2_L]_#R?P[;:%+X5LY=*MYVN8H'+G;(
MPP3N+;N1P1G&*]&HI#/,/'7P \.>.-*\'Z+/!'!X>\.7 ECTL(626,0M$L>[
M<"H ;(/)XKHM-^%/A/2(Y8[/0+.".73UTMXU3Y&M5+$1%2<$9=CZG)KK*,4_
M(1Y_8? ?P#I>F6NG6GABS@M+6]348D3=E;A1A9-V<D@<8)QCC%/TSX'^!=&2
M9;+PU:6J3W<=ZZ1[L>=&VY& SQ@\@# ]J[W%&*!G,^'_ (;>&O#%WI]UI>DP
MV<^GV;:?:NA;,5N6WF,9/0L,UT])2T %(:6D(S0!X+^V%X;.J_#JVU.--TFF
MW09B!T1QM/Z[:^+*_3#QQX:C\7>#]7T>3[MY;/$">S8^4_@<5^:]_8S:9?7%
MI<(4G@D:*13V8'!%>GA97BX]CY+-J7+553NOR*]%%6+&PN=4NXK6SMY+FYE8
M*D42EF8GL *[3PDF]"OFMSPEX)UOQSJB6&B:?+?3DC<4'R1CU9NBCW)KW7X6
M_LBWNJ>3J'B^5M/MCAAIT+?OF_WC_#].OTKZE\-^%-)\'Z9'I^CV,-A:I_!$
MN,GU)ZD^YKCJ8B,=(ZL]O#994J>]4T7XGC'P;_9<M/ ]]9ZYKEU]NUF!A)%#
M <0PMZYZL?TKWJ6);B%XVY5@0:\0^.7[7O@7X)PRVD]X-;\0*,+I5@P9U/;S
M&Z(/KS[5XC\)O^"E&GZOK,EEX[T=-'M9I?W%_I^Z1(E)X$BGG_@0_*O.E-S=
MY'U%&A"A'EIJR/K>!+_PE&(TB^VZ8F2%08DC'7CL16]IFL6FK0^9;3!\?>0\
M,I]"#R*@\/>)=*\7Z3!J>C:A;:II\XW1W%K('1A]14.I>&X;F7[1;N]K=CI+
M$<'Z'U%0;FU17.0Z_=Z7((=6@Q'G"W<0^7_@0[?7I6_!/'<Q+)$ZR(W(93D&
M@"2BBB@ HHJM>:A!8)NFD"9Z+W8^@'>@"QG%9VH:Y!9R"% UQ<GI#%R1]?3\
M:J>9?ZUD*KV%J>^<2-_A6C8Z9;Z>A6) ,G)8\DGW- %*SL;J[NX[R]**T8(C
MB0?<!QGGN>!6E>6XO+.> G EC9"1VR,?UK@OB/\ '+PU\.(GBN;D7NI ?+8V
MS!GS_M'HH^M>7>#?VOX;K59(O$6F+9V<C_NKBU)<QCL'!Z_4?E0!-XN^%^K>
M%B\RH;ZQ'/GQ#)4?[0[?7I7'5]7:+KNG>)M/2]TV[AOK20?++"VX'V/I7)^+
M_A%I?B#?<68&GWIYW(/W;'W7_"@#Y]HK;\2>#M4\*W!COK=ECSA9TYC;Z'^E
M8E !0%W' ZT5TGP[T,Z]XNL("NZ)'\V3/3:O/Z\"@#Z%\)Z7_8WAO3;,KL:*
M!0P]&(R?U)K7HHH 3 ]*,4M% "8'I1M ["EHH 3 ]*,"EHH 3 ]*,#TI:* $
MP/2C ]*6B@!,#T%&!2T4 )@>E&!Z4M% "8HP*6B@!,#THQ2T4 )M'H*,"EHH
M 3 ]*, ]J6B@!,#THQ2T4 )BC%+10 F!Z48'I2T4 )@>E+110 4444 (:3;[
M4ZB@!N/:C''2G44 -*Y!XK!M/!.E67BJ\\1QP2/K%W"ML]Q-/))MB!SL168J
MBD\D*!D\G-=!10 W!]*-OM3J* &;?:LOQ-X9L_%NAW>D:DL[V%TACF2WN9+=
MF4]5WQLK $<$ \@D'@UKT4K7#8IZ7I=MHVG6MC90):V=K&L,,$8PJ(HPJCV
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%%% !1110 5Q_P 5?A9H/QA\'7GASQ#:B>SG&Y)%XD@D'W9$/9A_];O7844
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M6\JE)(I%#*ZGJ"#U%3T4 ?%GQ_\ ^">.E^)WN=:^'<T6BZDY+OI%PV+64_\
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M=Q;-%%O*LN?E('/?(Z4W2OV@/"VJ>&]3UP_VA9V%BJ.7N[1D\]7.$,74-N/
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MD,T"X212002>20P(.3QBJLO[/VA23+<"^U%+S)D>Y#QEY)_/:<3'*8#!W;@
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-44 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>plx-20240930x10q008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20240930x10q008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #@ M8# 2(  A$! Q$!_\0
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MXP/B,R70O_MD5[M#KY>^.VDMU&-N<;)6.,]<5TW]IP?WF_[YH_M.#^\W_?-
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M'1&M/LB&'>^[J;AF4D#[JGBLG1/VA?$.JZ%91SZGI>G2R:F]E>>(+FT1["T
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M+185O_M[_P"U/TVP?>C!]Z_,&35-3B8+)>7D9(# /*X)!&0>3T(YS3?[8O\
M_G_NO^_S?XT?4W_-_7WDOQ!IIV>&?_@7_P!J?J!@^]&#[U^7_P#;&H?\_P#<
M_P#?]O\ &C^V=0_Y_P"Z_P"_[?XT_J;_ )@_XB#3_P"@9_\ @7_VI^H&#[T8
M/O7Y?_VSJ'_/_=?]_F_QH_MG4/\ G_NO^_S?XTOJ;_F_K[P_XB#3_P"@9_\
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MO^@C=_\ @0_^-'U-_P WX!_Q$&G_ - S_P# O_M3]7LCU%&1ZBORA_MS4O\
MH(W?_@0_^-']N:E_T$;O_P "'_QH^IO^;\ _XB#3_P"@9_\ @7_VI^KV1ZBC
M(]17Y0_VYJ7_ $$;O_P(?_&C^W-2_P"@C=_^!#_XT?4W_-^ ?\1!I_\ 0,__
M  +_ .U/U>)'K65JHS<+C^Z.GU-?EK_;FI?]!"[_ / A_P#&D.M:@3S?W7_?
M]O\ &CZF_P";\ _XB#3_ .@9_P#@7_VI^G^#[T8/O7Y?_P!LZA_S_P!U_P!_
MF_QH_MG4/^?^Z_[_ #?XTOJ;_F_K[P_XB#3_ .@9_P#@7_VI^H&#[T8/O7Y?
M_P!LZA_S_P!U_P!_F_QH_MG4/^?^Z_[_ #?XT?4W_-_7WA_Q$&G_ - S_P#
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M\1!I_P#0,_\ P+_[4_5[(]11D>HK\H?[<U+_ *"-W_X$/_C1_;FI?]!&[_\
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M !H^IO\ F_ /^(@T_P#H&?\ X%_]J?I_@^]&#[U^8;:CJBJ[-=7JJC;&+2.
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MHW;31Z[&O+; ]BK%58@[=V[..!^7.:U<)O>K^9BITUM1M]Q?T+5'U*)MUO\
M9]A"XR?[H/3 ]<?A7EG[7Q_XL?JGO<6__HP5ZOI.FWEF\LE[J+7TCX 'EB-%
MQZ 5PG[1'A&X\=?#>?1+:XBMIKBXB(EF!*C:VXYQSVITO<DN9W\SS\VA+$X&
MM3I1UE%I+Y'P7X7O;9O#.LZ8UXEA>W,]M*KN_EB>%/,\R'S,$*26C89X.SU
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M/]5\X_Z!W]Z_S/FBBOI?_AA;Q1_T,&E?]\R?_$T?\,+>*/\ H8-*_P"^9/\
MXFCV]+N'^J^<?] [^]?YGS117TO_ ,,+>*/^A@TK_OF3_P")H_X86\4?]#!I
M7_?,G_Q-'MZ7</\ 5?./^@=_>O\ ,^:**^E_^&%O%'_0P:5_WS)_\34$_P"Q
M%XDMW"MXATG)&?NR?_$T>WI]P_U7SC_H'?WK_,^;Z*^C/^&*O$?_ $,.D_\
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MO^^9/_B:/^&%O%'_ $,&E?\ ?,G_ ,31[>EW#_5?./\ H'?WK_,^:**^E_\
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M0 C:3\HB5<CIYSUZC_PPMXH_Z&#2O^^9/_B:JO\ L3>)(Y"I\1:5E3C[LO\
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MYU/[#/([SF4O]H^T((UP& XCW'&,'/.<<>H_\,4^(^_B'23_ ,!E_P#B:/\
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M_NG^\>X_QKH#]:P[K_CXDZ_>- %?S7_YY/\ F/\ &CS7_P">3_F/\:?^!H_
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M?CFJ>C^*++5].L[M=]I]J3?'!>#RI@,XY4\@YI.K*2T1:HQB]9&M&@C15 P
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M,/\ B_\ Z#>B?]]3?_$4O_#$'B\_\QO1>F/O3?\ Q%?:&]O^>;?F/\:-[?\
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M:.([K[@_LO#=G]Y\7?\ ##_B_P#Z#>B?]]3?_$4?\,/^+_\ H-Z)_P!]3?\
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M !HWM_SS;\Q_C1_:.([K[@_LK#=G]Y\5?\,1>-.^L:%]/-F_^-4?\,1>-/\
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M;Z'-/8ZUXGTK6H=72XA%O#!;_93*)%+B3?\ Z,P 5"#N7GKA*G&Z3?\ 5_\
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M%#^87U>OV1\L#Q=X8FT^2T$6DV]XNGPI!J,NBK)']H^TEYRZ^27;='M"EE(
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M)T5]V_\ #MK2O^A^O/\ P5)_\>J6W_X)IZ5<2;1X^O.F>=+3_P"/4?6Z/?\
M,/J=?^7\CX-Q17WT/^"8FF9S_P )]=?^"M?_ ([3O^'8VF?]#_=_^"Q/_CE'
MUNCW#ZG7_E_(^ Z*^_/^'8NE_P#0_7G_ (+4_P#CE+_P[$TK_H?KS_P6I_\
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MHATZYA&H7EM'JDLEW)>SQ['$6J(8?)&> D4<@/ R ,[FQ7LT<K(,9S4HNO\
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MD]26W^O6JGVS_8_6I;2Y\RY0;<=>]#:"QJT445F:$,DDBL0(BP]<BF^;(/\
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M7WG?H[X_U9_,4[>W_/,_]]"N-3XR>#<?\AR'_OW)_P#$TO\ PN3P;_T'8?\
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M^_3_ /Q-'LY_RL/:P_F1N^=+_P \6_,4>=+_ ,\6_,5A?\+#T#_G_'_?I_\
MXFE_X6%H'_/_ /\ D)__ (FCV<_Y6'M8=S<\Z7_GBWYBCSI?^>+?F*Q!\0-!
M/_+_ /\ D)__ (FE_P"$_P!!_P"?[_R$_P#A1[.?9C]I#N;7G2_\\6_,4GFR
M?\\&_,5CCQ]H)_Y?Q_WZ?_"E_P"$\T+_ )_Q_P!^W_PH]G/LP]I#NC8\V3_G
MBWYBLS5'<W"YB(^7IN'J:B_X3O0S_P OW_D)_P#"J&H>+M)N)PT=WN 7'^K?
MU/M1[.?8/:0[ECS'_P">9_[Z%&]O^>9_,5G_ /"3:81_Q]?^.-_A1_PDFG'I
M<C_OAO\ "CV<^P>TAW-#>W_/,_\ ?0HWM_SS/_?0J@/$6G'_ )>1_P!\M_A2
M_P#"0:>?^7@?]\M_A2]G+L'/'N7M[?\ /,_]]"C>W_/,_P#?0JG_ &]8?\_
M_P"^6_PH_MRQ/_+?_P =;_"CDEV'SQ[ES>W_ #S/_?0HWM_SS/\ WT*J#6[(
M_P#+?_QT_P"%._MBS_Y[?^.G_"CDEV#GCW+.]O\ GF?^^A1O;_GF?^^A5?\
MM:T/_+7_ ,=/^%*-4M3_ ,M?_'3_ (4N278.>/<GWM_SS/\ WT*"[?\ /,_F
M*@&IVQ_Y:?\ CI_PIPO[=O\ EI_XZ:.1]A\R[G002RB&/]RWW1W'I4GG2_\
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M_N?J*/L$_P#<_44 5-[?\\S_ -]"C>W_ #S/_?0JW]@G_N?J*/L$Y_@_\>%
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MREP 92Q;*%3N\T\8Q@8]Z=>?$);BV:&*R>V"B15".C;PZ*C;BR%AD+_"0,$
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M (5HQF8 ?NT_[[/^%;?6*W\S,/JU#^1'!#]G_P '_P#/K=?^!34?\,_^#O\
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MJ_S#^KTOY3$_X5'HO_/6\_[[7_XFE'PDT8?\MKS_ +^+_P#$UU^^X_YY1?\
M?T__ !-&^Y_YY0_]_3_\32^L5?YF'U>E_*<A_P *FT8?\M;O_OM?_B:7_A4^
MC_\ /2[_ ._B_P#Q-==ON?\ GE#_ -_3_P#$T;[G_GE#_P!_3_\ $T?6*O\
M,P^KTOY4<B/A1HX_Y:W?_?Q?_B:7_A5.C_\ /2[_ ._B_P#Q-=;ON?\ GE#_
M -_3_P#$T;[C_GE#_P!_3_\ $T?6*O\ ,P^KTOY4<G_PJO2!_P M;O\ [[7_
M .)I1\+-)'_+6[_[[7_XFNKWW'_/*'_OZ?\ XFC?<?\ /&'_ +^G_P")H]O5
M_F8>PI?RG*CX7:2/^6EU_P!]C_XFG#X8:2/^6ET?^!C_ .)KJ-]S_P \H?\
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M.&C0#^)S]3_]:K6^;_GFG_?9_P *-\W_ #S3_OL_X4O:3[A[.'8K#2(1W?\
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MT_\ Q-+FD/E1$-,B]6_.E&FQCNWYU)YES_SRA_[^G_XFCS+G_GE#_P!_3_\
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MAU_V]Q?UKS,SQ,\'@ZN(I[Q3:N=^ H1Q6*IT)[2=M#-B^,7A!.NJ-_X"R_\
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M10 4444 %%%% !1110 4444 %%%% !5C3_\ C[C_ !_E5>K&G_\ 'W'^/\J
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(@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>plx-20240930.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.8.0.95 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/13/2024 11:42:22 PM-->
<!--Modified on: 11/13/2024 11:42:22 PM-->
<xsd:schema xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:currency="http://xbrl.sec.gov/currency/2024" targetNamespace="http://www.protalix.com/20240930" elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:plx="http://www.protalix.com/20240930" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:srt-roles="http://fasb.org/srt-roles/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap-ebp="http://fasb.org/us-gaap-ebp/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" id="StatementCondensedConsolidatedBalanceSheets">
        <link:definition>995200100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" id="StatementCondensedConsolidatedStatementsOfOperations">
        <link:definition>995200200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" id="StatementCondensedConsolidatedStatementsOfCashFlows">
        <link:definition>995200400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails" id="DisclosureInventoriesScheduleOfInventoryDetails">
        <link:definition>99940201 - Disclosure - INVENTORIES - Schedule of Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails" id="DisclosureEarningsLossPerShareDetails">
        <link:definition>99940601 - Disclosure - EARNINGS (LOSS) PER SHARE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeSummaryOfTaxesOnIncomeDetails" id="DisclosureTaxesOnIncomeSummaryOfTaxesOnIncomeDetails">
        <link:definition>99940701 - Disclosure - TAXES ON INCOME - Summary of Taxes on Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationDetails" id="DisclosureSupplementaryFinancialStatementInformationDetails">
        <link:definition>99940801 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" id="StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency">
        <link:definition>995200300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical" id="StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical">
        <link:definition>995200305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails" id="DisclosureSignificantAccountingPoliciesDetails">
        <link:definition>99940101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesConvertibleNotesDetails" id="DisclosureSignificantAccountingPoliciesConvertibleNotesDetails">
        <link:definition>99940102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Convertible notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureRevenuesDisaggregationOfRevenuesDetails" id="DisclosureRevenuesDisaggregationOfRevenuesDetails">
        <link:definition>99940401 - Disclosure - REVENUES - Disaggregation of Revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureStockTransactionsDetails" id="DisclosureStockTransactionsDetails">
        <link:definition>99940501 - Disclosure - STOCK TRANSACTIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails" id="DisclosureTaxesOnIncomeAdditionalInformationDetails">
        <link:definition>99940702 - Disclosure - TAXES ON INCOME - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" id="DisclosureSubsequentEventsDetails">
        <link:definition>99940901 - Disclosure - SUBSEQUENT EVENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>995200090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPolicies" id="DisclosureSignificantAccountingPolicies">
        <link:definition>995210101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureInventories" id="DisclosureInventories">
        <link:definition>995210201 - Disclosure - INVENTORIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurement" id="DisclosureFairValueMeasurement">
        <link:definition>995210301 - Disclosure - FAIR VALUE MEASUREMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureRevenues" id="DisclosureRevenues">
        <link:definition>995210401 - Disclosure - REVENUES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureStockTransactions" id="DisclosureStockTransactions">
        <link:definition>995210501 - Disclosure - STOCK TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureEarningsLossPerShare" id="DisclosureEarningsLossPerShare">
        <link:definition>995210601 - Disclosure - EARNINGS (LOSS) PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncome" id="DisclosureTaxesOnIncome">
        <link:definition>995210701 - Disclosure - TAXES ON INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformation" id="DisclosureSupplementaryFinancialStatementInformation">
        <link:definition>995210801 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>995210901 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies" id="DisclosureSignificantAccountingPoliciesPolicies">
        <link:definition>99920102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesTables" id="DisclosureSignificantAccountingPoliciesTables">
        <link:definition>99930103 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureInventoriesTables" id="DisclosureInventoriesTables">
        <link:definition>99930203 - Disclosure - INVENTORIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureRevenuesTables" id="DisclosureRevenuesTables">
        <link:definition>99930403 - Disclosure - REVENUES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureEarningsLossPerShareTables" id="DisclosureEarningsLossPerShareTables">
        <link:definition>99930603 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeTables" id="DisclosureTaxesOnIncomeTables">
        <link:definition>99930703 - Disclosure - TAXES ON INCOME (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationTables" id="DisclosureSupplementaryFinancialStatementInformationTables">
        <link:definition>99930803 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20240930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20240930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20240930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20240930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="https://xbrl.org/2023/calculation-1.1" schemaLocation="https://www.xbrl.org/2023/calculation-1.1.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/ecd-sub/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd" />
  <xsd:element name="ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <xsd:element id="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" name="ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" name="GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element name="ChangeInOperatingLeaseRightOfUseAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_ChangeInOperatingLeaseRightOfUseAssets" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <xsd:element id="plx_RevenueDisclosureTextBlock" name="RevenueDisclosureTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element name="NatureOfOperationsPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_NatureOfOperationsPolicyTextBlock" substitutionGroup="xbrli:item" />
  <xsd:element name="SignificantAccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_SignificantAccountingPoliciesTable" substitutionGroup="xbrldt:hypercubeItem" />
  <xsd:element name="AmendedPfizerAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_AmendedPfizerAgreementMember" substitutionGroup="xbrli:item" />
  <xsd:element name="ChiesiUSAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_ChiesiUSAgreementMember" substitutionGroup="xbrli:item" />
  <xsd:element name="ChiesiExUSAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_ChiesiExUSAgreementMember" substitutionGroup="xbrli:item" />
  <xsd:element name="ProtalixBioTherapeuticsIncorporationMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_ProtalixBioTherapeuticsIncorporationMember" substitutionGroup="xbrli:item" />
  <xsd:element name="SignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_SignificantAccountingPoliciesLineItems" substitutionGroup="xbrli:item" />
  <xsd:element id="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" name="CollaborativeArrangementRevenuesExpensesSharingPercentage" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_UpfrontNonrefundableNoncreditablePaymentReceivable" name="UpfrontNonrefundableNoncreditablePaymentReceivable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" name="AdditionalAmountsPayableToCoverDevelopmentCosts" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element name="PaymentOnNetSalesPercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_PaymentOnNetSalesPercentage" substitutionGroup="xbrli:item" />
  <xsd:element id="plx_PfizerMember" name="PfizerMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_EmployeeStockIncentivePlan2006Member" name="EmployeeStockIncentivePlan2006Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="plx_SupplementalInformationAbstract" name="SupplementalInformationAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_SupplementaryBalanceSheetsInformationTableTextBlock" name="SupplementaryBalanceSheetsInformationTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_IncomeTaxDisclosureTable" name="IncomeTaxDisclosureTable" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_IncomeTaxDisclosureLineItems" name="IncomeTaxDisclosureLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" name="AccountsPayablePropertyAndEquipmentSuppliersCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" name="ChiesiUsAgreementAndChiesiExUsAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_ShortTermBankDeposits" name="ShortTermBankDeposits" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="plx_IncreaseDecreaseInBankDeposits" name="IncreaseDecreaseInBankDeposits" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_VicePresidentResearchAndDevelopmentMember" name="VicePresidentResearchAndDevelopmentMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_ChiesiAgreementsMember" name="ChiesiAgreementsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_SaleOfStockMaximumOfferingPrice" name="SaleOfStockMaximumOfferingPrice" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" abstract="false" />
  <xsd:element id="plx_AtMarketEquityOfferingMember" name="AtMarketEquityOfferingMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_InterestReceivedNet" name="InterestReceivedNet" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="plx_SeniorVicePresidentAndChiefFinancialOfficerMember" name="SeniorVicePresidentAndChiefFinancialOfficerMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" name="AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="plx_StockIssuedDuringPeriodSharesSalesAgreement" name="StockIssuedDuringPeriodSharesSalesAgreement" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_StockIssuedDuringPeriodValueSalesAgreement" name="StockIssuedDuringPeriodValueSalesAgreement" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="plx_AgreementAmendmentPaymentReceivable" name="AgreementAmendmentPaymentReceivable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" name="ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" name="SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_StockIssuedDuringPeriodValueWarrantsExercises" name="StockIssuedDuringPeriodValueWarrantsExercises" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="plx_StockIssuedDuringPeriodSharesWarrantsExercises" name="StockIssuedDuringPeriodSharesWarrantsExercises" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element name="ConvertibleNotesDue2021And2024Member" id="plx_ConvertibleNotesDue2021And2024Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="MilestonePaymentReceived" id="plx_MilestonePaymentReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ExtendedTermOfAgreement" id="plx_ExtendedTermOfAgreement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="GainLossOnDebtConversion" id="plx_GainLossOnDebtConversion" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="NumberOfGlobalLicensingAndSupplyAgreements" id="plx_NumberOfGlobalLicensingAndSupplyAgreements" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="OutstandingStockOptionsAndWarrantsMember" id="plx_OutstandingStockOptionsAndWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="OutstandingStockOptionsWarrantsAnd2024NotesMember" id="plx_OutstandingStockOptionsWarrantsAnd2024NotesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ReserveForDeductionsFromRevenueCurrent" id="plx_ReserveForDeductionsFromRevenueCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="FillFinishAgreementMember" id="plx_FillFinishAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="OfficersAndOtherEmployeesMember" id="plx_OfficersAndOtherEmployeesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ProceedsFromWithdrawalOfShortTermDeposits" id="plx_ProceedsFromWithdrawalOfShortTermDeposits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>plx-20240930_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.8.0.95 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/13/2024 11:42:22 PM-->
<!--Modified on: 11/13/2024 11:42:22 PM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef xlink:type="simple" xlink:href="plx-20240930.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240930.xsd#StatementCondensedConsolidatedStatementsOfOperations" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240930.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240930.xsd#DisclosureInventoriesScheduleOfInventoryDetails" roleURI="http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240930.xsd#DisclosureEarningsLossPerShareDetails" roleURI="http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240930.xsd#DisclosureTaxesOnIncomeSummaryOfTaxesOnIncomeDetails" roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeSummaryOfTaxesOnIncomeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240930.xsd#DisclosureSupplementaryFinancialStatementInformationDetails" roleURI="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationDetails" />
  <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:type="simple" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" />
  <link:calculationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="995200100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638671381406780819" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_638671381406780819" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638671381406780819" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638671381406780819" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638671381406780819" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_ShortTermBankDeposits" xlink:label="plx_ShortTermBankDeposits_638671381406780819" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638671381406780819" xlink:to="plx_ShortTermBankDeposits_638671381406780819" order="2" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_638671381406780819" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638671381406780819" xlink:to="us-gaap_AccountsReceivableNetCurrent_638671381406780819" order="3" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_638671381406780819" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638671381406780819" xlink:to="us-gaap_OtherAssetsCurrent_638671381406780819" order="4" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638671381406790833" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638671381406780819" xlink:to="us-gaap_InventoryNet_638671381406790833" order="5" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_638671381406790833" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_638671381406790833" order="2" use="optional" weight="1" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638671381406790833" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638671381406790833" order="3" use="optional" weight="1" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_638671381406790833" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_638671381406790833" order="4" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638671381406790833" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638671381406790833" order="5" use="optional" weight="1" priority="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_637041422967477240" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638671381406790833" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity_637041422967477240" xlink:to="us-gaap_Liabilities_638671381406790833" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent_638671381406790833" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638671381406790833" xlink:to="us-gaap_LiabilitiesNoncurrent_638671381406790833" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_638671381406800816" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_638671381406790833" xlink:to="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_638671381406800816" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638671381406800816" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_638671381406790833" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638671381406800816" order="2" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638671381406800816" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638671381406790833" xlink:to="us-gaap_LiabilitiesCurrent_638671381406800816" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent_638671381406810900" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638671381406800816" xlink:to="us-gaap_AccountsPayableTradeCurrent_638671381406810900" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent_638671381406810900" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638671381406800816" xlink:to="us-gaap_AccountsPayableOtherCurrent_638671381406810900" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638671381406810900" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638671381406800816" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638671381406810900" order="3" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="us-gaap_ConvertibleDebtCurrent_638671381406810900" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638671381406800816" xlink:to="us-gaap_ConvertibleDebtCurrent_638671381406810900" order="4" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638671381406810900" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity_637041422967477240" xlink:to="us-gaap_CommitmentsAndContingencies_638671381406810900" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638671381406810900" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity_637041422967477240" xlink:to="us-gaap_StockholdersEquity_638671381406810900" order="3" use="optional" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="995200200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637041422967477240" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638671381406820811" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_637041422967477240" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638671381406820811" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638671381406820811" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638671381406820811" xlink:to="us-gaap_OperatingIncomeLoss_638671381406820811" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_638671381406820811" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638671381406820811" xlink:to="us-gaap_Revenues_638671381406820811" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue_638671381406820811" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638671381406820811" xlink:to="us-gaap_CostOfRevenue_638671381406820811" order="2" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638671381406820811" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638671381406820811" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638671381406820811" order="3" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_638671381406820811" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638671381406820811" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_638671381406820811" order="4" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_638671381406830812" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638671381406820811" xlink:to="us-gaap_NonoperatingIncomeExpense_638671381406830812" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense_638671381406830812" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_638671381406830812" xlink:to="us-gaap_OtherNonoperatingExpense_638671381406830812" order="1" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome_638671381406830812" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_638671381406830812" xlink:to="us-gaap_OtherNonoperatingIncome_638671381406830812" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638671381406830812" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_637041422967477240" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638671381406830812" order="2" use="optional" weight="-1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="995200400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638671381406830812" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638671381406830812" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638671381406830812" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638671381406830812" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_638671381406840809" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638671381406830812" xlink:to="us-gaap_ProceedsFromWarrantExercises_638671381406840809" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_638671381406840809" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638671381406830812" xlink:to="us-gaap_RepaymentsOfConvertibleDebt_638671381406840809" order="2" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638671381406840809" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638671381406830812" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638671381406840809" order="3" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638671381406840809" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638671381406840809" order="3" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_638671381406840809" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638671381406840809" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_638671381406840809" order="1" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_ProceedsFromWithdrawalOfShortTermDeposits" xlink:label="plx_ProceedsFromWithdrawalOfShortTermDeposits_638671381406840809" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638671381406840809" xlink:to="plx_ProceedsFromWithdrawalOfShortTermDeposits_638671381406840809" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638671381406840809" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638671381406840809" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638671381406840809" order="3" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638671381406840809" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638671381406840809" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638671381406840809" order="4" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_IncreaseDecreaseInBankDeposits" xlink:label="plx_IncreaseDecreaseInBankDeposits_638671381406850808" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638671381406840809" xlink:to="plx_IncreaseDecreaseInBankDeposits_638671381406850808" order="5" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638671381406850808" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638671381406850808" order="4" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638671381406850808" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638671381406850808" xlink:to="us-gaap_ProfitLoss_638671381406850808" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638671381406850808" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638671381406850808" xlink:to="us-gaap_ShareBasedCompensation_638671381406850808" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638671381406850808" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638671381406850808" xlink:to="us-gaap_Depreciation_638671381406850808" order="3" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_638671381406850808" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638671381406850808" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_638671381406850808" order="4" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_638671381406850808" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638671381406850808" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense_638671381406850808" order="5" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_638671381406860804" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638671381406850808" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_638671381406860804" order="6" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_638671381406860804" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638671381406850808" xlink:to="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_638671381406860804" order="7" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638671381406860804" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638671381406850808" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638671381406860804" order="8" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_GainLossOnDebtConversion" xlink:label="plx_GainLossOnDebtConversion_638671381406860804" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638671381406850808" xlink:to="plx_GainLossOnDebtConversion_638671381406860804" order="9" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638671381406860804" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638671381406850808" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638671381406860804" order="10" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_638671381406860804" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638671381406850808" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_638671381406860804" order="11" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_638671381406860804" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638671381406850808" xlink:to="plx_ChangeInOperatingLeaseRightOfUseAssets_638671381406860804" order="12" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_638671381406870806" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638671381406850808" xlink:to="us-gaap_IncreaseDecreaseInInventories_638671381406870806" order="13" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638671381406870806" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638671381406850808" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638671381406870806" order="14" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638671381406870806" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638671381406850808" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638671381406870806" order="15" use="optional" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails" xlink:type="extended" xlink:title="99940201 - Disclosure - INVENTORIES - Schedule of Inventory (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_638671381406870806" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_638671381406870806" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_638671381406880810" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_638671381406880810" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_638671381406880810" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_638671381406880810" order="3" use="optional" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails" xlink:type="extended" xlink:title="99940601 - Disclosure - EARNINGS (LOSS) PER SHARE (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DilutiveSecurities" xlink:label="us-gaap_DilutiveSecurities_638671381406880810" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_1" xlink:to="us-gaap_DilutiveSecurities_638671381406880810" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638671381406880810" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_1" xlink:to="us-gaap_NetIncomeLoss_638671381406880810" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638671381406880810" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638671381406880810" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_638671381406880810" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1" xlink:to="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_638671381406880810" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_638671381406880810" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_638671381406880810" order="3" use="optional" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.protalix.com/role/DisclosureTaxesOnIncomeSummaryOfTaxesOnIncomeDetails" xlink:type="extended" xlink:title="99940701 - Disclosure - TAXES ON INCOME - Summary of Taxes on Income (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_638671381406890810" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit_1" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_638671381406890810" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_638671381406890810" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit_1" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_638671381406890810" order="2" use="optional" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationDetails" xlink:type="extended" xlink:title="99940801 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_637041422969008821" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638671381406890810" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableCurrent_637041422969008821" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638671381406890810" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent_638671381406890810" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableCurrent_637041422969008821" xlink:to="us-gaap_InterestPayableCurrent_638671381406890810" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedVacationCurrent" xlink:label="us-gaap_AccruedVacationCurrent_638671381406890810" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableCurrent_637041422969008821" xlink:to="us-gaap_AccruedVacationCurrent_638671381406890810" order="3" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638671381406890810" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableCurrent_637041422969008821" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638671381406890810" order="4" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrent_638671381406900829" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableCurrent_637041422969008821" xlink:to="us-gaap_AccruedRoyaltiesCurrent_638671381406900829" order="5" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" xlink:label="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_638671381406900829" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableCurrent_637041422969008821" xlink:to="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_638671381406900829" order="6" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent_638671381406900829" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableCurrent_637041422969008821" xlink:to="us-gaap_TaxesPayableCurrent_638671381406900829" order="7" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_ReserveForDeductionsFromRevenueCurrent" xlink:label="plx_ReserveForDeductionsFromRevenueCurrent_638671381406900829" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableCurrent_637041422969008821" xlink:to="plx_ReserveForDeductionsFromRevenueCurrent_638671381406900829" order="8" use="optional" weight="1" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>plx-20240930_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.8.0.95 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/13/2024 11:42:22 PM-->
<!--Modified on: 11/13/2024 11:42:22 PM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef xlink:type="simple" xlink:href="plx-20240930.xsd#StatementCondensedConsolidatedStatementsOfOperations" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240930.xsd#StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240930.xsd#DisclosureSignificantAccountingPoliciesDetails" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240930.xsd#DisclosureSignificantAccountingPoliciesConvertibleNotesDetails" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesConvertibleNotesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240930.xsd#DisclosureRevenuesDisaggregationOfRevenuesDetails" roleURI="http://www.protalix.com/role/DisclosureRevenuesDisaggregationOfRevenuesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240930.xsd#DisclosureStockTransactionsDetails" roleURI="http://www.protalix.com/role/DisclosureStockTransactionsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240930.xsd#DisclosureEarningsLossPerShareDetails" roleURI="http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240930.xsd#DisclosureTaxesOnIncomeAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240930.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:roleRef roleURI="http://www.protalix.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="plx-20240930.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <link:roleRef xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="Extensible Enumeration Domain Members" />
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1" xlink:title="us-gaap_StatementClassOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1" xlink:title="us-gaap_ClassOfStockDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementClassOfStockAxis_1" xlink:to="us-gaap_ClassOfStockDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementClassOfStockAxis_1 To us-gaap_ClassOfStockDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_1" xlink:title="srt_ProductOrServiceAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_1" xlink:title="srt_ProductsAndServicesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ProductOrServiceAxis_1" xlink:to="srt_ProductsAndServicesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ProductOrServiceAxis_1 To srt_ProductsAndServicesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_1" xlink:title="us-gaap_IncomeStatementLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_1" xlink:title="us-gaap_IncomeStatementLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementLocationAxis_1" xlink:to="us-gaap_IncomeStatementLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeStatementLocationAxis_1 To us-gaap_IncomeStatementLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_1" xlink:title="us-gaap_StatementEquityComponentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1" xlink:title="us-gaap_EquityComponentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementEquityComponentsAxis_1" xlink:to="us-gaap_EquityComponentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementEquityComponentsAxis_1 To us-gaap_EquityComponentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_1" xlink:title="us-gaap_AwardTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AwardTypeAxis_1" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AwardTypeAxis_1 To us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_1" xlink:title="us-gaap_DebtInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_1" xlink:title="us-gaap_DebtInstrumentNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DebtInstrumentAxis_1" xlink:to="us-gaap_DebtInstrumentNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DebtInstrumentAxis_1 To us-gaap_DebtInstrumentNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_1" xlink:title="us-gaap_TypeOfArrangementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TypeOfArrangementAxis_1" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TypeOfArrangementAxis_1 To us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_1" xlink:title="dei_LegalEntityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_1" xlink:title="dei_EntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_LegalEntityAxis_1" xlink:to="dei_EntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_LegalEntityAxis_1 To dei_EntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_1" xlink:title="srt_StatementGeographicalAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_1" xlink:title="srt_SegmentGeographicalDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementGeographicalAxis_1" xlink:to="srt_SegmentGeographicalDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementGeographicalAxis_1 To srt_SegmentGeographicalDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_1" xlink:title="srt_RangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1" xlink:title="srt_RangeMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RangeAxis_1" xlink:to="srt_RangeMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RangeAxis_1 To srt_RangeMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:title="us-gaap_SubsidiarySaleOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsidiarySaleOfStockAxis_1 To us-gaap_SaleOfStockNameOfTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_1" xlink:title="us-gaap_SubsequentEventTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_1" xlink:title="us-gaap_SubsequentEventTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsequentEventTypeAxis_1" xlink:to="us-gaap_SubsequentEventTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsequentEventTypeAxis_1 To us-gaap_SubsequentEventTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_1" xlink:title="srt_CounterpartyNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_1" xlink:title="srt_RepurchaseAgreementCounterpartyNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CounterpartyNameAxis_1" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CounterpartyNameAxis_1 To srt_RepurchaseAgreementCounterpartyNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_1" xlink:title="srt_StatementScenarioAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_1" xlink:title="srt_ScenarioUnspecifiedDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementScenarioAxis_1" xlink:to="srt_ScenarioUnspecifiedDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementScenarioAxis_1 To srt_ScenarioUnspecifiedDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis_1" xlink:title="us-gaap_ShortTermDebtTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain_1" xlink:title="us-gaap_ShortTermDebtTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ShortTermDebtTypeAxis_1" xlink:to="us-gaap_ShortTermDebtTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ShortTermDebtTypeAxis_1 To us-gaap_ShortTermDebtTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByFairValueHierarchyLevelAxis_1 To us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_1" xlink:title="us-gaap_MeasurementInputTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_1" xlink:title="us-gaap_MeasurementInputTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_MeasurementInputTypeAxis_1" xlink:to="us-gaap_MeasurementInputTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_MeasurementInputTypeAxis_1 To us-gaap_MeasurementInputTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis_1" xlink:title="us-gaap_DebtInstrumentRedemptionPeriodAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_1" xlink:title="us-gaap_DebtInstrumentRedemptionPeriodDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis_1" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DebtInstrumentRedemptionPeriodAxis_1 To us-gaap_DebtInstrumentRedemptionPeriodDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:label="us-gaap_ChangeInAccountingEstimateByTypeAxis_1" xlink:title="us-gaap_ChangeInAccountingEstimateByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:label="us-gaap_ChangeInAccountingEstimateTypeDomain_1" xlink:title="us-gaap_ChangeInAccountingEstimateTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ChangeInAccountingEstimateByTypeAxis_1" xlink:to="us-gaap_ChangeInAccountingEstimateTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ChangeInAccountingEstimateByTypeAxis_1 To us-gaap_ChangeInAccountingEstimateTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_1" xlink:title="srt_TitleOfIndividualAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:title="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_TitleOfIndividualAxis_1" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_TitleOfIndividualAxis_1 To srt_TitleOfIndividualWithRelationshipToEntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_1" xlink:title="us-gaap_GranteeStatusAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_1" xlink:title="us-gaap_GranteeStatusDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_GranteeStatusAxis_1" xlink:to="us-gaap_GranteeStatusDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_GranteeStatusAxis_1 To us-gaap_GranteeStatusDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_1" xlink:title="us-gaap_PlanNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1" xlink:title="us-gaap_PlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PlanNameAxis_1" xlink:to="us-gaap_PlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PlanNameAxis_1 To us-gaap_PlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PropertyPlantAndEquipmentByTypeAxis_1 To us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:title="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_1" xlink:title="us-gaap_TypeOfAdoptionMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:to="us-gaap_TypeOfAdoptionMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1 To us-gaap_TypeOfAdoptionMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="us-gaap_RetirementPlanTypeAxis_1" xlink:title="us-gaap_RetirementPlanTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="us-gaap_RetirementPlanTypeDomain_1" xlink:title="us-gaap_RetirementPlanTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RetirementPlanTypeAxis_1" xlink:to="us-gaap_RetirementPlanTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RetirementPlanTypeAxis_1 To us-gaap_RetirementPlanTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis_1" xlink:title="us-gaap_LongtermDebtTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_1" xlink:title="us-gaap_LongtermDebtTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LongtermDebtTypeAxis_1" xlink:to="us-gaap_LongtermDebtTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_LongtermDebtTypeAxis_1 To us-gaap_LongtermDebtTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1" xlink:title="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" xlink:title="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1 To us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1 To us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:title="us-gaap_ClassOfWarrantOrRightAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1" xlink:title="us-gaap_ClassOfWarrantOrRightDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ClassOfWarrantOrRightAxis_1 To us-gaap_ClassOfWarrantOrRightDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:title="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_1" xlink:title="us-gaap_RelatedPartyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="us-gaap_RelatedPartyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1 To us-gaap_RelatedPartyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_1" xlink:title="us-gaap_IncomeTaxAuthorityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_1" xlink:title="us-gaap_IncomeTaxAuthorityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="us-gaap_IncomeTaxAuthorityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeTaxAuthorityAxis_1 To us-gaap_IncomeTaxAuthorityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis_1" xlink:title="srt_ConsolidatedEntitiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain_1" xlink:title="srt_ConsolidatedEntitiesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ConsolidatedEntitiesAxis_1" xlink:to="srt_ConsolidatedEntitiesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ConsolidatedEntitiesAxis_1 To srt_ConsolidatedEntitiesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis_1" xlink:title="us-gaap_BalanceSheetLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_1" xlink:title="us-gaap_BalanceSheetLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_BalanceSheetLocationAxis_1" xlink:to="us-gaap_BalanceSheetLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_BalanceSheetLocationAxis_1 To us-gaap_BalanceSheetLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis_1" xlink:title="srt_MajorCustomersAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_1" xlink:title="srt_NameOfMajorCustomerDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_MajorCustomersAxis_1" xlink:to="srt_NameOfMajorCustomerDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_MajorCustomersAxis_1 To srt_NameOfMajorCustomerDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1 To us-gaap_AntidilutiveSecuritiesNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_1" xlink:title="us-gaap_VestingAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_1" xlink:title="us-gaap_VestingDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_VestingAxis_1" xlink:to="us-gaap_VestingDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_VestingAxis_1 To us-gaap_VestingDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis_1" xlink:title="us-gaap_RelatedPartyTransactionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_1" xlink:title="us-gaap_RelatedPartyTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionAxis_1" xlink:to="us-gaap_RelatedPartyTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionAxis_1 To us-gaap_RelatedPartyTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis_1" xlink:title="srt_CumulativeEffectPeriodOfAdoptionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain_1" xlink:title="srt_CumulativeEffectPeriodOfAdoptionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis_1" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CumulativeEffectPeriodOfAdoptionAxis_1 To srt_CumulativeEffectPeriodOfAdoptionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis_1" xlink:title="srt_RestatementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain_1" xlink:title="srt_RestatementDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RestatementAxis_1" xlink:to="srt_RestatementDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RestatementAxis_1 To srt_RestatementDomain_1" order="1" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="995200200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseAndServiceMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostOfRevenue" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingExpense" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncome" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpense" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" xlink:type="extended" xlink:title="995200300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate202006Member" xlink:label="us-gaap_AccountingStandardsUpdate202006Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate202006Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_StockIssuedDuringPeriodValueSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_StockIssuedDuringPeriodValueSalesAgreement" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_StockIssuedDuringPeriodSharesSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_StockIssuedDuringPeriodSharesSalesAgreement" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_StockIssuedDuringPeriodValueWarrantsExercises" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsExercises" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_StockIssuedDuringPeriodValueWarrantsExercises" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_StockIssuedDuringPeriodSharesWarrantsExercises" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsExercises" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_StockIssuedDuringPeriodValueWarrantsExercises" xlink:to="plx_StockIssuedDuringPeriodSharesWarrantsExercises" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="99940101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)">
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_AmendedPfizerAgreementMember" xlink:label="plx_AmendedPfizerAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_AmendedPfizerAgreementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_ChiesiAgreementsMember" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_ChiesiUSAgreementMember" xlink:label="plx_ChiesiUSAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_ChiesiAgreementsMember" xlink:to="plx_ChiesiUSAgreementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_ChiesiExUSAgreementMember" xlink:label="plx_ChiesiExUSAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="plx_ChiesiAgreementsMember" xlink:to="plx_ChiesiExUSAgreementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" xlink:label="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="plx_ChiesiAgreementsMember" xlink:to="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_FillFinishAgreementMember" xlink:label="plx_FillFinishAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_FillFinishAgreementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="plx_ProtalixBioTherapeuticsIncorporationMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_BR" xlink:label="country_BR" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_BR" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_ConvertibleNotesDue2021And2024Member" xlink:label="plx_ConvertibleNotesDue2021And2024Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_ConvertibleNotesDue2021And2024Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_ConvertibleNotesDue2021And2024Member" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_AtMarketEquityOfferingMember" xlink:label="plx_AtMarketEquityOfferingMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="plx_AtMarketEquityOfferingMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_SignificantAccountingPoliciesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_NumberOfGlobalLicensingAndSupplyAgreements" xlink:label="plx_NumberOfGlobalLicensingAndSupplyAgreements" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_NumberOfGlobalLicensingAndSupplyAgreements" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_UpfrontNonrefundableNoncreditablePaymentReceivable" xlink:label="plx_UpfrontNonrefundableNoncreditablePaymentReceivable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_UpfrontNonrefundableNoncreditablePaymentReceivable" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_SaleOfStockMaximumOfferingPrice" xlink:label="plx_SaleOfStockMaximumOfferingPrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_SaleOfStockMaximumOfferingPrice" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_ExtendedTermOfAgreement" xlink:label="plx_ExtendedTermOfAgreement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_ExtendedTermOfAgreement" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_AgreementAmendmentPaymentReceivable" xlink:label="plx_AgreementAmendmentPaymentReceivable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_AgreementAmendmentPaymentReceivable" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_MilestonePaymentReceived" xlink:label="plx_MilestonePaymentReceived" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_MilestonePaymentReceived" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_PaymentOnNetSalesPercentage" xlink:label="plx_PaymentOnNetSalesPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_PaymentOnNetSalesPercentage" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesConvertibleNotesDetails" xlink:type="extended" xlink:title="99940102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Convertible notes (Details)">
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate202006Member" xlink:label="us-gaap_AccountingStandardsUpdate202006Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate202006Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_SignificantAccountingPoliciesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="us-gaap_ConvertibleDebtCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ConvertibleDebtCurrent" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureRevenuesDisaggregationOfRevenuesDetails" xlink:type="extended" xlink:title="99940401 - Disclosure - REVENUES - Disaggregation of Revenues (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseAndServiceMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_ChiesiAgreementsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_PfizerMember" xlink:label="plx_PfizerMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="plx_PfizerMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_BR" xlink:label="country_BR" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_BR" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureStockTransactionsDetails" xlink:type="extended" xlink:title="99940501 - Disclosure - STOCK TRANSACTIONS (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_SeniorVicePresidentAndChiefFinancialOfficerMember" xlink:label="plx_SeniorVicePresidentAndChiefFinancialOfficerMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="plx_SeniorVicePresidentAndChiefFinancialOfficerMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_OfficersAndOtherEmployeesMember" xlink:label="plx_OfficersAndOtherEmployeesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="plx_OfficersAndOtherEmployeesMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_VicePresidentResearchAndDevelopmentMember" xlink:label="plx_VicePresidentResearchAndDevelopmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="plx_VicePresidentResearchAndDevelopmentMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_EmployeeStockIncentivePlan2006Member" xlink:label="plx_EmployeeStockIncentivePlan2006Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="plx_EmployeeStockIncentivePlan2006Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_VestingAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails" xlink:type="extended" xlink:title="99940601 - Disclosure - EARNINGS (LOSS) PER SHARE (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_OutstandingStockOptionsAndWarrantsMember" xlink:label="plx_OutstandingStockOptionsAndWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="plx_OutstandingStockOptionsAndWarrantsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_OutstandingStockOptionsWarrantsAnd2024NotesMember" xlink:label="plx_OutstandingStockOptionsWarrantsAnd2024NotesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="plx_OutstandingStockOptionsWarrantsAnd2024NotesMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_NetIncomeLossAbstract" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DilutiveSecurities" xlink:label="us-gaap_DilutiveSecurities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_DilutiveSecurities" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails" xlink:type="extended" xlink:title="99940702 - Disclosure - TAXES ON INCOME - Additional Information (Details)">
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_IncomeTaxDisclosureTable" xlink:label="plx_IncomeTaxDisclosureTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="plx_IncomeTaxDisclosureTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_ChiesiAgreementsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_IncomeTaxDisclosureLineItems" xlink:label="plx_IncomeTaxDisclosureLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="plx_IncomeTaxDisclosureLineItems" xlink:to="plx_IncomeTaxDisclosureTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="plx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="plx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_MilestonePaymentReceived" xlink:label="plx_MilestonePaymentReceived" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="plx_IncomeTaxDisclosureLineItems" xlink:to="plx_MilestonePaymentReceived" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="plx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="99940901 - Disclosure - SUBSEQUENT EVENTS (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_ChiesiAgreementsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromCustomers" xlink:label="us-gaap_ProceedsFromCustomers" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromCustomers" priority="1" use="optional" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>plx-20240930_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.8.0.95 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/13/2024 11:42:22 PM-->
<!--Modified on: 11/13/2024 11:42:22 PM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Document and Entity Information</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Securities Act File Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">CONDENSED CONSOLIDATED BALANCE SHEETS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_ShortTermBankDeposits" xlink:label="plx_ShortTermBankDeposits" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShortTermBankDeposits" xlink:to="plx_ShortTermBankDeposits_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShortTermBankDeposits_lbl" xml:lang="en-US">Carrying value of deposits held with banks for short period, usually less than one year or the normal operating cycle, whichever is longer.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShortTermBankDeposits_lbl" xml:lang="en-US">Short-term Bank Deposits</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShortTermBankDeposits_lbl" xml:lang="en-US">Short-term bank deposits</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable - Trade</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other Assets, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory, Net</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventories</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Total inventory</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Assets, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">Assets, Noncurrent [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">NON-CURRENT ASSETS:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:to="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_lbl" xml:lang="en-US">Assets for Plan Benefits, Defined Benefit Plan</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_lbl" xml:lang="en-US">Funds in respect of employee rights upon retirement</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xml:lang="en-US">Deferred income tax asset</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right of use assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Assets</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Accounts payable and accruals:</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Accounts payable and accruals - other:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xml:lang="en-US">Accounts Payable, Trade, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xml:lang="en-US">Trade</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl" xml:lang="en-US">Accounts Payable, Other, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl" xml:lang="en-US">Other</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="us-gaap_ConvertibleDebtCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtCurrent" xlink:to="us-gaap_ConvertibleDebtCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtCurrent_lbl" xml:lang="en-US">Convertible Debt, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConvertibleDebtCurrent_lbl" xml:lang="en-US">Convertible notes</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Liabilities, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">LONG TERM LIABILITIES:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:to="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_lbl" xml:lang="en-US">Liability, Pension and Other Postretirement and Postemployment Benefits, Noncurrent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_lbl" xml:lang="en-US">Liability for employee rights upon retirement</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Total long term liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Liabilities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">COMMITMENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Ending balance</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Beginning balance</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">STOCKHOLDERS' EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductMember_lbl" xml:lang="en-US">Product [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProductMember_lbl" xml:lang="en-US">GOODS</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProductMember_lbl" xml:lang="en-US">Goods</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAndServiceMember" xlink:to="us-gaap_LicenseAndServiceMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicenseAndServiceMember_lbl" xml:lang="en-US">License and Service [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LicenseAndServiceMember_lbl" xml:lang="en-US">LICENSE AND R&amp;D SERVICES</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LicenseAndServiceMember_lbl" xml:lang="en-US">License and R&amp;D Services</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">TOTAL REVENUE</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Cost of Revenue</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">COST OF GOODS SOLD</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and Development Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">RESEARCH AND DEVELOPMENT EXPENSES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">OPERATING INCOME (LOSS)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US">Other Nonoperating Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US">FINANCIAL EXPENSES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US">Other Nonoperating Income</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US">FINANCIAL INCOME</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">FINANCIAL INCOME (EXPENSES), NET</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">INCOME (LOSS) BEFORE TAXES ON INCOME</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">TAXES ON INCOME</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total taxes on income</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">NET INCOME (LOSS) FOR THE PERIOD</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net income (loss) for the period</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">EARNINGS (LOSS) PER SHARE OF COMMON STOCK - BASIC (in dollars per share)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">EARNINGS (LOSS) PER SHARE OF COMMON STOCK - DILUTED (in dollars per share)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING EARNINGS (LOSS) PER SHARE - BASIC (in shares)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average shares of Common Stock outstanding for basic calculation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING EARNINGS (LOSS) PER SHARE - DILUTED (in shares)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average shares of Common Stock outstanding for diluted calculation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xml:lang="en-US">Accounting Standards Update [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xml:lang="en-US">Accounting Standards Update [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate202006Member" xlink:label="us-gaap_AccountingStandardsUpdate202006Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate202006Member" xlink:to="us-gaap_AccountingStandardsUpdate202006Member_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingStandardsUpdate202006Member_lbl" xml:lang="en-US">Accounting Standards Update 2020-06 [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountingStandardsUpdate202006Member_lbl" xml:lang="en-US">ASU 2020-06</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis_lbl" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain_lbl" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_lbl" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_lbl" xml:lang="en-US">Adjustment</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_lbl" xml:lang="en-US">Effect of Change</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_StockIssuedDuringPeriodValueSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_StockIssuedDuringPeriodValueSalesAgreement" xlink:to="plx_StockIssuedDuringPeriodValueSalesAgreement_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement_lbl" xml:lang="en-US">Equity impact of the value of new stock issued during the period. Includes shares issued in a sales agreement.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement_lbl" xml:lang="en-US">Stock Issued During Period, Value, Sales Agreement</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement_lbl" xml:lang="en-US">Issuance of common stock under the Sales Agreement, net</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_StockIssuedDuringPeriodSharesSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_StockIssuedDuringPeriodSharesSalesAgreement" xlink:to="plx_StockIssuedDuringPeriodSharesSalesAgreement_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Sales Agreement</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Sales Agreement</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement_lbl" xml:lang="en-US">Issuance of common stock under the Sales Agreement, net (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Convertible notes conversions</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Convertible notes conversions (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Share-based compensation related to stock options</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_lbl" xml:lang="en-US">Amount of recognized equity-based compensation during the period for restricted stock awards.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_lbl" xml:lang="en-US">Share Based Compensation Restricted Stock Awards Net Of Forfeitures</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_lbl" xml:lang="en-US">Share-based compensation related to restricted stock awards</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_lbl" xml:lang="en-US">Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_lbl" xml:lang="en-US">Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_lbl" xml:lang="en-US">Share-based compensation related to restricted stock awards (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_StockIssuedDuringPeriodValueWarrantsExercises" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsExercises" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_StockIssuedDuringPeriodValueWarrantsExercises" xlink:to="plx_StockIssuedDuringPeriodValueWarrantsExercises_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsExercises_lbl" xml:lang="en-US">Value of shares issued during period for exercise of warrants.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsExercises_lbl" xml:lang="en-US">Stock Issued During Period, Value, Warrants Exercises</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsExercises_lbl" xml:lang="en-US">Exercise of warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_StockIssuedDuringPeriodSharesWarrantsExercises" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsExercises" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_StockIssuedDuringPeriodSharesWarrantsExercises" xlink:to="plx_StockIssuedDuringPeriodSharesWarrantsExercises_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsExercises_lbl" xml:lang="en-US">Number of shares issued during period for exercise of warrants.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsExercises_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercises</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsExercises_lbl" xml:lang="en-US">Exercise of warrants (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net Income (loss)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments required to reconcile net income (loss) to net cash provided by operating activities:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xml:lang="en-US">Unrealized Gain (Loss), Foreign Currency Transaction, before Tax</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xml:lang="en-US">Financial expenses (income), net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl" xml:lang="en-US">Pension and Other Postretirement Benefits Cost (Reversal of Cost)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl" xml:lang="en-US">Changes in accrued liability for employee rights upon retirement</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Changes in deferred income tax asset</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred taxes on income</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:to="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" xml:lang="en-US">Gain (loss) on amounts funded in respect of employee rights upon retirement.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" xml:lang="en-US">Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" xml:lang="en-US">Gain on amounts funded in respect of employee rights upon retirement</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Gain on sale of fixed assets</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_GainLossOnDebtConversion" xlink:label="plx_GainLossOnDebtConversion" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_GainLossOnDebtConversion" xlink:to="plx_GainLossOnDebtConversion_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_GainLossOnDebtConversion_lbl" xml:lang="en-US">The amount of gain (loss) on conversion of convertible debt.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_GainLossOnDebtConversion_lbl" xml:lang="en-US">Gain (Loss) On Debt Conversion</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_GainLossOnDebtConversion_lbl" xml:lang="en-US">Gain on conversions of convertible notes</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US">Amortization of debt issuance costs and debt discount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Decrease in contracts liability</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Decrease (increase) in accounts receivable-trade and other assets</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:to="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Amount of Net Change in Operating Lease Right Of use Assets.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Change in Operating Lease Right Of use Assets</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Changes in operating lease right of use assets, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Decrease (increase) in inventories</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Increase (decrease) in accounts payable and accruals</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) operating activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_IncreaseDecreaseInBankDeposits" xlink:label="plx_IncreaseDecreaseInBankDeposits" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_IncreaseDecreaseInBankDeposits" xlink:to="plx_IncreaseDecreaseInBankDeposits_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_IncreaseDecreaseInBankDeposits_lbl" xml:lang="en-US">Amount of increase (decrease) in deposits held with banks.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_IncreaseDecreaseInBankDeposits_lbl" xml:lang="en-US">Increase (Decrease) in Bank Deposits</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_IncreaseDecreaseInBankDeposits_lbl" xml:lang="en-US">Investment in bank deposits</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_ProceedsFromWithdrawalOfShortTermDeposits" xlink:label="plx_ProceedsFromWithdrawalOfShortTermDeposits" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProceedsFromWithdrawalOfShortTermDeposits" xlink:to="plx_ProceedsFromWithdrawalOfShortTermDeposits_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ProceedsFromWithdrawalOfShortTermDeposits_lbl" xml:lang="en-US">The amount of cash inflow from the withdrawal of short-term deposits during the period.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ProceedsFromWithdrawalOfShortTermDeposits_lbl" xml:lang="en-US">Proceeds From Withdrawal Of Short-Term Deposits</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ProceedsFromWithdrawalOfShortTermDeposits_lbl" xml:lang="en-US">Short-term deposit withdrawal</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US">Proceeds from sale of property and equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" xml:lang="en-US">Amounts funded in respect of employee rights upon retirement, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfConvertibleDebt" xlink:to="us-gaap_RepaymentsOfConvertibleDebt_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_lbl" xml:lang="en-US">Repayments of Convertible Debt</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_lbl" xml:lang="en-US">Payment for convertible notes redemption</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of common stock under the Sales Agreement, net</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Stock issuance proceeds</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Exercise of warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">NET INCREASE IN CASH AND CASH EQUIVALENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease right of use assets obtained in exchange for new operating lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xml:lang="en-US">Convertible notes conversions</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">SUPPLEMENTARY DISCLOSURE ON CASH FLOWS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest paid</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_InterestReceivedNet" xlink:label="plx_InterestReceivedNet" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_InterestReceivedNet" xlink:to="plx_InterestReceivedNet_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_InterestReceivedNet_lbl" xml:lang="en-US">Amount of cash received for interest.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_InterestReceivedNet_lbl" xml:lang="en-US">Interest Received, Net</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_InterestReceivedNet_lbl" xml:lang="en-US">Interest received</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US">INVENTORIES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">INVENTORIES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">FAIR VALUE MEASUREMENT</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">FAIR VALUE MEASUREMENT</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:to="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_lbl" xml:lang="en-US">REVENUES</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_RevenueDisclosureTextBlock" xlink:label="plx_RevenueDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_RevenueDisclosureTextBlock" xlink:to="plx_RevenueDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_RevenueDisclosureTextBlock_lbl" xml:lang="en-US">The entire disclosure pertaining to revenue.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_RevenueDisclosureTextBlock_lbl" xml:lang="en-US">Revenue Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_RevenueDisclosureTextBlock_lbl" xml:lang="en-US">REVENUES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">STOCK TRANSACTIONS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">STOCK TRANSACTIONS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">EARNINGS (LOSS) PER SHARE</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">EARNINGS (LOSS) PER SHARE</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">TAXES ON INCOME</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">TAXES ON INCOME</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_SupplementalInformationAbstract" xlink:label="plx_SupplementalInformationAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SupplementalInformationAbstract" xlink:to="plx_SupplementalInformationAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SupplementalInformationAbstract_lbl" xml:lang="en-US">SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:label="us-gaap_AdditionalFinancialInformationDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:to="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_lbl" xml:lang="en-US">Additional Financial Information Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_lbl" xml:lang="en-US">SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_NatureOfOperationsPolicyTextBlock" xlink:label="plx_NatureOfOperationsPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_NatureOfOperationsPolicyTextBlock" xlink:to="plx_NatureOfOperationsPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_NatureOfOperationsPolicyTextBlock_lbl" xml:lang="en-US">Nature Of Operations Policy</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_NatureOfOperationsPolicyTextBlock_lbl" xml:lang="en-US">Nature Of Operations [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_NatureOfOperationsPolicyTextBlock_lbl" xml:lang="en-US">General</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of presentation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings (Loss) per share</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="us-gaap_DebtPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xml:lang="en-US">Debt, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xml:lang="en-US">Convertible notes</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">New accounting pronouncements</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xml:lang="en-US">Schedule of ASU 2020-06 on the condensed consolidated balance sheet</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of inventory</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US">Schedule of Company's disaggregation of revenues</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of basic and diluted net earnings (loss) per share</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of taxes on income</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_SupplementaryBalanceSheetsInformationTableTextBlock" xlink:label="plx_SupplementaryBalanceSheetsInformationTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SupplementaryBalanceSheetsInformationTableTextBlock" xlink:to="plx_SupplementaryBalanceSheetsInformationTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SupplementaryBalanceSheetsInformationTableTextBlock_lbl" xml:lang="en-US">The tabular disclosure for supplemental balance sheets information.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SupplementaryBalanceSheetsInformationTableTextBlock_lbl" xml:lang="en-US">Supplementary Balance Sheets Information [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_SupplementaryBalanceSheetsInformationTableTextBlock_lbl" xml:lang="en-US">Schedule of supplemental information of balance sheets</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="plx_SignificantAccountingPoliciesTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SignificantAccountingPoliciesTable_lbl" xml:lang="en-US">Significant Accounting Policies [Table].</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SignificantAccountingPoliciesTable_lbl" xml:lang="en-US">Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_AmendedPfizerAgreementMember" xlink:label="plx_AmendedPfizerAgreementMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AmendedPfizerAgreementMember" xlink:to="plx_AmendedPfizerAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AmendedPfizerAgreementMember_lbl" xml:lang="en-US">Amended Pfizer Agreement [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AmendedPfizerAgreementMember_lbl" xml:lang="en-US">Amended Pfizer Agreement</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiAgreementsMember" xlink:to="plx_ChiesiAgreementsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChiesiAgreementsMember_lbl" xml:lang="en-US">Chiesi Agreements [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiAgreementsMember_lbl" xml:lang="en-US">Chiesi Agreements</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ChiesiAgreementsMember_lbl" xml:lang="en-US">Chiesi Agreements</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_ChiesiAgreementsMember_lbl" xml:lang="en-US">Chiesi</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_ChiesiUSAgreementMember" xlink:label="plx_ChiesiUSAgreementMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiUSAgreementMember" xlink:to="plx_ChiesiUSAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiUSAgreementMember_lbl" xml:lang="en-US">Chiesi US Agreement</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_ChiesiExUSAgreementMember" xlink:label="plx_ChiesiExUSAgreementMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiExUSAgreementMember" xlink:to="plx_ChiesiExUSAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiExUSAgreementMember_lbl" xml:lang="en-US">Chiesi Ex-US Agreement</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" xlink:label="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" xlink:to="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_lbl" xml:lang="en-US">n/a</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_lbl" xml:lang="en-US">Chiesi US Agreement and Chiesi Ex-US Agreement</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_FillFinishAgreementMember" xlink:label="plx_FillFinishAgreementMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_FillFinishAgreementMember" xlink:to="plx_FillFinishAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_FillFinishAgreementMember_lbl" xml:lang="en-US">Fill/Finish Agreement [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_FillFinishAgreementMember_lbl" xml:lang="en-US">Fill/Finish Agreement</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US">All Entities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProtalixBioTherapeuticsIncorporationMember" xlink:to="plx_ProtalixBioTherapeuticsIncorporationMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember_lbl" xml:lang="en-US">Protalix Bio Therapeutics Incorporation [Member].</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember_lbl" xml:lang="en-US">Protalix Bio Therapeutics Incorporation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_BR" xlink:label="country_BR" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_BR" xlink:to="country_BR_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_BR_lbl" xml:lang="en-US">BRAZIL</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_BR_lbl" xml:lang="en-US">Brazil</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_ConvertibleNotesDue2021And2024Member" xlink:label="plx_ConvertibleNotesDue2021And2024Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ConvertibleNotesDue2021And2024Member" xlink:to="plx_ConvertibleNotesDue2021And2024Member_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ConvertibleNotesDue2021And2024Member_lbl" xml:lang="en-US">Represents information pertaining to convertible notes due 2021 and 2024.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ConvertibleNotesDue2021And2024Member_lbl" xml:lang="en-US">Notes 2021 and 2024</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_lbl" xml:lang="en-US">Represents the information pertaining to seven point five percentage senior secured convertible notes due 2024.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_lbl" xml:lang="en-US">2024 Notes</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_AtMarketEquityOfferingMember" xlink:label="plx_AtMarketEquityOfferingMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AtMarketEquityOfferingMember" xlink:to="plx_AtMarketEquityOfferingMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AtMarketEquityOfferingMember_lbl" xml:lang="en-US">Represents the information pertaining to At The Market equity offering.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AtMarketEquityOfferingMember_lbl" xml:lang="en-US">ATM Shares</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_SignificantAccountingPoliciesLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US">Significant Accounting Policies [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_SignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_NumberOfGlobalLicensingAndSupplyAgreements" xlink:label="plx_NumberOfGlobalLicensingAndSupplyAgreements" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_NumberOfGlobalLicensingAndSupplyAgreements" xlink:to="plx_NumberOfGlobalLicensingAndSupplyAgreements_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_NumberOfGlobalLicensingAndSupplyAgreements_lbl" xml:lang="en-US">Represents the number of global licensing and supply agreements.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_NumberOfGlobalLicensingAndSupplyAgreements_lbl" xml:lang="en-US">Number Of Global Licensing And Supply Agreements</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_NumberOfGlobalLicensingAndSupplyAgreements_lbl" xml:lang="en-US">Number of global licensing and supply agreements</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_UpfrontNonrefundableNoncreditablePaymentReceivable" xlink:label="plx_UpfrontNonrefundableNoncreditablePaymentReceivable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_UpfrontNonrefundableNoncreditablePaymentReceivable" xlink:to="plx_UpfrontNonrefundableNoncreditablePaymentReceivable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_UpfrontNonrefundableNoncreditablePaymentReceivable_lbl" xml:lang="en-US">The amount of upfront, non refundable and non creditable payment receivable under the agreement for licensing rights.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_UpfrontNonrefundableNoncreditablePaymentReceivable_lbl" xml:lang="en-US">Upfront Nonrefundable Non creditable Payment Receivable</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_UpfrontNonrefundableNoncreditablePaymentReceivable_lbl" xml:lang="en-US">Non-refundable payment receivable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Number of shares issued (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_SaleOfStockMaximumOfferingPrice" xlink:label="plx_SaleOfStockMaximumOfferingPrice" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SaleOfStockMaximumOfferingPrice" xlink:to="plx_SaleOfStockMaximumOfferingPrice_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SaleOfStockMaximumOfferingPrice_lbl" xml:lang="en-US">Sale of stock, maximum offering price.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SaleOfStockMaximumOfferingPrice_lbl" xml:lang="en-US">Sale Of Stock Maximum Offering Price</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_SaleOfStockMaximumOfferingPrice_lbl" xml:lang="en-US">Sale of stock, maximum offering price</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:to="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_lbl" xml:lang="en-US">The maximum amount payable to the entity to cover development costs under agreement.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_lbl" xml:lang="en-US">Additional Amounts Payable To Cover Development Costs</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_lbl" xml:lang="en-US">Additional amounts payable to cover development costs</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_ExtendedTermOfAgreement" xlink:label="plx_ExtendedTermOfAgreement" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ExtendedTermOfAgreement" xlink:to="plx_ExtendedTermOfAgreement_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ExtendedTermOfAgreement_lbl" xml:lang="en-US">Extended term  of agreement.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ExtendedTermOfAgreement_lbl" xml:lang="en-US">Extended Term Of Agreement</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ExtendedTermOfAgreement_lbl" xml:lang="en-US">Extended term of agreement</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_AgreementAmendmentPaymentReceivable" xlink:label="plx_AgreementAmendmentPaymentReceivable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AgreementAmendmentPaymentReceivable" xlink:to="plx_AgreementAmendmentPaymentReceivable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AgreementAmendmentPaymentReceivable_lbl" xml:lang="en-US">Agreement Amendment Payment Receivable</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AgreementAmendmentPaymentReceivable_lbl" xml:lang="en-US">Agreement Amendment Payment Receivable</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_AgreementAmendmentPaymentReceivable_lbl" xml:lang="en-US">Agreement amendment payment receivable</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" xlink:to="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">Change in amount receivable for achievement of regulatory and commercial milestones</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:to="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">The total amount payable to entity for the achievement of regulatory and commercial milestones.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">Additional amount payable for achievement of regulatory and commercial milestones</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_MilestonePaymentReceived" xlink:label="plx_MilestonePaymentReceived" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_MilestonePaymentReceived" xlink:to="plx_MilestonePaymentReceived_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_MilestonePaymentReceived_lbl" xml:lang="en-US">Amount of milestone payment received upon achievement of certain milestone.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_MilestonePaymentReceived_lbl" xml:lang="en-US">Milestone Payment Received</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_MilestonePaymentReceived_lbl" xml:lang="en-US">Amount of milestone payment received</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_PaymentOnNetSalesPercentage" xlink:label="plx_PaymentOnNetSalesPercentage" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PaymentOnNetSalesPercentage" xlink:to="plx_PaymentOnNetSalesPercentage_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_PaymentOnNetSalesPercentage_lbl" xml:lang="en-US">Represents the payment as a percentage of future net sales.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PaymentOnNetSalesPercentage_lbl" xml:lang="en-US">Payment On Net Sales Percentage</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_PaymentOnNetSalesPercentage_lbl" xml:lang="en-US">Payment on net sales percentage</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:to="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_lbl" xml:lang="en-US">Collaborative arrangement revenues and expense sharing percentage.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_lbl" xml:lang="en-US">Collaborative Arrangement Revenues Expenses Sharing Percentage</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_lbl" xml:lang="en-US">Collaborative arrangement revenues and expenses sharing percentage</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Interest rate (as a percent)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_lbl" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjusted Balance [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_lbl" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjusted Balance</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid in capital</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xml:lang="en-US">Raw materials</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xml:lang="en-US">Work in progress</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xml:lang="en-US">Finished goods</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_PfizerMember" xlink:label="plx_PfizerMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PfizerMember" xlink:to="plx_PfizerMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_PfizerMember_lbl" xml:lang="en-US">Global except for Brazil</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PfizerMember_lbl" xml:lang="en-US">Pfizer</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_EmployeeStockIncentivePlan2006Member" xlink:label="plx_EmployeeStockIncentivePlan2006Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EmployeeStockIncentivePlan2006Member" xlink:to="plx_EmployeeStockIncentivePlan2006Member_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_EmployeeStockIncentivePlan2006Member_lbl" xml:lang="en-US">It represent the employee stock incentive plan for the particular period.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_EmployeeStockIncentivePlan2006Member_lbl" xml:lang="en-US">2006 Employee Stock Incentive Plan</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_EmployeeStockIncentivePlan2006Member_lbl" xml:lang="en-US">Plan</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US">Shares of restricted Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Options</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title and Position [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Title and Position [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US">Chief Executive Officer [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US">Chief Executive Officer</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_SeniorVicePresidentAndChiefFinancialOfficerMember" xlink:label="plx_SeniorVicePresidentAndChiefFinancialOfficerMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SeniorVicePresidentAndChiefFinancialOfficerMember" xlink:to="plx_SeniorVicePresidentAndChiefFinancialOfficerMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SeniorVicePresidentAndChiefFinancialOfficerMember_lbl" xml:lang="en-US">Sr. Vice President And Chief Financial Officer</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SeniorVicePresidentAndChiefFinancialOfficerMember_lbl" xml:lang="en-US">Senior Vice President And Chief Financial Officer</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_OfficersAndOtherEmployeesMember" xlink:label="plx_OfficersAndOtherEmployeesMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OfficersAndOtherEmployeesMember" xlink:to="plx_OfficersAndOtherEmployeesMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_OfficersAndOtherEmployeesMember_lbl" xml:lang="en-US">Officers And Other Employees</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_OfficersAndOtherEmployeesMember_lbl" xml:lang="en-US">Officers And Other Employees [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_OfficersAndOtherEmployeesMember_lbl" xml:lang="en-US">Officers And Other Employees</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_VicePresidentResearchAndDevelopmentMember" xlink:label="plx_VicePresidentResearchAndDevelopmentMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_VicePresidentResearchAndDevelopmentMember" xlink:to="plx_VicePresidentResearchAndDevelopmentMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_VicePresidentResearchAndDevelopmentMember_lbl" xml:lang="en-US">This member stands for vice president research and development.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_VicePresidentResearchAndDevelopmentMember_lbl" xml:lang="en-US">Vice President Research And Development</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_VicePresidentResearchAndDevelopmentMember_lbl" xml:lang="en-US">Vice President Research And Development</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingDomain_lbl" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US">Share Based Compensation Award Tranche One</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xml:lang="en-US">Share Based Compensation Award Tranche Two</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">STOCK TRANSACTIONS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of shares granted</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US">Vesting Percentage</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Term of award</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of options to purchase shares</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercise price</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Vesting period</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements_lbl" xml:lang="en-US">Number of equal quarterly increments over which the awards vest under the share based payment arrangement.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements_lbl" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Quarterly Increments</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements_lbl" xml:lang="en-US">Number of equal quarterly increments</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_lbl" xml:lang="en-US">Share based compensation arrangement by share based payment award grant date fair value.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Grant Date Fair Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_lbl" xml:lang="en-US">Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_OutstandingStockOptionsAndWarrantsMember" xlink:label="plx_OutstandingStockOptionsAndWarrantsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OutstandingStockOptionsAndWarrantsMember" xlink:to="plx_OutstandingStockOptionsAndWarrantsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_OutstandingStockOptionsAndWarrantsMember_lbl" xml:lang="en-US">Outstanding stock options and warrants.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_OutstandingStockOptionsAndWarrantsMember_lbl" xml:lang="en-US">Outstanding Stock Options And Warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_OutstandingStockOptionsWarrantsAnd2024NotesMember" xlink:label="plx_OutstandingStockOptionsWarrantsAnd2024NotesMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OutstandingStockOptionsWarrantsAnd2024NotesMember" xlink:to="plx_OutstandingStockOptionsWarrantsAnd2024NotesMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_OutstandingStockOptionsWarrantsAnd2024NotesMember_lbl" xml:lang="en-US">Outstanding stock options and warrants and 2024 notes.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_OutstandingStockOptionsWarrantsAnd2024NotesMember_lbl" xml:lang="en-US">Outstanding Stock Options Warrants And 2024 Notes</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">EARNINGS (LOSS) PER SHARE</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLossAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xml:lang="en-US">Numerator:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DilutiveSecurities" xlink:label="us-gaap_DilutiveSecurities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DilutiveSecurities" xlink:to="us-gaap_DilutiveSecurities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DilutiveSecurities_lbl" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DilutiveSecurities_lbl" xml:lang="en-US">Financial expenses of 2024 Notes</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xml:lang="en-US">Net income (loss) for diluted calculation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US">Denominator:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:to="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_lbl" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_lbl" xml:lang="en-US">Weighted average dilutive effect of 2024 Notes</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xml:lang="en-US">Weighted average dilutive effect of stock options</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Current taxes on income</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_IncomeTaxDisclosureTable" xlink:label="plx_IncomeTaxDisclosureTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_IncomeTaxDisclosureTable" xlink:to="plx_IncomeTaxDisclosureTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_IncomeTaxDisclosureTable_lbl" xml:lang="en-US">Income Tax Disclosure Table</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_IncomeTaxDisclosureTable_lbl" xml:lang="en-US">Income Tax Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_IncomeTaxDisclosureLineItems" xlink:label="plx_IncomeTaxDisclosureLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_IncomeTaxDisclosureLineItems" xlink:to="plx_IncomeTaxDisclosureLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_IncomeTaxDisclosureLineItems_lbl" xml:lang="en-US">Income Tax Disclosure Line Items</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_IncomeTaxDisclosureLineItems_lbl" xml:lang="en-US">Income Tax Disclosure [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_IncomeTaxDisclosureLineItems_lbl" xml:lang="en-US">TAXES ON INCOME</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective income tax rate (as a percent)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Statutory income tax rate</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance related to deferred tax assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Payroll and related expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US">Interest Payable, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US">Interest payable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedVacationCurrent" xlink:label="us-gaap_AccruedVacationCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedVacationCurrent" xlink:to="us-gaap_AccruedVacationCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedVacationCurrent_lbl" xml:lang="en-US">Accrued Vacation, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedVacationCurrent_lbl" xml:lang="en-US">Provision for vacation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRoyaltiesCurrent" xlink:to="us-gaap_AccruedRoyaltiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedRoyaltiesCurrent_lbl" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedRoyaltiesCurrent_lbl" xml:lang="en-US">Royalties payable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesPayableCurrent" xlink:to="us-gaap_TaxesPayableCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxesPayableCurrent_lbl" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxesPayableCurrent_lbl" xml:lang="en-US">Income tax payable</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_ReserveForDeductionsFromRevenueCurrent" xlink:label="plx_ReserveForDeductionsFromRevenueCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ReserveForDeductionsFromRevenueCurrent" xlink:to="plx_ReserveForDeductionsFromRevenueCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ReserveForDeductionsFromRevenueCurrent_lbl" xml:lang="en-US">Carrying value as of the balance sheet date of reserve for deductions from revenue.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ReserveForDeductionsFromRevenueCurrent_lbl" xml:lang="en-US">Reserve For Deductions From Revenue Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_ReserveForDeductionsFromRevenueCurrent_lbl" xml:lang="en-US">Sales reserve</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" xlink:label="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" xlink:to="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_lbl" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred and payable to property and equipment suppliers. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_lbl" xml:lang="en-US">Accounts Payable, Property And Equipment Suppliers, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_lbl" xml:lang="en-US">Property and equipment suppliers</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable and accruals - other</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromCustomers" xlink:label="us-gaap_ProceedsFromCustomers" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromCustomers" xlink:to="us-gaap_ProceedsFromCustomers_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromCustomers_lbl" xml:lang="en-US">Proceeds from Customers</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromCustomers_lbl" xml:lang="en-US">Total proceeds from sale of products</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>plx-20240930_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.8.0.95 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/13/2024 11:42:22 PM-->
<!--Modified on: 11/13/2024 11:42:22 PM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef xlink:type="simple" xlink:href="plx-20240930.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.protalix.com/role/DocumentDocumentAndEntityInformation" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240930.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240930.xsd#StatementCondensedConsolidatedStatementsOfOperations" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240930.xsd#StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240930.xsd#StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240930.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240930.xsd#DisclosureSignificantAccountingPolicies" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPolicies" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240930.xsd#DisclosureInventories" roleURI="http://www.protalix.com/role/DisclosureInventories" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240930.xsd#DisclosureFairValueMeasurement" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurement" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240930.xsd#DisclosureRevenues" roleURI="http://www.protalix.com/role/DisclosureRevenues" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240930.xsd#DisclosureStockTransactions" roleURI="http://www.protalix.com/role/DisclosureStockTransactions" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240930.xsd#DisclosureEarningsLossPerShare" roleURI="http://www.protalix.com/role/DisclosureEarningsLossPerShare" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240930.xsd#DisclosureTaxesOnIncome" roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncome" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240930.xsd#DisclosureSupplementaryFinancialStatementInformation" roleURI="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformation" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240930.xsd#DisclosureSubsequentEvents" roleURI="http://www.protalix.com/role/DisclosureSubsequentEvents" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240930.xsd#DisclosureSignificantAccountingPoliciesPolicies" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240930.xsd#DisclosureSignificantAccountingPoliciesTables" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesTables" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240930.xsd#DisclosureInventoriesTables" roleURI="http://www.protalix.com/role/DisclosureInventoriesTables" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240930.xsd#DisclosureRevenuesTables" roleURI="http://www.protalix.com/role/DisclosureRevenuesTables" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240930.xsd#DisclosureEarningsLossPerShareTables" roleURI="http://www.protalix.com/role/DisclosureEarningsLossPerShareTables" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240930.xsd#DisclosureTaxesOnIncomeTables" roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeTables" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240930.xsd#DisclosureSupplementaryFinancialStatementInformationTables" roleURI="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationTables" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240930.xsd#DisclosureSignificantAccountingPoliciesDetails" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240930.xsd#DisclosureSignificantAccountingPoliciesConvertibleNotesDetails" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesConvertibleNotesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240930.xsd#DisclosureInventoriesScheduleOfInventoryDetails" roleURI="http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240930.xsd#DisclosureRevenuesDisaggregationOfRevenuesDetails" roleURI="http://www.protalix.com/role/DisclosureRevenuesDisaggregationOfRevenuesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240930.xsd#DisclosureStockTransactionsDetails" roleURI="http://www.protalix.com/role/DisclosureStockTransactionsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240930.xsd#DisclosureEarningsLossPerShareDetails" roleURI="http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240930.xsd#DisclosureTaxesOnIncomeSummaryOfTaxesOnIncomeDetails" roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeSummaryOfTaxesOnIncomeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240930.xsd#DisclosureTaxesOnIncomeAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240930.xsd#DisclosureSupplementaryFinancialStatementInformationDetails" roleURI="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240930.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" />
  <link:presentationLink xlink:role="http://www.protalix.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="995200090 - Document - Document and Entity Information">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638671381407320834" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_638671381407320834" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport_638671381407320834" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentQuarterlyReport_638671381407320834" order="2" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638671381407320834" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638671381407320834" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_638671381407320834" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport_638671381407320834" order="4" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638671381407320834" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_638671381407320834" order="5" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638671381407320834" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_638671381407320834" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638671381407320834" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638671381407320834" order="7" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638671381407320834" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638671381407320834" order="8" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638671381407320834" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638671381407320834" order="9" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_638671381407330842" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2_638671381407330842" order="10" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638671381407330842" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638671381407330842" order="11" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638671381407330842" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638671381407330842" order="12" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638671381407330842" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638671381407330842" order="13" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638671381407330842" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_638671381407330842" order="14" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638671381407330842" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_638671381407330842" order="15" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638671381407330842" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_638671381407330842" order="16" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638671381407330842" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_638671381407330842" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638671381407330842" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName_638671381407330842" order="18" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_638671381407330842" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_638671381407330842" order="19" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_638671381407340824" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_638671381407340824" order="20" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_638671381407340824" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory_638671381407340824" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_638671381407340824" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness_638671381407340824" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638671381407340824" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638671381407340824" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_638671381407340824" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany_638671381407340824" order="24" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_638671381407340824" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_638671381407340824" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638671381407340824" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638671381407340824" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_638671381407340824" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_638671381407340824" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_638671381407350824" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_638671381407350824" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_638671381407350824" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_638671381407350824" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638671381407350824" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_638671381407350824" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="995200100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_637041422967320790" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_638671381407350824" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_637041422967320790" xlink:to="us-gaap_AssetsAbstract_638671381407350824" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_638671381407350824" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638671381407350824" xlink:to="us-gaap_AssetsCurrentAbstract_638671381407350824" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638671381407350824" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638671381407350824" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638671381407350824" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_ShortTermBankDeposits" xlink:label="plx_ShortTermBankDeposits_638671381407350824" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638671381407350824" xlink:to="plx_ShortTermBankDeposits_638671381407350824" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_638671381407360828" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638671381407350824" xlink:to="us-gaap_AccountsReceivableNetCurrent_638671381407360828" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_638671381407360828" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638671381407350824" xlink:to="us-gaap_OtherAssetsCurrent_638671381407360828" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638671381407360828" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638671381407350824" xlink:to="us-gaap_InventoryNet_638671381407360828" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638671381407360828" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638671381407350824" xlink:to="us-gaap_AssetsCurrent_638671381407360828" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract_638671381407360828" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638671381407350824" xlink:to="us-gaap_AssetsNoncurrentAbstract_638671381407360828" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_638671381407360828" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_638671381407360828" xlink:to="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_638671381407360828" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638671381407360828" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_638671381407360828" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638671381407360828" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_638671381407360828" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_638671381407360828" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_638671381407360828" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638671381407360828" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_638671381407360828" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638671381407360828" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_638671381407360828" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638671381407350824" xlink:to="us-gaap_Assets_638671381407360828" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638671381407360828" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_637041422967320790" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638671381407360828" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_638671381407370831" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638671381407360828" xlink:to="us-gaap_LiabilitiesCurrentAbstract_638671381407370831" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638671381407370831" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638671381407370831" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638671381407370831" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent_638671381407370831" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638671381407370831" xlink:to="us-gaap_AccountsPayableTradeCurrent_638671381407370831" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent_638671381407370831" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638671381407370831" xlink:to="us-gaap_AccountsPayableOtherCurrent_638671381407370831" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638671381407370831" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638671381407370831" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638671381407370831" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="us-gaap_ConvertibleDebtCurrent_638671381407370831" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638671381407370831" xlink:to="us-gaap_ConvertibleDebtCurrent_638671381407370831" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638671381407370831" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638671381407370831" xlink:to="us-gaap_LiabilitiesCurrent_638671381407370831" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_638671381407370831" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638671381407360828" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_638671381407370831" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_638671381407370831" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_638671381407370831" xlink:to="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_638671381407370831" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638671381407380830" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_638671381407370831" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638671381407380830" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent_638671381407380830" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638671381407360828" xlink:to="us-gaap_LiabilitiesNoncurrent_638671381407380830" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638671381407380830" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638671381407360828" xlink:to="us-gaap_Liabilities_638671381407380830" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638671381407380830" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638671381407360828" xlink:to="us-gaap_CommitmentsAndContingencies_638671381407380830" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638671381407380830" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638671381407360828" xlink:to="us-gaap_StockholdersEquity_638671381407380830" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_638671381407380830" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638671381407360828" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_638671381407380830" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="995200200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract_637041422967477240" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638671381407390823" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_637041422967477240" xlink:to="us-gaap_StatementTable_638671381407390823" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638671381407390823" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638671381407390823" xlink:to="srt_ProductOrServiceAxis_638671381407390823" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638671381407390823" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638671381407390823" xlink:to="srt_ProductsAndServicesDomain_638671381407390823" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember_638671381407390823" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638671381407390823" xlink:to="us-gaap_ProductMember_638671381407390823" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember_638671381407390823" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638671381407390823" xlink:to="us-gaap_LicenseAndServiceMember_638671381407390823" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638671381407390823" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638671381407390823" xlink:to="us-gaap_StatementLineItems_638671381407390823" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_638671381407390823" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638671381407390823" xlink:to="us-gaap_Revenues_638671381407390823" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue_638671381407390823" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638671381407390823" xlink:to="us-gaap_CostOfRevenue_638671381407390823" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638671381407390823" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638671381407390823" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638671381407390823" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_638671381407390823" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638671381407390823" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_638671381407390823" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638671381407390823" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638671381407390823" xlink:to="us-gaap_OperatingIncomeLoss_638671381407390823" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense_638671381407400832" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638671381407390823" xlink:to="us-gaap_OtherNonoperatingExpense_638671381407400832" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome_638671381407400832" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638671381407390823" xlink:to="us-gaap_OtherNonoperatingIncome_638671381407400832" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_638671381407400832" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638671381407390823" xlink:to="us-gaap_NonoperatingIncomeExpense_638671381407400832" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638671381407400832" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638671381407390823" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638671381407400832" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638671381407400832" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638671381407390823" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638671381407400832" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638671381407400832" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638671381407390823" xlink:to="us-gaap_NetIncomeLoss_638671381407400832" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638671381407400832" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638671381407390823" xlink:to="us-gaap_EarningsPerShareBasic_638671381407400832" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638671381407400832" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638671381407390823" xlink:to="us-gaap_EarningsPerShareDiluted_638671381407400832" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638671381407400832" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638671381407390823" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638671381407400832" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638671381407400832" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638671381407390823" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638671381407400832" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" xlink:type="extended" xlink:title="995200300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_676" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638671381407410821" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_676" xlink:to="us-gaap_StatementTable_638671381407410821" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638671381407410821" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638671381407410821" xlink:to="us-gaap_StatementEquityComponentsAxis_638671381407410821" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638671381407410821" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638671381407410821" xlink:to="us-gaap_CommonStockMember_638671381407410821" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_638671381407410821" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638671381407410821" xlink:to="us-gaap_AdditionalPaidInCapitalMember_638671381407410821" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_638671381407410821" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638671381407410821" xlink:to="us-gaap_RetainedEarningsMember_638671381407410821" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638671381407410821" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638671381407410821" xlink:to="us-gaap_EquityComponentDomain_638671381407410821" order="4" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_638671381407410821" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638671381407410821" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_638671381407410821" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate202006Member" xlink:label="us-gaap_AccountingStandardsUpdate202006Member_638671381407410821" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_638671381407410821" xlink:to="us-gaap_AccountingStandardsUpdate202006Member_638671381407410821" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_638671381407410821" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_638671381407410821" xlink:to="us-gaap_TypeOfAdoptionMember_638671381407410821" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis_638671381407420829" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638671381407410821" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAxis_638671381407420829" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_638671381407420829" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis_638671381407420829" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_638671381407420829" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain_638671381407420829" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis_638671381407420829" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain_638671381407420829" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638671381407420829" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638671381407410821" xlink:to="us-gaap_StatementLineItems_638671381407420829" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638671381407420829" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638671381407420829" xlink:to="us-gaap_StockholdersEquity_638671381407420829" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638671381407420829" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638671381407420829" xlink:to="us-gaap_SharesOutstanding_638671381407420829" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="6" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_StockIssuedDuringPeriodValueSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement_638671381407420829" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638671381407420829" xlink:to="plx_StockIssuedDuringPeriodValueSalesAgreement_638671381407420829" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_StockIssuedDuringPeriodSharesSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement_638671381407420829" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638671381407420829" xlink:to="plx_StockIssuedDuringPeriodSharesSalesAgreement_638671381407420829" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_638671381407420829" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638671381407420829" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_638671381407420829" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_638671381407420829" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638671381407420829" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_638671381407420829" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638671381407430827" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638671381407420829" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638671381407430827" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_638671381407430827" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638671381407420829" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_638671381407430827" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_638671381407430827" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_638671381407430827" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_638671381407430827" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_StockIssuedDuringPeriodValueWarrantsExercises" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsExercises_638671381407430827" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638671381407420829" xlink:to="plx_StockIssuedDuringPeriodValueWarrantsExercises_638671381407430827" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_StockIssuedDuringPeriodSharesWarrantsExercises" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsExercises_638671381407430827" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_StockIssuedDuringPeriodValueWarrantsExercises_638671381407430827" xlink:to="plx_StockIssuedDuringPeriodSharesWarrantsExercises_638671381407430827" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638671381407430827" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638671381407420829" xlink:to="us-gaap_NetIncomeLoss_638671381407430827" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638671381407430827" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638671381407420829" xlink:to="us-gaap_StockholdersEquity_638671381407430827" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638671381407430827" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638671381407420829" xlink:to="us-gaap_SharesOutstanding_638671381407430827" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="6" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical" xlink:type="extended" xlink:title="995200305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_738" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638671381407440826" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_738" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638671381407440826" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638671381407440826" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_738" xlink:to="us-gaap_CommonStockSharesAuthorized_638671381407440826" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="995200400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_746" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638671381407440826" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638671381407440826" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638671381407440826" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638671381407440826" xlink:to="us-gaap_ProfitLoss_638671381407440826" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638671381407440826" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638671381407440826" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638671381407440826" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638671381407440826" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638671381407440826" xlink:to="us-gaap_ShareBasedCompensation_638671381407440826" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638671381407440826" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638671381407440826" xlink:to="us-gaap_Depreciation_638671381407440826" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_638671381407440826" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638671381407440826" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_638671381407440826" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_638671381407450842" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638671381407440826" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense_638671381407450842" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_638671381407450842" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638671381407440826" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_638671381407450842" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_638671381407450842" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638671381407440826" xlink:to="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_638671381407450842" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638671381407450842" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638671381407440826" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638671381407450842" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_GainLossOnDebtConversion" xlink:label="plx_GainLossOnDebtConversion_638671381407450842" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638671381407440826" xlink:to="plx_GainLossOnDebtConversion_638671381407450842" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638671381407450842" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638671381407440826" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638671381407450842" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638671381407450842" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638671381407440826" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638671381407450842" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638671381407450842" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638671381407450842" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638671381407450842" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_638671381407450842" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638671381407450842" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_638671381407450842" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_638671381407450842" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638671381407450842" xlink:to="plx_ChangeInOperatingLeaseRightOfUseAssets_638671381407450842" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_638671381407450842" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638671381407450842" xlink:to="us-gaap_IncreaseDecreaseInInventories_638671381407450842" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638671381407460819" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638671381407450842" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638671381407460819" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638671381407460819" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638671381407440826" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638671381407460819" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638671381407460819" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638671381407460819" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_IncreaseDecreaseInBankDeposits" xlink:label="plx_IncreaseDecreaseInBankDeposits_638671381407460819" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638671381407460819" xlink:to="plx_IncreaseDecreaseInBankDeposits_638671381407460819" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_ProceedsFromWithdrawalOfShortTermDeposits" xlink:label="plx_ProceedsFromWithdrawalOfShortTermDeposits_638671381407460819" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638671381407460819" xlink:to="plx_ProceedsFromWithdrawalOfShortTermDeposits_638671381407460819" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638671381407460819" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638671381407460819" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638671381407460819" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638671381407460819" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638671381407460819" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638671381407460819" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_638671381407460819" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638671381407460819" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_638671381407460819" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638671381407470824" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638671381407460819" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638671381407470824" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638671381407470824" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638671381407470824" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_638671381407470824" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638671381407470824" xlink:to="us-gaap_RepaymentsOfConvertibleDebt_638671381407470824" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638671381407470824" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638671381407470824" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638671381407470824" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_638671381407470824" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638671381407470824" xlink:to="us-gaap_ProceedsFromWarrantExercises_638671381407470824" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638671381407470824" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638671381407470824" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638671381407470824" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638671381407470824" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638671381407470824" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638671381407470824" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638671381407470824" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638671381407480822" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638671381407480822" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6386713814074808221" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6386713814074808221" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638671381407480822" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638671381407480822" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_638671381407480822" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638671381407480822" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_638671381407480822" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_638671381407480822" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638671381407480822" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_638671381407480822" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_638671381407480822" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638671381407480822" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_638671381407480822" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_638671381407480822" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_638671381407480822" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet_638671381407490823" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638671381407480822" xlink:to="us-gaap_InterestPaidNet_638671381407490823" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_InterestReceivedNet" xlink:label="plx_InterestReceivedNet_638671381407490823" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638671381407480822" xlink:to="plx_InterestReceivedNet_638671381407490823" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPolicies" xlink:type="extended" xlink:title="995210101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_802" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_638671381407490823" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_802" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_638671381407490823" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureInventories" xlink:type="extended" xlink:title="995210201 - Disclosure - INVENTORIES">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock_638671381407490823" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_8" xlink:to="us-gaap_InventoryDisclosureTextBlock_638671381407490823" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurement" xlink:type="extended" xlink:title="995210301 - Disclosure - FAIR VALUE MEASUREMENT">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_638671381407500830" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_23" xlink:to="us-gaap_FairValueDisclosuresTextBlock_638671381407500830" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureRevenues" xlink:type="extended" xlink:title="995210401 - Disclosure - REVENUES">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_RevenueDisclosureTextBlock" xlink:label="plx_RevenueDisclosureTextBlock_638671381407500830" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:to="plx_RevenueDisclosureTextBlock_638671381407500830" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureStockTransactions" xlink:type="extended" xlink:title="995210501 - Disclosure - STOCK TRANSACTIONS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638671381407500830" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638671381407500830" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureEarningsLossPerShare" xlink:type="extended" xlink:title="995210601 - Disclosure - EARNINGS (LOSS) PER SHARE">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_638671381407500830" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock_638671381407500830" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureTaxesOnIncome" xlink:type="extended" xlink:title="995210701 - Disclosure - TAXES ON INCOME">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637041422967633303" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_638671381407510833" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637041422967633303" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_638671381407510833" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformation" xlink:type="extended" xlink:title="995210801 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION">
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_SupplementalInformationAbstract" xlink:label="plx_SupplementalInformationAbstract_637041422967789587" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:label="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_638671381407510833" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SupplementalInformationAbstract_637041422967789587" xlink:to="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_638671381407510833" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="995210901 - Disclosure - SUBSEQUENT EVENTS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_638671381407510833" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract_1" xlink:to="us-gaap_SubsequentEventsTextBlock_638671381407510833" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="99920102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_NatureOfOperationsPolicyTextBlock" xlink:label="plx_NatureOfOperationsPolicyTextBlock_638671381407510833" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="plx_NatureOfOperationsPolicyTextBlock_638671381407510833" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638671381407510833" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638671381407510833" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_638671381407510833" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_638671381407510833" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock_638671381407520831" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DebtPolicyTextBlock_638671381407520831" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638671381407520831" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638671381407520831" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesTables" xlink:type="extended" xlink:title="99930103 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_638671381407520831" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_3" xlink:to="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_638671381407520831" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureInventoriesTables" xlink:type="extended" xlink:title="99930203 - Disclosure - INVENTORIES (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_101" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_638671381407520831" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_101" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_638671381407520831" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureRevenuesTables" xlink:type="extended" xlink:title="99930403 - Disclosure - REVENUES (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_637167842398709852" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_638671381407520831" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_637167842398709852" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_638671381407520831" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureEarningsLossPerShareTables" xlink:type="extended" xlink:title="99930603 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_638671381407530828" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_1" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_638671381407530828" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureTaxesOnIncomeTables" xlink:type="extended" xlink:title="99930703 - Disclosure - TAXES ON INCOME (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637041422967854703" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_638671381407530828" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637041422967854703" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_638671381407530828" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationTables" xlink:type="extended" xlink:title="99930803 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)">
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_SupplementalInformationAbstract" xlink:label="plx_SupplementalInformationAbstract_637041422967854703" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_SupplementaryBalanceSheetsInformationTableTextBlock" xlink:label="plx_SupplementaryBalanceSheetsInformationTableTextBlock_638671381407530828" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SupplementalInformationAbstract_637041422967854703" xlink:to="plx_SupplementaryBalanceSheetsInformationTableTextBlock_638671381407530828" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="99940101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_177" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable_638671381407530828" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_177" xlink:to="plx_SignificantAccountingPoliciesTable_638671381407530828" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638671381407530828" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638671381407530828" xlink:to="us-gaap_TypeOfArrangementAxis_638671381407530828" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638671381407540825" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638671381407530828" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638671381407540825" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_AmendedPfizerAgreementMember" xlink:label="plx_AmendedPfizerAgreementMember_638671381407540825" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638671381407540825" xlink:to="plx_AmendedPfizerAgreementMember_638671381407540825" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember_638671381407540825" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638671381407540825" xlink:to="plx_ChiesiAgreementsMember_638671381407540825" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_ChiesiUSAgreementMember" xlink:label="plx_ChiesiUSAgreementMember_638671381407540825" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ChiesiAgreementsMember_638671381407540825" xlink:to="plx_ChiesiUSAgreementMember_638671381407540825" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_ChiesiExUSAgreementMember" xlink:label="plx_ChiesiExUSAgreementMember_638671381407540825" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ChiesiAgreementsMember_638671381407540825" xlink:to="plx_ChiesiExUSAgreementMember_638671381407540825" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" xlink:label="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_638671381407540825" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ChiesiAgreementsMember_638671381407540825" xlink:to="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_638671381407540825" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_FillFinishAgreementMember" xlink:label="plx_FillFinishAgreementMember_638671381407540825" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638671381407540825" xlink:to="plx_FillFinishAgreementMember_638671381407540825" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638671381407540825" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638671381407530828" xlink:to="dei_LegalEntityAxis_638671381407540825" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638671381407540825" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638671381407540825" xlink:to="dei_EntityDomain_638671381407540825" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember_638671381407540825" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638671381407540825" xlink:to="plx_ProtalixBioTherapeuticsIncorporationMember_638671381407540825" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_638671381407540825" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638671381407530828" xlink:to="srt_StatementGeographicalAxis_638671381407540825" order="3" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_638671381407540825" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_638671381407540825" xlink:to="srt_SegmentGeographicalDomain_638671381407540825" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_BR" xlink:label="country_BR_638671381407550827" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638671381407540825" xlink:to="country_BR_638671381407550827" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638671381407550827" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638671381407530828" xlink:to="srt_RangeAxis_638671381407550827" order="4" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638671381407550827" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638671381407550827" xlink:to="srt_RangeMember_638671381407550827" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638671381407550827" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638671381407550827" xlink:to="srt_MinimumMember_638671381407550827" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638671381407550827" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638671381407550827" xlink:to="srt_MaximumMember_638671381407550827" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638671381407550827" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638671381407530828" xlink:to="us-gaap_DebtInstrumentAxis_638671381407550827" order="5" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638671381407550827" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638671381407550827" xlink:to="us-gaap_DebtInstrumentNameDomain_638671381407550827" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_ConvertibleNotesDue2021And2024Member" xlink:label="plx_ConvertibleNotesDue2021And2024Member_638671381407550827" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638671381407550827" xlink:to="plx_ConvertibleNotesDue2021And2024Member_638671381407550827" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_638671381407550827" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ConvertibleNotesDue2021And2024Member_638671381407550827" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_638671381407550827" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638671381407550827" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638671381407530828" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638671381407550827" order="6" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638671381407560819" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638671381407550827" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638671381407560819" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_AtMarketEquityOfferingMember" xlink:label="plx_AtMarketEquityOfferingMember_638671381407560819" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638671381407560819" xlink:to="plx_AtMarketEquityOfferingMember_638671381407560819" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems_638671381407560819" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638671381407530828" xlink:to="plx_SignificantAccountingPoliciesLineItems_638671381407560819" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_NumberOfGlobalLicensingAndSupplyAgreements" xlink:label="plx_NumberOfGlobalLicensingAndSupplyAgreements_638671381407560819" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638671381407560819" xlink:to="plx_NumberOfGlobalLicensingAndSupplyAgreements_638671381407560819" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_UpfrontNonrefundableNoncreditablePaymentReceivable" xlink:label="plx_UpfrontNonrefundableNoncreditablePaymentReceivable_638671381407560819" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638671381407560819" xlink:to="plx_UpfrontNonrefundableNoncreditablePaymentReceivable_638671381407560819" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638671381407560819" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638671381407560819" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638671381407560819" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638671381407560819" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638671381407560819" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638671381407560819" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_SaleOfStockMaximumOfferingPrice" xlink:label="plx_SaleOfStockMaximumOfferingPrice_638671381407560819" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638671381407560819" xlink:to="plx_SaleOfStockMaximumOfferingPrice_638671381407560819" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638671381407570823" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638671381407560819" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638671381407570823" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_638671381407570823" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638671381407560819" xlink:to="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_638671381407570823" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_ExtendedTermOfAgreement" xlink:label="plx_ExtendedTermOfAgreement_638671381407570823" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638671381407560819" xlink:to="plx_ExtendedTermOfAgreement_638671381407570823" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_AgreementAmendmentPaymentReceivable" xlink:label="plx_AgreementAmendmentPaymentReceivable_638671381407570823" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638671381407560819" xlink:to="plx_AgreementAmendmentPaymentReceivable_638671381407570823" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones_638671381407570823" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638671381407560819" xlink:to="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones_638671381407570823" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_638671381407570823" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638671381407560819" xlink:to="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_638671381407570823" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_MilestonePaymentReceived" xlink:label="plx_MilestonePaymentReceived_638671381407570823" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638671381407560819" xlink:to="plx_MilestonePaymentReceived_638671381407570823" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_PaymentOnNetSalesPercentage" xlink:label="plx_PaymentOnNetSalesPercentage_638671381407580827" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638671381407560819" xlink:to="plx_PaymentOnNetSalesPercentage_638671381407580827" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_638671381407580827" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638671381407560819" xlink:to="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_638671381407580827" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_638671381407580827" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638671381407560819" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_638671381407580827" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesConvertibleNotesDetails" xlink:type="extended" xlink:title="99940102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Convertible notes (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable_638671381407580827" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_2" xlink:to="plx_SignificantAccountingPoliciesTable_638671381407580827" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_638671381407580827" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638671381407580827" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_638671381407580827" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_638671381407580827" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_638671381407580827" xlink:to="us-gaap_TypeOfAdoptionMember_638671381407580827" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate202006Member" xlink:label="us-gaap_AccountingStandardsUpdate202006Member_638671381407580827" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember_638671381407580827" xlink:to="us-gaap_AccountingStandardsUpdate202006Member_638671381407580827" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis_638671381407590825" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638671381407580827" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAxis_638671381407590825" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain_638671381407590825" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis_638671381407590825" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain_638671381407590825" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_638671381407590825" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CumulativeEffectPeriodOfAdoptionDomain_638671381407590825" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_638671381407590825" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_638671381407590825" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CumulativeEffectPeriodOfAdoptionDomain_638671381407590825" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_638671381407590825" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems_638671381407590825" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638671381407580827" xlink:to="plx_SignificantAccountingPoliciesLineItems_638671381407590825" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="us-gaap_ConvertibleDebtCurrent_638671381407590825" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638671381407590825" xlink:to="us-gaap_ConvertibleDebtCurrent_638671381407590825" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_638671381407590825" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638671381407590825" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_638671381407590825" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638671381407590825" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638671381407590825" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638671381407590825" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails" xlink:type="extended" xlink:title="99940201 - Disclosure - INVENTORIES - Schedule of Inventory (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_261" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_638671381407590825" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_638671381407590825" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_638671381407600822" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_638671381407600822" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_638671381407600822" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_638671381407600822" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638671381407600822" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryNet_638671381407600822" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureRevenuesDisaggregationOfRevenuesDetails" xlink:type="extended" xlink:title="99940401 - Disclosure - REVENUES - Disaggregation of Revenues (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638671381407600822" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:to="us-gaap_StatementTable_638671381407600822" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638671381407600822" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638671381407600822" xlink:to="srt_ProductOrServiceAxis_638671381407600822" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638671381407600822" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638671381407600822" xlink:to="srt_ProductsAndServicesDomain_638671381407600822" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember_638671381407600822" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638671381407600822" xlink:to="us-gaap_ProductMember_638671381407600822" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember_638671381407600822" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638671381407600822" xlink:to="us-gaap_LicenseAndServiceMember_638671381407600822" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638671381407600822" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638671381407600822" xlink:to="us-gaap_TypeOfArrangementAxis_638671381407600822" order="2" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638671381407600822" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638671381407600822" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638671381407600822" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember_638671381407600822" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638671381407600822" xlink:to="plx_ChiesiAgreementsMember_638671381407600822" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_638671381407610823" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638671381407600822" xlink:to="srt_StatementGeographicalAxis_638671381407610823" order="3" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_638671381407610823" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_638671381407610823" xlink:to="srt_SegmentGeographicalDomain_638671381407610823" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_PfizerMember" xlink:label="plx_PfizerMember_638671381407610823" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638671381407610823" xlink:to="plx_PfizerMember_638671381407610823" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_BR" xlink:label="country_BR_638671381407610823" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638671381407610823" xlink:to="country_BR_638671381407610823" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638671381407610823" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638671381407600822" xlink:to="us-gaap_StatementLineItems_638671381407610823" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_638671381407610823" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638671381407610823" xlink:to="us-gaap_Revenues_638671381407610823" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureStockTransactionsDetails" xlink:type="extended" xlink:title="99940501 - Disclosure - STOCK TRANSACTIONS (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_638671381407610823" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_2" xlink:to="us-gaap_ScheduleOfStockByClassTable_638671381407610823" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638671381407610823" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638671381407610823" xlink:to="us-gaap_PlanNameAxis_638671381407610823" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638671381407610823" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638671381407610823" xlink:to="us-gaap_PlanNameDomain_638671381407610823" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_EmployeeStockIncentivePlan2006Member" xlink:label="plx_EmployeeStockIncentivePlan2006Member_638671381407620824" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638671381407610823" xlink:to="plx_EmployeeStockIncentivePlan2006Member_638671381407620824" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638671381407620824" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638671381407610823" xlink:to="us-gaap_AwardTypeAxis_638671381407620824" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638671381407620824" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638671381407620824" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638671381407620824" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember_638671381407620824" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638671381407620824" xlink:to="us-gaap_RestrictedStockMember_638671381407620824" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638671381407620824" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638671381407620824" xlink:to="us-gaap_EmployeeStockOptionMember_638671381407620824" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_638671381407620824" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638671381407610823" xlink:to="srt_TitleOfIndividualAxis_638671381407620824" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638671381407620824" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_638671381407620824" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638671381407620824" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember_638671381407620824" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638671381407620824" xlink:to="srt_ChiefExecutiveOfficerMember_638671381407620824" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_SeniorVicePresidentAndChiefFinancialOfficerMember" xlink:label="plx_SeniorVicePresidentAndChiefFinancialOfficerMember_638671381407620824" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638671381407620824" xlink:to="plx_SeniorVicePresidentAndChiefFinancialOfficerMember_638671381407620824" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_OfficersAndOtherEmployeesMember" xlink:label="plx_OfficersAndOtherEmployeesMember_638671381407620824" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638671381407620824" xlink:to="plx_OfficersAndOtherEmployeesMember_638671381407620824" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_VicePresidentResearchAndDevelopmentMember" xlink:label="plx_VicePresidentResearchAndDevelopmentMember_638671381407620824" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638671381407620824" xlink:to="plx_VicePresidentResearchAndDevelopmentMember_638671381407620824" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_638671381407620824" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638671381407610823" xlink:to="us-gaap_VestingAxis_638671381407620824" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_638671381407630826" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis_638671381407620824" xlink:to="us-gaap_VestingDomain_638671381407630826" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_638671381407630826" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638671381407630826" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_638671381407630826" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_638671381407630826" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638671381407630826" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_638671381407630826" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_638671381407630826" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638671381407610823" xlink:to="us-gaap_ClassOfStockLineItems_638671381407630826" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638671381407630826" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638671381407630826" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638671381407630826" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_638671381407630826" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638671381407630826" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_638671381407630826" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638671381407630826" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638671381407630826" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638671381407630826" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638671381407630826" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638671381407630826" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638671381407630826" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638671381407630826" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638671381407630826" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638671381407630826" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638671381407640841" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638671381407630826" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638671381407640841" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements_638671381407640841" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638671381407630826" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements_638671381407640841" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_638671381407640841" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638671381407630826" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_638671381407640841" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails" xlink:type="extended" xlink:title="99940601 - Disclosure - EARNINGS (LOSS) PER SHARE (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638671381407640841" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_3" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638671381407640841" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638671381407640841" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638671381407640841" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638671381407640841" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_638671381407640841" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638671381407640841" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_638671381407640841" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_OutstandingStockOptionsAndWarrantsMember" xlink:label="plx_OutstandingStockOptionsAndWarrantsMember_638671381407640841" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638671381407640841" xlink:to="plx_OutstandingStockOptionsAndWarrantsMember_638671381407640841" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_OutstandingStockOptionsWarrantsAnd2024NotesMember" xlink:label="plx_OutstandingStockOptionsWarrantsAnd2024NotesMember_638671381407650838" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638671381407640841" xlink:to="plx_OutstandingStockOptionsWarrantsAnd2024NotesMember_638671381407650838" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638671381407650838" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638671381407640841" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638671381407650838" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract_638671381407650838" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638671381407650838" xlink:to="us-gaap_NetIncomeLossAbstract_638671381407650838" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638671381407650838" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract_638671381407650838" xlink:to="us-gaap_NetIncomeLoss_638671381407650838" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DilutiveSecurities" xlink:label="us-gaap_DilutiveSecurities_638671381407650838" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract_638671381407650838" xlink:to="us-gaap_DilutiveSecurities_638671381407650838" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_638671381407650838" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract_638671381407650838" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_638671381407650838" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638671381407650838" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638671381407650838" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638671381407650838" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638671381407650838" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638671381407650838" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638671381407650838" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_638671381407650838" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638671381407650838" xlink:to="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_638671381407650838" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_638671381407650838" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638671381407650838" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_638671381407650838" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638671381407650838" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638671381407650838" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638671381407650838" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638671381407660826" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638671381407650838" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638671381407660826" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureTaxesOnIncomeSummaryOfTaxesOnIncomeDetails" xlink:type="extended" xlink:title="99940701 - Disclosure - TAXES ON INCOME - Summary of Taxes on Income (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_638671381407660826" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_638671381407660826" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_638671381407660826" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_638671381407660826" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638671381407660826" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638671381407660826" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails" xlink:type="extended" xlink:title="99940702 - Disclosure - TAXES ON INCOME - Additional Information (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637041422968852328" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_IncomeTaxDisclosureTable" xlink:label="plx_IncomeTaxDisclosureTable_638671381407660826" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637041422968852328" xlink:to="plx_IncomeTaxDisclosureTable_638671381407660826" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638671381407660826" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_IncomeTaxDisclosureTable_638671381407660826" xlink:to="us-gaap_TypeOfArrangementAxis_638671381407660826" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638671381407660826" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638671381407660826" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638671381407660826" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember_638671381407660826" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638671381407660826" xlink:to="plx_ChiesiAgreementsMember_638671381407660826" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_IncomeTaxDisclosureLineItems" xlink:label="plx_IncomeTaxDisclosureLineItems_638671381407670831" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_IncomeTaxDisclosureTable_638671381407660826" xlink:to="plx_IncomeTaxDisclosureLineItems_638671381407670831" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638671381407670831" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_IncomeTaxDisclosureLineItems_638671381407670831" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638671381407670831" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638671381407670831" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_IncomeTaxDisclosureLineItems_638671381407670831" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638671381407670831" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_MilestonePaymentReceived" xlink:label="plx_MilestonePaymentReceived_638671381407670831" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_IncomeTaxDisclosureLineItems_638671381407670831" xlink:to="plx_MilestonePaymentReceived_638671381407670831" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_638671381407670831" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_IncomeTaxDisclosureLineItems_638671381407670831" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_638671381407670831" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationDetails" xlink:type="extended" xlink:title="99940801 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Details)">
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_SupplementalInformationAbstract" xlink:label="plx_SupplementalInformationAbstract_637041422969008821" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638671381407670831" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SupplementalInformationAbstract_637041422969008821" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638671381407670831" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638671381407670831" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638671381407670831" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638671381407670831" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent_638671381407670831" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638671381407670831" xlink:to="us-gaap_InterestPayableCurrent_638671381407670831" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedVacationCurrent" xlink:label="us-gaap_AccruedVacationCurrent_638671381407670831" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638671381407670831" xlink:to="us-gaap_AccruedVacationCurrent_638671381407670831" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638671381407670831" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638671381407670831" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638671381407670831" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrent_638671381407680823" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638671381407670831" xlink:to="us-gaap_AccruedRoyaltiesCurrent_638671381407680823" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent_638671381407680823" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638671381407670831" xlink:to="us-gaap_TaxesPayableCurrent_638671381407680823" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_ReserveForDeductionsFromRevenueCurrent" xlink:label="plx_ReserveForDeductionsFromRevenueCurrent_638671381407680823" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638671381407670831" xlink:to="plx_ReserveForDeductionsFromRevenueCurrent_638671381407680823" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" xlink:label="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_638671381407680823" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638671381407670831" xlink:to="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_638671381407680823" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638671381407680823" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638671381407670831" xlink:to="us-gaap_AccountsPayableCurrent_638671381407680823" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="99940901 - Disclosure - SUBSEQUENT EVENTS (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable_638671381407680823" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract_2" xlink:to="us-gaap_SubsequentEventTable_638671381407680823" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638671381407680823" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638671381407680823" xlink:to="us-gaap_TypeOfArrangementAxis_638671381407680823" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638671381407680823" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638671381407680823" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638671381407680823" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240930.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember_638671381407680823" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638671381407680823" xlink:to="plx_ChiesiAgreementsMember_638671381407680823" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems_638671381407690831" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638671381407680823" xlink:to="us-gaap_SubsequentEventLineItems_638671381407690831" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromCustomers" xlink:label="us-gaap_ProceedsFromCustomers_638671381407690831" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638671381407690831" xlink:to="us-gaap_ProceedsFromCustomers_638671381407690831" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended" xlink:title="995445 - Disclosure - Insider Trading Arrangements" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46191743589664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Nov. 01, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Securities Act File Number</a></td>
<td class="text">001-33357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PROTALIX BIOTHERAPEUTICS,&#160;INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">65-0643773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2 University Plaza<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Hackensack<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07601<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">696-9345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PLX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,633,583<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001006281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46191740440864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 27,409<span></span>
</td>
<td class="nump">$ 23,634<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShortTermBankDeposits', window );">Short-term bank deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,926<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable - Trade</a></td>
<td class="nump">2,195<span></span>
</td>
<td class="nump">5,272<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other assets</a></td>
<td class="nump">1,050<span></span>
</td>
<td class="nump">1,055<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">17,199<span></span>
</td>
<td class="nump">19,045<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">47,853<span></span>
</td>
<td class="nump">69,932<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>NON-CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">Funds in respect of employee rights upon retirement</a></td>
<td class="nump">561<span></span>
</td>
<td class="nump">528<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">4,648<span></span>
</td>
<td class="nump">4,973<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred income tax asset</a></td>
<td class="nump">2,856<span></span>
</td>
<td class="nump">3,092<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="nump">5,645<span></span>
</td>
<td class="nump">5,909<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">61,563<span></span>
</td>
<td class="nump">84,434<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window );"><strong>Accounts payable and accruals:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade</a></td>
<td class="nump">3,135<span></span>
</td>
<td class="nump">4,320<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Other</a></td>
<td class="nump">19,577<span></span>
</td>
<td class="nump">19,550<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">1,508<span></span>
</td>
<td class="nump">1,409<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,251<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">24,220<span></span>
</td>
<td class="nump">45,530<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>LONG TERM LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent', window );">Liability for employee rights upon retirement</a></td>
<td class="nump">730<span></span>
</td>
<td class="nump">714<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">4,176<span></span>
</td>
<td class="nump">4,621<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long term liabilities</a></td>
<td class="nump">4,906<span></span>
</td>
<td class="nump">5,335<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">29,126<span></span>
</td>
<td class="nump">50,865<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="nump">32,437<span></span>
</td>
<td class="nump">33,569<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 61,563<span></span>
</td>
<td class="nump">$ 84,434<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShortTermBankDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of deposits held with banks for short period, usually less than one year or the normal operating cycle, whichever is longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShortTermBankDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480535/715-20-45-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480535/715-20-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for pension, other postretirement and postemployment benefits, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480535/715-20-45-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480535/715-20-45-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46191744830064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUE</a></td>
<td class="nump">$ 17,959<span></span>
</td>
<td class="nump">$ 10,345<span></span>
</td>
<td class="nump">$ 35,181<span></span>
</td>
<td class="nump">$ 55,008<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">COST OF GOODS SOLD</a></td>
<td class="num">(8,375)<span></span>
</td>
<td class="num">(4,893)<span></span>
</td>
<td class="num">(20,433)<span></span>
</td>
<td class="num">(14,126)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">RESEARCH AND DEVELOPMENT EXPENSES</a></td>
<td class="num">(2,998)<span></span>
</td>
<td class="num">(3,669)<span></span>
</td>
<td class="num">(8,846)<span></span>
</td>
<td class="num">(13,991)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES</a></td>
<td class="num">(2,595)<span></span>
</td>
<td class="num">(3,670)<span></span>
</td>
<td class="num">(9,194)<span></span>
</td>
<td class="num">(10,816)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">OPERATING INCOME (LOSS)</a></td>
<td class="nump">3,991<span></span>
</td>
<td class="num">(1,887)<span></span>
</td>
<td class="num">(3,292)<span></span>
</td>
<td class="nump">16,075<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">FINANCIAL EXPENSES</a></td>
<td class="num">(299)<span></span>
</td>
<td class="num">(460)<span></span>
</td>
<td class="num">(1,056)<span></span>
</td>
<td class="num">(2,406)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">FINANCIAL INCOME</a></td>
<td class="nump">151<span></span>
</td>
<td class="nump">628<span></span>
</td>
<td class="nump">1,186<span></span>
</td>
<td class="nump">1,323<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">FINANCIAL INCOME (EXPENSES), NET</a></td>
<td class="num">(148)<span></span>
</td>
<td class="nump">168<span></span>
</td>
<td class="nump">130<span></span>
</td>
<td class="num">(1,083)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">INCOME (LOSS) BEFORE TAXES ON INCOME</a></td>
<td class="nump">3,843<span></span>
</td>
<td class="num">(1,719)<span></span>
</td>
<td class="num">(3,162)<span></span>
</td>
<td class="nump">14,992<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">TAXES ON INCOME</a></td>
<td class="num">(607)<span></span>
</td>
<td class="num">(133)<span></span>
</td>
<td class="num">(400)<span></span>
</td>
<td class="num">(636)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET INCOME (LOSS) FOR THE PERIOD</a></td>
<td class="nump">$ 3,236<span></span>
</td>
<td class="num">$ (1,852)<span></span>
</td>
<td class="num">$ (3,562)<span></span>
</td>
<td class="nump">$ 14,356<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">EARNINGS (LOSS) PER SHARE OF COMMON STOCK - BASIC (in dollars per share)</a></td>
<td class="nump">$ 0.04<span></span>
</td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="num">$ (0.05)<span></span>
</td>
<td class="nump">$ 0.22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">EARNINGS (LOSS) PER SHARE OF COMMON STOCK - DILUTED (in dollars per share)</a></td>
<td class="nump">$ 0.03<span></span>
</td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="num">$ (0.05)<span></span>
</td>
<td class="nump">$ 0.16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING EARNINGS (LOSS) PER SHARE - BASIC (in shares)</a></td>
<td class="nump">73,549,745<span></span>
</td>
<td class="nump">72,281,681<span></span>
</td>
<td class="nump">73,301,091<span></span>
</td>
<td class="nump">65,811,506<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING EARNINGS (LOSS) PER SHARE - DILUTED (in shares)</a></td>
<td class="nump">81,217,068<span></span>
</td>
<td class="nump">83,782,679<span></span>
</td>
<td class="nump">73,301,091<span></span>
</td>
<td class="nump">81,040,281<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Goods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUE</a></td>
<td class="nump">$ 17,839<span></span>
</td>
<td class="nump">$ 10,168<span></span>
</td>
<td class="nump">$ 34,820<span></span>
</td>
<td class="nump">$ 30,309<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember', window );">License and R&amp;D Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUE</a></td>
<td class="nump">$ 120<span></span>
</td>
<td class="nump">$ 177<span></span>
</td>
<td class="nump">$ 361<span></span>
</td>
<td class="nump">$ 24,699<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46191739803520">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>Adjustment</div>
</th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th">
<div>Accumulated Deficit </div>
<div>Adjustment</div>
</th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Adjustment</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 379,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (389,861)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (10,640)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">53,790,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodValueSalesAgreement', window );">Issuance of common stock under the Sales Agreement, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,954<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesSalesAgreement', window );">Issuance of common stock under the Sales Agreement, net (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">12,560,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Convertible notes conversions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,783<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Convertible notes conversions (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">4,691,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,195<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures', window );">Share-based compensation related to restricted stock awards</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">887<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares', window );">Share-based compensation related to restricted stock awards (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,371,362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodValueWarrantsExercises', window );">Exercise of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">712<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesWarrantsExercises', window );">Exercise of warrants (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">538,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,356<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">413,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(375,505)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,247<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">72,952,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Jun. 30, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">412,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(373,653)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,001<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Jun. 30, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">71,580,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">383<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures', window );">Share-based compensation related to restricted stock awards</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">715<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares', window );">Share-based compensation related to restricted stock awards (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,371,362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,852)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,852)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">413,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(375,505)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,247<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">72,952,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">415,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(381,549)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,569<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">72,952,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,191<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures', window );">Share-based compensation related to restricted stock awards</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,408<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares', window );">Share-based compensation related to restricted stock awards (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">681,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,562)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,562)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance (ASU 2020-06) at Sep. 30, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (393)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (169)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">417,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(384,887)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,437<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">73,633,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Jun. 30, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">416,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(388,123)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,581<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Jun. 30, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">73,292,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">358<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures', window );">Share-based compensation related to restricted stock awards</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">262<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares', window );">Share-based compensation related to restricted stock awards (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">340,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,236<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance (ASU 2020-06) at Sep. 30, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (393)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (169)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 417,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (384,887)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,437<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">73,633,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="8"></td></tr>
<tr><td colspan="8"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Common stock, $0.001 par value; Authorized &#8211; as of September&#160;30, 2024 and December&#160;31, 2023 &#8211; 185,000,000 shares.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of recognized equity-based compensation during the period for restricted stock awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodSharesSalesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Sales Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodSharesSalesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodSharesWarrantsExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during period for exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodSharesWarrantsExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodValueSalesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in a sales agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodValueSalesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodValueWarrantsExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares issued during period for exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodValueWarrantsExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46191733865264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">185,000,000<span></span>
</td>
<td class="nump">185,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46191743542080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Income (loss)</a></td>
<td class="num">$ (3,562)<span></span>
</td>
<td class="nump">$ 14,356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments required to reconcile net income (loss) to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">2,599<span></span>
</td>
<td class="nump">2,081<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">970<span></span>
</td>
<td class="nump">878<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Financial expenses (income), net</a></td>
<td class="nump">173<span></span>
</td>
<td class="num">(511)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitExpense', window );">Changes in accrued liability for employee rights upon retirement</a></td>
<td class="nump">32<span></span>
</td>
<td class="num">(50)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Changes in deferred income tax asset</a></td>
<td class="nump">236<span></span>
</td>
<td class="num">(3,092)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement', window );">Gain on amounts funded in respect of employee rights upon retirement</a></td>
<td class="num">(20)<span></span>
</td>
<td class="num">(49)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain on sale of fixed assets</a></td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_GainLossOnDebtConversion', window );">Gain on conversions of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(421)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt issuance costs and debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Decrease in contracts liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,178)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Decrease (increase) in accounts receivable-trade and other assets</a></td>
<td class="nump">3,069<span></span>
</td>
<td class="num">(4,188)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ChangeInOperatingLeaseRightOfUseAssets', window );">Changes in operating lease right of use assets, net</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Decrease (increase) in inventories</a></td>
<td class="nump">1,846<span></span>
</td>
<td class="num">(4,779)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Increase (decrease) in accounts payable and accruals</a></td>
<td class="num">(670)<span></span>
</td>
<td class="nump">3,820<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="nump">4,683<span></span>
</td>
<td class="num">(4,913)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_IncreaseDecreaseInBankDeposits', window );">Investment in bank deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,420)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ProceedsFromWithdrawalOfShortTermDeposits', window );">Short-term deposit withdrawal</a></td>
<td class="nump">20,420<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(857)<span></span>
</td>
<td class="num">(899)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property and equipment</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Amounts funded in respect of employee rights upon retirement, net</a></td>
<td class="num">(25)<span></span>
</td>
<td class="num">(50)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">19,541<span></span>
</td>
<td class="num">(16,369)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Payment for convertible notes redemption</a></td>
<td class="num">(20,420)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock under the Sales Agreement, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,954<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">712<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="num">(20,420)<span></span>
</td>
<td class="nump">24,666<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS</a></td>
<td class="num">(29)<span></span>
</td>
<td class="num">(87)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">NET INCREASE IN CASH AND CASH EQUIVALENTS</a></td>
<td class="nump">3,775<span></span>
</td>
<td class="nump">3,297<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</a></td>
<td class="nump">23,634<span></span>
</td>
<td class="nump">17,111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD</a></td>
<td class="nump">27,409<span></span>
</td>
<td class="nump">20,408<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchase of property and equipment</a></td>
<td class="nump">402<span></span>
</td>
<td class="nump">253<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right of use assets obtained in exchange for new operating lease liabilities</a></td>
<td class="nump">376<span></span>
</td>
<td class="nump">1,395<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Convertible notes conversions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,783<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTARY DISCLOSURE ON CASH FLOWS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">1,532<span></span>
</td>
<td class="nump">2,743<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_InterestReceivedNet', window );">Interest received</a></td>
<td class="nump">$ 1,481<span></span>
</td>
<td class="nump">$ 303<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ChangeInOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Change in Operating Lease Right Of use Assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ChangeInOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) on amounts funded in respect of employee rights upon retirement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_GainLossOnDebtConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of gain (loss) on conversion of convertible debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_GainLossOnDebtConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_IncreaseDecreaseInBankDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deposits held with banks.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_IncreaseDecreaseInBankDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_InterestReceivedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash received for interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_InterestReceivedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ProceedsFromWithdrawalOfShortTermDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash inflow from the withdrawal of short-term deposits during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ProceedsFromWithdrawalOfShortTermDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost (reversal of cost) for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46191744640720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;1&#160;- SIGNIFICANT ACCOUNTING POLICIES</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">a.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">General</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#8220;Company&#8221;) and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (collectively, the &#8220;Subsidiaries&#8221;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#8217;s proprietary ProCellEx<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> protein expression system (&#8220;ProCellEx&#8221;). To date, the Company has successfully developed two enzyme replacement therapies (ERTs); Elfabrio<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (pegunigalsidase alfa) for the treatment of adult patients with a confirmed diagnosis of Fabry disease and Elelyso<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (taliglucerase alfa) for the treatment of adult patients with Gaucher disease. Elfabrio, which the Company referred to as PRX-102 during its development stage, has been approved for marketing in the United States, the European Union, Great Britain, Switzerland, Peru and Israel. The Company has partnered with Chiesi Farmaceutici S.p.A. (&#8220;Chiesi&#8221;) for the development and commercialization of Elfabrio.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company has licensed the rights to commercialize Elelyso worldwide (other than Brazil) to Pfizer Inc. (&#8220;Pfizer&#8221;), and in Brazil to Funda&#231;&#227;o Oswaldo Cruz (&#8220;Fiocruz&#8221;), an arm of the Brazilian Ministry of Health (the &#8220;Brazilian MoH&#8221;). Elelyso is marketed as BioManguinhos alfataliglicerase in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company is committed to leveraging its track record of success as the Company progresses with the development of treatments for rare and orphan diseases. In addition, the Company continuously works on the further development of its ProCellEx technology and bioreactor system. Accordingly, the Company is turning its focus to new, early-stage product candidates that treat indications for which there are high unmet needs in terms of efficacy and safety, including renal diseases. Treatments of interest will address both genetic and non-genetic diseases. The Company intends to use its ProCellEx platform and PEGylization capabilities, as well as other modalities such as small molecules and antibodies, to take advantage of highly innovative opportunities. The Company is also exploring novel platform technologies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On May&#160;5, 2023, the European Commission (&#8220;EC&#8221;) announced that it had approved the Marketing Authorization Application (&#8220;MAA&#8221;) for Elfabrio and on May&#160;9, 2023, the U.S. Food and Drug Administration (&#8220;FDA&#8221;) announced that it had approved the Biologics License Application (&#8220;BLA&#8221;) for Elfabrio, each for adult patients with a confirmed diagnosis of Fabry disease. Both approvals cover the 1&#160;mg/kg every two weeks dosage. The European Medicines Agency (&#8220;EMA&#8221;) approval followed the February 2023 adoption of a positive opinion and recommendation of marketing authorization for Elfabrio by the EMA&#8217;s Committee for Medicinal Products for Human Use the (&#8220;CHMP&#8221;). Elfabrio was approved by the FDA with a boxed warning for hypersensitivity reactions/anaphylaxis, consistent with Enzyme Replacement Therapy (ERT) class labeling, and warnings/precautions providing guidance on the signs and symptoms of hypersensitivity and infusion-associated reactions seen in the clinical studies as well as treatments to manage such events should they occur. The warnings/precautions for membranoproliferative glomerulonephritis (MPGN) alert prescribers to the possibility of MPGN and provide guidance for appropriate patient management. Overall, the FDA review team concluded that in the context of Fabry disease as a rare, serious disease with limited therapeutic options that may not be suitable to all individual patients, the benefit-risk of Elfabrio is favorable for the treatment of adults with confirmed Fabry disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">The Company has entered into two exclusive global licensing and supply agreements for Elfabrio with Chiesi. On October&#160;19, 2017, Protalix Ltd., the Company&#8217;s wholly-owned subsidiary, entered into an Exclusive License and Supply Agreement with Chiesi (the &#8220;Chiesi Ex-US Agreement&#8221;) pursuant to which Chiesi was granted an exclusive license for all markets outside of the United States to commercialize Elfabrio. On July&#160;23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#8220;Chiesi US Agreement&#8221;), with respect to the commercialization of Elfabrio in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">Elfabrio was the subject of a phase&#160;III clinical program studying the drug as a treatment of patients with Fabry disease, a rare, genetic lysosomal disorder. The phase&#160;III clinical program included three separate studies, which are referred to as the <i style="font-style:italic;">BALANCE</i> study, the <i style="font-style:italic;">BRIDGE</i> study and the <i style="font-style:italic;">BRIGHT</i> study. The phase&#160;III clinical program analyzed two potential dosing regimens: 1&#160;mg/kg every two weeks and 2&#160;mg/kg every four weeks. In addition, the phase&#160;III clinical program included two extension studies in which subjects that participated in the Company&#8217;s phase&#160;I/II clinical trials and phase&#160;III clinical trials had the opportunity to enroll and continue to be treated with PRX-102. As of March&#160;1, 2023, sponsorship </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">of the two open label extension studies was transferred to Chiesi, which is now administering the extension studies. From time to time, and as Elfabrio is approved for marketing in different jurisdictions, participants switch out of the open label extension studies. Most of the participants transfer to a commercial setting and others withdraw for other reasons.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">The BLA for Elfabrio for the treatment of adult patients with Fabry disease was resubmitted to the FDA on November&#160;9, 2022. An initial BLA for Elfabrio was submitted to the FDA on May&#160;27, 2020 under the FDA&#8217;s Accelerated Approval pathway, but resulted in a Complete Response Letter (&#8220;CRL&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">The MAA was submitted to the EMA on February&#160;7, 2022, after the October&#160;8, 2021 meeting the Company held, together with Chiesi, with the Rapporteur and Co-Rapporteur of the EMA regarding PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">The FDA publicly released the internal review documents for Elfabrio (pegunigalsidase alfa-iwxj) injection BLA 761161. These documents provide previously unavailable additional information regarding the basis for the FDA&#8217;s May 2023 approval decision. In particular, the FDA determined that substantial evidence of effectiveness for Elfabrio in Fabry patients was established with one adequate and well-controlled study (Study PB-102-F01/02) with confirmatory evidence provided by the <i style="font-style:italic;">BALANCE</i> study (also referred to as Study PB-102-F20). The FDA review team also concluded that the <i style="font-style:italic;">BALANCE</i> study met its primary efficacy endpoint, which assessed the annualized rate of change in eGFR (estimated glomerular filtration rate) over 104 weeks. However, the FDA also determined that the results from the <i style="font-style:italic;">BALANCE</i> study did not support a non-inferiority claim to the comparator product due to the lack of data to support a non-inferiority margin.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company continuously evaluates potential strategic marketing partnerships as well as collaboration programs with biotechnology and pharmaceutical companies and academic research institutions. Except with respect to Elfabrio and Elelyso, the Company holds the worldwide commercialization rights to its other proprietary development drug candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">The Company&#8217;s product pipeline currently includes, among other candidates:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:11pt;margin-left:54pt;margin-top:0pt;text-indent:0pt;"><span style="display:inline-block;min-width:18pt;white-space:nowrap;">(1)</span>PRX-115, the Company&#8217;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#8211; a chemically modified enzyme to treat uncontrolled gout; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-top:0pt;text-indent:0pt;"><span style="display:inline-block;min-width:18pt;white-space:nowrap;">(2)</span>PRX-119, the Company&#8217;s plant cell-expressed PEGylated recombinant human DNase&#160;I product candidate being designed to elongate half-life in the circulation for NETs-related diseases.</div><div style="margin-top:11pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#8217;s ability to implement the necessary regulatory steps required to obtain such approvals, and demonstrate the safety and efficacy of its product candidates. The Company cannot reasonably predict the outcome of these activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In March 2024, the Company initiated a phase&#160;I First-in-Human clinical trial of PRX-115. This study included 64 adult male and female subjects in a dose escalation design with eight sequential dosing cohorts, each composed of eight subjects (six active and two placebo). As of September&#160;30, 2024, the data is locked and is currently being analyzed. The Company plans to announce the results at an upcoming scientific meeting. In addition, the Company has commenced preparations for a phase&#160;II clinical trial of PRX-115 which the Company expects will commence in the second half of 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On July&#160;2, 2021, the Company entered into an At The Market Offering Agreement (the &#8220;2021 Sales Agreement&#8221;) with H.C.&#160;Wainwright &amp; Co., LLC, as the Company&#8217;s sales agent (the &#8220;Agent&#8221;) which was amended on May&#160;2, 2022. Pursuant to the terms of the 2021 Sales Agreement, the Company was able to sell, from time to time through the Agent, shares of its common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;), having an aggregate offering price of up to $20.0&#160;million (the &#8220;ATM Shares&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">During the term of the 2021 Sales Agreement which ended during the quarter ended March&#160;31, 2023, the Company sold a total of 13,980,060 ATM Shares for total gross proceeds of approximately $20.0&#160;million thereby completing the ATM program under said agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On February&#160;27, 2023, the Company entered into an At The Market Offering Agreement (the &#8220;2023 Sales Agreement&#8221;) with the Agent. Pursuant to the terms of the 2023 Sales Agreement, the Company may sell, from time to time through the Agent, ATM Shares having an aggregate offering price of up to $20.0&#160;million. As of September&#160;30, 2024, shares of Common Stock for total gross proceeds of approximately $6.4&#160;million remain available to be sold under the 2023 Sales Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively, the &#8220;Chiesi Agreements&#8221;), Chiesi made an upfront payment to Protalix&#160;Ltd. of $25.0&#160;million in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&#160;Ltd. is entitled to additional payments of up to $25.0&#160;million in pegunigalsidase alfa development costs and to receive additional payments of up to $320.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&#160;Ltd. is entitled to payments of up to a maximum of $20.0&#160;million to cover development costs for pegunigalsidase alfa and to receive additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. To date, Protalix Ltd. has received the complete amount of development costs to which it is entitled under the Chiesi Agreements. In addition, following the approval of Elfabrio by the FDA, the Company received a milestone payment equal to $20.0&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">On May&#160;13, 2021, the Company signed a binding term sheet with Chiesi pursuant to which the Company and Chiesi amended the Chiesi Agreements in order to provide the Company with near-term capital. Chiesi agreed to make a $10.0&#160;million payment to the Company before the end of the second quarter of 2021 in exchange for a $25.0&#160;million reduction in a longer term regulatory milestone payment provided in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. The Company received the payment in June&#160;2021. The Company also agreed to negotiate certain manufacturing related matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Under the terms of both of the Chiesi Agreements, Protalix Ltd. is required to manufacture all of the Elfabrio drug substance needed under the agreements, subject to certain exceptions, and Chiesi will purchase Elfabrio drug product from Protalix, subject to certain terms and conditions. The consideration for Protalix Ltd. is based on the drug product supplied to Chiesi and the average selling price of the drug product in the relevant territory multiplied by tiered payments as described in the relevant agreement. Under the Chiesi Ex-US Agreement, the price payable to the Company for drug product supplied is based on a range of 15% to 35% of the average selling price of the drug product in the applicable territory, and under the Chiesi US Agreement, such price is based on a range of 15% to 40% of the average selling price of the drug product in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">On August&#160;29, 2022, the Company entered into a Fill/Finish Agreement (the &#8220;F/F Agreement&#8221;) and a Letter Agreement (the &#8220;Letter Agreement&#8221;), in each case with Chiesi. The Company agreed to supply Chiesi with drug substance for pegunigalsidase alfa in connection with the commercial fill/finish services. Under the F/F Agreement, and, following relevant technology and technical information transfer activities, Chiesi agreed, among other things, to provide the Company with commercial fill/finish services for pegunigalsidase alfa, including to support the anticipated global launch of pegunigalsidase alfa. The F/F Agreement shall continue in force until December&#160;31, 2025, unless terminated earlier in accordance with the terms of the F/F Agreement and the term may be extended by mutual agreement for an additional period of&#160;seven years&#160;upon mutual written agreement prior to expiration of the initial term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer in accordance with the exclusive license and supply agreement entered into between Protalix Ltd. and Pfizer, which is referred to herein as the Pfizer Agreement. In October 2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement, which is referred to herein as the Amended Pfizer Agreement, pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#8220;Brazil Agreement&#8221;) with Fiocruz for BioManguinhos alfataliglicerase. Fiocruz&#8217;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Because the Company&#8217;s operations are conducted in the State of Israel, the business and operations may be directly affected by economic, political, geopolitical and military conditions in Israel.&#160;In October 2023, Hamas terrorists infiltrated Israel&#8217;s southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Hamas also launched extensive rocket attacks on Israeli population and industrial centers located along Israel&#8217;s border with the Gaza Strip and in other areas within the State of Israel attacking a number of civilian and military targets. At the same time, clashes between Israel and Hezbollah in Lebanon have increased. In response, Israel&#8217;s security cabinet declared war against the Hamas and a military campaign against these terrorist organizations commenced in parallel to their continued rocket and terror attacks. Moreover, the attacks by Hamas and Hezbollah, and Israel&#8217;s defensive measures, may result in a greater regional conflict. Since the outbreak of the war, other regional actors, including Iran, have taken military action against Israel. It is currently not possible to predict the duration or severity of the ongoing conflict or its effects on the Company&#8217;s business, operations and financial conditions. The ongoing conflict is rapidly evolving and developing, and could disrupt certain of the Company&#8217;s business and operations, among others. The Company has elected to store manufactured drug substance in multiple locations, both within and outside of Israel, to mitigate the risk of loss due to the military operations. As of the issuance of these financial statements, the impact of the war has not had an adverse effect on the Company&#8217;s operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">The Company expects to continue to incur significant expenditures in the near future due to research and developments efforts with respect to the product candidates. The Company believes that its cash and cash equivalents as of September&#160;30, 2024 are sufficient to satisfy the Company&#8217;s capital needs for at least 12&#160;months from the date that these financial statements are issued.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">b.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">Basis of presentation</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States (&#8220;GAAP&#8221;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form&#160;10-K for the year ended December&#160;31, 2023, filed by the Company with the U.S.&#160;Securities and Exchange Commission (the &#8220;Commission&#8221;). The comparative balance sheet at December&#160;31, 2023 has been derived from the audited financial statements at that date. There have been no material changes in our significant accounting policies as described in our consolidated financial statements for the year ended December&#160;31, 2023, except for convertible notes, as described below.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">c.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Earnings (loss) per share</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt 0pt 0pt 54pt;">Basic earnings (loss) per share is calculated by dividing the net income (loss) by the weighted average number of shares of Common Stock outstanding during each period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt 0pt 0pt 54pt;"><span style="color:#212529;">Diluted earnings per share is calculated by dividing the net income by the weighted-average number of shares of Common Stock outstanding during each period increased to include the number of additional shares of Common Stock that would have been outstanding if the potentially dilutive shares had been issued.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 0pt 54pt;"><span style="color:#212529;">In computing diluted earnings per share, basic earnings per share are adjusted to take into account the potential dilution that could occur upon: (i)&#160;the exercise of options granted under employee stock compensation plans using the treasury </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 54pt;"><span style="color:#212529;">stock method; (ii)&#160;the exercise of warrants using the treasury stock method; and (iii)&#160;the conversion of the convertible notes using the &#8220;if-converted&#8221; method.</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">d.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">Convertible notes</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In September 2024, the Company repaid in full all of the outstanding principal and interest payable under its 7.50% Senior Secured Convertible Promissory Notes due September 2024 (the &#8220;2024 Notes&#8221;). The repayment of the convertible notes at maturity was financed entirely with available cash.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Prior to January&#160;1, 2024, the Company accounted for its outstanding convertible notes using the guidance set forth in the Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 815 which required that the Company determine whether the embedded conversion option must be separated from the other features of the applicable note instrument and accounted for separately. ASC 470-20 regarding debt with conversion and other options requires the issuer of a convertible debt instrument that may be settled in cash upon conversion to separately account for the liability (debt) and equity (conversion option) components of the instrument in a manner that reflects the issuer&#8217;s nonconvertible debt borrowing rate. <span style="background:#ffffff;">The Company&#8217;s outstanding 2024 Notes were accounted for as a liability (debt) and equity component (conversion option) as the convertible notes may be settled wholly or partly in cash, at the option of the Company, when converted.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="background:#ffffff;">In August 2020, the FASB issued </span>ASU 2020-06 &#8220;Debt &#8211; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#8211; Contracts in Entity&#8217;s Own Equity (Subtopic 815 &#8211; 40)&#8221; (&#8220;<span style="background:#ffffff;">ASU 2020-06&#8221;). </span>ASU&#160;2020-06 simplifies the accounting for convertible instruments by removing certain separation models in ASC 470-20, Debt&#8212;Debt with Conversion and Other Options, for convertible instruments. ASU&#160;2020-06 updates the guidance on certain embedded conversion features that are not required to be accounted for as derivatives under Topic 815, Derivatives and Hedging, or that do not result in substantial premiums accounted for as paid-in capital, such that those features are no longer required to be separated from the host contract. The convertible debt instruments will be accounted for as a single liability measured at amortized cost. This will also result in the interest expense recognized for convertible debt instruments to be typically closer to the coupon interest rate when applying the guidance in Topic 835. On January&#160;1, 2024, the Company adopted ASU 2020-06<span style="background:#ffffff;"> </span>using the modified retrospective method of adoption. Under this method, the Company applied the guidance to the 2024 Notes at the adoption date and was required to make an adjustment to January&#160;1, 2024, opening accumulated deficit balance and additional paid in capital. <span style="background:#ffffff;">The prior period consolidated financial statements have not been retrospectively adjusted and continue to be reported under the accounting standards in effect for those periods. </span>Under ASU 2020-06, the 2024 Notes (debt and conversion option) are accounted for as a liability. The impact to the Company's consolidated balance sheet as of December&#160;31, 2023 resulting from its adoption of ASU 2020-06 is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:62.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As Reported December 31, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:13.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Updated January 1, 2024</b></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Effect of Change</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Convertible notes</p></td><td style="vertical-align:bottom;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,251</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,420</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 169</p></td></tr><tr><td style="vertical-align:bottom;width:62.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Additional paid in capital</p></td><td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 415,045</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 414,652</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (393)</p></td></tr><tr><td style="vertical-align:bottom;width:62.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 381,549</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 381,325</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 224</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><b style="font-weight:bold;background:#ffffff;">e.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><b style="font-weight:bold;background:#ffffff;">New accounting </b><b style="font-weight:bold;">pronouncements</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><i style="font-style:italic;background:#ffffff;">Recently adopted accounting pronouncements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="background:#ffffff;">ASU 2020-06, which was issued by the FASB in August 2020 and adopted by the Company in January 2024, simplifies the accounting for certain financial instruments with characteristics of both liability and equity, including convertible instruments and contracts on an entity&#8217;s own equity. The amendments to this guidance are effective for fiscal years beginning after December&#160;15, 2023, and interim periods within those fiscal years. See Note&#160;1(d).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><i style="font-style:italic;background:#ffffff;">Recently issued accounting pronouncements, not yet adopted</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="background:#ffffff;">In December 2023, the FASB issued ASU 2023-09 &#8220;Income Taxes (Topic 740): Improvements to Income Tax Disclosures.&#8221; This guidance is intended to enhance the transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid both in the United States and in foreign jurisdictions. ASU 2023-09 is effective for fiscal years beginning after December&#160;15, 2024 on a prospective basis. Early adoption is permitted, with the option to apply the standard retrospectively. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="background:#ffffff;">In November 2023, the FASB issued ASU 2023-07 &#8220;Segment Reporting: Improvements to Reportable Segment Disclosures.&#8221; This guidance expands public entities&#8217; segment disclosures primarily by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment&#8217;s profit or loss and assets. Public entities with a single reportable segment are required to provide the new disclosures and all of the disclosures required under ASC 280. The guidance is effective for fiscal years beginning after December&#160;15, 2023, and interim periods within fiscal years beginning after December&#160;15, 2024, with early adoption permitted. The amendments are required to be applied retrospectively to all prior periods presented in an entity&#8217;s financial statements. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements and related disclosures</span><span style="font-family:'Palatino Linotype';background:#ffffff;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46191744633472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;2&#160;- INVENTORIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Inventories at September&#160;30, 2024 and December&#160;31, 2023 consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,242</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,176</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Work in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,251</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,055</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 706</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,814</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17,199</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,045</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46191739450016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE MEASUREMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENT</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;3&#160;&#8211; FAIR VALUE MEASUREMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The Company discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level&#160;1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level&#160;2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level&#160;3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The fair value of the financial instruments included in the working capital of the Company is identical or close to their carrying value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46191744706272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract', window );"><strong>REVENUES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_RevenueDisclosureTextBlock', window );">REVENUES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;background:#ffffff;">NOTE&#160;4&#160;&#8211; REVENUES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="background:#ffffff;">The following table summarizes the Company&#8217;s disaggregation of revenues:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:39.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:39.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Pfizer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,431</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,972</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,430</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,304</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Brazil</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,314</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,120</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,048</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,320</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Chiesi</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,075</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,217</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,361</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,544</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total revenues from selling goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 34,820</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30,309</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,839</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,168</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues from license and R&amp;D services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 361</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24,699</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 120</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 177</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="color:#212529;font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_RevenueDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure pertaining to revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_RevenueDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionAndDeferredRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46191848678896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCK TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCK TRANSACTIONS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 5 &#8211; STOCK TRANSACTIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">On January&#160;15, 2024, the Company granted, with the approval of the Company&#8217;s compensation committee, 100,000 shares of restricted Common Stock, in the aggregate, to certain of the Company&#8217;s employees under the Company&#8217;s Amended and Restated 2006 Employee Stock Incentive Plan, as amended (the &#8220;Plan&#8221;). All such shares of restricted Common Stock vest over a three-year period in 12&#160;equal quarterly increments. The Company estimated the fair value of the restricted stock on the date of grant to be approximately $0.2&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">On April&#160;1, 2024, the Company granted, with the approval of the Company&#8217;s compensation committee, 263,960 shares of fully-vested restricted Common Stock to the Company&#8217;s President and Chief Executive Officer under the Plan instead of a cash bonus. The Company estimated the fair value of the restricted stock on the date of grant to be approximately $0.3&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">On July&#160;2, 2024, the Company granted, with the approval of the Company&#8217;s compensation committee,&#160;250,000&#160;shares of restricted Common Stock to its new Vice President, Research and Development, under the Plan. The&#160;<span style="-sec-ix-hidden:Hidden_Wv5n4SFqLUalXo86fgRQdg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">first third</span></span>&#160;of such shares of restricted Common Stock vest on the&#160;<span style="-sec-ix-hidden:Hidden_HDd_9eUnQUuEPgjlLh4OWA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">first</span></span>&#160;anniversary of the date of grant and the remaining&#160;<span style="-sec-ix-hidden:Hidden_UMFZm-Gn_k61nFAdjEsS9w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two-thirds</span></span>&#160;of the shares vest over the subsequent&#160;two-year&#160;period in&#160;eight&#160;equal quarterly increments. The Company estimated the fair value of the restricted stock on the date of grant to be approximately $0.3&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">On September&#160;23, 2024, the Company granted, with the approval of the Company&#8217;s compensation committee, 90,909 shares of fully-vested restricted Common Stock, in the aggregate, to its Sr.&#160;Vice President and Chief Financial Officer under the Plan. The Company estimated the fair value of the restricted stock on the date of grant to be approximately $0.1&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">On September&#160;23, 2024, the Company granted, with the approval of the Company&#8217;s compensation committee, 10-year options to purchase 1,015,725 shares of Common Stock, in the aggregate, to certain of the Company&#8217;s officers and other employees under the Plan. The options have an exercise price equal to $1.10 per share and vest over a three-year period in 12&#160;equal quarterly increments. Vesting of the options granted to executive officers is subject to automatic acceleration in full upon a Corporate Transaction or a Change in Control, as those terms are defined in the Plan, and are subject to certain other terms and conditions. The Company estimated the aggregate fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately $0.8&#160;million.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46191744716592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER SHARE<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>EARNINGS (LOSS) PER SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">EARNINGS (LOSS) PER SHARE</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 6 &#8211; EARNINGS (LOSS) PER SHARE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="color:#212529;">Basic and diluted net earnings (loss) per share attributable to common stockholders were calculated as follows:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.17%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:28.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:29.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(In&#160;thousands,&#160;except&#160;share&#160;data)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Numerator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,562)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,356</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,236</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,852)</p></td></tr><tr><td style="vertical-align:bottom;width:40.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Add:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Financial expenses of 2024 Notes*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,610)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (503)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,766)</p></td></tr><tr><td style="vertical-align:bottom;width:40.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net income (loss) for diluted calculation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,562)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,746</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,733</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,618)</p></td></tr><tr><td style="vertical-align:bottom;width:40.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Denominator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average shares of Common Stock outstanding for basic calculation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 73,301,091</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 65,811,506</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 73,549,745</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 72,281,681</p></td></tr><tr><td style="vertical-align:bottom;width:40.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average dilutive effect of 2024 Notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,981,660</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,667,323</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,500,998</p></td></tr><tr><td style="vertical-align:bottom;width:40.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average dilutive effect of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,247,115</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td></tr><tr><td style="vertical-align:bottom;width:40.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average shares of Common Stock outstanding for diluted calculation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 73,301,091</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 81,040,281</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 81,217,068</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 83,782,679</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 54pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 10pt 54pt;">* Financial expenses on 2024 Notes consists of add back of financial expense incurred during the period and inclusion of make-whole interest payments that will be incurred upon conversion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 10pt 36pt;"><span style="font-size:10pt;">Diluted earnings (loss) per share do not include </span><span style="font-size:10pt;">30,515,287</span> <span style="font-size:10pt;">shares of Common Stock underlying outstanding stock options, warrants and the 2024 Notes for the nine months ended September&#160;30, 2024, and </span><span style="font-size:10pt;">20,173,438</span><span style="font-size:10pt;"> shares of Common Stock underlying outstanding stock options and warrants for the three months ended September&#160;30, 2024, because the effect would be anti-dilutive.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Diluted earnings (loss) per share do not include 19,429,910 and 18,399,260 shares of Common Stock underlying outstanding stock options and warrants of the Company for the three and nine months ended September&#160;30, 2023, respectively, because the effect would be anti-dilutive.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46191843443952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAXES ON INCOME<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>TAXES ON INCOME</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">TAXES ON INCOME</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 7 &#8211; TAXES ON INCOME</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="background:#ffffff;">The following table summarizes the Company&#8217;s taxes on income:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current taxes on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 164</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,728</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 164</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 95</p></td></tr><tr><td style="vertical-align:bottom;width:40.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred taxes on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 236</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,092)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 443</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38</p></td></tr><tr><td style="vertical-align:bottom;width:40.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total taxes on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 636</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 607</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 133</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The Company had an effective tax rate of (13)% for the nine months ended September&#160;30, 2024, compared to an effective tax rate of 4% for the nine months ended September&#160;30, 2023. For the nine months ended September&#160;30, 2024, the difference between the Company&#8217;s effective tax rate and the U.S.&#160;federal statutory rate of 21% was the result of forecasted profits derived primarily from U.S.&#160;taxable GILTI income mainly due to Section&#160;174 of the U.S.&#160;Tax Cuts and Jobs Act, which was enacted in December 2017 (the &#8220;TCJA&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="color:#212529;background:#ffffff;">In the second quarter ended June&#160;30, 2023, following the regulatory approvals for Elfabrio in May 2023, the receipt of the </span><span style="color:#212529;background:#ffffff;">$20.0</span><span style="color:#212529;background:#ffffff;">&#160;million milestone payment and the launch of Elfabrio in the United States, the Company released valuation allowance previously recorded on deferred tax assets in respect of its net operating losses (&#8220;NOLs&#8221;) in the United States resulting in a net tax benefit of </span><span style="color:#212529;background:#ffffff;">$3.1</span><span style="color:#212529;background:#ffffff;">&#160;million. The Company concluded that, based upon the preponderance of positive evidence over negative evidence and the anticipated ability to use the deferred tax assets, it was more likely than not that these deferred tax </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="color:#212529;background:#ffffff;">assets would be realizable due to forecasted profits. The Company considered the following: (i)&#160;cumulative profits for tax over the previous 12 quarters in its U.S. operations; (ii)&#160;the impact of Section&#160;174 of the TCJA which requires the Company to capitalize and amortize its research and development expenses over 15 years; and (iii) its forecasted profits in the United States following the regulatory approvals of Elfabrio.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46191739447488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SupplementalInformationAbstract', window );"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock', window );">SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 8 &#8211; </b><b style="font-weight:bold;background:#ffffff;">SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><b style="font-weight:bold;">Balance sheets:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accounts payable and accruals &#8211; other:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payroll and related expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,251</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,437</p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 511</p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Provision for vacation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,713</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,605</p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,342</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,009</p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Royalties payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 571</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 637</p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income tax payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,040</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,876</p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Sales reserve</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,258</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,861</p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property and equipment suppliers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 402</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 614</p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,577</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,550</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SupplementalInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SupplementalInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalFinancialInformationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46191744727456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 9 &#8211; SUBSEQUENT EVENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">Since the end of the quarter ended September 30, 2024, the Company collected approximately $3.9&#160;million from sales to Chiesi<span style="background:#ffffff;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46191739428816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="nump">$ 3,236<span></span>
</td>
<td class="num">$ (1,852)<span></span>
</td>
<td class="num">$ (3,562)<span></span>
</td>
<td class="nump">$ 14,356<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46191744641760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46191739429104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_NatureOfOperationsPolicyTextBlock', window );">General</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">a.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">General</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#8220;Company&#8221;) and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (collectively, the &#8220;Subsidiaries&#8221;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#8217;s proprietary ProCellEx<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> protein expression system (&#8220;ProCellEx&#8221;). To date, the Company has successfully developed two enzyme replacement therapies (ERTs); Elfabrio<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (pegunigalsidase alfa) for the treatment of adult patients with a confirmed diagnosis of Fabry disease and Elelyso<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (taliglucerase alfa) for the treatment of adult patients with Gaucher disease. Elfabrio, which the Company referred to as PRX-102 during its development stage, has been approved for marketing in the United States, the European Union, Great Britain, Switzerland, Peru and Israel. The Company has partnered with Chiesi Farmaceutici S.p.A. (&#8220;Chiesi&#8221;) for the development and commercialization of Elfabrio.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company has licensed the rights to commercialize Elelyso worldwide (other than Brazil) to Pfizer Inc. (&#8220;Pfizer&#8221;), and in Brazil to Funda&#231;&#227;o Oswaldo Cruz (&#8220;Fiocruz&#8221;), an arm of the Brazilian Ministry of Health (the &#8220;Brazilian MoH&#8221;). Elelyso is marketed as BioManguinhos alfataliglicerase in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company is committed to leveraging its track record of success as the Company progresses with the development of treatments for rare and orphan diseases. In addition, the Company continuously works on the further development of its ProCellEx technology and bioreactor system. Accordingly, the Company is turning its focus to new, early-stage product candidates that treat indications for which there are high unmet needs in terms of efficacy and safety, including renal diseases. Treatments of interest will address both genetic and non-genetic diseases. The Company intends to use its ProCellEx platform and PEGylization capabilities, as well as other modalities such as small molecules and antibodies, to take advantage of highly innovative opportunities. The Company is also exploring novel platform technologies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On May&#160;5, 2023, the European Commission (&#8220;EC&#8221;) announced that it had approved the Marketing Authorization Application (&#8220;MAA&#8221;) for Elfabrio and on May&#160;9, 2023, the U.S. Food and Drug Administration (&#8220;FDA&#8221;) announced that it had approved the Biologics License Application (&#8220;BLA&#8221;) for Elfabrio, each for adult patients with a confirmed diagnosis of Fabry disease. Both approvals cover the 1&#160;mg/kg every two weeks dosage. The European Medicines Agency (&#8220;EMA&#8221;) approval followed the February 2023 adoption of a positive opinion and recommendation of marketing authorization for Elfabrio by the EMA&#8217;s Committee for Medicinal Products for Human Use the (&#8220;CHMP&#8221;). Elfabrio was approved by the FDA with a boxed warning for hypersensitivity reactions/anaphylaxis, consistent with Enzyme Replacement Therapy (ERT) class labeling, and warnings/precautions providing guidance on the signs and symptoms of hypersensitivity and infusion-associated reactions seen in the clinical studies as well as treatments to manage such events should they occur. The warnings/precautions for membranoproliferative glomerulonephritis (MPGN) alert prescribers to the possibility of MPGN and provide guidance for appropriate patient management. Overall, the FDA review team concluded that in the context of Fabry disease as a rare, serious disease with limited therapeutic options that may not be suitable to all individual patients, the benefit-risk of Elfabrio is favorable for the treatment of adults with confirmed Fabry disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">The Company has entered into two exclusive global licensing and supply agreements for Elfabrio with Chiesi. On October&#160;19, 2017, Protalix Ltd., the Company&#8217;s wholly-owned subsidiary, entered into an Exclusive License and Supply Agreement with Chiesi (the &#8220;Chiesi Ex-US Agreement&#8221;) pursuant to which Chiesi was granted an exclusive license for all markets outside of the United States to commercialize Elfabrio. On July&#160;23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#8220;Chiesi US Agreement&#8221;), with respect to the commercialization of Elfabrio in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">Elfabrio was the subject of a phase&#160;III clinical program studying the drug as a treatment of patients with Fabry disease, a rare, genetic lysosomal disorder. The phase&#160;III clinical program included three separate studies, which are referred to as the <i style="font-style:italic;">BALANCE</i> study, the <i style="font-style:italic;">BRIDGE</i> study and the <i style="font-style:italic;">BRIGHT</i> study. The phase&#160;III clinical program analyzed two potential dosing regimens: 1&#160;mg/kg every two weeks and 2&#160;mg/kg every four weeks. In addition, the phase&#160;III clinical program included two extension studies in which subjects that participated in the Company&#8217;s phase&#160;I/II clinical trials and phase&#160;III clinical trials had the opportunity to enroll and continue to be treated with PRX-102. As of March&#160;1, 2023, sponsorship </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">of the two open label extension studies was transferred to Chiesi, which is now administering the extension studies. From time to time, and as Elfabrio is approved for marketing in different jurisdictions, participants switch out of the open label extension studies. Most of the participants transfer to a commercial setting and others withdraw for other reasons.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">The BLA for Elfabrio for the treatment of adult patients with Fabry disease was resubmitted to the FDA on November&#160;9, 2022. An initial BLA for Elfabrio was submitted to the FDA on May&#160;27, 2020 under the FDA&#8217;s Accelerated Approval pathway, but resulted in a Complete Response Letter (&#8220;CRL&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">The MAA was submitted to the EMA on February&#160;7, 2022, after the October&#160;8, 2021 meeting the Company held, together with Chiesi, with the Rapporteur and Co-Rapporteur of the EMA regarding PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">The FDA publicly released the internal review documents for Elfabrio (pegunigalsidase alfa-iwxj) injection BLA 761161. These documents provide previously unavailable additional information regarding the basis for the FDA&#8217;s May 2023 approval decision. In particular, the FDA determined that substantial evidence of effectiveness for Elfabrio in Fabry patients was established with one adequate and well-controlled study (Study PB-102-F01/02) with confirmatory evidence provided by the <i style="font-style:italic;">BALANCE</i> study (also referred to as Study PB-102-F20). The FDA review team also concluded that the <i style="font-style:italic;">BALANCE</i> study met its primary efficacy endpoint, which assessed the annualized rate of change in eGFR (estimated glomerular filtration rate) over 104 weeks. However, the FDA also determined that the results from the <i style="font-style:italic;">BALANCE</i> study did not support a non-inferiority claim to the comparator product due to the lack of data to support a non-inferiority margin.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company continuously evaluates potential strategic marketing partnerships as well as collaboration programs with biotechnology and pharmaceutical companies and academic research institutions. Except with respect to Elfabrio and Elelyso, the Company holds the worldwide commercialization rights to its other proprietary development drug candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">The Company&#8217;s product pipeline currently includes, among other candidates:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:11pt;margin-left:54pt;margin-top:0pt;text-indent:0pt;"><span style="display:inline-block;min-width:18pt;white-space:nowrap;">(1)</span>PRX-115, the Company&#8217;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#8211; a chemically modified enzyme to treat uncontrolled gout; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-top:0pt;text-indent:0pt;"><span style="display:inline-block;min-width:18pt;white-space:nowrap;">(2)</span>PRX-119, the Company&#8217;s plant cell-expressed PEGylated recombinant human DNase&#160;I product candidate being designed to elongate half-life in the circulation for NETs-related diseases.</div><div style="margin-top:11pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#8217;s ability to implement the necessary regulatory steps required to obtain such approvals, and demonstrate the safety and efficacy of its product candidates. The Company cannot reasonably predict the outcome of these activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In March 2024, the Company initiated a phase&#160;I First-in-Human clinical trial of PRX-115. This study included 64 adult male and female subjects in a dose escalation design with eight sequential dosing cohorts, each composed of eight subjects (six active and two placebo). As of September&#160;30, 2024, the data is locked and is currently being analyzed. The Company plans to announce the results at an upcoming scientific meeting. In addition, the Company has commenced preparations for a phase&#160;II clinical trial of PRX-115 which the Company expects will commence in the second half of 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On July&#160;2, 2021, the Company entered into an At The Market Offering Agreement (the &#8220;2021 Sales Agreement&#8221;) with H.C.&#160;Wainwright &amp; Co., LLC, as the Company&#8217;s sales agent (the &#8220;Agent&#8221;) which was amended on May&#160;2, 2022. Pursuant to the terms of the 2021 Sales Agreement, the Company was able to sell, from time to time through the Agent, shares of its common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;), having an aggregate offering price of up to $20.0&#160;million (the &#8220;ATM Shares&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">During the term of the 2021 Sales Agreement which ended during the quarter ended March&#160;31, 2023, the Company sold a total of 13,980,060 ATM Shares for total gross proceeds of approximately $20.0&#160;million thereby completing the ATM program under said agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On February&#160;27, 2023, the Company entered into an At The Market Offering Agreement (the &#8220;2023 Sales Agreement&#8221;) with the Agent. Pursuant to the terms of the 2023 Sales Agreement, the Company may sell, from time to time through the Agent, ATM Shares having an aggregate offering price of up to $20.0&#160;million. As of September&#160;30, 2024, shares of Common Stock for total gross proceeds of approximately $6.4&#160;million remain available to be sold under the 2023 Sales Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively, the &#8220;Chiesi Agreements&#8221;), Chiesi made an upfront payment to Protalix&#160;Ltd. of $25.0&#160;million in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&#160;Ltd. is entitled to additional payments of up to $25.0&#160;million in pegunigalsidase alfa development costs and to receive additional payments of up to $320.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&#160;Ltd. is entitled to payments of up to a maximum of $20.0&#160;million to cover development costs for pegunigalsidase alfa and to receive additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. To date, Protalix Ltd. has received the complete amount of development costs to which it is entitled under the Chiesi Agreements. In addition, following the approval of Elfabrio by the FDA, the Company received a milestone payment equal to $20.0&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">On May&#160;13, 2021, the Company signed a binding term sheet with Chiesi pursuant to which the Company and Chiesi amended the Chiesi Agreements in order to provide the Company with near-term capital. Chiesi agreed to make a $10.0&#160;million payment to the Company before the end of the second quarter of 2021 in exchange for a $25.0&#160;million reduction in a longer term regulatory milestone payment provided in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. The Company received the payment in June&#160;2021. The Company also agreed to negotiate certain manufacturing related matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Under the terms of both of the Chiesi Agreements, Protalix Ltd. is required to manufacture all of the Elfabrio drug substance needed under the agreements, subject to certain exceptions, and Chiesi will purchase Elfabrio drug product from Protalix, subject to certain terms and conditions. The consideration for Protalix Ltd. is based on the drug product supplied to Chiesi and the average selling price of the drug product in the relevant territory multiplied by tiered payments as described in the relevant agreement. Under the Chiesi Ex-US Agreement, the price payable to the Company for drug product supplied is based on a range of 15% to 35% of the average selling price of the drug product in the applicable territory, and under the Chiesi US Agreement, such price is based on a range of 15% to 40% of the average selling price of the drug product in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">On August&#160;29, 2022, the Company entered into a Fill/Finish Agreement (the &#8220;F/F Agreement&#8221;) and a Letter Agreement (the &#8220;Letter Agreement&#8221;), in each case with Chiesi. The Company agreed to supply Chiesi with drug substance for pegunigalsidase alfa in connection with the commercial fill/finish services. Under the F/F Agreement, and, following relevant technology and technical information transfer activities, Chiesi agreed, among other things, to provide the Company with commercial fill/finish services for pegunigalsidase alfa, including to support the anticipated global launch of pegunigalsidase alfa. The F/F Agreement shall continue in force until December&#160;31, 2025, unless terminated earlier in accordance with the terms of the F/F Agreement and the term may be extended by mutual agreement for an additional period of&#160;seven years&#160;upon mutual written agreement prior to expiration of the initial term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer in accordance with the exclusive license and supply agreement entered into between Protalix Ltd. and Pfizer, which is referred to herein as the Pfizer Agreement. In October 2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement, which is referred to herein as the Amended Pfizer Agreement, pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#8220;Brazil Agreement&#8221;) with Fiocruz for BioManguinhos alfataliglicerase. Fiocruz&#8217;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Because the Company&#8217;s operations are conducted in the State of Israel, the business and operations may be directly affected by economic, political, geopolitical and military conditions in Israel.&#160;In October 2023, Hamas terrorists infiltrated Israel&#8217;s southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Hamas also launched extensive rocket attacks on Israeli population and industrial centers located along Israel&#8217;s border with the Gaza Strip and in other areas within the State of Israel attacking a number of civilian and military targets. At the same time, clashes between Israel and Hezbollah in Lebanon have increased. In response, Israel&#8217;s security cabinet declared war against the Hamas and a military campaign against these terrorist organizations commenced in parallel to their continued rocket and terror attacks. Moreover, the attacks by Hamas and Hezbollah, and Israel&#8217;s defensive measures, may result in a greater regional conflict. Since the outbreak of the war, other regional actors, including Iran, have taken military action against Israel. It is currently not possible to predict the duration or severity of the ongoing conflict or its effects on the Company&#8217;s business, operations and financial conditions. The ongoing conflict is rapidly evolving and developing, and could disrupt certain of the Company&#8217;s business and operations, among others. The Company has elected to store manufactured drug substance in multiple locations, both within and outside of Israel, to mitigate the risk of loss due to the military operations. As of the issuance of these financial statements, the impact of the war has not had an adverse effect on the Company&#8217;s operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">The Company expects to continue to incur significant expenditures in the near future due to research and developments efforts with respect to the product candidates. The Company believes that its cash and cash equivalents as of September&#160;30, 2024 are sufficient to satisfy the Company&#8217;s capital needs for at least 12&#160;months from the date that these financial statements are issued.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">b.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">Basis of presentation</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States (&#8220;GAAP&#8221;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form&#160;10-K for the year ended December&#160;31, 2023, filed by the Company with the U.S.&#160;Securities and Exchange Commission (the &#8220;Commission&#8221;). The comparative balance sheet at December&#160;31, 2023 has been derived from the audited financial statements at that date. There have been no material changes in our significant accounting policies as described in our consolidated financial statements for the year ended December&#160;31, 2023, except for convertible notes, as described below.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings (Loss) per share</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">c.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Earnings (loss) per share</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt 0pt 0pt 54pt;">Basic earnings (loss) per share is calculated by dividing the net income (loss) by the weighted average number of shares of Common Stock outstanding during each period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt 0pt 0pt 54pt;"><span style="color:#212529;">Diluted earnings per share is calculated by dividing the net income by the weighted-average number of shares of Common Stock outstanding during each period increased to include the number of additional shares of Common Stock that would have been outstanding if the potentially dilutive shares had been issued.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 0pt 54pt;"><span style="color:#212529;">In computing diluted earnings per share, basic earnings per share are adjusted to take into account the potential dilution that could occur upon: (i)&#160;the exercise of options granted under employee stock compensation plans using the treasury </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 54pt;"><span style="color:#212529;">stock method; (ii)&#160;the exercise of warrants using the treasury stock method; and (iii)&#160;the conversion of the convertible notes using the &#8220;if-converted&#8221; method.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Convertible notes</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">d.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">Convertible notes</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In September 2024, the Company repaid in full all of the outstanding principal and interest payable under its 7.50% Senior Secured Convertible Promissory Notes due September 2024 (the &#8220;2024 Notes&#8221;). The repayment of the convertible notes at maturity was financed entirely with available cash.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Prior to January&#160;1, 2024, the Company accounted for its outstanding convertible notes using the guidance set forth in the Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 815 which required that the Company determine whether the embedded conversion option must be separated from the other features of the applicable note instrument and accounted for separately. ASC 470-20 regarding debt with conversion and other options requires the issuer of a convertible debt instrument that may be settled in cash upon conversion to separately account for the liability (debt) and equity (conversion option) components of the instrument in a manner that reflects the issuer&#8217;s nonconvertible debt borrowing rate. <span style="background:#ffffff;">The Company&#8217;s outstanding 2024 Notes were accounted for as a liability (debt) and equity component (conversion option) as the convertible notes may be settled wholly or partly in cash, at the option of the Company, when converted.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="background:#ffffff;">In August 2020, the FASB issued </span>ASU 2020-06 &#8220;Debt &#8211; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#8211; Contracts in Entity&#8217;s Own Equity (Subtopic 815 &#8211; 40)&#8221; (&#8220;<span style="background:#ffffff;">ASU 2020-06&#8221;). </span>ASU&#160;2020-06 simplifies the accounting for convertible instruments by removing certain separation models in ASC 470-20, Debt&#8212;Debt with Conversion and Other Options, for convertible instruments. ASU&#160;2020-06 updates the guidance on certain embedded conversion features that are not required to be accounted for as derivatives under Topic 815, Derivatives and Hedging, or that do not result in substantial premiums accounted for as paid-in capital, such that those features are no longer required to be separated from the host contract. The convertible debt instruments will be accounted for as a single liability measured at amortized cost. This will also result in the interest expense recognized for convertible debt instruments to be typically closer to the coupon interest rate when applying the guidance in Topic 835. On January&#160;1, 2024, the Company adopted ASU 2020-06<span style="background:#ffffff;"> </span>using the modified retrospective method of adoption. Under this method, the Company applied the guidance to the 2024 Notes at the adoption date and was required to make an adjustment to January&#160;1, 2024, opening accumulated deficit balance and additional paid in capital. <span style="background:#ffffff;">The prior period consolidated financial statements have not been retrospectively adjusted and continue to be reported under the accounting standards in effect for those periods. </span>Under ASU 2020-06, the 2024 Notes (debt and conversion option) are accounted for as a liability. The impact to the Company's consolidated balance sheet as of December&#160;31, 2023 resulting from its adoption of ASU 2020-06 is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:62.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As Reported December 31, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:13.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Updated January 1, 2024</b></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Effect of Change</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Convertible notes</p></td><td style="vertical-align:bottom;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,251</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,420</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 169</p></td></tr><tr><td style="vertical-align:bottom;width:62.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Additional paid in capital</p></td><td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 415,045</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 414,652</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (393)</p></td></tr><tr><td style="vertical-align:bottom;width:62.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 381,549</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 381,325</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 224</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New accounting pronouncements</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><b style="font-weight:bold;background:#ffffff;">e.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><b style="font-weight:bold;background:#ffffff;">New accounting </b><b style="font-weight:bold;">pronouncements</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><i style="font-style:italic;background:#ffffff;">Recently adopted accounting pronouncements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="background:#ffffff;">ASU 2020-06, which was issued by the FASB in August 2020 and adopted by the Company in January 2024, simplifies the accounting for certain financial instruments with characteristics of both liability and equity, including convertible instruments and contracts on an entity&#8217;s own equity. The amendments to this guidance are effective for fiscal years beginning after December&#160;15, 2023, and interim periods within those fiscal years. See Note&#160;1(d).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><i style="font-style:italic;background:#ffffff;">Recently issued accounting pronouncements, not yet adopted</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="background:#ffffff;">In December 2023, the FASB issued ASU 2023-09 &#8220;Income Taxes (Topic 740): Improvements to Income Tax Disclosures.&#8221; This guidance is intended to enhance the transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid both in the United States and in foreign jurisdictions. ASU 2023-09 is effective for fiscal years beginning after December&#160;15, 2024 on a prospective basis. Early adoption is permitted, with the option to apply the standard retrospectively. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="background:#ffffff;">In November 2023, the FASB issued ASU 2023-07 &#8220;Segment Reporting: Improvements to Reportable Segment Disclosures.&#8221; This guidance expands public entities&#8217; segment disclosures primarily by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment&#8217;s profit or loss and assets. Public entities with a single reportable segment are required to provide the new disclosures and all of the disclosures required under ASC 280. The guidance is effective for fiscal years beginning after December&#160;15, 2023, and interim periods within fiscal years beginning after December&#160;15, 2024, with early adoption permitted. The amendments are required to be applied retrospectively to all prior periods presented in an entity&#8217;s financial statements. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements and related disclosures</span><span style="font-family:'Palatino Linotype';background:#ffffff;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_NatureOfOperationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nature Of Operations Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_NatureOfOperationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46191744677200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Schedule of ASU 2020-06 on the condensed consolidated balance sheet</a></td>
<td class="text">The impact to the Company's consolidated balance sheet as of December&#160;31, 2023 resulting from its adoption of ASU 2020-06 is as follows:<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:62.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As Reported December 31, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:13.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Updated January 1, 2024</b></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Effect of Change</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Convertible notes</p></td><td style="vertical-align:bottom;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,251</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,420</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 169</p></td></tr><tr><td style="vertical-align:bottom;width:62.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Additional paid in capital</p></td><td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 415,045</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 414,652</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (393)</p></td></tr><tr><td style="vertical-align:bottom;width:62.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 381,549</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 381,325</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 224</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482989/270-10-45-12<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482989/270-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46191738739680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of inventory</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Inventories at September&#160;30, 2024 and December&#160;31, 2023 consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,242</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,176</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Work in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,251</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,055</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 706</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,814</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17,199</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,045</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46191739473280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract', window );"><strong>REVENUES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Company's disaggregation of revenues</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="background:#ffffff;">The following table summarizes the Company&#8217;s disaggregation of revenues:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:39.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:39.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Pfizer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,431</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,972</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,430</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,304</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Brazil</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,314</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,120</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,048</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,320</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Chiesi</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,075</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,217</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,361</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,544</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total revenues from selling goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 34,820</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30,309</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,839</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,168</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues from license and R&amp;D services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 361</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24,699</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 120</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 177</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="color:#212529;font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionAndDeferredRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46191739485136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>EARNINGS (LOSS) PER SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of basic and diluted net earnings (loss) per share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="color:#212529;">Basic and diluted net earnings (loss) per share attributable to common stockholders were calculated as follows:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.17%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:28.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:29.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(In&#160;thousands,&#160;except&#160;share&#160;data)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Numerator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,562)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,356</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,236</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,852)</p></td></tr><tr><td style="vertical-align:bottom;width:40.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Add:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Financial expenses of 2024 Notes*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,610)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (503)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,766)</p></td></tr><tr><td style="vertical-align:bottom;width:40.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net income (loss) for diluted calculation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,562)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,746</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,733</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,618)</p></td></tr><tr><td style="vertical-align:bottom;width:40.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Denominator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average shares of Common Stock outstanding for basic calculation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 73,301,091</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 65,811,506</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 73,549,745</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 72,281,681</p></td></tr><tr><td style="vertical-align:bottom;width:40.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average dilutive effect of 2024 Notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,981,660</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,667,323</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,500,998</p></td></tr><tr><td style="vertical-align:bottom;width:40.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average dilutive effect of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,247,115</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td></tr><tr><td style="vertical-align:bottom;width:40.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average shares of Common Stock outstanding for diluted calculation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 73,301,091</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 81,040,281</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 81,217,068</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 83,782,679</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 54pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 10pt 54pt;">* Financial expenses on 2024 Notes consists of add back of financial expense incurred during the period and inclusion of make-whole interest payments that will be incurred upon conversion.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46191738952560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAXES ON INCOME (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>TAXES ON INCOME</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of taxes on income</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="background:#ffffff;">The following table summarizes the Company&#8217;s taxes on income:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current taxes on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 164</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,728</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 164</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 95</p></td></tr><tr><td style="vertical-align:bottom;width:40.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred taxes on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 236</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,092)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 443</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38</p></td></tr><tr><td style="vertical-align:bottom;width:40.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total taxes on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 636</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 607</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 133</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46191744736192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SupplementalInformationAbstract', window );"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SupplementaryBalanceSheetsInformationTableTextBlock', window );">Schedule of supplemental information of balance sheets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accounts payable and accruals &#8211; other:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payroll and related expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,251</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,437</p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 511</p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Provision for vacation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,713</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,605</p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,342</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,009</p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Royalties payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 571</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 637</p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income tax payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,040</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,876</p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Sales reserve</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,258</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,861</p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property and equipment suppliers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 402</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 614</p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,577</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,550</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SupplementalInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SupplementalInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SupplementaryBalanceSheetsInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure for supplemental balance sheets information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SupplementaryBalanceSheetsInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46191733720560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 29, 2022</div></th>
<th class="th">
<div>May 13, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 23, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 19, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Oct. 31, 2015</div></th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>agreement </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Feb. 27, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 02, 2021 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_NumberOfGlobalLicensingAndSupplyAgreements', window );">Number of global licensing and supply agreements | agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Stock issuance proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=plx_AtMarketEquityOfferingMember', window );">ATM Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,980,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SaleOfStockMaximumOfferingPrice', window );">Sale of stock, maximum offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Stock issuance proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">2024 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember', window );">Amended Pfizer Agreement | Protalix Bio Therapeutics Incorporation | Brazil</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage', window );">Collaborative arrangement revenues and expenses sharing percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember', window );">Chiesi Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_MilestonePaymentReceived', window );">Amount of milestone payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember', window );">Chiesi US Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_AdditionalAmountsPayableToCoverDevelopmentCosts', window );">Additional amounts payable to cover development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones', window );">Additional amount payable for achievement of regulatory and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 760,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember', window );">Chiesi US Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment on net sales percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember', window );">Chiesi US Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment on net sales percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember', window );">Chiesi Ex-US Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_AdditionalAmountsPayableToCoverDevelopmentCosts', window );">Additional amounts payable to cover development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_AgreementAmendmentPaymentReceivable', window );">Agreement amendment payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones', window );">Change in amount receivable for achievement of regulatory and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones', window );">Additional amount payable for achievement of regulatory and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 320,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember', window );">Chiesi Ex-US Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment on net sales percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember', window );">Chiesi Ex-US Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment on net sales percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUsAgreementAndChiesiExUsAgreementMember', window );">Chiesi US Agreement and Chiesi Ex-US Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_UpfrontNonrefundableNoncreditablePaymentReceivable', window );">Non-refundable payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_FillFinishAgreementMember', window );">Fill/Finish Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ExtendedTermOfAgreement', window );">Extended term of agreement</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount payable to entity for the achievement of regulatory and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AdditionalAmountsPayableToCoverDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum amount payable to the entity to cover development costs under agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AdditionalAmountsPayableToCoverDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AgreementAmendmentPaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreement Amendment Payment Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AgreementAmendmentPaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement revenues and expense sharing percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_CollaborativeArrangementRevenuesExpensesSharingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ExtendedTermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Extended term  of agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ExtendedTermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_MilestonePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of milestone payment received upon achievement of certain milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_MilestonePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_NumberOfGlobalLicensingAndSupplyAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of global licensing and supply agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_NumberOfGlobalLicensingAndSupplyAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_PaymentOnNetSalesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the payment as a percentage of future net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_PaymentOnNetSalesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SaleOfStockMaximumOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of stock, maximum offering price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SaleOfStockMaximumOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_UpfrontNonrefundableNoncreditablePaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of upfront, non refundable and non creditable payment receivable under the agreement for licensing rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_UpfrontNonrefundableNoncreditablePaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=plx_AtMarketEquityOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=plx_AtMarketEquityOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=plx_ProtalixBioTherapeuticsIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=plx_ProtalixBioTherapeuticsIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_BR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_BR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUsAgreementAndChiesiExUsAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiUsAgreementAndChiesiExUsAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_FillFinishAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_FillFinishAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46191739521200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES - Convertible notes (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Convertible notes</a></td>
<td class="nump">$ 20,251<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid in capital</a></td>
<td class="nump">415,045<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">381,549<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member', window );">ASU 2020-06 | Cumulative Effect, Period of Adoption, Adjusted Balance</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Convertible notes</a></td>
<td class="nump">20,420<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid in capital</a></td>
<td class="nump">414,652<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">381,325<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member', window );">ASU 2020-06 | Effect of Change</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Convertible notes</a></td>
<td class="nump">169<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid in capital</a></td>
<td class="num">(393)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 224<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46191739455936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVENTORIES - Schedule of Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 4,242<span></span>
</td>
<td class="nump">$ 4,176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in progress</a></td>
<td class="nump">12,251<span></span>
</td>
<td class="nump">9,055<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">706<span></span>
</td>
<td class="nump">5,814<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">$ 17,199<span></span>
</td>
<td class="nump">$ 19,045<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46191743678208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES - Disaggregation of Revenues (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 17,959<span></span>
</td>
<td class="nump">$ 10,345<span></span>
</td>
<td class="nump">$ 35,181<span></span>
</td>
<td class="nump">$ 55,008<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">GOODS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">17,839<span></span>
</td>
<td class="nump">10,168<span></span>
</td>
<td class="nump">34,820<span></span>
</td>
<td class="nump">30,309<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">GOODS | Pfizer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">3,430<span></span>
</td>
<td class="nump">2,304<span></span>
</td>
<td class="nump">11,431<span></span>
</td>
<td class="nump">7,972<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">GOODS | Brazil</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">2,048<span></span>
</td>
<td class="nump">2,320<span></span>
</td>
<td class="nump">9,314<span></span>
</td>
<td class="nump">5,120<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">GOODS | Chiesi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">12,361<span></span>
</td>
<td class="nump">5,544<span></span>
</td>
<td class="nump">14,075<span></span>
</td>
<td class="nump">17,217<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember', window );">LICENSE AND R&amp;D SERVICES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 120<span></span>
</td>
<td class="nump">$ 177<span></span>
</td>
<td class="nump">$ 361<span></span>
</td>
<td class="nump">$ 24,699<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=plx_PfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=plx_PfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_BR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_BR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46191741477648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCK TRANSACTIONS (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th">
<div>Sep. 23, 2024 </div>
<div>USD ($) </div>
<div>installment </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 02, 2024 </div>
<div>USD ($) </div>
<div>installment </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 01, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 15, 2024 </div>
<div>USD ($) </div>
<div>installment </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Shares of restricted Common Stock | Vice President Research And Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>STOCK TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue', window );">Grant Date Fair Value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Shares of restricted Common Stock | Vice President Research And Development | Share Based Compensation Award Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>STOCK TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Shares of restricted Common Stock | Vice President Research And Development | Share Based Compensation Award Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>STOCK TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements', window );">Number of equal quarterly increments | installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=plx_EmployeeStockIncentivePlan2006Member', window );">Plan | Shares of restricted Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>STOCK TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements', window );">Number of equal quarterly increments | installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue', window );">Grant Date Fair Value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=plx_EmployeeStockIncentivePlan2006Member', window );">Plan | Shares of restricted Common Stock | Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>STOCK TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">263,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue', window );">Grant Date Fair Value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=plx_EmployeeStockIncentivePlan2006Member', window );">Plan | Shares of restricted Common Stock | Senior Vice President And Chief Financial Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>STOCK TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted | shares</a></td>
<td class="nump">90,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue', window );">Grant Date Fair Value | $</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=plx_EmployeeStockIncentivePlan2006Member', window );">Plan | Options | Officers And Other Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>STOCK TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Term of award</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options to purchase shares | shares</a></td>
<td class="nump">1,015,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 1.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements', window );">Number of equal quarterly increments | installment</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue', window );">Grant Date Fair Value | $</a></td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equal quarterly increments over which the awards vest under the share based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=plx_VicePresidentResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=plx_VicePresidentResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=plx_EmployeeStockIncentivePlan2006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=plx_EmployeeStockIncentivePlan2006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=plx_SeniorVicePresidentAndChiefFinancialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=plx_SeniorVicePresidentAndChiefFinancialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=plx_OfficersAndOtherEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=plx_OfficersAndOtherEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46191743554912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER SHARE (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="nump">$ 3,236<span></span>
</td>
<td class="num">$ (1,852)<span></span>
</td>
<td class="num">$ (3,562)<span></span>
</td>
<td class="nump">$ 14,356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DilutiveSecurities', window );">Financial expenses of 2024 Notes</a></td>
<td class="num">(503)<span></span>
</td>
<td class="num">(1,766)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,610)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net income (loss) for diluted calculation</a></td>
<td class="nump">$ 2,733<span></span>
</td>
<td class="num">$ (3,618)<span></span>
</td>
<td class="num">$ (3,562)<span></span>
</td>
<td class="nump">$ 12,746<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares of Common Stock outstanding for basic calculation</a></td>
<td class="nump">73,549,745<span></span>
</td>
<td class="nump">72,281,681<span></span>
</td>
<td class="nump">73,301,091<span></span>
</td>
<td class="nump">65,811,506<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities', window );">Weighted average dilutive effect of 2024 Notes</a></td>
<td class="nump">7,667,323<span></span>
</td>
<td class="nump">11,500,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,981,660<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Weighted average dilutive effect of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,247,115<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares of Common Stock outstanding for diluted calculation</a></td>
<td class="nump">81,217,068<span></span>
</td>
<td class="nump">83,782,679<span></span>
</td>
<td class="nump">73,301,091<span></span>
</td>
<td class="nump">81,040,281<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=plx_OutstandingStockOptionsAndWarrantsMember', window );">Outstanding Stock Options And Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">20,173,438<span></span>
</td>
<td class="nump">19,429,910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,399,260<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=plx_OutstandingStockOptionsWarrantsAnd2024NotesMember', window );">Outstanding Stock Options Warrants And 2024 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,515,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise stock options, restrictive stock units (RSUs), convertible preferred stock of an employee stock ownership plan (ESOP), and other dilutive convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-42<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480454/718-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-22<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-28A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=plx_OutstandingStockOptionsAndWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=plx_OutstandingStockOptionsAndWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=plx_OutstandingStockOptionsWarrantsAnd2024NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=plx_OutstandingStockOptionsWarrantsAnd2024NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46191744698352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAXES ON INCOME - Summary of Taxes on Income (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>TAXES ON INCOME</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current taxes on income</a></td>
<td class="nump">$ 164<span></span>
</td>
<td class="nump">$ 95<span></span>
</td>
<td class="nump">$ 164<span></span>
</td>
<td class="nump">$ 3,728<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred taxes on income</a></td>
<td class="nump">443<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="nump">236<span></span>
</td>
<td class="num">(3,092)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total taxes on income</a></td>
<td class="nump">$ 607<span></span>
</td>
<td class="nump">$ 133<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">$ 636<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46191739274560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAXES ON INCOME - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_IncomeTaxDisclosureLineItems', window );"><strong>TAXES ON INCOME</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13.00%)<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory income tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance related to deferred tax assets</a></td>
<td class="num">$ (3.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember', window );">Chiesi Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_IncomeTaxDisclosureLineItems', window );"><strong>TAXES ON INCOME</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_MilestonePaymentReceived', window );">Amount of milestone payment received</a></td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_IncomeTaxDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Tax Disclosure Line Items</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_IncomeTaxDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_MilestonePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of milestone payment received upon achievement of certain milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_MilestonePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46191743761904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window );"><strong>Accounts payable and accruals - other:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and related expenses</a></td>
<td class="nump">$ 1,251<span></span>
</td>
<td class="nump">$ 1,437<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Interest payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">511<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedVacationCurrent', window );">Provision for vacation</a></td>
<td class="nump">1,713<span></span>
</td>
<td class="nump">1,605<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">8,342<span></span>
</td>
<td class="nump">9,009<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Royalties payable</a></td>
<td class="nump">571<span></span>
</td>
<td class="nump">637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Income tax payable</a></td>
<td class="nump">3,040<span></span>
</td>
<td class="nump">2,876<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ReserveForDeductionsFromRevenueCurrent', window );">Sales reserve</a></td>
<td class="nump">4,258<span></span>
</td>
<td class="nump">2,861<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent', window );">Property and equipment suppliers</a></td>
<td class="nump">402<span></span>
</td>
<td class="nump">614<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable and accruals - other</a></td>
<td class="nump">$ 19,577<span></span>
</td>
<td class="nump">$ 19,550<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable to property and equipment suppliers. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ReserveForDeductionsFromRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of reserve for deductions from revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ReserveForDeductionsFromRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedVacationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 25<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483070/710-10-25-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedVacationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46191733776400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Nov. 14, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember', window );">Chiesi Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCustomers', window );">Total proceeds from sale of products</a></td>
<td class="nump">$ 3.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash receipts from customers during the current period which are usually for sales of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>49
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M)$V3]%X4M&6<SCF*2[%$\U-$\5M$+$)T:=IINEO-JM@_7CCVV?#Q.#)&VVJ
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MRZ$C4%NFL26^X[><L].:1].^/-HP3TY?D\P&;35)1:X>)2/BJJ,8*-<&50M
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MC7X"*V]C[LL+EMK;R=@E\@-K1FN"5@($JP6(LP$!TDU9$KZC07L_W7@)W=-
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M@-^?8IB#Q8UX07F";?Q?4$L#!!0    ( &LX;EGJR[<Z,!\  &A;   8
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M2526&9*X46^1%$;7%&W96M) <NE>SI9MS<<\6)(VT(E9H]-U4>;E:L?K0C-
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M[0E0: I6L2DE8@T;07B_3$%DO5^P9E6(Z;"[384X@^5GCV+Q],N6]/<8BY;
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M=PDK%5\5S22X*M[DJ0O\+HC#G!]B2&+ WU>.R[^=2(#N:;?X&U!+ P04
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;+U7;6_C-@S^*X3O<-B
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MAR%>FU*2L_@/>*&BQ9)O"^K?-BN25PH=1*T^M(^*$N3N'#,%=M#/-MJ2@/-
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M3QD:GT#[E=9NY_@#NL<Q>P-02P,$%     @ :SAN60L^/G." @  O@<  !D
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ME'OV6?=+T4R+QE"\LNWPCBO=7.TRUP,6A 'H_27G:FN8 -W(CO\"4$L#!!0
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M^.70K!]^?8XI?G5):SK<\Q?3Z8LI+XO'NND\IJEH(4D7M(6Z5R9GM^ZS"XH
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MFIM7^*R=/<5DPZ/4*6+_AJK$,TAB0]T@N:JE2QIV@XRL$.0.HW Y*R=<"DI
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M'3V W^<E<(C[0 N$5ZF_^3]02P,$%     @ :SAN626X(OT5 P  '@<  !D
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M- UM?!GPS&"C]];$5K*4\M4:LV3B>%80<(B-9:#X>H,KX-P2H8S?-:?3I+3
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M*A6<2(AGUF5_,O>-?^GP/86M:NV)J60MQ+,1;J*9Y1A"P"#4!H'B\@(+8,P
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MP"*R&J^5H$5>CK2UT#@@RVV"+Q)(XX#V6 B]$TR"YHT+_@!02P,$%     @
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M--I<A?#-IW5K4V]K4Z=VG*NEO:N1U Q4,U'-0C4;U9Q&>^/3YZ*=>JCFHUJ
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M9'C,@5BF*>*_!YBR=<^ QO/"/9DOI%XP@VZ.YGB"Y30?<S4S:Y28I#@3A&6
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MZ8W9A "@HE00J'1 TB)0&H&BV>FH/7_@-OV'U14WI'<Z<$=E&8_'K<H"&I1
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M7N-Y/_,XYR<J[_7ABA*VU'C_Z%CG5FZ?D-Q^4"(O'P&\$TJ)M'R[8G3!I-E
M_[X40CU_,$\5[IY3G?X+4$L#!!0    ( &LX;EFX);_^$ 4  .T9   9
M>&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;+U9;7/B-A#^*QIZTTEF+K$EOZ?
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M02"?+Z@LG_5-(:#YPC/^!U!+ P04    " !K.&Y9>P7C2>0"  "<"0  &0
M 'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6RM5EUOFS 4_2L6JZ9.6@L!0MLL
M06I"IO6A'VK2;:\N7 (JV,PV2??O9QO"$J!1M/4EL<TYY]YS;? =;RA[X0F
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M [??,[BM%Y_7H"4H]L(+<D]N4>_:%KE^:U@U>^USL1\ER;EJ:UB$SW2[)XV
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M4?4>W'D?A<U[*ES_[VST#%!+ P04    " !K.&Y9EXJ[',     3 @  "P
M %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=
MOZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'
MTD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O@*\Z3'%":4A+,P[P
MS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T
M>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    ( &LX;EG-UB13D ,
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MS[H?K;,O4$L! A0#%     @ :SAN60=!36*!    L0   !
M ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " !K.&Y92L"UENX
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M=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ :SAN63L7ZQ0%!@
MVAD  !@              ("!YA,  'AL+W=O<FMS:&5E=',O<VAE970S+GAM
M;%!+ 0(4 Q0    ( &LX;EF30QEZL H  ,]C   8              " @2$:
M  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " !K.&Y9B^W4
M_84"  !)!@  &               @($')0  >&PO=V]R:W-H965T<R]S:&5E
M=#4N>&UL4$L! A0#%     @ :SAN6?,.6Q^;"   S28  !@
M ("!PB<  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( &LX
M;EGJR[<Z,!\  &A;   8              " @9,P  !X;"]W;W)K<VAE971S
M+W-H965T-RYX;6Q02P$"% ,4    " !K.&Y9^D\OX*H"  !X!@  &
M        @('Y3P  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%
M  @ :SAN668L0SE&!   Y@D  !@              ("!V5(  'AL+W=O<FMS
M:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( &LX;ED'R+D/$ ,  "L(   9
M              " @557  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L!
M A0#%     @ :SAN63#>W[7"!   TPT  !D              ("!G%H  'AL
M+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " !K.&Y9!)Q/=+T$
M  #=#@  &0              @(&57P  >&PO=V]R:W-H965T<R]S:&5E=#$R
M+GAM;%!+ 0(4 Q0    ( &LX;EF50M%$0P4  #X-   9              "
M@8ED  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ :SAN
M6<O9.Q,A P  *0@  !D              ("! VH  'AL+W=O<FMS:&5E=',O
M<VAE970Q-"YX;6Q02P$"% ,4    " !K.&Y9%#8X$DL"   H!0  &0
M        @(%;;0  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0
M   ( &LX;ED+/CYS@@(  +X'   9              " @=UO  !X;"]W;W)K
M<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ :SAN60!ZCZM# @  B@8
M !D              ("!EG(  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q0
M2P$"% ,4    " !K.&Y99R=#IH ?  !670  &0              @($0=0
M>&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( &LX;EDEN"+]
M%0,  !X'   9              " @<>4  !X;"]W;W)K<VAE971S+W-H965T
M,3DN>&UL4$L! A0#%     @ :SAN62JK"7&S @  =@8  !D
M ("!$Y@  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " !K
M.&Y9=A.T3!L#  !$"   &0              @(']F@  >&PO=V]R:W-H965T
M<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( &LX;EF5AP?X( 0  $8,   9
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M970R-BYX;6Q02P$"% ,4    " !K.&Y9A:G'?HL"  #+!@  &0
M    @('/N0  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    (
M &LX;EDQ .0!U0,  $P2   9              " @9&\  !X;"]W;W)K<VAE
M971S+W-H965T,C@N>&UL4$L! A0#%     @ :SAN6>!66L&^!@  LSH  !D
M             ("!G<   'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"
M% ,4    " !K.&Y9N"6__A %  #M&0  &0              @(&2QP  >&PO
M=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( &LX;EE[!>-)Y (
M )P)   9              " @=G,  !X;"]W;W)K<VAE971S+W-H965T,S$N
M>&UL4$L! A0#%     @ :SAN676G:\E. P  VPP  !D              ("!
M],\  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " !K.&Y9
MM0BVQU$#  !J"@  &0              @(%YTP  >&PO=V]R:W-H965T<R]S
M:&5E=#,S+GAM;%!+ 0(4 Q0    ( &LX;ED;,\,"%@(  +P$   9
M      " @0'7  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%
M  @ :SAN64ET\],R P  2!,   T              ( !3MD  'AL+W-T>6QE
M<RYX;6Q02P$"% ,4    " !K.&Y9EXJ[',     3 @  "P
M@ &KW   7W)E;',O+G)E;'-02P$"% ,4    " !K.&Y9S=8D4Y #   B%P
M#P              @ &4W0  >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @
M:SAN68S?7ZUN 0  W10  !H              ( !4>$  'AL+U]R96QS+W=O
M<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ :SAN60970G>/ 0  <!4  !,
M             ( !]^(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     "H
,*@!="P  M^0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>103</ContextCount>
  <ElementCount>183</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>32</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="plx-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995200090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="plx-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995200100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="plx-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995200200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="plx-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>995200300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="plx-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>995200305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="plx-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>995200400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="plx-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995210101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSignificantAccountingPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="plx-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995210201 - Disclosure - INVENTORIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureInventories</Role>
      <ShortName>INVENTORIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="plx-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995210301 - Disclosure - FAIR VALUE MEASUREMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureFairValueMeasurement</Role>
      <ShortName>FAIR VALUE MEASUREMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="plx-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995210401 - Disclosure - REVENUES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureRevenues</Role>
      <ShortName>REVENUES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="plx-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995210501 - Disclosure - STOCK TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureStockTransactions</Role>
      <ShortName>STOCK TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="plx-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995210601 - Disclosure - EARNINGS (LOSS) PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureEarningsLossPerShare</Role>
      <ShortName>EARNINGS (LOSS) PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="plx-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995210701 - Disclosure - TAXES ON INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureTaxesOnIncome</Role>
      <ShortName>TAXES ON INCOME</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="plx-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995210801 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformation</Role>
      <ShortName>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="plx-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995210901 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="plx-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="plx-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="plx-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>99920102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="plx-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>99930103 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesTables</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="plx-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>99930203 - Disclosure - INVENTORIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureInventoriesTables</Role>
      <ShortName>INVENTORIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureInventories</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="plx-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>99930403 - Disclosure - REVENUES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureRevenuesTables</Role>
      <ShortName>REVENUES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureRevenues</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="plx-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>99930603 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureEarningsLossPerShareTables</Role>
      <ShortName>EARNINGS (LOSS) PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureEarningsLossPerShare</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="plx-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>99930703 - Disclosure - TAXES ON INCOME (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureTaxesOnIncomeTables</Role>
      <ShortName>TAXES ON INCOME (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureTaxesOnIncome</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="plx-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>99930803 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationTables</Role>
      <ShortName>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformation</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="plx-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>99940101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="plx-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>99940102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Convertible notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesConvertibleNotesDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES - Convertible notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="plx-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>99940201 - Disclosure - INVENTORIES - Schedule of Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails</Role>
      <ShortName>INVENTORIES - Schedule of Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="plx-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>99940401 - Disclosure - REVENUES - Disaggregation of Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureRevenuesDisaggregationOfRevenuesDetails</Role>
      <ShortName>REVENUES - Disaggregation of Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="plx-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>99940501 - Disclosure - STOCK TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureStockTransactionsDetails</Role>
      <ShortName>STOCK TRANSACTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureStockTransactions</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="plx-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>99940601 - Disclosure - EARNINGS (LOSS) PER SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails</Role>
      <ShortName>EARNINGS (LOSS) PER SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureEarningsLossPerShareTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="plx-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>99940701 - Disclosure - TAXES ON INCOME - Summary of Taxes on Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureTaxesOnIncomeSummaryOfTaxesOnIncomeDetails</Role>
      <ShortName>TAXES ON INCOME - Summary of Taxes on Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="plx-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>99940702 - Disclosure - TAXES ON INCOME - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails</Role>
      <ShortName>TAXES ON INCOME - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="plx-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>99940801 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationDetails</Role>
      <ShortName>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="plx-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>99940901 - Disclosure - SUBSEQUENT EVENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSubsequentEventsDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSubsequentEvents</ParentRole>
      <Position>34</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>plx-20240930.xsd</File>
    <File>plx-20240930_cal.xml</File>
    <File>plx-20240930_def.xml</File>
    <File>plx-20240930_lab.xml</File>
    <File>plx-20240930_pre.xml</File>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="plx-20240930x10q.htm">plx-20240930x10q.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>plx-20240930x10q005.jpg</File>
    <File>plx-20240930x10q007.jpg</File>
    <File>plx-20240930x10q008.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="356">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>56
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "plx-20240930x10q.htm": {
   "nsprefix": "plx",
   "nsuri": "http://www.protalix.com/20240930",
   "dts": {
    "schema": {
     "local": [
      "plx-20240930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "plx-20240930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "plx-20240930_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "plx-20240930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "plx-20240930_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "plx-20240930x10q.htm"
     ]
    }
   },
   "keyStandard": 152,
   "keyCustom": 31,
   "axisStandard": 15,
   "axisCustom": 0,
   "memberStandard": 16,
   "memberCustom": 16,
   "hidden": {
    "total": 10,
    "http://xbrl.sec.gov/dei/2024": 5,
    "http://fasb.org/us-gaap/2024": 5
   },
   "contextCount": 103,
   "entityCount": 1,
   "segmentCount": 32,
   "elementCount": 389,
   "unitCount": 6,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 356,
    "http://xbrl.sec.gov/dei/2024": 30,
    "http://xbrl.sec.gov/ecd/2024": 4
   },
   "report": {
    "R1": {
     "role": "http://www.protalix.com/role/DocumentDocumentAndEntityInformation",
     "longName": "995200090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets",
     "longName": "995200100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations",
     "longName": "995200200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2024_To_9_30_2024_5srFek9aZ0STe4olK5gckA",
      "name": "us-gaap:Revenues",
      "unitRef": "Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240930x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2024_To_9_30_2024_5srFek9aZ0STe4olK5gckA",
      "name": "us-gaap:CostOfRevenue",
      "unitRef": "Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240930x10q.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency",
     "longName": "995200300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2u7hpIDa8UWFhyZbeZAEeQ",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2u7hpIDa8UWFhyZbeZAEeQ",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical",
     "longName": "995200305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical)",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "Unit_Divide_USD_shares_A4-BaHg86EmBShQ9tsexWA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "link:footnote",
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240930x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "link:footnote",
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240930x10q.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
     "longName": "995200400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.protalix.com/role/DisclosureSignificantAccountingPolicies",
     "longName": "995210101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.protalix.com/role/DisclosureInventories",
     "longName": "995210201 - Disclosure - INVENTORIES",
     "shortName": "INVENTORIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.protalix.com/role/DisclosureFairValueMeasurement",
     "longName": "995210301 - Disclosure - FAIR VALUE MEASUREMENT",
     "shortName": "FAIR VALUE MEASUREMENT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.protalix.com/role/DisclosureRevenues",
     "longName": "995210401 - Disclosure - REVENUES",
     "shortName": "REVENUES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg",
      "name": "plx:RevenueDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg",
      "name": "plx:RevenueDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.protalix.com/role/DisclosureStockTransactions",
     "longName": "995210501 - Disclosure - STOCK TRANSACTIONS",
     "shortName": "STOCK TRANSACTIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.protalix.com/role/DisclosureEarningsLossPerShare",
     "longName": "995210601 - Disclosure - EARNINGS (LOSS) PER SHARE",
     "shortName": "EARNINGS (LOSS) PER SHARE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.protalix.com/role/DisclosureTaxesOnIncome",
     "longName": "995210701 - Disclosure - TAXES ON INCOME",
     "shortName": "TAXES ON INCOME",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformation",
     "longName": "995210801 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION",
     "shortName": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.protalix.com/role/DisclosureSubsequentEvents",
     "longName": "995210901 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2024_To_9_30_2024_5srFek9aZ0STe4olK5gckA",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240930x10q.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R17": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2024_To_9_30_2024_5srFek9aZ0STe4olK5gckA",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2024_To_9_30_2024_5srFek9aZ0STe4olK5gckA",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies",
     "longName": "99920102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "18",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg",
      "name": "plx:NatureOfOperationsPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg",
      "name": "plx:NatureOfOperationsPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesTables",
     "longName": "99930103 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "19",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg",
      "name": "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:DebtPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg",
      "name": "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:DebtPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.protalix.com/role/DisclosureInventoriesTables",
     "longName": "99930203 - Disclosure - INVENTORIES (Tables)",
     "shortName": "INVENTORIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "20",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.protalix.com/role/DisclosureRevenuesTables",
     "longName": "99930403 - Disclosure - REVENUES (Tables)",
     "shortName": "REVENUES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "plx:RevenueDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "plx:RevenueDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.protalix.com/role/DisclosureEarningsLossPerShareTables",
     "longName": "99930603 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)",
     "shortName": "EARNINGS (LOSS) PER SHARE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.protalix.com/role/DisclosureTaxesOnIncomeTables",
     "longName": "99930703 - Disclosure - TAXES ON INCOME (Tables)",
     "shortName": "TAXES ON INCOME (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationTables",
     "longName": "99930803 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)",
     "shortName": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg",
      "name": "plx:SupplementaryBalanceSheetsInformationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg",
      "name": "plx:SupplementaryBalanceSheetsInformationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
     "longName": "99940101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "25",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g",
      "name": "plx:NumberOfGlobalLicensingAndSupplyAgreements",
      "unitRef": "Unit_Standard_agreement_ukZC-6VifkuWtCWLoRpkbA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "plx:NatureOfOperationsPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g",
      "name": "plx:NumberOfGlobalLicensingAndSupplyAgreements",
      "unitRef": "Unit_Standard_agreement_ukZC-6VifkuWtCWLoRpkbA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "plx:NatureOfOperationsPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesConvertibleNotesDetails",
     "longName": "99940102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Convertible notes (Details)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Convertible notes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q",
      "name": "us-gaap:ConvertibleDebtCurrent",
      "unitRef": "Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240930x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q",
      "name": "us-gaap:AdditionalPaidInCapitalCommonStock",
      "unitRef": "Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:DebtPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240930x10q.htm",
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails",
     "longName": "99940201 - Disclosure - INVENTORIES - Schedule of Inventory (Details)",
     "shortName": "INVENTORIES - Schedule of Inventory (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "unitRef": "Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "unitRef": "Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.protalix.com/role/DisclosureRevenuesDisaggregationOfRevenuesDetails",
     "longName": "99940401 - Disclosure - REVENUES - Disaggregation of Revenues (Details)",
     "shortName": "REVENUES - Disaggregation of Revenues (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2024_To_9_30_2024_5srFek9aZ0STe4olK5gckA",
      "name": "us-gaap:Revenues",
      "unitRef": "Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240930x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2024_To_9_30_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_m3nBp_5RP0q3hxfAVIwsKA",
      "name": "us-gaap:Revenues",
      "unitRef": "Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "plx:RevenueDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240930x10q.htm",
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
     "longName": "99940501 - Disclosure - STOCK TRANSACTIONS (Details)",
     "shortName": "STOCK TRANSACTIONS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "Duration_7_2_2024_To_7_2_2024_srt_TitleOfIndividualAxis_plx_VicePresidentResearchAndDevelopmentMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_AvLDv7dryEm2YrB3OLun0Q",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_2_2024_To_7_2_2024_srt_TitleOfIndividualAxis_plx_VicePresidentResearchAndDevelopmentMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_AvLDv7dryEm2YrB3OLun0Q",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails",
     "longName": "99940601 - Disclosure - EARNINGS (LOSS) PER SHARE (Details)",
     "shortName": "EARNINGS (LOSS) PER SHARE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2024_To_9_30_2024_5srFek9aZ0STe4olK5gckA",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240930x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2024_To_9_30_2024_5srFek9aZ0STe4olK5gckA",
      "name": "us-gaap:DilutiveSecurities",
      "unitRef": "Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240930x10q.htm",
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.protalix.com/role/DisclosureTaxesOnIncomeSummaryOfTaxesOnIncomeDetails",
     "longName": "99940701 - Disclosure - TAXES ON INCOME - Summary of Taxes on Income (Details)",
     "shortName": "TAXES ON INCOME - Summary of Taxes on Income (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2024_To_9_30_2024_5srFek9aZ0STe4olK5gckA",
      "name": "us-gaap:CurrentIncomeTaxExpenseBenefit",
      "unitRef": "Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2024_To_9_30_2024_5srFek9aZ0STe4olK5gckA",
      "name": "us-gaap:CurrentIncomeTaxExpenseBenefit",
      "unitRef": "Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails",
     "longName": "99940702 - Disclosure - TAXES ON INCOME - Additional Information (Details)",
     "shortName": "TAXES ON INCOME - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "unitRef": "Unit_Standard_pure_KYNrm9UG9EeMn48Y0if07Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "unitRef": "Unit_Standard_pure_KYNrm9UG9EeMn48Y0if07Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationDetails",
     "longName": "99940801 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Details)",
     "shortName": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "plx:SupplementaryBalanceSheetsInformationTableTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "plx:SupplementaryBalanceSheetsInformationTableTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.protalix.com/role/DisclosureSubsequentEventsDetails",
     "longName": "99940901 - Disclosure - SUBSEQUENT EVENTS (Details)",
     "shortName": "SUBSEQUENT EVENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "Duration_11_14_2024_To_11_14_2024_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_IuBQ2oW-QUW8AyxcNROv4A",
      "name": "us-gaap:ProceedsFromCustomers",
      "unitRef": "Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_11_14_2024_To_11_14_2024_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_IuBQ2oW-QUW8AyxcNROv4A",
      "name": "us-gaap:ProceedsFromCustomers",
      "unitRef": "Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingStandardsUpdate202006Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingStandardsUpdate202006Member",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesConvertibleNotesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update 2020-06 [Member]",
        "terseLabel": "ASU 2020-06",
        "documentation": "Accounting Standards Update 2020-06 Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities, Current [Abstract]",
        "terseLabel": "Accounts payable and accruals:",
        "verboseLabel": "Accounts payable and accruals - other:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Current",
        "totalLabel": "Accounts payable and accruals - other",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r589"
     ]
    },
    "us-gaap_AccountsPayableOtherCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableOtherCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Other, Current",
        "terseLabel": "Other",
        "documentation": "Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20240930",
     "localname": "AccountsPayablePropertyAndEquipmentSuppliersCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable to property and equipment suppliers. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Property And Equipment Suppliers, Current",
        "terseLabel": "Property and equipment suppliers"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableTradeCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableTradeCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Trade, Current",
        "terseLabel": "Trade",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r33"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable - Trade",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedRoyaltiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Royalties, Current",
        "terseLabel": "Royalties payable",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r557"
     ]
    },
    "us-gaap_AccruedVacationCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedVacationCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Vacation, Current",
        "terseLabel": "Provision for vacation",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r35"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r651"
     ]
    },
    "plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20240930",
     "localname": "AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount payable to entity for the achievement of regulatory and commercial milestones.",
        "label": "Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones",
        "terseLabel": "Additional amount payable for achievement of regulatory and commercial milestones"
       }
      }
     },
     "auth_ref": []
    },
    "plx_AdditionalAmountsPayableToCoverDevelopmentCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20240930",
     "localname": "AdditionalAmountsPayableToCoverDevelopmentCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum amount payable to the entity to cover development costs under agreement.",
        "label": "Additional Amounts Payable To Cover Development Costs",
        "terseLabel": "Additional amounts payable to cover development costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalFinancialInformationDisclosureTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Financial Information Disclosure [Text Block]",
        "terseLabel": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION",
        "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital, Common Stock",
        "verboseLabel": "Additional paid in capital",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r470",
      "r714",
      "r715",
      "r716",
      "r718",
      "r776",
      "r829"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesConvertibleNotesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Axis]",
        "documentation": "Information by amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r90",
      "r91",
      "r92",
      "r93",
      "r94",
      "r129",
      "r130",
      "r131",
      "r132",
      "r142",
      "r180",
      "r181",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r195",
      "r196",
      "r197",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r360",
      "r361",
      "r370",
      "r371",
      "r372",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r392",
      "r393",
      "r394",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation related to stock options",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r249"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments required to reconcile net income (loss) to net cash provided by operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r697"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r623",
      "r633",
      "r643",
      "r675"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r626",
      "r636",
      "r646",
      "r678"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "plx_AgreementAmendmentPaymentReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20240930",
     "localname": "AgreementAmendmentPaymentReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement Amendment Payment Receivable",
        "label": "Agreement Amendment Payment Receivable",
        "terseLabel": "Agreement amendment payment receivable"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r671"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r627",
      "r637",
      "r647",
      "r671",
      "r679",
      "r683",
      "r691"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r689"
     ]
    },
    "plx_AmendedPfizerAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20240930",
     "localname": "AmendedPfizerAgreementMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended Pfizer Agreement [Member]",
        "label": "Amended Pfizer Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of debt issuance costs and debt discount",
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r226",
      "r570",
      "r571",
      "r709",
      "r784"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share, amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "EARNINGS (LOSS) PER SHARE",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails",
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r319"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r85",
      "r99",
      "r122",
      "r166",
      "r169",
      "r174",
      "r175",
      "r183",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r321",
      "r325",
      "r362",
      "r429",
      "r498",
      "r564",
      "r565",
      "r589",
      "r614",
      "r737",
      "r738",
      "r788"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r105",
      "r122",
      "r183",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r321",
      "r325",
      "r362",
      "r589",
      "r737",
      "r738",
      "r788"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "CURRENT ASSETS:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsNoncurrentAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent [Abstract]",
        "terseLabel": "NON-CURRENT ASSETS:"
       }
      }
     },
     "auth_ref": []
    },
    "plx_AtMarketEquityOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20240930",
     "localname": "AtMarketEquityOfferingMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to At The Market equity offering.",
        "label": "ATM Shares"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r686"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r682"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r682"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r682"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r682"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r682"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r682"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r685"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r684"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r683"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r683"
     ]
    },
    "country_BR": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "BR",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "BRAZIL",
        "terseLabel": "Brazil"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "verboseLabel": "Basis of presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "verboseLabel": "SIGNIFICANT ACCOUNTING POLICIES",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "verboseLabel": "Purchase of property and equipment",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r12",
      "r13"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r98",
      "r555"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD",
        "periodStartLabel": "BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r61",
      "r120"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "NET INCREASE IN CASH AND CASH EQUIVALENTS",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r61"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:"
       }
      }
     },
     "auth_ref": []
    },
    "plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20240930",
     "localname": "ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones",
        "label": "Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones",
        "terseLabel": "Change in amount receivable for achievement of regulatory and commercial milestones"
       }
      }
     },
     "auth_ref": []
    },
    "plx_ChangeInOperatingLeaseRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20240930",
     "localname": "ChangeInOperatingLeaseRightOfUseAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Change in Operating Lease Right Of use Assets.",
        "label": "Change in Operating Lease Right Of use Assets",
        "negatedLabel": "Changes in operating lease right of use assets, net"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r662"
     ]
    },
    "srt_ChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ChiefExecutiveOfficerMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer [Member]",
        "terseLabel": "Chief Executive Officer"
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "plx_ChiesiAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20240930",
     "localname": "ChiesiAgreementsMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails",
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Chiesi Agreements [Member]",
        "label": "Chiesi Agreements",
        "terseLabel": "Chiesi Agreements",
        "verboseLabel": "Chiesi"
       }
      }
     },
     "auth_ref": []
    },
    "plx_ChiesiExUSAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20240930",
     "localname": "ChiesiExUSAgreementMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chiesi Ex-US Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "plx_ChiesiUSAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20240930",
     "localname": "ChiesiUSAgreementMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chiesi US Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "plx_ChiesiUsAgreementAndChiesiExUsAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20240930",
     "localname": "ChiesiUsAgreementAndChiesiExUsAgreementMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "Chiesi US Agreement and Chiesi Ex-US Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r659"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r657"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "terseLabel": "STOCK TRANSACTIONS",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r101",
      "r102",
      "r168",
      "r228",
      "r229",
      "r230",
      "r232",
      "r235",
      "r240",
      "r242",
      "r463",
      "r464",
      "r465",
      "r466",
      "r572",
      "r701",
      "r710"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r663"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r663"
     ]
    },
    "plx_CollaborativeArrangementRevenuesExpensesSharingPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.protalix.com/20240930",
     "localname": "CollaborativeArrangementRevenuesExpensesSharingPercentage",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement revenues and expense sharing percentage.",
        "label": "Collaborative Arrangement Revenues Expenses Sharing Percentage",
        "verboseLabel": "Collaborative arrangement revenues and expenses sharing percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "terseLabel": "COMMITMENTS",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r78",
      "r430",
      "r484"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r604",
      "r605",
      "r606",
      "r608",
      "r609",
      "r610",
      "r611",
      "r714",
      "r715",
      "r718",
      "r776",
      "r827",
      "r829"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r485"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r668"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r667"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r669"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r666"
     ]
    },
    "us-gaap_ConvertibleDebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleDebtCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesConvertibleNotesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debt, Current",
        "verboseLabel": "Convertible notes",
        "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "plx_ConvertibleNotesDue2021And2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20240930",
     "localname": "ConvertibleNotesDue2021And2024Member",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to convertible notes due 2021 and 2024.",
        "label": "Notes 2021 and 2024"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfRevenue",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of Revenue",
        "negatedLabel": "COST OF GOODS SOLD",
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r122",
      "r183",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r362",
      "r564",
      "r737"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjusted Balance [Member]",
        "terseLabel": "Cumulative Effect, Period of Adoption, Adjusted Balance"
       }
      }
     },
     "auth_ref": [
      "r703",
      "r704",
      "r717",
      "r728",
      "r729",
      "r730",
      "r770",
      "r771",
      "r772",
      "r773",
      "r775",
      "r776",
      "r777",
      "r786"
     ]
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesConvertibleNotesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Adjustment",
        "verboseLabel": "Effect of Change"
       }
      }
     },
     "auth_ref": [
      "r91",
      "r128",
      "r135",
      "r142",
      "r187",
      "r193",
      "r196",
      "r291",
      "r292",
      "r305",
      "r307",
      "r330",
      "r332",
      "r333",
      "r335",
      "r336",
      "r337",
      "r342",
      "r345",
      "r347",
      "r348",
      "r381"
     ]
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesConvertibleNotesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "auth_ref": [
      "r91",
      "r128",
      "r135",
      "r142",
      "r187",
      "r193",
      "r196",
      "r291",
      "r292",
      "r305",
      "r307",
      "r330",
      "r332",
      "r333",
      "r335",
      "r336",
      "r337",
      "r342",
      "r345",
      "r347",
      "r348",
      "r381"
     ]
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesConvertibleNotesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "auth_ref": [
      "r91",
      "r128",
      "r135",
      "r142",
      "r187",
      "r193",
      "r196",
      "r291",
      "r292",
      "r305",
      "r307",
      "r330",
      "r332",
      "r333",
      "r335",
      "r336",
      "r337",
      "r342",
      "r345",
      "r347",
      "r348",
      "r381"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeSummaryOfTaxesOnIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit)",
        "terseLabel": "Current taxes on income",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r290",
      "r713"
     ]
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Conversion, Converted Instrument, Amount",
        "verboseLabel": "Convertible notes conversions",
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r34",
      "r35",
      "r76",
      "r77",
      "r124",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r587",
      "r711",
      "r731",
      "r732",
      "r733",
      "r783",
      "r785"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "verboseLabel": "Interest rate (as a percent)",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r212"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r124",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r587",
      "r711",
      "r731",
      "r732",
      "r733",
      "r783",
      "r785"
     ]
    },
    "us-gaap_DebtPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtPolicyTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt, Policy [Policy Text Block]",
        "terseLabel": "Convertible notes",
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxAssetsNet",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred income tax asset",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r280",
      "r281"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeSummaryOfTaxesOnIncomeDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Changes in deferred income tax asset",
        "verboseLabel": "Deferred taxes on income",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r87",
      "r713"
     ]
    },
    "us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets for Plan Benefits, Defined Benefit Plan",
        "terseLabel": "Funds in respect of employee rights upon retirement",
        "documentation": "Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r244",
      "r245",
      "r246",
      "r497",
      "r575",
      "r797"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "verboseLabel": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r21"
     ]
    },
    "us-gaap_DilutiveSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DilutiveSecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dilutive Securities, Effect on Basic Earnings Per Share",
        "terseLabel": "Financial expenses of 2024 Notes",
        "documentation": "Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise stock options, restrictive stock units (RSUs), convertible preferred stock of an employee stock ownership plan (ESOP), and other dilutive convertible securities."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Table Text Block]",
        "verboseLabel": "Schedule of Company's disaggregation of revenues",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r618"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r650"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r661"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "EARNINGS (LOSS) PER SHARE"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic",
        "terseLabel": "EARNINGS (LOSS) PER SHARE OF COMMON STOCK - BASIC (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r144",
      "r146",
      "r158",
      "r159",
      "r160",
      "r165",
      "r309",
      "r318",
      "r348",
      "r349",
      "r426",
      "r438",
      "r561"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "EARNINGS (LOSS) PER SHARE OF COMMON STOCK - DILUTED (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r146",
      "r158",
      "r159",
      "r160",
      "r165",
      "r309",
      "r318",
      "r348",
      "r349",
      "r426",
      "r438",
      "r561"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Earnings (Loss) per share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r18",
      "r162"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "EARNINGS (LOSS) PER SHARE",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r161",
      "r163",
      "r164"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "terseLabel": "EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r782"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective income tax rate (as a percent)",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r283",
      "r579"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Statutory income tax rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r283",
      "r296",
      "r579"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Payroll and related expenses",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "plx_EmployeeStockIncentivePlan2006Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20240930",
     "localname": "EmployeeStockIncentivePlan2006Member",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represent the employee stock incentive plan for the particular period.",
        "label": "2006 Employee Stock Incentive Plan",
        "terseLabel": "Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Options",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Entities [Member]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Act File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r696"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r696"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r696"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r91",
      "r108",
      "r109",
      "r110",
      "r125",
      "r126",
      "r127",
      "r130",
      "r137",
      "r139",
      "r141",
      "r167",
      "r187",
      "r193",
      "r196",
      "r243",
      "r291",
      "r292",
      "r305",
      "r306",
      "r307",
      "r310",
      "r317",
      "r318",
      "r330",
      "r332",
      "r333",
      "r334",
      "r335",
      "r337",
      "r347",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r371",
      "r373",
      "r383",
      "r437",
      "r451",
      "r452",
      "r453",
      "r470",
      "r524"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r665"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r623",
      "r633",
      "r643",
      "r675"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r620",
      "r630",
      "r640",
      "r672"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r671"
     ]
    },
    "plx_ExtendedTermOfAgreement": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.protalix.com/20240930",
     "localname": "ExtendedTermOfAgreement",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extended term  of agreement.",
        "label": "Extended Term Of Agreement",
        "terseLabel": "Extended term of agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "FAIR VALUE MEASUREMENT"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "verboseLabel": "FAIR VALUE MEASUREMENT",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r425",
      "r582",
      "r584"
     ]
    },
    "plx_FillFinishAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20240930",
     "localname": "FillFinishAgreementMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fill/Finish Agreement [Member]",
        "label": "Fill/Finish Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionGainLossUnrealized",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrealized Gain (Loss), Foreign Currency Transaction, before Tax",
        "negatedLabel": "Financial expenses (income), net",
        "documentation": "Amount, before tax, of unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r506",
      "r612",
      "r780",
      "r781",
      "r828"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r627",
      "r637",
      "r647",
      "r679"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r627",
      "r637",
      "r647",
      "r679"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r627",
      "r637",
      "r647",
      "r679"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r627",
      "r637",
      "r647",
      "r679"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r627",
      "r637",
      "r647",
      "r679"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20240930",
     "localname": "GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (loss) on amounts funded in respect of employee rights upon retirement.",
        "label": "Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement",
        "negatedLabel": "Gain on amounts funded in respect of employee rights upon retirement"
       }
      }
     },
     "auth_ref": []
    },
    "plx_GainLossOnDebtConversion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20240930",
     "localname": "GainLossOnDebtConversion",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of gain (loss) on conversion of convertible debt.",
        "label": "Gain (Loss) On Debt Conversion",
        "negatedLabel": "Gain on conversions of convertible notes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedLabel": "Gain on sale of fixed assets",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "INCOME (LOSS) BEFORE TAXES ON INCOME",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r80",
      "r84",
      "r427",
      "r434",
      "r563",
      "r564",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "TAXES ON INCOME"
       }
      }
     },
     "auth_ref": []
    },
    "plx_IncomeTaxDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.protalix.com/20240930",
     "localname": "IncomeTaxDisclosureLineItems",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax Disclosure Line Items",
        "label": "Income Tax Disclosure [Line Items]",
        "terseLabel": "TAXES ON INCOME"
       }
      }
     },
     "auth_ref": []
    },
    "plx_IncomeTaxDisclosureTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.protalix.com/20240930",
     "localname": "IncomeTaxDisclosureTable",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax Disclosure Table",
        "label": "Income Tax Disclosure [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "TAXES ON INCOME",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r279",
      "r283",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r297",
      "r299",
      "r300",
      "r301",
      "r468",
      "r579"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeSummaryOfTaxesOnIncomeDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "TAXES ON INCOME",
        "totalLabel": "Total taxes on income",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r88",
      "r140",
      "r141",
      "r166",
      "r172",
      "r175",
      "r282",
      "r283",
      "r298",
      "r439",
      "r579"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Valuation allowance related to deferred tax assets",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r579",
      "r768"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "verboseLabel": "Increase (decrease) in accounts payable and accruals",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Decrease (increase) in accounts receivable-trade and other assets",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "plx_IncreaseDecreaseInBankDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20240930",
     "localname": "IncreaseDecreaseInBankDeposits",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deposits held with banks.",
        "label": "Increase (Decrease) in Bank Deposits",
        "negatedLabel": "Investment in bank deposits"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "verboseLabel": "Decrease in contracts liability",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r390",
      "r708"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Decrease (increase) in inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncrementalCommonSharesAttributableToConversionOfDebtSecurities",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities",
        "terseLabel": "Weighted average dilutive effect of 2024 Notes",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r155",
      "r160"
     ]
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "terseLabel": "Weighted average dilutive effect of stock options",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r148",
      "r149",
      "r160",
      "r250"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r627",
      "r637",
      "r647",
      "r671",
      "r679",
      "r683",
      "r691"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r689"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r619",
      "r695"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r619",
      "r695"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r619",
      "r695"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest paid",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r118",
      "r119"
     ]
    },
    "us-gaap_InterestPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPayableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Payable, Current",
        "verboseLabel": "Interest payable",
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "plx_InterestReceivedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20240930",
     "localname": "InterestReceivedNet",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash received for interest.",
        "label": "Interest Received, Net",
        "terseLabel": "Interest received"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "INVENTORIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventories"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Text Block]",
        "verboseLabel": "INVENTORIES",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r194"
     ]
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r558"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryNet",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Net",
        "terseLabel": "Inventories",
        "totalLabel": "Total inventory",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r556",
      "r589"
     ]
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryRawMaterialsNetOfReserves",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r560"
     ]
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryWorkInProcessNetOfReserves",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work in progress",
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r559"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r34",
      "r35",
      "r36",
      "r38",
      "r39",
      "r40",
      "r41",
      "r122",
      "r183",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r322",
      "r325",
      "r326",
      "r362",
      "r483",
      "r562",
      "r614",
      "r737",
      "r788",
      "r789"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r79",
      "r432",
      "r589",
      "r712",
      "r727",
      "r779"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r97",
      "r122",
      "r183",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r322",
      "r325",
      "r326",
      "r362",
      "r589",
      "r737",
      "r788",
      "r789"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "CURRENT LIABILITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total long term liabilities",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r38",
      "r39",
      "r40",
      "r41",
      "r122",
      "r183",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r322",
      "r325",
      "r326",
      "r362",
      "r737",
      "r788",
      "r789"
     ]
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "LONG TERM LIABILITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LicenseAndServiceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LicenseAndServiceMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License and Service [Member]",
        "terseLabel": "LICENSE AND R&amp;D SERVICES",
        "verboseLabel": "License and R&amp;D Services",
        "documentation": "Right to use intangible asset and performance of related service. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark."
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "auth_ref": [
      "r198",
      "r199",
      "r200",
      "r201",
      "r248",
      "r277",
      "r350",
      "r389",
      "r447",
      "r448",
      "r461",
      "r475",
      "r476",
      "r529",
      "r531",
      "r533",
      "r534",
      "r536",
      "r550",
      "r551",
      "r566",
      "r572",
      "r576",
      "r583",
      "r584",
      "r585",
      "r586",
      "r599",
      "r739",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r663"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r663"
     ]
    },
    "plx_MilestonePaymentReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20240930",
     "localname": "MilestonePaymentReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of milestone payment received upon achievement of certain milestone.",
        "label": "Milestone Payment Received",
        "terseLabel": "Amount of milestone payment received"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "auth_ref": [
      "r198",
      "r199",
      "r200",
      "r201",
      "r248",
      "r277",
      "r350",
      "r389",
      "r447",
      "r448",
      "r461",
      "r475",
      "r476",
      "r529",
      "r531",
      "r533",
      "r534",
      "r536",
      "r550",
      "r551",
      "r566",
      "r572",
      "r576",
      "r583",
      "r584",
      "r585",
      "r599",
      "r739",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r682"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r690"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "plx_NatureOfOperationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.protalix.com/20240930",
     "localname": "NatureOfOperationsPolicyTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature Of Operations Policy",
        "label": "Nature Of Operations [Policy Text Block]",
        "verboseLabel": "General"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by (used in) operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r62",
      "r64"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET INCOME (LOSS) FOR THE PERIOD",
        "verboseLabel": "Net income (loss) for the period",
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r64",
      "r81",
      "r95",
      "r106",
      "r107",
      "r110",
      "r122",
      "r129",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r140",
      "r141",
      "r156",
      "r183",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r309",
      "r318",
      "r349",
      "r362",
      "r436",
      "r507",
      "r522",
      "r523",
      "r612",
      "r737"
     ]
    },
    "us-gaap_NetIncomeLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAbstract",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "totalLabel": "Net income (loss) for diluted calculation",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r145",
      "r150",
      "r151",
      "r152",
      "r153",
      "r157",
      "r160"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "verboseLabel": "New accounting pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r663"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r627",
      "r637",
      "r647",
      "r671",
      "r679"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r654"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r653"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r671"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r690"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r690"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "FINANCIAL INCOME (EXPENSES), NET",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "plx_NumberOfGlobalLicensingAndSupplyAgreements": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.protalix.com/20240930",
     "localname": "NumberOfGlobalLicensingAndSupplyAgreements",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of global licensing and supply agreements.",
        "label": "Number Of Global Licensing And Supply Agreements",
        "terseLabel": "Number of global licensing and supply agreements"
       }
      }
     },
     "auth_ref": []
    },
    "plx_OfficersAndOtherEmployeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20240930",
     "localname": "OfficersAndOtherEmployeesMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Officers And Other Employees",
        "label": "Officers And Other Employees [Member]",
        "terseLabel": "Officers And Other Employees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "totalLabel": "OPERATING INCOME (LOSS)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r563",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "verboseLabel": "Operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r375"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r375"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "verboseLabel": "Operating lease right of use assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r374"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Current",
        "terseLabel": "Other assets",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r589"
     ]
    },
    "us-gaap_OtherNonoperatingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Expense",
        "negatedLabel": "FINANCIAL EXPENSES",
        "documentation": "Amount of expense related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_OtherNonoperatingIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncome",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income",
        "terseLabel": "FINANCIAL INCOME",
        "documentation": "Amount of income related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r663"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r625",
      "r635",
      "r645",
      "r677"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r628",
      "r638",
      "r648",
      "r680"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r628",
      "r638",
      "r648",
      "r680"
     ]
    },
    "plx_OutstandingStockOptionsAndWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20240930",
     "localname": "OutstandingStockOptionsAndWarrantsMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding stock options and warrants.",
        "label": "Outstanding Stock Options And Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "plx_OutstandingStockOptionsWarrantsAnd2024NotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20240930",
     "localname": "OutstandingStockOptionsWarrantsAnd2024NotesMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding stock options and warrants and 2024 notes.",
        "label": "Outstanding Stock Options Warrants And 2024 Notes"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r652"
     ]
    },
    "plx_PaymentOnNetSalesPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.protalix.com/20240930",
     "localname": "PaymentOnNetSalesPercentage",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the payment as a percentage of future net sales.",
        "label": "Payment On Net Sales Percentage",
        "terseLabel": "Payment on net sales percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Amounts funded in respect of employee rights upon retirement, net",
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other."
       }
      }
     },
     "auth_ref": [
      "r702",
      "r706"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r662"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r662"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability, Pension and Other Postretirement and Postemployment Benefits, Noncurrent",
        "terseLabel": "Liability for employee rights upon retirement",
        "documentation": "Amount of liability, recognized in statement of financial position, for pension, other postretirement and postemployment benefits, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r30",
      "r39",
      "r73"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementBenefitExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PensionAndOtherPostretirementBenefitExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension and Other Postretirement Benefits Cost (Reversal of Cost)",
        "terseLabel": "Changes in accrued liability for employee rights upon retirement",
        "documentation": "Amount of cost (reversal of cost) for pension and other postretirement benefits."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r654"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r671"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r653"
     ]
    },
    "plx_PfizerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20240930",
     "localname": "PfizerMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDisaggregationOfRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global except for Brazil",
        "label": "Pfizer"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r699"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r654"
     ]
    },
    "us-gaap_ProceedsFromCustomers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromCustomers",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Customers",
        "verboseLabel": "Total proceeds from sale of products",
        "documentation": "Cash receipts from customers during the current period which are usually for sales of goods and services."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock under the Sales Agreement, net",
        "verboseLabel": "Stock issuance proceeds",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Proceeds from sale of property and equipment",
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Exercise of warrants",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r707"
     ]
    },
    "plx_ProceedsFromWithdrawalOfShortTermDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20240930",
     "localname": "ProceedsFromWithdrawalOfShortTermDeposits",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash inflow from the withdrawal of short-term deposits during the period.",
        "label": "Proceeds From Withdrawal Of Short-Term Deposits",
        "terseLabel": "Short-term deposit withdrawal"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProductMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product [Member]",
        "terseLabel": "GOODS",
        "verboseLabel": "Goods",
        "documentation": "Article or substance produced by nature, labor or machinery."
       }
      }
     },
     "auth_ref": [
      "r573"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r176",
      "r391",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r553",
      "r573",
      "r598",
      "r599",
      "r600",
      "r602",
      "r603",
      "r735",
      "r736",
      "r740",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r176",
      "r391",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r553",
      "r573",
      "r598",
      "r599",
      "r600",
      "r602",
      "r603",
      "r735",
      "r736",
      "r740",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net Income (loss)",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r106",
      "r107",
      "r116",
      "r122",
      "r129",
      "r137",
      "r140",
      "r141",
      "r183",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r309",
      "r318",
      "r320",
      "r323",
      "r324",
      "r349",
      "r362",
      "r427",
      "r435",
      "r469",
      "r507",
      "r522",
      "r523",
      "r580",
      "r581",
      "r613",
      "r705",
      "r737"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r377",
      "r428",
      "r433",
      "r589"
     ]
    },
    "plx_ProtalixBioTherapeuticsIncorporationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20240930",
     "localname": "ProtalixBioTherapeuticsIncorporationMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Protalix Bio Therapeutics Incorporation [Member].",
        "label": "Protalix Bio Therapeutics Incorporation"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r652"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r652"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r198",
      "r199",
      "r200",
      "r201",
      "r247",
      "r248",
      "r273",
      "r274",
      "r275",
      "r277",
      "r350",
      "r387",
      "r388",
      "r389",
      "r447",
      "r448",
      "r461",
      "r475",
      "r476",
      "r529",
      "r531",
      "r533",
      "r534",
      "r536",
      "r550",
      "r551",
      "r566",
      "r572",
      "r576",
      "r583",
      "r584",
      "r585",
      "r586",
      "r599",
      "r606",
      "r734",
      "r739",
      "r778",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r198",
      "r199",
      "r200",
      "r201",
      "r247",
      "r248",
      "r273",
      "r274",
      "r275",
      "r277",
      "r350",
      "r387",
      "r388",
      "r389",
      "r447",
      "r448",
      "r461",
      "r475",
      "r476",
      "r529",
      "r531",
      "r533",
      "r534",
      "r536",
      "r550",
      "r551",
      "r566",
      "r572",
      "r576",
      "r583",
      "r584",
      "r585",
      "r586",
      "r599",
      "r606",
      "r734",
      "r739",
      "r778",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r620",
      "r630",
      "r640",
      "r672"
     ]
    },
    "us-gaap_RepaymentsOfConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfConvertibleDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayments of Convertible Debt",
        "negatedLabel": "Payment for convertible notes redemption",
        "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense",
        "negatedLabel": "RESEARCH AND DEVELOPMENT EXPENSES",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r278",
      "r552",
      "r564",
      "r796"
     ]
    },
    "plx_ReserveForDeductionsFromRevenueCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20240930",
     "localname": "ReserveForDeductionsFromRevenueCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of reserve for deductions from revenue.",
        "label": "Reserve For Deductions From Revenue Current",
        "verboseLabel": "Sales reserve"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r621",
      "r631",
      "r641",
      "r673"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r622",
      "r632",
      "r642",
      "r674"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r629",
      "r639",
      "r649",
      "r681"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock [Member]",
        "terseLabel": "Shares of restricted Common Stock",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r72",
      "r431",
      "r455",
      "r460",
      "r467",
      "r486",
      "r589"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r125",
      "r126",
      "r127",
      "r130",
      "r137",
      "r139",
      "r141",
      "r187",
      "r193",
      "r196",
      "r291",
      "r292",
      "r305",
      "r306",
      "r307",
      "r310",
      "r317",
      "r318",
      "r330",
      "r333",
      "r334",
      "r337",
      "r347",
      "r371",
      "r373",
      "r451",
      "r453",
      "r470",
      "r829"
     ]
    },
    "plx_RevenueDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.protalix.com/20240930",
     "localname": "RevenueDisclosureTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenues"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure pertaining to revenue.",
        "label": "Revenue Disclosure [Text Block]",
        "terseLabel": "REVENUES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueRecognitionAndDeferredRevenueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRecognitionAndDeferredRevenueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "REVENUES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Revenues",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues.",
        "terseLabel": "TOTAL REVENUE",
        "verboseLabel": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r83",
      "r111",
      "r122",
      "r166",
      "r170",
      "r171",
      "r173",
      "r175",
      "r176",
      "r177",
      "r179",
      "r183",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r362",
      "r427",
      "r564",
      "r737"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating lease right of use assets obtained in exchange for new operating lease liabilities",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r376",
      "r588"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r690"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r690"
     ]
    },
    "plx_SaleOfStockMaximumOfferingPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20240930",
     "localname": "SaleOfStockMaximumOfferingPrice",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of stock, maximum offering price.",
        "label": "Sale Of Stock Maximum Offering Price",
        "terseLabel": "Sale of stock, maximum offering price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of taxes on income",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r769"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of basic and diluted net earnings (loss) per share",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r719"
     ]
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "verboseLabel": "Schedule of inventory",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r49",
      "r50",
      "r51"
     ]
    },
    "us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update and Change in Accounting Principle [Table Text Block]",
        "terseLabel": "Schedule of ASU 2020-06 on the condensed consolidated balance sheet",
        "documentation": "Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r15",
      "r19",
      "r20",
      "r774"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r23",
      "r24",
      "r25",
      "r26",
      "r27",
      "r68",
      "r70",
      "r71",
      "r72",
      "r100",
      "r101",
      "r102",
      "r168",
      "r228",
      "r229",
      "r230",
      "r232",
      "r235",
      "r240",
      "r242",
      "r463",
      "r464",
      "r465",
      "r466",
      "r572",
      "r701",
      "r710"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r615"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r617"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r177",
      "r178",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r472",
      "r473",
      "r474",
      "r530",
      "r532",
      "r535",
      "r537",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r554",
      "r574",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r601",
      "r606",
      "r740",
      "r798",
      "r799",
      "r800",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, General and Administrative Expense",
        "negatedLabel": "SELLING, GENERAL AND ADMINISTRATIVE EXPENSES",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "plx_SeniorVicePresidentAndChiefFinancialOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20240930",
     "localname": "SeniorVicePresidentAndChiefFinancialOfficerMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sr. Vice President And Chief Financial Officer",
        "label": "Senior Vice President And Chief Financial Officer"
       }
      }
     },
     "auth_ref": []
    },
    "plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20240930",
     "localname": "SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to seven point five percentage senior secured convertible notes due 2024.",
        "label": "2024 Notes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "verboseLabel": "Vesting period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r577"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "verboseLabel": "Number of shares granted",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r265"
     ]
    },
    "plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20240930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award grant date fair value.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Grant Date Fair Value",
        "terseLabel": "Grant Date Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.protalix.com/20240930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of equal quarterly increments over which the awards vest under the share based payment arrangement.",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Quarterly Increments",
        "terseLabel": "Number of equal quarterly increments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Number of options to purchase shares",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r258"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "verboseLabel": "Exercise price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r258"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Share Based Compensation Award Tranche One",
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Share Based Compensation Award Tranche Two",
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20240930",
     "localname": "ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of recognized equity-based compensation during the period for restricted stock awards.",
        "label": "Share Based Compensation Restricted Stock Awards Net Of Forfeitures",
        "terseLabel": "Share-based compensation related to restricted stock awards"
       }
      }
     },
     "auth_ref": []
    },
    "plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.protalix.com/20240930",
     "localname": "ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares",
        "label": "Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares",
        "terseLabel": "Share-based compensation related to restricted stock awards (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Vesting Percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "verboseLabel": "Term of award",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r578"
     ]
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "plx_ShortTermBankDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20240930",
     "localname": "ShortTermBankDeposits",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of deposits held with banks for short period, usually less than one year or the normal operating cycle, whichever is longer.",
        "label": "Short-term Bank Deposits",
        "terseLabel": "Short-term bank deposits"
       }
      }
     },
     "auth_ref": []
    },
    "plx_SignificantAccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.protalix.com/20240930",
     "localname": "SignificantAccountingPoliciesLineItems",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesConvertibleNotesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Line Items]",
        "terseLabel": "SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "auth_ref": []
    },
    "plx_SignificantAccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.protalix.com/20240930",
     "localname": "SignificantAccountingPoliciesTable",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesConvertibleNotesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant Accounting Policies [Table].",
        "label": "Significant Accounting Policies [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r43",
      "r46",
      "r47",
      "r91",
      "r108",
      "r109",
      "r110",
      "r125",
      "r126",
      "r127",
      "r130",
      "r137",
      "r139",
      "r141",
      "r167",
      "r187",
      "r193",
      "r196",
      "r243",
      "r291",
      "r292",
      "r305",
      "r306",
      "r307",
      "r310",
      "r317",
      "r318",
      "r330",
      "r332",
      "r333",
      "r334",
      "r335",
      "r337",
      "r347",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r371",
      "r373",
      "r383",
      "r437",
      "r451",
      "r452",
      "r453",
      "r470",
      "r524"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r177",
      "r178",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r472",
      "r473",
      "r474",
      "r530",
      "r532",
      "r535",
      "r537",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r554",
      "r574",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r601",
      "r606",
      "r740",
      "r798",
      "r799",
      "r800",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r126",
      "r127",
      "r167",
      "r373",
      "r391",
      "r462",
      "r471",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r485",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r505",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r524",
      "r607"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED BALANCE SHEETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r126",
      "r127",
      "r167",
      "r182",
      "r373",
      "r391",
      "r462",
      "r471",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r485",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r505",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r524",
      "r607"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r624",
      "r634",
      "r644",
      "r676"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "verboseLabel": "Convertible notes conversions (in shares)",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r24",
      "r43",
      "r46",
      "r72",
      "r221"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, New Issues",
        "verboseLabel": "Number of shares issued (in shares)",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r42",
      "r43",
      "r72",
      "r463",
      "r524",
      "r538"
     ]
    },
    "plx_StockIssuedDuringPeriodSharesSalesAgreement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.protalix.com/20240930",
     "localname": "StockIssuedDuringPeriodSharesSalesAgreement",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Sales Agreement",
        "label": "Stock Issued During Period, Shares, Sales Agreement",
        "terseLabel": "Issuance of common stock under the Sales Agreement, net (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "plx_StockIssuedDuringPeriodSharesWarrantsExercises": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.protalix.com/20240930",
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercises",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during period for exercise of warrants.",
        "label": "Stock Issued During Period, Shares, Warrants Exercises",
        "terseLabel": "Exercise of warrants (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "verboseLabel": "Convertible notes conversions",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r43",
      "r46",
      "r47",
      "r72"
     ]
    },
    "plx_StockIssuedDuringPeriodValueSalesAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20240930",
     "localname": "StockIssuedDuringPeriodValueSalesAgreement",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in a sales agreement.",
        "label": "Stock Issued During Period, Value, Sales Agreement",
        "terseLabel": "Issuance of common stock under the Sales Agreement, net"
       }
      }
     },
     "auth_ref": []
    },
    "plx_StockIssuedDuringPeriodValueWarrantsExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20240930",
     "localname": "StockIssuedDuringPeriodValueWarrantsExercises",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares issued during period for exercise of warrants.",
        "label": "Stock Issued During Period, Value, Warrants Exercises",
        "terseLabel": "Exercise of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "verboseLabel": "STOCKHOLDERS' EQUITY",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r46",
      "r47",
      "r66",
      "r487",
      "r504",
      "r525",
      "r526",
      "r589",
      "r614",
      "r712",
      "r727",
      "r779",
      "r829"
     ]
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCK TRANSACTIONS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Text Block]",
        "terseLabel": "STOCK TRANSACTIONS",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r121",
      "r227",
      "r229",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r241",
      "r243",
      "r338",
      "r527",
      "r528",
      "r539"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "SUBSEQUENT EVENTS",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r369",
      "r385"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r369",
      "r385"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r384",
      "r386"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "verboseLabel": "SUPPLEMENTARY DISCLOSURE ON CASH FLOWS"
       }
      }
     },
     "auth_ref": []
    },
    "plx_SupplementalInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.protalix.com/20240930",
     "localname": "SupplementalInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION"
       }
      }
     },
     "auth_ref": []
    },
    "plx_SupplementaryBalanceSheetsInformationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.protalix.com/20240930",
     "localname": "SupplementaryBalanceSheetsInformationTableTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure for supplemental balance sheets information.",
        "label": "Supplementary Balance Sheets Information [Table Text Block]",
        "verboseLabel": "Schedule of supplemental information of balance sheets"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r670"
     ]
    },
    "us-gaap_TaxesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxesPayableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxes Payable, Current",
        "terseLabel": "Income tax payable",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r35"
     ]
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r725",
      "r787"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r662"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r669"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r689"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r691"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r692"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r693"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r693"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r691"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r691"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r694"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r692"
     ]
    },
    "us-gaap_TypeOfAdoptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfAdoptionMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesConvertibleNotesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Domain]",
        "documentation": "Amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r90",
      "r91",
      "r92",
      "r93",
      "r94",
      "r129",
      "r130",
      "r131",
      "r132",
      "r142",
      "r180",
      "r181",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r195",
      "r196",
      "r197",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r360",
      "r361",
      "r370",
      "r371",
      "r372",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r392",
      "r393",
      "r394",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails",
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r319"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r688"
     ]
    },
    "plx_UpfrontNonrefundableNoncreditablePaymentReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20240930",
     "localname": "UpfrontNonrefundableNoncreditablePaymentReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of upfront, non refundable and non creditable payment receivable under the agreement for licensing rights.",
        "label": "Upfront Nonrefundable Non creditable Payment Receivable",
        "terseLabel": "Non-refundable payment receivable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767"
     ]
    },
    "plx_VicePresidentResearchAndDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20240930",
     "localname": "VicePresidentResearchAndDevelopmentMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for vice president research and development.",
        "label": "Vice President Research And Development",
        "terseLabel": "Vice President Research And Development"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r658"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING EARNINGS (LOSS) PER SHARE - DILUTED (in shares)",
        "totalLabel": "Weighted average shares of Common Stock outstanding for diluted calculation",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r160"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING EARNINGS (LOSS) PER SHARE - BASIC (in shares)",
        "verboseLabel": "Weighted average shares of Common Stock outstanding for basic calculation",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r160"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "270",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-12"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "270",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-13"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "710",
   "SubTopic": "10",
   "Section": "25",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483070/710-10-25-3"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-2"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-3"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-6"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-22"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-23"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-28A"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-42"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/330/tableOfContent"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477123/405-50-65-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-2"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-3"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480454/718-10-45-1"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-5"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-6"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r702": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r703": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r704": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r705": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r706": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r707": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r708": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r709": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r710": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r715": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r716": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r717": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-6"
  },
  "r718": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r719": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r722": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r723": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r724": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r725": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r726": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r727": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r728": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r729": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r730": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r735": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r736": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r738": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r739": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r740": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r741": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r742": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r743": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r744": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r745": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r746": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r747": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r748": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r749": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r750": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r751": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r752": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r753": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r754": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r755": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r756": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r757": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r760": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r761": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r762": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r763": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r764": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r771": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r772": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r773": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r774": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r775": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>57
<FILENAME>0001558370-24-015612-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-24-015612-xbrl.zip
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MKM>(/1F+V*\I$);HF8?H;X>(SO1OL!*-$2S,CG'7DVO2&T(N236(W.#RAJE
MSBM6W,W&V_J ">P3"NDJ0788T@90%K&UTB<%Z_(,\B#_< CY]'X\'JH JD_^
MUOJ#$62_ WVXBZM@"WUC<J<RI@KS4U.G%:)+S =T*ASS^\JQ+<QX[X=+Q%,'
M;0CPA=J1F$3NN)7.KLKPSDW +H],P+[HH\_@0P8C:# Z?WPQAMW>9/H?K??G
M_6#VM_:FHX\',["O;J\_Z QZH\[?E2V]O"V-(=)3L<*"P#2\I&'%!RI@9>]^
MEI5I;V*R55:7$K7(DA) $U&AF^J0!S+&,9@%X,O3 E61/GFQJ940FP:?1P,
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M74#3=C;>N_=<A&5 ^6YGIK_OX3R@# JURA39F$?---<LGR4YRA3AZ.7MA>G
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M(M"^5Z,?T_$<D=S?'_*SO[[#=!.4>5#4\IJNI7S.RF$R'X2 LH9L'#2\(S9
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M,\ !1/[GL^N+JS,+^ YRH;_\?!:%B_/OSO[QP__\Y?O_/3__]7;Z8+G(B=;
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MN*5LA3W?I<<\-W3U5+H8D2C)MPJYLB;)HW0E(E%271[-KD/45(:4^>O>S60
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MFG)+5Q L!J_ B6C"Y'BQ@ XG0%1*K7NHJV&4N]11$;ZV;L6FES7_3!J:8!!
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M_SK/P<[AI_-/G\__\.G#2^+E?#78:A&>/?72 J$*_*\?Q</O_OQ/A(@QCJ.
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MR8ZZ*>0TZ>,NB%XI);%__\!&9+^+X'GJQ[P" ->:;V)(CZ:O(&4Z"3U(X>^
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MA2&.!2JK$T:JJC($7!55<Z3H@$9*V/'Z8G1).M4%D/;':(%%3#CIF*^EFV2
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M 9+AG,8Y$!G;I9ATISY6TG7C*U8^,_+A<-'<!>ZV<WF;H5JE^23TV@Y%="&
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MQG'E^/$W)]C3DO>V2%Z/@F<<)J)4C4,'CV(<[0PU].AJ,E^1;Y/KVQGY.IM
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M@Z(-?J'W0,A]0V=RR/ZA)[^M\Z*@*<+OXFQ 1I>\RRB_M]E1C#$RJ?-"$UA
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M\ER=1"0M-%)WU'8!BG:H:E"\_J=M/+45VN8JXB3$J9[F9'JTW:=P^2W<W)X
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MB?MPJ?<EBKQN-J7#M,"FV@63VI0:#=>FVOC2V52.2SBRM2;56<1"KGO &*&
M8>O_@\;JZUUKCY%*%"0L%C4)E6=X10@-)IH7!(J.3_0%!.6U:"U7N8U;4M#.
ML !![MWB,L7?%\?F+UZG@9,D&\EI,B,,Q"XM[8+46K.HP7'ZL;3Q(V_"<D8X
M7*7G+D=![O%\PQB%QL&:QN!U$#RUD;%:U9/J<Q3%:#+0]"/L7]F-*Q8T^,X9
MUC;S/@3"5P!UD^XZ!*H2:)MO5]1@M,;;L\==$+U2*EHJA; ]"Q<=L#<S0?ZH
M#'',T)!Z!700J6@<8("#UT7 F+EFL ]E,EGMIF@VDM$2S7'8NC.C1G:@;/DI
MDIT3I[Z[#YP8]NS]R,/J/]!?<@ @.7XVEQ84")# ;$K07RXMYR?:#$K2V'=3
MZHG&3#(?T0*+N>6C8;Z^RR,!1-K847(BV<O)8?/P$;<HH8\,HHV?.&M42&.T
MOWL2]:_9[I)706A-0 ./9P:M0E1-00D\FCD8[+&W,-70*@$R1G:UI?1LXZ>P
M"IR'GO_D>WLG4%P)KX##*1W3,IV7ADF!3E[ZI>&B>9 68'F]\$V4\$H+M-OC
M&VS_[*</*QKP(#!Y\'>;:,:/]DJ77;TH6*)*9H(JE4R/CJ]^)OP9*2;:9??3
M!Y]N9R_4W4-4NMQN?5>1[6Z%1BI\;1>@*&]5@YZ^B+6-%TE##89!"A22X6!'
M?8,*,\9UJ7!YXS=&_(:)[7ML]04'YN'U5W[HA'":7:?U/6E@78;:4]CR[M..
M!!"O.NW%:7,!$G\@0(449$17"*Z?!:56_1PU,S*8K.("U@'$[6V.&>&$O729
M/M XC^P3I?&U8N"8FJ$@N6&U@*.9D1%?S?55AL5UA^,5V3>DWE_#RX$]KY[X
MZ_2VZ)I;@EH-9D /[,V59LE*V^Z BV/EG87+[=T8$<WR.W(HZ5/E)^210Y D
M9:N9A.\H/,'DLBLFES@CS)<[E:;72'L,QPI],'7F%+BE56@@N@QL"4^2EOU&
M$[BH4E.A4(/ 2[U*&*TF6RN/478;&N]OJH. L*(V(>-%6YIP (/^Y=6%"34
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MV(..+7-(!Z'5\XL!$0OF'F,N3>:EG!A,2M4+FC)Z9R2C.+*A1JD3F,]/QXV
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M+.P.:FQ,.\@ACQ/BY#.$K7*[J%)!YJJ7<ZIP9N^S$%JC'IU,^IJ<DNUB ZN
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MI4 7<M)D%5+@#,T)4MBQ>V>CF38!H>372L'#JMDT%H7BU+V/F46&U3O36;X
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M@K+"1XRX56??07G;AUU[QG8XT1UD>G#@ *D6S7185APK<^U;N,T=?L6&UDP
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MQK!#6 #_N<!^GQE>%.RS!5M' $816^A$E];:JV9:>'E>.FAZW3AV,E9GH"-
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MD=<)194<M7DJSHY$9K%D>Z.IYH6L)MIT_ BG!&8A&X^] E[(BO"%'73"JBU
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M 1'>+Z#!BYZDW@:4^^0[LQR^=E'8#[9%10YWWP8Z11CL'>>_D\/ I'!U;NB
MS5&G71YE2^M,S6&J(.FS4H.OS^?I>C=R,;I/D\A==T?IN)'(XX2,9?.=.G);
M(5!.->0N07,U9\%VC=R,9^NY*4I,4Y$,^$1!.VX)=YMJQ++WI.Q-RS4:2PV7
M?0/-X".K,:Z-N.AM+)U*I'XBO\OP"\L%T$[?/MUR'N6Y4D]F*8 11K-6%/-%
M!IU$,@[P/.>?F-_WE('C%>+.:Y//%\G^BDI4,]*,KO.)D:T8J\4%"LKWL\GQ
MRY;#=]OD/&7T67:>,+$)UZLXM9+/2_RW7;0NTR:_<-E\M4W>(%H4/:ZZ-*:3
MO;'9:2V8%A5KQR^UR2]<]C@2K(NI.EZ1)K-A0B+U2;&<_K;J[2?R^RF;O.'D
M4K(PMS%,,)@D,V7&M77_ CG_!3;YU\G UB\C]V6 /+--OFS2-EX8D3,L+:(,
MZG<G&F[%D:"OMLG)U_N&9#3E\-TV^7*>F.;;_$PS_%DY1:T'=LX<_EP[*'HV
M^>7+YJMM<K_".&EUID\PIC(;);H))R&/+G 9_38V^>7+'N2P;TR6Z3(V2^48
M/=FOS#3WVRZX/Y'?3]GD8RH_DMF./#=ROJ[8="UEV/T+Y/QGV^1?*@/X%]CD
MB8FXTFHM:<)/\CG)]/L)KU;\N9D"$;+)7^L;1E0.WVV3K\D$OAS/YU-IEK*'
MTF#I>@OZY]I!D;3)+UPV7VV3H\-%<CBS.AULALT8OMUAC57NY\IB)&SR"Y>]
M3 -SYLE%R\=63G9)]+5B=A7-DPP1L<DOCM]/V>25I8>.:J[#\CFZE'/6FIKK
MUR^0\U]@DT=#!LC#>A=^W]4U77%6HA(<0 @3_.\,',ZK*(X!MF>4A<$ OMX:
M[NPC(FWJHELI20I3DVIS4,QKS<@9WG?G"IZ:Z,8">6ZF$9$+<N]\]BGD @H&
M=;>+MO?IW79OP4_5";N-UJ5VDELMU6I#F%.1LS6B9XY2*(ZC./6Z;;0'3<^6
MWGB24G2B(Z)RIEB<&>EFN<=JG>5,XB(7PHE<*;JHISV>1#8L34K7\PM\BHFD
M)#)35,ME,]%=/*(J&U';?C^);"S-9:NH\,8$2YNTN"S8O*\4(V=F1ELV(A@&
M/HELC/)CNY4Q$TE)-->FY EDWKOX^OJ?+QM?YXY0>[)Q7]*KI:VG8XT:5*1<
MDTJKZ77:H_6SL_4=A'OM(?U'9;+>3[BGJHIF0-\K6*[G^ ],<Q',@56S=<O+
M!L4+[JY"WM3[$8'J.\'):FL.'$_OFZ!J>\#-^,'5<=068K93FEJM$=\W<OTV
MW=7F1@=$[VS2#CN'=-@5./HH(4Z)O_/?L$;*LVQ]U/'22<$0L;4LU)+IE+0^
M^[+YMLF?N";@7O6X.5Z<.YDVF3>4L="=K)?E?N[\SN?;9G_Z(FO/>V\<'):F
MFV&QEE#B=0\ZMOQ2-7T-:%G'G@0KDN^%?0F#W?(#P;*IPK ZWL&=LA%\+YB!
M%MY$::N&$-Z3Z7*6UE8"O_HN,I#&/+:<7>:2F%XN-ZF<T\I[=&0MNC.2;:.;
M7DNWG^A5?I',[@@/>1 ,)UP-ML([S:<9OR0P0ZF4$+D5*M<R:3^R88RO$MZG
M"?@3_=_(:-YQM:":5<<B,'18[F'5+#7B0&3]I>^O>2/LET=&9@M)OT3CS-3E
MF75U1<Y[KI9NQ=;"5\KLI\<+#@KTAQ4=7W&7^^L:/KK*?>_.E3?<R'[_J]=<
MR"Z/F_5,L3#&%7YEU+ .F5H)\W+DQ#HL\_@*.F\+0KZ1T._/W+F#VULXM'>S
MS&M8=":/_WPWEYX!%$!+*:9BW>5\? 8RTIU5OR?1HH?Y>:"5$[8U'D3O\HQS
M(.,1M6-X?!P>B4VI>3SYZD0&R;W;ZM_60'=U?KGW[59,O1Y3:"Q*],1@!GFN
M2!G=!E>,G)B^.K_AE=,^#]?Q9& (WU<Y_[!2Q&2<#=B>.#G;S>70,*LII2,1
MT_% 5;*V-8M><<P+87L"Q3$49S\M!/K>RT3L<8O@F[G:4D*]X5*?]B@]+T>6
MZ5&X3"0Z <932,3SER^2KE2MMUUA:/AZ%J"X-N,H+[)1E5=*QZ==OA@=23E%
M@M.A[LCCZ%0<&^Q FG6+";VU2I3HBY>.3]4=4:LL<TK=@18D3ATD>W-)F,\5
MQVRTT\SBTJ7CRW1'5#< WJL[+-+5*J26;/$YC]8,WU,X@,5VQT6$UT\A$2_8
M'6AAFFH7VR.)L>Q!0F&*:'H6N1#B1>B."$J*/%[YR1S5[V#$<M&>8-.<SJRC
MD,(2'<*=(K/TR#6O%=YC*L/61"(J*E<U"KJ@>I<.JT]5NM$XWG8>I>M*97Z>
M+(IEH[2@]>Y(=JHZ%MG\CZ@KW:^3E'==2+J]XRS8;16\$7!VEX3M]JKO1.CH
M[58/KA3;[-L^^MW[+I/3FE.M0"]KCJ$OIE:N9:SR6C2+R#]SK]4+I#W!7LCQ
MVZR>9,K'WQB]2^7B2T=/=*E<<V%O^QFXR][8<]8K?M6709)&L^-.*7+K07RI
MW)LNE;MC[YD#G5]TJ1RTDNC[L]YW'SX"H_>M7'QYZM0!X6B\,D_IO-KBZ40V
MLM&OGWXE*8[B]"L%=K_IQT\[?9_;XE?3XLJ><JNVE+,PU)\6FIVL>6FF6GQ;
M_-FA]_B$V.E2(R[;U>DGJTW?2-1[QJ1;SLOS*N8DT$O#3^SJ7!1B(N&NM-15
MQA1%29;\3KN10'N,ZXQC-^.\"\:'Q7#?;O^H&%*[O>BGQ3#,ZPV687X)U/ $
MP5?;.X,VD>8*LX6(K;+*0L\2G1E9NR2Q#9-WGR9I1 3U8O7T?@&%#R=]?J$C
MNQ@7O%0[R9N22*]%KYZM&DHS<G9)+'./?=-3U5O82PIZ?PE%TRUY<C:/,Y+"
M)Y0,K_4762FRT9"(E% \7RT-:/4E3E8><VBFEDDT5ZI+RE P9-IK]4>3F+>O
MYBT)+2F42)S8IL=/P=HNWR2<58W0>-TTD[1!R%8V'[/VU:S%3V4G[V\V;0_]
M;':;MA\"\[@1'(2X,Y8KNJ5/_,DC$^#%HR+BXT,AR;17&I99<XR5"-=KT-U:
M8XQ%;OD/;-F[^6],VP<$^/A2__)QD\>D.U>\^O&)HF?BU8^;GF:W\Y4"J"Q/
M(H!68S[@DDI-D_PDW>CW!#+1;ER$ .X3(!; 4PG@W@&X8(OO_M.I=""_/!3"
MR2)A6$F;2$OM!CK&K?*RWQI<A!!^LA8\0KRSB>&C(W;/B>&CII\LAN_2A,?$
M<&WEW$E2655X!LO76FF#-;I"Y)+F(Z +?XX8/GN,Y\V5[5<#?)6:=?NDH9.$
M;3-YU#3\R.FY5XO!)U:V_\(#.L<KS;Y;!J:3A,)-AX;*S\9,I\V),E4E(Q?8
MCIX,?$71W#L92,H$NZD/"H7@_L/+0I"%GGT6&@GNZ/%B(YA8;6G85)/W2S*7
M3K=]K+>X1#EX<HIG$P4"Q9(H\9HEX7'3$UDF@2E";PT3<OM) [I<!D/%Y,-I
MW$E S;$]Q=27*=UNCH"C3('OZ:I;L%3;F=J;3K<B\?H;DE^4.PY^TH"VN:+Q
ML>CE"XF.5IJ*,E8R"LL&R#5KU73DXDZ0H+>/"+J]=_+5%'V_*?3Q"]Y. :WG
MN'@V@XL.K*A7*=I-T]/>)G3T&$[?=Z@%E2=KO-B=]JQ21I0](HIEW;_N5 HM
MX^0F, TI=__A(^Y095FL5&9P1EC:=)5*>M;E.2YR[E 4G98@,@VQ\:H3$X^:
M?C3G]32L'R2+B=5P8HRE$N$;0PXE[#I^B<;)I[#^X9;$/C>_H C9 2^!D*PU
M*6;"8^GA1*"UL6SXT<NDB48<-E*%Q8X!<UXBG'DVWQ8E= 9D)ZN"R65Z#9\,
MS-,5#'N<OI'$\<Q(-0=S@]'E_HISR6PN$07;Y'SY#7N50_.=E5OH]N2N1%1G
MS"K;*(T&B<A=%O(YUV70KI,%!JOT,+$)*-LLT4/5B%S=A:\HE+45F[MH:K:D
ME==<8SK!B#:53!5\RS$R4:#4 \S@^$ER#%\()A='CL)T*WF:GTR(9*_!4]V,
M& 7]\2416-_2-U23X!_RKHBL[ 8'+UW9TY:N6]#G J_GU>E08!*%?OM>;B9
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M-[@T9_3',U".%DIP2NT)V^8T8O^5%L8FG+0+BKQU<T*6SYVEL!&GIK(L; ^
MJF%_!Y[Q8J2FAI6A/>2%3%\L4NO*I" <[MM]B1@Q-(HQ%)E(D*^(M;Z"W'>2
M%R&]]&$C/502B.T@=G Y&#+V'=W5=#4@9W3RUZ#[H.]KMG"\SE"Q]'7X^:^]
MZ&*$],.'F5.X:=R(-\CV!A,G.@QYJ!60JGUSE 4O V4";0L3?!X['DQQ-^07
M)292HXR0]HE&R);3- >X[O8_9;@PX/N[X88J]%P[14@HVY!&F"CC _<M*]35
M;P*1+&C6.M",72$U4UDK7YQT]P4D)?9(:J>$6I<>&D6>J.)T/\'D\_WA&Q,,
M?!TN.]#R_R&43 ?WFSA->V'M;RY7NCQ62[*X-"F#J4GWB^M,XRUT/*/QE%=4
M([BL7#4^9#R=<837QQ)QSL?!T% 2G!ITX* MLA_:30%IWN?QBB.)QC#?'RW&
MG74V(FRL%M_I1&U":#]P&:G90;V0GCY]X#+SRRQ1RK.]+$:0'#LR";+6']>#
M.M_1X#.68()*.\^Q.D)VPX<-XRVO@GV%J0/AJ$\5$P&[2S/AU\&MF>Y?W\XA
M@&*)!'+YUQ$[^U<8E/VVVWMO/Z_U)4#\\]R+4F!)< Y0[M53N C-)WF!+I?[
M>:Q=6F*YKMW'LJ.(+$+$$ZHI D/["STWO\HV5#2UD6T=II50;9TQ1NF.P>>F
MLX6:'<W3;.KPS,_7!,]8!F5)BH[P_O+]7GN@</#$WR[B 1-, UIO<U>N@[B1
MZ0=*'%$@:"!KM9.?&+G($W,?H_XY+=9?7'3B7']F;0?*? CGZW!'!WY0ML:'
M8FF[KP:Z"U&^B=0$.?]0[@9!2H,U!-#H"/P%Q%1<#W'"_.)8 $_ &A$:>X[N
MZ?!]F]02X$!:3WW']8,<$\]&8(M OK8)T,2?_6V,$AJ-09HNIWJW%Y??O$U3
MH&B0)$@,R(,$D9 IBB#D)$ZHLH(#DAXD,4 EP,'VORT5/=V2F\:D59_FTY@[
MY]?<=M?O0<MVO^GC["@M\PI5EDLK9\$7,O5@_7O<4LH64N-%C\(EW7&*&8Z:
M$34_Z)/ZCHD"#WQB$KMAR?\^KE Q73ZJ3[%]OCD.\=33;>&2IQYO2H8\?GC<
M3T'H&YS>)JUO_OP[J,KS"M^'O,&)Z,WG= &&UU8*>6V5G->'3T@\K%L4-=+&
MHA)!4;DHK?)R2.E2)Q<! Z>I>V:8.0L4=82HT'YTWQS/.B%0OP:)[\^N.:#H
M^XVNLZGZ-THI=2>D5%1DU%%"WWISW/'/=T1<WR2AD5PL+DY$8RW\!@FO;H\O
MA$H8+#<^/6);R&*DPV_N7<_WIXC]+(9\]6;?-FZPPHE^N,+>;?&IK>JBS)22
MHI0K$4G7H!.R.N"VR?G/97$&Q^;LX*FM&M?(_\5N, Q'IHJ#S!73!W<H_4 >
MZP]>QL^E$O>(>UE+]E?C9[OD;U;\._#096=6)W02PTJI"="Q(;?&J."\"O$"
M>&KESJ<CY)N9$9\ D7B%>MM9C\!0.,LQC]WJQ6\MD?M3IL%!M&:1+7*M#"NM
MLC6L8L_+8JD;@)!Z 835KL@C7#@5Q7H1CF?(-@CVA78'&^\#Y!'+/GC]N8Z"
MI06IT0#IKQ!U!%0#F035ZA8C$";9![L/>\=A_\2W&Q,CQ0T/WFN(8IK;O:)@
M=V/FZ\'>AF<C?;!M #M^N+U!!CGQ>_5=MIL<>[LD.Y$)-CX"BS:H[X)H\"GT
MWX*F4P>H(/3F<&+31UC%RD7^A#U# 4=<'QJ\[L@.SNGN*IMX(\5[/)^%\G#0
M82V!\,?;*?UU'>Z=_4GLS;L/L0(;]<=P5L&/PO;PE\%XMIT%I7K<<"3A<(/]
M-!;;]* I*_?FKFS&V5/%TK[CP,%LJ@4%BZ&G>+Z[M[//B.4.52,-3T)S$B?V
M'1PHQO %J>D&%S8=Q][+AX@>'B4Z:/^4S/]]V%N29=FG.WKBQ57[U,-@$\17
M@3@*A5#.I6P"K$&8373/@^@$)H2;8UO!JF^N$  M@!52")8[10TSZ3**IR!!
M393':NB^C_TMUX9O@HT(4!@=*)D&&/J;FRL0$6TB?P8/$ULI(4CB9MO,&^EA
M"8!I4 +@4Y329OQW:@:X?WVB_MBC<$#@K3K9TQ\=H<F1:1$XTHPO*.F12C>Y
M<?T\^@/Y J6!Q/KBC(5SWZ81(/(4Q(2_!XBBJE C0!&'& E X00+]=%O$2A=
MZ-$'[@2J$O@69[<X0@!-X&17UX&% KN#ZW@PUB$R=.R%-]H]OH&V"@C'IH&!
M;H4GQL,$WX!D!/;W4R,,'^-_[YJ]V.#I\>T:!K;)MO$38]VUU*T]C8<3?91
MMG;7OK%U>U'BN"N$P2;H <$P\H!1$S*%)31949*83!$J8!($12G@H!1%%2NP
M"27;SAKB@F!LL]D:ML7AL0P339-)@>RDFCS:TGH%86'S=F5XK&1&QRWFYJR-
M3[%<V^OW'3.AKWO<L5P40<J5I;F<ZV#B?&VL<N4"[K-!2_)Q2SF[K'/+?&*"
M 5USQ:P^3F:F]6/%->1A>52WVD,32_L"7<A+M45>JF_#&@]:5C3<<<=$0C?\
M2FK4025,8MV%3-ZUC&(F#(O=X!^MF4'0-RS[=-;\*Q,*DC<8\=%."/JC/>#8
M#9MXMI.WQ/5?H,PY-'_YN))\6[#G>5Z<I=+[DPO_04'5O?JI;X]C/2<AYY@7
M]R%&O""-D65$M#!R9-E\(787FN@ANP(C:F@[JS-5:PG\*B>]?<==%(_MTT23
M2MH>-J$G%=E/X1@F#E^Q#U4]9I*=)+@>)8UPX H<N!]1U@CB4]9GQ#3#FU%S
MSCK=&[2$I$OYKFX!U[U#2[6-M<9K/$OR:;SK"\0RG5P. PN-?),V.^9/AI='
MO"86?AI=%Q%+Z1Q2SQ]WHV*9?TGF=X3+A71+;\AVO]^3F+26/;W2E8"R1L?D
M(#6L-@*?XP2R3[U2]K_WJ=/#T,K@F1!&<-KL:.1%'QP+PX;!5[A.6W88._7=
M3?@#BM#FGI$C=>1M)WR7N0I>OM#AJ^%K$0M.Q0[6%$B6<-VW%$O5%3-P!(+R
M;T%CUU,L37$T%PE*T.G:LV=ER#^5A]M(^^&,&^2-B_//C<R=-9(?QNW<$3#-
MG?PA?T*I"J-GF[JZKXA-_76#=(%[+!;[U:I/#&;V0..%D7%CL4*71:W7Y G.
M!;WQQ#71&7=.??=L[/SI/;"7P^IO-D)^$G0.-*\0E!F;AY<2;65Z<S'1-:),
MH4I;ZE ^@;E"MH*;#?=7H.KT+7TCEQ+\0Q:W:E!V1XH#7-G3EJY;T.<"K^?5
MZ5!@$H5^F[MZ<*&3Y4\TV]. "E]A7B'!24\X,>RAU'.N+ QD_$[FLR6MO.8:
MTPE&M*EDJN!;CI&!'6^[<?^]*E2S1W:6PUQ",4@E%,,1"KX7JFZHP_?WAUII
M/YN1UT!2;%3@1@/7;4(0_4Z0UPQ)7M-)<B?&.SK\1C8SWBF!(X>GU6?S&*^1
M!7  8M^/Y^9G2>13MU8_OMC[89;4L9N\]U.=/G"E]0EHH>GNU%16[[G.>S]E
MY[4<Q#XTZ@?U@8-__\^KJIOOW5Z_'2X1<FT(T$T18V7@ >=6,1?*RMTZ&\GD
M#4'=53F_8PFYR31+)O^+W/\93'<SJ+W1!!'[O=.F#R+RFU\]C,EOOWNADO*6
M=N$-\?=1_(,[[3\M#S$B=M2;Y&>/G'N2L;^K@D)7<T]2-PRZ__(A8Y\HOP_7
M"/7/H 7ROW"5"G[YUR->/KPH[7"79O/5"]7]=Q>Z8RP]P*"%Q>#)A$PQ"57N
M$Q0F]P>) 0"D0N,:O=V&^OJ+TX.KEI'[FXOOMAR;0CHR8VQRJ3(?7(*6%JI-
MOMH\]<7SYT_M/=5VX_E/U3\HKIJX89*1*U4?5 4+G?' *KP-_X*_!G]BURA\
M]-=9U/"ICR"_^M* !^Q(,C=4S([(L(.^>7:O[ *X\8X['MZD'Z)B:IP.8I<W
MHQ>D]&R.V.&"_]*!E=<;!#7H+KS_A.=S4GMWQ6CB!F?/QO)7ESJ_'_3G".9S
M5EI(%G+SWXVU.W*"6,M_:ERC6<@6JEPU7>#*A6I@4G+!9;<RR9!,@CI@9O@W
M]'*=B6(>*T<==(@4PJP_'/\;N>L:V>M[PW[E;?O+SV#A;(P_@P=W4HD_EU:[
M$X^"!R9X=K<+$A9N#L^.R"S#XO3QPU!/"<CVJZO?0:?;P./-'6E>)0T/3M]_
MA;H_+V'N^D/N.WP?@4:Z!U#X0S5X86"=Q""Z?&,G.M(/??D,7Q7Y#/Q#%,J%
M#-?D,RFN#%4]+^9YOBG*%$NQ]/M@D+:#*^Z#_5?X5VAFA$E8*<54@O*/X@@
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M_.K#HE7= D@%?C]R$=[2@(:<Z*CH2^O>E\K- 2&^0I#8[R1'S9$#GA6D6.]
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M( PCY_:T^?_/WI<V)ZXL:7^?7T'TW(DXYQWHT88D^LZ<""'$#@*$V+XHA"1
M2$B@!0&__JT2=K?;8+?=S2*@3MSVM7%9JB7SJ<RGLC)YH=X5;6CW0PZ 3-/T
M883+.3B I#K\3WG]TJF2T!0Z7#UV_+E"H]*L2%U85[LGG,GW1S=J$G"CYMY8
M <FP;3!_)<,Q/-4&&,'I"],Q_<"+RT6\#1.4M&F&I*.6Y!) E'EEQX >1@H+
MZ8%<&L]1Z!P=7:]#8'!3+,%O@X$OU'NNH4=K82794B:_UG5\.@5@D(VCWE@<
M'= C-$!H<%NLP6^C0<DO<N4R-^QB?&DQ-*1V9]:CV@ -8OH@FT,G_P@,$!C<
M%HOPVV!@"KM:WR,Z$XN8U[EF-,@L:CHT#9[H!.8P#<=OT0DW&C\@M@1(&C1+
MJ4J3%QM"ZJ^Z*$E_GSMJX)% (G&C3PAN7(1?$)<&?)TSK3B:NS#JK@^OS8"A
M@^<<00M]4:M6&IK!RG168"-AV>L,I AT#][$3Q,Y @4=7/WD 6%'0K'CSF[D
M'X>.@[/*[L::R9ME**\<8[7):QF3"3C0*T@]T&GL2)PQ.JM$B($0X[*(<1'&
MXF.(,5_U^FTW#/M"V+7D1JT<M/$%M#%8:&,<"VU"@($  P'&/=(:GW1/N)U)
MUZG,NB#PS?5F4VBW2S-["KH77^]/L^QANL _)C.2REP4*TVNR5>X^GG"'>Y(
MQ1]#7R]#)P0SPVNZCONLMV\3CX'=5[)3O6D*&7U:7:E%<<E4.07'()> I['L
M.2\PH%T=Z>]MZN^9??J/ZR]=Z>5J?:96M,)AF#/$#K4=;*90?V&2_S2%H9@"
MI+](?R_L87]<?RMC3>,XRJ.MK5Z7S'9[7:N$L?[",( C%3J0]B+M?73M/;.W
M^W'M]<.Y4.R+P08C!+XVWSDJL\M'4'OC5 #T8Y_:__!]]Z?VZ+C^0?FP.\N1
M?P 0>UKL"#YT]%P)7PP+:ROTF_[8&DR76Q;L[OC>N\;90^L<'=0C%AVAQCT>
MU'\8-3!E.B-K[)S%Q$S!7-(5I=? (X@:\+0^31*'^870V1M"#80:]WA8_V'4
MT+>!;<PH=RJ8MM':#/+=;1F+;0V8=#^+SNL19B#,2 AF7)C >!,SZ)#/M[6\
MW[96%7I>* R(L3QI0\R _ 5-O%>RYU[/Z9]O&#R?U_^=3C6%+DI2<'>7C^Z,
ME3A4^+=Y2TN:&6-F4MO(XJA6<-S :U4<X&$0,2]!GJOF+SKR1\J?$.6_MY"!
M][3_S4 ];]%;=;2M%,A2OTRH<U;A,W(;PD!,-&#LV<I\H.-'A 2/AP0780Q^
M"PFVM(*+X:2[$ P>=[")UFN/81@1$9,'U#E3&2(<0#B0!!RX,Q+@,^[ )-\M
MNF7<REI]I4YYW2'6&KH<U/XX8I\^/0UP0U$,/V4<2.6%HM@14EUN($@IL7FA
MR(:'QL@'3W]Z$?+@Q\6>HN<N>- /TPG!A#[=_'$=/V^ AQG[=EUU8_C")O!4
M .>FHWK;2F L?  Y< 2>&R=!J8"Q>(8?O&=V1&Y[:E#5ZD8V-7N2Q1IMU^&!
MV4'N,QG@-,ID</UCBX>>E"2"SYT%1IP7>UY#CM17!:+NN",A,^]LP(+7& WC
M(.3LRR3FCF1/02>E"'(0Y-Q15,5E(2>#]09S5NS-!56O#/4V6\\ME-C*B7,I
ML!2*YT*(@Q#GVK3L>?F8*WE835MR9*E;,V5IR37RO-8JEJH1Q)Y],@8&/U&A
MBEL(\C@K:W,]9O-F ":YY.]]\CD 19Y(W[SA&!/SF'%B#HUVY*J&B4FXZ^4F
MT[$B+X!Q0D$*AL+>O<&&8D$0:"#0N)L8DH^#1MF0@S:YGF_EL$;X'799K63G
M$02-[)=_:!+EG$"@@4#CZJ!Q02KE(Z"A.=M.;LJY%8NVO>6X.^!<F8Y!@P6@
M@;V;% Z!!@(-!!IW1H9\!#2HA6UG5^S0E8F@.U^&M:6[J<;N2<Q?D.]&J)ZL
MS.8-A:LTA>[/13)21;&3ZI:%5$OH5,3"99-PD$"+=#<<VT82HMG^=<$+;I<?
M>4( Y#*778S@8[EH[45!H7O3E8)EF*!3+ RG0U5H*WAV'V&211$F"3A\N;;F
M(,QX@#"3UY#Q&BD6*JZWV:*=M?K9$4]3M0K.-&.DV >&D$=2X:)C6H04""GN
M+3KDET@A]$=*;L/L+#H_Q2JCF5/8L1%$BCB>@SC"?R*@0$"!@.+N>(P/NR%\
M<5ORYLOY4-C.9XM>=U?EIJT8,IYJ8F3?]4-.1F0DE;40N$ZSTBQ)SYQ%2^BD
MI#+7$5)B,<6+C8;83$E=D:]]NY7R&<F'SK,G#HZGX%-P</4Y07$)2"^07J!3
M-*072"^07B"]>&R]>,3STSPG57AT2(K8B0^P$P5S;>I&S$WX,]4S?(6C,GFU
M/&5I89&79NU<X!N;_JE/2HE/,!2"ZCE@#OV6X4FPBWG5-[5#I@+[P53,N))D
M-.<CV9BL=KW-1A7+Q4C!&7A@"F<'G9<B<A/!QPE.04Z#'I\^-#T%>KP&C0JW
M;:_(S#PG$QMIK'&N6VBV8M#(0M @T)5ZA!D(,ZZ/&;][?'H.S, -?.U[\]%4
MSF1VEK>M9ED=BS&#C0T-"F$&P@R$&==W4W[W)/6L;DJ?#G*V130I(>3">@^O
M*E80QN@!#U3!]%PF,#RI+$:A4I>[PHF#O1\$#9#J7Y6A*)AV&!CZ>\HO\O2H
MN2'ET")";"X&:K2F]+:"LQ?@*)"A<&T%03CP"%3##QAXK?US9C%T59=>R^K$
M<*IC?=N6@PAJ?TPVX&>,OD3*?VVM0,K_")S!V\I/:6:GP2KMHI5Q_1&1]7-$
M79Y"Y6??,/N1\B/EOQ_E?P3G_P,>0,O)D:J>48MRK<=TRJI TWF-@S#PY/X?
MLH</?B^\+U1*Y:Y02'$]H<.5A%13;N2%#HROC@.MI=>1UBE4U.#.4F[>9'P=
M"@M "H44ZK0!JTAVD$(AA4(*A10**5320\>3ZD_)$O"E*DWH,K7D;J592KUY
MAQ7=645W+="=570'">D%NIN'] +IQ;6E ND%THN[U8M'/-MY^#NK)R]3G[SA
MGR7_WM.)<*!O?+]BKD7!+&O+J4@SE?')8T*Q3YP(]V/Q-G0.+)\Z-9KA8FQX
MXB0^'?;%,/#A , ,OW6W1(CTSCB[H)9"9MTWI]-)KMG4I@J!PP!1ADR3&)[&
M<OB98D70D14"%00JOP,JGXXPO22HU!=C5]QM14)0\RNW-R75Z1R+0046/<JF
M61Q/9S&4^Q.!"@*51(#*[T:N7A)4U)'DR3S3&&/B>$VX+C4HCC-M""IL;*ED
MJ5R:H0XOM"!00:""0.5ZH/+I@-A+@DK!<$=F8Y4M8;6)W=6H^4XW5QP$%1@=
MRQ!I@L73-/N>_W/WY[>/=D/VY!B! .'J?,A3H/P!+AR!!'N=$0RA:63EOAX.
M6N9PL&AW@/-"7(H104;%M34&H<-C$1N?0 >L-6,)/E.RY(S4&V["77/>(R*(
M#MDO_P!; :,P:#.@NW4('1 ZW =#\0ETJ/'A)G *JZ8<SF6OU,AGBK-R&Z(#
M&Z,#@3-IC&81.B!T0.AP'U3#)]"!84KK9GNE*C(_'??LH)-;]8NQ[0#)!I9,
M,RR1IIG<K\B&_PE4L,BG5^G7.KS_S?<RW\3'%?GD03&: 5;=>ZU<L$L?83"Z
M,R.E:IJ[ !W<@K5).6X >@)6+ 5&:X)'3SW53BU5+TBYDU0 F@,QTV&];1U^
M%U<W5\$JIR:FHSJ:"1J#=0Z,!>B6__4[,W+N!?DHC.KF^ODK^/+\UYIMJ!Z$
MEMF_?UY9$K[J&5BP_SI+5-/! H*WD*][^Q\ON_N#6LUHKNUZWYY![<4X9OME
M)F)\FQJ9L6>H5D:=@%=]4^U(W?I/XV+9KP3U#)C?O@,C''DJ^Y5E_ROUXULX
M_H/)6ZB;S(LI>D+3C&U,@F_[OWK^*$;"Y\]<WX0:_,TS;(!4:P,^^Z>GQNL0
MN,OS+<(KG2&Q'SJCIF8>Q-'_[(K\T?T;?@^0"""D_>^7>O7T$= LB$109W@(
MRT 9OLNA^E(6WY7"> XS8$O[T=NG2?SQX<^3?S"K^U\"O-7^@BU2_YTBXK_\
M^]5\_[1L^(MM\>F%^X_>>/SSLJ@QGBM9FC5(AL(5G<54A:(I3,FQE*HP*I[+
MTN!_*D-]V4_$:1;R -A^H5ZMCMCEZI5!*E\1NV6AP[4$N5OAI?3>#*DT^:_Q
M$NW'PXO-@M"4A +X1A+KE0+7%0I2%WQM",VN)!;Y,M<L"=)5A_2]DZF7O4S]
MZ&:<FF'?T52E>4)0_FQ/X\009;%>$#H2A&B<^7=*:,N5[C#U%\^U*F!E4@6A
M6.$K0I,?_GVA71-T["_YJ_05V(FVK7H^V/O ;N>&/K!9_'3*V&@&0(?8 DN!
M#4^]:+\<-=2!O:M?\*4G,G>>$0$?8Q.58!0=HP$B4 RFL)2>53"<'.<F!/BJ
MLT_JHS[;A!DRV-2+E#JUQ-4P7"L^MQ8)#IBSS.N6$EDSN+ RVLFUN3MUNM8.
M\UG@6T):^N>61H?.FC*[E61B(9KEEA)(\PP'6E*O6PJ*KB][(Z(M2\TRARV+
ML\&H")]Y\/:^FY\-ACUM8M5TNF44[!S-E8'MJN#8ZZ:3_I#C,6LL8M(TN]&*
ME$YF-E.%/.SH>*:M"6]6L&71'9;4>H7MY6P.M#SH:+@U%%&UL!P6;LK%GC!>
ME' -MCSHZ%)N#1>58E'!)),;U*N%$=8>1:#E84>QE48V!!)O""6GG1FQRYK=
M[K9A4_)UTZG0-NW^&,M9(8/5=AC=VUEY3J$.Q\1YNQ*EK H;8=NINVN?]5?-
ML*UD#UNJEA=D.ME*7^@7_5H_6*V7;G<*6AZ,?J:J]%;V6C)F&.O\Q"5S886/
M%%HY&-)NL:,;N9826;6=2+=(NR:5"K#EP3.[AMATYBW*M$)J2VTXIK'"2AQH
M>3"C_K:J!1KF$4)MR^1$.C_O3[9MT/)P1L>LB74RA4)%R(Q:LUK "S-F"!]Z
M.*.]A9YS@FI-P,+.IC;SV++J[*; DSMXZ+!3'9:W=;XC][T.;^=EBVO4I@I[
MV+++U:2LP?N>8.#<V)')JKTUVL C/&A)E\U0<*DH:ZD=)=IRW(8>T$#ML,.F
M47'5'S!T*6.91)#G3;XCJBYHBA\V5<*50*CKE2V4MI0]J&^5W2X$38G#IEXM
MOW-F+#Z6MT1FW:T4F,UJ/(5-LZ^;$H.<LER-!%D(%Y-YS^OGN%X FI*'3S5,
MRK:466\CJ*UBV,IN"NY6 4VIPZ9+#=.*2LDG!'.@%ZWV2 7=:<.F!Z+26?D>
M,?9[+$;O:CRQDM=-=<3!I@>RPIG-8:FO#C5YQ>?: =:EE/4V@DV/J-_4:_:)
MI3RRZ!4])JJVX6ITW(-#::F--CFSA75D*RRW^%J3TXPJ-855@0\>JRN[ 5YP
M<H9E>C:3U;!QPRQPL.G!P"@5FW8R>2>/A=U508UTALAMXUK#!P,;]/26:\GK
MGK @'85BMR;%-MMQ6>*#'IBL!UQW8IN5:Q.S4)&$4="@]FT/!M:OEIUNV*E'
M6'_2$5=5KRV4>Z +1W2[&V'%]KBD<)A47.>M8:M06UL<3.1]T+0SR$D#)@*[
M0&U::X[6C%(*<G'BSX.F5(%@.&&P\V6B'+4QE^Z5=CJ8V2-*4ZOWI^LE$U0$
ML\<'C&_/E0X.]H C2F,T5S/;E1N<L%7GUFC9G^NE003C*@Z:YK%HT<HVJYQL
M3-U"K8*OAVH[;GJP7GUZ03F5=GYNJ:RSUN8MG.GGXVB-P_V*,)<8:4EY3"VN
M75OL!=BB$S_U<+VF'6)=&.9+>:PV+'2X_K;1Z^?CR++#]5+9I=_9F4Q'"&O^
M8EVL3<UV/>9P#AXK<,:F@[6CK:4.1,FSR]':&<9D\,' BMW=AMW4EKA@D,J\
M.15H4<ERL.G!P&8S1]ZHK9TLUR2#K2PVN%R9QT\]')@K4%L[I[(YJR:SM6Y_
MK@W#:?S8PX'E;+.TM;RJ+O2G'5[KT*M6"2[N$91IUAK=NL02C$#0NX7<R.EK
M*0)=.((RO(8UA@I-= 6B.%%GQ* Z:^*@!T?TEJE:.:\ZE.J"JJV 1F@8N5Z"
MIQ[1A)XS9"KK"<,*B^8:6_2(>F.=FRK$$4TH\R91H)Q(LE9X=L/D:F+5("/8
M]& 1++E3XM20]S!1[F5(LMA=6W;\U(-%<$:*.Q3L(6@ZVWD3?CJHEW-MV/1P
M$6I%8;IJ$,LY5MO*E4&]GLN2^\<>+D)^W18[3:(SE/OK]KJ[[=>,C0S:'M';
M:<D-<94=1U9I+(GV8-P:EJ0(-CV$N<G:R78ZPY60*9IC6UB-+0G8F*#IP<#X
MBD%F5MQP:*UZXVI];!/3M1$W/8+?0YOF0Y/LR]LJ8RD;B]Y.U_NV!P/C[<(8
MKP52#5M-Z+%*YL6<.P$3=@1EB$J&&[IT=22+[?9H3DK57E_D(*E[J&%>?3I2
M-T%=$(5<19!\UM( 'I!'4$;2#,W+=LH% 8 G*XR&Y-;- [/PB-X.EK66V59[
M2]F<N 4>V!*F#9L>T021506NKD\QJ]2TRQ7<GDE"OPV;'BQ"@YY@W:PB"U9I
MSFKBHID;E"KQ4P\6(=_0PD6H%O+"5FFU_#F143("!YL>+L*(J1"1-.YC0BCK
MW7*%-LEQ8]_V>1%BMO@[J[8_,M"@_[?TC6_/W[QTG&C@^3PQ:Y!YT?;4SD]T
MC1H&[L]<3?S)3_S*(;UR2'$%WG/'GEZ([_VR7YZ,/ ?.O7LW\P7S\^+Q+GCD
MQ':C9Y?N^><,/&#YMJ<0(S!-OV3OGCS%GS@C=>R[\$#@$E3>1T[?\$^<OKV@
MC?_T).[].[-H7:ZS+NS7'(76)7GK@O0EJ>M"H'5)X+HPOXAU0>N"< RM"\*Q
MI*\+PK%DK@O"L:2N"\*Q)*X+PK%DK@O"L:2N"_7N?5^T+M?",>K==(=H7?YH
M73Y^4_Y#[/XCW&@Y<^[)/\H+L \C/?QZHD0!OR*K+W3'X*,"<3!!2$+.+2&_
M<@>N"A#7D8=?6>)(:>Y':337AC,25Y#\78AELF>?B$\*RWM3PX'>0:M(M4^&
M('<A"0@^$7P^$'R^K1<G&-O[GODMC^U7WFW"A/L\J>R19WD9';X][#^[OWEB
M8XAW%PO7N15#Z)KR\'B&,I(-)!MOR49+-?5,!0D'$HYC'K8&KQ[8,-<)$I#S
M&5]G=C)N;THNXYM<8TI.DAXZ<1KT_!;.,U4;/+-LV&L##@H^7W7\S.%+/G-R
MB!#G'+[-S^GB\.4F%2>VND*VN#_=IJ3 U:S47_C?:).ZG!5S9^*#1 >)SF]X
MUNK2#&[G_ D)3Y*$IV!,3,T,D/!<1GCNR^;IN@>X<T_''G=ZEGE[4W)KYR#[
M1,S[4U)W@K#UC.G5DSLE*#HD.6*"-.>6- <%6B5VDI J(55"JH14"9U"WM4I
M9#)4"7$'B<>4$UP>..E=O 25F_KC$Z"X7!,B"SY!Q.+X[S*Q%'Y//"RW<$,G
M. $1>Z1V?%+!)*_:JJ,9*35(554G5+UM"D^G8)&UDZK0#<W(.>#UXJ/_5/V^
M=Z?C#,7].%\1)[ @ AG7]B.4IT)\\&'[RFO"*@0HQKN+I>O VE/<QO2_M]J'
M0,<G_0T#,L0*$3*S9:6@LG*_.-N.QL:($XSVRW* E6;Q$P4!/U+R;]G;1#NG
M4VT)M89+=]DQ1TU96#N#^/)/EDPS.2R-T\R1@G\WJU6W:,<1MX4]_SJ1>.R9
M@T> '5DJ*!U\)Q2-#,-;)K>CB!PS&K.-ZV-.AOP,Y,!'S\#8#<_?]^0[YI#?
M,6=5J<F-W=#GL,5F,+>YR:)B\!!SL@!S*(0U"&L0UMP^UOS(A0 O]%2<I\"T
M)]R9R62P\28X91F\5JYWV%DDLM%Y<6<WR*_G8M/1Y'! S_I5J[Y9ZQ!WV"__
MD$P.&3H(?!#X_.9,I/Y*%OITC$ U'4,75,\!L^8_P0Z996H-&;,LH2:K^;57
MDW*B=6)S!\PF>,P1_&&\W;0[%S)M2YWTQ4)_YAE&,ZY3B , 8G-IEL8/ .BT
M-P@0 GWDS.DA$0B>+"$$>@^!UGAU[17Z9-E2Y^)PL=O4QR6*NQ!X3%B[5?#"
M.2N'>.1$17U<<[(Q>%!?_L&Q-$UAO\*.I)VH_9'@\S/5F8(WZ:$'^I0*9D8*
M +V1 ?YM,$LMP;M</64XNJ&G)&,9&#]B,$GLJ< XI(>_W<H1R\?R\MQ">.WK
M,^8/Z/V5XRH3?7YV'V%-%Q/OLT<C?7I7.WF&,"2L2%B1L")A1<**A/7&0C(O
M**QGCJ0\D;#>0>!.Q??#.#C'G0#_&AY @C?"]!B@?X87>VX2<';]%#?UC)C9
M2Z<<([A1SNO"?EJR&)N# ZLSA-T40D^%CU)P)>9E2*7K*CE8?CW^X4\/Q.<-
M(: ;T]Y")AH:U[0JIJ@%OQ&$L[0W>X8'BK^A%V*:HA73$ONXG%CFOXO\D="<
M:8L<L36":@LF)@7V1*8JV(936!B:@Q/I+(VE\>PAZ7.C>G,#>]_E#Z<2/RE)
M/+CZ;1#Z*#%\=03Z$,W\#@#U5#LTWL"?'XSS8LQ.56':F%KAHDIT%7Y!5O$I
MP)\LP!\2X0["'80[MXL[[X?G^')=6+-5J6[5HJPYG"E>T\0^'Y[SQQBTE&3%
M)DJK@FSV6"8P>8]R(XA![)=_"#*=HPX/S!$.(1RZ:QRZU?,S)#I7#S5)_*0D
M,0SEVOOZ./2HB"J3+4$:+D=.K2 I 3&]_%X<+F>&M:F/>6S!A9MYT<$U)POW
M8AB! C?CH['[MQI\PKM.W#]X?=AQ _!8+?[$!\/RT6'"+02:(+;R\U<&WV,L
M^>\*($Y>J(=D:*!I8!K^$1*3PXC,-K?,KV1UT>CV[('?-\H1F 'BRS]4FL[A
M:9HX(Y?PR/J5Z%1$]Y%Y*.FF0T*HR%^@2VQ^?!Q<?E@D\VB%#<-N?X/5S-R(
MY'0KSX\X,'YXD1"!"@(5!"I7!Y6+\(SG AC"=W?U4;6Y$/A!J;6C:D'9TR'
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M4OEGR&,)8\<+=C(5,3-;-B7!QCH3R-\0,7F,I[,LEF:.'$8A94-)H,[E-3T
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MFF&NU;%M9(!DZ4;,);@PN<")0TD3,S'(G7H<+N'.[H@?;@C<DQYWOJOQ>[N
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M&RF"-/E[A)LBJB0;!11(4^!$982(. 9BU]#Z.*\E$7<78:\>I#EGA .?,*6
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M2E/S;SR#JQ!7K>9"6W6_O@6SR<#2:/NM4-<6> WA!:GV@DHTM%E#&/7R0XU
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M0NZHT >]8I.]\@L:1\Y7R?;'+F]LE)/ *W4D66$R#UDRH=C]RA\<1E(H\@[
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MZUD$\-@)S"R@V&(7#[MM?F_I]0L01?FEGMW>WM?T>9@@MJ$Z]^AB?U!127:
M0B+[J\-D_;<.69SXA2#7/O(LM/G#+Q(ERW/SB3*3AG]3U<$S#:W["[._0JL_
MP-4EGWG0J-MHJY19OO]L<S*MF<9?0W-)<VDCZDVG$PCM8_([:UQ/E4+3$W17
MF)UCOP$+-B@XYX=S7@/U>HNVICQM;:,10>6EZ (0*N^H*?T3<4N\IU]75[0T
M =R",]V!!AT?(690:?,+'#5P-ALH0,Z JA#@<  1INTD?26!IIZ!OLS>( SZ
M.8#.C;7)U8CPP5)49C,(J/-81= $TNM9[ID*@E1L>8I&6IM[(07I#NHC^3*D
M:C(7]G[\CB$6)JP\T-\U1/".IZ1[ 35&T*?91WFE8C;UMD^B<[33@C<<5N2I
MO1GD!,E$FBY8:YZPK_GQV.9L:/AIVPBPT!N;S&!]0SPT[MTQ&2W7<,Z,FJP7
MZV)C7N1%ZWXWP3_Y0[@,PSC'1=,\U>6@@3]L:/@!R\:L%-JT8[X1V]DZMNDU
M0#ZB]C9L-)@[3=N H@;>(1L1@&9U7ZB]SR*=W"("Q8D/"%4_:Z9[QO%9D(^&
M!'ZC;G!5_(^S,M'_V>]*O=* ;/>3@YAB$N@E=RWQ)B+25F8PT/':QQ=^8P[<
M[[^GEF]BG;18R?+J?#%S%^%9/C7<V\]0<M$PJ63:;3'<N75RTZ%1*I7V]C.L
MH=&DG9IT;\3H1)&BUP^Q\&-NM*]+X="M#R.KGE*?J(-:5IU7Y7LMNMC7I;!W
MHYG%Z:);G=3%5"9F/N5B3Z/FOBZ%BW'?3=?2L<9DE7/D>,_)MO7X8E_O03.9
MZUT_5N1:MYZ=]1]ST905U> 6PL[;$\9"M.?]0:RK]O3VLMA?+L9Y*+_;>7MK
MM513B>JUV$7='M*;$31(5)N!?H;^DY6TK71<^2G?K>3MR?5<J$3OI$4_L?MD
M0<GH[M!JC,3I+-.O=8?F.-48]9.[3V;4?K::F:[R8N\!]>S[VIVNY!?XR9T5
MV?7)+.7,47Z"0QY[5KUM3B)) 3_IK>C IR1E[.[JV-U=K??Z/2<B$[>57-6J
M&3ZL&W%UK/1O;\>[+?@.VCANTUM:YP-8UP_ZGS!7KMWB@+_>*HOM8QPRK<'N
M?4*RZWTDP;,7QGZ0,(SLP]U4%7/Q-OZQ-IPFJ]OG2R\]N@MC?T"_E%E#;WDJ
M;0OAMT!CV/<\"Q%H$YR]L/BPQ:BD@P)S'2CL/?BB>_.SSP/?/TN5"_#]B8'O
M4]$K/G[!4-SU&$Z *II.7!AQ%HQ(7AAQ%HS@KR(7Q..SX,3%-IT+(Q(7Z.ES
M8$3F*GF!GCX'1D2N+EO$)_+AG7<>7PT?CK?J]#M6?=#-\%\O.;VSXI<*#FG0
MOOOO3N7EVR%U7[@.E$J?%&8W_7JMU8O$VLV"/$.LBVB\6S2BIT5@_K>BL9,$
M^V3).#V*NT^FG=6_QVY^;(<XL6!L4.;GRQTACM 0XL!6XGC"<-E6B.WX &C_
M13C^E(WE$SN!_/&[R/$O;6Y0HR4MN*D$12R2]I[.!2\K^ZE7=8J[R,DS6/>G
M )O3'/4?>)MX??">CD3R8UD;SB=)M3]8"7:L4$R-/GP5US^7Q]IVXRE;#3GU
M80MA4LR1O><J;L\>#!."DHITD^&>V"LU>H*0]' Q0]'X09#G_ESU39P&2N#3
MU9>F<?] [3T<W-&'U-?.E$1G5D_&)VJB)J>5YDHUS 6#C@Q%4LG#J.]I+/?G
M:.\7R-3V#&L"$;1I&2.XJO$-PJ,CND='7>2GH<>]>FC_/>SGX;T?4)ZRWK ,
M&6O.:_93S;F51U.IRQ/4J9AFM%CHW(0%"A<7B1ZJ;=,?HHPO'[E_BT6^=IS]
M/93V"$[/N[36F,;APG;\H1NN:76]JU>5:)GAH65"?.(@:&@GSB%]_R110=55
M>XP4;F08RB5+=( LT:G[O![4<SK#]9[:;A_>V?)TM@@J^YK9'H]:O:>4$9]-
M<L:]9602J4HD(_03X&RE^ .%JG^J"7@FTW1JE3@+?^T,Z7)J4W$$%^]=MB)6
MU/2&'I['^5DIM4@NVMF&W(6[BMC%2X32D9= (B^)K7--;'4,AX"\,8FXA-+O
M<N@V3%0,FRC%<.%ZW4EL]V<> IYZ8:<VOH?WT["YW6-DX^WV5*XT<H_\+&W=
M=\=30T?7<"4;LE^I4"1SD%X)?XC*)G9*L[Z#RC('ZM3K.K7&'L%=VJ^RZ;M9
M9S9(FME)-.W4''<22?:G3:RRV"^*9 [5QO*KY;X.BA7,OP<YY;TP*<?'-']Q
M31]<Q8&Q* J2:MU*FHL"L%V[6!XI.3-:=4:V-%E-:HW[2:27O'\2=M'-]S_W
M#+KY"9$_8MY5A'0T$OF;*PCE%G<K5+LB=R,*[6Z+ ( >&+N-R4@0H8E!).&A
MAY@M'$ T(0]4C (J4>PK#VF)8G<1_ P/Q%D%T,+"^MNJ#8![@)]!L0!-+$6(
M@J$M#%=3 (;*0C)2YX#A9!E3"K$G49Q90"N#=X0 ,HS@"@)4&D J#@$0;0T=
M'6*@5&0S P0K>(;M$@/D+! "%#5K@AP\#-A+%2_8(:@@\+[ &CF D_I,O-A7
M:!] W_2!!9$-1@\B;#S#("_&*K(D2QZO* 4)0!>F^1- KPT@ "<8'< /5P]\
MH.JFBQ?KVA3YRX.)"PRLZ@2#SD*(&UB&A/F)YDBS/31QP ZC6'$#0 I'<&_P
M."2JPCP8\-EOKND:@,5"A,CF?KJZQ)H)_2+\I_ALE,\!Q#U,8F3;!#_\&7X3
MN6;2#.!T06$&)NUEP0B_C&*AC['V8YYY_"  :F3B7(31_D@"%:!6]#=77TL
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M>:U4?S_?R2FLGE&6@^NEW^1W]9LH_(FE.^3EE P$C#WA>[3E!YNB%]-LPZW
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M.2VVMA-=Z@^/?6!OX:Y'V/+]WT_,CQ+Z 0):TQ1D_"6)Y.)L,A:'_580V-Z
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M-+CV30'EVKQ3-2AKA.L/G/"*3R*&:00H?(B"B%")3UA=&_@;G;C=C5"(*OT
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MYS U!&L4^ B<.G([8$WD ("#A4]A8O W"".0XO2:K@K,Y!+' %Q25D2(#W-
MV@(Q'TDP*0LM [5BF)]M#9#]"53R!N@%=/4^O=EK,E.FF<>M& P=@I9U<,C
M^$+M*V*B5-(&GU7_!KNS1VX>Y'9]+9F6&ZXV'+?/=#-,6462FU]RU%;*'>6J
MD=L<WK/G;W:;^[;CHGV!1A_L]41Q7B)AD-:L [%U[PI3,H =HGE2& 'KE(PN
MS:B FMF8DV8764$D,^ZW0=Y;(>C/9!+"^OG,X3?H/**+)#4QE.5![)":]@'T
M=#AJL,>%1W8^"!\G#&,X65@7^H_ 0%:S[_EHN.KO7;M[A1\+L,%01@ARZ?5
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M%3+KNK8SXE@QVUX@B 3: W9W(OU0=F3:X8:NF0Q.\49RMXF0E :6>A0QI(?
M?LRJ6AB]@X=I%J'3$^9O6'^-/6U!@GZ%:<<"_8%.=ZEVI,63:1)2J)X^Y:=
M%0&)E.0L)0Y+,MU3;D@R)94'4QOU'#++ALN.^K![ 9$()WLOS\1T,-HCK"7B
MY"-E7W,HG@[!#EEMHW^@"@@*!O+LY29JPN8<)M*$,7<D<$9@6OEC?"OKSP+)
MD0PLX$8VQ]VS[(^X%VCBMN?Y,;DS M;!P^%RJU-N 7(3.F1?=";6EN-W@_B.
MV88#3!E47C@03(/022BA3,#0$1$I,$1WZ(&6.)#V$*9'V*K Q;1?99**2IU0
M]JRRF+! AVT3,G;=T#<"'2JWS/ -LEVN7O2F3Y=3OP:>@W+<0U?##=HK83H9
M$-XW]%T\05=G2ZGS<4+R(\/.RLUVG3Z(:>)B@L*$(##>[!XCQ??$&--DB*=X
M9NX6Y_0X02^/LG3"^6JPRZQDB>#:Z4J;6X814\>"%\Z/I:B51Y(-(,HQWNSV
MLX,-,Z,QE'!OOH_RB5 B>! /,!\XPE-*A9)TXE T&0L2%8$P?OFV-UGZ%?LI
M]Q+&PSD/A)+.9$!$114T^\?/X"JP*L\IILX;)MJ945$I-G&#B4 52<+7K%^_
MV>U* BK*[G0=9>;05K++G'>5&&N7 UXJ!&:Y2++TG=ITQPOC@%ATU\<(YN#M
MIG\EN4,RA-G'D 5N(.VA*<!T;A"FY7JF?8YJ.95:QWQ,#!I)[INDN"7ARFS]
M=/#?^!(U')T%A2IG!/LQ1*6E)>5C]&-,LA48,^ZJ7\V?B,XS4DNB\"T,^:R'
M_WK/_GY3"V0F1Q^[* 11:\Q90>P*E?I.$4G2_*56B(7S6)$?<8 _2&J6"K/\
MMGKU)>GUY&>>.T5X&S,#<+ZA2"L).6N2E(^A@P.VNTM)]S%59;$YY*O?SJMP
MV% "3D=ZAC;H@UT14Z8K;6#'\0WC2(;T\"=D":&;0*#OS-3<0Q&A\YU&!?L(
MYT/YX\C0\O#^@9C.VL#$>1GT-VX;6,>4]6\).\#<-:E,:O=AVJ+N.Y0(P/%F
MLJPRKRE8B'>!\<*^?>VS%R_"3 =4MM <!PN"8T]4637+-L?X>$KNY732)[P4
M<T(P3?">.#C:A'AB')"D- ?.T2"+$F-HQ,B2V#O%W2E]Q<Z>#?PX?32R($9G
MFIJ3+"RFZ'%>2>:)P!B.QKO8-*+3NBKSK3&U'<_ !6%,D!N\PV/;H9Q4%!M4
M=Z2R0.,(BUAZ?#? _G+&\I:2LPDH6;6),KP<5 -Q@%6:5$)$PT^43BQK/BFW
M'7_&U9PVAG0CSJF]L4,5P^U9J-T$0E4NVM>VX[)#W@Z'KXEYSJ7$H\#? ,G;
MOGUO'<+^(.HC,#3*\X5_1P(VOLUE+W@#3R<A'-#""H?UY) 72>5"3T_9@ERZ
M"#*0K[>0#B<OQMPPCK(#-^C@J464AP5K0K=BX,>#(5681E87WI+OV"'W:%>K
MA;6'<8@A=OB+2N!0J%*5B1.$D<RK<!-N Y- 526=]4Y,4KY7S;'WD/?+$C*5
M9Q0PSS#'50G_=%/@6LDHSHUO9L'J)4^]6U;8TBXNABDF!XJUU4X821F"&QB(
M(>[T-1= 8:JA<=@IFY3=[F/=D#==0B4LJO7J)](6I1C(";BP,"W!JBIIIWKO
MK2Z(4*251(2 %/;@.N.S<6B2%V=CWN;,^>64=H S[%(161(22$X I9%M76-E
M)NO2PQCV4U6R $LZ9!HG4C$(,:1KA]F:E(,?47$;S 03 E5&0RC<)&MM"%<\
MKP; ^(_< IP9*AW$IG#=R,%#WDP./2<_FGEOF&O*^8PIEPX6P,6I^%S@NT+I
M3^(6+#HS:[7K!V.?$C1U-3?P4_1-VY@Q&<J-EIX*P\6#3?\<UP^H:(!V/S4Y
M]F"0+I#L-5DOOKEP??[*T=$=BI'\:N3WL *6]"3CPHB\>A9,K2@O%0CB!F<$
M<)4F*!I%:2O**35K<CK:FAC)3&'H9\2\+F'D\G9@"7W<I0[EB>%#DM 3@LN&
M5ZT541@4X-S=2=</)Z[T0PYMMY]'1S!<F=$H]GS8'J<+DFVU\'NA!-67V2[+
M;)=GSG9!E5912;G,RW[J])?G%KA2IY-"US"0),?M4P(KJ"ZQY_R(!<M,-$K3
M-0&*T5C^. (#DPO&T -C)BX,@06Z6C[.D&/A!ZL/WY!NG2AH*F8B>9LLFE8Z
MBE"1=Y+SPAO:LC!"NZO1>=VST*R\P^I#ET'Q\O$8742(GP &9-])ZDR1-ZO4
M:4O:RR;#5N&W:R?@/.+(5H^$; :/[!&0L&-[M%;?H["_MCRFW5C)IBY&R_JB
MPQ^PZN3T6;_T/8VL<J_NDYC-B6&:,Q62K(I-+MH96C:'(I76C)Y %G9]Y,UZ
MUT%LBL!+6_"D;BM-P!,WN9]+?!"/<:A$HX<F&YZ?TA-)W[)!*G183,8CBIOK
M^+:U>=""X[4'#'C@J:(FWB>@QI$?^B/$=5#01/@UR$\#!L?85/3)P;+8^S(6
M7=0+DJF2LY:-5-8D4A/+8^D)!QEH>CZ72\*PH=I+O'B<P:TTI*F7Y(S=!VE*
MVD%/);_RC6!%VL/<+C*B&%Q$1H-H=P1B?9@:J]95%T+)][(O-6LLH[QC\T^2
MI^8_LVD$Z(D]Y!KY 8^;W$-=UT97=4[7!PCO;C+"#T:^YW==2K1'?(N.WR-N
M!#P'OJ$"T4F$#D5IFUS;W2[^H91$=!/,4NLE%\HQ5P%MC^Z&%X.<\R-4!/&=
M<JXN[)'($VLS&9DBO)1Y"7>58#E4>H?$0;:V?;^' &P&XSTB*-"NR!/T4'=[
M_RB?TXDD48[87X!HK(8O7YHI<QE(C#Y_HMAD.[MV$/BR?@*)O>M;*^O?\N55
M]2#3*\UYX/_4?#,U^)3F+0-+2/=PJVX\BQB6]M8J"<'5MNC,\D.\3+E$. $G
M LK'! EIZO"2I=G3\V%MZ+ETO&O?O1:&/$#[SD/\UCRL@4K=$PE!X"EXGTGG
MMN "NKV\G&  :T?+B3:57$XHD\>^XR5U!U/2:S%7$.\>[6,T3!$J>6>5J(4Y
MB+&4CK;R9GA76HK?0[T(BQ-*ESV=!FIXH,'Y,(Q9<H/>/WDV.7Q5X. _N-PZ
MCSFH X0<&/ON1$1#V S//$))#OK49%F,Z2F@Z6$PP/%<V%A07H5PS2%D*HT[
MT3A9^LREVX9I@Q6J&:+0RIJ."5?3[R!&;8<3KLM1?BR'$!6DV.'A[U-XY#I3
MM&EJ- F=SM!MF,3-->-\;O H,?-(HC88MYYI0HI<J6BA7>EQ50I0?\ZTL'M@
MP^(IR9^AB(M'R@FK#BJ16-G#)5\;*Y_34Y$,"&-=\G!QKQ1#5?4W7,BI:[CP
M+;25,#G<01*H).[PQV UOX9 P1$MDN[@47)O6EJA?$G,2V<$#"#H4O>@/#K6
MB\U*\;94_%$L5@N7X\$[H-GH_[S;ADV&8WTW-WR@[:Q2H4G ,Q2;2"QC%;V@
M[@0SK"H5NV#KJKI&4_SK-X,^;BR=&DNGQB*=&HWG<6H8XQEPYX__5:E>4JP@
M7RO4ZL9*[4[HNW'$%S]?9[0J\_+?4?3Q]GVY6JI5&\";[GM%L5!-&(ZQ7LUQ
MUF9SG!2G><HU3TUH:LV95T\7*IK_?1W119)3<X#&IG[[Z\AC<R?TGJ*:\--;
M WY:6H%L<J<E;C8 >B3#9:]4[M9_6>[6"XVY<K?T>+G[TI27I*')/ZPC9RQP
M\:_T]!J_>'JE&G#'UW@(:%'L4RJ/T(?PU"KK7#?H/?%PFD<.C"TP-D!6ZX()
M$/?MD[,/5ML5[B3TB794C'U!QL ].H?$WYZQQVJNRF5[9J(G;MMQ%_,\-]EK
M]_2M6N:@>LIYK>#,!V[<%8%"@90 D)Q$,7TR.4JST8 ]$F 5<RJ %Y>+I3*M
MU?$42HNM#D[O ?KX\EA<]',L29O@U1SRL/8<>^#Y$ET>BPDDP*K>1NG\+%@[
M8(/% S!1<3YK2=:;GK1Y*LE,R6PEWVY < ,\D8)^V@F-[!+#OE7.I%F.A<BG
MTMP9NS433S.S%(Y:A)0\HL? ;:[(WD 2S"*=8)%*&LU9ZX%]Y[@YB428P-<\
MDX<*\T'3J\AQ<=F5A\XT( <D-Q\(3G0"G]%'R;VYO;&9(S\$EW+FZ,I; 3D*
MI8_1CB-T\TNPRI#24> E9";)?!_M[1_YDGSA9/?@^/AWIY&/>>EXY>A7(;UZ
M[W23(FJ,X.@';@^(B'"5Y8"(^^>#?L0N=OZEA-KF8CKMWY=>:?Z2#0]W8I&E
M9_5P _IV%$T(!5QB/+-/"EU*"F ,_:TP@;YLT\4#$N2UP[D?C$.-CB2$%9&A
M+'?"E&X,37[XV'%[EG0_=9!$,3!QZW0+4]0FW=(W%,"P7 <=6>@>0K\0GEDX
M<9%/C"@+ IX=8>)HDI'+(1"-/.JAZS4(_)N<Y<;> %W-8U<(#[$;04UDOQ\&
M;2)G)%-F.H'M>-/S"B>C,>@YO!Z),XS[Z QB0O(6(\?.L7.N$\2<A4NKA==Q
M@34AJLE)C3$'#+^&'SAT-OX5++C#L0)RTCFAQ%]'+Q>*(0GPB9AK'KDC>W(Q
M,@T_@(OO8YAA+#S'!I8!6P>S8F_[C'M-(9OP@R4S35VXL(%-7GJ992()"#1;
MRE)B_.[L* %GE9-?MUBH%W&*I4*]BM5RP.R+N6*QJ [G]_*U-)>^EJ6OY?>#
M2WENK4V!38W]L:P4(65G+/PQ[W4K' (O WEO?1(W3CBT@%TXZ(H&]BA[?3"2
M2=(7X)K*$2@TE.KF6&(5 ]C'6I$YB_Z@42W*=RY&[<8HA 2.,[!+I[0,XIBZ
ML<RI[?E]1_L1-H#_HR!]'CSUG'4Z= *AW[9B=R6Z&VA\9_:5Z-G64;HH0E47
M[#'FQZKU&1'+G@GNG9K?3&U(3[@#^[DVQ ;%:R U3;89_ETJU)B&.K*G)5D,
MY0JI>EB/TK5#6;RIE.:DN2C\N#KKUVM*24X/@($LCA=1C#>FSD;4H4F&N"C3
M=66CM7VR2AI>ZFWY8J%4_@]?"YQAOERL%)^2V#,>G&D=^LP I YEYU2J#$8]
M< ;YXPZ D67@"]@:(S4Q,;C=E6FHF.HEFT)D8F#JBK+$J*<(AX')? /IJY30
M2=B/O:Y$.>2AB"--W4WSE:#HX_P<KZ]J \SA1W%$GCX"[%.XJ2I?"'^J7I,Q
MRRC^:[L@WSV&WT.3<ZYQ!2_F.V%M\Y@+8A9$L,P4$H9!_$,R@><FM!F=8E.T
M]RMN#G;#S/9S<$>(9_-R_,H2D]H,*A,7"$CZ8&='>T-F9JHR.*ECM\_9[$@;
M^5./I8LZX<-]>T)<ABL0?M92HV"M^^@:D94FLL"71I8B>C3XZVJ 98I8FG&#
M#8O$58C8SJ (%*Q# I=V$[>(!*R-A#U"=XOLCB>EJ2J[0HT].4OMGU F.II8
ML)UQJ+^BB6M *R/;RQ_+=G]#JMWB,D-J2>5HX%,L),,*23"%*%=3[@;/66;<
MYU7BA"8^% *Z6/+^?B5R4Q//4F9[L4]]H&":Z5SW6T GYK;)*?Q%4P"]Q)86
MFCD55A:O$[,>D>"(N?94$<)*ZLVKG&^!1\(PIBXU$A.4P<*8',3=-*AUSP<;
MG*@$%ZM=H;+[5O*MJEQ :Q+/"!-EO*0BS@"J-3L%)BWL&"@W=)+F=#!'S;HT
M]>K:)^R2'6KE5'<13"A.X8XK,I,N"\H'$3A5N9UIW'%SD;BIO'G)3<&<0*J>
M <57@>"AP:\1"[CGE^OFC;PYQ&>7G=G&B+_$-VCG_^[L9&%ALL2?2Y$15]#J
MR<LMU\Q@?MO&]=9>ZV"CC3V=>$())9B7D]QHF1OZ"X.#7A QYE0 ^DXP2? (
MA=>CK#:=ZH,)A8KZ6'VB!!_2G5 9X3:(F#>YO75BK2@; _U%V&H#3QWK@J-
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M&Z>RP[$IQ F4V%)4B7V/9@<C.#UJ0,'V<%83DT?$NJ]$$Z,"(MDS@*-:W+2
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M*0R5'SIA9(^TK8[X)K[34TT:S5Z7[-Q,B":];6K?;YV0#Y5Z6;!W7?\D=5;
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M]S55,B]STW*XG91>D!X L3G*2TNH>3Q-67K4RKK$;KMV7(7H",;\E]O0N!%
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MC@-.V\9B9QEGTI*[,MM_+JW(>&UL<$L1:H&K,GUB%>N>3;C]NFK-,U(-V-+
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MQ&S6VIU&S6PWX' 0FTS9_!(I+DY"^YND'&I:=O51>6F W G:%<B 0R%DVF:
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MY!$880@+\,-;VB_LL \;%4OTUK&(Z%WIX6?7<#>]!-^J1G-)[C+6'GIK6+&
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M?T)BKE(Q*A7C&9/_@>I 3_4$#D=)>ZHG<#!:Y%,]@ -2<Y_L$1R.'GYX1[#
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MR0<#\8IT)$Y5O#K;$.'DF55V!'C%4JJI 7*?WP&2BI(W[@G=)29Z>S;6B,U
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MJ'Q 040D#E#?/ (&IFGN$U>[U+U1XD_S E6T9#=#%_)0N?Z9_,*J$5@7MW>
M&Z_0O-OS0_A4Q"B:E1O#\7*2*(-TRX5*8SER5+;6<^T6&(-"[QS\3Y_Q?LP<
MI/ #X'O0 ^!YZ0-@\\A+ R;[J1@1[E3D**)/D>E6.N:]N;I18GG$R9GRFH_*
MJJLR'!:(4GV>)DU"\LZ1$J?T+''2:)@E-?;/A]%>%[.OATH,\V47^'>4/ ^
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M\;:VXGN+;1/26;L2PYPM^C;"(+1IU^P'@(9:Z6R5_JNQ!H\H[J[ZF$%W.?J
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M7#G@5%+?IN!@!S%)37LGY/'C-J3';&;]Z&M,CS0U#U3Y [0.?0NK:8#EHJ9
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MJ</O^E3_JC#9L9/A?R><^'V/?4YEF7FD\_*9BOW'80HUBN6E&+<OXN?CTF)
MZETP3P>-/3R[+[^,$4HX5NRAPF!]XT&G1;)M59"IC/0PV8V%G?9<WQ*6W,^T
MMPXY[ VR]'S[#+HY5VC;R=+FWT?KVA.NDNT[)AG?TH@^EQRA[%QDIB2N2#'A
MEU/^FZ:0?KY-D) J-ZJN%5%><@A%-S27KHXJ-I'W!'_+=%CE\L++$MM>+U]^
M(F/>FN]4D;XQG\[[W2MP-2S/P_]Z(E;L@F81E.LQ,T(O'5#M$RIR< UN$8+Z
M9H6X^]#&LQKNZL5FTJ;TB[=<WM F/5'R-N[L)914G;6M3^4M?CE$1S)"\'Z
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M-?:[E._@7(^\YMMT'4=9?&]I?=1N4$.V4U"6\2;HN<>VT!AEVK05];(5J\]
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MA+TI3W0F.NCDQ$\X(W4YXN<I^%>/*)< O#;T6/(]2@6T.ZD6-NUQWA1<HM)
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M,9YE$+L+99?5.PY:MOKF9(5(L:R[FO4\2G/R%B1B4L" <V@052;,T'#]1,
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M?VP%ZMB_'[DD9YBIOCVR"N#.6'6EVQ6V)&PJAHZ%[1S)Q)L&7/)+]HT X E
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M\1XQ 2J9"#KURN5-N(9-7)S Z/C8M>BG4FX.Y*V%AFN.V![2"XR#=<*.;U9
MD"(]6)J0NOQC3.+SWGF8T.-UJ7=;Y'WEX(\@KKFF(W^%ZF81WX@ALS,P#_RI
MQT0'?&H4':("=;*L[U9TS_N_SGE_LYH15]AK:-(/%*T3]MOXC25EI2( *<F*
M?<AD_JN-/=TE1>)F/2V_M'2I^%QD M?=UQ/%') D8EXI0&MZ/^UQCA3E0">L
MX=1?WT_I:;H-6I2/C95?DXRW#K(YO:+YEU..S.Q\HU5B\?8IU%*@Y-26-9K8
MDJ!Q37YW1+YLA+;=4YI_[\FZ\CBSNV_X^\M,?^J4+A"$B_"3]5N#$[K0* E)
MK5;#RBG'OJYI9\09NI) ,KEO*,K8![_$@C+;3;YYS\[*)P>#>^7I[PLRHI@[
M1N@VZ%Y@KZ/[#HTM2=&!K6VG:@?,U$:-5CM'FA"72RRNW4QO0#VZRZ<7%04F
M+*%"S7N9\N,.SZ5; ;AFF\3?CL;K/&2^*_Y1WA]FUS^Z3/BY&(0FLRP775C'
M4%08!COH_K3\8&'F]C,E2DLC&P_ZI?DB*,J=.H;/GTIB\NH+E7V27PT\KJ08
MIWLF&3R6%NS3Q>C.8O%+INS\K@\AY$E<,WK^VWB?!.=HJ1 ='=^D@PDR'X7Q
MR.O0IIX\>J.)X:@+3M>H_W<KKK;1=:,C\FRH5"++0E(LKU8BLG!S=.(>+:'
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M'0O]>+"X]U4T>*020N/6&&ZY1US*; 'I[+V7NWX#/-R] 4:3[N?? "B;N6\
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MV@W:N_86CHROU;V_'W9#O[G--*S\::?DG^BYN#S:9$$WN][L=L[.>TS5_,^
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M?CM -(B,\_JJ1\C Z0J_.,).GE"^R,F\DD"-ILV11:I'0G)#OG'VY"1NQBI
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MBZ[Q?Y"G&T%AT>(EEEQ:<2GQ%C8.0*358V9U"[APA^C?.%]\F2WL^"4W=?P
M% /AW#6&1P4E1)S7RH=?G@&=_.[*#[//@)M'T!D'Z.\ESDEWJN[)VW+]?NJD
MFE#D#Q+2_?82'C?$OB[3:A5@< .[19ZI!^@_NR;Y#YZF>:IQ!E> G-9U%>1_
M2M375-1$T@:J>%"QZK*;.18&UN%L\/N-N!=B=OVE(8UG*%V$+=_<UIPG*"/7
MM8_4#R?:&>ZL@""SU+-6*YLM[!V2BN6F-(PH(>!DJ<N<W49%L)74,8UZ4RSN
MV9WC\CK30*$L#D0$P_MM>*1<V_$S8"VUB?[IX!GP !6^31;^3]+@K>29K-Z9
MZD1G44Y5I^M]2NVY1 XA,&!3(G_I^_Q&6BNSO)-FX,9U[:"9;;)@"N2\N+)O
MT 5K@5P\))Z5_1-F&#(R:K$\=FJJ'U7>,R#8]33OINP9</)R9:Z;_X-LV1)S
M)JE8>0KY5EKS,=*CS(7*RLT#,A@ Q]:7M8T($SQ-?#;:_/G6XZSS\UEN5>Y"
MOXT!^4M/;%@;$WX&:W$=Q5OI4$5E)E_<=)UG8XW0^I<GH3GY^*55 ^?Q"'U>
MVK1._]VZ*X9YA<<*XT%*,(@!</:H0])TH?3H>8;^*]D8R.<;Q3@;P[\P2!XC
M$$!&#VP/[7&#1[274(X)#) A6 #]Q5'%@LX2E +74I=;F%;YXE(/U2ZT.T2C
MMN?F4%&*4+E5C6])X>E;!*R253=QW9*!W GJ-JA<OP9]@7%KP8Y?B3>L%>A'
M00RUYK!9_R)V5F!0E%;'J*'[V+Q0.FF:"_]T]>(^)</;!I.+[8_AF_ZSX?X3
MJ8B]/K[:@_%R7'/:U%66"+P0NS??CP@4'<)9\8#@WYN>I.@)Z+70UA+YLK\L
MP>)4_@V$DC)WNVXWUIS4DNG( $YM%\C@H T5<@7VP&^BJ2XVUED!-0Y0-6X%
M=R@'$_K ?,_%@\(6'C,^?F@?Y@VY-5B:IT^TE^@;AP>R9:G+,^!T9!D;>O4,
M>'H&D#W*D?UGT:'S^MLLZ?G\/ F[?%W\]@##84E'3VUWO 3+)Y.85W7GIQX;
MJ*XI1I#'+V?*FJ<[H9E2$8FU/NA$)X>_==@'V1>1!KH.;KZC\IF0\NQ0S%FI
M&\O^I7>EW)^>,FH6CJBDP?PH9#5ZRZ)Y=V^KDGXQ&B"LB^MX1^R8 !!5=U+0
M@+<G152+DFZ&QD8KYN 97+ )[; TB91YUX*?07A[^B"L?S\50TZ[I3/97WKG
MJ"9,?#6*?:O_(#.WE\QQX/(%LS(N;%$JTF9>4C0%F])4Y[K'2:WZ)-*7?/K8
MVJ"F8L)-9\^FL'&0H=CU-N+GX3DK.4, @-&=8 2!?@X]ZJ]="UOK#:<YB_]Z
MHTY/[/9Y9$PF.BI& YX'CIW!OC/.E/1)Y*  9NM?'(=G$/;_ECI=YD*O)YM0
M2[[D)H6S09*7G8YY>_A6/=72LJ#Y4!RGEP8^ZO(9X S2RLM_!A0^YL/^L/M]
MT3'[R=2U985BV8&G1T%X*?L?JVZ2_!F@E'X<"OZ7UY8"+7;GN\ALU,^(27_)
M[;M'^=K9840*^#$M^WB ](SL],^0&@C8(S>2SI@H3=( 1[(^0UU@YZ_/>>7#
MF6GJ.BOW7*ZK^??%V(]G0AAB-6U TM[,_-(F70N2RUJU\='\I:[&- :IFZ^7
M:KXX&M=P@9&>RE5X;#4CW'\-7M(DZPTG<V]8"[:^LY=F:^K=+X@6:JPXT>9S
MAKS5RM+I,?H1_H.G[S$$:AI<4C>I8#SREQ?,T:6NZ8/R%*<Y<[55*AL1;Y?:
MS=M^(J9U&\0AD>QH-JE.@S/--.HS8#)WF#>W^:RBML:R3][HA8Q?]QL< D%>
MFFB=[;_$W\'H2<<4RN,LR<GY6LZ<=PT?OUEO7%]:"QGT]V/J);EQ.=%9CGD0
MNXU_4 K>U)*X3@B-D33_X+OU>W*'>1C_':Q-NV$_\87$AB>_\,%]Q>Z_R#23
M6]#Z#&3]/;Z[8X]X^:1!70,8Y2?=EN;6#Q2:1*G2[+*$IGQX4&-XRGK&F"_+
M@9C:3X5F+CPEL?R2EO9ZVE3JIF3,K7R>I_D>%)<^@8T"5[?RLISAE5LSN]<@
MSY?!\R5)H311_UFLJ$F/2!Z)+='7)N$;+D'(H_D)5ZR#7]MO'6RA(.>G@^40
M^;9,@#GHK$ICRL4EU(=K1A9^6EW:K'IYE!U_RY##@V?>.]-_Q,UEXT=-E1B7
M\%^$<MM;^:Q11T[ND&/7^I#:1LY:"26C9P_'M%;I./45W]#<=3MB&J/&H^=4
M#7*,7%!\2O3"R"R&%U5A\Q :EH(-P093RP?LB]1F='.MHN_+_^I"@X7BI146
MH503FD3CK]4EKR.[W5E1VK)^'PPVD^>V7I38O!.R98#TVBA>\2MP\7LA96H>
MVE&9_YY\$*4.8,M((?$;8'&$60*+$&28*?R+9G'V;<ZCSQG.E)/.$WC P<&^
M]E2TA6<"K8#5U,Q#5<H)%W&XQWTIG#1A[1G0;6/<T\)1 :E_0 O*CG<;94Y
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MX\%RE0KO'WHSR [+UB+CQK1[V5!E#J@\"X^@N;EM)/E4D0Q<PTKE*MRX]DL
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MZ4SVQW$+V?ZYI58*EB3;H#FO'B_53'/N[\<^U6]B4,[STU/:$$87Y&*.G.:
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M3;Y3 >@ ,/.ID$B>G%*2D2#LVM=TOP("0NDRX/)W:D.WV< ]E9G[I1FA\:&
MXGN7ZDB"C)!$U%>?L1!SWO^F6-0>B'(BCJUV=$JND X%^#,:1-GV&>M@=5K"
M!'BFEZA,"/#G[:I96!E;1W^(' $0\(< 4](\8^]F4K%A5*L7U*,,(=]SC[H_
M&1-<]98@RM?P7]AAKMP\ UR%[,I*M+*SX5CGQ8C#][ 8PUE&L%])UN>6IEKA
M4]BLBX@B6L)$>X96B;.\J_UI^7NXB2DVS9C$QT*K9VG^PS@5 0L9'?K:KH_E
M,#:,^B%N]V<B]_)LMHA 0.179>%*&]1QN6OWIKF4OL@WKXI%X9ZD@+Z<KJ%P
M(HP9Z",4X?QO9&T(@,XT55=D*'N>)=DSLUPQB:9$)DA<>'K[4NWO/#''(FO*
MI$/%*+BBG1ZR>4=\%5?*SK$[\[3*#6S6*7XZP>)OWJ=[5H72AW;S</QD, <&
M\YO/$  M=+D""'Z'L6/N2]-DXZKM-WYD#1H5"21A?2SLH>NFB(.VVY*S(%&^
M2:LX)%)8F_#_ @#>L6Y&9!\11RELJ;%*T'\/X.>A=.Q'M>R&X"+!T,X*54L;
MPQ4/G?8<#M8D16-)9EX7G,E*F9 9?P7 22'FCN]%;76;[9'B3G)0-^"J.71>
M_TQH_+%!G6.ZJ)V6<GVD-57=5ISLTV2, F>)[H[$?U58"R69/.(D>M@]BM;5
M9ZL^3Y.-$Q>=S1LH:KLLX:-[U:C1=GAH%/Y':\WF,"E4'9:WD.N :A!;MX9(
M.WN@9I[Q^L#XU1"U1K0,^[=Y-C9'CT?+;NS/,(HZSX#\V*?)QT*MT)VGC^G'
MZ5LB;_;^?!DO@@$J>OJ$<<'Q&9:I=9/6ZQD @'[X->LM:K6V:[.\XR4XU(%$
M$832S_@5=S[#BX',(/NZP.8_%"L>O3FZ)TI,I\!;RPQUPWESB<7/ '/K7T@C
M$LBH;9L;<#OA$Z_"A?&:&("S+,.%XF:"U6DZIWJP*#VNB,"BU54&U.14*.VM
MH+*7>^ GV$&V"[YPYJ-ZX5-FUEG.]L6]%32[P^R&J>QZ:8.Z)+/(;8NT-=-W
M%5+X]$:]-S(\?7T;)4*=DK>ZZUX/5<;NS+13-'=#; -PYU)'-)\W,$8.-]XA
M.'4K3>GE>0I1N)O*RLFLHZF-[''L^HX[,RWR2Y*RU_DOA):NX B0O1VIM&IP
M_D"/^F7Y"U*71"5)R=B:#NC=>O4@&>RM::=6]:2SCY(70JUSJSFW5$P7J3AM
M?/]B/T5??UM_6[?I 5<Z:@N5_M#UJ:Y[\+Z+YE:49 ,JZU:N=)>_J*H*W"MT
MJ=7MO *UL<N<V\S5FV_#NB!Y\\%B@Y ?6Y&'& 5S*S?]E[E[SP!<;PK?^%P2
MWT&? 7&@HH"_":7(:^^\:"FJR*;0C;SQ%J+]9,T96@_R:O ZSR!');T;_[9H
M-9;'VT;G/D0!XU ^5'V40V_U[.XLCEFMP,7"MK%^*LI^8@O"*BP)B9<2C':(
M64Z>DH2@JU44,W'6-<D6+.I:XD[N@KO?5%5%SA6/U8TFZLGUNEN'HZ(:U:KG
MP#F($)-U*Z"LW%9X<]N9V9@Y1EL&> 5-,4'';:EP+YCU! ?K;$WP1^$"YYL&
M)CO)WE8WZE=85 [F>'R&_ ;/XV_6:@<*](C )'WXH-)=SE:ON@N+2J9WMA*Y
M=OK^^B.$:Y2IY&A!>YBO_-42+K*I!;H".5*DR,T]J3S&/']'@K9XBMML5\\$
MY#<6_2MR<W7&@4V7-"$8H,DF*B&<P_BR.U2V%6MA+ZST$SG$2L.P,8TFGB@/
M4NOB'=^SU&.$+L_F]>;=IB_);11:6,.2_D)@/IQYIDNL#>1W/QHA8T74U8+3
M!6SXJ815PZ00N[E6;B9)DVM#N':>K*89&!ZSDU\.B$(4W;O-]N&@C2J/AR.-
MXG8VT]VNBR%S<6%YL$"JG2)XR<B)E4V2#'9HX'$BCQF;>-,,N]?I;=<RP=F7
MD9I,2U<G/<ZMM$C*>!/G;\,IB]KQ6.1&Z(HF//TD]I[JJ1)I+%,;-:<UW=,7
MEE -S2,;9J,WW:\[80A4A:F^,;L9O/*1@/>\BNJQX=><OO1B8NLXWV<XR+3B
MG*3[6!/=-FEM*_V^1A)@O$U\7< L1*6CK;%R\$UL)5.[>4C.A:3C*2,1A9Z&
M#7%@)#P+5>&#"$''/DD4IQ<&V:U35\*-A%> "]%<]4]CSHZJ?MN))?@?+M2_
M)$+./7J<DH^;0#;K)T=>%UD1\E(C*05Y1 2_-&9V;M(,$Z4Z!3S<!2XFFYWY
M%,)S8[LDQ6<.#28Y$6JT%YQ(>I/!%#;AC:&E)-(ZX0;'JVE6^ATM%%%=\\X)
MR 3!&LPTU6E8CDI2V72=@CWJY/>8TD69I/PT06>$%]K3)L$^1F@$1E$/7$1A
M=8^321M8R/:.\J,<X6E?W;JY.]/PSEIBLN;$[5W:+6S@N(8MK-S3#!9,LQCJ
M*YX!9(#-V+T%SI.ZZRSB:?V,T01O]M7TT&2)S/PEG>KK2GTY(CT%2R535Q1[
M-\H0XXTA$YY%OD@DA,9G ()Y"[,"D8:^5:=BFCM3V7KRL0>EMG*+5$1+WWCD
MS%R>*W_PYB;AM6#61+C+>ES[OO?DFM4)B7OEN6+>?D/XJ%4V8EW"44Q-HZ4$
M34\'ND#E+;\" "::CT1.6>ZV!/T7<S7ME+X<,Q#7,W5(PG"SE^@K+6U(-CO%
MCA^B:.C-98CQ0S[VVUC_4%_$')AM[ZU,;YZSGJ#U5+4GTZDO]>IJLE7.C<RR
M"K83)-E/$V'O!T1ZMW1/(DH>->:7\YVWIO6X(F&,K*E##%4Z/=8ZR_F? 0WV
M'O3A@+G+<]X]$=(I0=6OU4(^4\Z@, S2*H<<G14Q-@$QB>#C=2Y%@KI$[C3>
MQ8^F["/R7,^ -YQ)+JMD^):$C^HAQL4^X?K:B_W7@_E#0XK%;HZE[D^+.[8.
MYY=[^K+&\^&*Y>,7,Q&9CW*Z;S]5I=8P6&W5J32#&;ZKP5ALBU=_A+G3H7GJ
M KC[RJLU1,%KW2X/=E\_ ^9+\G7VEEV&Y*X3%(D_(_[LMQ_8&:+^2!ZL:NM4
MYR?NN0MPS2;W5'0@Y?YEGL97?88W;^*57:6K":C%ROAV& '<5J/#H$5@]KQW
M*^8O ]RVC/:D44P[3T]1@-B.O7CAY\ZW+*AKWK%H'Q])L^7!!A[IB\ <20CF
MSWFET9MENO_Q!MA.J UG?=G[&NV?'!H94A,4.UN01)VA.\2MG@]T;6W]Y(IA
MTK=^+?3@_6TFE5N7U&DEY$R\=8QE;*6'JM1-TE;G4M!W]6:C<"]%'UL&,L$]
M+;QN_RQ-Z0)+[GX08P*9)<MA:DR Y":V(J,YGI"K1SNU(^N$H=T9&P@SB>:;
M>M@'E^]+G38.9.EUTEQG*'BKT88"-OAPKIPGC4XO9M:1">\MDYT=_^!4J?ZF
M&3C:D+;>)S@E:5VI<[(D/"*J3Q>)("&V:D:P]]ZZ23+/':6=ZT:=&\MR])U/
MBW:]0 =S1%,PRR8(J>[\EMCY2*]!L@9>E-C/?,]P13N-TY@[G$/AFV?V?//5
M^LHS((M=F@](JA2L4 T7/?0,8(7OB*UQ<VXK60E*HT_;Z41ANKF.FUC<=V/1
MDG-LL<)OVH/S^-+W#D=R>!)_\ZI,T@0U^PT^9@"&)R:."B!39!5 A[DJ]/Z6
MN^0V8*$7+\:#"U*UK"-G8).!XN588EU12!3Q**$M3*$X$'I9]GK)TI=$3@_-
M0%]G(>*3I"%'X(BK_Y!E/56*G>G!&(:H;JE@?J\@G98YX'^T;Z5!3699- $"
M-$;6@"#;N+0@R"X@^Z;8;(: K!'9PB9(1 @-@@+!8 -1"8YA4< .2@S-ZD#"
M'A ((D2BB&R- B)"6"00)4@('4:9GS-5TU53U57SX_[YZIWS[KEUO_?N??6>
MN'U$."$M_S^6_%:OB9N$DD*$%5-FZZ7C: _D7HWXPFG'%<V+QM/D3-""=_V'
M_B>.583IN)QE87>*C,O?5L?UT.Y]EEFM%UY0D*R8SS!4,"H>M]20.;4G--BY
M3\H^$_IVPR[UW$SRZ**+]^DF6.'*.)O3<1$T\5J_=6@12SL1)-<'"43<"\(@
MIT)6*=).EZT#L^9;3E(EH\V]@P;5(OV4B1CGQ^0/;N#NUKP$K=F/="%)K^C?
M8VV'1B1<"(5$,:#YYCK131YV"@+XLW;6RXIYF-_2; ,T\(3&;0!,;9.XX2ID
MNGN]I]1Q&Y"3_,]G%X ^Y,8/;[<![58Y90N%6F74X"_PKC"LZ?.*6["7K]$5
M%;HV0BC( FP;(*,YP)'@H34^'Q&10*W$/LU[]<.1P8FR56Y9WI(T,F:VP"&X
M&:_=-;/66\[_L<%<L\FTL@OQ\:O=$5,+D7@RV;V%A%(<Y_<C]3\![B?3FKEG
MC?$X?U_Z17UD!D)]8? R#FWE&_39_/Q@EZJX-KM7>[FZNF*JX697;;.+9,+8
M:12FI1KW3-]RJ#=J_SS[P"12];SS\21*\?(;4=QL76ZX3Y!>:KDJ%OT0(3BL
M,./9P8%-!1*S?WQU5^MNUV/2L2R/'N#==(342'JW_\IZ*ML*[ ]-(GIO%3/#
MWZC%:E*?/P (3UO/&=QJ=0&28-?VSY4$1-I!2/O&\$P#<*6,;9]\IJV^I+74
MS=8K,L7U<D4K>9V^'A_N#M7?J7@#;?N];E4WFPB0P5XZ4=4)J0-;ZZH3:A>U
MZWO-G4@=/P=&BM]0BE'4;%C>XV*0D]S.6GJ:1A,_$PY,MINZ:-P-@Y\B68?=
M>NMOJ==0I1A\X(4INHII,YEAB*7^P#65DSJ\S]C26?C-H9C$8YB#6C)1?OV7
M#,!A*^N&^[H]6_WD&*,3;WV!\1G(VFZ##=P2$M<O0C^EIJJ/0 O;" T7EBAQ
ME@?/9-#&AMTIS8G#O?C5I_ :,N_D>-&,E$!* BFUW5)4*-9:!5/&56*PJ;)^
MD:(_(G)/%IL9:&XXG"B,*+0U#LQ,','>SE,ZNYJLLM+R=>9*"]ZM?L9K+THE
M&C&2>SQ34]=E1"&!46SF51C19L&Y85BQ&/":3J^\3P_>2[O=:.C3D;?G4+D:
M'N#]A3Q"07#K2XA<&Q:W^&"V4YY7(SXXE&+$L'MHM(DWT-#O'X@N]DT=R! K
MQ?2:P6/*0:1%3U6Q9!-^+OW\A9QK8_&P+>X"13IJS4@?B7BA0-8[AQM403\J
MF2JY414=DIMTI/CH8;Q[Y+$JALA='T2,@IF=;FBO(.=>H^'4UVM4EHB37(AV
MBUUL#.@ZX0"*V)*-BI.3KG6Z+O:@[?.[--J9R<N.S'TE4CK+T9+G$[*=;B_!
MJ$7(Z(%:$#W_A#A6;#'".]4$V'2S'2OA-V0I.^HR8Y%-TQ;"':/L+VR=R1!=
MEY(V.*&WVI.3='^V"2K&B=<!S[^"'\Y(#&W@EQ#Y ;W'<@UJ>P+Q[<JI BUO
M5"43B-W^8,/-QC+J(&J/#YZN"DUS[E]IJNQZW P_D.^0EOYTQ>2W\W+#+6$5
M?I&>KYQB(-5A9H?\(GC.\<8'[;W=C#3,AX[69YHU*CP34C=JN.U#:(M_U1+,
MTNFR_'&P*K1^*$YSSYJ,0S0>2&\)I\ 9G]Q^+9C&SJQE0A (3THG5#9AP)^3
M#K[RA-EY&GXZW^+#'7AU/K/@9NU^G><=Z/0&;$E!TV"-A:'%BZR5<:H\YV54
M 7V6)$37ZG3&A8?0Z\H5GU'L:F[<7-'G' [^5#5%$?:7YCH7[I5><+L:>L"B
M;\)OS#OB-Q[V8,OJ&ZGK?9JT]J*>^P*B"H1.RQQ"6U0=:Z!KRW&,.]Y6*=81
M8LC6/Q>^,.NDGG7$6U3W,6WMX)(K7$&Q5[$\A?,33XV:B8H$E7C<VG.Q5YDS
M",GL"MIZC5$/!F7!21HFH*2:A^"OVOBVT"'S&)9,U_ZB7SQ8PGFA8>3<9<VK
M.F%WR+,CNNX?]-2?K=[)"[)ENXI6[K6B64D_?+DDPSNB>\%-=!(_P28L(,4/
M=K?'GZO#%*1KRJ1>FQMSD!L6*:UEN\B^5Y%@^=]\Q*JZ%U*^U735O"\V4HWK
MQ*WI4QHLAVHF.I9>>7@2<LD2^3DAX/0_&,!3_-[ZWYBP)8E?G\[SYGCU4/[B
MZK'A07<.<X6N6]'*_:N"CP.IWPZEO/:R=&B^ZYB0P0!&7#XJNV]*_=;$"%IY
MW[4SXO%WP?K C:ROPRC1K><I34<=CP9TVP0RWA?:F5MSH9P<7(=B@N=;A[&W
M#BK>%<B6RO<QML;VJH3)7UTO]Z%M*EN-:=<,M@'7HYF\A9]P2']8IO0$>SX6
MU&R+A??9'^-<MK>9++XV7^W1SBX59+@?Z<D>3>B9-B)-+VEK%BD<WU);^J3T
M#D$IR+=K ,[6X3 O3"8494W,67:<]],6&!Y1R5+9%"OI8G#J2W:8NW[B'(Y@
M.BF!&WUB=RFCM53P%5;"T12\.B# ^=AC2J:6C26D=WXAD[V,5LU^]X%/ !4S
MHJ(-"%'R@(N=TF<2Y V9?\\7K-<2$%,GI&$@,&O0G[%3L3P"=!VZ2KI@=GOG
M#FRXP-[=8PZW^1+6^WWO=S;&UZB,KU>[M+<:U.;=[^7?\'%-:<>XMPDF>3JW
MAST"Q/E?N,&[0MQBJV^>M5H;LOKTZSF:R -^H%Q%H%\>IWPL3WEG>[O>;AM@
MX<[[*ML?<$5,UP*TLR/_5S#:M,PV0(O_"7*5H+K!+%EG5(4),F!I<^J"C]:F
MM@'%_&2Z*I8*GY_>7&K6:AO]L&$5/M86EG=_<6(X.K''L:.=#>%S >:=5[8!
M XAM0!OFD).@ /BQS20V:W;% B2O@DXUK@BH&=0J)=?!D^#A-&EY#Q@$-2D.
M@G[LY+MS1_63V&S-MX&F_J82&\QT%B1QA^TLMSO66P6-E;"Q5M8ID>!^AO;#
M/MI\5T#?54 (3_GX9$><I>K&XH[_D;O^&W1^&_N=;<>W?_'I%DM]UTW]'C?-
M_%TIO*&=N3;G8+MQ:^1#[$4>/! O67+=95+]2\ B?F'C)+BB7GII<QK]CL9Q
M$&#IY=\L&"$FP!@<S&\\VJ[;FSRGX="V!'!0[C_ORV6>F#MS]-WN9/OGP.SR
MZ-*=*%/_ETGY?]A?$S;-W%U,1HG8IY.F][&78L\QU=FR\2,2CH"A)W[XVNJR
ME"+9PU9,?!9@>_0/4$L#!!0    ( &LX;EE&QW\2_,8  "+,   7    <&QX
M+3(P,C0P.3,P>#$P<3 P-RYJ<&?$NW50'%'W+3HX!'>")KB[NVN X XA.)/!
M97 -!+< P1.<X#"#NR9H\#"X!V?0P1_??>^^>ZO>K^K9'W?WV=75=5K.ZCY[
MG[6J=C__?5X'$*@KJRD#D) ! *27#?"\!%  H" C_Z>]&.I+0\-$0T-%17N%
M@8&.B?,*!P?[%38V+AX1 2X>(1XV-@$9 2$Q"2DI*0X^.049"041"2G)?VZ"
MA/)R#2H:%AH:%@DN-B[)_VM[[@$08B()(L-0D.@!R(1(*(1(SP, NI=QHB']
M-P/\'X:$_#)&= Q,K%?8+R= "0#(2"@HR*@H_QGU2V_02S\ E1"-Z"V?'#JQ
MCC4&O3L)?UC*#TP&^?I>4MVI,T:!CQ[A6*_(R"E>4S(QL["RL0L*"8N(BHDK
M*"HIJZBJJ>OI&Q@:&9N8VMC:V3LX.CE[>GG[^(+]_",B/T=%?XF)34W[FIZ1
M^2TKN["HN*2TK+SB9T,C!-K4W-+:UM<_,#@T_.OWR/3,[-S\PM]%V,;FUO;.
M[MZ__0/X^<7EU?4-XO;N/[B0 "A(_]W^2UR$+[B045%14#'^@PL)V?<_)Q"B
MHKWE0R>2T\&P=B>FYP_#))%/^5'?B\4@H'M&^M%CZA49H^ &$_P_T/X;LO]G
MP,+_/R'[/X']#UPP  X*TLO'0R$$R  >=5E(7$B2;C3![[J$%J@VEC/5?FI>
MPS<W/C"ANA \MK!DSI1.2*=7B[L4-9Q;!4<9L+,[GTZ>&4FMN16YU5)%;!G6
M\GS1K(*18!4U-;H7,FW[*H[8*7'6UM7PRE^,V^T_ ZB$*D/PG-SW8;)SIPQ3
MMO.N);,\PH0$/N])PP/'U/-[/AC<8\%VK4RBUA84 X8<Q_U>!;JWB#-7!WJ5
M1YC@<D9>)$U>-[T/<&_VI6TY?G=V,YR3$+(IV89J2=LFKKLR:O-81*W':T(L
MYB A65<<[[9]\:OHX,I[YL/=.)?0\C5-_WQ"ST(B8LEP]JK@-3A"F_;M;(=4
MJ:,/[_+QU/% LP@^\VF.RY"]3JAP^?9N7:V,8RM$DZ,_X\XN?3B^YH0S^V#S
MF',OIEC_Z\#?&)N/52;&@4M&B1U3E,396E)*G._>K EG/'7KK=W@3).A=()/
M?L#[#:%S)P^U> -> 1*C5,"8W5:^B6XG@R&&I3D-G'"EC]W'^)6':>#8)8VS
MH[->-.CI7R@;?<XHD6R\)P/%-< GUSI)%*,:&U^G\B\M<[;/IYN5OOC8VV>
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M+4"V'/GSAXJ,X'A9 ++CM7XU''_)L+OWT4?*Q@K1N7&*AYU54R-7'S7.$[Q
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MD'3H]"4,M#O;7O QC'LLY3XYUUV!Y/S@=*9@OB49_OJN(6$\;-)T',XS_ S
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MF5JS#B&X%J;F)BKVIJOGRI^SREK!XH+6X>$Y$:2C''AH7!DO9)#P&9"24O:
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MZ/,N8]N&A4V21!\S!*%7^E_\<_STS<S4U+1XXORQ?B=;C/1:<?@#;]-K!6J
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M=^KU[MY#"EB32%;#L&'J*^I.,2+J?=H90&<''M[4C@I$^V2_ &W7%+7AH&[
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MJ4BI\0M$@TB]'AE^S/E+[C!Y;/R*N1+,L7X:%4A8Z#AO>.=%3KR?TL/0F2[
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M\I??O<A-8HV>;,23%_&@VOCU(C=-+U+D,WIQX4F>I^^_=_XHU6_,W/0T$6J
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MF3<7<WT%R9]]AKS$N8 D!XS2#>^ZAVPO3R=%;[(5</P%F1[*/P$P@+K&/D^
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M@IP3ZQ29S8*3ZK:(QG-*4[RNFOW>&Y;^*,_CK@Y/[7HV\DY[\$09\&)K;LC
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MTW6;IX7BA"P3Z-7KC.!F43V_OGIQO+EK_*P +&@81E8=WSZV(PAK=K,X;$V
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M"N!"]*/P:U^AMZ<NUS<#O]B<6K)01?<ZJ'-?Q&*O;II'_0^AL-BA(=MU$7/
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M[XO#0K5_;JF;O%R42')RAX#8A]J,SF#6[ZJ%G7=MF3?_WNKDWBLA\AL,'&K
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MK&S2D<IY^XD!-2R28*&LBRZX2=GF]_H5J=?'H65.=<;B&UA5<1BG3F*T @2
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ML3;K'>['B #IO/]]&J"W[_E(F/6L1BQS3/JO6>WBGYC!R3LF&I870)7PLWF
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MJRYLOQ=X=Z-:U-P<_M.JJ:0;@$6U3W61^I^_M[U5MDO6[-?I,Q_TVY0()/Z
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M#'_D>B_BC$P2BQ /IM./ZC96S%TR$<=5I^"JJH6+YXF1&Q2:3XH>4^NN'
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MY//!A59PBS)SRMH^I=Q:-:#QM+\.R^Q!LPR3BB>D$PV2/"!.&K8_MS7K]J7
M*#1HPS+(;LH>W6G/3.>UA/DF5A"0,3IQ"A%VX[L@]*?R;UVQ72-,:V/#/JGI
M>[2#9=)FS67!IU<U*K%*YOJOR<@J*R>W]X)]BQ4=L:.+OQ  WTNMR)91E]>U
M1 LF<+5YG.N<:$<718. @[0D@I,H()(D\<2,PR%73B<N.-IC%=\(1C8ISO(0
MDT[@:@0E@>[4E415D+1 VX)0AK]_&+C!6/DT5SAV1"2.2!LF]\KW69_S$-PS
M.(7FD$?L^!%!#E<E[1-?#,MNF7;@O.9PV;O?5')@R#JNZ:E16$49\]J(=U):
M7F^-XKD)G+J68+4R%O@<M'?*X77\U3J"3^A0S<"<+V 'ZR?TC". 'T(WK](5
MM1CW*-)TP6Y[ ':5KGN*Y^(IL,*WWNGK^%U&%6D9@#LWW9G%TP]2$=0YW^CK
M(H%(]#>UGG0T_C*W+; H6#;]:-&:JO .>%OSO%-)%A^&NZ;;*$T'96R^F*@J
M6WVJY=!WK&>>2:Q>MW0A]SS=IN61=9(KEGQ_03N0*AR3=XAW ,,^]@[->9.)
ML6Y$IYLD&]''NX\L)NG+KH<HJ9#//[Q?O!%*;Q4.YZPV'4[^RN3Q(SR5F"VH
MU.4-''WE[/WB_7-;N%W5]9.MRZT,TJ,\8YP]"?^!MW Q@7LLT^[X_B\#L\_,
M!GTT'SX)U(-?.U&2"R;<>%Q@_[;WMY_CM  KGXUU&H^=6I!BVNOMLY.?WRPY
MMB5"(RW WC%1SPP\(5M18*Z%Y]V_#QGJ%F*R;T->L8A*&4PKSMWK">1"0:V^
M/,H=<_5+#M$5G!J&0-O*2R5&2*H6U5A-\2O-%I2_A90,./N;'FW4#;N[D12<
M%!4G!?/?;A9%FCPU?J8RJ@N.LEK;& ?OPK)+!GTR)HD?:><>WV]-XA[$F1@J
M+!A^:#7N&VES'(L+^ VX"_W3S>X<JTZ?:PI+[B[D* *=9&I@8Z3D,&^2Z[Z-
M5'H'/<Z[+1 5^X->:-]5WQCY3-DZ!Y4I6CN:A0U:MD2L#FHM$MSY=\3I!XF\
MV9-Z1/)V58ZB3@Z4Y"NU$X]N*CVB_1+ZH)/$##(6K.LC&"*+A!Z7&D3SJTU'
MHXJ.')>-N>/&M-*D8*H+A9;<V-@ Q19><T"U/H<_5J5)"N"VDS+$Q8V;G"</
MJDH,M,+L[ H.O=W[1EP!H*5M]'U@;7CN[S:7MI_[I[$0QB"VPZ6X/T3:[RUG
M2[#^O]4YC@_ BYNI=7C\G+MD/W7@29%13A$Y\,&C]B-*--!CE4<[(R;F5KW
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M3D]NW4%5P:["#3= Q@6+ADOFC-B5M?1F+.&RRAD7$=]U5>^B?IY@\9CH^A=
MB#=X+WV1A$+2E;LXW(/^7SP%ETLT _(3TW+[(HIFML#@0Y\1,QGQ"-#PVU0T
M$WEEF^$H==WND0%H7!Z4")%RTX4Q4G)PM7I8;7A0TU?16 N8[A<EY6O_^ +H
MY#>[S F<9-39WM3[(<B#=G"U M$!I:XF>Z_>)WZ[SZ5?+9^D:]!UI7OE47N>
M;]&)*U?&S'7L"QY@W@5D E 33$G^O #J7@"1Y>W(.4M-@0WH)*0=/N,DCGA]
MY ]?1TD3O*/C$_$'&N;>FG=3;288QOF-KXOXZDJI:"I?2YD^>/>PM%,D,22K
MD01QU-5!MM+H(AU$43"XBIG<?!V_%,/L&YV-EU?EW4&L:U13S6[.AVB;<]ZZ
M=5\J8;YE:NVA-TM*%U[5HN[KD9J+#,UF<C2YG4*SS\A0N=E'@4U?FJ'ND<*1
M[#LM; 5J:QEAL:0SM_$8P:!:!7X ^4Z0XL<;$&VH(>QY\IGN?. D:FKN],R=
M?&9A\))U-XZQ(TF_.S8CV(5_AT"4D4K;?J1>J*+2)XS\IK2UL,(JYV!1Y#YD
M3%=7=]@J%>Z)%I=-54<XA7$G+!.<A<=T?A9"/]=.U[2@BW1*YB:AZF30\3/Z
MHIY42XG1BC/'")]26."R9(08->(9"ZI\01K^"(1FDD4/5/WM4%0#_0 ;,T:_
M *!V-^:C#*<HQ&;*F$$0LKW$AM=[OD'1"?2M>,-]+M4[^$NSM=EZO]<)$$P7
M,FJ(H[*CJR-"NQN" =Z&.9WWS@2#4]\B2")_D]V!KRRL-Y+/7%6V-T)EB$P'
M2&N&'* J(%_7O#7U*GE7[/CLA@0!W+KD84;7D&$&*43^<<4>NG&6CI.:?65&
MJ<'APA[\-USBUX<8\GCAX=7RSZ&^<BA^Q)=-QUF;57C"-?F0K =N8Q%Y'\PE
M'IZ"N?'N^7Q0X:72]QJ^._MR,>3*-R =*.6%T#?OC'II<H'W[/;X!WN8P_1
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M4E6!71H+F$6 M"N#+@GEH?S_FP!02P,$%     @ :SAN61=2%K94:@  .X$
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MZ'3\^)+3\]L)%APF2O7VH6H2^"$,:KU3EP.6:3#IB2(P(\'=G,<2:G.I^&5
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M9#CL]F;=MM5%F5NV_DDE$>V]C*_I([@1:4J(T.QE32T11@P_I6/A*@4[4S2
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M2%/P&HC7Z.G3JOT05O@4[VJ5J.E!(A6LGA@!IT:-]O O5=B@6$(11L14.VB
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M?6[KX 2[2@J\#)"A@:W8X])_6;&^4^O%293OSG'7<_CTLRI/D(HVQ+"IFV@
M:1*#HI9HAH-*T<!WK99_)_D?13\TQC2L;0.ZHO*GU'=?-DZPD9!?OA3^BR\_
MF[$F7=>&-/DWD<7O(K!%$$@-#31@1$PGMYJFU5UP#C)T6G-9&]"_W#$<J_1\
MKS(N.B'U<S),H3Z?-J$MOI.7DM;\X#"*)\9,VSC-RCU8/0FB'PVT0Z]#]D=L
M4,)0BPV;PX7)TX]71'^4WVF.5M9_3"<*4,"EKSH_R5-R&(X88-ILN'_:4ZK!
MG@(S^=;:<__]=#(\35"V5X.T (-P/*$GVVD'Z889,=$P5G3Z+:$*3KEF8?/O
M['^;KY2P^O,NS:&(MV"];(/GKYWX2QJ#J<HY#ZOY/EH2_MG^U/=&O&6#Y,<-
MX@]=RR%+2/;XQE,C8FI8M^7-GSS=C_Z/%=B"%A]<M73C %/XLXLR;\%.<'95
MOE>+V3\B^(WEAO\T'W=5O"&%N/[5U!Y*?7LG-]3[>'(, \Q&.$W"RKF>$SX"
M3BR_CO\L?4W'!6-7QKL^76RA*CDWMP86J2AWO>3"VC[NSJ61KU=UU':K*LJZ
M+GZXT/A ?@NS7E ?6I/ VJMKB>U4&72_07?L<CT-SD88YI!8HS7\!I1[&5H8
M4I[A(M^D&]]>*FCIAR*EZ"DRZQVF.A'0<2J\C;,P\>(6X13/NCPF!7G\>OO<
M7,Y#3P*K+=QZJEB-I@S<ET)OBMJ<AH7GG'N$^$7OTM0_8)3'.LB)8[@^JE88
ML-ZYP%EI'N/H4#?=TVQ$34\"%9>98J+P#*W3*M55KIS!VY52LXR+A^@%*@:X
M.H^\GHUF\XFFVH:&+YR?E#BOC&TB:S,[B3?JHE[OI$5Y1+'A;V/S.$ZYZ!9S
M=.=X&EG@%OF=KVPDV9]'M7.7(C\]7N)6,[F2G?TV? _[0Y*55X%P<;L6 7TP
MP>NW?%KJONHAS\_+,.2KX^(FX5+L4/E[7-Z"W@PPJ^*T3!^U'BR6NBE</)X7
MPQR!D/0R$L?R?5[.)+KU(-=6UGWR#%*_1W.]N3[FZD!\ULK5G+ZQP_W"JF"V
MSX,1P';>>@GE6$KH6_H,ZM35F)T+QR9%\Z9]?<LB@X6C-Z3:[W;8-UX(D<?O
M_:C6P"&EC"'&X".,E7"A[X+@86S4>SK7B!&KOO3M><]*5FL7DXDRW,@RX_0\
MPM)-6&@Q;U UTX#PJ_[UW1.(=OGKUD7=X*N<FH4NT_QR=)VDUD9TS$'YRV?"
M-L@09(VBTAQ;THDV21U2(<4SGIRZ?EJ*_K)5?'HGKSZSJ<V _>%K.W"/>?V^
MV_05NPKPOUIHX,*Q@M (= #>?N"Z)Z&H5ZEGGIODN_#UXU.J,-Q7Z6W86/,?
MQ<6^7FF5WMMY[$6 *#P7G[Q\UMW5?8;EJ+ZL/[7$)?MEP,."LSXUQO-D;0X'
M92TI6\J16^9(&BO+Z9Z9HNJ=W(<[3QCDE47QZL8EWQV[F+57=HK.P<Y?T;B^
M[V6\GR#?*U/AH(QT@(HA_)00?2>E,^:."GD/ ]9K N4K(P;%UE+;):_'C;JO
MD:V9;->P68_7,J9M6C<W[#.>YW<I6)@!*W5-K>C2%JM.Q!FY1OL(,2/QVO&W
MQI(+KS*VL\98U=^,M*\W<I-KFDS_^#+O&<:H11B]@7K=X,77',?V]LH0GY4>
MR[D-Q&48I/ Y;)^N& UT/\IZ[CKWWE3<7K9EV0/B</X1HP5L\OHG*L5*/Z.9
M>V"#>.'%/CP\)I5EX/]0)(.EH0];@N(+OP9[_POC4&/= Q$J-X.QP9@P!<LG
MF*_G?>]J]/C=E9FCW=7$1P.6FY+-H:5?D"JC;!5^F <9X*S&=QX!5]R$UM,?
MD7> 6?BB\DUS&@V--Z^G-5S9!CQE3K\XIK(?>@!A0N"NA?YU6+J/&+FO<OQ5
M:\8<RZ[38JWI1?J(^<=E,AU]66-^58KZ"R35,].VX^?NJ!$C,-U4]QBK3IL/
M.'P<ML ?O'I//C =KB8>=">O@3>+KH??XKH\_&5LF;3(Z6.K'4ORYS9JKNLL
MT4YBJQ0*TC4#)YQU;H.5UD.TUE&NGF?RE39OMA-@1"0SN>9WXBASN-!YPFLH
MC3V3$&B@!F+J]<,YU?W7L,4"$#XXV2WIT[T\>D'$,^?C>0*'H+=3IIN0\.1E
MXD,X@.I!;<R":_))_O$=R,XP9"-)*1HUB#>B8&T4(+S<.86!&)IQ7KPE-_VL
M95?RF7P_Y!.XC(8>P,CVDU&DW.RHI]&P@Q-P9B)N.>8=G1U& Y-[8.-%:FP;
MH\ 5:)(E]#*D#!ZEU4^U0W;R'@W$;$$LT$#I+OSHK"[LV]'2#RY^BHI/]=2*
M,,WG.JLG]A!1\^P'6MODOFQ2JBK]:D=^!WX_)!W AI=XA*_SPP@4<6LW$@WP
M2T".4?!9J*\1&U,-/(I1#68'NR*==#*%ZH&U(1++$S?#S:&[I$5H +Z"$H)O
MABV9HHPT$T^]AA-6%:.^(C.<.% DAZ>63O'X)@0?/3(]P;*";6Q_^^9<A8WE
ML3H:L(I!6FXV&Z$!1Z:Z&/"?)]\,;=1 BJ#;*/9UY_V%1#0 &9P\.#S=(K(P
MT0!O"1HXV#NUY,1[(#\OU_,5\E,$5@G:00,C^^PHJ!4:V #G&*UJYC"L:Y7I
MFP3!?JC,H=H4R!_B#2^,D^23R8:3;E1_P9HK!AHH208O%WU@3(GIL(VI4\1Y
M5X;"Y7#?I?WM= ^JMY@5)9T$1OXT?=FZ0#E5F^^+..[8T/2B[@GW24@U"ZS.
M<%-=X:E.U>@X39S2:_Y%BP<-L(U1<+1ZQ];EDO2&"J\[WFVZTCM?'/J^)K5V
M-SM#N,U*9#R7E\>PJ%0?)]J54HB&F3"?F3 "=U9K%W[^BT4F4?Q>SDR8LM6"
MCA@N%C+E ,O3,O#5NGHY3]]7LQ%/(J@F46]TB.H.S;%*4K+YKK 1]^U>RP_%
MBNGWYYVM7SQ4FZ5SB.ITF7B#!EP]916D&C0S<X1>DA9F6Q@\?=IN^\ZTG V0
MB%1\)1[@_ET^Z4ZLV=J,JTFXT4ORPI;5,^GT$0I?@85$#@?RDL0;<GU?+8X^
M/B%,H6!E#O%](]R@67NG-T4FWEAM%4<GA)SP@,UGCR7D[L+E-6G?X+3NP1?D
M]G[\;F.A+-*PY[ KD:S]FE8,Z?/GC!6_?U]44*BH_,;KWN_?<NYX#QJAU?GV
M'4V=(M7/]$W1W[X>JFEUJB3U^S>:XV3ID]K-2?G[-2D^+\SH$\\(6P>(WWC=
M!2)!IY*4@\\!*H>8[PI92?L6<22_$@\Z2>ON*3JB[7X/>B6X_RT"R^O_J<A
M(';CF"LC_'/VO>C)E>@8;M\4Z/N *[>IFZH*&Z!%E.%)]^5MSH5G+*>.WJT?
M*:[@&161+7O<=N4ACM6[)Q?U,#]XJOKA5*DHGKS=_:1RMX^N8= I-C?Q_<1R
M@:[VI)Z\'?F*LVUABI^34Y%'&BM[9#--F?U)LOB.9\1XVAK_].B:/1V>X[C"
MN^CESP,V"J4$U<MB<WX'<E"QH#O>X33 HN09RW>;>4W<@HW5/&6; Q_BTANS
MM ]![O/KRP5PB8C=W,&SA[C']ZR-E\M(&N6OPTW'A:M,76?:]-*S]Y:$+:UN
MCVP][O]495<3IF 57U-DSU(B3\UU[JRN=>#F6:%Q9]6!W"J9)YYVN?)VE-7O
M)#F]<H?]#!4PKQE"PV]'.$402PZ&#CNBW@3LEQ:BPOOO(U5[5E&L7Q"7DZLB
M-<N+HW<Z].RY9V_511#Z ?GGS@VT,FR%)]A#1]CK Z<-5!I(1BQP>MNTE:@O
M]EZ,:Q/D>DSONNZC_MA[_O/FV>;;7YOKZ21@Y"Z*&D45T02P<\/Z7^HM+Y@'
MO>3P/],K07G1(ZFU57QN\-%DG664G[Z5A &E5FQ(F7!1M)6TA/^,S26QJH+_
M5=MW!C3Q='M'!0$;BE0I04'I(+V(1%1 0 Q%Z45 J2)2!02B6%!:0)K20B\B
M(+U*E"Z]"5(T% 'I@4!(2+)Y%_%??*[/O9_>#[MDLW/*S)SR.[O,),P7>F:Y
MO>U#2E6;8J$.K# ;B=K>H$*D4['#$2YU&GGU*6+VI75FG &7;O4<#PYQF=2J
MN]O^1?*= K\G;Z1J(<JA2)Q@C4T#H,Y#:\U\'5GS?BP52$?EPFSM9TR?1 O;
M57YT\.ZK.+)?$J6?KB6_I14L;8GM].B/=YB.<!PT]!:]*]FK_^A1*W.9 ?ON
MMDB[A]$G#%:_CPIAGX12GBTC-CB<%T]@5T=)D^65S8BG<=NTGY=J_.%YE^23
M#^R_>8-_FBYB,TLN0V8DUKA:-3/P&L%IZUH5-BXMXYM58:)R/'[8K4-42I-3
MF!_,[>5V=%NIR'@Z.GXWR[Q"?S6L76V![&#-+:G1\0Z$[!")ANV:Z;TA,#&.
M5<DUMQY^])*1H\B\'W%39__W0G^37&366\2T!1B-CV<TEO *M)BF]E"4U #9
M15$UMEIEUWPC,[XY&.%*W4G\P>\DP^>C2?'IVF9IDYUFC<YSK XAOAH>D=<?
MSR2G:1&#W?C@EPGA$^%\+7*5%35>Y7&O[4\7=.6=L)%MTC^3SN__J?3!,9>H
MCF/K#Z4NR&YH42$?Y<D*&N2(A!Q@KQH@LTKP7@V&_?#\#,,R2:QE%S/#7ED9
M%8U 11G9?&Q<5+156:-=?6K\A?9GB(>4:."19?%)-<338YX/+L;I0V@OF+]4
MZG*>LG_H)29E(4=_B%62B+()FNI+.6=S>M!4JEW_P@6S5\_VUA^<H[,N>D"%
M!+OZ> #!.F FVG-JI]B='*OGHD+2!D!H].$*NB6^(LW9/+#QV A4 <7E(_Z9
M/T#&<=N_(&M![KZ93'3]NJ.+<F[*F1%2IO@UHZT+_JTW#Y?== @4ZA4O0^U7
MRS4OB*EA'A#M;:_DO5)T]O7=DSZ*3!%&L\(J5[KA6(H9%7+D*Q9#.?*KXU#"
MF:U@1G+W[J6L]C%5+P"$<%*6/+4DD>U*(E3> 1 E>!TFG5_.*MMV'AM3HV&:
M3UPIF*-YD1-G@:K3/YA<BSHW/$-+>],9X,>2K0YW/\H:']/T-H.G./*5>![O
M./'UQ16[,#F-1/H.ES8ZNN)M-,!=.XG>YI:%DVE"R8Z(R;%O_^[]RR+5@/04
M4+P@@=<SO7[K?PS7'0Q6!\-8=DMMVD63?ZG'EO/1YIY67$%@M49U\&"^M\J!
M+HZB&BID<DS)GL*XA2 (P0&8-MCMT7X0P0>"&.ZC/F)M 6&6@<&Q#2Z"N?V[
MOX!:P-C/%NA_&L1A (:<+'/-,I]M7+9O_P 5@M3;K#E/A9S=3D;,D)&/W=0"
M-F 3KQ+L/*@0ALUAX, P%1(Q@)[\,KHK5Q0.*&H,_=ABS!L&K-H(1T)(.( [
M- O$QQ1?*B1H$"R28]#8)1T1('BQA\R:0X5P92S&/ @>7/16V9M>#T"Q5RT$
MP'L8,IO SCV0.!/1N[-I2M#W'=H =^2][>2[K1]DC##3 $-X!LB9& #>!6/.
MU#P"U -&88S'$"3@@#BR4&\%JE_TA4R%I*,OP":_;,M3&.]3(00(BFRQ#V!
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MIB/K2-PV()I8CJ)P?._^\B:X'(CF1,UP+(_!\>5K1&\<A6XMP($SC]:@C:V
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M#(/%G3ZF8.BJ&JF(5QXX\MJ'Y[*<1W#8W:BK.C'L;?RVC\(&$86^"51(_(Z
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M;^OGS&H?/^#"I;\<.V-W2^1'NW?$" U2:_. 2/#QH(S0R@JC"HSTFV=G"GF
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MVU'I_SSGGT"0 UH)5(CPV&X$A5%'_A]02P,$%     @ :SAN6; H2CV["
MHS   !<   !P;'@M,C R-# Y,S!X97@S,60Q+FAT;>U:;6_;.!+^*[P4W::
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M67F84#;R)POA\KV_S7_P7U!+ P04    " !K.&Y9=**$]=\(  !,,0  %P
M '!L>"TR,#(T,#DS,'AE>#,Q9#(N:'1M[5O[4]LZ%OY7M'2VI3-QG/#H,@YE
MI@4ZEYG;Q[+I/GZ4;2768%N^DIR0^]?O=R0[.! H])9M+@LSA%@ZDH[.^<Y+
M%H=_"8+3,N-E(E+VR_CCKRQ525V(TK)$"V[1.I<V8V-55;QD'X76,L_9>RW3
MJ6!L..B_Z0]W]ON#(#@ZQ%S'S2!51FPX#(>[X<Y@9P]?H[V=:+#/OGQDVU_'
MQZ\=^<GGX_%_OISZ=;]\??_KV3';"L+P7[O'87@R/O$=>_W!D(TU+XVT4I4\
M#\/33UML*[.VBL)P/I_WY[M]I:?A^#S,;)'OA;E21O13FVX='5(+/@5/CPX+
M83E+,JZ-L&^WOHX_! >@L-+FXN@P;/]ZVEBEBZ/#5,Z8L8M<O-TJN)[*,K"J
MBG8'E1UA9(CN:S27P5RF-HN&@\%?1Q5/4UE.@UQ,;+3?/SBX:M)RFBW;E-]:
MI$7.K9P)FKLS:Y(+KJ-8V6QT?8%U(ZMVW$25-ICP0N:+Z-58%L*P3V+.SE7!
MRU<]WX*_1F@Y>35RU$;^+C UMF?%I0UX+J>8G'@=^?U'Z&/T.VR^T(KQRHIS
MX?86JSQ%Y^F_?SE[?S9^^6+X9C#:'?9W#L,8DJL>@<\$L!7Z>QD]/CT?GWTX
M.WXW/OO\Z3&8E&4*!J.=O?Y^=9<XSWKL=,%S=E['LNRQ1&@K)PMF,VXCQY/E
M<2Y8K'0J]-NMP19(\KP!UO+95#QIGC%"XS=MMS*C&1.>-V)SS '6HWDFK0AH
MH(A*-=<<30YKNV_ 6+- U(CRQPBF,2I@VZIBI8GLS"\U[+M=AS;M;N*GL</.
M6,9G@FDQDV(.7V<S:=AO-=< 7[Y >Z6TA0=D'Y0NH-C@[TQ-V!>M+.1]R=Y+
M-<X$A"MJ:,'TV%F9]$=76PQ)6:'3\?^=JG<V2]7ON7&QC!4+=@$QY0)1K^<5
MWJ@Y55BU5 B7F)[+DO%RP>K2ZEJ 3<1"%TNA?\X*/&D)PY[P!$V:J4):9I6G
MNT%0BD08P_6"2 I^(;!N9TZ#MA3,8,F<W!BM002)U C@($-(-^ $P&'0=I(Q
M4]/'U?BYT**9A#902(,X0X+V(5\+4XG$,4CS5F!-I=@F( 6AQ(NN&)[AZY;:
M_9/ 5[")+ $0PMH5('K +LC1K3O]LIS C7'*,O ]R>L4<P)T'>WW %A)KJ\"
M9@CN9 ;($I=X;J!DKBT-DTE=^M(CBCH' 4"L@#2WG''\)-QD;)*KN6D1KL54
M&HN$T#).C9YO<-GK -6TS-S@]AFK;JF]S<+J>$6Q+U\<[ S_-C(-&IL4B%R3
MFDPD'IW*SQC7PH$+8)&D/8" "4.:E"8C<B(KX);)-=-S*DV2*U-C'#ELK7*/
MLDHK5$!H-FP;H$H%4.J1<WJ)@J%$L?,.OO"\SD$QW.7!<'];O'9#A_NI?_*/
MDG+0TJ.;YF?D,#N@]R D7NZ]T&1EH0D6HGU>-P504%X2/1*\;\?L-0C]R>R
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M^:6BQ OJVBX59W!OB?"-8*1)^VCD]8<;AK%C@7DP8G\!,3^I'/X-4$L#!!0
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MV36ST@TE@D!BJA]#F#"JXA:/ KC=Z"QWZ!)IGJJYT?+W]FY0@FX"*0>&<Q]
MW[?>$2%04<: 20V!:]W:H0Q632X4L"F%74(;6F8Z)K8-$0J+CW2;3<9L4?4>
M\S4[E?LD>[Q&F>[<+"-6LIAQIM9AQ@AL<#! &^OW1V-/#[2EABFE[=JN)]HE
MKHL<CHN2ALU#6[5><9DMXW1IK#$&(&K :.IN7"G1--BJV[1LU>;^_<*MQY@B
M35OC<+P653VI57IWD*$%J,Y-_69HIK&\MBBPP7B04>SRJ84>@,Q6$'>6;>LT
MT!(N0&#*Q:H);//N:%(*8SB+?716$,5_/&'4"]DH;H;B&*J&2M$MIY\>+JV!
MT/DOP6,/8O7_OV7Q'S%_LI@;GMS>:Q\?_"=P^11X/407D+#[2C\8V$K_2SOG
MBS+^,93Z\K."FD_O<R?;'.Y_!2Q_)-$X5N^>38E6W"%SU$?-;<&S)=DKO=89
M^#$Y>\@UI2\)"RSO*X#O-Z^ZSG[.I.J;O?^4Q.\V0?^K8U]]@?2=IZHYIMFR
MY*68UZJ4LLTA(<;)QX4454YV[G%;U_W;'745JFE4W^@Z];N_==RQ/RELG7>V
MFC:_7Q1X01U;K^(43C AOA6,U&D?#MW>8$,VMLTW=R3V=Q'S0\O17U!+ 0(4
M Q0    ( &LX;ED![A7&9 X   A]   0              "  0    !P;'@M
M,C R-# Y,S N>'-D4$L! A0#%     @ :SAN605@(F&0#0  CJT  !0
M         ( !D@X  '!L>"TR,#(T,#DS,%]C86PN>&UL4$L! A0#%     @
M:SAN60!3^)TE'P  A+D! !0              ( !5!P  '!L>"TR,#(T,#DS
M,%]D968N>&UL4$L! A0#%     @ :SAN6>UAX.>K10  RIP# !0
M     ( !JSL  '!L>"TR,#(T,#DS,%]L86(N>&UL4$L! A0#%     @ :SAN
M62U"W&_ +@  PNT" !0              ( !B($  '!L>"TR,#(T,#DS,%]P
M<F4N>&UL4$L! A0#%     @ :SAN63GD088XH $ KM(0 !0
M ( !>K   '!L>"TR,#(T,#DS,'@Q,'$N:'1M4$L! A0#%     @ :SAN69#B
MY(XLS0  4^0  !<              ( !Y% " '!L>"TR,#(T,#DS,'@Q,'$P
M,#4N:G!G4$L! A0#%     @ :SAN64;'?Q+\Q@  (LP  !<
M ( !11X# '!L>"TR,#(T,#DS,'@Q,'$P,#<N:G!G4$L! A0#%     @ :SAN
M61=2%K94:@  .X$  !<              ( !=N4# '!L>"TR,#(T,#DS,'@Q
M,'$P,#@N:G!G4$L! A0#%     @ :SAN6; H2CV["   HS   !<
M     ( !_T\$ '!L>"TR,#(T,#DS,'AE>#,Q9#$N:'1M4$L! A0#%     @
M:SAN672BA/7?"   3#$  !<              ( ![U@$ '!L>"TR,#(T,#DS
M,'AE>#,Q9#(N:'1M4$L! A0#%     @ :SAN6:B;K6+L!0  *!H  !<
M         ( ! V($ '!L>"TR,#(T,#DS,'AE>#,R9#$N:'1M4$L! A0#%
M  @ :SAN6=Z_0.SS!0  /AH  !<              ( !)&@$ '!L>"TR,#(T
E,#DS,'AE>#,R9#(N:'1M4$L%!@     -  T :P,  $QN!     $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>plx-20240930x10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:plx="http://www.protalix.com/20240930"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="plx-20240930.xsd" xlink:type="simple"/>
    <context id="As_Of_9_30_2024_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_1blOGzJfIE-UlAziRRMUpw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_kuJQxZc4AESkk-yYQ3ajEg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_M3cptLGAykWR18u7qZj8rA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Cz0rkmpxTkehEUfvAgkZxw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_AlOFNjsJxk-mD6nKmhSf7A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_xF7FRPyjM0KtHl4ouLxL6A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_e96ler1a0U-r6gjxosRRSw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_c7VyEDTT0Ei2Nt_xe1-AZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_73hlr4ekFUSMz6sOdxmmxw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_YMjyliv9AkaFVW600tbKzg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_IAh-6HHWoUOrjiOkQywBhw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_7nASCJwWaUKNuXPn2KOuug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_EOHIo_NnGUyQjFf3rWGMHg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_mturlRZStkyYVoFlmzAAKA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_igBrNBUN8kSCsy4h33jyHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_357KMU0kkEKUaBvrKS9OkQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_hU3txrf14keCcHLR8hwO8w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_b_5zJrCjPUuLgiN0Qyd3yA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_UZznz_h0nU6MCrNFCI65kA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_3O2OkQ1pv0CKVkSu2N82xA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jyJnbb5Xj02LTfUAsaSZlA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_sY0xRPgRwEmrWK7PpsEQ0g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2u7hpIDa8UWFhyZbeZAEeQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_9_23_2024_To_9_23_2024_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_fjlRxFeRF0GsDO6ftqcY3w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:SeniorVicePresidentAndChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-23</startDate>
            <endDate>2024-09-23</endDate>
        </period>
    </context>
    <context id="Duration_7_2_2024_To_7_2_2024_srt_TitleOfIndividualAxis_plx_VicePresidentResearchAndDevelopmentMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_AvLDv7dryEm2YrB3OLun0Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:VicePresidentResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-02</startDate>
            <endDate>2024-07-02</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2024_To_4_1_2024_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_p_CUFtHXL0eyiopN2TaoPQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-04-01</endDate>
        </period>
    </context>
    <context id="Duration_7_2_2024_To_7_2_2024_srt_TitleOfIndividualAxis_plx_VicePresidentResearchAndDevelopmentMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_Cp-s3NgOGkGiTXZG6ZzZdA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:VicePresidentResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-02</startDate>
            <endDate>2024-07-02</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2024_To_9_30_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_m3nBp_5RP0q3hxfAVIwsKA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2024_To_9_30_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_YVdXplgBIUiqKREQvvCQYg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2024_To_9_30_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_Y25APrw9YkGqE9QGp-2pBw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2024_To_9_30_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_pLP50Bgxbk-D1hnRjPhAlA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2024_To_9_30_2024_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_-EAKZ_94e02kTPJSHJ6-mQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_vw8by47NDUq5QE7hoakywQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_E4kb99v7l0mAZMrPKuEUEA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_R2V45jNs50i3ZjlXVw6V4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_A3ezJBQ1MUmqg7U3imJLCA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_RrGB_Ovo00Ok686p6jPzbA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_xT5o1Ih3q0CS-6-uYmd1nw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_xv7pHWEqdkuqLB4zfoGlgQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_uM6rCcqim06Mqh7Y7r7_hA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_ierukmxCL0qBG6i8bMqdsw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_j4Hh_9X_vkGuiao5PBkobw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_7mSydPVUmEmHGUlub7tPJg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_z371xjvvpUqBogUfxstw5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_-gw8gqnXX0q0q6EWX9kyGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_DR0rv8wVu0yrFx2bdJFyPQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_Mxt-hPsr9EG5KGrzdcGbQQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_u2CliSsMKUa6PUPveJHdTg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_11_14_2024_To_11_14_2024_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_IuBQ2oW-QUW8AyxcNROv4A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-14</startDate>
            <endDate>2024-11-14</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_SrS-_DJJqkCTLZ9dXxqUAw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ndUCQHw1p0S3US6p-dGFDg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_xlxVJaEkm0Cl5SxIoEuaJQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_hHjoVDl78USlzlUtO3Htzg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_Vdzpjd4fMUGT4CcCzCt5ig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_orKpnVhEbkGbW5YdvkXelA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_qFQhXtC8OkS0z_OP8CBUzQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_v1JvrDW3HkajOYmzxLbG4A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_7_1_2024_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsAndWarrantsMember_C0t9LFxG80iLLT4GrVHt5Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">plx:OutstandingStockOptionsAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsWarrantsAnd2024NotesMember_pHC6uKO6gUK7SAy-_PDCuw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">plx:OutstandingStockOptionsWarrantsAnd2024NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsAndWarrantsMember_jNIclNrn20-gLZ0NF4hAeg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">plx:OutstandingStockOptionsAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsAndWarrantsMember_I8uK516psE6zNy3vZsdCVQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">plx:OutstandingStockOptionsAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_jTQDJIj1aEykP0X3ByOvLQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_CXybZU5St0uHedL7onjfxA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_tZ6IRwK5mk6fHAJ4kYRAJA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUsAgreementAndChiesiExUsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-23</instant>
        </period>
    </context>
    <context id="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_lxgklNBaXU2pjfcaFonqKA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUsAgreementAndChiesiExUsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-19</instant>
        </period>
    </context>
    <context id="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ojV2ETGPxU-tgxipZ4iH_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3sUNQWsOgkuiFe-1dqA4tg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_H1-pSjk9fUqYJ7iVy7K5tg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_-IUAcf8ZvUOvvarlRWC6wg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_n3sdM3d8VEGt5dkutaAe0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3-IpBWJWhU6nof7a6J-CqQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023__jyu8G4bX02xwWm0pGi6zA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jMEt6MgVmU2McANkIiOctQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sULEv8JSLkKw5iYh_rNi0w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_9_23_2024_To_9_23_2024_srt_TitleOfIndividualAxis_plx_OfficersAndOtherEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_dTpdI5xPrkiwpnGVkyHdmQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:OfficersAndOtherEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-23</startDate>
            <endDate>2024-09-23</endDate>
        </period>
    </context>
    <context id="Duration_7_2_2024_To_7_2_2024_srt_TitleOfIndividualAxis_plx_VicePresidentResearchAndDevelopmentMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_fsxZjtrzyEyb_e85-FjXKw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:VicePresidentResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-02</startDate>
            <endDate>2024-07-02</endDate>
        </period>
    </context>
    <context id="Duration_1_15_2024_To_1_15_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_ELprQe2rdEavBiEcVE57Fg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-15</startDate>
            <endDate>2024-01-15</endDate>
        </period>
    </context>
    <context id="As_Of_9_23_2024_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_ypJyopAyWUGn0-upITXFlQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:SeniorVicePresidentAndChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-23</instant>
        </period>
    </context>
    <context id="As_Of_9_23_2024_srt_TitleOfIndividualAxis_plx_OfficersAndOtherEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_b8NTuk7QZkmYLH_vN0r7-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:OfficersAndOtherEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-23</instant>
        </period>
    </context>
    <context id="As_Of_7_2_2024_srt_TitleOfIndividualAxis_plx_VicePresidentResearchAndDevelopmentMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_VcyDlSSU_UuXWR7-Z6srjw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:VicePresidentResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-02</instant>
        </period>
    </context>
    <context id="As_Of_4_1_2024_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_fW2CAIqwS0yFawiF2Xq3Pw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-01</instant>
        </period>
    </context>
    <context id="As_Of_1_15_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_wjItBW8ElUS5zStQFNkaTQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-15</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_lsKt_FH16UaE7aDEdbwFUg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_2_27_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_glBx8-GKQUagOk_5tVbhmg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-27</instant>
        </period>
    </context>
    <context id="As_Of_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_YET2ryP2dEill85k2_nFHg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_8CtKgL9lj0K2stR5YPRj0Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-23</startDate>
            <endDate>2018-07-23</endDate>
        </period>
    </context>
    <context id="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_nRvfA8aPdUu85RbZO37WRQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-23</startDate>
            <endDate>2018-07-23</endDate>
        </period>
    </context>
    <context id="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_mw7kn8o2CUWR-j1nLxbVfQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-19</startDate>
            <endDate>2017-10-19</endDate>
        </period>
    </context>
    <context id="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_znGsm8ayME60HPVCk9kYOA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-19</startDate>
            <endDate>2017-10-19</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_yf1yBqYb3ki32oo6H-lkuQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_pm7aApgkcEqj6XWAS_4N3w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_8_29_2022_To_8_29_2022_us-gaap_TypeOfArrangementAxis_plx_FillFinishAgreementMember_Ol0Pxko4TEuK_ACCWu0Zww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:FillFinishAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-29</startDate>
            <endDate>2022-08-29</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2015_To_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_HI7XdKpS_0KkIxReGTPNCg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:AmendedPfizerAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">plx:ProtalixBioTherapeuticsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-10-01</startDate>
            <endDate>2015-10-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_5_13_2021_To_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_MxJMMq-010ClsaMCqYEAAA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-13</startDate>
            <endDate>2021-05-13</endDate>
        </period>
    </context>
    <context id="As_Of_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_f8J7ygmkjUK2ukgA-2oQ1w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-13</instant>
        </period>
    </context>
    <context id="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_eO8PT46mE0CgmO5dj_kuPw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-23</instant>
        </period>
    </context>
    <context id="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_vK2rvFHWSU-qe_rFcemZww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-19</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_7_1_2024_To_9_30_2024_5srFek9aZ0STe4olK5gckA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_11_1_2024_FKdLzARpm02W48BIunrkDA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2024-11-01</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_pure_KYNrm9UG9EeMn48Y0if07Q">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_agreement_ukZC-6VifkuWtCWLoRpkbA">
        <measure>plx:agreement</measure>
    </unit>
    <unit id="Unit_Standard_installment_GQ9uxVOtz0-sYFwS4P9Gzg">
        <measure>plx:installment</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_A4-BaHg86EmBShQ9tsexWA">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g"
      id="Hidden_BnJKc6cYMECkbSqz4tNmhQ"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q"
      id="Hidden_ZE0iLoUV80CQ00P_T_VKHw"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA"
      xsi:nil="true"/>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      id="Tc_lrdZw1pa30CPd-cD4nhV5Q_2_1">0001006281</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      id="Tc_e3hUVPLCUE2fZi-S61JwQg_3_1">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      id="Tc_cPvjmaDfRkWco1btGDM3uA_4_1">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      id="Tc_p34_EdIPWEed2GU5LxPypg_5_1">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      id="Tc_TkXGng-EjEiXcyhd84OD4g_6_1">false</dei:AmendmentFlag>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_7_2_2024_To_7_2_2024_srt_TitleOfIndividualAxis_plx_VicePresidentResearchAndDevelopmentMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_Cp-s3NgOGkGiTXZG6ZzZdA"
      decimals="INF"
      id="Hidden_Wv5n4SFqLUalXo86fgRQdg"
      unitRef="Unit_Standard_pure_KYNrm9UG9EeMn48Y0if07Q">0.333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_7_2_2024_To_7_2_2024_srt_TitleOfIndividualAxis_plx_VicePresidentResearchAndDevelopmentMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_Cp-s3NgOGkGiTXZG6ZzZdA"
      id="Hidden_HDd_9eUnQUuEPgjlLh4OWA">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_7_2_2024_To_7_2_2024_srt_TitleOfIndividualAxis_plx_VicePresidentResearchAndDevelopmentMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_fsxZjtrzyEyb_e85-FjXKw"
      decimals="INF"
      id="Hidden_UMFZm-Gn_k61nFAdjEsS9w"
      unitRef="Unit_Standard_pure_KYNrm9UG9EeMn48Y0if07Q">0.666</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <dei:DocumentType
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      id="Narr_JF6He4iTUk2-i0VF7vsr3g">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      id="Narr_q_v7q10hUUeNYvpmqdxeNw">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      id="Narr_dJcGPkurOk-NcKDQ-wiHGQ">2024-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      id="Narr_xve6g4LYsE6GVu0zPWyNAA">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      id="Narr_1Rw5Xu5800mghE6PFwXBGQ">001-33357</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      id="Narr_-vzBKGZaNU-VWhgn5WJvkA">PROTALIX BIOTHERAPEUTICS,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      id="Tc_gsW8iMHxaEe8iT_Ck5thaw_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      id="Narr_whcBgMgogEODbSJ4zMmIOw">65-0643773</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      id="Narr_dkcOZsoB2U-9RUh0S_1fsw">2 University Plaza</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      id="Narr_oBOPY5gkJE2N15b76HHbgQ">Suite 100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      id="Narr_xMYE0P891UmLepl5bJzDRQ">Hackensack</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      id="Narr_BeUvbE1MrUSkgHbhwjXzFQ">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      id="Tc_ExF2KH9ZF023A9hl23PbjQ_4_1">07601</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      id="Narr_vmHO5LLbH0WKx0GYob0FhQ">201</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      id="Narr_4Wi6khCXkEGpqwcFhvC9Bg">696-9345</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      id="Tc_cVNwL6K8SUGK28sk57_cfA_2_0">Common stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      id="Tc_5LrqQ2i300KBmei0gAz04g_2_2">PLX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      id="Tc_0TJ9JAVD9UyFP0MovLSKYg_2_4">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      id="Narr_6SLX4P3ktU-GUASbr1eakg">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      id="Narr_XOTA3CSerUqEIaChc5TAjQ">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      id="Tc_9b52T48ot0m5mM_uB100Sg_2_0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      id="Tc_NW0Vjz1F3EC1YuO2xC8xgQ_2_3">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      id="Tc_07mVxZiMYUeaz-j3fBgNRw_3_3">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      id="Narr_kwy-xJdZTE2AseZjmsl-qA">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_11_1_2024_FKdLzARpm02W48BIunrkDA"
      decimals="INF"
      id="Narr_XVCuFD_zeUao-OAhfssTSg"
      unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA">73633583</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g"
      decimals="-3"
      id="Tc_ZFldj6egR0SwNm6jrT6RXQ_6_3"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">27409000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q"
      decimals="-3"
      id="Tc_re7cqt390kCRRis3RqMVPw_6_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">23634000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <plx:ShortTermBankDeposits
      contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q"
      decimals="-3"
      id="Tc_kebPAPmmqkS2xSibZEGCgw_7_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">20926000</plx:ShortTermBankDeposits>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g"
      decimals="-3"
      id="Tc_SU7vpANuXkaHY9tiY-ID6A_8_3"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">2195000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q"
      decimals="-3"
      id="Tc_qkNcvgXomkG-9EezBkXlsw_8_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">5272000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g"
      decimals="-3"
      id="Tc_xEMNvZujcUWgaGofgy2DNg_9_3"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">1050000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q"
      decimals="-3"
      id="Tc_1vPYOThJpkWdrqZ-VfCKZg_9_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">1055000</us-gaap:OtherAssetsCurrent>
    <us-gaap:InventoryNet
      contextRef="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g"
      decimals="-3"
      id="Tc_zedPMHoR10Ket3a-1nk75Q_10_3"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">17199000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q"
      decimals="-3"
      id="Tc_Hu_8MEGjt0KlhpR_DF9pGQ_10_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">19045000</us-gaap:InventoryNet>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g"
      decimals="-3"
      id="Tc_hDnEJbsfi0GzvifBokhWxg_11_3"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">47853000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q"
      decimals="-3"
      id="Tc_GjEsYNEIXkqWTMvLdGjYYQ_11_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">69932000</us-gaap:AssetsCurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g"
      decimals="-3"
      id="Tc_eCYNBhbiuEW6d_ePjxoXwg_14_3"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">561000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q"
      decimals="-3"
      id="Tc_l9EjWA4aBk2mKpqp5l9FJQ_14_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">528000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g"
      decimals="-3"
      id="Tc__Zxd33hr00ONwy5aQDMpyA_15_3"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">4648000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q"
      decimals="-3"
      id="Tc_NvVK_ks-WEKnCs1_UUtf1g_15_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">4973000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g"
      decimals="-3"
      id="Tc_2O_2qbkiR0mDG0fSSNjqtQ_16_3"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">2856000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q"
      decimals="-3"
      id="Tc_HuOTr_7REU6uos9AHhiEMw_16_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">3092000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g"
      decimals="-3"
      id="Tc_wuYKXkqY2ESpmjcXWH_tIg_17_3"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">5645000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q"
      decimals="-3"
      id="Tc_xFuSgDTbCUS1k1rcglWxbA_17_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">5909000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Assets
      contextRef="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g"
      decimals="-3"
      id="Tc_hIQWg2XjFESaFOW69OVZzg_18_3"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">61563000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q"
      decimals="-3"
      id="Tc_D5pojc0bPUG2n_yRLyEZdA_18_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">84434000</us-gaap:Assets>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g"
      decimals="-3"
      id="Tc_zt9ZLhTNhkWv3SINu3cjXA_24_3"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">3135000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q"
      decimals="-3"
      id="Tc_ueS4d2qNS0SSMQ8ORhdVjQ_24_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">4320000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g"
      decimals="-3"
      id="Tc_YstaWRzH20-c-eveGB-qyg_25_3"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">19577000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q"
      decimals="-3"
      id="Tc_taHEbyIXm0eWEqrbL0jlnw_25_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">19550000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g"
      decimals="-3"
      id="Tc_yJYdrc8trEmsZl4BaZ5Dzg_26_3"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">1508000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q"
      decimals="-3"
      id="Tc_Q9xF3kQh4Ui8Di_soFoRHQ_26_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">1409000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ConvertibleDebtCurrent
      contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q"
      decimals="-3"
      id="Tc_99GJrmrq7UCL_QIPY4K_bg_27_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">20251000</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g"
      decimals="-3"
      id="Tc_YO5yYM1S3UqwXirK1nBbUg_28_3"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">24220000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q"
      decimals="-3"
      id="Tc_2ruWZnvdNEurNbLM06u_eg_28_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">45530000</us-gaap:LiabilitiesCurrent>
    <us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent
      contextRef="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g"
      decimals="-3"
      id="Tc_1yATXY4_LEauozEfN1aXQg_31_3"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">730000</us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q"
      decimals="-3"
      id="Tc_kt5Oh5WN9EiSc9Xpfamg0A_31_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">714000</us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g"
      decimals="-3"
      id="Tc_eUuMWDtMkk2QpC7FBC7-2g_32_3"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">4176000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q"
      decimals="-3"
      id="Tc_Vm2-VKR6PUONbEKrvLI1hw_32_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">4621000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g"
      decimals="-3"
      id="Tc_O2tRGS2iiUK5M2HQTmhHwQ_33_3"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">4906000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q"
      decimals="-3"
      id="Tc_S44eH9T2u0KqWcWsdab-XA_33_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">5335000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g"
      decimals="-3"
      id="Tc_IbkWoITQUku62gB6AACBOQ_34_3"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">29126000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q"
      decimals="-3"
      id="Tc_bPjtTkIkyUSc5eAB9zR_NA_34_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">50865000</us-gaap:Liabilities>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g"
      decimals="-3"
      id="Tc_Z-IBhgnCHk6e4oqijbMwqQ_38_3"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">32437000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q"
      decimals="-3"
      id="Tc_MX0sHRyu6EyI-uTbRonH5A_38_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">33569000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g"
      decimals="-3"
      id="Tc_2Uu4piMGqkafoTmdYw1rcg_39_3"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">61563000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q"
      decimals="-3"
      id="Tc_rd_rHeMEy0Op4J3yFj5ezA_39_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">84434000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2024_To_9_30_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_A3ezJBQ1MUmqg7U3imJLCA"
      decimals="-3"
      id="Tc_IN_Ph4oCH06mA3SEpWshxA_3_2"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">34820000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_DR0rv8wVu0yrFx2bdJFyPQ"
      decimals="-3"
      id="Tc_KFZSdkO-vEyqOn2_xZIjWA_3_5"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">30309000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2024_To_9_30_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_pLP50Bgxbk-D1hnRjPhAlA"
      decimals="-3"
      id="Tc_5pLw20mK50GOTguKqVDzVA_3_8"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">17839000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_ierukmxCL0qBG6i8bMqdsw"
      decimals="-3"
      id="Tc_T0bVoQSqYkCbgxp00aABLA_3_11"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">10168000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2024_To_9_30_2024_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_RrGB_Ovo00Ok686p6jPzbA"
      decimals="-3"
      id="Tc_kq6jgpYvQ0Wx56cPN2h83g_4_2"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">361000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_Mxt-hPsr9EG5KGrzdcGbQQ"
      decimals="-3"
      id="Tc_3OS7b-DSSEW2gnwI9uYUIw_4_5"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">24699000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2024_To_9_30_2024_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_-EAKZ_94e02kTPJSHJ6-mQ"
      decimals="-3"
      id="Tc_G60jqX5JQk6mdCZyyKV5jw_4_8"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">120000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_j4Hh_9X_vkGuiao5PBkobw"
      decimals="-3"
      id="Tc_uMA7Yi40SUCjwayWJx3tPA_4_11"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">177000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      decimals="-3"
      id="Tc_MsPPoSxQ_EC_5lO0TVJQnw_5_2"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">35181000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g"
      decimals="-3"
      id="Tc_EKcKLFOsiU-TYU5AJp-x0Q_5_5"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">55008000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2024_To_9_30_2024_5srFek9aZ0STe4olK5gckA"
      decimals="-3"
      id="Tc_moNucDbNAEC36QRAmXf2CQ_5_8"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">17959000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2023_To_9_30_2023__jyu8G4bX02xwWm0pGi6zA"
      decimals="-3"
      id="Tc_yiwcupd-RU6AOqxzoAwXCw_5_11"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">10345000</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      decimals="-3"
      id="Tc_iC0f4O7vr0iLPXCFaqdTbQ_6_2"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">20433000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g"
      decimals="-3"
      id="Tc_EdCqXVjyIk-eemvEzWeUyA_6_5"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">14126000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="Duration_7_1_2024_To_9_30_2024_5srFek9aZ0STe4olK5gckA"
      decimals="-3"
      id="Tc_Ipwlu9g14EWxgE4ak5nkHA_6_8"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">8375000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="Duration_7_1_2023_To_9_30_2023__jyu8G4bX02xwWm0pGi6zA"
      decimals="-3"
      id="Tc_jXsr4WXmY0yAQ-A0TYcCDA_6_11"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">4893000</us-gaap:CostOfRevenue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      decimals="-3"
      id="Tc_p-bW5f9b40Km5zOOkoX91w_7_2"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">8846000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g"
      decimals="-3"
      id="Tc_cOeT3_-8eEGr27c00_QhwQ_7_5"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">13991000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_7_1_2024_To_9_30_2024_5srFek9aZ0STe4olK5gckA"
      decimals="-3"
      id="Tc_LNrQQec4fEmDM1MKZ4DTVA_7_8"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">2998000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_7_1_2023_To_9_30_2023__jyu8G4bX02xwWm0pGi6zA"
      decimals="-3"
      id="Tc_j465Hu22kkGsZdvCELTOlw_7_11"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">3669000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      decimals="-3"
      id="Tc_4SxNu3naGUGopmjIz730_w_8_2"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">9194000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g"
      decimals="-3"
      id="Tc_sELVoedwvEqSlS-Bvdd1gg_8_5"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">10816000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_7_1_2024_To_9_30_2024_5srFek9aZ0STe4olK5gckA"
      decimals="-3"
      id="Tc_GsFAHHAYT0CGmYeSQRhV4Q_8_8"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">2595000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_7_1_2023_To_9_30_2023__jyu8G4bX02xwWm0pGi6zA"
      decimals="-3"
      id="Tc_iEzKWr2Rfk2jLANwX-mKdg_8_11"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">3670000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      decimals="-3"
      id="Tc_dmKJIMce8U65E8wEpVRXSw_9_2"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">-3292000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g"
      decimals="-3"
      id="Tc_LTxkhUxpuUqneqxBc-i7tA_9_5"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">16075000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_7_1_2024_To_9_30_2024_5srFek9aZ0STe4olK5gckA"
      decimals="-3"
      id="Tc_jqVWQouuWEuTkUMKHtQ1mw_9_8"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">3991000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_7_1_2023_To_9_30_2023__jyu8G4bX02xwWm0pGi6zA"
      decimals="-3"
      id="Tc_Azi6L4-vDECNvxxDQQGhlg_9_11"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">-1887000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      decimals="-3"
      id="Tc_tlW_5gdNiE-dgJqaFOp7JA_10_2"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">1056000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g"
      decimals="-3"
      id="Tc_6IV9KW7KFkuYu9eOR4yXxg_10_5"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">2406000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_7_1_2024_To_9_30_2024_5srFek9aZ0STe4olK5gckA"
      decimals="-3"
      id="Tc_IbccAA4r6kydLSiQQvKIug_10_8"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">299000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_7_1_2023_To_9_30_2023__jyu8G4bX02xwWm0pGi6zA"
      decimals="-3"
      id="Tc_sujEFWOtx02ECKjzna7zBw_10_11"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">460000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      decimals="-3"
      id="Tc_Rd9G1mYDvkusNsbkXgpy8g_11_2"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">1186000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g"
      decimals="-3"
      id="Tc_0_gh3K8j80O-Dip6I_VM1w_11_5"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">1323000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_7_1_2024_To_9_30_2024_5srFek9aZ0STe4olK5gckA"
      decimals="-3"
      id="Tc_dytleh4ogEilePxXBTyH0g_11_8"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">151000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_7_1_2023_To_9_30_2023__jyu8G4bX02xwWm0pGi6zA"
      decimals="-3"
      id="Tc_6uCBQcBsQkqI6jDDX2bUfQ_11_11"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">628000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      decimals="-3"
      id="Tc_kSheb7fKxUOZKDnotrPInw_12_2"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">130000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g"
      decimals="-3"
      id="Tc_rmVqRcyStUSWH2aj8_C-UQ_12_5"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">-1083000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_7_1_2024_To_9_30_2024_5srFek9aZ0STe4olK5gckA"
      decimals="-3"
      id="Tc_y6_1OufTmEeC1n0fcVQbxg_12_8"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">-148000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_7_1_2023_To_9_30_2023__jyu8G4bX02xwWm0pGi6zA"
      decimals="-3"
      id="Tc_fBTFoH1k5kW_L4rTY0PYoA_12_11"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">168000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      decimals="-3"
      id="Tc_woQge4JJxUiclf50MQonCg_13_2"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">-3162000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g"
      decimals="-3"
      id="Tc_SWaE2LnoZE-jRxaceK7c0A_13_5"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">14992000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_7_1_2024_To_9_30_2024_5srFek9aZ0STe4olK5gckA"
      decimals="-3"
      id="Tc_-0VXj8OVjEadIYdQ8L9m_g_13_8"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">3843000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_7_1_2023_To_9_30_2023__jyu8G4bX02xwWm0pGi6zA"
      decimals="-3"
      id="Tc_NlSnUSTKiUSpAMBCcPFGJw_13_11"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">-1719000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      decimals="-3"
      id="Tc_iYeQwoaei0S1or9fgb_Umg_14_2"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">400000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g"
      decimals="-3"
      id="Tc_HeUtQ3vjyUuK2sR8pJI5jw_14_5"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">636000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_7_1_2024_To_9_30_2024_5srFek9aZ0STe4olK5gckA"
      decimals="-3"
      id="Tc_cnyR9gAoIk6lrpbTXAoU6w_14_8"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">607000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_7_1_2023_To_9_30_2023__jyu8G4bX02xwWm0pGi6zA"
      decimals="-3"
      id="Tc_4mll5q8YoU2tTjpuKpoxJg_14_11"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">133000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      decimals="-3"
      id="Tc_lmD_6Vgq_0-7tRFDYgYaEQ_15_2"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">-3562000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g"
      decimals="-3"
      id="Tc_ma1dQ8Fl5kW5ZC64KI17NQ_15_5"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">14356000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2024_To_9_30_2024_5srFek9aZ0STe4olK5gckA"
      decimals="-3"
      id="Tc_mEWZ_9x7zk6Bg0IZhnDz8w_15_8"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">3236000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2023_To_9_30_2023__jyu8G4bX02xwWm0pGi6zA"
      decimals="-3"
      id="Tc_CFyGrjpjYEyjhmVTzJAgPw_15_11"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">-1852000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      decimals="2"
      id="Tc_ChAGSeNjZUefqzVxxaOHFw_17_2"
      unitRef="Unit_Divide_USD_shares_A4-BaHg86EmBShQ9tsexWA">-0.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g"
      decimals="2"
      id="Tc_IAyQq3-j9U2xSbcAooDNPw_17_5"
      unitRef="Unit_Divide_USD_shares_A4-BaHg86EmBShQ9tsexWA">0.22</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_7_1_2024_To_9_30_2024_5srFek9aZ0STe4olK5gckA"
      decimals="2"
      id="Tc_1e1vsrjZgU--zkryJ58d0w_17_8"
      unitRef="Unit_Divide_USD_shares_A4-BaHg86EmBShQ9tsexWA">0.04</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_7_1_2023_To_9_30_2023__jyu8G4bX02xwWm0pGi6zA"
      decimals="2"
      id="Tc_W6t9lk2N4EuAuLV1J_ktuw_17_11"
      unitRef="Unit_Divide_USD_shares_A4-BaHg86EmBShQ9tsexWA">-0.03</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      decimals="2"
      id="Tc_OC6ZNx3Uuk2u0jOtawv4dQ_18_2"
      unitRef="Unit_Divide_USD_shares_A4-BaHg86EmBShQ9tsexWA">-0.05</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g"
      decimals="2"
      id="Tc_j7mYoao6vUafenJbdyQUtw_18_5"
      unitRef="Unit_Divide_USD_shares_A4-BaHg86EmBShQ9tsexWA">0.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_7_1_2024_To_9_30_2024_5srFek9aZ0STe4olK5gckA"
      decimals="2"
      id="Tc_4ciRM8_QFk-osZ25s92LUg_18_8"
      unitRef="Unit_Divide_USD_shares_A4-BaHg86EmBShQ9tsexWA">0.03</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_7_1_2023_To_9_30_2023__jyu8G4bX02xwWm0pGi6zA"
      decimals="2"
      id="Tc_Pn93ad-aFUKV7RHaE66BcA_18_11"
      unitRef="Unit_Divide_USD_shares_A4-BaHg86EmBShQ9tsexWA">-0.04</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      decimals="0"
      id="Tc_EwdRb5m4pE-vWiggf9NNcg_21_2"
      unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA">73301091</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g"
      decimals="0"
      id="Tc_LmboOzyO2EaBqoVg3agj0g_21_5"
      unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA">65811506</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_7_1_2024_To_9_30_2024_5srFek9aZ0STe4olK5gckA"
      decimals="0"
      id="Tc_aZSrUC7Mb0Obv2oo4XFb-Q_21_8"
      unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA">73549745</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_7_1_2023_To_9_30_2023__jyu8G4bX02xwWm0pGi6zA"
      decimals="0"
      id="Tc_DeoZiMq5G0KflTc4jzdiqA_21_11"
      unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA">72281681</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      decimals="0"
      id="Tc_lv-EeENe5UWduXPiYXmQRg_22_2"
      unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA">73301091</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g"
      decimals="0"
      id="Tc_0Ph82C-GkU-SVYxuzNjV2w_22_5"
      unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA">81040281</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_7_1_2024_To_9_30_2024_5srFek9aZ0STe4olK5gckA"
      decimals="0"
      id="Tc_KCuxtnDqNUujUrGMB-FhHQ_22_8"
      unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA">81217068</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_7_1_2023_To_9_30_2023__jyu8G4bX02xwWm0pGi6zA"
      decimals="0"
      id="Tc_77GvNQqa_UCgbVltR9qWFw_22_11"
      unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA">83782679</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2u7hpIDa8UWFhyZbeZAEeQ"
      decimals="INF"
      id="Tc_pVxwznRJPEKMo6T8bA4g8Q_6_2"
      unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA">53790167</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2u7hpIDa8UWFhyZbeZAEeQ"
      decimals="-3"
      id="Tc_qIKUMzYsA0mxXjlAfmIeCQ_6_5"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">54000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_hU3txrf14keCcHLR8hwO8w"
      decimals="-3"
      id="Tc_zXBvjONncUuX6hWJkLxvdQ_6_8"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">379167000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_357KMU0kkEKUaBvrKS9OkQ"
      decimals="-3"
      id="Tc_7rzgTjE-QkafWODWhreeNQ_6_11"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">-389861000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_v1JvrDW3HkajOYmzxLbG4A"
      decimals="-3"
      id="Tc_f8lPDruj8Uu1wnwFdbKn5Q_6_14"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">-10640000</us-gaap:StockholdersEquity>
    <plx:StockIssuedDuringPeriodSharesSalesAgreement
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jMEt6MgVmU2McANkIiOctQ"
      decimals="INF"
      id="Tc_gP3Z8K24QEi0StlfU4I0xA_8_2"
      unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA">12560150</plx:StockIssuedDuringPeriodSharesSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jMEt6MgVmU2McANkIiOctQ"
      decimals="-3"
      id="Tc_mb8gaEgMgkumJ2T_Cm3J1g_8_5"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">13000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sULEv8JSLkKw5iYh_rNi0w"
      decimals="-3"
      id="Tc_pSU_l2GqDUiV87tiCr4owg_8_8"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">23941000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g"
      decimals="-3"
      id="Tc_uphekxLbC0mAuxjFn1cn5g_8_14"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">23954000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jMEt6MgVmU2McANkIiOctQ"
      decimals="INF"
      id="Tc_A02-y9pBqUamMTVlXsWeHw_9_2"
      unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA">4691623</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jMEt6MgVmU2McANkIiOctQ"
      decimals="-3"
      id="Tc_jwq0YuTWx0Ki9Z3AdkBCZA_9_5"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">5000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sULEv8JSLkKw5iYh_rNi0w"
      decimals="-3"
      id="Tc_2sozLZJNmECXGPz4KtHrdA_9_8"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">7778000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g"
      decimals="-3"
      id="Tc_C2q14ehRlEOo0_naYR8cmg_9_14"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">7783000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sULEv8JSLkKw5iYh_rNi0w"
      decimals="-3"
      id="Tc_iQbl8-3IekOYfTw7x_T7Gg_10_8"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">1195000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g"
      decimals="-3"
      id="Tc_eSZ5iLU90UCKX0scHVHb1A_10_14"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">1195000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jMEt6MgVmU2McANkIiOctQ"
      decimals="INF"
      id="Tc_ou5xw0ZH3UOzwMqFkX8ZXw_11_2"
      unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA">1371362</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jMEt6MgVmU2McANkIiOctQ"
      decimals="-3"
      id="Tc_n3EbmtnYO06ZZwGMV6A9dA_11_5"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">1000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sULEv8JSLkKw5iYh_rNi0w"
      decimals="-3"
      id="Tc__yB92M0gYEuW4H1TRVZXjw_11_8"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">886000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g"
      decimals="-3"
      id="Tc_TZIqxllf5k2W-Uwki1EIeg_11_14"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">887000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:StockIssuedDuringPeriodSharesWarrantsExercises
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jMEt6MgVmU2McANkIiOctQ"
      decimals="INF"
      id="Tc_9_aCVK5OUUSmQnmWd-Iaag_12_2"
      unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA">538822</plx:StockIssuedDuringPeriodSharesWarrantsExercises>
    <plx:StockIssuedDuringPeriodValueWarrantsExercises
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sULEv8JSLkKw5iYh_rNi0w"
      decimals="-3"
      id="Tc_JUu79IYFmEm0yyZtImuguA_12_8"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">712000</plx:StockIssuedDuringPeriodValueWarrantsExercises>
    <plx:StockIssuedDuringPeriodValueWarrantsExercises
      contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g"
      decimals="-3"
      id="Tc_ZYxf8mw2B0SQ7F7AfLAT4w_12_14"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">712000</plx:StockIssuedDuringPeriodValueWarrantsExercises>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_hHjoVDl78USlzlUtO3Htzg"
      decimals="-3"
      id="Tc_rg1EhVY_R06v3FDec_L2wg_13_11"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">14356000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g"
      decimals="-3"
      id="Tc_M8YiT7HQkUKaLbjkFAyGqg_13_14"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">14356000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jyJnbb5Xj02LTfUAsaSZlA"
      decimals="INF"
      id="Tc_UtQwCJekdUasg7dOkWRNag_14_2"
      unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA">72952124</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jyJnbb5Xj02LTfUAsaSZlA"
      decimals="-3"
      id="Tc_Af_gUFLus0yOwbfNY3ehSA_14_5"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">73000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_7nASCJwWaUKNuXPn2KOuug"
      decimals="-3"
      id="Tc_SvapjiBLNUykyMy0uGP46Q_14_8"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">413679000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_IAh-6HHWoUOrjiOkQywBhw"
      decimals="-3"
      id="Tc_3BODSVNJ_EukxQZYQzfSXw_14_11"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">-375505000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2023_qFQhXtC8OkS0z_OP8CBUzQ"
      decimals="-3"
      id="Tc_rG7m2Km8x0-nxykZnOdBrA_14_14"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">38247000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_3O2OkQ1pv0CKVkSu2N82xA"
      decimals="INF"
      id="Tc_Lh0LWu1Zxk6bjyikcZldlg_15_2"
      unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA">72952124</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_3O2OkQ1pv0CKVkSu2N82xA"
      decimals="-3"
      id="Tc_RBPA-dVnU0Cr_Z1lC7mcbA_15_5"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">73000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_YMjyliv9AkaFVW600tbKzg"
      decimals="-3"
      id="Tc_yxXCjkG1BUKTQc1kpBbuhw_15_8"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">415045000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_73hlr4ekFUSMz6sOdxmmxw"
      decimals="-3"
      id="Tc_jLB3IvR-gUudefDPBy46rA_15_11"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">-381549000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q"
      decimals="-3"
      id="Tc_ettfR7XzQk6v7un9DFuHNA_15_14"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">33569000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2024_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_kuJQxZc4AESkk-yYQ3ajEg"
      decimals="-3"
      id="Tc_ZkkO4M1iU0WhFtnc69cAdA_17_8"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">-393000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2024_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_1blOGzJfIE-UlAziRRMUpw"
      decimals="-3"
      id="Tc_owd4aMzRKEu8tT_9bmtsqQ_17_11"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">224000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2024_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_M3cptLGAykWR18u7qZj8rA"
      decimals="-3"
      id="Tc_26Ebrrl7a0q3NSeVYGr6rw_17_14"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">-169000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_-IUAcf8ZvUOvvarlRWC6wg"
      decimals="-3"
      id="Tc_a-kLkescvU-euu9-drCWfg_18_8"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">1191000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      decimals="-3"
      id="Tc_T6T7q3TwkE2tDy-gtCQfDA_18_14"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">1191000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_H1-pSjk9fUqYJ7iVy7K5tg"
      decimals="INF"
      id="Tc_VWvVYHPsI0-a0UWwtx9QAA_19_2"
      unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA">681459</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_H1-pSjk9fUqYJ7iVy7K5tg"
      decimals="-3"
      id="Tc_l1PBOW9sBU-Slb8YhNF1og_19_5"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">1000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_-IUAcf8ZvUOvvarlRWC6wg"
      decimals="-3"
      id="Tc_puL8hellS0WOEyvmdTzRbA_19_8"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">1407000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      decimals="-3"
      id="Tc_h0TJcu76AEGuyOq0Q-ZMGQ_19_14"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">1408000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ndUCQHw1p0S3US6p-dGFDg"
      decimals="-3"
      id="Tc_Mos_V_Gf4kKWMWYnMeA0Uw_20_11"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">-3562000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      decimals="-3"
      id="Tc_nGFsIEH2gEGmMZh8p1ZUOA_20_14"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">-3562000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_b_5zJrCjPUuLgiN0Qyd3yA"
      decimals="INF"
      id="Tc_Ho1JiaXHzkKwcRlvVUSVZw_21_2"
      unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA">73633583</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_b_5zJrCjPUuLgiN0Qyd3yA"
      decimals="-3"
      id="Tc_kPeLE32VREaQK_PQQOj6gg_21_5"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">74000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_AlOFNjsJxk-mD6nKmhSf7A"
      decimals="-3"
      id="Tc_r0FnZtZK1kiC_4mw-nKdKA_21_8"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">417250000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Cz0rkmpxTkehEUfvAgkZxw"
      decimals="-3"
      id="Tc__tTeNxa4cEmdPPYSBgwAXg_21_11"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">-384887000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g"
      decimals="-3"
      id="Tc_pzNZzNFp30u3JsVTrwVZcg_21_14"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">32437000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_sY0xRPgRwEmrWK7PpsEQ0g"
      decimals="INF"
      id="Tc_S08bm8fgO0i5HiSEl0Rfgg_22_2"
      unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA">71580762</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_sY0xRPgRwEmrWK7PpsEQ0g"
      decimals="-3"
      id="Tc_cXBwp6bOu0qGCDkSFY4x1g_22_5"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">72000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_mturlRZStkyYVoFlmzAAKA"
      decimals="-3"
      id="Tc__gQMfK9550uVdvllfD-E8w_22_8"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">412582000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_EOHIo_NnGUyQjFf3rWGMHg"
      decimals="-3"
      id="Tc_2wWqLzpf7kymQRhH2TSb8g_22_11"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">-373653000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2023_igBrNBUN8kSCsy4h33jyHA"
      decimals="-3"
      id="Tc_BJ6y6XOeAkOpA4G7VA9MvQ_22_14"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">39001000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3-IpBWJWhU6nof7a6J-CqQ"
      decimals="-3"
      id="Tc_ysYu5ObRzk-wJypf2_qeDQ_24_8"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">383000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2023_To_9_30_2023__jyu8G4bX02xwWm0pGi6zA"
      decimals="-3"
      id="Tc_74VnDwYThkegU4DlXsEKqw_24_14"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">383000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_n3sdM3d8VEGt5dkutaAe0A"
      decimals="INF"
      id="Tc_aC_OasVPQ0KRxRUvZLjfIw_25_2"
      unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA">1371362</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_n3sdM3d8VEGt5dkutaAe0A"
      decimals="-3"
      id="Tc_fiGq0qMM70yEw5SJHZ55Cw_25_5"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">1000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3-IpBWJWhU6nof7a6J-CqQ"
      decimals="-3"
      id="Tc_IRHF428KZU6ke_uDo2MVuA_25_8"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">714000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_7_1_2023_To_9_30_2023__jyu8G4bX02xwWm0pGi6zA"
      decimals="-3"
      id="Tc_lfDoXrhXP06wepA3uj4EwQ_25_14"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">715000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_xlxVJaEkm0Cl5SxIoEuaJQ"
      decimals="-3"
      id="Tc__ojOuu40eUiwQIwQHGev9A_26_11"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">-1852000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2023_To_9_30_2023__jyu8G4bX02xwWm0pGi6zA"
      decimals="-3"
      id="Tc_ZyqwOHfWNESKSzLQD3F-6A_26_14"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">-1852000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jyJnbb5Xj02LTfUAsaSZlA"
      decimals="INF"
      id="Tc_UyvHhvotHUadHVP182UZOQ_27_2"
      unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA">72952124</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jyJnbb5Xj02LTfUAsaSZlA"
      decimals="-3"
      id="Tc_c5-rEDh23Uu_P9mo32v4UQ_27_5"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">73000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_7nASCJwWaUKNuXPn2KOuug"
      decimals="-3"
      id="Tc_HfIiICoeYkK-A_B0ceDMYA_27_8"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">413679000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_IAh-6HHWoUOrjiOkQywBhw"
      decimals="-3"
      id="Tc_9Gh1VzBayEOj7iLAf13ELQ_27_11"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">-375505000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2023_qFQhXtC8OkS0z_OP8CBUzQ"
      decimals="-3"
      id="Tc_zgjvu7LTL0irlNM4DWa_kw_27_14"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">38247000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_UZznz_h0nU6MCrNFCI65kA"
      decimals="INF"
      id="Tc_LmE8scvYJEOagyeAR2Z9NA_28_2"
      unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA">73292674</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_UZznz_h0nU6MCrNFCI65kA"
      decimals="-3"
      id="Tc_E-5DRkN9lUmzT1ENVwCW7Q_28_5"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">73000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_e96ler1a0U-r6gjxosRRSw"
      decimals="-3"
      id="Tc_sHQSSfANJUqTYc2oSKAvaQ_28_8"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">416631000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_xF7FRPyjM0KtHl4ouLxL6A"
      decimals="-3"
      id="Tc_PtcJQ-M8w0myKu9ewLiMkg_28_11"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">-388123000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2024_c7VyEDTT0Ei2Nt_xe1-AZA"
      decimals="-3"
      id="Tc_-OhaBczME06g5ribHFTiKg_28_14"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">28581000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3sUNQWsOgkuiFe-1dqA4tg"
      decimals="-3"
      id="Tc_0C1r3llR-kyAHMK2RaybAg_30_8"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">358000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2024_To_9_30_2024_5srFek9aZ0STe4olK5gckA"
      decimals="-3"
      id="Tc_2TLpOlQsPU6y5Qij-xeAdg_30_14"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">358000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares
      contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ojV2ETGPxU-tgxipZ4iH_A"
      decimals="INF"
      id="Tc_e_OsxemFjU2UD0V-bpKAXw_31_2"
      unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA">340909</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ojV2ETGPxU-tgxipZ4iH_A"
      decimals="-3"
      id="Tc_rKN6zfKTREmU024KVveFZA_31_5"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">1000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3sUNQWsOgkuiFe-1dqA4tg"
      decimals="-3"
      id="Tc_4yaz7D1jqUGFwCZSAtpGsQ_31_8"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">261000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_7_1_2024_To_9_30_2024_5srFek9aZ0STe4olK5gckA"
      decimals="-3"
      id="Tc_isIBTlcC3EevCePGj8Uofg_31_14"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">262000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_SrS-_DJJqkCTLZ9dXxqUAw"
      decimals="-3"
      id="Tc_3tRr0-tt5kK_IzT76IBEWQ_32_11"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">3236000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2024_To_9_30_2024_5srFek9aZ0STe4olK5gckA"
      decimals="-3"
      id="Tc_tLXwdRuN8k-6yn2wuXScAw_32_14"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">3236000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_b_5zJrCjPUuLgiN0Qyd3yA"
      decimals="INF"
      id="Tc_fgMVVUijQkKbf4CfNl5g6Q_33_2"
      unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA">73633583</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_b_5zJrCjPUuLgiN0Qyd3yA"
      decimals="-3"
      id="Tc_ou9U20TWNkydlFdg4xkdvQ_33_5"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">74000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_AlOFNjsJxk-mD6nKmhSf7A"
      decimals="-3"
      id="Tc_C9zk7myqykaAizqr94Ul1A_33_8"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">417250000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Cz0rkmpxTkehEUfvAgkZxw"
      decimals="-3"
      id="Tc_kDCMOWkaJUWJ8fUzpczGIw_33_11"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">-384887000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g"
      decimals="-3"
      id="Tc_veTwFSQxrkW-h3mLk4IcoQ_33_14"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">32437000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g"
      decimals="INF"
      id="Narr_1wNyvYqvL0aGRZEI_8OCtw"
      unitRef="Unit_Divide_USD_shares_A4-BaHg86EmBShQ9tsexWA">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q"
      decimals="INF"
      id="Narr_ygoxfnuvhUqSnLAtWPaQSw"
      unitRef="Unit_Divide_USD_shares_A4-BaHg86EmBShQ9tsexWA">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g"
      decimals="INF"
      id="Narr_gMMq1MOHVUO3JRRobwiIew"
      unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA">185000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q"
      decimals="INF"
      id="Narr_5CRZFZknkUuY4eW3C1WKrw"
      unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA">185000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      decimals="-3"
      id="Tc_r0kYSenwBEuYG-R-lm5qNQ_4_3"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">-3562000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g"
      decimals="-3"
      id="Tc_7CZSYne8YESx8oEXXJxEGw_4_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">14356000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      decimals="-3"
      id="Tc_7IvMAo3Xj0CZ3d_18jh__g_6_3"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">2599000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g"
      decimals="-3"
      id="Tc_ccZsTwKN0UCVClXoIbAu6g_6_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">2081000</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      decimals="-3"
      id="Tc_-wvhMXPQukuH-_QkQApB_w_7_3"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">970000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g"
      decimals="-3"
      id="Tc_jT2BrHkqKEC-tXCNXBsucw_7_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">878000</us-gaap:Depreciation>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      decimals="-3"
      id="Tc_3PKTWX5ZnUqCTkXRq4qndw_8_3"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">-173000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g"
      decimals="-3"
      id="Tc_wf5v1Y2Tg02hdgY51o0Liw_8_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">511000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:PensionAndOtherPostretirementBenefitExpense
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      decimals="-3"
      id="Tc_6gbjyajnnEqmslWNHYmGJw_9_3"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">32000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
    <us-gaap:PensionAndOtherPostretirementBenefitExpense
      contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g"
      decimals="-3"
      id="Tc_xQwYR4F260Gneat-OBvsTg_9_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">-50000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      decimals="-3"
      id="Tc_wp3ZoHassUqMRTZ_jlEj7Q_10_3"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">236000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g"
      decimals="-3"
      id="Tc_-J8OQ4NSlUiDKmSp2IE0MA_10_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">-3092000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      decimals="-3"
      id="Tc_mchNWKMvMUikqCM-DYHurw_11_3"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">20000</plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement>
    <plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement
      contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g"
      decimals="-3"
      id="Tc_GUQoiAtOEEOK1XHOoMbcMQ_11_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">49000</plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      decimals="-3"
      id="Tc_22OLz8nZLEiix06OC8PROA_12_3"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">3000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <plx:GainLossOnDebtConversion
      contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g"
      decimals="-3"
      id="Tc_GpGs8WdW1Uu-2k0L3bKU_A_13_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">421000</plx:GainLossOnDebtConversion>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g"
      decimals="-3"
      id="Tc_-mF9V-spkkGCY87YiWKh1g_14_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">208000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g"
      decimals="-3"
      id="Tc_SCGb-Ibq10OkrJ_8C7FDlw_16_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">-13178000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      decimals="-3"
      id="Tc_lBFQnQsPLkKeNN5elBsorw_17_3"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">-3069000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g"
      decimals="-3"
      id="Tc_XwqK2sHiYkGsBJSr2pfZDQ_17_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">4188000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <plx:ChangeInOperatingLeaseRightOfUseAssets
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      decimals="-3"
      id="Tc_HUwLcawlREabpp_P9HyV_Q_18_3"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">-13000</plx:ChangeInOperatingLeaseRightOfUseAssets>
    <plx:ChangeInOperatingLeaseRightOfUseAssets
      contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g"
      decimals="-3"
      id="Tc_aBkuDJk9mU6PFpmXIwjzyg_18_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">-12000</plx:ChangeInOperatingLeaseRightOfUseAssets>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      decimals="-3"
      id="Tc_ftHO0D07Ik-ojl7UO-R9Lw_19_3"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">-1846000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g"
      decimals="-3"
      id="Tc_Pk1cH_ixF0-RnnSNRE5hrg_19_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">4779000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      decimals="-3"
      id="Tc__R61YuQAoEyDukzxwpC0lQ_20_3"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">-670000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g"
      decimals="-3"
      id="Tc_2a2AZDd9IkeNvl3LM44gqg_20_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">3820000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      decimals="-3"
      id="Tc_2erb4O7pc0S21YowM8n3Bw_21_3"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">4683000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g"
      decimals="-3"
      id="Tc_pA3IBab2BUyUPWkmtYJEqA_21_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">-4913000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <plx:IncreaseDecreaseInBankDeposits
      contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g"
      decimals="-3"
      id="Tc_-s2VQqvO_kSHp2dmevm_RA_24_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">20420000</plx:IncreaseDecreaseInBankDeposits>
    <plx:ProceedsFromWithdrawalOfShortTermDeposits
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      decimals="-3"
      id="Tc_RCAXJxJMTkixium-3WolVA_25_3"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">20420000</plx:ProceedsFromWithdrawalOfShortTermDeposits>
    <plx:ProceedsFromWithdrawalOfShortTermDeposits
      contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g"
      decimals="-3"
      id="Tc_bUXMTL0XMkSn0WuF0FDYrA_25_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">5000000</plx:ProceedsFromWithdrawalOfShortTermDeposits>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      decimals="-3"
      id="Tc_OXF8pxHKx06ntmlZOpCbMw_26_3"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">857000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g"
      decimals="-3"
      id="Tc_UswGTp0NP0eDZu4X-C4TrQ_26_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">899000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      decimals="-3"
      id="Tc_Vo_7o86fMkeFSbG6hamPTg_27_3"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">3000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      decimals="-3"
      id="Tc_17JhM5Kew0ugzUX05mfKgg_28_3"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">25000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g"
      decimals="-3"
      id="Tc_Cu312memVkyGUn9lFxSTFg_28_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">50000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      decimals="-3"
      id="Tc_peiBoWB2EkqjYMntFk2hUA_29_3"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">19541000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g"
      decimals="-3"
      id="Tc_gVYAQmRD6USYwscjsY00XA_29_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">-16369000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      decimals="-3"
      id="Tc_lkyePe2DzUK3-z7SyfS9UA_32_3"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">20420000</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g"
      decimals="-3"
      id="Tc_CkuYHLZSHEiyUzqAL4asCQ_33_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">23954000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g"
      decimals="-3"
      id="Tc_0qSAFvHOikOqisvpyz072Q_34_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">712000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      decimals="-3"
      id="Tc_M1aALg82XkCk9EnwMigXmQ_35_3"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">-20420000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g"
      decimals="-3"
      id="Tc_C_qECooC0Ei9u5PS1AEXvw_35_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">24666000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      decimals="-3"
      id="Tc_tHrKn_nwh0i2NZbkCr0H6A_36_3"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">-29000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g"
      decimals="-3"
      id="Tc_bZZ61RPW6EeRroGOHBgrQg_36_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">-87000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      decimals="-3"
      id="Tc_dmSYFJ5fsE2mFxhKuQBT5A_37_3"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">3775000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g"
      decimals="-3"
      id="Tc_uLlFtV4V1EO31WEU6vsCMw_37_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">3297000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q"
      decimals="-3"
      id="Tc_SsZTmKGA0Ee81F7tJRDeGw_38_3"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">23634000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2022_v1JvrDW3HkajOYmzxLbG4A"
      decimals="-3"
      id="Tc_6kKGBwlSjEitz0Ha79ukwA_38_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">17111000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g"
      decimals="-3"
      id="Tc_RxR_QudTFUmcR2wyQYM9og_39_3"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">27409000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_9_30_2023_qFQhXtC8OkS0z_OP8CBUzQ"
      decimals="-3"
      id="Tc_vwPcKPoiJ062NyPWqKrtEg_39_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">20408000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      decimals="-3"
      id="Tc_RZR7HsFOb0y9a-9s8-clxQ_4_3"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">402000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g"
      decimals="-3"
      id="Tc_P2x9BJiP2EWEN0RATkc1Lg_4_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">253000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      decimals="-3"
      id="Tc_4dLG6yNTzkOzZqahBDdzxQ_5_3"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">376000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g"
      decimals="-3"
      id="Tc_NwjdexfMlU-JmkwR92QMqQ_5_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">1395000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g"
      decimals="-3"
      id="Tc_2a4UJ9-EWEynEtnAYhGpkA_6_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">7783000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      decimals="-3"
      id="Tc_8Idvm_GVdkKZ-oGg0-fQLw_9_3"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">1532000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g"
      decimals="-3"
      id="Tc_nmt1uYSX_EW50gAR6w8q0Q_9_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">2743000</us-gaap:InterestPaidNet>
    <plx:InterestReceivedNet
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      decimals="-3"
      id="Tc_Vf4nsDLW3kOXDn4UJBrOTQ_10_3"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">1481000</plx:InterestReceivedNet>
    <plx:InterestReceivedNet
      contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g"
      decimals="-3"
      id="Tc_AXfB0Is3eUyA3c4nLyfuKA_10_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">303000</plx:InterestReceivedNet>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      id="Tb_i0MCB9qVkEmyTZvNqiIC0w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;1&#160;- SIGNIFICANT ACCOUNTING POLICIES&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;a.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;General&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#x201c;Company&#x201d;) and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (collectively, the &#x201c;Subsidiaries&#x201d;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#x2019;s proprietary ProCellEx&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; protein expression system (&#x201c;ProCellEx&#x201d;). To date, the Company has successfully developed two enzyme replacement therapies (ERTs); Elfabrio&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; (pegunigalsidase alfa) for the treatment of adult patients with a confirmed diagnosis of Fabry disease and Elelyso&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; (taliglucerase alfa) for the treatment of adult patients with Gaucher disease. Elfabrio, which the Company referred to as PRX-102 during its development stage, has been approved for marketing in the United States, the European Union, Great Britain, Switzerland, Peru and Israel. The Company has partnered with Chiesi Farmaceutici S.p.A. (&#x201c;Chiesi&#x201d;) for the development and commercialization of Elfabrio.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company has licensed the rights to commercialize Elelyso worldwide (other than Brazil) to Pfizer Inc. (&#x201c;Pfizer&#x201d;), and in Brazil to Funda&#xe7;&#xe3;o Oswaldo Cruz (&#x201c;Fiocruz&#x201d;), an arm of the Brazilian Ministry of Health (the &#x201c;Brazilian MoH&#x201d;). Elelyso is marketed as BioManguinhos alfataliglicerase in Brazil.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company is committed to leveraging its track record of success as the Company progresses with the development of treatments for rare and orphan diseases. In addition, the Company continuously works on the further development of its ProCellEx technology and bioreactor system. Accordingly, the Company is turning its focus to new, early-stage product candidates that treat indications for which there are high unmet needs in terms of efficacy and safety, including renal diseases. Treatments of interest will address both genetic and non-genetic diseases. The Company intends to use its ProCellEx platform and PEGylization capabilities, as well as other modalities such as small molecules and antibodies, to take advantage of highly innovative opportunities. The Company is also exploring novel platform technologies.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On May&#160;5, 2023, the European Commission (&#x201c;EC&#x201d;) announced that it had approved the Marketing Authorization Application (&#x201c;MAA&#x201d;) for Elfabrio and on May&#160;9, 2023, the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) announced that it had approved the Biologics License Application (&#x201c;BLA&#x201d;) for Elfabrio, each for adult patients with a confirmed diagnosis of Fabry disease. Both approvals cover the 1&#160;mg/kg every two weeks dosage. The European Medicines Agency (&#x201c;EMA&#x201d;) approval followed the February 2023 adoption of a positive opinion and recommendation of marketing authorization for Elfabrio by the EMA&#x2019;s Committee for Medicinal Products for Human Use the (&#x201c;CHMP&#x201d;). Elfabrio was approved by the FDA with a boxed warning for hypersensitivity reactions/anaphylaxis, consistent with Enzyme Replacement Therapy (ERT) class labeling, and warnings/precautions providing guidance on the signs and symptoms of hypersensitivity and infusion-associated reactions seen in the clinical studies as well as treatments to manage such events should they occur. The warnings/precautions for membranoproliferative glomerulonephritis (MPGN) alert prescribers to the possibility of MPGN and provide guidance for appropriate patient management. Overall, the FDA review team concluded that in the context of Fabry disease as a rare, serious disease with limited therapeutic options that may not be suitable to all individual patients, the benefit-risk of Elfabrio is favorable for the treatment of adults with confirmed Fabry disease.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;"&gt;The Company has entered into two exclusive global licensing and supply agreements for Elfabrio with Chiesi. On October&#160;19, 2017, Protalix Ltd., the Company&#x2019;s wholly-owned subsidiary, entered into an Exclusive License and Supply Agreement with Chiesi (the &#x201c;Chiesi Ex-US Agreement&#x201d;) pursuant to which Chiesi was granted an exclusive license for all markets outside of the United States to commercialize Elfabrio. On July&#160;23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#x201c;Chiesi US Agreement&#x201d;), with respect to the commercialization of Elfabrio in the United States.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;Elfabrio was the subject of a phase&#160;III clinical program studying the drug as a treatment of patients with Fabry disease, a rare, genetic lysosomal disorder. The phase&#160;III clinical program included three separate studies, which are referred to as the &lt;i style="font-style:italic;"&gt;BALANCE&lt;/i&gt; study, the &lt;i style="font-style:italic;"&gt;BRIDGE&lt;/i&gt; study and the &lt;i style="font-style:italic;"&gt;BRIGHT&lt;/i&gt; study. The phase&#160;III clinical program analyzed two potential dosing regimens: 1&#160;mg/kg every two weeks and 2&#160;mg/kg every four weeks. In addition, the phase&#160;III clinical program included two extension studies in which subjects that participated in the Company&#x2019;s phase&#160;I/II clinical trials and phase&#160;III clinical trials had the opportunity to enroll and continue to be treated with PRX-102. As of March&#160;1, 2023, sponsorship &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;"&gt;of the two open label extension studies was transferred to Chiesi, which is now administering the extension studies. From time to time, and as Elfabrio is approved for marketing in different jurisdictions, participants switch out of the open label extension studies. Most of the participants transfer to a commercial setting and others withdraw for other reasons.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;"&gt;The BLA for Elfabrio for the treatment of adult patients with Fabry disease was resubmitted to the FDA on November&#160;9, 2022. An initial BLA for Elfabrio was submitted to the FDA on May&#160;27, 2020 under the FDA&#x2019;s Accelerated Approval pathway, but resulted in a Complete Response Letter (&#x201c;CRL&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;"&gt;The MAA was submitted to the EMA on February&#160;7, 2022, after the October&#160;8, 2021 meeting the Company held, together with Chiesi, with the Rapporteur and Co-Rapporteur of the EMA regarding PRX-102.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;"&gt;The FDA publicly released the internal review documents for Elfabrio (pegunigalsidase alfa-iwxj) injection BLA 761161. These documents provide previously unavailable additional information regarding the basis for the FDA&#x2019;s May 2023 approval decision. In particular, the FDA determined that substantial evidence of effectiveness for Elfabrio in Fabry patients was established with one adequate and well-controlled study (Study PB-102-F01/02) with confirmatory evidence provided by the &lt;i style="font-style:italic;"&gt;BALANCE&lt;/i&gt; study (also referred to as Study PB-102-F20). The FDA review team also concluded that the &lt;i style="font-style:italic;"&gt;BALANCE&lt;/i&gt; study met its primary efficacy endpoint, which assessed the annualized rate of change in eGFR (estimated glomerular filtration rate) over 104 weeks. However, the FDA also determined that the results from the &lt;i style="font-style:italic;"&gt;BALANCE&lt;/i&gt; study did not support a non-inferiority claim to the comparator product due to the lack of data to support a non-inferiority margin.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company continuously evaluates potential strategic marketing partnerships as well as collaboration programs with biotechnology and pharmaceutical companies and academic research institutions. Except with respect to Elfabrio and Elelyso, the Company holds the worldwide commercialization rights to its other proprietary development drug candidates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;"&gt;The Company&#x2019;s product pipeline currently includes, among other candidates:&lt;/p&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:11pt;margin-left:54pt;margin-top:0pt;text-indent:0pt;"&gt;&lt;span style="display:inline-block;min-width:18pt;white-space:nowrap;"&gt;(1)&lt;/span&gt;PRX-115, the Company&#x2019;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#x2013; a chemically modified enzyme to treat uncontrolled gout; and&lt;/div&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-top:0pt;text-indent:0pt;"&gt;&lt;span style="display:inline-block;min-width:18pt;white-space:nowrap;"&gt;(2)&lt;/span&gt;PRX-119, the Company&#x2019;s plant cell-expressed PEGylated recombinant human DNase&#160;I product candidate being designed to elongate half-life in the circulation for NETs-related diseases.&lt;/div&gt;&lt;div style="margin-top:11pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#x2019;s ability to implement the necessary regulatory steps required to obtain such approvals, and demonstrate the safety and efficacy of its product candidates. The Company cannot reasonably predict the outcome of these activities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;In March 2024, the Company initiated a phase&#160;I First-in-Human clinical trial of PRX-115. This study included 64 adult male and female subjects in a dose escalation design with eight sequential dosing cohorts, each composed of eight subjects (six active and two placebo). As of September&#160;30, 2024, the data is locked and is currently being analyzed. The Company plans to announce the results at an upcoming scientific meeting. In addition, the Company has commenced preparations for a phase&#160;II clinical trial of PRX-115 which the Company expects will commence in the second half of 2025.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On July&#160;2, 2021, the Company entered into an At The Market Offering Agreement (the &#x201c;2021 Sales Agreement&#x201d;) with H.C.&#160;Wainwright &amp;amp; Co., LLC, as the Company&#x2019;s sales agent (the &#x201c;Agent&#x201d;) which was amended on May&#160;2, 2022. Pursuant to the terms of the 2021 Sales Agreement, the Company was able to sell, from time to time through the Agent, shares of its common stock, par value $0.001 per share (the &#x201c;Common Stock&#x201d;), having an aggregate offering price of up to $20.0&#160;million (the &#x201c;ATM Shares&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;During the term of the 2021 Sales Agreement which ended during the quarter ended March&#160;31, 2023, the Company sold a total of 13,980,060 ATM Shares for total gross proceeds of approximately $20.0&#160;million thereby completing the ATM program under said agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On February&#160;27, 2023, the Company entered into an At The Market Offering Agreement (the &#x201c;2023 Sales Agreement&#x201d;) with the Agent. Pursuant to the terms of the 2023 Sales Agreement, the Company may sell, from time to time through the Agent, ATM Shares having an aggregate offering price of up to $20.0&#160;million. As of September&#160;30, 2024, shares of Common Stock for total gross proceeds of approximately $6.4&#160;million remain available to be sold under the 2023 Sales Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively, the &#x201c;Chiesi Agreements&#x201d;), Chiesi made an upfront payment to Protalix&#160;Ltd. of $25.0&#160;million in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&#160;Ltd. is entitled to additional payments of up to $25.0&#160;million in pegunigalsidase alfa development costs and to receive additional payments of up to $320.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&#160;Ltd. is entitled to payments of up to a maximum of $20.0&#160;million to cover development costs for pegunigalsidase alfa and to receive additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. To date, Protalix Ltd. has received the complete amount of development costs to which it is entitled under the Chiesi Agreements. In addition, following the approval of Elfabrio by the FDA, the Company received a milestone payment equal to $20.0&#160;million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;On May&#160;13, 2021, the Company signed a binding term sheet with Chiesi pursuant to which the Company and Chiesi amended the Chiesi Agreements in order to provide the Company with near-term capital. Chiesi agreed to make a $10.0&#160;million payment to the Company before the end of the second quarter of 2021 in exchange for a $25.0&#160;million reduction in a longer term regulatory milestone payment provided in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. The Company received the payment in June&#160;2021. The Company also agreed to negotiate certain manufacturing related matters.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;Under the terms of both of the Chiesi Agreements, Protalix Ltd. is required to manufacture all of the Elfabrio drug substance needed under the agreements, subject to certain exceptions, and Chiesi will purchase Elfabrio drug product from Protalix, subject to certain terms and conditions. The consideration for Protalix Ltd. is based on the drug product supplied to Chiesi and the average selling price of the drug product in the relevant territory multiplied by tiered payments as described in the relevant agreement. Under the Chiesi Ex-US Agreement, the price payable to the Company for drug product supplied is based on a range of 15% to 35% of the average selling price of the drug product in the applicable territory, and under the Chiesi US Agreement, such price is based on a range of 15% to 40% of the average selling price of the drug product in the United States.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;On August&#160;29, 2022, the Company entered into a Fill/Finish Agreement (the &#x201c;F/F Agreement&#x201d;) and a Letter Agreement (the &#x201c;Letter Agreement&#x201d;), in each case with Chiesi. The Company agreed to supply Chiesi with drug substance for pegunigalsidase alfa in connection with the commercial fill/finish services. Under the F/F Agreement, and, following relevant technology and technical information transfer activities, Chiesi agreed, among other things, to provide the Company with commercial fill/finish services for pegunigalsidase alfa, including to support the anticipated global launch of pegunigalsidase alfa. The F/F Agreement shall continue in force until December&#160;31, 2025, unless terminated earlier in accordance with the terms of the F/F Agreement and the term may be extended by mutual agreement for an additional period of&#160;seven years&#160;upon mutual written agreement prior to expiration of the initial term.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer in accordance with the exclusive license and supply agreement entered into between Protalix Ltd. and Pfizer, which is referred to herein as the Pfizer Agreement. In October 2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement, which is referred to herein as the Amended Pfizer Agreement, pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#x201c;Brazil Agreement&#x201d;) with Fiocruz for BioManguinhos alfataliglicerase. Fiocruz&#x2019;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;Because the Company&#x2019;s operations are conducted in the State of Israel, the business and operations may be directly affected by economic, political, geopolitical and military conditions in Israel.&#160;In October 2023, Hamas terrorists infiltrated Israel&#x2019;s southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Hamas also launched extensive rocket attacks on Israeli population and industrial centers located along Israel&#x2019;s border with the Gaza Strip and in other areas within the State of Israel attacking a number of civilian and military targets. At the same time, clashes between Israel and Hezbollah in Lebanon have increased. In response, Israel&#x2019;s security cabinet declared war against the Hamas and a military campaign against these terrorist organizations commenced in parallel to their continued rocket and terror attacks. Moreover, the attacks by Hamas and Hezbollah, and Israel&#x2019;s defensive measures, may result in a greater regional conflict. Since the outbreak of the war, other regional actors, including Iran, have taken military action against Israel. It is currently not possible to predict the duration or severity of the ongoing conflict or its effects on the Company&#x2019;s business, operations and financial conditions. The ongoing conflict is rapidly evolving and developing, and could disrupt certain of the Company&#x2019;s business and operations, among others. The Company has elected to store manufactured drug substance in multiple locations, both within and outside of Israel, to mitigate the risk of loss due to the military operations. As of the issuance of these financial statements, the impact of the war has not had an adverse effect on the Company&#x2019;s operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;The Company expects to continue to incur significant expenditures in the near future due to research and developments efforts with respect to the product candidates. The Company believes that its cash and cash equivalents as of September&#160;30, 2024 are sufficient to satisfy the Company&#x2019;s capital needs for at least 12&#160;months from the date that these financial statements are issued.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"&gt;b.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"&gt;Basis of presentation&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States (&#x201c;GAAP&#x201d;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form&#160;10-K for the year ended December&#160;31, 2023, filed by the Company with the U.S.&#160;Securities and Exchange Commission (the &#x201c;Commission&#x201d;). The comparative balance sheet at December&#160;31, 2023 has been derived from the audited financial statements at that date. There have been no material changes in our significant accounting policies as described in our consolidated financial statements for the year ended December&#160;31, 2023, except for convertible notes, as described below.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;c.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;Earnings (loss) per share&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt 0pt 0pt 54pt;"&gt;Basic earnings (loss) per share is calculated by dividing the net income (loss) by the weighted average number of shares of Common Stock outstanding during each period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt 0pt 0pt 54pt;"&gt;&lt;span style="color:#212529;"&gt;Diluted earnings per share is calculated by dividing the net income by the weighted-average number of shares of Common Stock outstanding during each period increased to include the number of additional shares of Common Stock that would have been outstanding if the potentially dilutive shares had been issued.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 0pt 54pt;"&gt;&lt;span style="color:#212529;"&gt;In computing diluted earnings per share, basic earnings per share are adjusted to take into account the potential dilution that could occur upon: (i)&#160;the exercise of options granted under employee stock compensation plans using the treasury &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 54pt;"&gt;&lt;span style="color:#212529;"&gt;stock method; (ii)&#160;the exercise of warrants using the treasury stock method; and (iii)&#160;the conversion of the convertible notes using the &#x201c;if-converted&#x201d; method.&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;d.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;Convertible notes&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;In September 2024, the Company repaid in full all of the outstanding principal and interest payable under its 7.50% Senior Secured Convertible Promissory Notes due September 2024 (the &#x201c;2024 Notes&#x201d;). The repayment of the convertible notes at maturity was financed entirely with available cash.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Prior to January&#160;1, 2024, the Company accounted for its outstanding convertible notes using the guidance set forth in the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) 815 which required that the Company determine whether the embedded conversion option must be separated from the other features of the applicable note instrument and accounted for separately. ASC 470-20 regarding debt with conversion and other options requires the issuer of a convertible debt instrument that may be settled in cash upon conversion to separately account for the liability (debt) and equity (conversion option) components of the instrument in a manner that reflects the issuer&#x2019;s nonconvertible debt borrowing rate. &lt;span style="background:#ffffff;"&gt;The Company&#x2019;s outstanding 2024 Notes were accounted for as a liability (debt) and equity component (conversion option) as the convertible notes may be settled wholly or partly in cash, at the option of the Company, when converted.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;span style="background:#ffffff;"&gt;In August 2020, the FASB issued &lt;/span&gt;ASU 2020-06 &#x201c;Debt &#x2013; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#x2013; Contracts in Entity&#x2019;s Own Equity (Subtopic 815 &#x2013; 40)&#x201d; (&#x201c;&lt;span style="background:#ffffff;"&gt;ASU 2020-06&#x201d;). &lt;/span&gt;ASU&#160;2020-06 simplifies the accounting for convertible instruments by removing certain separation models in ASC 470-20, Debt&#x2014;Debt with Conversion and Other Options, for convertible instruments. ASU&#160;2020-06 updates the guidance on certain embedded conversion features that are not required to be accounted for as derivatives under Topic 815, Derivatives and Hedging, or that do not result in substantial premiums accounted for as paid-in capital, such that those features are no longer required to be separated from the host contract. The convertible debt instruments will be accounted for as a single liability measured at amortized cost. This will also result in the interest expense recognized for convertible debt instruments to be typically closer to the coupon interest rate when applying the guidance in Topic 835. On January&#160;1, 2024, the Company adopted ASU 2020-06&lt;span style="background:#ffffff;"&gt; &lt;/span&gt;using the modified retrospective method of adoption. Under this method, the Company applied the guidance to the 2024 Notes at the adoption date and was required to make an adjustment to January&#160;1, 2024, opening accumulated deficit balance and additional paid in capital. &lt;span style="background:#ffffff;"&gt;The prior period consolidated financial statements have not been retrospectively adjusted and continue to be reported under the accounting standards in effect for those periods. &lt;/span&gt;Under ASU 2020-06, the 2024 Notes (debt and conversion option) are accounted for as a liability. The impact to the Company's consolidated balance sheet as of December&#160;31, 2023 resulting from its adoption of ASU 2020-06 is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:62.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:62.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;(U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As Reported December 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:13.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Updated January 1, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:9.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Effect of Change&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Convertible notes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,251&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,420&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 169&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Additional paid in capital&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 415,045&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 414,652&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (393)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Accumulated deficit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 381,549&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 381,325&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 224&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;&lt;b style="font-weight:bold;background:#ffffff;"&gt;e.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;&lt;b style="font-weight:bold;background:#ffffff;"&gt;New accounting &lt;/b&gt;&lt;b style="font-weight:bold;"&gt;pronouncements&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;i style="font-style:italic;background:#ffffff;"&gt;Recently adopted accounting pronouncements&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;span style="background:#ffffff;"&gt;ASU 2020-06, which was issued by the FASB in August 2020 and adopted by the Company in January 2024, simplifies the accounting for certain financial instruments with characteristics of both liability and equity, including convertible instruments and contracts on an entity&#x2019;s own equity. The amendments to this guidance are effective for fiscal years beginning after December&#160;15, 2023, and interim periods within those fiscal years. See Note&#160;1(d).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;i style="font-style:italic;background:#ffffff;"&gt;Recently issued accounting pronouncements, not yet adopted&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;span style="background:#ffffff;"&gt;In December 2023, the FASB issued ASU 2023-09 &#x201c;Income Taxes (Topic 740): Improvements to Income Tax Disclosures.&#x201d; This guidance is intended to enhance the transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid both in the United States and in foreign jurisdictions. ASU 2023-09 is effective for fiscal years beginning after December&#160;15, 2024 on a prospective basis. Early adoption is permitted, with the option to apply the standard retrospectively. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;span style="background:#ffffff;"&gt;In November 2023, the FASB issued ASU 2023-07 &#x201c;Segment Reporting: Improvements to Reportable Segment Disclosures.&#x201d; This guidance expands public entities&#x2019; segment disclosures primarily by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment&#x2019;s profit or loss and assets. Public entities with a single reportable segment are required to provide the new disclosures and all of the disclosures required under ASC 280. The guidance is effective for fiscal years beginning after December&#160;15, 2023, and interim periods within fiscal years beginning after December&#160;15, 2024, with early adoption permitted. The amendments are required to be applied retrospectively to all prior periods presented in an entity&#x2019;s financial statements. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements and related disclosures&lt;/span&gt;&lt;span style="font-family:'Palatino Linotype';background:#ffffff;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <plx:NatureOfOperationsPolicyTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      id="Tb_aDze9TXe4EK0XQAR-9HDhQ">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;a.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;General&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#x201c;Company&#x201d;) and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (collectively, the &#x201c;Subsidiaries&#x201d;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#x2019;s proprietary ProCellEx&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; protein expression system (&#x201c;ProCellEx&#x201d;). To date, the Company has successfully developed two enzyme replacement therapies (ERTs); Elfabrio&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; (pegunigalsidase alfa) for the treatment of adult patients with a confirmed diagnosis of Fabry disease and Elelyso&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; (taliglucerase alfa) for the treatment of adult patients with Gaucher disease. Elfabrio, which the Company referred to as PRX-102 during its development stage, has been approved for marketing in the United States, the European Union, Great Britain, Switzerland, Peru and Israel. The Company has partnered with Chiesi Farmaceutici S.p.A. (&#x201c;Chiesi&#x201d;) for the development and commercialization of Elfabrio.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company has licensed the rights to commercialize Elelyso worldwide (other than Brazil) to Pfizer Inc. (&#x201c;Pfizer&#x201d;), and in Brazil to Funda&#xe7;&#xe3;o Oswaldo Cruz (&#x201c;Fiocruz&#x201d;), an arm of the Brazilian Ministry of Health (the &#x201c;Brazilian MoH&#x201d;). Elelyso is marketed as BioManguinhos alfataliglicerase in Brazil.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company is committed to leveraging its track record of success as the Company progresses with the development of treatments for rare and orphan diseases. In addition, the Company continuously works on the further development of its ProCellEx technology and bioreactor system. Accordingly, the Company is turning its focus to new, early-stage product candidates that treat indications for which there are high unmet needs in terms of efficacy and safety, including renal diseases. Treatments of interest will address both genetic and non-genetic diseases. The Company intends to use its ProCellEx platform and PEGylization capabilities, as well as other modalities such as small molecules and antibodies, to take advantage of highly innovative opportunities. The Company is also exploring novel platform technologies.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On May&#160;5, 2023, the European Commission (&#x201c;EC&#x201d;) announced that it had approved the Marketing Authorization Application (&#x201c;MAA&#x201d;) for Elfabrio and on May&#160;9, 2023, the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) announced that it had approved the Biologics License Application (&#x201c;BLA&#x201d;) for Elfabrio, each for adult patients with a confirmed diagnosis of Fabry disease. Both approvals cover the 1&#160;mg/kg every two weeks dosage. The European Medicines Agency (&#x201c;EMA&#x201d;) approval followed the February 2023 adoption of a positive opinion and recommendation of marketing authorization for Elfabrio by the EMA&#x2019;s Committee for Medicinal Products for Human Use the (&#x201c;CHMP&#x201d;). Elfabrio was approved by the FDA with a boxed warning for hypersensitivity reactions/anaphylaxis, consistent with Enzyme Replacement Therapy (ERT) class labeling, and warnings/precautions providing guidance on the signs and symptoms of hypersensitivity and infusion-associated reactions seen in the clinical studies as well as treatments to manage such events should they occur. The warnings/precautions for membranoproliferative glomerulonephritis (MPGN) alert prescribers to the possibility of MPGN and provide guidance for appropriate patient management. Overall, the FDA review team concluded that in the context of Fabry disease as a rare, serious disease with limited therapeutic options that may not be suitable to all individual patients, the benefit-risk of Elfabrio is favorable for the treatment of adults with confirmed Fabry disease.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;"&gt;The Company has entered into two exclusive global licensing and supply agreements for Elfabrio with Chiesi. On October&#160;19, 2017, Protalix Ltd., the Company&#x2019;s wholly-owned subsidiary, entered into an Exclusive License and Supply Agreement with Chiesi (the &#x201c;Chiesi Ex-US Agreement&#x201d;) pursuant to which Chiesi was granted an exclusive license for all markets outside of the United States to commercialize Elfabrio. On July&#160;23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#x201c;Chiesi US Agreement&#x201d;), with respect to the commercialization of Elfabrio in the United States.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;Elfabrio was the subject of a phase&#160;III clinical program studying the drug as a treatment of patients with Fabry disease, a rare, genetic lysosomal disorder. The phase&#160;III clinical program included three separate studies, which are referred to as the &lt;i style="font-style:italic;"&gt;BALANCE&lt;/i&gt; study, the &lt;i style="font-style:italic;"&gt;BRIDGE&lt;/i&gt; study and the &lt;i style="font-style:italic;"&gt;BRIGHT&lt;/i&gt; study. The phase&#160;III clinical program analyzed two potential dosing regimens: 1&#160;mg/kg every two weeks and 2&#160;mg/kg every four weeks. In addition, the phase&#160;III clinical program included two extension studies in which subjects that participated in the Company&#x2019;s phase&#160;I/II clinical trials and phase&#160;III clinical trials had the opportunity to enroll and continue to be treated with PRX-102. As of March&#160;1, 2023, sponsorship &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;"&gt;of the two open label extension studies was transferred to Chiesi, which is now administering the extension studies. From time to time, and as Elfabrio is approved for marketing in different jurisdictions, participants switch out of the open label extension studies. Most of the participants transfer to a commercial setting and others withdraw for other reasons.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;"&gt;The BLA for Elfabrio for the treatment of adult patients with Fabry disease was resubmitted to the FDA on November&#160;9, 2022. An initial BLA for Elfabrio was submitted to the FDA on May&#160;27, 2020 under the FDA&#x2019;s Accelerated Approval pathway, but resulted in a Complete Response Letter (&#x201c;CRL&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;"&gt;The MAA was submitted to the EMA on February&#160;7, 2022, after the October&#160;8, 2021 meeting the Company held, together with Chiesi, with the Rapporteur and Co-Rapporteur of the EMA regarding PRX-102.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;"&gt;The FDA publicly released the internal review documents for Elfabrio (pegunigalsidase alfa-iwxj) injection BLA 761161. These documents provide previously unavailable additional information regarding the basis for the FDA&#x2019;s May 2023 approval decision. In particular, the FDA determined that substantial evidence of effectiveness for Elfabrio in Fabry patients was established with one adequate and well-controlled study (Study PB-102-F01/02) with confirmatory evidence provided by the &lt;i style="font-style:italic;"&gt;BALANCE&lt;/i&gt; study (also referred to as Study PB-102-F20). The FDA review team also concluded that the &lt;i style="font-style:italic;"&gt;BALANCE&lt;/i&gt; study met its primary efficacy endpoint, which assessed the annualized rate of change in eGFR (estimated glomerular filtration rate) over 104 weeks. However, the FDA also determined that the results from the &lt;i style="font-style:italic;"&gt;BALANCE&lt;/i&gt; study did not support a non-inferiority claim to the comparator product due to the lack of data to support a non-inferiority margin.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company continuously evaluates potential strategic marketing partnerships as well as collaboration programs with biotechnology and pharmaceutical companies and academic research institutions. Except with respect to Elfabrio and Elelyso, the Company holds the worldwide commercialization rights to its other proprietary development drug candidates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;"&gt;The Company&#x2019;s product pipeline currently includes, among other candidates:&lt;/p&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:11pt;margin-left:54pt;margin-top:0pt;text-indent:0pt;"&gt;&lt;span style="display:inline-block;min-width:18pt;white-space:nowrap;"&gt;(1)&lt;/span&gt;PRX-115, the Company&#x2019;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#x2013; a chemically modified enzyme to treat uncontrolled gout; and&lt;/div&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-top:0pt;text-indent:0pt;"&gt;&lt;span style="display:inline-block;min-width:18pt;white-space:nowrap;"&gt;(2)&lt;/span&gt;PRX-119, the Company&#x2019;s plant cell-expressed PEGylated recombinant human DNase&#160;I product candidate being designed to elongate half-life in the circulation for NETs-related diseases.&lt;/div&gt;&lt;div style="margin-top:11pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#x2019;s ability to implement the necessary regulatory steps required to obtain such approvals, and demonstrate the safety and efficacy of its product candidates. The Company cannot reasonably predict the outcome of these activities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;In March 2024, the Company initiated a phase&#160;I First-in-Human clinical trial of PRX-115. This study included 64 adult male and female subjects in a dose escalation design with eight sequential dosing cohorts, each composed of eight subjects (six active and two placebo). As of September&#160;30, 2024, the data is locked and is currently being analyzed. The Company plans to announce the results at an upcoming scientific meeting. In addition, the Company has commenced preparations for a phase&#160;II clinical trial of PRX-115 which the Company expects will commence in the second half of 2025.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On July&#160;2, 2021, the Company entered into an At The Market Offering Agreement (the &#x201c;2021 Sales Agreement&#x201d;) with H.C.&#160;Wainwright &amp;amp; Co., LLC, as the Company&#x2019;s sales agent (the &#x201c;Agent&#x201d;) which was amended on May&#160;2, 2022. Pursuant to the terms of the 2021 Sales Agreement, the Company was able to sell, from time to time through the Agent, shares of its common stock, par value $0.001 per share (the &#x201c;Common Stock&#x201d;), having an aggregate offering price of up to $20.0&#160;million (the &#x201c;ATM Shares&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;During the term of the 2021 Sales Agreement which ended during the quarter ended March&#160;31, 2023, the Company sold a total of 13,980,060 ATM Shares for total gross proceeds of approximately $20.0&#160;million thereby completing the ATM program under said agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On February&#160;27, 2023, the Company entered into an At The Market Offering Agreement (the &#x201c;2023 Sales Agreement&#x201d;) with the Agent. Pursuant to the terms of the 2023 Sales Agreement, the Company may sell, from time to time through the Agent, ATM Shares having an aggregate offering price of up to $20.0&#160;million. As of September&#160;30, 2024, shares of Common Stock for total gross proceeds of approximately $6.4&#160;million remain available to be sold under the 2023 Sales Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively, the &#x201c;Chiesi Agreements&#x201d;), Chiesi made an upfront payment to Protalix&#160;Ltd. of $25.0&#160;million in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&#160;Ltd. is entitled to additional payments of up to $25.0&#160;million in pegunigalsidase alfa development costs and to receive additional payments of up to $320.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&#160;Ltd. is entitled to payments of up to a maximum of $20.0&#160;million to cover development costs for pegunigalsidase alfa and to receive additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. To date, Protalix Ltd. has received the complete amount of development costs to which it is entitled under the Chiesi Agreements. In addition, following the approval of Elfabrio by the FDA, the Company received a milestone payment equal to $20.0&#160;million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;On May&#160;13, 2021, the Company signed a binding term sheet with Chiesi pursuant to which the Company and Chiesi amended the Chiesi Agreements in order to provide the Company with near-term capital. Chiesi agreed to make a $10.0&#160;million payment to the Company before the end of the second quarter of 2021 in exchange for a $25.0&#160;million reduction in a longer term regulatory milestone payment provided in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. The Company received the payment in June&#160;2021. The Company also agreed to negotiate certain manufacturing related matters.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;Under the terms of both of the Chiesi Agreements, Protalix Ltd. is required to manufacture all of the Elfabrio drug substance needed under the agreements, subject to certain exceptions, and Chiesi will purchase Elfabrio drug product from Protalix, subject to certain terms and conditions. The consideration for Protalix Ltd. is based on the drug product supplied to Chiesi and the average selling price of the drug product in the relevant territory multiplied by tiered payments as described in the relevant agreement. Under the Chiesi Ex-US Agreement, the price payable to the Company for drug product supplied is based on a range of 15% to 35% of the average selling price of the drug product in the applicable territory, and under the Chiesi US Agreement, such price is based on a range of 15% to 40% of the average selling price of the drug product in the United States.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;On August&#160;29, 2022, the Company entered into a Fill/Finish Agreement (the &#x201c;F/F Agreement&#x201d;) and a Letter Agreement (the &#x201c;Letter Agreement&#x201d;), in each case with Chiesi. The Company agreed to supply Chiesi with drug substance for pegunigalsidase alfa in connection with the commercial fill/finish services. Under the F/F Agreement, and, following relevant technology and technical information transfer activities, Chiesi agreed, among other things, to provide the Company with commercial fill/finish services for pegunigalsidase alfa, including to support the anticipated global launch of pegunigalsidase alfa. The F/F Agreement shall continue in force until December&#160;31, 2025, unless terminated earlier in accordance with the terms of the F/F Agreement and the term may be extended by mutual agreement for an additional period of&#160;seven years&#160;upon mutual written agreement prior to expiration of the initial term.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer in accordance with the exclusive license and supply agreement entered into between Protalix Ltd. and Pfizer, which is referred to herein as the Pfizer Agreement. In October 2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement, which is referred to herein as the Amended Pfizer Agreement, pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#x201c;Brazil Agreement&#x201d;) with Fiocruz for BioManguinhos alfataliglicerase. Fiocruz&#x2019;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;Because the Company&#x2019;s operations are conducted in the State of Israel, the business and operations may be directly affected by economic, political, geopolitical and military conditions in Israel.&#160;In October 2023, Hamas terrorists infiltrated Israel&#x2019;s southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Hamas also launched extensive rocket attacks on Israeli population and industrial centers located along Israel&#x2019;s border with the Gaza Strip and in other areas within the State of Israel attacking a number of civilian and military targets. At the same time, clashes between Israel and Hezbollah in Lebanon have increased. In response, Israel&#x2019;s security cabinet declared war against the Hamas and a military campaign against these terrorist organizations commenced in parallel to their continued rocket and terror attacks. Moreover, the attacks by Hamas and Hezbollah, and Israel&#x2019;s defensive measures, may result in a greater regional conflict. Since the outbreak of the war, other regional actors, including Iran, have taken military action against Israel. It is currently not possible to predict the duration or severity of the ongoing conflict or its effects on the Company&#x2019;s business, operations and financial conditions. The ongoing conflict is rapidly evolving and developing, and could disrupt certain of the Company&#x2019;s business and operations, among others. The Company has elected to store manufactured drug substance in multiple locations, both within and outside of Israel, to mitigate the risk of loss due to the military operations. As of the issuance of these financial statements, the impact of the war has not had an adverse effect on the Company&#x2019;s operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;The Company expects to continue to incur significant expenditures in the near future due to research and developments efforts with respect to the product candidates. The Company believes that its cash and cash equivalents as of September&#160;30, 2024 are sufficient to satisfy the Company&#x2019;s capital needs for at least 12&#160;months from the date that these financial statements are issued.&lt;/p&gt;</plx:NatureOfOperationsPolicyTextBlock>
    <plx:NumberOfGlobalLicensingAndSupplyAgreements
      contextRef="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g"
      decimals="INF"
      id="Narr_kOVvU26-wEWQNQiZHxbKgw"
      unitRef="Unit_Standard_agreement_ukZC-6VifkuWtCWLoRpkbA">2</plx:NumberOfGlobalLicensingAndSupplyAgreements>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_YET2ryP2dEill85k2_nFHg"
      decimals="INF"
      id="Narr_ZasDT-AZF0aPBSjX9exAFw"
      unitRef="Unit_Divide_USD_shares_A4-BaHg86EmBShQ9tsexWA">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <plx:SaleOfStockMaximumOfferingPrice
      contextRef="As_Of_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_YET2ryP2dEill85k2_nFHg"
      decimals="-5"
      id="Narr_MMAjGF6MZEy9bSFslsxsfg"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">20000000.0</plx:SaleOfStockMaximumOfferingPrice>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_u2CliSsMKUa6PUPveJHdTg"
      decimals="INF"
      id="Narr_aQTeLIg0LUGH8VsmwvcIiw"
      unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA">13980060</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_u2CliSsMKUa6PUPveJHdTg"
      decimals="-5"
      id="Narr_wpvCtzIgI0moVACzAyhTAw"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">20000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <plx:SaleOfStockMaximumOfferingPrice
      contextRef="As_Of_2_27_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_glBx8-GKQUagOk_5tVbhmg"
      decimals="-5"
      id="Narr_9SALtpsUNUSl_qJ75QIz9Q"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">20000000.0</plx:SaleOfStockMaximumOfferingPrice>
    <plx:SaleOfStockMaximumOfferingPrice
      contextRef="As_Of_9_30_2024_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_lsKt_FH16UaE7aDEdbwFUg"
      decimals="-5"
      id="Narr_Sgo6YwFhN0-xfWkRb5JB_g"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">6400000</plx:SaleOfStockMaximumOfferingPrice>
    <plx:UpfrontNonrefundableNoncreditablePaymentReceivable
      contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_lxgklNBaXU2pjfcaFonqKA"
      decimals="-5"
      id="Narr_vh35iPa5SE6mQDq5cG0ulA"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">25000000.0</plx:UpfrontNonrefundableNoncreditablePaymentReceivable>
    <plx:UpfrontNonrefundableNoncreditablePaymentReceivable
      contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_tZ6IRwK5mk6fHAJ4kYRAJA"
      decimals="-5"
      id="Narr_asMXL0RT60ehWrr4cL61fg"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">25000000.0</plx:UpfrontNonrefundableNoncreditablePaymentReceivable>
    <plx:AdditionalAmountsPayableToCoverDevelopmentCosts
      contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_vK2rvFHWSU-qe_rFcemZww"
      decimals="-5"
      id="Narr_LGRxsw_Ni0Gzm4SLhQEZrA"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">25000000.0</plx:AdditionalAmountsPayableToCoverDevelopmentCosts>
    <plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones
      contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_vK2rvFHWSU-qe_rFcemZww"
      decimals="-5"
      id="Narr_hLFiaI0NvESNQj7pH5c6lw"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">320000000.0</plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones>
    <plx:AdditionalAmountsPayableToCoverDevelopmentCosts
      contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_eO8PT46mE0CgmO5dj_kuPw"
      decimals="-5"
      id="Narr_aJp-uj9i90GgLi4vyaQQZg"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">20000000.0</plx:AdditionalAmountsPayableToCoverDevelopmentCosts>
    <plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones
      contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_eO8PT46mE0CgmO5dj_kuPw"
      decimals="-5"
      id="Narr_FJQe7_oQQEm9hErY_e8BcA"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">760000000.0</plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones>
    <plx:MilestonePaymentReceived
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_yf1yBqYb3ki32oo6H-lkuQ"
      decimals="-5"
      id="Narr_Dyk2PBKaQ0OduNS0hPMsSg"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">20000000.0</plx:MilestonePaymentReceived>
    <plx:AgreementAmendmentPaymentReceivable
      contextRef="As_Of_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_f8J7ygmkjUK2ukgA-2oQ1w"
      decimals="-5"
      id="Narr_a0zBQLVtVkuCFQ1JCvomNA"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">10000000.0</plx:AgreementAmendmentPaymentReceivable>
    <plx:ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones
      contextRef="Duration_5_13_2021_To_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_MxJMMq-010ClsaMCqYEAAA"
      decimals="-5"
      id="Narr_I3HB4jujpUS9Y36CwsLiow"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">25000000.0</plx:ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones>
    <plx:PaymentOnNetSalesPercentage
      contextRef="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_mw7kn8o2CUWR-j1nLxbVfQ"
      decimals="INF"
      id="Narr_nz7r3h842kqbMr7sKD_laA"
      unitRef="Unit_Standard_pure_KYNrm9UG9EeMn48Y0if07Q">0.15</plx:PaymentOnNetSalesPercentage>
    <plx:PaymentOnNetSalesPercentage
      contextRef="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_znGsm8ayME60HPVCk9kYOA"
      decimals="INF"
      id="Narr_wvpZBpKCd02FzEzV8so9qw"
      unitRef="Unit_Standard_pure_KYNrm9UG9EeMn48Y0if07Q">0.35</plx:PaymentOnNetSalesPercentage>
    <plx:PaymentOnNetSalesPercentage
      contextRef="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_8CtKgL9lj0K2stR5YPRj0Q"
      decimals="INF"
      id="Narr_OsLhKTKzGk-0k3FYQppqaw"
      unitRef="Unit_Standard_pure_KYNrm9UG9EeMn48Y0if07Q">0.15</plx:PaymentOnNetSalesPercentage>
    <plx:PaymentOnNetSalesPercentage
      contextRef="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_nRvfA8aPdUu85RbZO37WRQ"
      decimals="INF"
      id="Narr_WOyYn23SfUydoxlzToDoyA"
      unitRef="Unit_Standard_pure_KYNrm9UG9EeMn48Y0if07Q">0.40</plx:PaymentOnNetSalesPercentage>
    <plx:ExtendedTermOfAgreement
      contextRef="Duration_8_29_2022_To_8_29_2022_us-gaap_TypeOfArrangementAxis_plx_FillFinishAgreementMember_Ol0Pxko4TEuK_ACCWu0Zww"
      id="Narr_oJBJGQTDxUqZsPtkEhMunA">P7Y</plx:ExtendedTermOfAgreement>
    <plx:CollaborativeArrangementRevenuesExpensesSharingPercentage
      contextRef="Duration_10_1_2015_To_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_HI7XdKpS_0KkIxReGTPNCg"
      decimals="2"
      id="Narr_lu1R9KxvZ06-rE5iUwR1-Q"
      unitRef="Unit_Standard_pure_KYNrm9UG9EeMn48Y0if07Q">1</plx:CollaborativeArrangementRevenuesExpensesSharingPercentage>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      id="Tb_VcHi3DXIdUmPAVfz-jLYLw">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"&gt;b.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"&gt;Basis of presentation&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States (&#x201c;GAAP&#x201d;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form&#160;10-K for the year ended December&#160;31, 2023, filed by the Company with the U.S.&#160;Securities and Exchange Commission (the &#x201c;Commission&#x201d;). The comparative balance sheet at December&#160;31, 2023 has been derived from the audited financial statements at that date. There have been no material changes in our significant accounting policies as described in our consolidated financial statements for the year ended December&#160;31, 2023, except for convertible notes, as described below.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      id="Tb_NxQumnbvmESY_6_Q_m545A">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;c.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;Earnings (loss) per share&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt 0pt 0pt 54pt;"&gt;Basic earnings (loss) per share is calculated by dividing the net income (loss) by the weighted average number of shares of Common Stock outstanding during each period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt 0pt 0pt 54pt;"&gt;&lt;span style="color:#212529;"&gt;Diluted earnings per share is calculated by dividing the net income by the weighted-average number of shares of Common Stock outstanding during each period increased to include the number of additional shares of Common Stock that would have been outstanding if the potentially dilutive shares had been issued.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 0pt 54pt;"&gt;&lt;span style="color:#212529;"&gt;In computing diluted earnings per share, basic earnings per share are adjusted to take into account the potential dilution that could occur upon: (i)&#160;the exercise of options granted under employee stock compensation plans using the treasury &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 54pt;"&gt;&lt;span style="color:#212529;"&gt;stock method; (ii)&#160;the exercise of warrants using the treasury stock method; and (iii)&#160;the conversion of the convertible notes using the &#x201c;if-converted&#x201d; method.&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:DebtPolicyTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      id="Tb_BYU7xUQsbUGjn0iapJoYRA">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;d.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;Convertible notes&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;In September 2024, the Company repaid in full all of the outstanding principal and interest payable under its 7.50% Senior Secured Convertible Promissory Notes due September 2024 (the &#x201c;2024 Notes&#x201d;). The repayment of the convertible notes at maturity was financed entirely with available cash.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Prior to January&#160;1, 2024, the Company accounted for its outstanding convertible notes using the guidance set forth in the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) 815 which required that the Company determine whether the embedded conversion option must be separated from the other features of the applicable note instrument and accounted for separately. ASC 470-20 regarding debt with conversion and other options requires the issuer of a convertible debt instrument that may be settled in cash upon conversion to separately account for the liability (debt) and equity (conversion option) components of the instrument in a manner that reflects the issuer&#x2019;s nonconvertible debt borrowing rate. &lt;span style="background:#ffffff;"&gt;The Company&#x2019;s outstanding 2024 Notes were accounted for as a liability (debt) and equity component (conversion option) as the convertible notes may be settled wholly or partly in cash, at the option of the Company, when converted.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;span style="background:#ffffff;"&gt;In August 2020, the FASB issued &lt;/span&gt;ASU 2020-06 &#x201c;Debt &#x2013; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#x2013; Contracts in Entity&#x2019;s Own Equity (Subtopic 815 &#x2013; 40)&#x201d; (&#x201c;&lt;span style="background:#ffffff;"&gt;ASU 2020-06&#x201d;). &lt;/span&gt;ASU&#160;2020-06 simplifies the accounting for convertible instruments by removing certain separation models in ASC 470-20, Debt&#x2014;Debt with Conversion and Other Options, for convertible instruments. ASU&#160;2020-06 updates the guidance on certain embedded conversion features that are not required to be accounted for as derivatives under Topic 815, Derivatives and Hedging, or that do not result in substantial premiums accounted for as paid-in capital, such that those features are no longer required to be separated from the host contract. The convertible debt instruments will be accounted for as a single liability measured at amortized cost. This will also result in the interest expense recognized for convertible debt instruments to be typically closer to the coupon interest rate when applying the guidance in Topic 835. On January&#160;1, 2024, the Company adopted ASU 2020-06&lt;span style="background:#ffffff;"&gt; &lt;/span&gt;using the modified retrospective method of adoption. Under this method, the Company applied the guidance to the 2024 Notes at the adoption date and was required to make an adjustment to January&#160;1, 2024, opening accumulated deficit balance and additional paid in capital. &lt;span style="background:#ffffff;"&gt;The prior period consolidated financial statements have not been retrospectively adjusted and continue to be reported under the accounting standards in effect for those periods. &lt;/span&gt;Under ASU 2020-06, the 2024 Notes (debt and conversion option) are accounted for as a liability. The impact to the Company's consolidated balance sheet as of December&#160;31, 2023 resulting from its adoption of ASU 2020-06 is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:62.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:62.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;(U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As Reported December 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:13.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Updated January 1, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:9.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Effect of Change&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Convertible notes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,251&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,420&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 169&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Additional paid in capital&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 415,045&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 414,652&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (393)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Accumulated deficit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 381,549&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 381,325&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 224&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DebtPolicyTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_9_30_2024_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_orKpnVhEbkGbW5YdvkXelA"
      decimals="4"
      id="Narr_KAoP65LjmUu3gpbZkwehwQ"
      unitRef="Unit_Standard_pure_KYNrm9UG9EeMn48Y0if07Q">0.0750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      id="Group_RrlFzQKII0iQQXfy_AomQw">The impact to the Company's consolidated balance sheet as of December&#160;31, 2023 resulting from its adoption of ASU 2020-06 is as follows:&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:62.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:62.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;(U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As Reported December 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:13.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Updated January 1, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:9.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Effect of Change&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Convertible notes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,251&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,420&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 169&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Additional paid in capital&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 415,045&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 414,652&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (393)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Accumulated deficit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 381,549&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 381,325&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 224&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:ConvertibleDebtCurrent
      contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q"
      decimals="-3"
      id="Tc_Zxr79h5DIkGY94A-izHHyg_2_3"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">20251000</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:ConvertibleDebtCurrent
      contextRef="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_CXybZU5St0uHedL7onjfxA"
      decimals="-3"
      id="Tc_wyoXbJOv5kSDNvM0k6kdbQ_2_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">20420000</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:ConvertibleDebtCurrent
      contextRef="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_jTQDJIj1aEykP0X3ByOvLQ"
      decimals="-3"
      id="Tc_R27LvcrdgE2-H5yzWs2xxw_2_9"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">169000</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q"
      decimals="-3"
      id="Tc_JGD7mYjmjUO8d6yG0zEZcA_3_3"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">415045000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_CXybZU5St0uHedL7onjfxA"
      decimals="-3"
      id="Tc_82Z6h3QackmmRit33WKJFg_3_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">414652000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_jTQDJIj1aEykP0X3ByOvLQ"
      decimals="-3"
      id="Tc_R_BI19Bpzk2C9hWw9HMdeg_3_9"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">-393000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q"
      decimals="-3"
      id="Tc_SH9sebtF4USd-LMx9umR-g_4_3"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">381549000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_CXybZU5St0uHedL7onjfxA"
      decimals="-3"
      id="Tc_nEmDOI68mkOD79ISjokutg_4_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">381325000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_jTQDJIj1aEykP0X3ByOvLQ"
      decimals="-3"
      id="Tc_7Z3AmloPEUC2kJsl5F3qFw_4_9"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">224000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      id="Tb_6Sc0X9aaK0Oa-akDs6CX2Q">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;&lt;b style="font-weight:bold;background:#ffffff;"&gt;e.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;&lt;b style="font-weight:bold;background:#ffffff;"&gt;New accounting &lt;/b&gt;&lt;b style="font-weight:bold;"&gt;pronouncements&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;i style="font-style:italic;background:#ffffff;"&gt;Recently adopted accounting pronouncements&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;span style="background:#ffffff;"&gt;ASU 2020-06, which was issued by the FASB in August 2020 and adopted by the Company in January 2024, simplifies the accounting for certain financial instruments with characteristics of both liability and equity, including convertible instruments and contracts on an entity&#x2019;s own equity. The amendments to this guidance are effective for fiscal years beginning after December&#160;15, 2023, and interim periods within those fiscal years. See Note&#160;1(d).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;i style="font-style:italic;background:#ffffff;"&gt;Recently issued accounting pronouncements, not yet adopted&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;span style="background:#ffffff;"&gt;In December 2023, the FASB issued ASU 2023-09 &#x201c;Income Taxes (Topic 740): Improvements to Income Tax Disclosures.&#x201d; This guidance is intended to enhance the transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid both in the United States and in foreign jurisdictions. ASU 2023-09 is effective for fiscal years beginning after December&#160;15, 2024 on a prospective basis. Early adoption is permitted, with the option to apply the standard retrospectively. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;span style="background:#ffffff;"&gt;In November 2023, the FASB issued ASU 2023-07 &#x201c;Segment Reporting: Improvements to Reportable Segment Disclosures.&#x201d; This guidance expands public entities&#x2019; segment disclosures primarily by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment&#x2019;s profit or loss and assets. Public entities with a single reportable segment are required to provide the new disclosures and all of the disclosures required under ASC 280. The guidance is effective for fiscal years beginning after December&#160;15, 2023, and interim periods within fiscal years beginning after December&#160;15, 2024, with early adoption permitted. The amendments are required to be applied retrospectively to all prior periods presented in an entity&#x2019;s financial statements. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements and related disclosures&lt;/span&gt;&lt;span style="font-family:'Palatino Linotype';background:#ffffff;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      id="Tb_6kuR6yNL90-no4ihd_VVhA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;2&#160;- INVENTORIES&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Inventories at September&#160;30, 2024 and December&#160;31, 2023 consisted of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,242&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,176&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Work in progress&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,251&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,055&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 706&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,814&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total inventory&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17,199&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,045&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-size:1pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      id="Group_b5ooBZXmiEC4SooBNfm6LQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Inventories at September&#160;30, 2024 and December&#160;31, 2023 consisted of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,242&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,176&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Work in progress&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,251&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,055&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 706&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,814&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total inventory&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17,199&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,045&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-size:1pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g"
      decimals="-3"
      id="Tc_Wsbf5Ad71U6-WEWHPWAA6A_3_3"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">4242000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q"
      decimals="-3"
      id="Tc_s9HEtqO64ki5Nc8dQyiopw_3_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">4176000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g"
      decimals="-3"
      id="Tc_iCuKjpdOckeTKpp2GFTM-A_4_3"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">12251000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q"
      decimals="-3"
      id="Tc_om4ERAP4ZU-NlOnUnLd2Ig_4_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">9055000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g"
      decimals="-3"
      id="Tc_hgRWz7o4qkCoYro957K19A_5_3"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">706000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q"
      decimals="-3"
      id="Tc_3GlnPn-v40qH7w6wSBPcUw_5_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">5814000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g"
      decimals="-3"
      id="Tc_4SSmcKPCj0q8rYUhmoneJA_6_3"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">17199000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q"
      decimals="-3"
      id="Tc_8XqTqb6pBk28tNtuk16_mQ_6_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">19045000</us-gaap:InventoryNet>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      id="Tb_7c9gyTgsakykNPYk1W6YzA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;3&#160;&#x2013; FAIR VALUE MEASUREMENT&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;The Company discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Level&#160;1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Level&#160;2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Level&#160;3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;The fair value of the financial instruments included in the working capital of the Company is identical or close to their carrying value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <plx:RevenueDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      id="Tb_iQ485AwSzUq1EIFw2DtGvQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;background:#ffffff;"&gt;NOTE&#160;4&#160;&#x2013; REVENUES&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;&lt;span style="background:#ffffff;"&gt;The following table summarizes the Company&#x2019;s disaggregation of revenues:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:39.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Pfizer&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,431&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,972&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,430&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,304&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Brazil&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,314&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,120&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,048&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,320&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Chiesi&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14,075&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17,217&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,361&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,544&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total revenues from selling goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 34,820&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30,309&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17,839&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,168&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Revenues from license and R&amp;amp;D services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 361&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 24,699&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 120&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 177&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="color:#212529;font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</plx:RevenueDisclosureTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      id="Group_xj8SuOihxkyoh0Lb-XagbQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;&lt;span style="background:#ffffff;"&gt;The following table summarizes the Company&#x2019;s disaggregation of revenues:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:39.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Pfizer&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,431&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,972&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,430&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,304&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Brazil&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,314&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,120&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,048&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,320&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Chiesi&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14,075&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17,217&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,361&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,544&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total revenues from selling goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 34,820&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30,309&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17,839&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,168&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Revenues from license and R&amp;amp;D services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 361&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 24,699&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 120&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 177&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="color:#212529;font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2024_To_9_30_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_vw8by47NDUq5QE7hoakywQ"
      decimals="-3"
      id="Tc_k_lhp7mDR02MBhSxEpVNGQ_3_3"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">11431000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_7mSydPVUmEmHGUlub7tPJg"
      decimals="-3"
      id="Tc_Ctnw80YbfESa_kEwi0MkrQ_3_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">7972000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2024_To_9_30_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_m3nBp_5RP0q3hxfAVIwsKA"
      decimals="-3"
      id="Tc_byejTCKGLE6hd2sbcC9xYw_3_11"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">3430000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_xT5o1Ih3q0CS-6-uYmd1nw"
      decimals="-3"
      id="Tc_ZLfW11TXr0Sbais4rLbqmA_3_14"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">2304000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2024_To_9_30_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_R2V45jNs50i3ZjlXVw6V4Q"
      decimals="-3"
      id="Tc_k-dBpIp4OkeLdImWwLYl0w_4_3"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">9314000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_-gw8gqnXX0q0q6EWX9kyGA"
      decimals="-3"
      id="Tc_1YCDz_0_U02fL9CohGyVFg_4_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">5120000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2024_To_9_30_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_Y25APrw9YkGqE9QGp-2pBw"
      decimals="-3"
      id="Tc__OlH1ac-TEqPG9FFcKq1oA_4_11"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">2048000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_uM6rCcqim06Mqh7Y7r7_hA"
      decimals="-3"
      id="Tc_UmIhyshtfUGlk_oHwMx_OA_4_14"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">2320000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2024_To_9_30_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_E4kb99v7l0mAZMrPKuEUEA"
      decimals="-3"
      id="Tc_0bK2vaAJBUCxGQxsoWejhw_5_3"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">14075000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_z371xjvvpUqBogUfxstw5A"
      decimals="-3"
      id="Tc_pQvGm-qyeEOVRWxk3PA57w_5_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">17217000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2024_To_9_30_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_YVdXplgBIUiqKREQvvCQYg"
      decimals="-3"
      id="Tc_OHIuqrGxdECb_29cvtgofA_5_11"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">12361000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_xv7pHWEqdkuqLB4zfoGlgQ"
      decimals="-3"
      id="Tc_9FLouBigv0CjM--QbQ1uYg_5_14"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">5544000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2024_To_9_30_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_A3ezJBQ1MUmqg7U3imJLCA"
      decimals="-3"
      id="Tc_tieSArUOKECmcwPMLxgNWQ_6_3"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">34820000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_DR0rv8wVu0yrFx2bdJFyPQ"
      decimals="-3"
      id="Tc_2QjG0kmQikevPqBsqq4_ww_6_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">30309000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2024_To_9_30_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_pLP50Bgxbk-D1hnRjPhAlA"
      decimals="-3"
      id="Tc_Bc2eobMCp0ubhh0l8PjUEw_6_11"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">17839000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_ierukmxCL0qBG6i8bMqdsw"
      decimals="-3"
      id="Tc_6ydTpw3_RUqEEAnylF_KrA_6_14"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">10168000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2024_To_9_30_2024_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_RrGB_Ovo00Ok686p6jPzbA"
      decimals="-3"
      id="Tc_t00uraDNoE2g9ClX3M5LEA_7_3"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">361000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_Mxt-hPsr9EG5KGrzdcGbQQ"
      decimals="-3"
      id="Tc_iDXubHNV7UG-lMSRKCsGzw_7_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">24699000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2024_To_9_30_2024_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_-EAKZ_94e02kTPJSHJ6-mQ"
      decimals="-3"
      id="Tc_NIZRHHnEYkuJXwkU_iD2cg_7_11"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">120000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_j4Hh_9X_vkGuiao5PBkobw"
      decimals="-3"
      id="Tc_kvID1KAyXUu1hGZYuy2pGw_7_14"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">177000</us-gaap:Revenues>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      id="Tb_Q_HNgMkPWUudjk6aDAcK-w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 5 &#x2013; STOCK TRANSACTIONS&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;On January&#160;15, 2024, the Company granted, with the approval of the Company&#x2019;s compensation committee, 100,000 shares of restricted Common Stock, in the aggregate, to certain of the Company&#x2019;s employees under the Company&#x2019;s Amended and Restated 2006 Employee Stock Incentive Plan, as amended (the &#x201c;Plan&#x201d;). All such shares of restricted Common Stock vest over a three-year period in 12&#160;equal quarterly increments. The Company estimated the fair value of the restricted stock on the date of grant to be approximately $0.2&#160;million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;On April&#160;1, 2024, the Company granted, with the approval of the Company&#x2019;s compensation committee, 263,960 shares of fully-vested restricted Common Stock to the Company&#x2019;s President and Chief Executive Officer under the Plan instead of a cash bonus. The Company estimated the fair value of the restricted stock on the date of grant to be approximately $0.3&#160;million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;On July&#160;2, 2024, the Company granted, with the approval of the Company&#x2019;s compensation committee,&#160;250,000&#160;shares of restricted Common Stock to its new Vice President, Research and Development, under the Plan. The&#160;&lt;span style="-sec-ix-hidden:Hidden_Wv5n4SFqLUalXo86fgRQdg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;first third&lt;/span&gt;&lt;/span&gt;&#160;of such shares of restricted Common Stock vest on the&#160;&lt;span style="-sec-ix-hidden:Hidden_HDd_9eUnQUuEPgjlLh4OWA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;first&lt;/span&gt;&lt;/span&gt;&#160;anniversary of the date of grant and the remaining&#160;&lt;span style="-sec-ix-hidden:Hidden_UMFZm-Gn_k61nFAdjEsS9w;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;two-thirds&lt;/span&gt;&lt;/span&gt;&#160;of the shares vest over the subsequent&#160;two-year&#160;period in&#160;eight&#160;equal quarterly increments. The Company estimated the fair value of the restricted stock on the date of grant to be approximately $0.3&#160;million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;On September&#160;23, 2024, the Company granted, with the approval of the Company&#x2019;s compensation committee, 90,909 shares of fully-vested restricted Common Stock, in the aggregate, to its Sr.&#160;Vice President and Chief Financial Officer under the Plan. The Company estimated the fair value of the restricted stock on the date of grant to be approximately $0.1&#160;million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;On September&#160;23, 2024, the Company granted, with the approval of the Company&#x2019;s compensation committee, 10-year options to purchase 1,015,725 shares of Common Stock, in the aggregate, to certain of the Company&#x2019;s officers and other employees under the Plan. The options have an exercise price equal to $1.10 per share and vest over a three-year period in 12&#160;equal quarterly increments. Vesting of the options granted to executive officers is subject to automatic acceleration in full upon a Corporate Transaction or a Change in Control, as those terms are defined in the Plan, and are subject to certain other terms and conditions. The Company estimated the aggregate fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately $0.8&#160;million.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_15_2024_To_1_15_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_ELprQe2rdEavBiEcVE57Fg"
      decimals="INF"
      id="Narr_f3f39kfMd0OHJikNz7FUnA"
      unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_15_2024_To_1_15_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_ELprQe2rdEavBiEcVE57Fg"
      id="Narr_N5srNWE9uEO69aaivj1Qww">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements
      contextRef="Duration_1_15_2024_To_1_15_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_ELprQe2rdEavBiEcVE57Fg"
      decimals="INF"
      id="Narr_G9KRprAbZ06uf8pmOuKX6w"
      unitRef="Unit_Standard_installment_GQ9uxVOtz0-sYFwS4P9Gzg">12</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue
      contextRef="As_Of_1_15_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_wjItBW8ElUS5zStQFNkaTQ"
      decimals="-5"
      id="Narr_euL2_ugiF02_fVPcKD7vpw"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">200000</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_4_1_2024_To_4_1_2024_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_p_CUFtHXL0eyiopN2TaoPQ"
      decimals="INF"
      id="Narr_hAeYy9tQTUKLvkg852n_2w"
      unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA">263960</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue
      contextRef="As_Of_4_1_2024_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_fW2CAIqwS0yFawiF2Xq3Pw"
      decimals="-5"
      id="Narr_xRLWyUiq9EuBeAYGkvpBuQ"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">300000</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_7_2_2024_To_7_2_2024_srt_TitleOfIndividualAxis_plx_VicePresidentResearchAndDevelopmentMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_AvLDv7dryEm2YrB3OLun0Q"
      decimals="INF"
      id="Narr_7KJKLEwbf0mLhBFHAplLGg"
      unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA">250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_7_2_2024_To_7_2_2024_srt_TitleOfIndividualAxis_plx_VicePresidentResearchAndDevelopmentMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_fsxZjtrzyEyb_e85-FjXKw"
      id="Narr_Kp1m-pRQe0aNkYGFPN53hw">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements
      contextRef="Duration_7_2_2024_To_7_2_2024_srt_TitleOfIndividualAxis_plx_VicePresidentResearchAndDevelopmentMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_fsxZjtrzyEyb_e85-FjXKw"
      decimals="INF"
      id="Narr_jfAxyhDmwUKrrnLh6g2bwA"
      unitRef="Unit_Standard_installment_GQ9uxVOtz0-sYFwS4P9Gzg">8</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue
      contextRef="As_Of_7_2_2024_srt_TitleOfIndividualAxis_plx_VicePresidentResearchAndDevelopmentMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_VcyDlSSU_UuXWR7-Z6srjw"
      decimals="-5"
      id="Narr_TAXW9f8FSUekqpcxZWCzsQ"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">300000</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_9_23_2024_To_9_23_2024_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_fjlRxFeRF0GsDO6ftqcY3w"
      decimals="INF"
      id="Narr_u3gK4KZFzUqdvZapqmO9Wg"
      unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA">90909</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue
      contextRef="As_Of_9_23_2024_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_ypJyopAyWUGn0-upITXFlQ"
      decimals="-5"
      id="Narr_dx3x61WEG0SAtbW1kesRWw"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">100000</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_9_23_2024_To_9_23_2024_srt_TitleOfIndividualAxis_plx_OfficersAndOtherEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_dTpdI5xPrkiwpnGVkyHdmQ"
      id="Narr_ZYEYujJi7ESXPzd9QB0bZg">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_9_23_2024_To_9_23_2024_srt_TitleOfIndividualAxis_plx_OfficersAndOtherEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_dTpdI5xPrkiwpnGVkyHdmQ"
      decimals="INF"
      id="Narr_85niEQdOskKfun8eR1eedg"
      unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA">1015725</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_9_23_2024_To_9_23_2024_srt_TitleOfIndividualAxis_plx_OfficersAndOtherEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_dTpdI5xPrkiwpnGVkyHdmQ"
      decimals="2"
      id="Narr_fklgoYw2SUWoLbd4bA4obA"
      unitRef="Unit_Divide_USD_shares_A4-BaHg86EmBShQ9tsexWA">1.10</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_9_23_2024_To_9_23_2024_srt_TitleOfIndividualAxis_plx_OfficersAndOtherEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_dTpdI5xPrkiwpnGVkyHdmQ"
      id="Narr_uWTi_sTojU674DstaBB6yQ">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements
      contextRef="Duration_9_23_2024_To_9_23_2024_srt_TitleOfIndividualAxis_plx_OfficersAndOtherEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_dTpdI5xPrkiwpnGVkyHdmQ"
      decimals="INF"
      id="Narr_LidDnV9RcEaaMdOfvyxdWg"
      unitRef="Unit_Standard_installment_GQ9uxVOtz0-sYFwS4P9Gzg">12</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue
      contextRef="As_Of_9_23_2024_srt_TitleOfIndividualAxis_plx_OfficersAndOtherEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_b8NTuk7QZkmYLH_vN0r7-Q"
      decimals="-5"
      id="Narr_wfuckwXjMUOnbZfQ8elezg"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">800000</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      id="Tb_M8dPWnpSMU6shfuv_CJv8w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 6 &#x2013; EARNINGS (LOSS) PER SHARE&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;&lt;span style="color:#212529;"&gt;Basic and diluted net earnings (loss) per share attributable to common stockholders were calculated as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.17%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:40.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:28.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:29.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(In&#160;thousands,&#160;except&#160;share&#160;data)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Numerator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,562)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14,356&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,236&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,852)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Add:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Financial expenses of 2024 Notes*&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,610)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (503)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,766)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net income (loss) for diluted calculation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,562)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,746&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,733&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,618)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Denominator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average shares of Common Stock outstanding for basic calculation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 73,301,091&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 65,811,506&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 73,549,745&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 72,281,681&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average dilutive effect of 2024 Notes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,981,660&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,667,323&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,500,998&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average dilutive effect of stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,247,115&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average shares of Common Stock outstanding for diluted calculation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 73,301,091&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 81,040,281&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 81,217,068&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 83,782,679&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 54pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 10pt 54pt;"&gt;* Financial expenses on 2024 Notes consists of add back of financial expense incurred during the period and inclusion of make-whole interest payments that will be incurred upon conversion.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 10pt 36pt;"&gt;&lt;span style="font-size:10pt;"&gt;Diluted earnings (loss) per share do not include &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;30,515,287&lt;/span&gt; &lt;span style="font-size:10pt;"&gt;shares of Common Stock underlying outstanding stock options, warrants and the 2024 Notes for the nine months ended September&#160;30, 2024, and &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;20,173,438&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; shares of Common Stock underlying outstanding stock options and warrants for the three months ended September&#160;30, 2024, because the effect would be anti-dilutive.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Diluted earnings (loss) per share do not include 19,429,910 and 18,399,260 shares of Common Stock underlying outstanding stock options and warrants of the Company for the three and nine months ended September&#160;30, 2023, respectively, because the effect would be anti-dilutive.&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      id="Group_SA1jJOjq70mIfWp6QFqBcg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;&lt;span style="color:#212529;"&gt;Basic and diluted net earnings (loss) per share attributable to common stockholders were calculated as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.17%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:40.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:28.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:29.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(In&#160;thousands,&#160;except&#160;share&#160;data)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Numerator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,562)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14,356&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,236&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,852)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Add:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Financial expenses of 2024 Notes*&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,610)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (503)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,766)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net income (loss) for diluted calculation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,562)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,746&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,733&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,618)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Denominator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average shares of Common Stock outstanding for basic calculation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 73,301,091&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 65,811,506&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 73,549,745&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 72,281,681&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average dilutive effect of 2024 Notes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,981,660&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,667,323&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,500,998&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average dilutive effect of stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,247,115&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average shares of Common Stock outstanding for diluted calculation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 73,301,091&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 81,040,281&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 81,217,068&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 83,782,679&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 54pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 10pt 54pt;"&gt;* Financial expenses on 2024 Notes consists of add back of financial expense incurred during the period and inclusion of make-whole interest payments that will be incurred upon conversion.&lt;/p&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      decimals="-3"
      id="Tc_NMS38b7Zi0GQpMtFO-uRzg_4_3"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">-3562000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g"
      decimals="-3"
      id="Tc_rD-3OU4n7kCdgCKbh6sVeg_4_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">14356000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2024_To_9_30_2024_5srFek9aZ0STe4olK5gckA"
      decimals="-3"
      id="Tc_-TP_4EwxCE2qJoWLXiWDQg_4_9"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">3236000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2023_To_9_30_2023__jyu8G4bX02xwWm0pGi6zA"
      decimals="-3"
      id="Tc_1MGZEvsbKECZ2cVOjvWdbw_4_12"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">-1852000</us-gaap:NetIncomeLoss>
    <us-gaap:DilutiveSecurities
      contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g"
      decimals="-3"
      id="Tc_lGM9Vo-1q0G-JfQxMcvVHw_6_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">-1610000</us-gaap:DilutiveSecurities>
    <us-gaap:DilutiveSecurities
      contextRef="Duration_7_1_2024_To_9_30_2024_5srFek9aZ0STe4olK5gckA"
      decimals="-3"
      id="Tc_6J3DqoDXN0ayPiXM094-_A_6_9"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">-503000</us-gaap:DilutiveSecurities>
    <us-gaap:DilutiveSecurities
      contextRef="Duration_7_1_2023_To_9_30_2023__jyu8G4bX02xwWm0pGi6zA"
      decimals="-3"
      id="Tc_6Ajqc4-Yu0uVCPSqVlQUSQ_6_12"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">-1766000</us-gaap:DilutiveSecurities>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      decimals="-3"
      id="Tc_uZn-cIKf1UGOmYmZpqxOrA_7_3"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">-3562000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g"
      decimals="-3"
      id="Tc_eOOZN5R90E2bKfeluiF3sg_7_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">12746000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="Duration_7_1_2024_To_9_30_2024_5srFek9aZ0STe4olK5gckA"
      decimals="-3"
      id="Tc_ZSiPk-3PY0Kjv2samNbSUg_7_9"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">2733000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="Duration_7_1_2023_To_9_30_2023__jyu8G4bX02xwWm0pGi6zA"
      decimals="-3"
      id="Tc_a4CiWWGd3kyA9CE6NUh3CQ_7_12"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">-3618000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      decimals="0"
      id="Tc_ZLmVtJIl_EGoLpJjVPZibw_9_3"
      unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA">73301091</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g"
      decimals="0"
      id="Tc_0lddb4zKt0SPh5NXP2uevQ_9_6"
      unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA">65811506</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_7_1_2024_To_9_30_2024_5srFek9aZ0STe4olK5gckA"
      decimals="0"
      id="Tc_2vOBnVHtuEW-jLGIulSSCA_9_9"
      unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA">73549745</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_7_1_2023_To_9_30_2023__jyu8G4bX02xwWm0pGi6zA"
      decimals="0"
      id="Tc_1Ia0wqhJIUuKzY-8-5orjw_9_12"
      unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA">72281681</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g"
      decimals="0"
      id="Tc_amEH7UAuSUOxmpYHfWscnA_10_6"
      unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA">13981660</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="Duration_7_1_2024_To_9_30_2024_5srFek9aZ0STe4olK5gckA"
      decimals="0"
      id="Tc_DRsKqxyHpUqD8z43fT5DGg_10_9"
      unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA">7667323</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="Duration_7_1_2023_To_9_30_2023__jyu8G4bX02xwWm0pGi6zA"
      decimals="0"
      id="Tc_S5dlk0po3Euc57lL7iuueg_10_12"
      unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA">11500998</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g"
      decimals="0"
      id="Tc_9aybVS5APEGmT6KZthxWBQ_11_6"
      unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA">1247115</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      decimals="0"
      id="Tc_j5fhJsYTY06HxePAF9bI9g_12_3"
      unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA">73301091</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g"
      decimals="0"
      id="Tc_4fpQ3D_TDUCSLuvS1v4Grw_12_6"
      unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA">81040281</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_7_1_2024_To_9_30_2024_5srFek9aZ0STe4olK5gckA"
      decimals="0"
      id="Tc_ehRjnO_nXEWwsxyD2cOntA_12_9"
      unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA">81217068</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_7_1_2023_To_9_30_2023__jyu8G4bX02xwWm0pGi6zA"
      decimals="0"
      id="Tc_f-IMY_cZgkCTOrAjIjTbCA_12_12"
      unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA">83782679</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsWarrantsAnd2024NotesMember_pHC6uKO6gUK7SAy-_PDCuw"
      decimals="INF"
      id="Narr_nEyGdbqn_0aai-MovgPtOQ"
      unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA">30515287</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsAndWarrantsMember_C0t9LFxG80iLLT4GrVHt5Q"
      decimals="INF"
      id="Narr_EkOqxYuVi0eBIsIb8C9BRw"
      unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA">20173438</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsAndWarrantsMember_jNIclNrn20-gLZ0NF4hAeg"
      decimals="INF"
      id="Narr_tdv3rlLt-UKtmCNVsQz8_w"
      unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA">19429910</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsAndWarrantsMember_I8uK516psE6zNy3vZsdCVQ"
      decimals="INF"
      id="Narr_S3XMSL1-jkypieXim4JJAw"
      unitRef="Unit_Standard_shares_tdxssIivOEiHcpgO67IbWA">18399260</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      id="Tb_S5M4TwA52E6FetM_t2BsWA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 7 &#x2013; TAXES ON INCOME&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;&lt;span style="background:#ffffff;"&gt;The following table summarizes the Company&#x2019;s taxes on income:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:40.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;(U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Current taxes on income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 164&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,728&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 164&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 95&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred taxes on income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 236&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,092)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 443&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 38&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total taxes on income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 400&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 636&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 607&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 133&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;The Company had an effective tax rate of (13)% for the nine months ended September&#160;30, 2024, compared to an effective tax rate of 4% for the nine months ended September&#160;30, 2023. For the nine months ended September&#160;30, 2024, the difference between the Company&#x2019;s effective tax rate and the U.S.&#160;federal statutory rate of 21% was the result of forecasted profits derived primarily from U.S.&#160;taxable GILTI income mainly due to Section&#160;174 of the U.S.&#160;Tax Cuts and Jobs Act, which was enacted in December 2017 (the &#x201c;TCJA&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="color:#212529;background:#ffffff;"&gt;In the second quarter ended June&#160;30, 2023, following the regulatory approvals for Elfabrio in May 2023, the receipt of the &lt;/span&gt;&lt;span style="color:#212529;background:#ffffff;"&gt;$20.0&lt;/span&gt;&lt;span style="color:#212529;background:#ffffff;"&gt;&#160;million milestone payment and the launch of Elfabrio in the United States, the Company released valuation allowance previously recorded on deferred tax assets in respect of its net operating losses (&#x201c;NOLs&#x201d;) in the United States resulting in a net tax benefit of &lt;/span&gt;&lt;span style="color:#212529;background:#ffffff;"&gt;$3.1&lt;/span&gt;&lt;span style="color:#212529;background:#ffffff;"&gt;&#160;million. The Company concluded that, based upon the preponderance of positive evidence over negative evidence and the anticipated ability to use the deferred tax assets, it was more likely than not that these deferred tax &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;&lt;span style="color:#212529;background:#ffffff;"&gt;assets would be realizable due to forecasted profits. The Company considered the following: (i)&#160;cumulative profits for tax over the previous 12 quarters in its U.S. operations; (ii)&#160;the impact of Section&#160;174 of the TCJA which requires the Company to capitalize and amortize its research and development expenses over 15 years; and (iii) its forecasted profits in the United States following the regulatory approvals of Elfabrio.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      id="Group_HSGtdPZsQUKUrNj7aw9hIg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;&lt;span style="background:#ffffff;"&gt;The following table summarizes the Company&#x2019;s taxes on income:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:40.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;(U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Current taxes on income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 164&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,728&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 164&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 95&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred taxes on income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 236&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,092)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 443&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 38&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total taxes on income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 400&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 636&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 607&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 133&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      decimals="-3"
      id="Tc_EOeTGbmmPEWu4AraUnlrJg_3_3"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">164000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g"
      decimals="-3"
      id="Tc_PvstwrXySUir5labijZTKg_3_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">3728000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="Duration_7_1_2024_To_9_30_2024_5srFek9aZ0STe4olK5gckA"
      decimals="-3"
      id="Tc_9y184QZ8VkOrYrbAayyFhg_3_9"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">164000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="Duration_7_1_2023_To_9_30_2023__jyu8G4bX02xwWm0pGi6zA"
      decimals="-3"
      id="Tc_z6dhq4Ii3kiwBeIMofWXJA_3_12"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">95000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      decimals="-3"
      id="Tc_LD3ToC6W7k656NvMagod3w_4_3"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">236000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g"
      decimals="-3"
      id="Tc_MumwioNuUkaGwZ4iTlPMlg_4_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">-3092000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="Duration_7_1_2024_To_9_30_2024_5srFek9aZ0STe4olK5gckA"
      decimals="-3"
      id="Tc_naMq9xP2sECqjIuRLWpC5A_4_9"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">443000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="Duration_7_1_2023_To_9_30_2023__jyu8G4bX02xwWm0pGi6zA"
      decimals="-3"
      id="Tc_Qlf-kLi4Vk-ow7XMD1NScg_4_12"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">38000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      decimals="-3"
      id="Tc_7X0NndZyQ0qqt4iSMYfX5w_5_3"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">400000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g"
      decimals="-3"
      id="Tc_rTruQbzBwk6LN0j6Mxs3wg_5_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">636000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_7_1_2024_To_9_30_2024_5srFek9aZ0STe4olK5gckA"
      decimals="-3"
      id="Tc_3fazCOAKhUODFYIlh0qkvg_5_9"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">607000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_7_1_2023_To_9_30_2023__jyu8G4bX02xwWm0pGi6zA"
      decimals="-3"
      id="Tc_GEfZrFQzXUSMM6GL9X2laQ_5_12"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">133000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      decimals="2"
      id="Narr_S0COT9Yfn0m8D02wlMordw"
      unitRef="Unit_Standard_pure_KYNrm9UG9EeMn48Y0if07Q">-0.13</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2023_To_9_30_2023_bur4w4H3PESYpZnKDS_t2g"
      decimals="2"
      id="Narr_67bm9otCD06sKsOeyDWPNw"
      unitRef="Unit_Standard_pure_KYNrm9UG9EeMn48Y0if07Q">0.04</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      decimals="2"
      id="Narr_aWt8HsEKTE2UBqbFQlXlug"
      unitRef="Unit_Standard_pure_KYNrm9UG9EeMn48Y0if07Q">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <plx:MilestonePaymentReceived
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_pm7aApgkcEqj6XWAS_4N3w"
      decimals="-5"
      id="Narr_pNiQ3UYvHEiZlQEcDGKk1g"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">20000000.0</plx:MilestonePaymentReceived>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_4_1_2023_To_6_30_2023_Vdzpjd4fMUGT4CcCzCt5ig"
      decimals="-5"
      id="Narr_0YJa2WD0S0GEOSKn_fKrXQ"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">-3100000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:AdditionalFinancialInformationDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      id="Tb_oPxE6xHOr0mwUYcBjKLj8Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 8 &#x2013; &lt;/b&gt;&lt;b style="font-weight:bold;background:#ffffff;"&gt;SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance sheets:&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Accounts payable and accruals &#x2013; other:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Payroll and related expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,251&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,437&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Interest payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 511&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Provision for vacation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,713&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,605&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,342&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,009&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Royalties payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 571&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 637&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Income tax payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,040&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,876&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Sales reserve&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,258&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,861&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Property and equipment suppliers&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 402&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 614&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,577&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,550&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:AdditionalFinancialInformationDisclosureTextBlock>
    <plx:SupplementaryBalanceSheetsInformationTableTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      id="Tb_4wejWjfZQk2fw_R22MvBQQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Accounts payable and accruals &#x2013; other:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Payroll and related expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,251&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,437&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Interest payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 511&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Provision for vacation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,713&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,605&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,342&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,009&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Royalties payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 571&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 637&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Income tax payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,040&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,876&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Sales reserve&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,258&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,861&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Property and equipment suppliers&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 402&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 614&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,577&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,550&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</plx:SupplementaryBalanceSheetsInformationTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g"
      decimals="-3"
      id="Tc_uMym4rSoZUWbWQzjyJCi_w_4_3"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">1251000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q"
      decimals="-3"
      id="Tc_NXIzvPHC6EaNXSMk_6A0ng_4_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">1437000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q"
      decimals="-3"
      id="Tc_Op2ynv5x-EaQvfI0zWql7Q_5_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">511000</us-gaap:InterestPayableCurrent>
    <us-gaap:AccruedVacationCurrent
      contextRef="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g"
      decimals="-3"
      id="Tc_zrhDC6p0bkaUBMMx6o6yCw_6_3"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">1713000</us-gaap:AccruedVacationCurrent>
    <us-gaap:AccruedVacationCurrent
      contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q"
      decimals="-3"
      id="Tc_Od6_CrlEq0KdafkdtsILpg_6_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">1605000</us-gaap:AccruedVacationCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g"
      decimals="-3"
      id="Tc_Xa97ueMsJk2Be6D71oVcYw_7_3"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">8342000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q"
      decimals="-3"
      id="Tc_WlaMpkVOO0CmhvF6oD1QRg_7_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">9009000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g"
      decimals="-3"
      id="Tc_NDesqp1A1UGSe4YBWBM66Q_8_3"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">571000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q"
      decimals="-3"
      id="Tc_RZeQRDG8tkKJ9rnDGty29Q_8_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">637000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g"
      decimals="-3"
      id="Tc_GrBnWbAfXE-AOi9nkf7luQ_9_3"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">3040000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q"
      decimals="-3"
      id="Tc_FZJyfHNLYECIQwGx_gzgRg_9_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">2876000</us-gaap:TaxesPayableCurrent>
    <plx:ReserveForDeductionsFromRevenueCurrent
      contextRef="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g"
      decimals="-3"
      id="Tc_Y_Fj-GyFw0KZxVW6W65M9Q_10_3"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">4258000</plx:ReserveForDeductionsFromRevenueCurrent>
    <plx:ReserveForDeductionsFromRevenueCurrent
      contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q"
      decimals="-3"
      id="Tc_K20v4CqCc0erpBnvqB82XA_10_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">2861000</plx:ReserveForDeductionsFromRevenueCurrent>
    <plx:AccountsPayablePropertyAndEquipmentSuppliersCurrent
      contextRef="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g"
      decimals="-3"
      id="Tc_DlvofN2HzEepQRL9_G7kag_11_3"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">402000</plx:AccountsPayablePropertyAndEquipmentSuppliersCurrent>
    <plx:AccountsPayablePropertyAndEquipmentSuppliersCurrent
      contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q"
      decimals="-3"
      id="Tc_5gyyiDkx9UuSKM3eTCD07w_11_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">614000</plx:AccountsPayablePropertyAndEquipmentSuppliersCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_9_30_2024_811Dhclfvk6i_byAs3FG7g"
      decimals="-3"
      id="Tc_rsSRdAGya0Wf6Vx4In6e8w_12_3"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">19577000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2023_HXysIYZ_YU2Nq6yFRKhf7Q"
      decimals="-3"
      id="Tc_gcSAObl54Uu5ly-MaYSMjw_12_6"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">19550000</us-gaap:AccountsPayableCurrent>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_Jhra6YMH5Emm28ZRE4YDSg"
      id="Tb_UOZ386WrTkK0QCPfgAhYsg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 9 &#x2013; SUBSEQUENT EVENTS&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;Since the end of the quarter ended September 30, 2024, the Company collected approximately $3.9&#160;million from sales to Chiesi&lt;span style="background:#ffffff;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 36pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ProceedsFromCustomers
      contextRef="Duration_11_14_2024_To_11_14_2024_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_IuBQ2oW-QUW8AyxcNROv4A"
      decimals="-5"
      id="Narr_mQ5onepGKkm85fULKhxQPw"
      unitRef="Unit_Standard_USD_R1zEFe-7CkiAz4297Zb8MA">3900000</us-gaap:ProceedsFromCustomers>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="Duration_7_1_2024_To_9_30_2024_5srFek9aZ0STe4olK5gckA"
      id="Narr_B9qvXggsfUGCl-WUu8g5wQ">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="Duration_7_1_2024_To_9_30_2024_5srFek9aZ0STe4olK5gckA"
      id="Narr_G6WSRul9BE2r4Hr4bLvkeA">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="Duration_7_1_2024_To_9_30_2024_5srFek9aZ0STe4olK5gckA"
      id="Narr_91g6uR2LJUyeAx7tWtqI0Q">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="Duration_7_1_2024_To_9_30_2024_5srFek9aZ0STe4olK5gckA"
      id="Narr_STuqb18ZakGqqKYcDBnXMg">false</ecd:NonRule10b51ArrTrmntdFlag>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Tc_ou5xw0ZH3UOzwMqFkX8ZXw_11_2"
          xlink:label="Tc_ou5xw0ZH3UOzwMqFkX8ZXw_11_2"
          xlink:type="locator"/>
        <link:footnote id="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" xlink:label="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Common stock, $0.001 par value; Authorized &#x2013; as of September&#160;30, 2024 and December&#160;31, 2023 &#x2013; 185,000,000 shares.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_ou5xw0ZH3UOzwMqFkX8ZXw_11_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_aC_OasVPQ0KRxRUvZLjfIw_25_2"
          xlink:label="Tc_aC_OasVPQ0KRxRUvZLjfIw_25_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_aC_OasVPQ0KRxRUvZLjfIw_25_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_VWvVYHPsI0-a0UWwtx9QAA_19_2"
          xlink:label="Tc_VWvVYHPsI0-a0UWwtx9QAA_19_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_VWvVYHPsI0-a0UWwtx9QAA_19_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_e_OsxemFjU2UD0V-bpKAXw_31_2"
          xlink:label="Tc_e_OsxemFjU2UD0V-bpKAXw_31_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_e_OsxemFjU2UD0V-bpKAXw_31_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_gP3Z8K24QEi0StlfU4I0xA_8_2"
          xlink:label="Tc_gP3Z8K24QEi0StlfU4I0xA_8_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_gP3Z8K24QEi0StlfU4I0xA_8_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_9_aCVK5OUUSmQnmWd-Iaag_12_2"
          xlink:label="Tc_9_aCVK5OUUSmQnmWd-Iaag_12_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_9_aCVK5OUUSmQnmWd-Iaag_12_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_pVxwznRJPEKMo6T8bA4g8Q_6_2"
          xlink:label="Tc_pVxwznRJPEKMo6T8bA4g8Q_6_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_pVxwznRJPEKMo6T8bA4g8Q_6_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_S08bm8fgO0i5HiSEl0Rfgg_22_2"
          xlink:label="Tc_S08bm8fgO0i5HiSEl0Rfgg_22_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_S08bm8fgO0i5HiSEl0Rfgg_22_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_UyvHhvotHUadHVP182UZOQ_27_2"
          xlink:label="Tc_UyvHhvotHUadHVP182UZOQ_27_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_UyvHhvotHUadHVP182UZOQ_27_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_UtQwCJekdUasg7dOkWRNag_14_2"
          xlink:label="Tc_UtQwCJekdUasg7dOkWRNag_14_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_UtQwCJekdUasg7dOkWRNag_14_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_Lh0LWu1Zxk6bjyikcZldlg_15_2"
          xlink:label="Tc_Lh0LWu1Zxk6bjyikcZldlg_15_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_Lh0LWu1Zxk6bjyikcZldlg_15_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_LmE8scvYJEOagyeAR2Z9NA_28_2"
          xlink:label="Tc_LmE8scvYJEOagyeAR2Z9NA_28_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_LmE8scvYJEOagyeAR2Z9NA_28_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_fgMVVUijQkKbf4CfNl5g6Q_33_2"
          xlink:label="Tc_fgMVVUijQkKbf4CfNl5g6Q_33_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_fgMVVUijQkKbf4CfNl5g6Q_33_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_Ho1JiaXHzkKwcRlvVUSVZw_21_2"
          xlink:label="Tc_Ho1JiaXHzkKwcRlvVUSVZw_21_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_Ho1JiaXHzkKwcRlvVUSVZw_21_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_A02-y9pBqUamMTVlXsWeHw_9_2"
          xlink:label="Tc_A02-y9pBqUamMTVlXsWeHw_9_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_A02-y9pBqUamMTVlXsWeHw_9_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
